<SEC-DOCUMENT>0001558370-19-006287.txt : 20190725
<SEC-HEADER>0001558370-19-006287.hdr.sgml : 20190725
<ACCEPTANCE-DATETIME>20190725063814
ACCESSION NUMBER:		0001558370-19-006287
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		35
CONFORMED PERIOD OF REPORT:	20190723
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190725
DATE AS OF CHANGE:		20190725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gemphire Therapeutics Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		19972376

	BUSINESS ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
		BUSINESS PHONE:		248-980-6538

	MAIL ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:57 AM-->
<html>
	<head>
		<title>
			gemp_Current_Folio_8K
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt solid #000000 ;border-bottom:1pt solid #000000 ;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Washington, D.C.&nbsp;&nbsp;20549</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">FORM&nbsp;8-K</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Current Report Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">the Securities Exchange Act of 1934</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Date of Report (Date of earliest event reported):&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">July 23, 2019</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Gemphire Therapeutics&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(Exact name of registrant as specified in its charter)</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Delaware</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">001-37809</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">47</font><font style="display:inline;font-family:MS Mincho;font-weight:bold;">&#x2011;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">2389984</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(State or other jurisdiction of</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(Commission File Number)</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">(IRS Employer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">incorporation)</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17199 N. Laurel Park Drive, Suite 401, Livonia, MI 48152</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(Address of principal executive offices)&nbsp; (Zip Code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(734) 245</font><font style="display:inline;font-family:MS Mincho;font-weight:bold;">&#x2011;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">1700</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(Registrant&#x2019;s telephone number, including area code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Not Applicable</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(Former name or former address, if changed since last report)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 5.4pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:9pt;">&#x2612;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 5.4pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 5.4pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 5.4pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</font>
		</p>
		<p style="margin:0pt 0pt 0pt 5.4pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Securities registered pursuant to Section 12(b) of the Act:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:40.66%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">Title of each class</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">Trading&nbsp;Symbol(s)</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.54%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">Name&nbsp;of&nbsp;each&nbsp;exchange&nbsp;on&nbsp;which&nbsp;registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.66%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Common Stock, $0.001 par value</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">GEMP</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.54%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">The Nasdaq Stock Market LLC</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&#xA7;230.405 of this chapter) or Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (&#xA7;240.12b-2 of this chapter).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Emerging growth company </font><font style="display:inline;font-family:Segoe UI Symbol;">&#x2612;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. </font><font style="display:inline;font-family:Segoe UI Symbol;">&#x2612;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-family:Segoe UI Symbol;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt solid #000000 ;border-bottom:3pt solid #000000 ;line-height:1pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Segoe UI Symbol;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Item 1.01<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Entry into a Material Definitive Agreement</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger Agreement with NeuroBo</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On July 24, 2019, Gemphire Therapeutics Inc., a Delaware corporation (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Gemphire</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), GR Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Gemphire (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger Sub</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), and NeuroBo Pharmaceuticals, Inc., a Delaware corporation (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">NeuroBo</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into NeuroBo, with NeuroBo continuing as a wholly owned subsidiary of Gemphire and the surviving corporation of the merger (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Effective Time</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), (a) each share of NeuroBo common stock outstanding immediately prior to the Effective Time (excluding shares held as treasury stock, held by NeuroBo and dissenting shares) will be converted into the right to receive shares of Gemphire common stock (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Gemphire Common Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) equal to the Exchange Ratio described below; and (b) each outstanding NeuroBo stock option that has not previously been exercised prior to the Effective Time will be assumed by Gemphire.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Under the exchange ratio formula in the Merger Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Exchange Ratio</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), upon the closing of the Merger, on a pro forma basis and based upon the number of shares of Gemphire Common Stock expected to be issued in the Merger, current Gemphire securityholders are expected to own approximately 4.06% of the combined company and current NeuroBo securityholders are expected to own approximately 95.94% of the combined company, on a fully-diluted basis and assuming that Gemphire has the minimum Parent Cash Amount (as described below) allowable under the Merger Agreement and that NeuroBo raises the minimum required amount in the Pre-Closing Financing (as described below). &nbsp;The ownership percentages are subject to adjustment to the extent that Gemphire&#x2019;s Parent Cash Amount (as defined in the Merger Agreement) at the Effective Time is negative or to reflect aggregate gross proceeds received by NeuroBo in its Pre-Closing Financing before the closing of the Merger above the minimum required amount and up to and including $50 million.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In connection with the Merger, Gemphire will prepare and file with the U.S. Securities and Exchange Commission (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">SEC</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) a registration statement on Form&nbsp;S-4 that will contain a proxy statement / prospectus / information statement, and will seek the approval of Gemphire&#x2019;s stockholders with respect to certain actions, including, but not limited to, the following (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Gemphire Stockholder Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;):</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">the issuance of Gemphire Common Stock to the NeuroBo stockholders pursuant to the Merger Agreement and the change of control of Gemphire resulting from the Merger pursuant to pertinent Nasdaq rules;</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">the amendment of Gemphire&#x2019;s certificate of incorporation to effect a reverse split of all outstanding shares of the Gemphire Common Stock at a reverse stock split ratio as mutually agreed to by Gemphire and NeuroBo; and</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">the amendment of Gemphire&#x2019;s certificate of incorporation to change the name of Gemphire to &#x201C;NeuroBo Pharmaceuticals, Inc.&#x201D;</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of Gemphire and NeuroBo, the continued listing of the Gemphire Common Stock on the Nasdaq Capital Market, &nbsp;the conversion of all NeuroBo preferred stock and NeuroBo convertible notes into NeuroBo common stock and satisfaction by Gemphire of a minimum Parent Cash Amount&nbsp;of negative $3 million at closing.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Prior to signing the Merger Agreement, NeuroBo entered into subscription agreements with investors for a Series B Preferred Stock financing for approximate gross proceeds of $24,240,000, the minimum required amount under the Merger Agreement, and may enter into additional subscription agreements and receive additional proceeds between signing and closing of the Merger (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Pre-Closing Financing</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">2</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Merger Agreement contains certain termination rights for both Gemphire and NeuroBo, and further provides that, upon termination of the Merger Agreement under specified circumstances, either party may be required to pay the other party a termination fee of $1,000,000, or in some circumstances reimburse the other party&#x2019;s expenses up to a maximum of $500,000.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Following the Closing, John L. Brooks III will serve as Gemphire&#x2019;s Chief Executive Officer. &nbsp;The board of directors of Gemphire (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Gemphire Board</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) will consist of six directors with five directors to be designated by NeuroBo, as well as Steven Gullans (Gemphire&#x2019;s current President and Chief Executive Officer and member of the board of directors).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Contingent Value Rights Agreement</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">At the Effective Time, Gemphire, &nbsp;Grand Rapids Holders&#x2019; Representative, LLC, as representative of the Gemphire stockholders prior to the Effective Time, and Computershare Inc., as the Rights Agent, will enter into a Contingent Value Rights Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">CVR Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). Pursuant to the Merger Agreement and the CVR Agreement, for each share of Gemphire Common Stock held, Gemphire stockholders of record as of immediately prior to the Effective Time will receive one contingent value right (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">CVR</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) entitling such holders to receive in the aggregate, 80% of the Gross Consideration (as defined in the CVR Agreement which contemplates the post-Merger combined company&#x2019;s prior retention of an aggregate of $500,000) less other Permitted Deductions (each as defined in the CVR Agreement) received during the 15-year period after the closing of the Merger (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">CVR Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) from the grant, sale or transfer of rights to Gemphire&#x2019;s product candidate gemcabene (other than a grant, sale or transfer of rights involving a sale or disposition of the post-Merger combined company) that is entered into during the 10-year period after the closing of the Merger&nbsp;or pursuant to the License Agreement (as defined below), but not including the $2.5 million upfront gross payment pursuant to the License Agreement. Under the CVR Agreement, the combined company agreed to commit $1 million to support the further development of gemcabene through the quarter ending March 31, 2020, to be funded following execution of the License Agreement and the receipt by Gemphire of the $2.5 million upfront gross payment payable under the License Agreement.&nbsp; The CVRs are not transferable, except in certain limited circumstances, will not be certificated or evidenced by any instrument, will not accrue interest and will not be registered with the SEC or listed for trading on any exchange.&nbsp; The CVR Agreement will be effective prior to the closing of the Merger and will continue in effect until the later of the end of the CVR Term and the payment of all amounts payable thereunder, unless and until earlier terminated upon termination of the Merger Agreement.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Voting Agreements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Concurrently with the execution of the Merger Agreement, the executive officers and directors and certain other stockholders of Gemphire entered into voting agreements with NeuroBo and Gemphire relating to the Merger covering approximately 26% of the outstanding capital stock of Gemphire, as of date of the Merger Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Gemphire Voting Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The Gemphire Voting Agreements provide, among other things, that the stockholders who are parties to the Gemphire Voting Agreements will vote all of the shares held by them in favor of the Gemphire Stockholder Matters and against any competing acquisition proposals.&nbsp; The Gemphire Voting Agreements also place certain restrictions on the transfer of the shares of Gemphire held by the respective signatories thereto.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of NeuroBo entered into voting agreements with Gemphire and NeuroBo covering approximately 90% of the outstanding capital stock of NeuroBo as of the date of the Merger Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">NeuroBo Voting Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">,&#x201D; and together with Gemphire Voting Agreements, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Voting Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The NeuroBo Voting Agreements provide, among other things, that the directors, officers and securityholders party to the NeuroBo Voting Agreements will vote all of the shares of NeuroBo held by them in favor of the adoption of the Merger Agreement, the approval of the Merger and the other transactions contemplated by the Merger Agreement and against any competing acquisition proposals.&nbsp; The NeuroBo Voting Agreements also place certain restrictions on the transfer of the shares of NeuroBo held by the respective signatories thereto.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">3</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Lock-Up Agreements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Concurrently with the execution of the Merger Agreement, the officers and directors of Gemphire and the officers, directors and certain securityholders of NeuroBo entered into lock-up agreements (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Lock-Up Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), pursuant to which they accepted certain restrictions on transfers of any shares of Gemphire&#x2019;s common stock for the 180-day period following the Effective Time.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The foregoing descriptions of the Merger Agreement, the CVR Agreement, the Gemphire Voting Agreements, the NeuroBo Voting Agreements, and the Lock-Up Agreements, are not complete and are qualified in their entirety by reference to those agreements or the forms thereof, as applicable, which are attached hereto as Exhibit&nbsp;2.1, 2.2, 2.3, 2.4, and 2.5, respectively, and incorporated herein by reference.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Merger Agreement (and the foregoing description of the Merger Agreement and the transactions contemplated thereby) has been included to provide investors and stockholders with information regarding the terms of the Merger Agreement and the transactions contemplated thereby. It is not intended to provide any other factual information about Gemphire or NeuroBo or to modify or supplement any factual disclosures about Gemphire in its public reports filed with the SEC. The representations, warranties and covenants contained in the Merger Agreement were made only as of specified dates for the purposes of the Merger Agreement, were solely for the benefit of the parties to the Merger Agreement and may be subject to qualifications and limitations agreed upon by such parties. In particular, in reviewing the representations, warranties and covenants contained in the Merger Agreement, it is important to bear in mind that such representations, warranties and covenants were negotiated with the principal purpose of allocating risk between the parties, rather than establishing matters as facts. Such representations, warranties and covenants may also be subject to a contractual standard of materiality different from those generally applicable to stockholders and reports and documents filed with the SEC. Investors and stockholders are not third-party beneficiaries under the Merger Agreement. Accordingly, investors and stockholders should not rely on such representations, warranties and covenants as characterizations of the actual state of facts or circumstances described therein. Information concerning the subject matter of such representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the parties&#x2019; public disclosures.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">License Agreement with Beijing SL</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On July 23, 2019, &nbsp;Gemphire entered into a License and Collaboration Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">License Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) with Beijing SL Pharmaceutical Co., Ltd. (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Beijing SL</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), pursuant to which Gemphire granted Beijing SL an exclusive royalty-bearing license to research, develop, manufacture and commercialize pharmaceutical products comprising, as an active ingredient, gemcabene in mainland China, Hong Kong, Macau and Taiwan (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">region</font><font style="display:inline;font-family:Times New Roman,Times,serif;">,&#x201D; and collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Territory</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). Gemphire retains all rights to gemcabene outside of the Territory. The parties have agreed to collaborate with respect to development and commercialization activities under the License Agreement through a joint steering committee composed of an equal number of representatives of Beijing SL and Gemphire.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Under the terms of the License Agreement, Beijing SL will be responsible, at its expense, for developing and commercializing products containing gemcabene (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Licensed Product</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) in the Territory, with certain assistance from Gemphire. &nbsp;To the extent mutually agreed to in writing, Gemphire and Beijing SL will collaborate on the Phase 3 clinical trial for homozygous familial hypercholesterolemia or other clinical trials with Gemphire as the sponsor designed to enroll patients both inside and outside the Territory (a &nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Global Study</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), but Beijing SL will be responsible, at its expense, for the conduct of any Global Study to the extent solely in the Territory, subject to Gemphire&#x2019;s final decision making authority, and Gemphire will be responsible, at its expense, for the conduct of any Global Study to the extent solely outside of the Territory. &nbsp;Under a territory development plan, the parties shall develop Licensed Products with respect to the Territory. Beijing SL will be responsible for development activities, including non-clinical and clinical studies directed at obtaining regulatory approval of the Licensed Product in the Territory.&nbsp; Beijing SL has agreed to use commercially reasonable efforts to commercialize the Licensed Products for each indication that receives regulatory approval in the Territory and shall prepare and present a commercialization plan that shall be subject to approval by the joint steering committee.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">4</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Pursuant to the License Agreement, Beijing SL will make an upfront gross payment of $2.5&nbsp;million to Gemphire within 45 days of the effective date of the License Agreement. Additionally, with respect to each Licensed Product, Gemphire will be eligible to receive (i) payments for specified developmental and regulatory milestones (including submission of a new drug application to China&#x2019;s National Medical Product Administration, dosing of the first patient in a phase 3 clinical trial in mainland China and regulatory approval for the first and each additional indication of a Licensed Product in the Territory) totaling up to $6&nbsp;million in the aggregate and (ii) payments for specified global net sales milestones of up to $20 million in the aggregate multiplied by the ratio of the net sales of a Licensed Product sold by Beijing SL in the Territory divided by the global net sales of a Licensed Product, which net sales milestone payments are payable once, upon the first achievement of such milestone.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Beijing SL will also be obligated to pay Gemphire tiered royalties ranging from the mid-teens to twenty percent on the net sales of all Licensed Products in the Territory until the latest of (a) the date on which any applicable regulatory exclusivity with respect to such Licensed Product expires in such region, (b) the expiration or abandonment of the last valid patent claim or joint patent claim covering such Licensed Product in each region and (c) the fifth anniversary of the first commercial sale of such Licensed Product in such region (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Royalty Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). &nbsp;Future milestone payments under the License Agreement, if any, are not expected to begin for at least one year and will extend over a number of subsequent years. Gemphire cannot determine the date on which Beijing SL&#x2019;s potential royalty payment obligations to Gemphire would expire because Beijing SL has not yet developed any Licensed Products under the License Agreement and therefore Gemphire cannot at this time identify the date of the first commercial sale or the periods of any regulatory exclusivity or patent claims with respect to any Licensed Product.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On a Licensed Product-by-Licensed Product and region-by-region basis upon the expiration of the Royalty Term, the license granted to Beijing SL shall be deemed perpetual, fully paid-up and royalty free with respect to such Licensed Product in such region. Either party may terminate the Agreement (x) with written notice for the other party&#x2019;s material breach following a cure period or (y) if the other party becomes subject to certain insolvency proceedings. &nbsp;In addition, Gemphire may terminate the agreement in its entirety if Beijing SL or its affiliates or sublicensees commence a proceeding challenging the validity, enforceability or scope of any of Gemphire&#x2019;s patents.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">To the extent rights granted to Beijing SL under the License Agreement are controlled by Gemphire pursuant to the Amended and Restated License Agreement between Gemphire and Pfizer Inc. (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Pfizer</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), such rights are subject to the terms and conditions of such agreement with Pfizer, and Beijing SL has agreed to comply with such terms and conditions.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The License Agreement contemplates that Beijing SL and Gemphire shall, no later than 60 days following the effective date of the License Agreement, negotiate in good faith and execute a clinical supply agreement and, no later than twelve months prior to the anticipated date of the first commercial sale of a Licensed Product, if any, negotiate in good faith and execute a commercial supply agreement, pursuant to which Beijing SL shall purchase from Gemphire, and Gemphire shall use commercially reasonable efforts to supply, gemcabene or Licensed Product for clinical or commercial purposes, as applicable, until manufacturing and regulatory transfers are complete.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Each of Gemphire and Beijing SL has agreed to indemnify the other party against certain losses and expenses relating to the development or commercialization of a Licensed Product by the indemnifying party, the negligence or willful misconduct of the indemnifying party or its directors, officers, employees or agents or a breach of the indemnifying party&#x2019;s representations, warranties or covenants.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">The foregoing description of the </font><font style="display:inline;font-family:Times New Roman,Times,serif;">License Agreement </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">is not complete and is qualified in its entirety by reference to the </font><font style="display:inline;font-family:Times New Roman,Times,serif;">License Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">, which </font><font style="display:inline;font-family:Times New Roman,Times,serif;">is attached hereto as Exhibit 10.6 &nbsp;and incorporated herein by reference</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Item 5.02.<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On July 24, &nbsp;2019, Gemphire entered into amendments to the employment agreements (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Amendments</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) of Dr. Steven Gullans, Chief Executive Officer and President, Dr. Charles Bisgaier, Chief Scientific Officer and Chairman of the Gemphire Board, and Seth Reno, Chief Commercial Officer (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Executives</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) to reduce the cash severance obligation </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">5</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">owed to each Executive in connection with the termination of their employment upon the closing of the Merger. Pursuant to the Amendments, if the Merger is completed, each of Dr. Gullans, Dr. Bisgaier and Mr. Reno will receive a lump sum cash payment within thirty days after the effective date of the Merger in an amount equal to $75,000, &nbsp;$330,000 and $297,536, respectively, subject to a reduction for withholding tax, in lieu of the cash compensation such Executives would otherwise be entitled to receive in connection with a termination following a change in control pursuant to such Executives&#x2019; employment agreements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In connection with the Executives agreeing to the Amendments, on July 24, &nbsp;2019, Gemphire issued each of Dr. Gullans, Dr. Bisgaier and Mr. Reno a restricted stock award representing 300,000, &nbsp;100,000 and 100,000 shares, respectively, of Gemphire Common Stock. The restricted stock awards were made pursuant to Restricted Stock Grant Notices and Restricted Stock Agreements (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Award Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). &nbsp;Such Award Agreements provide that such shares shall fully vest immediately prior to the Effective Time, provided that the Executive has executed and delivered to Gemphire a release and waiver of claims and such release is not subsequently revoked. &nbsp;Gemphire shall automatically reacquire for no consideration all unvested shares upon the earliest to occur of (i) the Executive&#x2019;s termination of continuous service (unless such termination results from the completion of the Merger prior to March 31, 2020) or (ii) March 31, 2020 if the Merger has not been completed. The Award Agreements provide that the holders shall have all rights and privileges of a holder of Gemphire Common Stock, including for purposes of voting and receiving dividends.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Grants were also made to Gemphire&#x2019;s non-employee directors (45,000 shares of restricted stock in the aggregate) and employees (62,000 shares of restricted stock in the aggregate) pursuant to Award Agreements on July 24, &nbsp;2019. The non-employee director Award Agreements do not require the execution and delivery of a release and waiver of claims.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On July 23,&nbsp;2019, Gemphire&#x2019;s non-employee directors agreed to waive payment of the cash retainer for the remainder of 2019 otherwise payable to such directors pursuant to Gemphire&#x2019;s non-employee director compensation policy.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">The foregoing descriptions of the </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Amendments </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">and the </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Award Agreements </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">are not complete and are qualified in their entirety by reference to </font><font style="display:inline;font-family:Times New Roman,Times,serif;">those agreements or the forms thereof, as applicable, which are attached hereto as Exhibit&nbsp;10.1, 10.2, 10.3, 10.4, and 10.5 respectively, and incorporated herein by reference.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Item 8.01<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Other Events.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Attached as Exhibit 99.1 is a copy of the joint press release issued by Gemphire and NeuroBo on July 24, &nbsp;2019 announcing the execution of the Merger Agreement and Gemphire&#x2019;s execution of the License Agreement with Beijing SL. Gemphire and NeuroBo will host a joint conference call on July 25, &nbsp;2019 at 8:30 a.m. Eastern Time to discuss the proposed Merger. &nbsp;Copies of the script and the slides to be used during the joint conference call are attached hereto as Exhibit 99.2 and 99.3, respectively.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Beginning on July 25, 2019, Gemphire and NeuroBo are making available the frequently asked questions attached hereto as Exhibit 99.4.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This communication contains forward-looking statements (including within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, and Section&nbsp;27A of the Securities Act of 1933, as amended) concerning Gemphire, NeuroBo, Beijing SL, the proposed Merger, the CVR Agreement, the License Agreement and other matters.&nbsp; These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Gemphire, as well as assumptions made by, and information currently available to, management.&nbsp; Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#x201C;may,&#x201D; &#x201C;will,&#x201D; &#x201C;should,&#x201D; &#x201C;would,&#x201D; &#x201C;expect,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;plan,&#x201D; &#x201C;likely,&#x201D; &#x201C;believe,&#x201D; &#x201C;estimate,&#x201D; &#x201C;project,&#x201D; &#x201C;intend,&#x201D; and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the conditions to the closing of the proposed Merger are not </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">6</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">satisfied, including the failure to obtain stockholder approval for the proposed Merger in a timely manner or at all; uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Gemphire and NeuroBo to consummate the Merger; risks related to Gemphire&#x2019;s ability to correctly estimate and manage its operating expenses and its expenses associated with the proposed Merger pending closing; risks related to Gemphire&#x2019;s continued listing on the Nasdaq Capital Market until closing of the proposed Merger; &nbsp;risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger; the risk that as a result of adjustments to the Exchange Ratio, Gemphire stockholders or NeuroBo stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Gemphire Common Stock relative to the Exchange Ratio; the risk that the conditions to payment under the CVRs will be not be met and that the CVRs may otherwise never deliver any value to Gemphire stockholders; risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results; the ability of Gemphire or NeuroBo to protect their respective intellectual property rights; competitive responses to the Merger and changes in expected or existing competition; unexpected costs, charges or expenses resulting from the proposed Merger; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger; the success and timing of regulatory submissions and pre-clinical and clinical trials; regulatory requirements or developments; changes to clinical trial designs and regulatory pathways; changes in capital resource requirements; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Gemphire&#x2019;s most recent Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q and Current Reports on Form&nbsp;8-K filed with the SEC. Gemphire can give no assurance that the conditions to the Merger will be satisfied. Except as required by applicable law, Gemphire undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Important Additional Information Will be Filed with the SEC</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In connection with the proposed Merger, Gemphire intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus/information statement.&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"> INVESTORS AND STOCKHOLDERS OF GEMPHIRE ARE URGED TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GEMPHIRE, THE MERGER AND RELATED MATTERS</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; Investors and stockholders will be able to obtain free copies of the proxy statement, prospectus and other documents filed by Gemphire with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov.&nbsp; In addition, investors and stockholders will be able to obtain free copies of the proxy statement, prospectus and other documents filed by Gemphire with the SEC by contacting Gemphire by mail at Gemphire Therapeutics&nbsp;Inc., 17199 N. Laurel Park Drive, Suite 401, Livonia, MI 48152, Attention: Corporate Secretary. Investors and stockholders are urged to read the proxy statement, prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the Merger.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">No Offer or Solicitation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Participants in the Solicitation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Gemphire and its directors and executive officers and NeuroBo and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Gemphire in connection with the Merger. &nbsp;Information regarding the special interests of these directors and executive officers in the Merger will be included in the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">7</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;">proxy statement/prospectus/information statement referred to above.&nbsp;&nbsp;Additional information about Gemphire&#x2019;s directors and executive officers is included in Gemphire&#x2019;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2018, filed with the SEC on March&nbsp;18, 2019.&nbsp; These documents are available free of charge at the SEC website (www.sec.gov) and from the Corporate Secretary of Gemphire at the address above.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Item&nbsp;9.01<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font></font><font style="display:inline;font-weight:bold;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Financial Statements and Exhibits.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(d)<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 9pt 0pt 0pt;"></font></font><font style="display:inline;font-weight:bold;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibits. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Exhibit</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">No.</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.1*</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-2d1.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Agreement and Plan of Merger, dated as of July 24, 2019, by and among Gemphire, Merger Sub and NeuroBo.</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.2*</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-2d2.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Form of CVR Agreement by and among Gemphire, Grand Rapids Holders&#x2019; Representative, LLC, as Holders&#x2019; Representative, and Computershare Inc., as Rights Agent.</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.3</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-2d3.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Form of Gemphire Voting Agreement, by and between NeuroBo, Gemphire and certain stockholders of Gemphire.</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.4*</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-2d4.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Form of NeuroBo Voting Agreement, by and between Gemphire, NeuroBo and certain stockholders of NeuroBo.</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">2.5</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-2d5.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Form of Lock-Up Agreement, by and between Gemphire, NeuroBo and certain stockholders of Gemphire and NeuroBo.</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">10.1+</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-10d1.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">First Amendment to Employment Agreement dated as of July 24, 2019 by and between Gemphire and Steve Gullans.</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">10.2+</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-10d2.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">First Amendment to Employment Agreement dated as of July 24, 2019 by and between Gemphire and Charles L. Bisgaier.</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">10.3+</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-10d3.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">First Amendment to Employment Agreement dated as of July 24, 2019 by and between Gemphire and Seth Reno.</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">10.4+</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-10d4.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Form of Restricted Stock Grant Notice and Restricted Stock Agreement under the Amended and Restated 2015 Equity Incentive Plan (Employees).</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">10.5+</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-10d5.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Form of Restricted Stock Grant Notice and Restricted Stock Agreement under the Amended and Restated 2015 Equity Incentive Plan (Directors).</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">10.6**</font></p>
				</td>
				<td valign="top" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-10d6.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">License and Collaboration Agreement dated as of July 23, 2019 by and between Gemphire and Beijing SL.</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">99.1</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-99d1.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Joint Press Release dated July 24, 2019 issued by Gemphire and NeuroBo.</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">99.2</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-99d2.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Conference Call Script for Call to be held on July 25, 2019.</font></a>&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">99.3</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-99d3.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Slides to be used during Conference Call to be held on July 25, 2019.</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:06.06%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">99.4</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:91.88%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="ex-99d4.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;">Questions and Answers about the Merger dated July 25, 2019.</font></a> &nbsp; &nbsp;</p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div>
		<p style="margin:0pt 0pt 0pt 21.6pt;text-indent: -21.6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2)&nbsp;of Regulation S-K.&nbsp; A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 21.6pt;text-indent: -21.6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">**&nbsp;&nbsp;&nbsp;&nbsp;Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.&nbsp; A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. Certain portions of the License Agreement that are not material and would be competitively harmful if publicly disclosed have been redacted pursuant to Item 601(b)(10)(iv)&nbsp;of Regulation S-K. A copy of the unredacted License Agreement will be furnished to the SEC upon request.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">+&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management compensation plan or arrangement.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">8</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">SIGNATURES</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:20pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:43.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Dated: July 25, 2019</font></p>
				</td>
				<td colspan="3" valign="top" style="width:56.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">GEMPHIRE THERAPEUTICS&nbsp;INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Dr. Steven Gullans</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Dr. Steven Gullans</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">President and Chief Executive Officer </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">9</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex-2d1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:39 AM-->
<html>
	<head>
		<title>
			gemp_Ex2_1
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit 2.1</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">EXECUTION VERSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">AGREEMENT AND PLAN OF MERGER</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">AND REORGANIZATION</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">among:</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">GEMPHIRE THERAPEUTICS INC.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">,</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;a Delaware corporation;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">GR MERGER SUB INC.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">,</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;a Delaware corporation; and</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">NEUROBO PHARMACEUTICALS, INC.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">,</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&nbsp;a Delaware corporation</font>
		</p>
		<p style="margin:0pt 0pt 78pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Dated as of July 24, 2019</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">TABLE OF CONTENTS</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 1.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">DESCRIPTION OF TRANSACTION</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">The Merger</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Effects of the Merger</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Closing; Effective Time</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.4</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Certificate of Incorporation and Bylaws; Directors and Officers</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.5</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Conversion of Shares</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.6</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Contingent Value Right</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.7</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Closing of the Company&#x2019;s Transfer Books</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.8</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Surrender of Certificates</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.9</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Appraisal Rights</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.10</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Further Action</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.11</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Withholding</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.12</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Calculation of Parent Cash Amount</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 2.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Due Organization; Subsidiaries</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Organizational Documents</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Authority; Binding Nature of Agreement</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.4</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Vote Required</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.5</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Non-Contravention; Consents</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.6</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Capitalization</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">11</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.7</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Financial Statements</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">13</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.8</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Absence of Changes</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">14</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.9</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Absence of Undisclosed Liabilities</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">14</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.10</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Title to Assets</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">14</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.11</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Real Property; Leasehold</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">14</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.12</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Intellectual Property</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">14</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.13</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Agreements, Contracts and Commitments</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">16</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.14</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Compliance; Permits; Restrictions</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">18</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.15</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Legal Proceedings; Orders</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">20</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.16</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Tax Matters</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">20</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.17</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Employee and Labor Matters; Benefit Plans</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">22</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.18</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Environmental Matters</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">26</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.19</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Insurance</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">26</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.20</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">No Financial Advisors</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">27</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.21</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Disclosure; Company Information</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">27</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.22</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Transactions with Affiliates</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">27</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.23</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Anti-Bribery</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">27</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.24</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Disclaimer of Other Representations or Warranties</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">28</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 3.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">28</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Due Organization; No Subsidiaries</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">28</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Organizational Documents</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">29</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Authority; Binding Nature of Agreement</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">29</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.4</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Vote Required</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">30</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.5</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Non-Contravention; Consents</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">30</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">i</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">TABLE OF CONTENTS</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">(continued)</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.14%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.66%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.20%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.14%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.66%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.20%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.6</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Capitalization</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">31</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.7</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">SEC Filings; Financial Statements</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">32</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.8</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Absence of Changes</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">34</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.9</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Absence of Undisclosed Liabilities</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">34</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.10</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Title to Assets</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">34</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.11</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Real Property; Leasehold</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">34</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.12</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Intellectual Property</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">35</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.13</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Agreements, Contracts and Commitments</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">36</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.14</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Compliance; Permits</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">38</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.15</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Legal Proceedings; Orders</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">39</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.16</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Tax Matters</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">40</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.17</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Employee and Labor Matters; Benefit Plans</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">41</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.18</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Environmental Matters</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">45</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.19</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Transactions with Affiliates</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">45</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.20</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Insurance</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">45</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.21</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">No Financial Advisors</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">46</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.22</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Anti-Bribery</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">46</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.23</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Valid Issuance</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">46</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.24</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Opinion of Financial Advisor</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">46</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.25</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Disclosure; Parent Information</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">46</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.26</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Disclaimer of Other Representations or Warranties</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">46</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 4.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">CERTAIN COVENANTS OF THE PARTIES</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">47</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Operation of Parent&#x2019;s Business</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">47</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Operation of the Company&#x2019;s Business</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">49</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Access and Investigation</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">51</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.4</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Parent Non-Solicitation</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">52</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.5</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Company Non-Solicitation</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">53</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.6</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Notification of Certain Matters</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">54</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 5.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">ADDITIONAL AGREEMENTS OF THE PARTIES</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">54</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Registration Statement; Proxy Statement</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">54</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Company Information Statement; Stockholder Written Consent</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">55</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Parent Stockholders&#x2019; Meeting</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">57</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.4</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Regulatory Approvals</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">59</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.5</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Company Options, Parent Options and Parent Warrants</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">60</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.6</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Employee Benefits</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">62</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.7</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Indemnification of Officers and Directors</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">62</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.8</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Additional Agreements</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">63</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.9</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Disclosure</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">63</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.10</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Listing</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">64</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.11</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Tax Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. &nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">64</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.12</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Legends</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">65</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.13</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Directors and Officers</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">65</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.14</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Termination of Certain Agreements and Rights</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">65</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.15</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 16 Matters</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">65</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">ii</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">TABLE OF CONTENTS</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">(continued)</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.14%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.66%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.20%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.14%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.66%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.20%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.16</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Cooperation</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">66</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.17</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Allocation Certificates</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">66</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.18</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Takeover Statutes</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">66</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.19</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Stockholder Litigation</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">66</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.20</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Company Preferred Stock, Company Convertible Note Conversion and the Stock Split</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">67</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.21</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Company Financial Statements</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">67</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.22</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Permitted Disposition</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">67</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.23</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">2019 Equity Incentive Plan</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">67</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 6.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">67</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">6.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Effectiveness of Registration Statement</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">67</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">6.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">No Restraints</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">68</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">6.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Stockholder Approval</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">68</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">6.4</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Listing</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">68</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 7.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">68</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Accuracy of Representations</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">68</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Performance of Covenants</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">68</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Documents</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">68</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.4</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">FIRPTA Certificate</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">69</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.5</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">No Company Material Adverse Effect</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">69</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.6</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Termination of Investor Agreements</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">69</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.7</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Company Lock-Up Agreements</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">69</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.8</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Preferred Stock Conversion, Convertible Note Conversion and Stock Split</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">69</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.9</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Pre-Closing Financing</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">69</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.10</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Company Stockholder Written Consent</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">69</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 8.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">69</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Accuracy of Representations</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">70</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Performance of Covenants</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">70</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Documents</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">70</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.4</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">No Parent Material Adverse Effect</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">70</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.5</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Minimum Parent Cash Amount</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">70</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.6</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Parent Lock-Up Agreements</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">70</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.7</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Board of Directors and Officers</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">71</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 9.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">TERMINATION</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">71</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Termination</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">71</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Effect of Termination</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">73</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Expenses; Termination Fees</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">73</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">iii</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">TABLE OF CONTENTS</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;">(continued)</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.14%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.66%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.20%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.14%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:81.66%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.20%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">SECTION 10.</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">MISCELLANEOUS PROVISIONS</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.1</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Non-Survival of Representations and Warranties</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.2</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Amendment</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.3</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Waiver</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">76</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.4</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">76</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.5</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Applicable Law; Jurisdiction</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">76</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.6</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Assignability</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">76</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.7</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Notices</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">76</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.8</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Cooperation</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">77</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.9</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Severability</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">77</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.10</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Other Remedies; Specific Performance</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">78</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.11</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">No Third Party Beneficiaries</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">78</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:14.16%;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 0pt 36pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.12</font></p>
				</td>
				<td valign="top" style="width:81.68%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Construction</font></p>
				</td>
				<td valign="top" style="width:04.16%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">78</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">iv</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibits:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="top" style="width:99.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:14.85pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Exhibit A</font></p>
				</td>
				<td valign="bottom" style="width:365.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:14.85pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Certain Definitions</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:99.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Exhibit B-1</font></p>
				</td>
				<td valign="bottom" style="width:365.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Form of Company Stockholder Support Agreement</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:99.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Exhibit B-2</font></p>
				</td>
				<td valign="bottom" style="width:365.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Form of Parent Stockholder Support Agreement</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:99.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Exhibit C</font></p>
				</td>
				<td valign="bottom" style="width:365.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Form of Contingent Value Right Agreement</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:99.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Exhibit D-1</font></p>
				</td>
				<td valign="bottom" style="width:365.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Form of Company Lock-Up Agreement</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:99.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Exhibit D-2</font></p>
				</td>
				<td valign="bottom" style="width:365.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Form of Parent Lock-Up Agreement</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:99.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Exhibit E</font></p>
				</td>
				<td valign="bottom" style="width:365.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Warrants</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:99.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:365.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">v</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (this &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) is made and entered into as of July 24, 2019, by and among </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">GEMPHIRE THERAPEUTICS INC.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, a Delaware corporation (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">GR MERGER SUB INC.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, a Delaware corporation and wholly owned subsidiary of Parent (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Merger Sub</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">NEUROBO PHARMACEUTICALS, INC.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, a Delaware corporation (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;Certain capitalized terms used in this Agreement are defined in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">RECITALS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent and the Company intend to effect a merger of Merger Sub with and into the Company (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) in accordance with this Agreement and the DGCL.&nbsp;&nbsp;Upon consummation of the Merger, Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The Parties intend that the Merger qualify as either a tax-free contribution pursuant to Section 351 of the Code or a &#x201C;reorganization&#x201D; within the meaning of Section 368(a) of the Code, and by executing this Agreement, the Parties intend to adopt a plan of reorganization within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, including each of the Parent Stockholder Matters, and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Parent Stockholder Matters.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The Merger Sub Board has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to approve the Company Stockholder Matters.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#x2019;s willingness to enter into this Agreement, the officers, directors and certain stockholders of the Company listed on Schedule A of the Company Disclosure Schedule (solely in their capacity as stockholders of the Company) (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Signatories</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) are executing (a) support agreements in favor of Parent in substantially the form attached hereto as </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit B-1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Stockholder Support Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), pursuant to which the Company Signatories have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Capital Stock in favor of the Company Stockholder Matters and against any proposals that compete with the Contemplated Transactions, and (b) lock-up agreements in substantially the form attached hereto as </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit D-1 </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Lock-Up Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#x2019;s willingness to enter into this Agreement, (a) the officers and directors and certain stockholders of Parent listed on Schedule A of the Parent Disclosure Schedule (solely in their capacity as stockholders of Parent) (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Signatories</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) are executing support agreements in favor of the Company in substantially the form attached hereto as </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit B-2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Stockholder Support Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), pursuant to which the Parent Signatories have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Parent Common Stock in favor of the Parent Stockholder Matters and against any proposals that compete with the Contemplated Transactions and (b) the officers and directors of Parent are executing lock-up agreements in substantially the form attached hereto as </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit D-2 </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Lock-Up Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">H.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">It is expected that within five Business Days after the Registration Statement is declared effective under the Securities Act, the Company Signatories will execute and deliver an action by written consent adopting the Company Stockholder Matters in a form reasonably acceptable to Parent (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Stockholder Written Consent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; and collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Stockholder Written Consents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Prior to the execution and delivery of this Agreement, and as a condition of the willingness of Parent to enter into this Agreement, certain investors have executed one or more Subscription Agreements with Company pursuant to which such investors have purchased and/or agreed to purchase certain shares of capital stock of the Company prior to the Closing in connection with the Pre-Closing Financing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The Parties, intending to be legally bound, agree as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DESCRIPTION OF TRANSACTION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">The Merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time, Merger Sub shall be merged with and into the Company, and the separate existence of Merger Sub shall cease.&nbsp;&nbsp;The Company will continue as the surviving corporation in the Merger (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Surviving Corporation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Effects of the Merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Merger shall have the effects set forth in this Agreement, the Certificate of Merger and in the applicable provisions of the DGCL.&nbsp;&nbsp;As a result of the Merger, the Company will become a wholly owned subsidiary of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Closing; Effective Time</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Unless this Agreement is earlier terminated pursuant to the provisions of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, and subject to the satisfaction or waiver of the conditions set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the consummation of the Merger (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Closing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) shall take place remotely as promptly as practicable (but in no event later than the third Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing.&nbsp;&nbsp;The date on which the Closing actually takes place is referred to as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Closing Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&#x201D; At the Closing, the Parties shall cause the Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, satisfying the applicable requirements of the DGCL and in a form reasonably acceptable to Parent and the Company (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Certificate of Merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;The Merger shall become effective at the time of the filing of such Certificate of Merger with the Secretary of State of the State of Delaware or at such later</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">time as may be specified in such Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Effective Time</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Certificate of Incorporation and Bylaws; Directors and Officers</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;At the Effective Time:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the certificate of incorporation of the Surviving Corporation shall be amended and restated in its entirety to read identically to the certificate of incorporation of Merger Sub as in effect immediately prior to the Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that at the Effective Time, Parent shall file one or more amendments to its certificate of incorporation, to the extent approved by the holders of Parent Common Stock as contemplated by </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, to (i) change the name of Parent to NeuroBo Pharmaceuticals, Inc., (ii) effect the Reverse Split, and (iii) make such other changes as are mutually agreeable to Parent and the Company;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the bylaws of the Surviving Corporation shall be amended and restated in their entirety to read identically to the bylaws of Merger Sub as in effect immediately prior to the Effective Time, until thereafter amended as provided by the DGCL and such bylaws;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the parties shall take all actions necessary to cause the directors and officers of Parent, each to hold office in accordance with the certificate of incorporation and bylaws of Parent, to be as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.13</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and to amend the bylaws of Parent to reflect the name identified in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.4(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the parties shall take all actions necessary to cause the directors and officers of the Surviving Corporation to be the directors and officers of Parent as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.13</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, after giving effect to the provisions of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.13</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, or such other persons as shall be mutually agreed upon by Parent and the Company each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Conversion of Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any stockholder of the Company or Parent:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any shares of Company Common Stock held as treasury stock or held or owned by the Company, Merger Sub or any Subsidiary of the Company immediately prior to the Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.5(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, each share of Company Common Stock outstanding immediately prior to the Effective Time (excluding shares to be canceled pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.5(a)(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, excluding Dissenting Shares and after giving effect to the Pre-Closing Financing, the Preferred Stock Conversion, the Convertible Note Conversion and the Stock Split) shall be automatically converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Merger Consideration</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any shares of Company Common Stock outstanding immediately prior to the Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of Parent Common Stock issued in exchange for such shares of Company Common Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Common Stock shall accordingly be marked with appropriate legends.&nbsp;&nbsp;The Company shall take all actions that may be necessary to ensure that, from and after the Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement in accordance with its terms.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No fractional shares of Parent Common Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued.&nbsp;&nbsp;Any holder of Company Common Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (after aggregating all fractional shares of Parent Common Stock issuable to such holder) shall, in lieu of such fraction of a share and upon surrender by such holder of a letter of transmittal in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and any accompanying documents as required therein, be paid in cash the dollar amount (rounded to the nearest whole cent), without interest, determined by multiplying such fraction by the Parent Closing Price.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Company Options outstanding immediately prior to the Effective Time under the Company Plan shall be treated in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.5(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Parent Options outstanding immediately prior to the Effective Time under the Parent Stock Plans shall be treated in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.5(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Parent Warrants outstanding immediately prior to the Effective Time shall be treated in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.5(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of common stock, $0.0001 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.0001 par value per share, of the Surviving Corporation.&nbsp;&nbsp;Each stock certificate of Merger Sub evidencing ownership of any such shares shall, as of the Effective Time, evidence ownership of such shares of common stock of the Surviving Corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, between the time of calculating the Exchange Ratio and the Effective Time, the outstanding shares of Company Capital Stock or Parent Common Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Reverse Split or Stock Split to the extent such split has not been previously taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital Stock, Parent Common Stock, Company Options, Parent Options and Parent Warrants with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split (including the Reverse Split or Stock Split to the extent such split has not been previously taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided, however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Common Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Contingent Value Right</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of Parent Common Stock of record as of immediately prior to the Effective Time shall be entitled to one contractual contingent value right (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">CVR</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) issued by Parent subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, attached hereto as </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit C </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">CVR Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), for each share of Parent Common Stock held by such holders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At or prior to the Effective Time, Parent shall authorize and duly adopt, execute and deliver, and will ensure that Exchange Agent and Holders&#x2019; Representative (as defined in the CVR Agreement) execute and deliver, the CVR Agreement, subject to any reasonable revisions to the CVR Agreement that are requested by such Exchange Agent (provided that such revisions are immaterial and not, individually or in the aggregate, detrimental or adverse, taken as a whole, to any holder of CVR).&nbsp;&nbsp;Parent and the Company shall cooperate, including by making changes to the form of CVR Agreement, as necessary to ensure that the CVRs are not subject to registration under the Securities Act, the Exchange Act or any applicable state securities or &#x201C;blue sky&#x201D; laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent, the Exchange Agent and (if necessary) Holders&#x2019; Representative shall, at or prior to the Effective Time, duly authorize, execute and deliver the CVR Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Closing of the Company&#x2019;s Transfer Books</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;At the Effective Time: (a) all shares of Company Common Stock outstanding immediately prior to the Effective Time (after giving effect to the Pre-Closing Financing, Preferred Stock Conversion, Convertible Note Conversion and the Stock Split) shall be treated in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.5(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, and all holders of certificates representing shares of Company Capital Stock that were outstanding immediately prior to the Effective Time shall cease to have any rights as stockholders of the Company; and (b) the stock transfer books of the Company shall be closed with respect to all shares of Company Capital Stock outstanding immediately prior to the Effective Time.&nbsp;&nbsp;No further transfer of any such shares of Company Capital Stock shall be made on such stock transfer books after the Effective Time.&nbsp;&nbsp;If, after the Effective Time, a valid certificate previously representing any shares of Company Capital Stock, including any valid certificate representing any shares of Company Preferred Stock previously converted into shares of Company Common Stock in connection with the Preferred Stock Conversion, outstanding immediately prior to the Effective Time (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Stock Certificate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) is presented to the Exchange Agent or to the Surviving Corporation, such Company Stock Certificate shall be canceled and shall be exchanged as provided in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;1.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">1.8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Surrender of Certificates</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On or prior to the Closing Date, Parent and the Company shall agree upon and select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Exchange Agent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;At the Effective Time, Parent shall deposit with the Exchange Agent: (i) certificates or evidence of book-entry shares representing the Parent Common Stock issuable pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.5(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and (ii) cash sufficient to make payments in lieu of fractional shares in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.5(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Parent Common Stock and cash amounts so deposited with the Exchange Agent, together with any dividends or distributions received by the Exchange Agent with respect to such shares, are referred to collectively as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Exchange Fund</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly after the Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of Company Capital Stock that were converted into the right to receive the Merger Consideration: (i) a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (including a provision confirming that</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">5</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">delivery of Company Stock Certificates shall be effected, and risk of loss and title to Company Stock Certificates shall pass, only upon proper delivery of such Company Stock Certificates to the Exchange Agent); and (ii) instructions for effecting the surrender of Company Stock Certificates in exchange for shares of Parent Common Stock.&nbsp;&nbsp;Upon surrender of a Company Stock Certificate to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent: (A) the holder of such Company Stock Certificate shall be entitled to receive in exchange therefor a certificate or certificates or book-entry shares representing the Merger Consideration (in a number of whole shares of Parent Common Stock) that such holder has the right to receive pursuant to the provisions of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.5(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (and cash in lieu of any fractional share of Parent Common Stock pursuant to the provisions of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.5(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">); and (B) the Company Stock Certificate so surrendered shall be canceled.&nbsp;&nbsp;Until surrendered as contemplated by this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.8(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, each Company Stock Certificate shall be deemed, from and after the Effective Time, to represent only the right to receive a certificate or certificates or book-entry shares of Parent Common Stock representing the Merger Consideration (and cash in lieu of any fractional share of Parent Common Stock).&nbsp;&nbsp;If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of Parent Common Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate that includes an obligation of such owner to indemnify Parent against any claim suffered by Parent related to the lost, stolen or destroyed Company Stock Certificate as Parent may reasonably request.&nbsp;&nbsp;In the event of a transfer of ownership of a Company Stock Certificate that is not registered in the transfer records of the Company, payment of the Merger Consideration may be made to a Person other than the Person in whose name such Company Stock Certificate so surrendered is registered if such Company Stock Certificate shall be properly endorsed or otherwise be in proper form for transfer and the Person requesting such payment shall pay any transfer or other Taxes required by reason of the transfer or establish to the reasonable satisfaction of Parent that such Taxes have been paid or are not applicable.&nbsp;&nbsp;The Merger Consideration and any dividends or other distributions as are payable pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.8(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall be deemed to have been in full satisfaction of all rights pertaining to Company Capital Stock formerly represented by such Company Stock Certificates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No dividends or other distributions declared or made with respect to Parent Common Stock with a record date on or after the Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Common Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or provides an affidavit of loss or destruction in lieu thereof in accordance with this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (at which time (or, if later, on the applicable payment date) such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any portion of the Exchange Fund that remains undistributed to holders of Company Stock Certificates as of the date that is 180 days after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates who have not theretofore surrendered their Company Stock Certificates in accordance with this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall thereafter look only to Parent for satisfaction of their claims for Parent Common Stock, cash in lieu of fractional shares of Parent Common Stock and any dividends or distributions with respect to shares of Parent Common Stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Party shall be liable to any holder of any Company Stock Certificate or to any other Person with respect to any shares of Parent Common Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">6</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Appraisal Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the Effective Time and which are held by stockholders who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the DGCL (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Dissenting Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), shall not be converted into or represent the right to receive the Merger Consideration described in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> attributable to such Dissenting Shares.&nbsp;&nbsp;Such stockholders shall be entitled to receive payment of the appraised value of such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL.&nbsp;&nbsp;All Dissenting Shares held by stockholders who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Capital Stock under the DGCL (whether occurring before, at or after the Effective Time), shall thereupon be deemed to be converted into and to have become exchangeable for, as of the Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;1.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">1.8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shall give Parent prompt written notice of any demands by dissenting stockholders received by the Company, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with such demands, and the Company shall have the right to direct all negotiations and proceedings with respect to such demands; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> that Parent shall have the right to participate in such negotiations and proceedings.&nbsp;&nbsp;Neither Parent nor the Company shall, except with the prior written consent of the other Party, voluntarily make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree to do any of the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Further Action</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;If, at any time after the Effective Time, any further action is determined by the Surviving Corporation to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the Surviving Corporation shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of Merger Sub, in the name of the Surviving Corporation and otherwise) to take such action.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Withholding</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Parties and the Exchange Agent shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this Agreement to any holder of Company Capital Stock or any other Person such amounts as such Party or the Exchange Agent reasonably determines it is required to deduct and withhold under the Code or any other Law with respect to the making of such payment and shall be entitled to request any reasonably appropriate Tax forms, including an IRS Form W-9 (or the appropriate IRS Form W-8, as applicable), from any recipient of payments hereunder; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided, however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that before making any such deduction or withholding, Parent shall provide to the Company commercially reasonable notice of any applicable payor&#x2019;s intention to make such deduction or withholding and such notice shall include in reasonable detail the authority, basis and method of calculation for the proposed deduction or withholding and shall be given at least a commercially reasonable period of time before such deduction or withholding is required in order for the Company to obtain reduction or relief from the applicable Governmental Authority.&nbsp;&nbsp;The payor shall provide commercially reasonable notice to the payee upon becoming aware of any such withholding obligation, and the Parties shall cooperate with each other to the extent reasonable to obtain a reduction of or relief from such withholding.&nbsp;&nbsp;To the extent that amounts are so deducted and withheld and paid to the appropriate Governmental Body, such deducted and withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding was made.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">7</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Calculation of Parent Cash Amount</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of this Agreement, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Determination Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; shall be the date that is ten calendar days prior to the anticipated date for Closing, as agreed upon by the Company and Parent at least ten calendar days prior to the date of the Parent Stockholders&#x2019; Meeting (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Anticipated Closing Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;). Within five calendar days following the Determination Date, Parent shall deliver to the Company a schedule (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Cash Schedule</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) setting forth, in reasonable detail, Parent&#x2019;s good faith, estimated calculation of the Parent Cash Amount (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Cash Calculation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) as of the Anticipated Closing Date prepared and certified by Parent&#x2019;s Chief Financial Officer (or if there is no Chief Financial Officer, the principal accounting officer for Parent). Parent shall make the work papers and back-up materials used in preparing the Parent Cash Schedule, as reasonably requested by the Company, available to the Company and, if requested by the Company, its accountants and counsel at reasonable times and upon reasonable notice.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within three calendar days after Parent delivers the Parent Cash Schedule to the Company (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Response Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), the Company will have the right to dispute any part of such Parent Cash Schedule by delivering a written notice to that effect to Parent (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Dispute Notice</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;). Any Dispute Notice shall identify in reasonable detail the nature of any proposed revisions to the Parent Cash Calculation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If on or prior to the Response Date, (i) the Company notifies Parent in writing that it has no objections to the Parent Cash Calculation or (ii) the Company fails to deliver a Dispute Notice as provided in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, then the Parent Cash Calculation as set forth in the Parent Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Cash Amount at the Anticipated Closing Date for purposes of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company delivers a Dispute Notice on or prior to the Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of the Parent Cash Amount, which agreed upon the Parent Cash Amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Cash Amount at the Anticipated Closing Date for purposes of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If Representatives of Parent and the Company are unable to negotiate an agreed-upon determination of the Parent Cash Amount at the Anticipated Closing Date pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> within three calendar days after delivery of the Dispute Notice (or such other period as Parent and the Company may mutually agree upon), then Parent and the Company shall jointly select an independent auditor of recognized national standing (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Accounting Firm</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) to resolve any remaining disagreements as to the Parent Cash Calculation. Parent shall promptly deliver to the Accounting Firm the work papers and back-up materials used in preparing the Parent Cash Schedule, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its determination within ten calendar days of accepting its selection. The Company and Parent shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that no such presentation or discussion shall occur without the presence of a Representative of each of the Company and Parent. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the Parent Cash Amount made by the Accounting Firm shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Cash Amount at the Anticipated Closing Date for purposes of this Agreement, and the Parties shall delay the Closing until the resolution of the matters described in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">8</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">of the Parent Cash Amount that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Parent Cash Amount (and for the avoidance of doubt the fees and expenses to be paid by Parent shall reduce the Parent Cash Amount). If this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> applies as to the determination of the Parent Cash Amount at the Anticipated Closing Date described in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, upon resolution of the matter in accordance with this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the Parties shall not be required to determine the Parent Cash Amount again even though the Closing Date may occur later than the Anticipated Closing Date, except that either Party may request a re-determination of the Parent Cash Amount if the Closing Date is more than five Business Days after the Anticipated Closing Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within five (5) Business Days following the end of each calendar month before the Closing Date, Parent shall provide the Company in writing its good faith estimated calculation of the Parent Cash Amount as of the last day of such calendar month.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;10.12(h)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, except as set forth in the disclosure schedule delivered by the Company to Parent (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Disclosure Schedule</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), the Company represents and warrants to Parent and Merger Sub as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Due Organization; Subsidiaries</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is a corporation duly incorporated, validly existing and in good standing under the Laws of Delaware and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted; (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except where the failure to have such power or authority would not reasonably be expected to prevent or materially delay the ability of the Company to consummate the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has no Subsidiaries, except for the Entities identified in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.1(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule.&nbsp;&nbsp;Neither the Company nor any of the Entities identified in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.1(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule owns any capital stock of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity other than the Entities identified in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.1(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule.&nbsp;&nbsp;Each of the Company&#x2019;s Subsidiaries is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and, if applicable, in good standing under the Laws of the jurisdiction of its incorporation or organization, as applicable, and has all necessary corporate or other power and authority to conduct its business in the manner in which its business is currently being conducted and to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used, except where the failure to have such power or authority would not be reasonably expected to have a Company Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is or has otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">9</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">business entity.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Organizational Documents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company has made available to Parent accurate and complete copies of the Organizational Documents of the Company and each of its Subsidiaries in effect as of the date of this Agreement.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is in breach or violation of its respective Organizational Documents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Authority; Binding Nature of Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and each of its Subsidiaries have all necessary corporate or other applicable entity power and authority to enter into and to perform its obligations under this Agreement and, subject to the receipt of the Required Company Stockholder Vote, to consummate the Contemplated Transactions.&nbsp;&nbsp;The Company Board (at meetings duly called and held) has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) authorized, approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to approve the Company Stockholder Matters.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by Parent and Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Vote Required</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. &nbsp; The affirmative vote (or written consent) of (a) (i) the holders of a majority of the shares of Company Common Stock and Company Preferred Stock, on an as-converted to Company Common Stock basis, each outstanding on the record date for the Company Stockholder Written Consent and entitled to vote thereon, and (ii) the holders of at least two-thirds of the outstanding shares of Company Preferred Stock, together as a single class, on an as-converted to Company Common Stock basis, and (b) the holders at least a majority of the outstanding shares of Series A Preferred Stock (with respect to the Convertible Note Conversion only) (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Required Company Stockholder Vote</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), is the only vote (or written consent) of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Non-Contravention; Consents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. &nbsp; Subject to obtaining the Required Company Stockholder Vote, the filing of the Certificate of Merger required by the DGCL, neither (x) the execution, delivery or performance of this Agreement by the Company, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation of any of the provisions of the Company&#x2019;s Organizational Documents;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a material violation of, or, to the Knowledge of the Company, give any Governmental Body or other Person the right to challenge the Contemplated Transactions or to exercise any material remedy or obtain any material relief under, any Law or any order, writ, injunction, judgment or decree to which the Company or its Subsidiaries, or any</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">of the assets owned or used by the Company or its Subsidiaries, is subject, except as would not reasonably be expected to be material to the Company or its business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or its Subsidiaries, except as would not reasonably be expected to be material to the Company or its business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any Company Material Contract; (ii) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract; (iii) accelerate the maturity or performance of any Company Material Contract; or (iv) cancel, terminate or modify any term of any Company Material Contract, except in any such case as would not be reasonably likely to result in a Company Material Adverse Effect; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;result in the imposition or creation of any Encumbrance upon or with respect to any material asset owned or used by the Company or its Subsidiaries (except for Permitted Encumbrances).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Except for (i) any Consent set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule under any Company Contract, (ii) the Required Company Stockholder Vote, (iii) the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL, and (iv) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities Laws, neither the Company nor any of its Subsidiaries is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (A) the execution, delivery or performance of this Agreement and the Company Stockholder Support Agreements, and the Company Lock-up Agreements, or (B) the consummation of the Contemplated Transactions, which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially delay the ability of the Company to consummate the Contemplated Transactions.&nbsp;&nbsp;The Company Board has taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section 203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions.&nbsp;&nbsp;No Takeover Statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Stockholder Support Agreements, the Company Lock-up Agreements, or any of the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Capitalization</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The authorized Company Capital Stock as of the date of this Agreement consists of (i) 5,000 shares of Company Common Stock, par value $1.000000 per share, of which 586 shares have been issued and are outstanding as of the date of this Agreement, and (ii) 1,200 shares of preferred stock, par value $1.000000 per share (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Preferred Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), of which 723 have been issued and are outstanding as of the date of this Agreement, consisting of 420 shares of Series A Preferred Stock and 303 shares of Series B Preferred Stock.&nbsp;&nbsp;The Company does not hold any shares of its capital stock in its treasury.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2.6(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule lists, as of the date of this Agreement (A) each record holder of issued and outstanding Company Capital Stock and the number and type of shares of Company Capital Stock held by such holder; and (B)(1) each holder of issued and outstanding Company Convertible Notes; (2) the underlying principal amount of such Company Convertible Notes; and (3) the maturity date of each such Company Convertible Note. Each share of Company Preferred Stock is convertible into one share of Company Common Stock.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">11</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of the outstanding shares of Company Common Stock and Company Preferred Stock have been duly authorized and validly issued, and are fully paid and nonassessable.&nbsp;&nbsp;Except as set forth in the Investor Agreements, none of the outstanding shares of Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Company Capital Stock is subject to any right of first refusal in favor of the Company.&nbsp;&nbsp;Except as contemplated herein and in the Investor Agreements, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Company Capital Stock.&nbsp;&nbsp;The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Company Capital Stock or other securities.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.6(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule accurately and completely lists all repurchase rights held by the Company, and forfeiture obligations of any holder, with respect to shares of Company Capital Stock (including shares issued pursuant to the exercise of stock options).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except for the Company&#x2019;s 2018 Stock Option Plan (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person.&nbsp;&nbsp;Pursuant to the terms of the Company Plan, the maximum number of shares of Common Stock that may be issued under the Company Plan shall be not more than ten percent (10%) of the then outstanding shares of Company Capital Stock on a fully-diluted basis.&nbsp;&nbsp;As of the date of this Agreement, no shares of Company Common Stock have been issued upon the exercise of Company Options previously granted and are currently outstanding, and 84 shares of Common Stock have been reserved for issuance upon the exercise of Company Options previously granted under the Company Plan.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.6(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule sets forth the following information with respect to each Company Option outstanding as of the date of this Agreement: (i) the name of the optionee; (ii) the number of shares of Company Common Stock subject to such Company Option at the time of grant; (iii) the number of shares of Company Common Stock subject to such Company Option as of the date of this Agreement; (iv) the exercise price of such Company Option; (v) the date on which such Company Option was granted; (vi) the applicable vesting schedule, including the number of vested and unvested shares as of the date of this Agreement and any acceleration provisions; (vii) the date on which such Company Option expires; and (viii) whether such Company Option is intended to constitute an &#x201C;incentive stock option&#x201D; (as defined in the Code) or a non-qualified stock option.&nbsp;&nbsp;The Company has made available to Parent an accurate and complete copy of the Company Plan and all stock option agreements evidencing outstanding options granted thereunder.&nbsp;&nbsp;No vesting of Company Options will accelerate in connection with the closing of the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except for the Company Preferred Stock and the Company Convertible Notes set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2.6(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule and the Company Options set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.6(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of the Company or any of its Subsidiaries; (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company or any of its Subsidiaries; or (iii) condition or circumstance that could be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company or any of its Subsidiaries.&nbsp;&nbsp;There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company or any of its Subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All outstanding shares of Company Common Stock, Company Preferred Stock, Company Options, Company Convertible Notes and other securities of the Company have been issued and granted in material compliance with (i) the Organizational Documents of the Company in</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">12</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">effect as of the relevant time and all applicable securities Laws and other applicable Law, and (ii) all requirements set forth in applicable Contracts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All distributions, dividends, repurchases and redemptions of the Company Capital Stock or other equity interests of the Company were undertaken in material compliance with (i) the Organizational Documents of the Company in effect as of the relevant time and all applicable securities Laws and other applicable Law, and (ii) all requirements set forth in applicable Contracts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Financial Statements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has provided to Parent true and complete copies of (i) the Company&#x2019;s unaudited consolidated balance sheets at December 31, 2018 and 2017, together with related unaudited consolidated statements of income, stockholders&#x2019; equity and cash flows, and notes thereto, of the Company for the fiscal years then ended and (ii) the Company Unaudited Interim Balance Sheet, together with the unaudited consolidated statements of income, stockholders&#x2019; equity and cash flows of the Company for the period reflected in the Company Unaudited Interim Balance Sheet (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Financial Statements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;The Company Financial Statements were prepared in accordance with GAAP (except that the Company Financial Statements may not contain footnotes and are subject to normal and recurring year-end adjustments, none of which are material) and fairly present, in all material respects, the financial position and operating results of the Company and its consolidated Subsidiaries as of the dates and for the periods indicated therein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Company and its Subsidiaries maintains accurate books and records reflecting their assets and liabilities and maintains a system of internal accounting controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management&#x2019;s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of the financial statements of the Company and its Subsidiaries and to maintain accountability of the Company&#x2019;s and its Subsidiaries&#x2019; assets; (iii) access to the Company&#x2019;s and its Subsidiaries&#x2019; assets is permitted only in accordance with management&#x2019;s general or specific authorization; (iv) the recorded accountability for the Company&#x2019;s and its Subsidiaries&#x2019; assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences; and (v) accounts, notes and other receivables and inventory are recorded accurately, and proper and adequate procedures are implemented to effect the collection thereof on a current and timely basis.&nbsp;&nbsp;The Company and each of its Subsidiaries maintains internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is a party to or bound by &#x201C;off-balance sheet arrangements&#x201D; (as defined in Item 303(e) of Regulation S-K under the Exchange Act).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since July 25, 2017, the date of the Company&#x2019;s incorporation, there have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof.&nbsp;&nbsp;Since July 25, 2017, neither the Company nor its independent auditors have identified (i) any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company and its Subsidiaries, (ii) any fraud, whether or not material, that involves the Company, any of its Subsidiaries, the Company&#x2019;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company and its Subsidiaries or (iii) any claim or allegation regarding any of the foregoing.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">13</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Absence of Changes</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule, between the date of the Company Unaudited Interim Balance Sheet and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Company Material Adverse Effect or (b) action, event or occurrence that would have required the consent of Parent pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.2(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> had such action, event or occurrence taken place after the execution and delivery of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Absence of Undisclosed Liabilities</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;As of the date hereof, neither the Company nor any of its Subsidiaries has any liability, indebtedness, obligation or expense of any kind, whether accrued, absolute, contingent, matured or unmatured (each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Liability</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), individually or in the aggregate, of a type required to be recorded or reflected on a balance sheet or disclosed in the footnotes thereto under GAAP, except for: (a) Liabilities disclosed, reflected or reserved against in the Company Unaudited Interim Balance Sheet; (b) Liabilities that have been incurred by the Company or its Subsidiaries since the date of the Company Unaudited Interim Balance Sheet in the Ordinary Course of Business; (c) Liabilities for performance of obligations of the Company or any of its Subsidiaries under Company Contracts; (d) Liabilities incurred in connection with the Contemplated Transactions; (e) Liabilities which would not, individually or in the aggregate, reasonably be expected to be material to the Company; and (f) Liabilities described in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.9</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Title to Assets</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Each of the Company and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it that are material to the Company, its Subsidiaries or their business, including: (a) all tangible assets reflected on the Company Unaudited Interim Balance Sheet; and (b) all other tangible assets reflected in the books and records of the Company or any of its Subsidiaries as being owned by the Company or such Subsidiary.&nbsp;&nbsp;All of such assets are owned or, in the case of leased assets, leased by the Company or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Real Property; Leasehold</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries owns or has ever owned any real property.&nbsp;&nbsp;The Company has made available to Parent (a) an accurate and complete list of all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of, or occupied or leased by the Company or any of its Subsidiaries, and (b) copies of all leases under which any such real property is possessed, occupied or leased (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Real Estate Leases</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), each of which is in full force and effect, with no existing material default thereunder.&nbsp;&nbsp;The Company&#x2019;s possession, occupancy, lease and/or operation of each such leased property conforms to all applicable Laws in all material respects, and the Company has exclusive possession of each such leased property and has not granted any occupancy rights to tenants or licensees with respect to such leased property.&nbsp;&nbsp;In addition, each such leased property and leasehold interest is free and clear of all Encumbrances other than Permitted Encumbrances.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has received any written notice of existing, pending or threatened condemnation proceedings affecting such leased property or existing, pending or threatened zoning, building code or other moratorium proceedings, or similar matters which could reasonably be expected to adversely affect the ability to operate on the leased property as currently operated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Intellectual Property</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2.12(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule identifies (i) all Registered IP owned in whole or in part by, or exclusively licensed to or exclusively sublicensed to, the Company or its Subsidiaries (collectively, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Registered IP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), including, with respect to each</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">14</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">registration and application: (A) the nature of the Intellectual Property Right, (B)&nbsp;the name of the applicant/registrant/owner/assignee/licensee/sublicensee, (C)&nbsp;the jurisdiction of application/registration, (D)&nbsp;the application or registration number, (E) any other co-owners, (F) legal status, and (G) in case of a sublicense the nature of the right granted to the Company; (ii) all unregistered Company IP owned in whole or in part by, or exclusively licensed to or sublicensed to, the Company or its Subsidiaries, including without limitation unregistered trademarks, copyrights (including software), trade secrets, know-how, domain names, trade names, proprietary or confidential information; and (iii) all other Company IP used or held for use in the business as currently conducted.&nbsp;&nbsp;To the Knowledge of the Company, each of the patents and patent applications included in the Company Registered IP properly identifies by name each and every inventor of the inventions claimed therein as determined in accordance with applicable Laws of the United States.&nbsp;&nbsp;As of the date of this Agreement, no cancellation, interference, opposition, reissue, reexamination or other proceeding of any nature (other than office actions or similar communications issued by any Governmental Body in the ordinary course of prosecution of any pending applications for registration) is outstanding, pending, threatened in writing or, to the Knowledge of the Company, threatened, in which the scope, validity, enforceability or ownership of any Company Registered IP is being or has been contested or challenged.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company or its Subsidiaries owns, exclusively licensed or exclusively sublicensed all right, title and interest in and to all Company IP (other than as disclosed on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2.12(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule), free and clear of all Encumbrances other than Permitted Encumbrances.&nbsp;&nbsp;Each Company Associate involved in the creation or development of any Company IP, pursuant to such Company Associate&#x2019;s activities on behalf of the Company or its Subsidiaries, has signed a written agreement containing an assignment of such Company Associate&#x2019;s rights in such Company IP to the Company or its Subsidiaries and confidentiality provisions protecting the Company IP.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of the Company, no funding, facilities or personnel of any Governmental Body or any university, college, research institute or other educational institution has been used to create Company IP, except for any such funding or use of facilities or personnel that does not result in such Governmental Body or institution obtaining ownership or usage rights, or other licensable or sublicensable rights, to such Company IP or the right to receive royalties for the practice of such Company IP.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2.12(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule sets forth each agreement pursuant to which the Company (i) is granted a license (including a covenant not to sue) or sublicense under or other right or interest in any Intellectual Property Right owned by any third party (each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company In-bound License</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) or (ii) grants to any third party a license (including a covenant not to sue) or sublicense under or other right or interest in any Company IP or Intellectual Property Right licensed to the Company or its Subsidiaries under a Company In-bound License (each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Out-bound License</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that, Company In-bound Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, clinical trial agreements, services agreements, licenses ancillary to the purchase of reagents or other materials, non-disclosure agreements, commercially available Software-as-a-Service offerings, or off-the-shelf software licenses; and Company Out-bound Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, clinical trial agreements and services agreements that grant non-exclusive licenses solely for the purpose of conducting activities for the Company or non-disclosure agreements).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of the Company, the operation of the businesses of the Company and its Subsidiaries as currently conducted, and as conducted during the six years preceding the date of this Agreement, does not and has not infringed, misappropriated or otherwise violated any</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">15</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">valid and enforceable Registered IP or any other Intellectual Property Right owned by any other Person and, to the Company&#x2019;s Knowledge, no other Person is infringing, misappropriating or otherwise violating any Company IP or any Intellectual Property Rights exclusively licensed or sublicensed to the Company or its Subsidiaries.&nbsp;&nbsp;As of the date of this Agreement, no Legal Proceeding is pending or threatened in writing (or, to the Knowledge of the Company, is threatened) (A)&nbsp;against the Company or its Subsidiaries alleging that the operation of the businesses of the Company or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights of another Person or (B)&nbsp;by the Company or its Subsidiaries alleging that another Person has infringed, misappropriated or otherwise violated any of the Company IP or any Intellectual Property Rights exclusively licensed to the Company or its Subsidiaries.&nbsp;&nbsp;Since July 25, 2017, neither the Company nor its Subsidiaries has received any written notice or other written communication alleging that the operation of the business of the Company or its Subsidiaries infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another Person.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the Company IP or, to the Knowledge of the Company, any Intellectual Property Rights exclusively licensed to or exclusively sublicensed to the Company or its Subsidiaries is subject to any threatened, pending or outstanding injunction, directive, order, judgment or other disposition of dispute that restricts the use, transfer, registration or licensing by the Company or its Subsidiaries of any such Company IP or Intellectual Property Rights exclusively licensed to the Company or its Subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of the Company, the Company, its Subsidiaries and the operation of the Company&#x2019;s and its Subsidiaries&#x2019; business are in material compliance with all Laws pertaining to data privacy and data security of any personally identifiable information and sensitive business information (collectively, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Sensitive Data</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp; To the Knowledge of the Company, since July 25, 2017, there have been (i) no material losses or thefts of data or security breaches relating to Sensitive Data used in the business of the Company or its Subsidiaries, (ii) no violations of any security policy of the Company regarding any such Sensitive Data used in the business of the Company or its Subsidiaries, and (iii) no unauthorized access, unauthorized use or unintended or improper disclosure of any Sensitive Data used in the business of the Company or its Subsidiaries.&nbsp;&nbsp;The Company has and, to its Knowledge, each of its service providers that has access to Sensitive Data in connection with conducting services for the Company has, taken reasonable actions and implemented policies and procedures that are reasonably appropriate to protect and maintain the security of all Sensitive Data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Agreements, Contracts and Commitments</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.13(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule lists the following Company Contracts in effect as of the date of this Agreement other than any Company Benefit Plans (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Material Contract</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; and collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Material Contracts</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;):</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract containing (A) any covenant limiting the freedom of the Company, its Subsidiaries or the Surviving Corporation to engage in any line of business or compete with any Person, (B) any most-favored pricing arrangement or similar term by which any Person is or could become entitled to any benefit, right or privilege that must be at least as favorable to such Person as those offered to another Person, (C) any exclusivity provision, right of first refusal or right of first negotiation or similar covenant, or (D) any non-solicitation provision, in each case, other than restrictions or limitations that do not or would not materially affect the ability of the Company to conduct its business;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">16</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract relating to the disposition or acquisition of material assets outside of the Ordinary Course of Business and requiring payments after the date of this Agreement in excess of $100,000 or any ownership interest in any Entity;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit (whether as debtor or creditor)&nbsp;&nbsp;or creating any material Encumbrances with respect to any assets of the Company or any of its Subsidiaries or any advancement or loan of money or equipment or other debt obligations to any employee or independent contractor, other than advancement of expenses in the Ordinary Course of Business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions); (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company; (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by the Company; or (D) any Contract to license or engage any third party to manufacture or produce any product, drug substance, service or technology of the Company, any Contract for raw materials or warehousing of products or any Contract to sell, distribute or commercialize any products or service of the Company;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Real Estate Lease;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract with any Governmental Body;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Out-bound License and Company In-bound License;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company or any of its Subsidiaries, or obligation to pay any royalties, fees or other payments to any owner, licensor, or other claimant to any Intellectual Property Rights;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Company Contract, offer letter, employment agreement, or independent contractor agreement with any employee or service provider that (A) is not immediately terminable at-will by the Company without notice, severance, or other cost or liability, or (B) provides for retention payments, change of control payments, severance, accelerated vesting, an exercise period of more than three months following a termination of service or any payment or benefit that may or will become due as a result of the Merger;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">17</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any other Company Contract that is not terminable at will (with no penalty or payment) by the Company or its Subsidiaries, as applicable, and (A) which involves payment or receipt by the Company or its Subsidiaries after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate, or (B) that is material to the business or operations of the Company and its Subsidiaries, taken as a whole; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Subscription Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto.&nbsp;&nbsp;Except as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.13(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule, there are no Company Material Contracts that are not in written form.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has, nor to the Company&#x2019;s Knowledge, as of the date of this Agreement has any other party to a Company Material Contract, materially breached, violated or defaulted under, or received notice that it materially breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract.&nbsp;&nbsp;As to the Company and its Subsidiaries, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions.&nbsp;&nbsp;As of the date of this Agreement, no Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract, and no Person has indicated in writing to the Company that it desires to renegotiate, modify, not renew or cancel any Company Material Contract.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Compliance; Permits; Restrictions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and each of its Subsidiaries are, and since July 25, 2017 have been, in compliance in all material respects with all applicable Laws, including the Federal Food, Drug, and Cosmetic Act (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">FDCA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), the Food and Drug Administration (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">FDA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) regulations adopted thereunder, and any other similar Law administered or promulgated by the FDA or other comparable Governmental Body responsible for regulation of the development, clinical testing, manufacturing, sale, marketing, distribution and importation or exportation of drug and biopharmaceutical products (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Drug Regulatory Agency</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), except for any noncompliance, either individually or in the aggregate, which would not be material to the Company.&nbsp;&nbsp;No investigation, claim, suit, proceeding, audit or other action by any Governmental Body is pending or, to the Knowledge of the Company, threatened in writing against the Company or any of its Subsidiaries.&nbsp;&nbsp;There is no agreement, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of material property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently conducted, (ii) would be reasonably likely to have an adverse effect on the Company&#x2019;s ability to comply with or perform any covenant or obligation under this Agreement, or (iii) would be reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of the Company, the Company and its Subsidiaries hold all required Governmental Authorizations which are material to the operation of the business of the Company and its Subsidiaries as currently conducted (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Permits</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.14(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule identifies each Company Permit.&nbsp;&nbsp;Each of the Company and its Subsidiaries is in material compliance with the terms of the Company Permits.&nbsp;&nbsp;No Legal Proceeding is pending or, to the Knowledge of the Company, threatened, which seeks to revoke, limit, suspend, or materially modify any Company Permit.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">18</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no proceedings pending or, to the Knowledge of the Company, threatened with respect to an alleged violation by the Company or any of its Subsidiaries of the FDCA, &nbsp;FDA regulations adopted thereunder, the Public Health Service Act or any other similar Law administered or promulgated by any Drug Regulatory Agency.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company or its Subsidiaries, or in which the Company or its Subsidiaries or their respective current products or product candidates have participated, were and, if still pending, are being conducted in all material respects in accordance with standard medical and scientific research procedures and in compliance in all material respects with the applicable regulations of any applicable Drug Regulatory Agency and other applicable Law, including 21 C.F.R. Parts 50, 54, 56, 58 and 312.&nbsp;&nbsp;No preclinical or clinical trial conducted by or on behalf of the Company or any of its Subsidiaries has been terminated or suspended prior to completion for safety or non-compliance reasons.&nbsp;&nbsp;Since July 25, 2017, neither the Company nor any of its Subsidiaries has received any notices, correspondence, or other communications from any Drug Regulatory Agency requiring or threatening to initiate the termination or suspension of any clinical studies conducted by or on behalf of, or sponsored by, the Company or any of its Subsidiaries or in which the Company or any of its Subsidiaries or their respective current products or product candidates have participated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is the subject of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products by the FDA pursuant to its &#x201C;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#x201D; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto.&nbsp;&nbsp;To the Knowledge of the Company, neither the Company nor any of its Subsidiaries has committed any acts, made any statement, or failed to make any statement, in each case in respect of its business or products that would violate the FDA&#x2019;s &#x201C;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#x201D; Final Policy, and any amendments thereto.&nbsp;&nbsp;None of the Company, any of its Subsidiaries or any of their respective officers, employees or, to the Knowledge of the Company, agents has been convicted of any crime or engaged in any conduct that could result in a debarment or exclusion (i) under 21 U.S.C. Section 335a or (ii) any similar applicable Law.&nbsp;&nbsp;No debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or, to the Knowledge of the Company, threatened against the Company, any of its Subsidiaries or any of their respective officers, employees or, to the Knowledge of the Company, agents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and its Subsidiaries have complied with all Laws relating to patient, medical or individual health information, including the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations promulgated thereunder, all as amended from time to time (collectively &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">HIPAA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), including the standards for the privacy of Individually Identifiable Health Information at 45 C.F.R. Parts 160 and 164, Subparts A and E, the standards for the protection of Electronic Protected Health Information set forth at 45 C.F.R. Part 160 and 45 C.F.R. Part 164, Subpart A and Subpart C, the standards for transactions and code sets used in electronic transactions at 45 C.F.R. Part 160, Subpart A and Part 162, and the standards for Breach Notification for Unsecured Protected Health Information at 45 C.F.R. Part 164, Subpart D, all as amended from time to time.&nbsp; The Company and its Subsidiaries have entered into, where required, and are in compliance in all material respects with the terms of all Business Associate (as defined in HIPAA) agreements (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Business Associate Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) to which the Company or a Subsidiary is a party or otherwise bound.&nbsp; The Company and its Subsidiaries have created and maintained written policies and procedures to protect the privacy of all protected health information, provide training to all employees and agents as required under HIPAA, and have implemented security procedures, including physical, technical and administrative safeguards, to protect all personal information and Protected Health Information stored or transmitted in electronic form.&nbsp; Neither the Company nor its Subsidiaries have received written notice from the Office for Civil</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">19</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Rights for the U.S. Department of Health and Human Services or any other Governmental Body of any allegation regarding its failure to comply with HIPAA or any other state law or regulation applicable to the protection of individually identifiable health information or personally identifiable information.&nbsp; No successful Security Incident, Breach of Unsecured Protected Health Information or breach of personally identifiable information under applicable state or federal laws have occurred with respect to information maintained or transmitted to the Company, any of its Subsidiaries, or an agent or third party subject to a Business Associate Agreement with the Company or a Subsidiary of the Company.&nbsp; The Company is currently submitting, receiving and handling or is capable of submitting receiving and handling transactions in accordance with the Standard Transaction Rule.&nbsp; All capitalized terms in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2.14(f)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> not otherwise defined in this Agreement shall have the meanings set forth under HIPAA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Legal Proceedings; Orders</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the date of this Agreement, there is no material pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves (A) the Company, (B) any of its Subsidiaries, (C) any Company Associate (in his or her capacity as such) or (D) any of the material assets owned or used by the Company or its Subsidiaries; or (ii) that challenges, or that would have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.15(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule, since July 25, 2017 through the date of this Agreement, no Legal Proceeding has been pending against the Company that resulted in material liability to the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no order, writ, injunction, judgment or decree to which the Company or any of its Subsidiaries, or any of the material assets owned or used by the Company or any of its Subsidiaries, is subject.&nbsp;&nbsp;To the Knowledge of the Company, no officer or employee of the Company or any of its Subsidiaries is subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of the Company or any of its Subsidiaries or to any material assets owned or used by the Company or any of its Subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Tax Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and each of its Subsidiaries have timely filed all income Tax Returns and other material Tax Returns, other than Tax Returns subject to a valid extension granted in the ordinary course of business, that they were required to file under applicable Law.&nbsp;&nbsp;All such Tax Returns are correct and complete in all material respects and have been prepared in compliance with all applicable Law.&nbsp;&nbsp;No claim has ever been made by any Governmental Body in any jurisdiction where the Company or any of its Subsidiaries does not file a particular Tax Return or pay a particular Tax that the Company or such Subsidiary is subject to taxation by that jurisdiction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All income and other material Taxes due and owing by the Company or any of its Subsidiaries on or before the date hereof (whether or not shown on any Tax Return) have been fully paid.&nbsp;&nbsp;The unpaid Taxes of the Company and its Subsidiaries did not, as of the date of the Company Unaudited Interim Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax items) set forth on the face of the Company Unaudited Interim Balance Sheet.&nbsp;&nbsp;Since the date of the Company Unaudited Interim Balance Sheet, neither the Company nor any of its Subsidiaries has incurred any material Liability for Taxes outside the Ordinary Course of Business.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">20</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Taxes that the Company or any of its Subsidiaries are or were required by Law to withhold or collect have been duly and timely withheld or collected in all material respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers or other third parties and, have been timely paid to the proper Governmental Body or other Person or properly set aside in accounts for this purpose.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no Encumbrances for material Taxes (other than Taxes not yet delinquent) upon any of the assets of the Company or any of its Subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No deficiencies for income or other material Taxes with respect to the Company or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Body in writing.&nbsp;&nbsp;There are no pending or ongoing, and to the Knowledge of the Company, threatened audits, assessments or other actions for or relating to any liability in respect of a material amount of Taxes of the Company or any of its Subsidiaries.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries (or any of their predecessors) has waived any statute of limitations in respect of any income or other material Taxes or agreed to any extension of time with respect to any income or other material Tax assessment or deficiency.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is a party to any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement, other than customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of Parent, the Company nor any of its Subsidiaries will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of accounting for Tax purposes; (ii) use of an improper method of accounting for a Tax period ending on or prior to the Closing Date; (iii) &#x201C;closing agreement&#x201D; as described in Section 7121 of the Code (or any similar provision of state, local or foreign Law) executed on or prior to the Closing Date; (iv) intercompany transaction or excess loss account described in Treasury Regulations under Section 1502 of the Code (or any similar provision of state, local or foreign Law); (v) installment sale or open transaction disposition made on or prior to the Closing Date; (vi) prepaid amount received or deferred revenue accrued on or prior to the Closing Date; or (vii) election under Section 108(i) of the Code (or any similar provision of state, local or foreign Law) made on or prior to the Closing Date.&nbsp;&nbsp;The Company has not made any election under Section 965(h) of the Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has ever been (i) a member of a consolidated, combined or unitary Tax group (other than such a group the common parent of which is the Company) or (ii) a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax purposes.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has any Liability for any material Taxes of any Person (other than the Company and any of its Subsidiaries) under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local, or foreign Law), or as a transferee or successor.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has, since July 25, 2017, distributed stock of another Person, or had its stock distributed by another Person, in a transaction that</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">21</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">was purported or intended to be governed in whole or in part by Section 355 of the Code or Section 361 of the Code (or any similar provisions of state, local or foreign Law).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2.16(k)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule, neither the Company nor any of its Subsidiaries (i) is a &#x201C;controlled foreign corporation&#x201D; as defined in Section 957 of the Code; (ii) is a &#x201C;passive foreign investment company&#x201D; within the meaning of Section 1297 of the Code; (iii) has ever had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed place of business in a country other than the country in which it is organized; (iv) is or was a &#x201C;surrogate foreign corporation&#x201D; within the meaning of Section 7874(a)(2)(B) or is treated as a U.S. corporation under Section 7874(b) of the Code; or (v) was created or organized in the U.S. such that such entity would be taxable in the U.S. as a domestic entity pursuant to the dual charter provision of Treasury Regulations Section 301.7701-5(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a &#x201C;listed transaction&#x201D; that is required to be reported to the IRS pursuant to Section 6011 of the Code and applicable Treasury Regulations thereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has taken or agreed to take any action or knows of any fact that would reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">For purposes of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.16</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, each reference to the Company or any of its Subsidiaries shall be deemed to include any Person that was liquidated into, merged with, or is otherwise a predecessor to, the Company or such Subsidiary, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Employee and Labor Matters; Benefit Plans</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.17(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule is a list of all material Company Benefit Plans, including, without limitation, each Company Benefit Plan that provides for retirement, change in control, stay or retention, deferred compensation, incentive compensation, severance or retiree medical or life insurance benefits.&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Benefit Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means each (i) &#x201C;employee benefit plan&#x201D; as defined in Section 3(3) of ERISA and (ii) other pension, retirement, deferred compensation, excess benefit, profit sharing, bonus, incentive, equity or equity-based, phantom equity, employment (other than at-will employment offer letters on the Company&#x2019;s standard form, other than individual Company Options or other compensatory equity award agreements made pursuant to the Company&#x2019;s standard forms, in which case only representative standard forms of such agreements shall be scheduled and other than consulting agreements that may be terminated with 30 days or less days of notice), consulting, severance, change-of-control, retention, health, life, disability, group insurance, paid-time off, holiday, welfare and fringe benefit plan, program, agreement, contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded and including any that have been frozen), in any case, maintained, contributed to, or required to be contributed to, by the Company or any of its Subsidiaries or Company ERISA Affiliates for the benefit of any current or former employee, director, officer or independent contractor of the Company or any of its Subsidiaries or under which the Company or any of its Subsidiaries has any actual or contingent liability (including, without limitation, as to the result of it being treated as a single employer under Code Section 414 with any other person).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As applicable with respect to each material Company Benefit Plan, the Company has made available to Parent, true and complete copies of (i) each material Company Benefit Plan, including all amendments thereto, and in the case of an unwritten material Company Benefit Plan, a written description thereof, (ii) all current trust documents, investment management contracts, custodial</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">22</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">agreements, administrative services agreements and insurance and annuity contracts relating thereto, (iii) the current summary plan description and each summary of material modifications thereto, (iv) the most recently filed annual reports with any Governmental Body (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, Form 5500 and all schedules thereto), (v) the most recent IRS determination, opinion or advisory letter, (vi) the most recent summary annual reports, nondiscrimination testing reports, actuarial reports, financial statements and trustee reports, (vii) all records, notices and filings concerning IRS or Department of Labor or other Governmental Body audits or investigations, &#x201C;prohibited transactions&#x201D; within the meaning of Section 406 of ERISA or Section 4975 of the Code, (viii) all policies and procedures established to comply with the privacy and security rules of HIPAA and (ix) any written reports constituting a valuation of the Company Capital Stock for purposes of Sections 409A or 422 of the Code, whether prepared internally by the Company or by an outside, third-party valuation firm.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Company Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and any related documents or agreements and the applicable provisions of ERISA, the Code and all other Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company Benefit Plans which are &#x201C;employee pension benefit plans&#x201D; within the meaning of Section 3(2) of ERISA and which are intended to meet the qualification requirements of Section 401(a) of the Code have received determination or opinion letters from the IRS on which they may currently rely to the effect that such plans are qualified under Section 401(a) of the Code and the related trusts are exempt from federal income Taxes under Section 501(a) of the Code, respectively, and to the Knowledge of the Company, nothing has occurred that would reasonably be expected to materially adversely affect the qualification of such Company Benefit Plan or the tax exempt status of the related trust.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company, any of its Subsidiaries nor any Company ERISA Affiliate maintains, contributes to, is required to contribute to, or has any actual or contingent liability with respect to, (i) any &#x201C;employee pension benefit plan&#x201D; (within the meaning of Section 3(2) of ERISA) that is subject to Title IV or Section 302 of ERISA or Section 412 of the Code, (ii) any &#x201C;multiemployer plan&#x201D; (within the meaning of Section 3(37) of ERISA), (iii) any &#x201C;multiple employer plan&#x201D; (within the meaning of Section 413 of the Code) or (iv) any &#x201C;multiple employer welfare arrangement&#x201D; (within the meaning of Section 3(40) of ERISA).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no pending audits or investigations by any Governmental Body involving any Company Benefit Plan, and no pending or, to the Knowledge of the Company, reasonably threatened claims (except for individual claims for benefits payable in the normal operation of the Company Benefit Plans), suits or proceedings involving any Company Benefit Plan, any fiduciary thereof or service provider thereto, in any case except as would not be reasonably expected to result in material liability to the Company or any of its Subsidiaries.&nbsp;&nbsp;All contributions and premium payments required to have been made under any of the Company Benefit Plans or by applicable Law (without regard to any waivers granted under Section 412 of the Code), have been timely made in all material respects and neither the Company nor any Company ERISA Affiliate has any material liability for any unpaid contributions with respect to any Company Benefit Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company, any of its Subsidiaries or Company ERISA Affiliates, nor to the Knowledge of the Company, any fiduciary, trustee or administrator of any Company Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Company Benefit Plan which would subject any such Company Benefit Plan, the Company, any of its Subsidiaries or Company ERISA Affiliates or Parent to a material Tax, material penalty or material liability for a &#x201C;prohibited transaction&#x201D; under Section 406 of ERISA or Section 4975 of the Code.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">23</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Company Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service or retirement other than coverage mandated by Law and neither the Company nor any of its Subsidiaries or Company ERISA Affiliates has made a written or oral representation promising the same.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the execution of this Agreement, nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment), will (i)&nbsp;result in any payment becoming due to any current or former employee, director, officer, or independent contractor of the Company or any Subsidiary thereof, (ii) increase any amount of compensation or benefits otherwise payable under any Company Benefit Plan, (iii) result in the acceleration of the time of payment, funding or vesting of any benefits under any Company Benefit Plan, (iv) require any contribution or payment to fund any obligation under any Company Benefit Plan or (v)&nbsp;limit the right to merge, amend or terminate any Company Benefit Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the execution of this Agreement, nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) will result in the receipt or retention by any person who is a &#x201C;disqualified individual&#x201D; (within the meaning of Code Section 280G) with respect to the Company and its Subsidiaries of any payment or benefit that is or could be characterized as a &#x201C;parachute payment&#x201D; (within the meaning of Code Section 280G), determined without regard to the application of Code Section 280G(b)(5).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The exercise price of each Company Option is not and never has been and can never be less than the fair market value of one share of Company Common Stock as of the grant date of such Company Option.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Company Benefit Plan or other agreement, arrangement, practice or program providing for deferred compensation that constitutes a &#x201C;nonqualified deferred compensation plan&#x201D; (as defined in Section 409A(d)(1) of the Code and the regulations promulgated thereunder) is, and has been, established, administered and maintained in compliance with the requirements of Section 409A of the Code and the regulations promulgated thereunder in all material respects.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No current or former employee, officer, director, independent contractor or other service provider of the Company or any of its Subsidiaries has any &#x201C;gross up&#x201D; agreements with the Company or any of its Subsidiaries or other right or assurance of reimbursement by the Company or any of its Subsidiaries for any Taxes imposed under Code Section 409A or Code Section 4999.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Company Benefit Plan maintained outside of the United States (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Foreign Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) has obtained from the Governmental Body having jurisdiction with respect to such plan any required determinations that such plan is in material compliance with the Laws of any such Governmental Body.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The assets of each of the Company Foreign Plans (which is an employee pension benefit plan as defined in Section 3(2) of ERISA (whether or not subject to ERISA) or otherwise provides retirement, medical or life insurance benefits following retirement or other termination of service or employment) are at least equal to the liabilities of such plans.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has provided to Parent a true and correct list, as of the date of this Agreement, containing the names of all current full-time, part-time or temporary employees and independent contractors (and indication as such), and, as applicable: (i) the annualized rates of all</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">24</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">compensation (including wages, salary or fees, commissions, director&#x2019;s fees, fringe benefits, bonuses, profit sharing payments, and other payments or benefits of any type) each person is eligible to receive; (ii), dates of employment or service; (iii) title and, with respect to independent contractors, a current written description of such person&#x2019;s contracting services; (iv) any eligibility to receive severance, notice of termination, retention payment, change of control payment, or other similar compensation; (v) visa status, if applicable; and (vi) with respect to employees, a designation of whether they are classified as exempt or non-exempt for purposes of the Fair Labor Standards Act, as amended (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">FLSA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) and any similar state, federal or foreign law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is or has ever been a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union, labor organization, or similar Person representing any of its employees, and there is no labor union, labor organization, or similar Person representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company or its Subsidiaries, including through the filing of a petition for representation election.&nbsp;&nbsp;There is not and has not been in the past three years, nor is there or has there been in the past three years any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or, to the Knowledge of the Company, any union organizing activity, against the Company or any of its Subsidiaries.&nbsp;&nbsp;No event has occurred, and, to the Knowledge of the Company, no condition or circumstance exists, that might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, any similar activity or dispute, or, to the Knowledge of the Company, any union organizing activity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and each of its Subsidiaries is, and since July 25, 2017 has been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, harassment and retaliation, equal employment opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health, payment of wages (including overtime wages), unemployment and workers&#x2019; compensation, leaves of absence, and hours of work.&nbsp;&nbsp;Except as would not be reasonably likely to result in a material liability to the Company or any of its Subsidiaries, with respect to employees of the Company and its Subsidiaries, each of the Company and its Subsidiaries, since July 25, 2017: (i) has withheld and reported all amounts required by Law or by agreement to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees, (ii) is not liable for any arrears of wages (including overtime wages), severance pay or any Taxes or any penalty for failure to comply with any of the foregoing, and (iii) is not liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Body, with respect to unemployment compensation benefits, disability, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business).&nbsp;&nbsp;There are no actions, suits, claims, charges, lawsuits, investigations, audits or administrative matters pending or, to the Knowledge of the Company, threatened or reasonably anticipated against the Company or any of its Subsidiaries relating to any employee, applicant for employment, consultant, employment agreement or Company Benefit Plan (other than routine claims for benefits).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as would not be reasonably likely to result in a material liability to the Company or any of its Subsidiaries, with respect to each individual who currently renders services to the Company or any of its Subsidiaries, the Company and each of its Subsidiaries has accurately classified each such individual as an employee, independent contractor, or otherwise under all applicable Laws and, for each individual classified as an employee, the Company and each of its Subsidiaries has accurately classified him or her as exempt from or ineligible for overtime under all applicable Laws.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has any material liability with respect to any</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">25</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">misclassification of: (a) any Person as an independent contractor rather than as an employee, (b) any employee leased from another employer, or (c) any employee currently or formerly classified as exempt from or ineligible for overtime under all applicable Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within the preceding five years, the Company has not implemented any "plant closing" or "mass layoff" of employees that would reasonably be expected to require notification under the WARN Act or any similar state or local Law, no such "plant closing" or "mass layoff" will be implemented before the Closing Date without advance notification to and approval of Parent, and there has been no "employment loss" as defined by the WARN Act within the ninety (90) days prior to the Closing Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no Legal Proceeding, claim, unfair labor practice charge or complaint, labor dispute or grievance pending or, to the Knowledge of the Company, threatened against the Company relating to labor, employment, employment practices, or terms and conditions of employment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Environmental Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. &nbsp; The Company and each of its Subsidiaries are and since July 25, 2017 have complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected to be material to the Company or its business.&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries has received since July 25, 2017 (or prior to that time, which is pending and unresolved), any written notice or other communication (in writing or otherwise), whether from a Governmental Body or other Person, that alleges that the Company or any of its Subsidiaries is not in compliance with or has liability pursuant to any Environmental Law and, to the Knowledge of the Company, there are no circumstances that would reasonably be expected to prevent or interfere with the Company&#x2019;s or any of its Subsidiaries&#x2019; compliance in any material respects with any Environmental Law, except where such failure to comply would not reasonably be expected to be material to the Company or its business.&nbsp;&nbsp;No current or (during the time a prior property was leased or controlled by the Company or any of its Subsidiaries) prior property leased or controlled by the Company or any of its Subsidiaries has had a release of or exposure to Hazardous Materials in material violation of or as would reasonably be expected to result in any material liability of the Company or any of its Subsidiaries pursuant to Environmental Law.&nbsp;&nbsp;No consent, approval or Governmental Authorization of or registration or filing with any Governmental Body is required by Environmental Laws in connection with the execution and delivery of this Agreement or the Contemplated Transactions.&nbsp;&nbsp;Prior to the date hereof, the Company has provided or otherwise made available to Parent true and correct copies of all material environmental reports, assessments, studies and audits in the possession or control of the Company or any of its Subsidiaries with respect to any property leased or controlled by the Company or any of its Subsidiaries or any business operated by them.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Insurance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company has delivered or made available to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company and each of its Subsidiaries.&nbsp;&nbsp;Each of such insurance policies is in full force and effect and the Company and each of its Subsidiaries are in compliance in all material respects with the terms thereof.&nbsp;&nbsp;Other than customary end of policy notifications from insurance carriers, since July 25, 2017, neither the Company nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy; or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy.&nbsp;&nbsp;The Company and each of its Subsidiaries have provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against the Company or any of its Subsidiaries for which the</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">26</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company or any of its Subsidiaries of its intent to do so.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">No Financial Advisors</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.20</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&#x2019;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company or any of its Subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Disclosure; Company Information</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The information supplied by the Company and each of its Subsidiaries for inclusion in the Registration Statement (including the Company Audited Financial Statements and Company Interim Financial Statements) will not, on the date the Registration Statement is filed with the SEC, at any time it is amended or supplemented, or at the time it becomes effective under the Securities Act, contain any untrue statement of a material fact, or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not false or misleading at the time and in light of the circumstances under which such statement is made.&nbsp;&nbsp;The information supplied by the Company for use in the Proxy Statement relating to the Company and its Subsidiaries (including any Company Financial Statements) will not, on the date the Proxy Statement is first mailed to the Parent&#x2019;s stockholders or at the time of the Parent Stockholders&#x2019; Meeting, contain any untrue statement of any material fact, or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not false or misleading at the time and in light of the circumstances under which such statement is made. Notwithstanding the foregoing, no representation is made by the Company with respect to the information that has been or will be supplied by Parent and Merger Sub or any of their Representatives for inclusion in the Registration Statement or Proxy Statement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Transactions with Affiliates</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.22(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule describes any material transactions or relationships, since July 25, 2017, between, on one hand, the Company or any of its Subsidiaries and, on the other hand, any (i) officer or director of the Company or, to the Knowledge of the Company, any of its Subsidiaries or any of such officer&#x2019;s or director&#x2019;s immediate family members, (ii) owner of more than 5% of the voting power of the outstanding Company Capital Stock or (iii) to the Knowledge of the Company, any &#x201C;related person&#x201D; (within the meaning of Item 404 of Regulation S-K under the Securities Act) of any such officer, director or owner (other than the Company or its Subsidiaries) in the case of each of (i), (ii) or (iii) that is of the type that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;2.22(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule lists each stockholders agreement, voting agreement, registration rights agreement, co-sale agreement or other similar Contract between the Company and any holders of Company Capital Stock, including any such Contract granting any Person investor rights, rights of first refusal, rights of first offer, registration rights, director designation rights or similar rights (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Investor Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Anti-Bribery</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;None of the Company or any of its Subsidiaries or any of their respective directors, officers, employees or, to the Company&#x2019;s Knowledge, agents or any other Person acting on their behalf has directly or indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of the Foreign Corrupt Practices Act of 1977, the UK Bribery Act of 2010 or any other anti-bribery or anti-corruption Law (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Anti-Bribery</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">27</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Laws</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is or has been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Disclaimer of Other Representations or Warranties</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as previously set forth in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or in any certificate delivered by the Company to Parent and/or Merger Sub pursuant to this Agreement, the Company makes no representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets, liabilities or operations, and any such other representations or warranties are hereby expressly disclaimed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges and agrees that, except for the representations and warranties of Parent and Merger Sub set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the Company is not relying on any other representation or warranty of Parent or any other Person made outside of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, including regarding the accuracy or completeness of any such other representations or warranties or the omission of any material information, whether express or implied, in each case, with respect to the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;10.12(h)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, except (a) as set forth in the disclosure schedule delivered by Parent to the Company (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Disclosure Schedule</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) or (b) as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#x2019;s Electronic Data Gathering Analysis and Retrieval system (but (i) without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (ii) excluding any disclosures contained under the heading &#x201C;Risk Factors&#x201D; and any disclosure of risks included in any &#x201C;forward-looking statements&#x201D; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being understood that any matter disclosed in Parent SEC Documents (x) shall not be deemed disclosed for the purposes of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">3.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">3.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">3.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">3.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">3.6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, and (y) shall be deemed to be disclosed in a section of the Parent Disclosure Schedule only to the extent that it is readily apparent from a reading of such Parent SEC Document that it is applicable to such section of the Parent Disclosure Schedule, Parent and Merger Sub represent and warrant to the Company as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Due Organization; No Subsidiaries</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of Parent and Merger Sub is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted; (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used; and (iii) to perform its obligations under all Contracts by which it is bound, except where the failure to have such power or authority would not reasonably be expected to prevent or materially delay the ability of Parent and Merger Sub to consummate the Contemplated Transactions.&nbsp;&nbsp;Since the date of its incorporation, Merger Sub has not engaged in any activities other than activities incident to its formation or in connection with or as contemplated by this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">28</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">to be so qualified individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than Merger Sub, Parent does not have any Subsidiary.&nbsp;&nbsp;Merger Sub is a corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware.&nbsp;&nbsp;Merger Sub was formed solely for the purpose of engaging in the Contemplated Transactions.&nbsp;&nbsp;All of the issued and outstanding capital stock of Merger Sub, which consists of 1,000 shares of Common Stock, $0.0001 par value, is validly issued, fully paid and non-assessable and is owned, beneficially and of record, by Parent, free and clear of any claim, lien, Encumbrance, or agreement with respect thereto.&nbsp;&nbsp;Except for obligations and liabilities incurred in connection with its incorporation and the Contemplated Transactions, Merger Sub has not, and will not have, incurred, directly or indirectly, any obligations or liabilities or engaged in any business activities of any type or kind whatsoever or entered into any agreements or arrangements with any Person.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity.&nbsp;&nbsp;Parent has not agreed and is not obligated to make, and is not bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity.&nbsp;&nbsp;Parent has not, at any time, been a general partner of, and has not otherwise been liable for, any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Organizational Documents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Parent has made available to the Company accurate and complete copies of Parent&#x2019;s and Merger Sub&#x2019;s Organizational Documents in effect as of the date of this Agreement.&nbsp;&nbsp;Neither Parent nor Merger Sub is in breach or violation of its respective Organizational Documents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Authority; Binding Nature of Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of Parent and Merger Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and, subject, with respect to Parent, to receipt of the Required Parent Stockholder Vote and, with respect to Merger Sub, the adoption of this Agreement by Parent in its capacity as sole stockholder of Merger Sub, to perform its obligations hereunder and to consummate the Contemplated Transactions.&nbsp;&nbsp;The Parent Board (at meetings duly called and held) has: (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders; (ii) authorized, approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Common Stock to the stockholders of the Company pursuant to the terms of this Agreement and the treatment of the Company Options pursuant to this Agreement; and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Parent Stockholder Matters.&nbsp;&nbsp;The Merger Sub Board (by unanimous written consent) has: (A) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder; (B) deemed advisable and approved this Agreement and the Contemplated Transactions; and (C) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement has been duly executed and delivered by Parent and Merger Sub and, assuming the due authorization, execution and delivery by the Company, constitutes the legal, valid and binding obligation of Parent and Merger Sub, enforceable against each of Parent and Merger Sub in accordance with its terms, subject to the Enforceability Exceptions.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">29</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Vote Required</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;(a) The affirmative vote of the holders of a majority of the shares of Parent Common Stock outstanding on the record date for the Parent Stockholders&#x2019; Meeting and entitled to vote thereon is the only vote of the holders of any class or series of Parent&#x2019;s capital stock necessary to approve the proposal in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3(a)(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and (b) the affirmative vote of the holders of a majority of the shares of Parent Common Stock present in person or represented by proxy at the Parent Stockholders&#x2019; Meeting and entitled to vote thereon is the only vote of the holders of any class or series of Parent&#x2019;s capital stock necessary to approve the proposal in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3(a)(iii)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Required Parent Stockholder Vote</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Non-Contravention; Consents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, subject to obtaining the Required Parent Stockholder Vote and the filing of the Certificate of Merger required by the DGCL, neither (x) the execution, delivery or performance of this Agreement by Parent or Merger Sub, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or Merger Sub;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a material violation of, or, to the Knowledge of Parent, give any Governmental Body or other Person the right to challenge the Contemplated Transactions or to exercise any material remedy or obtain any material relief under, any Law or any order, writ, injunction, judgment or decree to which Parent or Merger Sub, or any of the assets owned or used by Parent or Merger Sub, is subject, except as would not reasonably be expected to be material to Parent or its business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent, except as would not reasonably be expected to be material to Parent or its business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (i) declare a default or exercise any remedy under any Parent Material Contract; (ii) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Parent Material Contract; (iii) accelerate the maturity or performance of any Parent Material Contract; or (iv) cancel, terminate or modify any term of any Parent Material Contract, except in the case of any non-material breach, default, penalty or modification; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;result in the imposition or creation of any Encumbrance upon or with respect to any material asset owned or used by Parent (except for Permitted Encumbrances).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Except for (i) any Consent set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule under any Parent Contract, (ii) the Required Parent Stockholder Vote, (iii) the filing of the Certificate of Merger with the Secretary of State of the State of Delaware pursuant to the DGCL, and (iv) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities Laws, neither Parent nor Merger Sub is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement and the Parent Stockholder Support Agreements, or (y) the consummation of the Contemplated Transactions, which if individually or in the aggregate were not given or obtained, would reasonably be expected to prevent or materially delay the ability of Parent and Merger Sub to consummate the Contemplated Transactions.&nbsp;&nbsp;The Parent Board and the Merger Sub</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">30</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section 203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions.&nbsp;&nbsp;No Takeover Statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Capitalization</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The authorized capital stock of Parent as of the date of this Agreement consists of (i) 100,000,000 shares of Parent Common Stock, par value $0.001 per share, of which 14,872,411 shares have been issued and are outstanding as of the close of business on the Reference Date and (ii) 10,000,000 shares of preferred stock of Parent, par value $0.001 per share, of which no shares have been issued and are outstanding as of the date of this Agreement.&nbsp;&nbsp;Parent does not hold any shares of its capital stock in its treasury.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable.&nbsp;&nbsp;None of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent.&nbsp;&nbsp;Except as contemplated herein or as otherwise set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.6(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock.&nbsp;&nbsp;Parent is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities.&nbsp;&nbsp;There are outstanding Parent Warrants to purchase 1,014,204 shares of Parent Common Stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except for the Parent Stock Plans, and except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.6(c)(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person.&nbsp; As of the close of business on the Reference Date, 2,793,973 shares have been reserved for issuance upon exercise of Parent Options granted under the Parent Stock Plans that are outstanding as of the date of this Agreement and 673,062 shares remain available for future issuance pursuant to the Parent Stock Plans.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.6(c)(ii)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule sets forth the following information with respect to each Parent Option outstanding as of the date of this Agreement: (i) the name of the holder; (ii) the number of shares of Parent Common Stock subject to such Parent Option at the time of grant; (iii) the number of shares of Parent Common Stock subject to such Parent Option as of the date of this Agreement; (iv) the exercise price of such Parent Option; (v) the date on which such Parent Option was granted; (vi) the applicable vesting schedule, including the number of vested and unvested shares as of the date of this Agreement and any acceleration provisions; (vii) the date on which such Parent Option expires (and whether there has been any extension of such Parent Option beyond the date(s) provided in the form of stock option agreement provided to the Company); and (viii) whether such Parent Option is intended to constitute an &#x201C;incentive stock option&#x201D; (as defined in the Code) or a non-qualified stock option.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except for the Parent Warrants, the Parent Stock Plans, including the Parent Options, and as otherwise set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.6(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Parent or any of its Subsidiaries; (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent or any of its Subsidiaries; (iii) condition or circumstance that is reasonably likely to give rise to or provide a basis for the assertion of a claim by any</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">31</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent or any of its Subsidiaries; or (iv) outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent or any of its Subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All outstanding shares of Parent Common Stock, Parent Options, Parent Warrants and other securities of Parent have been issued and granted in material compliance with (i) all applicable securities Laws and other applicable Law, and (ii) all requirements set forth in applicable Contracts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">SEC Filings; Financial Statements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent has delivered or made available to the Company accurate and complete copies of all registration statements, proxy statements, Certifications (as defined below) and other statements, reports, schedules, forms and other documents filed by Parent with the SEC since January 1, 2017 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent SEC Documents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), except for documents that have been filed electronically on the SEC&#x2019;s Electronic Data Gathering, Analysis, and Retrieval System (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">EDGAR</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) and can be obtained on the SEC&#x2019;s website at www.sec.gov.&nbsp;&nbsp;All statements, reports, schedules, forms and other documents required to have been filed by Parent or its officers with the SEC have been so filed on a timely basis.&nbsp;&nbsp;As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be), including in each case, the rules and regulations promulgated thereunder, and, as of the time they were filed, or if amended or superseded by a filing prior to the date of this Agreement, on the date of the last such amendment or superseding filing prior to the date of this Agreement, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.&nbsp;&nbsp;The certifications and statements required by (i) Rule 13a-14 under the Exchange Act and (ii) 18 U.S.C. &#xA7;1350 (Section 906 of the Sarbanes-Oxley Act) relating to any Parent SEC Documents (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Certifications</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) are accurate and complete and comply as to form and content with all applicable Laws, except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.7(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule.&nbsp;&nbsp;As used in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.7(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the term &#x201C;file&#x201D; and variations thereof shall be broadly construed to include any manner in which a document or information is filed, furnished, supplied or otherwise made available to the SEC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto; (ii) were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, except as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated; and (iii) fairly present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby.&nbsp;&nbsp;Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof, there has been no material change in Parent&#x2019;s accounting methods or principles that would be required to be disclosed in Parent&#x2019;s financial statements in accordance with GAAP.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent&#x2019;s auditor has at all times since its first date of service to Parent been: (i) a registered public accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act); (ii) to the Knowledge of Parent, &#x201C;independent&#x201D; with respect to Parent within the meaning of Regulation S-X</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">32</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">under the Exchange Act; and (iii) to the Knowledge of Parent, in compliance with subsections (g) through (l) of Section 10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.7(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, since January 1, 2017 through the date of this Agreement, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from officials of Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq.&nbsp;&nbsp;As of the date of this Agreement, Parent has timely responded to all comment letters of the staff of the SEC relating to the Parent SEC Documents, and the SEC has not advised Parent that any final responses are inadequate, insufficient or otherwise non-responsive.&nbsp;&nbsp;Parent has made available to the Company true, correct and complete copies or all comment letters, written inquiries and enforcement correspondences between the SEC, on the one hand, and Parent, on the other hand, occurring since January 1, 2017 and will, reasonably promptly following the receipt thereof, make available to the Company any such correspondence sent or received after the date of this Agreement.&nbsp;&nbsp;To the Knowledge of Parent, as of the date of this Agreement, none of the Parent SEC Documents is the subject of ongoing SEC report or outstanding SEC comment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Parent nor, to the Knowledge of Parent, any director, officer, employee, or internal or external auditor of Parent has received or otherwise had or obtained actual Knowledge of any substantive material complaint, allegation, assertion or claim, whether written or oral, that Parent has engaged in questionable accounting or auditing practices.&nbsp;&nbsp;Since January 1, 2017, there have been no formal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, principal accounting officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.7(f)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, Parent is in compliance in all material respects with (i) the applicable current listing and governance rules and regulations of Nasdaq and (ii) the applicable provisions of the Sarbanes-Oxley Act.&nbsp;&nbsp;Parent has delivered or made available to the Company correct and complete copies of all material correspondences between Nasdaq and Parent since January 1, 2017.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and to provide reasonable assurance (i) that Parent maintains records that in reasonable detail accurately and fairly reflect Parent&#x2019;s transactions and dispositions of the assets of Parent and Merger Sub, (ii) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with authorizations of management and the Parent Board and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#x2019;s assets that could have a material effect on Parent&#x2019;s financial statements.&nbsp;&nbsp;Parent has evaluated the effectiveness of Parent&#x2019;s internal control over financial reporting as of December 31, 2018, and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation.&nbsp;&nbsp;Parent has disclosed, based on its most recent evaluation of internal control over financial reporting, to Parent&#x2019;s auditors and audit committee (and made available to the Company a summary of the significant aspects of such disclosure) (A) all significant deficiencies and material weaknesses, if any, in the design or operation of internal control over financial reporting that are reasonably likely to adversely</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">33</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">affect Parent&#x2019;s ability to record, process, summarize and report financial information and (B) any known fraud that involves management or other employees who have a significant role in Parent&#x2019;s internal control over financial reporting.&nbsp;&nbsp;Parent has not identified, based on its most recent evaluation of internal controls over financial reporting, any material weaknesses in the design or operation of Parent&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent maintains &#x201C;disclosure controls and procedures&#x201D; (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are reasonably designed to ensure that (i) all information required to be disclosed by Parent in the periodic reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods required by the SEC, and (ii) all such information is accumulated and communicated to Parent&#x2019;s management as appropriate to allow timely decisions regarding required disclosure and to make the Certifications.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Absence of Changes</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, between the date of the Parent Balance Sheet and the date of this Agreement, Parent and its Subsidiaries have conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Parent Material Adverse Effect or (b) action, event or occurrence that would have required the consent of the Company pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.1(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> had such action, event or occurrence taken place after the execution and delivery of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Absence of Undisclosed Liabilities</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. &nbsp; As of the date hereof, Parent does not have any Liability, individually or in the aggregate, of a type required to be recorded or reflected on a balance sheet or disclosed in the footnotes thereto under GAAP except for: (a) Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet; (b) Liabilities that have been incurred by Parent since the date of the Parent Balance Sheet in the Ordinary Course of Business, and which are not in excess of $100,000 in the aggregate; (c) Liabilities for performance of obligations of Parent under Parent Contracts (other than for breach thereof); (d) Liabilities incurred in connection with the Contemplated Transactions; and (e) Liabilities described in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.9</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Title to Assets</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. Parent owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it that are material to Parent or its business, including: (a) all tangible assets reflected on the Parent Balance Sheet; and (b) all other tangible assets reflected in the books and records of Parent as being owned by Parent.&nbsp;&nbsp;All of such assets are owned or, in the case of leased assets, leased by Parent free and clear of any Encumbrances, other than Permitted Encumbrances.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Real Property; Leasehold</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. Parent does not own any real property.&nbsp;&nbsp;Parent has made available to the Company (a) an accurate and complete list of all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or occupied or leased by Parent, and (b) copies of all leases under which any such real property is possessed, occupied or leased (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Real Estate Leases</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), each of which is in full force and effect, with no existing material default thereunder.&nbsp;&nbsp;Parent&#x2019;s possession, occupancy, lease use and operation of each such leased property conforms to all applicable Laws in all material respects, and Parent has exclusive possession of each such leased property and leasehold interest and has not granted any occupancy rights to tenants or licensees with respect to such leased property.&nbsp;&nbsp;In addition, each such leased property is free and clear of all Encumbrances other than Permitted Encumbrances. Parent has not received any written notice of existing, pending or threatened condemnation proceedings affecting such leased property or existing, pending or threatened zoning, building code or other moratorium proceedings,</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">34</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">or similar matters which could reasonably be expected to adversely affect the ability to operate on the leased property as currently operated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Intellectual Property</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.12(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule identifies each item of Registered IP owned in whole or in part by, or exclusively licensed to, Parent (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Registered IP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), including, with respect to each registration and application: (i) the name of the applicant/registrant, (ii) the jurisdiction of application/registration, (iii) the application or registration number and (iv) any other co-owners.&nbsp;&nbsp;To the Knowledge of Parent, each of the patents and patent applications included in the Parent Registered IP properly identifies by name each and every inventor of the inventions claimed therein as determined in accordance with applicable Laws of the United States.&nbsp;&nbsp;As of the date of this Agreement, no cancellation, interference, opposition, reissue, reexamination or other proceeding of any nature (other than office actions or similar communications issued by any Governmental Body in the ordinary course of prosecution of any pending applications for registration) is pending, threatened in writing, or, to the Knowledge of Parent, threatened, in which the scope, validity, enforceability or ownership of any Parent Registered IP is being or has been contested or challenged.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, Parent owns all right, title and interest in and to all Parent IP (other than as disclosed on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.12(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule), free and clear of all Encumbrances other than Permitted Encumbrances.&nbsp;&nbsp;To the Knowledge of Parent, each Parent Associate involved in the creation or development of any Parent IP, pursuant to such Parent Associate&#x2019;s activities on behalf of Parent, has signed a written agreement containing an assignment of such Parent Associate&#x2019;s rights in such Parent IP to Parent and confidentiality provisions protecting the Parent IP.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of Parent, no funding, facilities or personnel of any Governmental Body or any university, college, research institute or other educational institution has been used to create Parent IP, except for any such funding or use of facilities or personnel that does not result in such Governmental Body or institution obtaining ownership rights to such Parent IP or the right to receive royalties for the practice of such Parent IP.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.12(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of Parent Disclosure Schedule sets forth each agreement pursuant to which Parent (i) is granted a license (including a covenant not to sue) under, or other right or interest in any Intellectual Property Right owned by any third party (each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent In-bound License</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) or (ii) grants to any third party a license (including a covenant not to sue) under, or any other right or interest in any Parent IP or material Intellectual Property Right licensed to Parent&nbsp;&nbsp;under a Parent In-bound License (each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Out-bound License</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) (provided, that, Parent In-bound Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, services agreements, clinical trial agreements, licenses ancillary to the purchase of reagents or other materials, non-disclosure agreements, commercially available Software-as-a-Service offerings or off-the-shelf software licenses; and Parent Out-bound Licenses shall not include, when entered into in the Ordinary Course of Business, material transfer agreements, clinical trial agreements and services agreements that grant non-exclusive licenses solely for the purpose of conducting activities for Parent, non-disclosure agreements).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of Parent: (i) the operation of the business of Parent as currently conducted does not infringe, misappropriate or otherwise violate any valid and enforceable Registered IP or any other Intellectual Property Right owned by any other Person and (ii) no other Person is infringing, misappropriating or otherwise violating any Parent IP or any Intellectual Property Rights</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">35</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">exclusively licensed to Parent.&nbsp;&nbsp;As of the date of this Agreement, no Legal Proceeding is pending or threatened in writing (or, to the Knowledge of Parent, is threatened) (A) against Parent alleging that the operation of the business of Parent infringes or constitutes the misappropriation or other violation of any Intellectual Property Rights of another Person or (B) by Parent alleging that another Person has infringed, misappropriated or otherwise violated any of Parent IP or any Intellectual Property Rights exclusively licensed to Parent.&nbsp;&nbsp;Since January 1, 2017, Parent has not received any written notice or other written communication alleging that the operation of the business of Parent infringes or constitutes the misappropriation or other violation of any Intellectual Property Right of another Person.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of Parent IP or, to the Knowledge of Parent, any Intellectual Property Rights exclusively licensed to Parent is subject to any pending or outstanding injunction, directive, order, judgment or other disposition of dispute that restricts the use, transfer, registration or licensing by Parent of any such Parent IP or Intellectual Property Rights exclusively licensed to Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of Parent, the operation of Parent&#x2019;s business are in material compliance with all Laws pertaining to data privacy and data security of Sensitive Data.&nbsp;&nbsp;To the Knowledge of Parent, since January 1, 2017, there have been (i) no losses or thefts of data or security breaches relating to Sensitive Data used in the business of Parent, (ii) no violations of any security policy of Parent regarding any such Sensitive Data used in the business of Parent, (iii) no unauthorized access, unauthorized use or unintended or improper disclosure of any Sensitive Data used in the business of Parent. Parent has, and to its Knowledge, each of its service providers that has access to Sensitive Data in connection with conducting services for Parent has, taken reasonable actions and implemented policies and procedures that are reasonably appropriate to protect and maintain the security of all Sensitive Data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Agreements, Contracts and Commitments</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.13</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule lists the following Parent Contract in effect as of the date of this Agreement other than any Parent Benefit Plan (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Material Contract</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; and collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Material Contracts</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;):</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a material contract as defined in Item 601(b)(10) of Regulation S-K as promulgated under the Securities Act;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Contract containing (i) any covenant limiting the freedom of Parent to engage in any line of business or compete with any Person, (ii) any most-favored pricing arrangement or similar term by which any Person is or could become entitled to any benefit, right or privilege that must be at least as favorable to such Person as those offered to another Person, (iii) any exclusivity provision, right of first refusal or right of first negotiation or similar covenant, or (iv) any non-solicitation provision, in each case, other than restrictions or limitations that do not or would not materially affect the ability of Parent to conduct its business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Contract relating to the disposition or acquisition of material assets outside of the Ordinary Course of Business and requiring payments after the date of this Agreement in excess of $100,000 or any ownership interest in any Entity;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">36</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit (whether as debtor or creditor)&nbsp;&nbsp;or creating any material Encumbrances with respect to any assets of Parent or any advancement or loan of money or equipment or other debt obligations to any employee or independent contractor, other than advancement of expenses in the Ordinary Course of Business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (i) any distribution agreement (identifying any that contain exclusivity provisions); (ii) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Parent; (iii) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Parent has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent has continuing obligations to develop any Intellectual Property Rights that will not be owned, in whole or in part, by Parent; or (iv) any Contract to license or engage any third party to manufacture or produce any product, drug substance, service or technology of Parent, any Contract for raw materials or warehousing of products or any Contract to sell, distribute or commercialize any products or service of Parent;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Parent in connection with the Contemplated Transactions;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Parent Real Estate Lease;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Contract with any Governmental Body;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Parent Out-bound License and Parent In-bound License;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent, or obligation to pay any royalties, fees or other payments to any owner, licensor or other claimant to any Intellectual Property Rights;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each Parent Contract, offer letter, employment agreement, or independent contractor agreement with any employee or service provider (other than documents that can be obtained on the SEC&#x2019;s website at www.sec.gov) that (i) is not immediately terminable at will by Parent without notice, severance, or other cost or liability, or (ii) provides for retention payments, change of control payments, severance, accelerated vesting, an exercise period of more than three months following a termination of service or any payment or benefit that may or will become due as a result of the Merger; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any other Contract that is not terminable at will (with no penalty or payment) by Parent, and (i) which involves payment or receipt by Parent after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate, or (ii) that is material to the business or operations of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto.&nbsp;&nbsp;There are no Parent Material Contracts that are not in written form.&nbsp;&nbsp;Parent has not, nor to Parent&#x2019;s Knowledge, as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">37</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract.&nbsp;&nbsp;As to Parent, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions.&nbsp;&nbsp;As of the date of this Agreement, no Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract, and no Person has indicated in writing to Parent that it desires to renegotiate, modify, not renew or cancel any Parent Material Contract.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Compliance; Permits</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent is, and since January 1, 2016 has been, in compliance in all material respects with all applicable Laws, including the FDCA, the FDA regulations adopted thereunder and any other similar Law administered or promulgated by the FDA or other Drug Regulatory Agency, except for any noncompliance, either individually or in the aggregate, which would not be material to Parent.&nbsp;&nbsp;No investigation, claim, suit, proceeding, audit or other action by any Governmental Body is pending or, to the Knowledge of Parent, threatened in writing against Parent.&nbsp;&nbsp;There is no agreement, judgment, injunction, order or decree binding upon Parent which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent, any acquisition of material property by Parent or the conduct of business by Parent as currently conducted, (ii) would be reasonably likely to have an adverse effect on Parent&#x2019;s ability to comply with or perform any covenant or obligation under this Agreement, or (iii) would be reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent holds all required Governmental Authorizations which are material to the operation of the business of Parent as currently conducted (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Permits</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.14(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule identifies each Parent Permit.&nbsp;&nbsp;Parent is in compliance with the terms of the Parent Permits.&nbsp;&nbsp;No Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, limit, suspend, or materially modify any Parent Permit.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no proceedings pending or, to the Knowledge of Parent, threatened with respect to an alleged violation by Parent of the FDCA, FDA regulations adopted thereunder or any other similar Law administered or promulgated by any Drug Regulatory Agency.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Parent, or in which Parent or its respective current products or product candidates have participated, were and, if still pending, are being conducted in all material respects in accordance with standard medical and scientific research procedures and in compliance in all material respects with the applicable regulations of any applicable Drug Regulatory Agency and other applicable Law, including 21 C.F.R. Parts 50, 54, 56, 58 and 312.&nbsp;&nbsp;No preclinical or clinical trial conducted by or on behalf of Parent has been terminated or suspended prior to completion for safety or non-compliance reasons.&nbsp;&nbsp;Since January 1, 2016, Parent has not received any notices, correspondence, or other communications from any Drug Regulatory Agency requiring or threatening to initiate the termination or suspension of any clinical studies conducted by or on behalf of, or sponsored by, Parent or in which Parent or its current products or product candidates have participated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent is not the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its businesses or products by the FDA pursuant to its &#x201C;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#x201D; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto.&nbsp;&nbsp;To the Knowledge of Parent, Parent has not committed any acts, made any statement, or has not failed to make any statement, in each case in respect of its business or products that would violate the FDA&#x2019;s &#x201C;Fraud, Untrue Statements of Material Facts,</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">38</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Bribery, and Illegal Gratuities&#x201D; Final Policy, and any amendments thereto.&nbsp;&nbsp;Neither Parent nor any of its officers, employees or, to the Knowledge of the Company, agents has been convicted of any crime or engaged in any conduct that could result in a debarment or exclusion (i) under 21 U.S.C. Section 335a or (ii) any similar applicable Law.&nbsp;&nbsp;No debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or, to the Knowledge of Parent, threatened against Parent, or any of its officers, employees or, to the Knowledge of Parent, agents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent has complied with all Laws relating to patient, medical or individual health information, including HIPAA, including the standards for the privacy of Individually Identifiable Health Information at 45 C.F.R. Parts 160 and 164, Subparts A and E, the standards for the protection of Electronic Protected Health Information set forth at 45 C.F.R. Part 160 and 45 C.F.R. Part 164, Subpart A and Subpart C, the standards for transactions and code sets used in electronic transactions at 45 C.F.R. Part 160, Subpart A and Part 162, and the standards for Breach Notification for Unsecured Protected Health Information at 45 C.F.R. Part 164, Subpart D, all as amended from time to time.&nbsp; Parent has entered into, where required, and is in compliance in all material respects with the terms of all Business Associate Agreements to which Parent is a party or otherwise bound.&nbsp; Parent has created and maintained written policies and procedures to protect the privacy of all protected health information, provide training to all employees and agents as required under HIPAA, and has implemented security procedures, including physical, technical and administrative safeguards, to protect all personal information and Protected Health Information stored or transmitted in electronic form.&nbsp; Parent has not received written notice from the Office for Civil Rights for the U.S. Department of Health and Human Services or any other Governmental Body of any allegation regarding its failure to comply with HIPAA or any other state law or regulation applicable to the protection of individually identifiable health information or personally identifiable information.&nbsp; No successful Security Incident, Breach of Unsecured Protected Health Information or breach of personally identifiable information under applicable state or federal laws have occurred with respect to information maintained or transmitted to Parent or an agent or third party subject to a Business Associate Agreement with Parent.&nbsp; Parent is currently submitting, receiving and handling or is capable of submitting receiving and handling transactions in accordance with the Standard Transaction Rule.&nbsp; All capitalized terms in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.14(f)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> not otherwise defined in this Agreement shall have the meanings set forth under HIPAA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Legal Proceedings; Orders</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.15(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, as of the date of this Agreement, there is no material pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves (A) Parent, (B) any Parent Associate (in his or her capacity as such) or (C) any of the material assets owned or used by Parent; or (ii) that challenges, or that would have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.15(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, since January 1, 2016 through the date of this Agreement, no Legal Proceeding has been pending against Parent that resulted in material liability to Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no order, writ, injunction, judgment or decree to which Parent, or any of the material assets owned or used by Parent, is subject.&nbsp;&nbsp;To the Knowledge of Parent, no officer or employee of Parent is subject to any order, writ, injunction, judgment or decree that prohibits such officer or employee from engaging in or continuing any conduct, activity or practice relating to the business of Parent or to any material assets owned or used by Parent.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">39</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Tax Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent and Merger Sub have timely filed all income Tax Returns and other material Tax Returns, other than Tax Returns subject to a valid extension granted in the ordinary course of business, that they were required to file under applicable Law.&nbsp;&nbsp;All such Tax Returns are correct and complete in all material respects and have been prepared in compliance with all applicable Law.&nbsp;&nbsp;No claim has ever been made by any Governmental Body in any jurisdiction where Parent or Merger Sub does not file a particular Tax Return or pay a particular Tax that Parent or Merger Sub is subject to taxation by that jurisdiction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All income and other material Taxes due and owing by Parent or Merger Sub on or before the date hereof (whether or not shown on any Tax Return) have been fully paid.&nbsp;&nbsp;The unpaid Taxes of Parent Merger Sub did not, as of the date of the Parent Balance Sheet, materially exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax items) set forth on the face of the Parent Balance Sheet.&nbsp;&nbsp;Since the Parent Balance Sheet Date, neither Parent nor Merger Sub has incurred any material Liability for Taxes outside the Ordinary Course of Business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Taxes that Parent or Merger Sub are or was required by Law to withhold or collect have been duly and timely withheld or collected in all material respects on behalf of its respective employees, independent contractors, stockholders, lenders, customers or other third parties and, have been timely paid to the proper Governmental Body or other Person or properly set aside in accounts for this purpose.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no Encumbrances for material Taxes (other than Permitted Encumbrances) upon any of the assets of Parent or Merger Sub.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No deficiencies for income or other material Taxes with respect to Parent or Merger Sub have been claimed, proposed or assessed by any Governmental Body in writing.&nbsp;&nbsp;There are no pending or ongoing, and to the Knowledge of Parent, threatened audits, assessments or other actions for or relating to any liability in respect of a material amount of Taxes of Parent or Merger Sub.&nbsp;&nbsp;Neither Parent nor Merger Sub (or any of their predecessors) has waived any statute of limitations in respect of any income or other material Taxes or agreed to any extension of time with respect to any income or other material Tax assessment or deficiency.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent has not been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Parent nor Merger Sub is a party to any Tax allocation agreement, Tax sharing agreement, Tax indemnity agreement, or similar agreement or arrangement, other than customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Parent nor Merger Sub will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any Tax period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of accounting for Tax purposes; (ii) use of an improper method of accounting for a Tax period ending on or prior to the Closing Date; (iii) &#x201C;closing agreement&#x201D; as described in Section 7121 of the Code (or any similar provision of state, local or foreign Law) executed on or prior to the Closing Date; (iv) intercompany transaction or excess loss account described in Treasury Regulations under Section 1502 of the Code (or any similar</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">40</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">provision of state, local or foreign Law); (v) installment sale or open transaction disposition made on or prior to the Closing Date; (vi) prepaid amount received or deferred revenue accrued on or prior to the Closing Date; or (vii) election under Section 108(i) of the Code (or any similar provision of state, local or foreign Law).&nbsp;&nbsp;Parent has not made any election under Section 965(h) of the Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Parent nor Merger Sub has ever been (i) a member of a consolidated, combined or unitary Tax group (other than such a group the common parent of which is Parent) or (ii) a party to any joint venture, partnership, or other arrangement that is treated as a partnership for U.S. federal income Tax purposes.&nbsp;&nbsp;Neither Parent nor Merger Sub has any Liability for any material Taxes of any Person (other than Parent and Merger Sub) under Treasury Regulations Section 1.1502-6 (or any similar provision of state, local, or foreign Law), or as a transferee or successor.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Parent nor Merger Sub has, since January 1, 2017, distributed stock of another Person, or had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section 355 of the Code or Section 361 of the Code (or any similar provisions of state, local or foreign Law).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Parent nor Merger Sub (i) is a &#x201C;controlled foreign corporation&#x201D; as defined in Section 957 of the Code; (ii) is a &#x201C;passive foreign investment company&#x201D; within the meaning of Section 1297 of the Code; or (iii) has ever had a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise had an office or fixed place of business in a country other than the country in which it is organized.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Parent nor Merger Sub has participated in or been a party to a transaction that, as of the date of this Agreement, constitutes a &#x201C;listed transaction&#x201D; that is required to be reported to the IRS pursuant to Section 6011 of the Code and applicable Treasury Regulations thereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">For purposes of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.16</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, each reference to Parent or any of its Subsidiaries shall be deemed to include any Person that was liquidated into, merged with, or is otherwise a predecessor to, Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Employee and Labor Matters; Benefit Plans</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.17(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule is a list of all material Parent Benefit Plans, including, without limitation, each Parent Benefit Plan that provides for retirement, change in control, stay or retention deferred compensation, incentive compensation, severance or retiree medical or life insurance benefits.&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Benefit Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means each (i) &#x201C;employee benefit plan&#x201D; as defined in Section 3(3) of ERISA and (ii) other pension, retirement, deferred compensation, excess benefit, profit sharing, bonus, incentive, equity or equity-based, phantom equity, employment (other than at-will employment offer letters on Parent&#x2019;s standard form, other than individual Parent Options or other compensatory equity award agreements made pursuant to Parent&#x2019;s standard forms, in which case only representative standard forms of such agreements shall be scheduled and other than consulting agreements that may be terminated with 30 days or less days of notice), consulting, severance, change-of-control, retention, health, life, disability, group insurance, paid-time off, holiday, welfare and fringe benefit plan, program, agreement, contract, or arrangement (whether written or unwritten, qualified or nonqualified, funded or unfunded and including any that have been frozen), in any case, maintained, contributed to, or required to be contributed to, by Parent or Parent ERISA Affiliates for the benefit of any current or former employee, director, officer or independent contractor of Parent or under which Parent has any actual or contingent liability (including, without limitation, as to the result of it being treated as a single employer under Code Section 414 with any other person).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">41</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As applicable with respect to each material Parent Benefit Plan, Parent has made available to the Company, true and complete copies of (i) each material Parent Benefit Plan, including all amendments thereto, and in the case of an unwritten material Parent Benefit Plan, a written description thereof, (ii) all current trust documents, investment management contracts, custodial agreements, administrative services agreements and insurance and annuity contracts relating thereto, (iii) the current summary plan description and each summary of material modifications thereto, (iv) the most recently filed annual reports with any Governmental Body (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, Form 5500 and all schedules thereto), (v) the most recent IRS determination, opinion or advisory letter, (vi) the most recent summary annual reports, nondiscrimination testing reports, actuarial reports, financial statements and trustee reports, (vii) all records, notices and filings concerning IRS or Department of Labor or other Governmental Body audits or investigations, &#x201C;prohibited transactions&#x201D; within the meaning of Section 406 of ERISA or Section 4975 of the Code and (viii) all policies and procedures established to comply with the privacy and security rules of HIPAA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Parent Benefit Plan has been maintained, operated and administered in compliance in all material respects with its terms and any related documents or agreements and the applicable provisions of ERISA, the Code and all other Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Parent Benefit Plans which are &#x201C;employee pension benefit plans&#x201D; within the meaning of Section 3(2) of ERISA and which are intended to meet the qualification requirements of Section 401(a) of the Code have received determination or opinion letters from the IRS on which they may currently rely to the effect that such plans are qualified under Section 401(a) of the Code and the related trusts are exempt from federal income Taxes under Section 501(a) of the Code, respectively, and to the Knowledge of Parent nothing has occurred that would reasonably be expected to materially adversely affect the qualification of such Parent Benefit Plan or the tax exempt status of the related trust.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Parent nor any Parent ERISA Affiliate maintains, contributes to, is required to contribute to, or has any actual or contingent liability with respect to, (i) any &#x201C;employee pension benefit plan&#x201D; (within the meaning of Section 3(2) of ERISA) that is subject to Title IV or Section 302 of ERISA or Section 412 of the Code, (ii) any &#x201C;multiemployer plan&#x201D; (within the meaning of Section 3(37) of ERISA), (iii) any &#x201C;multiple employer plan&#x201D; (within the meaning of Section 413 of the Code) or (iv) any &#x201C;multiple employer welfare arrangement&#x201D; (within the meaning of Section 3(40) of ERISA).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no pending audits or investigations by any Governmental Body involving any Parent Benefit Plan, and no pending or, to the Knowledge of Parent, threatened claims (except for individual claims for benefits payable in the normal operation of the Parent Benefit Plans), suits or proceedings involving any Parent Benefit Plan, any fiduciary thereof or service provider thereto, in any case except as would not be reasonably expected to result in material liability to Parent.&nbsp;&nbsp;All contributions and premium payments required to have been made under any of the Parent Benefit Plans or by applicable Law (without regard to any waivers granted under Section 412 of the Code), have been timely made in all material respects and neither Parent nor any Parent ERISA Affiliate has any material liability for any unpaid contributions with respect to any Parent Benefit Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Parent nor any Parent ERISA Affiliates, nor to the Knowledge of Parent, any fiduciary, trustee or administrator of any Parent Benefit Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transaction with respect to any Parent Benefit Plan which would subject any such Parent Benefit Plan, Parent or Parent ERISA Affiliates to a material Tax, material penalty or material liability for a &#x201C;prohibited transaction&#x201D; under Section 406 of ERISA or Section 4975 of the Code.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">42</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Parent Benefit Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service or retirement other than coverage mandated by Law and neither Parent nor any Parent ERISA Affiliates has made a written or oral representation promising the same.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.17(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, neither the execution of this Agreement, nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) will: (i)&nbsp;result in any payment becoming due to any current or former employee, director, officer, or independent contractor of Parent, (ii) increase any amount of compensation or benefits otherwise payable under any Parent Benefit Plan, (iii) result in the acceleration of the time of payment, funding or vesting of any benefits under any Parent Benefit Plan, (iv) require any contribution or payment to fund any obligation under any Parent Benefit Plan or (v)&nbsp;limit the right to merge, amend or terminate any Parent Benefit Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.17(j)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, neither the execution of this Agreement, nor the consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) will result in the receipt or retention by any person who is a &#x201C;disqualified individual&#x201D; (within the meaning of Code Section 280G) with respect to Parent of any payment or benefit that is or could be characterized as a &#x201C;parachute payment&#x201D; (within the meaning of Code Section 280G), determined without regard to the application of Code Section 280G(b)(5).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The exercise price of each Parent Option is not and never has been and can never be less than the fair market value of one share of Company Common Stock as of the grant date of such Company Option.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Parent Benefit Plan or other agreement, arrangement, practice or program providing for deferred compensation that constitutes a &#x201C;nonqualified deferred compensation plan&#x201D; (as defined in Section 409A(d)(1) of the Code and the regulations promulgated thereunder) is, and has been, established, administered and maintained in compliance with the requirements of Section 409A of the Code and the regulations promulgated thereunder in all material respects.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No current or former employee, officer, director, independent contractor or other service provider of Parent has any &#x201C;gross up&#x201D; agreements with Parent or other right or assurance of reimbursement by Parent or any of its Subsidiaries for any Taxes imposed under Code Section 409A or Code Section 4999.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent does not maintain any employee benefit plan outside of the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent has provided to the Company a true and correct list, as of the date of this Agreement, containing the names of all current full-time, part-time or temporary employees and independent contractors (and indication as such), and, as applicable: (i) the annualized rates of all compensation (including wages, salary or fees, commissions, director&#x2019;s fees, fringe benefits, bonuses, profit sharing payments, and other payments or benefits of any type) to each person is eligible to receive; (ii), dates of employment or service; (iii) title and, with respect to independent contractors, a current written description of such person&#x2019;s contracting services; (iv) any eligibility to receive severance, notice of termination, retention payment, change of control payment, or other similar compensation; (v) visa status, if applicable; and (vi) with respect to employees, a designation of whether they are classified as exempt or non-exempt for purposes of FLSA and any similar state, federal or foreign law.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">43</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent is not and never has been a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other Contract with a labor union, labor organization, or similar Person representing any of its employees, and there is no labor union, labor organization, or similar Person representing or, to the Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent, including through the filing of a petition for representation election.&nbsp;&nbsp;There is not and has not been in the past three years, nor is there or has there been in the past three years any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute, or, to the Knowledge of Parent, any union organizing activity, against Parent or any of its Subsidiaries.&nbsp;&nbsp;No event has occurred, and no condition or circumstance exists, that might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, any similar activity or dispute, or, to the Knowledge of Parent, any union organizing activity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent is, and since January 1, 2016 has been, in material compliance with all applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, harassment and retaliation, equal employment opportunities, fair employment practices, meal and rest periods, immigration, employee safety and health, payment of wages (including overtime wages), unemployment and workers&#x2019; compensation, leaves of absence, and hours of work.&nbsp;&nbsp;Except as would not be reasonably likely to result in a material liability to Parent, with respect to employees of Parent, Parent, since January 1, 2016: (i) has withheld and reported all amounts required by Law or by agreement to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees, (ii) is not liable for any arrears of wages (including overtime wages), severance pay or any Taxes or any penalty for failure to comply with any of the foregoing, and (iii) is not liable for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Body, with respect to unemployment compensation benefits, disability, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business).&nbsp;&nbsp;There are no actions, suits, claims, charges, lawsuits, investigations, audits or administrative matters pending or, to the Knowledge of Parent, threatened or reasonably anticipated against Parent relating to any employee, applicant for employment, consultant, employment agreement or Parent Benefit Plan (other than routine claims for benefits).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as would not be reasonably likely to result in a material liability to Parent, with respect to each individual who currently renders services to Parent, Parent has accurately classified each such individual as an employee, independent contractor, or otherwise under all applicable Laws and, for each individual classified as an employee, Parent has accurately classified him or her as exempt from or ineligible for overtime under all applicable Laws.&nbsp;&nbsp;Parent has no material liability with respect to any misclassification of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer, or (iii) any employee currently or formerly classified as exempt from or ineligible for overtime under all applicable Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within the preceding five years, Parent has not implemented any &#x201C;plant closing&#x201D; or &#x201C;mass layoff&#x201D; of employees that would reasonably be expected to require notification under the WARN Act or any similar state or local Law, no such &#x201C;plant closing&#x201D; or &#x201C;mass layoff&#x201D; will be implemented before the Closing Date without advance notification to and approval of Parent, and there has been no &#x201C;employment loss&#x201D; as defined by the WARN Act within the ninety (90) days prior to the Closing Date.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">44</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no Legal Proceeding, claim, unfair labor practice charge or complaint, labor dispute or grievance pending or, to the Knowledge of Parent, threatened against Parent relating to labor, employment, employment practices, or terms and conditions of employment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Environmental Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. &nbsp; Parent is and since January 1, 2015 have complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in such compliance that, either individually or in the aggregate, would not reasonably be expected to be material to Parent or its business.&nbsp;&nbsp;Parent has not received since January 1, 2015 (or prior to that time, which is pending and unresolved), any written notice or other communication (in writing or otherwise), whether from a Governmental Body or other Person, that alleges that Parent is not in compliance with or has liability pursuant to any Environmental Law and, to the Knowledge of Parent, there are no circumstances that would reasonably be expected to prevent or interfere with Parent&#x2019;s compliance in any material respects with any Environmental Law, except where such failure to comply would not reasonably be expected to be material to Parent or its business.&nbsp;&nbsp;No current or (during the time a prior property was leased or controlled by Parent) prior property leased or controlled by Parent has had a release of or exposure to Hazardous Materials in material violation of or as would reasonably be expected to result in any material liability of Parent pursuant to Environmental Law.&nbsp;&nbsp;No consent, approval or Governmental Authorization of or registration or filing with any Governmental Body is required by Environmental Laws in connection with the execution and delivery of this Agreement or the consummation of Contemplated Transactions.&nbsp;&nbsp;Prior to the date hereof, Parent has provided or otherwise made available to the Company true and correct copies of all material environmental reports, assessments, studies and audits in the possession or control of Parent with respect to any property leased or controlled by Parent or any business operated by it.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Transactions with Affiliates</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.19</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule describes any material transactions or relationships since July 25, 2017, between, on the one hand, Parent and, on the other hand, any (a) executive officer or director of Parent or, to the Knowledge of Parent, any of such executive officer&#x2019;s or director&#x2019;s immediate family members, (b) any investment funds that are affiliated with such executive officer or director or (c) to the Knowledge of Parent, any &#x201C;related person&#x201D; (within the meaning of Item 404 of Regulation S-K under the Securities Act) of any such officer, director or owner (other than Parent) in each of the case of (a), (b) or (c) that is of the type that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act.&nbsp;&nbsp;Parent is not indebted to any director, officer or employee of Parent (except for amounts due as salaries and bonuses, other amounts due under employment agreements, retention agreements or employee benefit plans and amounts payable in reimbursement of expenses), and no such director, officer or employee is indebted to Parent.&nbsp;&nbsp;Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement or as disclosed in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3.19</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, since the date of Parent&#x2019;s last proxy statement filed in 2018 with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Insurance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Parent has delivered or made available to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent.&nbsp;&nbsp;Each of such insurance policies is in full force and effect and Parent is in compliance in all material respects with the terms thereof.&nbsp;&nbsp;Other than customary end of policy notifications from insurance carriers, since January 1, 2016, Parent has not received any notice or other communication regarding any actual or possible: (a) cancellation or invalidation of any insurance policy; or (b) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy.&nbsp;&nbsp;Parent has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding that is currently pending against Parent for which Parent has insurance coverage, and no such carrier has issued a denial of</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">45</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent of its intent to do so.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">No Financial Advisors</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;3.21</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage fee, finder&#x2019;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Anti-Bribery</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Neither Parent nor any of its directors, officers, employees or, to Parent&#x2019;s Knowledge, agents or any other Person acting on its behalf has directly or indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political contributions, or other payments, in the form of cash, gifts, or otherwise, or taken any other action, in violation of Anti-Bribery Laws.&nbsp;&nbsp;Parent is not and has not been the subject of any investigation or inquiry by any Governmental Body with respect to potential violations of Anti-Bribery Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Valid Issuance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Parent Common Stock to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, have been duly authorized and be validly issued, fully paid and nonassessable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Opinion of Financial Advisor</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Parent Board has received an opinion of Ladenburg Thalmann &amp; Co. Inc. to the effect that, as of the date of this Agreement and subject to the assumptions, qualifications, limitations and other matters set forth therein, the Consideration is fair, from a financial point of view, to the holders of Parent Common Stock.&nbsp;&nbsp;It is agreed and understood that such opinion is for the benefit of the Parent Board and may not be relied upon by the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Disclosure; Parent Information</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; The information relating to Parent to be contained in the Registration Statement will not, on the date the Registration Statement is filed with the SEC, at any time it is amended or supplemented, or at the time it becomes effective under the Securities Act, contain any untrue statement of any material fact, or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not false or misleading at the time and in light of the circumstances under which such statement is made.&nbsp;&nbsp;The information in the Proxy Statement relating to Parent will not, on the date the Proxy Statement is first mailed to Parent Stockholders or at the time of the Parent Stockholders&#x2019; Meeting, contain any untrue statement of any material fact, or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not false or misleading at the time and in light of the circumstances under which such statement is made.&nbsp; Notwithstanding the foregoing, no representation is made by Parent or Merger Sub with respect to the information that has been or will be supplied by the Company, any of its Subsidiaries or any of their respective Representatives for inclusion in the Registration Statement or Proxy Statement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Disclaimer of Other Representations or Warranties</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as previously set forth in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or in any certificate delivered by Parent or Merger Sub to the Company pursuant to this Agreement, neither Parent nor Merger Sub makes any representation or warranty, express or implied, at law or in equity, with respect to it or any of its assets, liabilities or operations, and any such other representations or warranties are hereby expressly disclaimed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of Parent and Merger Sub acknowledges and agrees that, except for the representations and warranties of the Company set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, none of Parent, Merger Sub or any of their respective Representatives is relying on any other representation or warranty of the Company</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">46</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">or any other Person made outside of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, including regarding the accuracy or completeness of any such other representations or warranties or the omission of any material information, whether express or implied, in each case, with respect to the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CERTAIN COVENANTS OF THE PARTIES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Operation of Parent&#x2019;s Business</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.1(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, as expressly permitted by this Agreement (including any Permitted Disposition or Parent Financing), as required by applicable Law or unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and the Effective Time (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Pre-Closing Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;): each of Parent and Merger Sub shall conduct its business and operations in the Ordinary Course of Business and in compliance in all material respects with all applicable Laws and the requirements of all Contracts that constitute Parent Material Contracts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except (i) as expressly permitted by this Agreement (including any Permitted Disposition or Parent Financing, in either case, that has been approved in writing by the Company (such approval not to be unreasonably withheld, conditioned or delayed)), (ii) as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.1(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, (iii) as required by applicable Law or (iv) with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit Merger Sub to, do any of the following:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except in connection with the payment of the exercise price and/or withholding Taxes incurred upon the exercise, settlement or vesting of any award granted under the Parent Stock Plan in accordance with the terms of such award in effect on the date of this Agreement);</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sell, issue, grant, pledge, accelerate the vesting of (as applicable), or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any capital stock or other security of Parent (except for Parent Common Stock issued upon the valid exercise of outstanding Parent Options or Parent Warrants); (B) any option, warrant or right to acquire any capital stock or any other security; or (C) any instrument convertible into or exchangeable for any capital stock or other security of Parent;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split, liquidation, dissolution or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;form any Subsidiary or acquire any equity interest, business or other interest in any other Entity, or enter into a joint venture with any other Entity or enter into a new line of business;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">47</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) lend or advance money to any Person (except for the advancement of expenses to employees, directors and consultants in the Ordinary Course of Business), (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others, (D) forgive or discharge in whole or in part any outstanding loans or advances, or prepay any indebtedness for borrowed money or (E) make any capital expenditure or commitment in excess of the budgeted capital expenditure and commitment amounts set forth in the Parent operating budget delivered to the Company concurrently with the execution of this Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Budget</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;);</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other than as required by applicable Law or the terms of any Parent Benefit Plan as in effect on the date of this Agreement: (A) adopt, terminate, establish or enter into any Parent Benefit Plan or increase costs under existing Parent Benefit Plans; (B) cause or permit any Parent Benefit Plan to be amended in any material respect; (C) issue, deliver, grant or sell or authorize or propose the issuance, delivery, grant or sale of any equity interests; (D) pay any bonus (including any transaction-related bonus or other similar success fee) or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, benefits or other compensation or remuneration payable to, any of its directors, officers or employees; (E) increase the severance or change of control benefits offered to any current or new employees, directors or consultants; (F) hire, terminate or give notice of termination to any (x) officer or (y) employee, other than a termination for cause; or (G) accelerate the vesting or extend the exercise period for outstanding equity awards.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognize any labor union, labor organization, work council or similar Person except as otherwise required by law and after using reasonable efforts to provide advance notice to the Company;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acquire any material asset or business or sell, lease or otherwise irrevocably dispose of any of its material assets or properties, or grant any Encumbrance with respect to such assets or properties;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sell, assign, transfer, license, sublicense, abandon or otherwise dispose of any Parent IP or any Intellectual Property Rights exclusively licensed to Parent or its Subsidiaries;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;make, change or revoke any material Tax election, fail to pay any income or other material Tax as such Tax becomes due and payable, file any amendment making any material change to any Tax Return, settle or compromise any income or other material Tax liability, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than six months), or adopt or change any material accounting method in respect of Taxes;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;enter into, materially amend or terminate any Parent Material Contract;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except as otherwise set forth in the Parent Budget, make any expenditures, incur any Liabilities or discharge or satisfy any Liabilities, in each case, in an</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">48</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">amount that exceeds the Parent Budget by $25,000 individually or that exceeds the aggregate amount of the Parent Budget by $50,000;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other than as required by Law or GAAP, take any action to change accounting policies or procedures;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;initiate or settle any Legal Proceeding; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;agree, resolve, offer or commit to do any of the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the Effective Time.&nbsp;&nbsp;Prior to the Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Operation of the Company&#x2019;s Business</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> &nbsp;.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule, as expressly permitted by this Agreement (including the Pre-Closing Financing), as required by applicable Law or unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, conditioned or delayed), during the Pre-Closing Period: each of the Company and its Subsidiaries shall conduct its business and operations in the Ordinary Course of Business and in compliance in all material respects with all applicable Laws and the requirements of all Contracts that constitute Company Material Contracts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except (i) as expressly permitted by this Agreement (including the Pre-Closing Financing), (ii) as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule, (iii) as required by applicable Law or (iv) with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company);</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sell, issue, grant, pledge, accelerate the vesting of (as applicable) or otherwise dispose of or encumber or authorize any of the foregoing with respect to: (A) any capital stock or other security of the Company or any of its Subsidiaries (except for shares of outstanding Company Common Stock issued upon the valid exercise of Company Options); (B) any option, warrant or right to acquire any capital stock or any other security, other than option grants to employees and service providers in the Ordinary Course of Business; or (C) any instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries&#x2019; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split, liquidation, dissolution or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">49</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;form any Subsidiary or acquire any equity interest, business or other interest in any other Entity or enter into a joint venture with any other Entity or enter into a new line of business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) lend or advance money to any Person (except for the advancement of expenses to employees, directors and consultants in the Ordinary Course of Business), (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others, (D) forgive or discharge in whole or in part any outstanding loans or advances, or prepay any indebtedness for borrowed money, or (E) make any capital expenditure or commitment in excess of the budgeted capital expenditure and commitment amounts set forth in the Company operating budget delivered to Parent concurrently with the execution of this Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Budget</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;);</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other than as required by applicable Law or the terms of any Company Benefit Plan as in effect on the date of this Agreement: (A) adopt, terminate, establish or enter into any Company Benefit Plan; (B) cause or permit any Company Benefit Plan to be amended in any material respect; (C) pay any bonus (including any transaction-related bonus or other similar success fee) or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, benefits or other compensation or remuneration payable to, any of its directors, officers or employees, other than increases in base salary and annual cash bonus opportunities and payments made in the Ordinary Course of Business consistent with past practice; (D) increase the severance or change of control benefits offered to any current or new employees, directors or consultants or (E) terminate or give notice of termination to any officer, other than any termination for cause;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognize any labor union, labor organization, work council or similar Person except as otherwise required by law and after using reasonable efforts to provide advance notice to Parent;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acquire any material asset or business or sell, lease or otherwise irrevocably dispose of any of its material assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sell, assign, transfer, license, sublicense or otherwise dispose of any Company IP or any Intellectual Property Rights exclusively licensed to the Company or its Subsidiaries (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;make, change or revoke any material Tax election, fail to pay any income or other material Tax as such Tax becomes due and payable, file any amendment making any material change to any Tax Return, settle or compromise any income or other material Tax liability, enter into any Tax allocation, sharing, indemnification or other similar agreement or arrangement (other than customary commercial contracts entered into in the Ordinary Course of Business the principal subject matter of which is not Taxes), request or consent to any extension or waiver of any limitation period with respect to any claim or assessment for any income or other material Taxes (other than pursuant to an extension of time to file any Tax Return granted in the Ordinary Course of Business of not more than six months), or adopt or change any material accounting method in respect of Taxes;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;enter into any Company Material Contract outside the Ordinary Course of Business, or materially amend or terminate any Company Material Contract;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">50</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except as otherwise set forth in the Company Budget, make any expenditures, incur any Liabilities or discharge or satisfy any Liabilities, in each case, in amounts that exceed the aggregate amount of the Company Budget by $50,000;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other than as required by Law or GAAP, take any action to change accounting policies or procedures;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;initiate or settle any Legal Proceeding; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;agree, resolve, offer or commit to do any of the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the Effective Time.&nbsp;&nbsp;Prior to the Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Access and Investigation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#x2019;s Representatives to: (i) provide the other Party and such other Party&#x2019;s Representatives with reasonable access during normal business hours to such Party&#x2019;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries; (ii) provide the other Party and such other Party&#x2019;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request; (iii) permit the other Party&#x2019;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#x2019;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary or appropriate and; (iv) make available to the other Party copies of unaudited financial statements, material operating and financial reports prepared for senior management or the board of directors of such Party, and any material notice, report or other document filed with or sent to or received from any Governmental Body in connection with the Contemplated Transactions.&nbsp;&nbsp;Any investigation conducted by either Parent or the Company pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.3(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, any Party may restrict the foregoing access to the extent that (i) any Law applicable to such Party requires such Party to restrict or prohibit access to any such properties or information, (ii) the consent of a third party is required to provide such access to any such properties or information, or (iii) as may be necessary in the reasonable good faith judgment of such Party to preserve the attorney-client privilege under any circumstances in which such privilege may be jeopardized by such disclosure or access; provided, that&nbsp;such Party shall use its commercially reasonable efforts to (A)&nbsp;obtain the required consent of any such third party to provide access to such properties or information, (B)&nbsp;develop an alternative to providing access to such properties or information so as to address such matters that is reasonably acceptable to Parent and the Company and (C) implement appropriate and mutually agreeable measures to permit the disclosure of such information in a manner to remove the basis for the objection, including by arrangement of appropriate clean room procedures, redaction or entry into a customary joint defense agreement with respect to any information to</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">51</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">be so provided, if the Parties determine that doing so would reasonably permit the disclosure of such information without violating applicable Law or jeopardizing such attorney-client privilege.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Parent Non-Solicitation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent agrees that, during the Pre-Closing Period, it shall not, and shall not authorize any of its Representatives to, directly or indirectly: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) furnish any non-public information regarding Parent to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv) approve, endorse or recommend any Acquisition Proposal (subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">); (v) execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction (other than a confidentiality agreement permitted under this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.4(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">); or (vi) publicly propose to do any of the foregoing;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;"> provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that, notwithstanding anything contained in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and subject to compliance with this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, prior to obtaining the Required Parent Stockholder Vote, Parent may, directly or indirectly through any of its Representatives, furnish non-public information regarding Parent to, and enter into discussions or negotiations with, any Person in response to a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">bona fide</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> Acquisition Proposal by such Person, which the Parent Board determines in good faith, after consultation with Parent&#x2019;s outside financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) neither Parent nor any of its Representatives shall have breached this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> in any material respect, (B) the Parent Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action is reasonably likely to be inconsistent with the fiduciary duties of the Parent Board under applicable Law; (C) at least two (2) Business Days prior to furnishing such nonpublic confidential information to, or entering into discussions with, such Person, Parent gives the Company written notice of the identity of such Person and of Parent&#x2019;s intention to furnish nonpublic information to, or enter into discussions with, such Person; (D) prior to furnishing any information, Parent receives from such Person an executed confidentiality agreement containing provisions, in the aggregate, at least as favorable to Parent as those contained in the Confidentiality Agreement; and (E) at least two Business Days prior to furnishing any such nonpublic information to such Person, Parent furnishes such nonpublic information to the Company (to the extent such information has not been previously furnished by Parent to the Company).&nbsp;&nbsp;Without limiting the generality of the foregoing, Parent acknowledges and agrees that, in the event any Representative of Parent (whether or not such Representative is purporting to act on behalf of Parent) takes any action that, if taken by Parent, would constitute a breach of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the taking of such action by such Representative shall be deemed to constitute a breach of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> by Parent for purposes of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If Parent or any Representative of Parent receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then Parent shall promptly (and in no event later than one Business Day after Parent becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the Company orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the material terms thereof).&nbsp;&nbsp;Parent shall keep the Company reasonably informed in all material respects with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or proposed material modification thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">52</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Acquisition Inquiry as of the date of this Agreement and promptly request the destruction or return of any nonpublic information of Parent provided to such Person.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Company Non-Solicitation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of its Representatives to, directly or indirectly: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) furnish any non-public information regarding the Company or any of its Subsidiaries to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv) approve, endorse or recommend any Acquisition Proposal; (v) execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction; or (vi) publicly propose to do any of the foregoing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;"> provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that, notwithstanding anything contained in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and subject to compliance with this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, prior to obtaining the Required Company Stockholder Vote, the Company may, directly or indirectly through any of its Representatives, furnish non-public information regarding Company to, and enter into discussions or negotiations with, any Person in response to a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">bona fide</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> Acquisition Proposal by such Person, which the Company Board determines in good faith, after consultation with the Company&#x2019;s outside financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) neither Company nor any of its Representatives shall have breached this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> in any material respect, (B) the Company Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action is reasonably likely to be inconsistent with the fiduciary duties of the Company Board under applicable Law; (C) at least two (2) Business Days prior to furnishing such nonpublic confidential information to, or entering into discussions with, such Person, the Company gives Parent written notice of the identity of such Person and of the Company&#x2019;s intention to furnish nonpublic information to, or enter into discussions with, such Person; (D) prior to furnishing any information, the Company receives from such Person an executed confidentiality agreement containing provisions, in the aggregate, at least as favorable to the Company as those contained in the Confidentiality Agreement; and (E) contemporaneously with furnishing any such nonpublic information to such Person, the Company furnishes such nonpublic information to Parent (to the extent such information has not been previously furnished by the Company to Parent).&nbsp;&nbsp;Without limiting the generality of the foregoing, the Company acknowledges and agrees that, in the event any Representative of the Company (whether or not such Representative is purporting to act on behalf of the Company) takes any action that, if taken by the Company, would constitute a breach of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the taking of such action by such Representative shall be deemed to constitute a breach of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> by the Company for purposes of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company or any Representative of the Company receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then the Company shall promptly (and in no event later than one Business Day after the Company becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise Parent orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the material terms thereof).&nbsp;&nbsp;The Company shall keep Parent reasonably informed in all material respects with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or proposed material modification thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">53</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Proposal or Acquisition Inquiry as of the date of this Agreement and promptly request the destruction or return of any nonpublic information of the Company or any of its Subsidiaries provided to such Person.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Notification of Certain Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the Pre-Closing Period, the Company shall promptly notify Parent (and, if in writing, furnish copies of) if any of the following occurs: (i) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions; (ii) any Legal Proceeding against or involving or otherwise affecting the Company or its Subsidiaries is commenced, or, to the Knowledge of the Company, threatened against the Company or its Subsidiaries or, to the Knowledge of the Company, any director or officer of the Company or its Subsidiaries; (iii) the Company becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv) the failure of the Company to comply with any covenant or obligation of the Company; in the case of (iii) and (iv) that would reasonably be expected to make the timely satisfaction of any of the conditions set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, as applicable, impossible or materially less likely.&nbsp;&nbsp;No notification given to Parent pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.6(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations of the Company or any of its Subsidiaries contained in this Agreement or the Company Disclosure Schedule for purposes of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, as applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the Pre-Closing Period, Parent shall promptly notify the Company (and, if in writing, furnish copies of) if any of the following occurs: (i) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions; (ii) any Legal Proceeding against or involving or otherwise affecting Parent is commenced, or, to the Knowledge of Parent, threatened against Parent or, to the Knowledge of Parent, any director or officer of Parent; (iii) Parent becomes aware of any inaccuracy in any representation or warranty made by it in this Agreement; or (iv) the failure of Parent to comply with any covenant or obligation of Parent or Merger Sub; in the case of (iii) and (iv) that would reasonably be expected to make the timely satisfaction of any of the conditions set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, as applicable, impossible or materially less likely.&nbsp;&nbsp;No notification given to the Company pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.6(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations of Parent contained in this Agreement or the Parent Disclosure Schedule for purposes of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, as applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADDITIONAL AGREEMENTS OF THE PARTIES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Registration Statement; Proxy Statement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As promptly as practicable after the date of this Agreement (but in no event later than the later of (i) 30 days following the date of this Agreement and (ii) five business days after Parent&#x2019;s receipt of the Company&#x2019;s Audited Financial Statements pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.21</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">), the Parties shall prepare, and Parent shall cause to be filed with the SEC, the Registration Statement, in which the Proxy Statement will be included as a prospectus.&nbsp;&nbsp;The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Proxy Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Proxy Statement, prior to the filing thereof with the SEC.&nbsp;&nbsp;Each of the Parties shall use commercially reasonable efforts to cause the Registration Statement and the Proxy Statement to comply with the applicable rules and regulations promulgated by the SEC in all material respects, to respond promptly to any comments of the SEC or its staff and to have the Registration Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC.&nbsp;&nbsp;As soon as reasonably practicable following the date of this Agreement, Parent shall establish a record date for, duly</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">54</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">call, give notice of and, as soon as reasonably practicable thereafter in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, convene the Parent Stockholders&#x2019; Meeting. Each of the Parties shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#x2019;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act.&nbsp;&nbsp;Each Party shall promptly furnish to the other Party all information concerning such Party and such Party&#x2019;s Affiliates and such Party&#x2019;s stockholders that may be required or reasonably requested in connection with any action contemplated by this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;If Parent, Merger Sub or the Company become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in filing such amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to Parent&#x2019;s stockholders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shall reasonably cooperate with Parent and provide, and require its Representatives to provide, Parent and its Representatives, with all true, correct and complete information regarding the Company or its Subsidiaries that is required by Law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement.&nbsp;&nbsp;Without limiting the foregoing, each Party will use commercially reasonable efforts to cause to be delivered to the other Party a consent letter of such Party&#x2019;s independent accounting firm, dated no more than two Business Days before the date on which the Registration Statement becomes effective (and reasonably satisfactory in form and substance to the other Party), that is customary in scope and substance for consent letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Company Information Statement; Stockholder Written Consent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly after the Registration Statement shall have been declared effective under the Securities Act, and in any event no later than five Business Days thereafter, the Company shall prepare, with the cooperation of Parent, and cause to be mailed to its stockholders an information statement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Information Statement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) to solicit (i) the Required Company Stockholder Vote pursuant to Section 228 of the DGCL: (A) adopting and approving this Agreement and the Contemplated Transactions, and (B) approving the Preferred Stock Conversion and the Stock Split (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Stockholder Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), and (ii) to the extent that the Convertible Note Conversion has not already been effected, the Required Company Stockholder Vote with respect to the Convertible Note Conversion adopting and approving the Convertible Note Conversion in accordance with the Stockholders&#x2019; Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Series A Stockholder Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp; The Information Statement and any other&nbsp;&nbsp;materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.2(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall be subject to Parent&#x2019;s advance review and reasonable approval, which approval shall not be unreasonably withheld, conditioned or delayed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company covenants and agrees that the Information Statement, including any pro forma financial statements included therein (and the letter to stockholders and form of Company Stockholder Written Consent included therewith), will not, at the time that the Information Statement or any amendment or supplement thereto is first mailed to the stockholders of the Company, and at the time of receipt of the Required Company Stockholder Vote, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.&nbsp;&nbsp;Notwithstanding the foregoing, the Company makes no covenant, representation or warranty with respect to statements made in the Information Statement or incorporated by reference from the Registration Statement (and the letter to the stockholders and form of Company Stockholder Written Consent included therewith), if any, based on information furnished in writing by Parent specifically for inclusion therein.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">55</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Each of the Parties shall use commercially reasonable efforts to cause the Information Statement to comply with the applicable rules and regulations promulgated by the SEC in all material respects.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly following receipt of the Required Company Stockholder Vote, the Company shall prepare and mail a notice (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Stockholder Notice</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) to every stockholder of the Company that did not execute the Company Stockholder Written Consent.&nbsp;&nbsp;The Stockholder Notice shall (i) provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions and (ii) include a notice of appraisal rights of the Company&#x2019;s stockholders under Section 262 of the DGCL, containing such r information as is required thereunder and pursuant to applicable Law.&nbsp;&nbsp;The Stockholder Notice (including any amendments thereto) submitted to the stockholders of the Company in accordance with this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.2(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall be subject to Parent&#x2019;s advance review and reasonable approval, which approval shall not be unreasonably withheld, conditioned or delayed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees that, subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.2(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">: (i) the Company Board shall recommend that the Company&#x2019;s stockholders vote to approve the Company Stockholder Matters and shall use its reasonable best efforts to solicit such approval from each of the Company Signatories within the time set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.2(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (the recommendation of the Company Board that the Company&#x2019;s stockholders vote to adopt and approve this Agreement being referred to as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Board Recommendation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;); and (ii) the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (ii), collectively, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Board Adverse Recommendation Change</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary contained in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.2(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and subject to compliance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, if at any time prior to receipt of the Required Company Stockholder Vote:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Company has received a written Acquisition Proposal (which Acquisition Proposal did not arise out of a material breach of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">) from any Person that has not been withdrawn and after consultation with outside legal counsel, the Company Board shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer, the Company Board may make a Company Board Adverse Recommendation Change, if and only if: (A) the Company Board determines in good faith, after consultation with the Company&#x2019;s outside legal counsel, that the failure to do so would&nbsp;&nbsp;be inconsistent with the fiduciary duties of the Company Board to the Company&#x2019;s stockholders under applicable Law; (B) the Company shall have given Parent prior written notice of its intention to consider making a Company Board Adverse Recommendation Change at least four Business Days prior to making any such Company Board Adverse Recommendation Change (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Determination Notice</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) (which notice shall not constitute a Company Board Adverse Recommendation Change); and (C) (1) the Company shall have provided to Parent a summary of the material terms and conditions of the Acquisition Proposal in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.5(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, (2) the Company shall have given Parent the four Business Days after delivery of the Company Determination Notice to propose revisions to the terms of this Agreement or make another proposal and shall have made its Representatives reasonably available to negotiate in good faith with Parent (to the extent Parent desires to negotiate) with respect to such proposed revisions or other proposal, if any, and (3) after considering the results of any such negotiations and giving effect to the proposals made by</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">56</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent, if any, after consultation with outside legal counsel, the Company Board shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer and that the failure to make the Company Board Adverse Recommendation Change would be inconsistent with  the fiduciary duties of the Company Board to the Company&#x2019;s stockholders under applicable Law.&nbsp;&nbsp;For the avoidance of doubt, the provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.2(e)(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall also apply to any material change to the facts and circumstances relating to such Acquisition Proposal and require a new Company Determination Notice, except that the references to four Business Days shall be deemed to be three Business Days.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other than in connection with an Acquisition Proposal, the Company Board may make a Company Board Adverse Recommendation Change in response to a Company Change in Circumstance, if and only if: (A) the Company Board determines in good faith, after consultation with the Company&#x2019;s outside legal counsel, that the failure to do so would&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;be inconsistent with the fiduciary duties of the Company Board to the Company&#x2019;s stockholders under applicable Law; (B) the Company shall have given Parent a Company Determination Notice at least four Business Days prior to making any such Company Board Adverse Recommendation Change; and (C) (1) the Company shall have specified the Company Change in Circumstance in reasonable detail, (2) the Company shall have given Parent the four Business Days after delivery of the Company Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with Parent with respect to such proposed revisions or other proposal, if any, and (3) after considering the results of any such negotiations and giving effect to the proposals made by Parent, if any, after consultation with outside legal counsel, the Company Board shall have determined, in good faith, that the failure to make the Company Board Adverse Recommendation Change in response to such Company Change in Circumstance would be inconsistent with the fiduciary duties of the Company Board to the Company&#x2019;s stockholders under applicable Law.&nbsp;&nbsp;For the avoidance of doubt, the provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.2(e)(ii)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall also apply to any material change to the facts and circumstances relating to such Company Change in Circumstance and require a new Company Determination Notice, except that the references to four Business Days shall be deemed to be three Business Days.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#x2019;s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.2(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.2(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or by any withdrawal or modification of the Company Board Recommendation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Parent Stockholders&#x2019; Meeting</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly after the Registration Statement has been declared effective by the SEC under the Securities Act, Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock for the purpose of seeking approval of the following (the matters contemplated by the clauses 5.3(a)(i) &#x2013; (iii) below are referred to as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Stockholder Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; and such meeting, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Stockholders&#x2019; Meeting</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;):</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the amendment of Parent&#x2019;s certificate of incorporation to effect the Reverse Split;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the amendment of Parent&#x2019;s certificate of incorporation to effect the name change of Parent; and</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">57</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the issuance of Parent Common Stock to the Company&#x2019;s stockholders pursuant to this Agreement and the change of control of Parent resulting from the Merger pursuant to Nasdaq rules.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Parent Stockholders&#x2019; Meeting shall be held as promptly as practicable after the Registration Statement is declared effective under the Securities Act.&nbsp;&nbsp;Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholders&#x2019; Meeting are solicited in compliance with all applicable Law.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholders&#x2019; Meeting, or a date preceding the date on which the Parent Stockholders&#x2019; Meeting is scheduled, Parent reasonably believes that (i) it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present or (ii) it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholders&#x2019; Meeting, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholders&#x2019; Meeting as long as the date of the Parent Stockholders&#x2019; Meeting is not postponed or adjourned more than an aggregate of 30 calendar days in connection with any postponements or adjournments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent agrees that, subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.3(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">: &nbsp;(i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters and use reasonable best efforts to solicit such approval, (ii) the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#x2019;s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board with respect to the Parent Stockholder Matters being referred to as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Board Recommendation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;); and (iii) the Parent Board Recommendation shall not be withheld, amended, withdrawn or modified (and the Parent Board shall not publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company (failure by Parent to take the actions set forth in the foregoing clauses (i), &nbsp;(ii) and/or (iii), collectively, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Board Adverse Recommendation Change</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary contained in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and subject to compliance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, if at any time prior to the approval of Parent Stockholder Matters by the Required Parent Stockholder Vote:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent has received a written Acquisition Proposal (which Acquisition Proposal did not arise out of a material breach of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">) from any Person that has not been withdrawn and after consultation with outside legal counsel, the Parent Board shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer, the Parent Board may make a Parent Board Adverse Recommendation Change, if and only if: (A)&nbsp;the Parent Board determines in good faith, after consultation with Parent&#x2019;s outside legal counsel, that the failure to do so would&nbsp; be inconsistent with the fiduciary duties of the Parent Board to Parent&#x2019;s stockholders under applicable Law; (B)&nbsp;Parent shall have given the Company prior written notice of its intention to consider making a Parent Board Adverse Recommendation Change at least four Business Days prior to making any such Parent Board Adverse Recommendation Change (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Determination Notice</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) (which notice shall not constitute a Parent Board Adverse Recommendation Change); and (C)&nbsp;(1)&nbsp;Parent shall have provided to the Company a summary of the material terms and conditions of the Acquisition Proposal in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.4(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, (2)&nbsp;Parent shall have given the Company the four Business Days after delivery of the Parent Determination Notice to propose revisions to the terms of this Agreement or make another proposal and shall have made its Representatives reasonably available to negotiate in good faith with the Company (to the extent the Company desires to negotiate) with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">58</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">and giving effect to the proposals made by the Company, if any, after consultation with outside legal counsel, the Parent Board shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer and that the failure to make the Parent Board Adverse Recommendation Change would be inconsistent with the fiduciary duties of the Parent Board to Parent&#x2019;s stockholders under applicable Law.&nbsp;&nbsp;For the avoidance of doubt, the provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3(d)(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall also apply to any material change to the facts and circumstances relating to such Acquisition Proposal and require a new Parent Determination Notice, except that the references to four Business Days shall be deemed to be three Business Days.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than in connection with an Acquisition Proposal, the Parent Board may make a Parent Board Adverse Recommendation Change in response to a Parent Change in Circumstance, if and only if: (A)&nbsp;the Parent Board determines in good faith, after consultation with Parent&#x2019;s outside legal counsel, that the failure to do so would  be inconsistent with the fiduciary duties of the Parent Board to Parent&#x2019;s stockholders under applicable Law; (B)&nbsp;Parent shall have given the Company a Parent Determination Notice at least four Business Days prior to making any such Parent Board Adverse Recommendation Change; and (C)&nbsp;(1)&nbsp;Parent shall have specified the Parent Change in Circumstance in reasonable detail, (2)&nbsp;Parent shall have given the Company the four Business Days after delivery of the Parent Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably available to negotiate in good faith with the Company with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals made by the Company, if any, after consultation with outside legal counsel, the Parent Board shall have determined, in good faith, that the failure to make the Parent Board Adverse Recommendation Change in response to such Parent Change in Circumstance would be inconsistent with the fiduciary duties of the Parent Board to Parent&#x2019;s stockholders under applicable Law.&nbsp;&nbsp;For the avoidance of doubt, the provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3(d)(ii)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall also apply to any material change to the facts and circumstances relating to such Parent Change in Circumstance and require a new Parent Determination Notice, except that the references to four Business Days shall be deemed to be three Business Days.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent&#x2019;s obligation to call, give notice of and hold the Parent Stockholders&#x2019; Meeting to approve the Parent Stockholder Matters in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or by any withdrawal or modification of the Parent Board Recommendation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i) complying with Rules 14d-9 and 14e-2(a) promulgated under the Exchange Act, (ii) issuing a &#x201C;stop, look and listen&#x201D; communication or similar communication of the type contemplated by Section 14d-9(f) under the Exchange Act or (iii) otherwise making any disclosure to Parent&#x2019;s stockholders if the Parent Board determines in good faith, after consultation with its outside legal counsel, that the failure to make such disclosure would be inconsistent with its fiduciary duties to Parent&#x2019;s stockholders under applicable Law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Regulatory Approvals</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall (i) consult and cooperate with one another, and consider in good faith the views of one another, in connection with any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals made or submitted by or on behalf of any Party in connection with proceedings under or relating to the HSR Act or any foreign or other antitrust Law, (ii)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">59</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">coordinate with one another in preparing and exchanging such materials and (iii) promptly provide one another (and its counsel) with copies of all filings, presentations or submissions made by such Party to any Governmental Body in connection with this Agreement.&nbsp;&nbsp;In addition, any Party may, as it deems advisable and necessary, reasonably designate any confidential and competitively sensitive material provided to the other parties under this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> as &#x201C;Outside Counsel Only&#x201D; or redact information regarding valuation or negotiation strategy.&nbsp;&nbsp;Materials identified as &#x201C;Outside Counsel Only&#x201D; and the information contained therein shall be given only to the outside legal counsel of the recipient and will not be disclosed by such outside counsel to employees, officers, or directors of the recipient, unless express written permission is obtained in advance from the source of the materials.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of Parent and the Company shall use its respective commercially reasonable efforts to resolve objections, if any, as may be asserted by any Governmental Body with respect to the Contemplated Transactions under any applicable antitrust Laws, including responding promptly to and complying with any requests for information relating to this Agreement or any initial filings required under the HSR Act and any other additional filings from any Governmental Body charged with enforcing, applying, administering or investigating any antitrust Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary herein (i) Parent shall not have any obligation to litigate or contest any such Legal Proceeding or order resulting therefrom and (ii) Parent shall be under no obligation to make proposals, execute or carry out agreements or submit to orders providing for (A) the sale, license, divestiture, or other disposition or holding separate of any assets of Parent or the Company or any of their respective Affiliates, (B) the imposition of any limitation or restriction on the ability of Parent or any of its Affiliates to freely conduct their business or, following the Closing, the business of the Company, or (C) any limitation or regulation on the ability of Parent or any of its Affiliates to exercise full rights of ownership of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Company Options, Parent Options and Parent Warrants</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Effective Time, each Company Option that is outstanding and unexercised immediately prior to the Effective Time under the Company Plan, whether or not vested, shall be converted into and become an option to purchase Parent Common Stock, and Parent shall assume the Company Plan and each such Company Option in accordance with the terms (as in effect as of the date of this Agreement) of the Company Plan and the terms of the stock option agreement by which such Company Option is evidenced.&nbsp;&nbsp;All rights with respect to Company Common Stock under Company Options assumed by Parent shall thereupon be converted into rights with respect to Parent Common Stock.&nbsp;&nbsp;Accordingly, from and after the Effective Time: (i) each Company Option assumed by Parent may be exercised solely for shares of Parent Common Stock; (ii) the number of shares of Parent Common Stock subject to each Company Option assumed by Parent shall be determined by multiplying (A) the number of shares of Company Common Stock that were subject to such Company Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Parent Common Stock; (iii) the per share exercise price for the Parent Common Stock issuable upon exercise of each Company Option assumed by Parent shall be determined by dividing (A) the per share exercise price of Company Common Stock subject to such Company Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent; and (iv) any restriction on the exercise of any Company Option assumed by Parent shall continue in full force and effect and the term, exercisability, vesting schedule and other provisions of such Company Option shall otherwise remain unchanged; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided, however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that: (A) to the extent provided under the terms of the stock option agreement by which the Company Options are evidenced and the Company Plan, such Company Option may be amended as necessary to reflect Parent&#x2019;s substitution of the Company Options with options to purchase Parent Common Stock (such as by making any change in control or similar definition relate to</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">60</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent and having any provision that provides for the adjustment of Company Options upon the occurrence of certain corporate events relate to corporate events that relate to Parent and/or Parent Common Stock), subject to the Company&#x2019;s consent, which shall not be unreasonably withheld, conditioned or delayed; and (B) the Parent Board or a committee thereof shall succeed to the authority and responsibility of the Company Board or any committee thereof with respect to each Company Option assumed by Parent.&nbsp;&nbsp;Notwithstanding anything to the contrary in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or any other provision of this Agreement, (i) the conversion of each Company Option which is an "incentive stock option" (within the meaning of Section 422(b) of the Code) into an option to purchase shares of Parent Common Stock shall be made in a manner which complies with all of the requirements of Treasury Regulation Section 1.424-1(a) so that such conversion does not constitute a "modification" of the Company Option within the meaning of Treasury Regulation Section 1.424-1(e), and (ii) the conversion of each Company Option which is not an "incentive stock option" into an option to purchase shares of Parent Common Stock shall be made in a manner which complies with all of the requirements of Treasury Regulation Section 1.409A-1(b)(5)(v)(D) so that such conversion does not constitute the grant of a new option for purposes of Section 409A of the Code and the regulations thereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent shall file with the SEC, promptly, but in any event not later than ten Business Days after the Effective Time, a registration statement on Form S-8 (or any successor form), relating to the shares of Parent Common Stock issuable with respect to Company Options assumed by Parent in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.5(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the Effective Time, the Company shall take all actions that may be necessary (under the Company Plan and otherwise) to effectuate the provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and to ensure that, from and after the Effective Time, holders of Company Options have no rights with respect thereto other than those specifically provided in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that each unexpired, unexercised and unvested Parent Option shall be accelerated in full effective as of immediately prior to the Effective Time.&nbsp; Effective as of the Effective Time, each outstanding and unexercised Parent Option having an exercise price per share less than the Parent Closing Price shall be entitled to receive a number of shares of Parent Common Stock calculated by dividing (a) the product of (i) the total number of shares of Parent Common Stock previously subject to such Parent Option, and (ii) the excess of the Parent Closing Price over the exercise price per share of the Parent Common Stock previously subject to such Parent Option by (b) the Parent Closing Price.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the tax withholding obligations for each holder receiving shares of Parent Common Stock in accordance with the preceding sentence shall be satisfied by Parent withholding from issuance that number of shares of Parent Common Stock calculated by multiplying the maximum statutory withholding rate for such holder in connection with such issuance by the number of shares of parent Common Stock to be issued in accordance with the preceding sentence, and rounding up to the nearest whole share.&nbsp;&nbsp;Each outstanding and unexercised Parent Option that has an exercise price equal to or greater than the Parent Closing Price shall be terminated and cease to exist as of immediately prior to the Effective Time for no consideration.&nbsp;&nbsp;Prior to the Effective time, Parent shall take all actions that may be necessary (under the Parent Stock Plans and otherwise, including, if it deems it necessary or desirable, adopting and approving amendments to the existing underlying grant agreements) to effectuate the provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and to ensure that, from and after the Effective Time, holders of Parent Options have no rights with respect thereto other than those specifically provided in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Effective Time, each Parent Warrant that is outstanding and unexercised immediately prior to the Effective Time, shall survive the Closing and remain outstanding in accordance with its terms.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">61</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Employee Benefits</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following the Closing, the Company Benefit Plans shall remain in full force and effect and shall not be terminated or discontinued in connection with or following the Closing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> are for the sole benefit of Parent and the Company and no provision of this Agreement shall (i) create any third-party beneficiary or other rights in any Person, including rights in respect of any benefits that may be provided, directly or indirectly, under any Company Benefit Plan or Parent Benefit Plan or rights to continued employment or service with the Company or Parent (or any Subsidiary thereof) or (ii) be treated as an amendment to or other modification to any Company Benefit Plan or Parent Benefit Plan, or shall limit the right of Parent to amend, terminate or otherwise modify any such plans following the Closing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Indemnification of Officers and Directors</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, each of Parent and the Surviving Corporation shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director, officer, fiduciary or agent of Parent or the Company and their respective Subsidiaries, respectively (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">D&amp;O Indemnified Parties</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#x2019; fees and disbursements (collectively, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Costs</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director, officer, fiduciary or agent of Parent or of the Company or their respective Subsidiaries, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest extent permitted under applicable Law.&nbsp;&nbsp;Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Corporation, jointly and severally, upon receipt by Parent or the Surviving Corporation from the D&amp;O Indemnified Party of a request therefor; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of Parent&#x2019;s Organizational Documents with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Parent that are presently set forth in the certificate of incorporation and bylaws of Parent shall not be amended, modified or repealed for a period of six years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Parent.&nbsp;&nbsp;The certificate of incorporation and bylaws of the Surviving Corporation shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Corporation to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From and after the Effective Time, (i) the Surviving Corporation shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#x2019;s Organizational Documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii) Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">62</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">under Parent&#x2019;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From and after the Effective Time, Parent shall maintain directors&#x2019; and officers&#x2019; liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent.&nbsp;&nbsp;In addition, prior to the Effective Time, Parent and the Company shall make equal payments to the applicable insurers &nbsp;in full satisfaction of the premium for a six-year prepaid &#x201C;tail policy&#x201D; for the non-cancellable extension of the directors&#x2019; and officers&#x2019; liability coverage of Parent&#x2019;s existing directors&#x2019; and officers&#x2019; insurance policies for a claims reporting or discovery period of at least six years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">D&amp;O Tail Policy</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;). &nbsp;Parent and the Company shall pay their respective portions of the premium for the D&amp;O Tail Policy within five Business Days of Parent&#x2019;s delivery of a written request for the Company&#x2019;s portion of the payment to be made.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From and after the Effective Time, Parent shall pay all expenses, including reasonable attorneys&#x2019; fees, that are incurred by the persons referred to in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> in connection with their successful enforcement of the rights provided to such persons in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event Parent or the Surviving Corporation or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Corporation, as the case may be, shall succeed to the obligations set forth in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Parent shall cause the Surviving Corporation to perform all of the obligations of the Surviving Corporation under this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> are intended to be for the benefit of, and shall be enforceable by each officer and director entitled to indemnification under this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, his or her heirs and his or her representatives and are in addition to, and not in substitution for, any other rights to indemnification or contribution that any such Person may have by contract or otherwise.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Additional Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Parties shall use commercially reasonable efforts to cause to be taken all actions necessary to consummate the Contemplated Transactions.&nbsp;&nbsp;Without limiting the generality of the foregoing, each Party: (a) shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions; (b) shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract (with respect to Contracts set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Schedule 5.8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">) to remain in full force and effect; (c) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions; and (d) shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Disclosure</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The initial press release relating to this Agreement shall be a joint press release issued by the Company and Parent and thereafter Parent and the Company shall consult with</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">63</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">each other before issuing any further press release(s) or otherwise making any public statement or making any announcement to Parent Associates or Company Associates (to the extent not previously issued or made in accordance with this Agreement) with respect to the Contemplated Transactions and shall not issue any such press release, public statement or announcement to Parent Associates or Company Associates without the other Party&#x2019;s written consent (which shall not be unreasonably withheld, conditioned or delayed).&nbsp;&nbsp;Notwithstanding the foregoing: (a)&nbsp;each Party may, without such consultation or consent, make any public statement in response to questions from the press, analysts, investors or those attending industry conferences, make internal announcements to employees and make disclosures in Parent SEC Documents, so long as such statements are consistent with previous press releases, public disclosures or public statements made jointly by the Parties (or individually, if approved by the other Parties); (b)&nbsp;a Party may, without the prior consent of the other Parties but subject to giving advance notice to the other Party, issue any such press release or make any such public announcement or statement as may be required by any Law; and (c)&nbsp;a Party need not consult with the other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or with respect to any Acquisition Proposal, Parent Board Adverse Recommendation Change or Company Board Adverse Recommendation, as applicable, or with respect to Parent only, pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.3(f)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Listing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Parent shall use its commercially reasonable efforts to (a) to maintain its existing listing on Nasdaq until the effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b) to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance); (c) effect the Reverse Split; and (d) to the extent required by Nasdaq Marketplace Rule 5110, file an initial listing application for the Parent Common Stock on Nasdaq (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Nasdaq Listing Application</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the Effective Time.&nbsp;&nbsp;The Parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations.&nbsp;&nbsp;Each Party will promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its representatives.&nbsp;&nbsp;The Company and Parent each agree to pay fifty percent (50%) of all Nasdaq fees associated with the Nasdaq Listing Application (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Nasdaq Fees</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;). The Company will cooperate with Parent as reasonably requested by Parent with respect to the Nasdaq Listing Application and promptly furnish to Parent all information concerning the Company and its stockholders that may be required or reasonably requested in connection with any action contemplated by this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.10</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Tax Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For United States federal income Tax purposes, (i) the Parties intend that the Merger qualify as either a tax-free contribution pursuant to Section 351 of the Code or a &#x201C;reorganization&#x201D; within the meaning of Section 368(a) of the Code (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Intended Tax Treatment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), and (ii) this Agreement is intended to be, and is hereby adopted as, a &#x201C;plan of reorganization&#x201D; for purposes of Section 354 and 361 of the Code and Treasury Regulations Section 1.368-2(g) and 1.368-3(a), to which Parent, Merger Sub and the Company are parties under Section 368(b) of the Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Parties shall use their respective reasonable best efforts to cause the Merger to qualify, and will not take any action or cause any action to be taken which action would reasonably be expected to prevent the Merger from qualifying, for the Intended Tax Treatment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of Parent and Company shall use its commercially reasonable efforts to deliver to Honigman LLP (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Tax Counsel</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Tax Counsel</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), as applicable, &#x201C;Tax Representation Letters,&#x201D; dated as of the</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">64</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Closing Date and the date of the opinions of Parent Tax Counsel and Company Tax Counsel described in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.11(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and signed by an officer of Parent and Company, respectively, containing representations of Parent and Merger Sub or Company, as applicable, in each case, as shall be reasonably necessary or appropriate to enable Company Tax Counsel to render the opinion described in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.11(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and Parent Tax Counsel and Company Tax Counsel to render the opinions described in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.11(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shall use its commercially reasonable efforts to obtain a tax opinion of Company Tax Counsel dated as of the Closing and issued to the Company to the effect that the Merger shall qualify for the Intended Tax Treatment. In rendering its opinion, Company Tax Counsel may require and rely upon (and may incorporate by reference) reasonable and customary representations and covenants, including the applicable Tax Representation Letters described in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.11(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of this Agreement from Parent and Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of Parent and the Company shall use commercially reasonable efforts to obtain an opinion of Parent Tax Counsel and Company Tax Counsel, respectively, satisfying the requirements of Item 601 of Regulation&nbsp;S-K&nbsp;under the Securities Act (i) dated as of a date as reasonably requested by Parent and Company, as applicable, prior to the Registration Statement being declared effective, and (ii) satisfying the requirements of Item 601 of Regulation&nbsp;S-K&nbsp;under the Securities Act.&nbsp;&nbsp;In rendering their respective opinions in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.11(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the Tax Counsels may require and rely upon (and may incorporate by reference) reasonable and customary representations and covenants, including the applicable Tax Representation Letters described in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.11(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Legends</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent Common Stock to be received in the Merger by equity holders of the Company who may be considered &#x201C;affiliates&#x201D; of Parent for purposes of Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for Parent Common Stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Directors and Officers</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Parties shall use commercially reasonable efforts and take all necessary action so that immediately after the Effective Time, (a) the Parent Board is composed of 6 members, with one such member to be designated by Parent, and 5 such members to be designated by the Company, &nbsp;such designees to be provided prior to the filing of the Registration Statement and (b) executive officers to be identified by the Company prior to the filing of the Registration Statement, are appointed to the applicable positions of Parent and the Surviving Corporation, in each case to serve in such positions effective as of the Effective Time until successors are duly elected or appointed and qualified in accordance with applicable Law.&nbsp;&nbsp;Prior to the Company sending the Information Statement, all members of the Parent Board and officers of Parent who will no longer be members of the Parent Board or officers of Parent shall provide executd resignation letters to be effective immediately after the Effective Time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Termination of Certain Agreements and Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company shall cause any Investor Agreements &nbsp;(including the Stockholders&#x2019; Agreement but excluding the Company Stockholder Support Agreements and Company Lock-Up Agreements) to be terminated effective as of the Effective Time, without any liability being imposed on the part of Parent or the Surviving Corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Section 16 Matters</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Prior to the Effective Time, Parent and the Company shall take all such steps as may be required (to the extent permitted under applicable Laws) to cause any acquisitions of Parent Common Stock, restricted stock awards to acquire Parent Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section 16(a) of</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">65</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Exchange Act with respect to Parent, to be exempt under Rule 16b-3 promulgated under the Exchange Act.&nbsp;&nbsp;The Company shall furnish the following information to Parent for each individual who, immediately after the Effective Time, will become subject to the reporting requirements of Section 16(a) of the Exchange Act with respect to Parent: (a) the number of shares of Company Capital Stock owned by such individual and expected to be exchanged for shares of Parent Common Stock pursuant to the Merger, and (b) the number of other derivative securities (if any) with respect to Company Capital Stock owned by such individual and expected to be converted into shares of Parent Common Stock, restricted stock awards to acquire Parent Common Stock or derivative securities with respect to Parent Common Stock in connection with the Merger.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Cooperation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Each Party shall cooperate reasonably with the other Party and shall provide the other Party with such assistance as may be reasonably requested for the purpose of facilitating the performance by each Party of its respective obligations under this Agreement and to enable the combined entity to continue to meet its obligations following the Effective Time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Allocation Certificates</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company will prepare and deliver to Parent at least five Business Days prior to the Closing Date a certificate signed by the Chief Financial Officer of the Company in a form reasonably acceptable to Parent setting forth (as of immediately prior to the Effective Time, after giving effect to the Pre-Closing Financing, Preferred Stock Conversion, Convertible Note Conversion and Stock Split) (i) each holder of Company Common Stock and Company Options; (ii) such holder&#x2019;s name and address; (iii) the number of shares of Company Common Stock held and/or underlying the Company Options as of the immediately prior to the Effective Time for each such holder and the per share exercise price of each Company Option; and (iv) the number of shares of Parent Common Stock to be issued to such holder, or to underlie any Parent Option to be issued to such holder, pursuant to this Agreement in respect of the Company Common Stock or Company Options held by such holder as of immediately prior to the Effective Time (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Allocation Certificate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent will prepare and deliver to the Company at least five Business Days prior to the Closing Date a certificate signed by the Chief Financial Officer of Parent (or, if there is no Chief Financial Officer, the principal accounting officer for Parent) in a form reasonably acceptable to the Company, setting forth, as of immediately prior to the Effective Time, the number of Parent Outstanding Shares and each component thereof (broken down by outstanding shares of Parent Common Stock, Parent Options, Parent Warrants and other relevant securities) (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Outstanding Shares Certificate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Takeover Statutes</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;If any Takeover Statute is or may become applicable to the Contemplated Transactions, each of the Company, the Company Board, Parent and the Parent Board, as applicable, shall grant such approvals and take such actions as are necessary so that the Contemplated Transactions may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such statute or regulation on the Contemplated Transactions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Stockholder Litigation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Each Party shall promptly notify the other Party in writing, and conduct and control the settlement and defense, of any stockholder litigation brought or threatened against such Party or any of its directors and officers relating to or challenging this Agreement or the consummation of the Contemplated Transactions; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> that prior to Closing, such Party shall (a) consult with the other Party with respect to any such stockholder litigation and in good faith take any comments of the other Party into account with respect to such stockholder litigation, and (b) keep the</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">66</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">other Party reasonably apprised of any material developments in connection with, any such stockholder litigation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Company Preferred Stock, Company Convertible Note Conversion and the Stock Split</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company shall take all necessary action to effect (i) the conversion of the Company Preferred Stock into Company Common Stock immediately prior to and conditioned upon the occurrence of the Effective Time (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Preferred Stock Conversion</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), (ii) the conversion of the Company Convertible Notes into Company Common Stock which shall occur not later than immediately prior to the Effective Time (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Convertible Note Conversion</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), and (iii) Stock Split.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Company Financial Statements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;As promptly as reasonably practicable following the date of this Agreement and no later than 30 days after the date of this Agreement, (i)&nbsp;the Company will furnish to Parent audited financial statements for the fiscal years ended December 31, 2017 and 2018 for inclusion in the Proxy Statement and the Registration Statement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Audited Financial Statements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) and (ii)&nbsp;the Company will furnish to Parent unaudited interim financial statements for each interim period completed prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Interim Financial Statements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp; Each of the Company Audited Financial Statements and the Company Interim Financial Statements will be suitable for inclusion in the Proxy Statement and the Registration Statement and prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on that basis will present fairly, in all material respects, the financial position and the results of operations, changes in stockholders&#x2019; equity, and cash flows of the Company as of the dates of and for the periods referred to in the Company Audited Financial Statements or the Company Interim Financial Statements, as the case may be.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Permitted Disposition</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Prior to Closing, without seeking or obtaining Company&#x2019;s prior written consent but upon reasonable prior written notice, Parent shall be permitted to sell or license, through one or more transactions, any or all of its assets related to its product candidate Gemcabene (also known as CI-1027) (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Gemcabene</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;). To the extent that any such sale or license of any such assets (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Permitted Disposition</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) results in obligations, whether contingent or otherwise, to Parent after the Closing, the terms of such sale or license shall be reasonably acceptable to the Company, in its sole discretion.&nbsp;&nbsp;The proceeds of any such Permitted Disposition shall be included in the calculation of Parent Cash Amount provided by Parent pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, beginning with the next monthly calculation required under </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12(f)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> following the consummation of the Permitted Disposition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">2019 Equity Incentive Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Parties shall use commercially reasonable efforts and take all necessary action to provide for the adoption, at the Parent Stockholders&#x2019; Meeting, of an equity incentive plan in form and substance mutually agreed to by Parent and the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable Law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Effectiveness of Registration Statement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or proceeding (or threatened proceeding by the SEC) seeking a stop order with respect to the Registration Statement that has not been withdrawn.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">67</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">No Restraints</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Body of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Stockholder Approval</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;(a) Parent shall have obtained the Required Parent Stockholder Vote with regard to the proposals in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections 5.3(a)(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">5.3(a)(iii)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, and (b) the Company shall have obtained the Required Company Stockholder Vote with regard to the Company Stockholder Matters and the Company Series A Stockholder Matters.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Listing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The shares of Parent Common Stock to be issued in the Merger pursuant to this Agreement shall have been approved for listing (subject to official notice of issuance) on Nasdaq as of the Closing, the approval of the listing of additional shares of Parent Common Stock on Nasdaq shall have been obtained, and the shares of Parent Common Stock outstanding prior to the Effective Time of the Merger shall have been continually listed on Nasdaq as of and from the date of this Agreement through the Closing Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The obligations of Parent and Merger Sub to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Accuracy of Representations</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct in all material respects as of such date).&nbsp;&nbsp;The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date, except (a) in each case, or in the aggregate, where the failure to be true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications), or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Performance of Covenants</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the Effective Time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Documents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Parent shall have received the following documents, each of which shall be in full force and effect:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">68</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i) that the conditions set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;7.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">7.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">7.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">7.6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> have been duly satisfied and (ii) that the information set forth in the Allocation Certificate delivered by the Company in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.17</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> is true and accurate in all respects as of the Closing Date;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a written resignation, in a form reasonably satisfactory to Parent, dated as of the Closing Date and effective as of the Closing, executed by each of the officers and directors of the Company who will not be an officer or director of Parent and the Surviving Corporation pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.13</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Allocation Certificate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">FIRPTA Certificate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Parent shall have received (i) an original signed statement from the Company that the Company is not, and has not been at any time during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code, a &#x201C;United States real property holding corporation,&#x201D; as defined in Section 897(c)(2) of the Code, conforming to the requirements of Treasury Regulations Section 1.1445-2(c)(3) and 1.897-2(h), and (ii) an original signed notice to be delivered to the IRS in accordance with the provisions of Treasury Regulations Section 1.897-2(h)(2), together with written authorization for Parent to deliver such notice to the IRS on behalf of the Company following the Closing, each dated as of the Closing Date, duly executed by an authorized officer of the Company, and in form and substance reasonably acceptable to Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">No Company Material Adverse Effect</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Termination of Investor Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Investor Agreements shall have been terminated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Company Lock-Up Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Parent shall have received the Company Lock-Up Agreements duly executed by each of the Company Signatories and each executive officer and director of the Company who is elected or appointed, as applicable, as an executive officer and director of Parent as of immediately following the Closing, each of which shall be in full force and effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Preferred Stock Conversion, Convertible Note Conversion and Stock Split</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company has effected the Preferred Stock Conversion, the Convertible Note Conversion and the Stock Split.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Pre-Closing Financing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Pre-Closing Financing shall have been consummated, and the Company shall have received all of the proceeds of the Pre-Closing Financing (including, for the avoidance of doubt, the minimum gross proceeds of $24,240,000) prior to the Effective Time on the terms and conditions set forth in the Subscription Agreements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">7.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Company Stockholder Written Consent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company Stockholder Written Consent evidencing the Required Company Stockholder Vote shall be in full force and effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADDITIONAL CONDITIONS PRECEDENT TO OBLIGATION OF THE COMPANY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">69</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Accuracy of Representations</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct in all material respects as of such date).&nbsp;&nbsp;The representations and warranties of Parent and Merger Sub contained in this Agreement (other than the Parent Fundamental Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications), or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Performance of Covenants</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Parent and Merger Sub shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the Effective Time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Documents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company shall have received the following documents, each of which shall be in full force and effect:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a certificate executed by the Chief Executive Officer or Chief Financial Officer of Parent confirming that the conditions set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;8.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">8.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">8.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> have been duly satisfied;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Parent Cash Schedule and a certificate executed by the Chief Financial Officer of Parent (or if there is no Chief Financial Officer, the principal accounting officer for Parent) certifying that the information set forth in the Parent Cash Schedule delivered by Parent in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> is true and accurate in all respects as of the Closing Date;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Parent Outstanding Shares Certificate; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a written resignation, in a form reasonably satisfactory to the Company, dated as of the Closing Date and effective as of the Closing, executed by each of the directors of Parent who are not to continue as directors of Parent after the Closing pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.13</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">No Parent Material Adverse Effect</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Minimum Parent Cash Amount</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Parent Cash Amount, calculated as of the Anticipated Closing Date, shall not be less than negative three million dollars (-$3,000,000).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Parent Lock-Up Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The Company shall have received the Parent Lock-Up Agreements duly executed by each of the officers and directors of Parent listed on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section A</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule, each of which shall be in full force and effect.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">70</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Board of Directors and Officers</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. Parent shall have taken all actions necessary to cause the Parent Board and the officers of Parent as of the Effective Time, to be constituted as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.13</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TERMINATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;This Agreement may be terminated prior to the Effective Time (whether before or after adoption of this Agreement by the Company&#x2019;s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent&#x2019;s stockholders, unless otherwise specified below):</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by mutual written consent of Parent and the Company;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by either Parent or the Company if the Contemplated Transactions shall not have been consummated by December 24, 2019 (subject to possible extension as provided in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">End Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;); </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that the right to terminate this Agreement under this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall not be available to the Company, on the one hand, or to Parent, on the other hand, if such Party&#x2019;s action or failure to act has been a principal cause of the failure of the Contemplated Transactions to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">further</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that, in the event that a request for additional information has been made by any Governmental Body, or in the event that the SEC has not declared effective under the Securities Act the Registration Statement by the date which is 60 days prior to the End Date, then either the Company or Parent shall be entitled to extend the End Date for an additional 60 days by written notice to the other the Party;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by either Parent or the Company if a court of competent jurisdiction or other Governmental Body shall have issued a final and nonappealable order, decree or ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by Parent if the Company Stockholder Written Consent executed by each Company Signatory shall not have been obtained within five (5) Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">,</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;"> however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that once the Company Stockholder Written Consent has been obtained, Parent may not terminate this Agreement pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by either Parent or the Company if (i) the Parent Stockholders&#x2019; Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent&#x2019;s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii) the Parent Stockholder Matters shall not have been approved at the Parent Stockholders&#x2019; Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided, however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that the right to terminate this Agreement pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall not be available to Parent if the failure to obtain the Required Parent Stockholder Vote shall have been directly caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">71</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by Parent (at any time prior to the Required Company Stockholder Vote being obtained) if a Company Triggering Event shall have occurred;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Sub or if any representation or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;8.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;8.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">further</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that if such inaccuracy in Parent&#x2019;s or Merger Sub&#x2019;s representations and warranties or breach by Parent or Merger Sub is curable by the End Date by Parent or Merger Sub, then this Agreement shall not terminate pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(h)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> as a result of such particular breach or inaccuracy until the expiration of a 15-day period commencing upon delivery of written notice from the Company to Parent or Merger Sub of such breach or inaccuracy and its intention to terminate pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1(h)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (it being understood that this Agreement shall not terminate pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1(h)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> as a result of such particular breach or inaccuracy if such breach by Parent or Merger Sub is cured prior to such termination becoming effective);</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;7.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;7.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">further</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that if such inaccuracy in the Company&#x2019;s representations and warranties or breach by the Company is curable by the End Date by the Company then this Agreement shall not terminate pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> as a result of such particular breach or inaccuracy until the expiration of a 15-day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (it being understood that this Agreement shall not terminate pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective);</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by Parent, at any time, if (i) all conditions in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections 6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> have been satisfied (other than those conditions that by their nature are to be satisfied by actions taken at the Closing), and remain so satisfied and (ii) Parent irrevocably confirms by written notice to the Company that (A) each of the conditions in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, other than the condition set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 7.9</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> has been satisfied or that Parent is willing to waive any such conditions that have not been satisfied (other than those conditions that by their nature are to be satisfied by actions taken at the Closing) and (B) it is prepared to consummate the Closing upon satisfaction of the condition set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 7.9</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> &nbsp;(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">i.e.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, consummation of the Pre-Closing Financing);</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;"> provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that this Agreement shall not terminate pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(j)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> unless the condition set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 7.9</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> has not been satisfied within fifteen (15) calendar days after delivery of the written notice from Parent to the Company pursuant to clause (ii) of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(j)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by Parent, at any time prior to the approval of the issuance of Parent Common Stock in the Merger by the Required Parent Stockholder Vote, upon Parent entering into a definitive agreement to effect a Superior Offer (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Permitted Alternative Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;);</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;"> provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">,</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;"> however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that Parent shall not enter into any Permitted Alternative Agreement unless (i) Parent shall have complied with its obligations under </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, (ii) the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">72</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Agreement would result in a breach of its fiduciary duties under applicable Law, and (iii) Parent shall concurrently pay to the Company the Company Termination Fee in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.3(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Effect of Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;In the event of the termination of this Agreement as provided in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, this Agreement shall be of no further force or effect; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that (a) this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.9</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 10</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and the definitions of the defined terms in such Sections shall survive the termination of this Agreement and shall remain in full force and effect, and (b) the termination of this Agreement and the provisions of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall not relieve any Party of any liability for common law fraud or for any Willful Breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement. For purposes of this Agreement, the term &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Willful Breach</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means a deliberate act or a deliberate failure to act, taken or not taken with the actual knowledge that such act or failure to act would result in or constitute a material breach of this Agreement, regardless of whether breaching was the object of the act or failure to act.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Expenses; Termination Fees</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.10</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;"> provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that the Company and Parent shall share equally all fees and expenses incurred in relation to the printing and filing with the SEC of the Registration Statement or Proxy Statement and any amendments and supplements thereto and paid to a financial printer or the SEC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If (i) this Agreement is terminated by (A) Parent or the Company pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or (B) the Company pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(h)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, (ii) an Acquisition Proposal with respect to Parent shall have been publicly announced or disclosed or otherwise communicated to Parent or the Parent Board after the date of this Agreement but prior to the termination of this Agreement and (iii) within twelve months after the date of such termination, Parent enters into a definitive agreement for any Subsequent Transaction or consummates any Subsequent Transaction, then Parent shall pay to the Company, upon such entry into a definitive agreement for or consummation of a Subsequent Transaction, a nonrefundable fee in an amount equal to $1,000,000 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Termination Fee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), less any amount actually paid to the Company pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.3(f)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If (i) this Agreement is terminated by (A) Parent or the Company pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or (B) Parent pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, (ii) an Acquisition Proposal with respect to the Company shall have been publicly announced or disclosed or otherwise communicated to the Company or the Company Board after the date of this Agreement but prior to the termination of this Agreement and (iii) within twelve months after the date of such termination, the Company enters into a definitive agreement for a Subsequent Transaction or consummates any Subsequent Transaction, then the Company shall pay to Parent, upon such entry into a definitive agreement for or consummation of a Subsequent Transaction, a nonrefundable fee in an amount equal to $1,000,000 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Termination Fee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), less any amount actually paid to Parent pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.3(g)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement is terminated by Parent pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(g)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, then the Company shall pay to Parent the Parent Termination Fee within ten (10) Business Days of such termination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement is terminated by the Company pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(f)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or by Parent pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(k)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, then Parent shall pay to Company the Company Termination Fee within five (5) Business Days of such termination.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">73</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If (A) this Agreement is terminated by the Company pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(h)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, or (B) the Company fails to consummate the Contemplated Transaction solely as a result of a Parent Material Adverse Effect as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 8.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (provided, that at such time all of the other conditions precedent to Parent&#x2019;s obligation to close set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections 6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> have been satisfied by the Company, are capable of being satisfied by the Company or have been waived by Parent), then Parent shall reimburse the Company for all reasonable fees and expenses incurred by the Company in connection with this Agreement and the transactions contemplated hereby, including: (i) all fees and expenses incurred in connection with the preparation, printing and filing, as applicable, of the Registration Statement or Proxy Statement (including any preliminary materials related thereto and all amendments and supplements thereto, as well as any financial statements and schedules thereto), (ii) reasonable legal and auditor fees and expenses; and (iii) all fees and expenses incurred in connection with the preparation and filing under any filing requirement of any Governmental Body applicable to this Agreement and the transactions contemplated hereby; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the fees and expenses for clauses (i) through (iii) above (collectively referred to as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Third Party Expenses</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) shall be capped at a maximum of $500,000 for such Third Party Expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If (A) this Agreement is terminated by Parent pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.1(j)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, or (B) Parent fails to consummate the Contemplated Transaction solely as a result of a Company Material Adverse Effect as set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 7.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (provided, that at such time all of the other conditions precedent to Parent&#x2019;s obligation to close set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections 6</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">8</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> have been satisfied by Parent, are capable of being satisfied by Parent or have been waived by the Company),then the Company shall reimburse Parent for all Third Party Expenses incurred by Parent up to a maximum of $500,000.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any Company Termination Fee, Parent Termination Fee or reimbursement of Third Party Expenses due under this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall be paid by wire transfer of same day funds.&nbsp;&nbsp;If a Party fails to pay when due any amount payable by it under this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, then such Party shall (i) reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred by it in connection with the collection of such overdue amount and the enforcement by such Party of its rights under this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3, and (ii) pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the Company in full) at a rate per annum equal to the &#x201C;prime rate&#x201D; (as published in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">The Wall Street Journal</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or any successor thereto) in effect on the date such overdue amount was originally required to be paid.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Parties agree that, (i) subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, payment of the Company Termination Fee shall, in the circumstances in which it is owed in accordance with the terms of this Agreement, constitute the sole and exclusive remedy of the Company following the termination of this Agreement, it being understood that in no event shall Parent be required to pay the amounts payable pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> on more than one occasion and (ii) following payment of the Company Termination Fee (A) Parent shall have no further liability to the Company in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by Parent giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (B) neither the Company nor any of its Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against Parent or Merger Sub or seek to obtain any recovery, judgment or damages of any kind against such Parties (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Parties) in connection with or arising out of this Agreement or the termination thereof, any breach by any such Parties giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (C) the Company and its Affiliates shall be precluded from any other remedy against Parent, Merger Sub and their respective Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">74</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Transactions to be consummated; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that nothing in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.3(i)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall limit the rights of the Company under </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 10.10</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or with respect to claims of common law fraud or Willful Breach of this Agreement by either Party prior to the date of termination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Parties agree that, (i) subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, payment of the Parent Termination Fee shall, in the circumstances in which it is owed in accordance with the terms of this Agreement, constitute the sole and exclusive remedy of Parent following the termination of this Agreement, it being understood that in no event shall the Company be required to pay the amounts payable pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> on more than one occasion and (ii) following payment of the Parent Termination Fee (A) the Company shall have no further liability to Parent in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the Company giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (B) neither Parent nor any of its Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against the Company or seek to obtain any recovery, judgment or damages of any kind against such Parties (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Parties) in connection with or arising out of this Agreement or the termination thereof, any breach by any such Parties giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (C) Parent and its Affiliates shall be precluded from any other remedy against the Company and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that nothing in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 9.3(j)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall limit the rights of Parent and Merger Sub under </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 10.10</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or with respect to claims of common law fraud or Willful Breach of this Agreement by either Party prior to the date of termination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Parties acknowledges that (i) the agreements contained in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> are an integral part of the Contemplated Transactions, (ii) without these agreements, the Parties would not enter into this Agreement and (iii) any amount payable pursuant to this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;9.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Company in the circumstances in which such amount is payable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section 10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS PROVISIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Non-Survival of Representations and Warranties</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;The representations and warranties of the Company, Parent and Merger Sub contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the Effective Time, and only the covenants that by their terms survive the Effective Time and this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 10</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> shall survive the Effective Time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Amendment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Sub and Parent at any time (whether before or after the adoption and approval of this Agreement by the Company&#x2019;s stockholders or before or after obtaining the Required Parent Stockholder Vote); </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that after any such approval of this Agreement by a Party&#x2019;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders.&nbsp;&nbsp;This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Sub and Parent.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">75</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Waiver</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;This Agreement and the other agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms.&nbsp;&nbsp;This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.&nbsp;&nbsp;The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by electronic transmission in .PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Applicable Law; Jurisdiction</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;This Agreement and all claims and causes of action hereunder shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws.&nbsp;&nbsp;In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;10.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party; (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;10.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of this Agreement; and (f) irrevocably and unconditionally waives the right to trial by jury.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Assignability</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that neither this Agreement nor any of a Party&#x2019;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#x2019;s prior written consent shall be void and of no effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Notices</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a) one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b) upon delivery in the case of delivery by hand, or (c) on the date delivered in the place of delivery if sent</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">76</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">by email (with a written or electronic confirmation of delivery) prior to 5:00 p.m. Eastern Time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">if to Parent or Merger Sub:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Gemphire Therapeutics Inc.<br />17199 N. Laurel Park Drive,</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Suite 401</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Livonia, MI 48152</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Attention: President<br />Email: </font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">with a copy to (which shall not constitute notice):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Honigman LLP</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">650 Trade Centre Way</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Suite 200</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Kalamazoo, MI 49002-0402<br />Attention: Phillip D. Torrence<br />Email: </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">if to the Company:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">NeuroBo Pharmaceuticals, Inc.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">177 Huntington Avenue, Suite 1700</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Boston, MA 02115</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Attn: President</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Email:&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">with a copy to (which shall not constitute notice):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.<br />One Financial Center</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Boston,&nbsp;MA&nbsp;02111<br />Attention: William T. Whelan and Marc D. Mantell<br />Email: </font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Cooperation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Each Party agrees to cooperate with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Severability</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.&nbsp;&nbsp;If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">77</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">provision, and this Agreement shall be valid and enforceable as so modified.&nbsp;&nbsp;In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.10&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Other Remedies; Specific Performance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy.&nbsp;&nbsp;The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any Party does not perform the provisions of this Agreement (including failing to take such actions as are required of it hereunder to consummate this Agreement) in accordance with its specified terms or otherwise breaches such provisions.&nbsp;&nbsp;Accordingly, the Parties acknowledge and agree that the Parties shall be entitled to an injunction, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy to which they are entitled at law or in equity.&nbsp;&nbsp;Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.&nbsp;&nbsp;Any Party seeking an injunction or injunctions to prevent breaches of this Agreement shall not be required to provide any bond or other security in connection with, any such order or injunction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.11&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">No Third Party Beneficiaries</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp;&nbsp;Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;5.7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">10.12&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Construction</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References to &#x201C;cash,&#x201D; &#x201C;dollars&#x201D; or &#x201C;$&#x201D; are to U.S. dollars.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Parties have participated jointly in the negotiating and drafting of this Agreement and agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As used in this Agreement, the words &#x201C;include&#x201D; and &#x201C;including,&#x201D; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#x201C;without limitation.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise indicated, all references in this Agreement to &#x201C;Sections,&#x201D; &#x201C;Exhibits&#x201D; and &#x201C;Schedules&#x201D; are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement, respectively.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">78</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any reference to legislation or to any provision of any legislation shall include any modification, amendment, re-enactment thereof, any legislative provision substituted therefore and all rules, regulations, and statutory instruments issued or related to such legislations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The bold-faced headings and table of contents contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Parties agree that each of the Company Disclosure Schedule and the Parent Disclosure Schedule shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in this Agreement.&nbsp;&nbsp;The disclosures in any section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule shall qualify other sections and subsections in this Agreement to the extent it is readily apparent on its face from a reading of the disclosure that such disclosure is applicable to such other sections and subsections.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of &#x201C;delivered&#x201D; or &#x201C;made available&#x201D; means, with respect to any documentation, that prior to 11:59 p.m. (Eastern Time) on the date that is two Business Days prior to the date of this Agreement (i) a copy of such material has been posted to and made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party or (ii) such material is disclosed in the Parent SEC Documents filed with the SEC at least two (2) Business Days prior to the date hereof and publicly made available on the SEC&#x2019;s Electronic Data Gathering Analysis and Retrieval system.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall upon a Saturday, Sunday, or any date on which banks in New York, New York are authorized or obligated by Law to be closed, the Party having such privilege or duty may exercise such privilege or discharge such duty on the next succeeding day which is a regular Business Day.</font>
		</p>
		<p style="margin:0pt 0pt 24pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">Remainder of page intentionally left blank</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">)</font>
		</p>
		<p style="margin:0pt 0pt 24pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">79</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">IN WITNESS WHEREOF,</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> the Parties have caused this Agreement to be executed as of the date first above written.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">/s/ STEVE GULLANS</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-left:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Steven Gullans</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-left:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Chief Executive Officer and President</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">GR MERGER SUB INC.</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">BY ITS SOLE STOCKHOLDER:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Gemphire Therapeutics Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">/s/ STEVE GULLANS</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Steven Gullans</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Chief Executive Officer and President</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">NEUROBO PHARMACEUTICALS, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">/s/ JOHN L. BROOKS III</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">John L. Brooks III</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:37.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:268.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:271.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">SIGNATURE PAGE TO</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">EXHIBIT A</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CERTAIN DEFINITIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement (including this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">):</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Acquisition Inquiry</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, with respect to a Party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other Party) that would reasonably be expected to lead to an Acquisition Proposal.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Acquisition Proposal</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Acquisition Transaction</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any transaction or series of related transactions involving:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a Party is a constituent entity; (ii) in which a Person or &#x201C;group&#x201D; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries; or (iii) in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;text-decoration:underline;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;text-decoration:underline;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that, in the case of the Company, to the extent that the Pre-Closing Financing is effected in accordance with the terms and conditions of this Agreement, the Pre-Closing Financing shall not constitute an Acquisition Transaction, and, in the case of Parent, to the extent that a Parent Financing is effected in accordance with the terms and conditions of this Agreement, the Parent Financing shall not constitute an Acquisition Transaction; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Affiliate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person.&nbsp;&nbsp;The term &#x201C;control&#x201D; (including the terms &#x201C;controlled by&#x201D; and &#x201C;under common control with&#x201D;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Business Day</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be closed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Cash and Cash Equivalents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means all (a)&nbsp;cash and cash equivalents (excluding Restricted Cash) and (b)&nbsp;marketable securities, in each case determined in accordance with GAAP, consistently applied.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Code</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Internal Revenue Code of 1986, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Affiliate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any Person that is (or at any relevant time was) under common control with the Company within the meaning of Sections 414(b), (c), (m) and (o) of the Code, and the regulations issued thereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Associate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any current or former employee, independent contractor, officer or director of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Board</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the board of directors of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Capital Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Company Common Stock and the Company Preferred Stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Change in Circumstance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means (a) a change in circumstances neither known nor reasonably foreseeable by the Company Board as of, or prior to, the date of this Agreement nor known nor reasonably foreseeable by any of the officers of the Company as of or prior to the date of this Agreement and (b) does not relate to (i) any Acquisition Proposal, (ii) any events, changes or circumstances relating to Parent, Merger Sub or any of their Subsidiaries, (iii) clearance of the Merger under any applicable antitrust Laws or (iv) the mere fact that the Company meets or exceeds any internal or analysts&#x2019; published projections, forecasts, estimates or predictions of revenue, earnings or other financial or operating metrics for any period ending on or after the date hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Common Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Common Stock, $1.000000 par value per share, of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Contract</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any Contract: (a) to which the Company or any of its Subsidiaries is a Party; (b) by which the Company or any of its Subsidiaries or any Company IP or any other asset of the Company or its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation; or (c) under which the Company or any of its Subsidiaries has or may acquire any right or interest.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Convertible Notes</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the outstanding notes convertible into Company Capital Stock set forth on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 2.5(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Company Disclosure Schedule.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company ERISA Affiliate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with the Company or any of its Subsidiaries as a single employer within the meaning of Section 414 of the Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Fundamental Representations</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the representations and warranties of the Company set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;2.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (Due Organization; Subsidiaries), </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">2.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (Authority; Binding Nature of Agreement), </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">2.6(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (Capitalization) and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">2.20</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (No Financial Advisors).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company IP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means all Intellectual Property Rights that are owned or purported to be owned by the Company or its Subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Material Adverse Effect</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any change, circumstance, condition, development, effect, event, occurrence, result or state of fact that, considered together with all other such change, circumstance, condition, development, effect, event, occurrence, result or state of fact that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, condition (financial or</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">otherwise), assets, liabilities or results of operations of the Company or its Subsidiaries or ability to consummate the Contemplated Transactions, taken as a whole; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that none of the following shall be taken into account in determining whether there has been a Company Material Adverse Effect: (a) general business or economic conditions affecting the industry in which the Company and its Subsidiaries operate, (b) acts of war, armed hostilities or terrorism, (c) changes in financial, banking or securities markets, (d) the failure by the Company to meet internal or analysts&#x2019; expectations or projections or the results of operations of the Company, (e) any clinical trial programs or studies, including any adverse data, event or outcome arising out of or relating to any such programs or studies, (f) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), (g) resulting from the announcement of this Agreement or the pendency of the Contemplated Transactions, (h) continued losses from operations or decreases in cash balances of the Company or any of its Subsidiaries, or (i) resulting from the taking of any action specifically required to be taken by this Agreement; except in each case with respect to clauses (a) through (c), to the extent they disproportionately affect the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Options</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means options or other rights to purchase shares of Company Common Stock issued by the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Triggering Event</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; shall be deemed to have occurred if: (a) the Company shall have made a Company Board Adverse Recommendation Change; (b) the Company Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal; or (c) the Company shall have entered into any letter of intent or similar document relating to any Acquisition Proposal (other than a confidentiality agreement permitted pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Unaudited Interim Balance Sheet</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the unaudited consolidated balance sheet of the Company and its consolidated Subsidiaries for the period ended March 31, 2019 provided to Parent prior to the date of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Confidentiality Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Mutual Non-Disclosure Agreement, dated as of April 17, 2019, by and between the Company and Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Consent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Consideration</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means (a) the Exchange Ratio used to determine the number of shares of Parent Common Stock to be issued to the holders of Company Common Stock as contemplated by </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and the number of Parent Options to be substituted for the Company Options to be assumed by Parent as contemplated by </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and (b) the right of the holders of Parent Common Stock as of immediately prior to the Effective Time to receive contingent cash payments pursuant to the CVR Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Contemplated Transactions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Merger, the Preferred Stock Conversion, the Convertible Note Conversion and the other transactions and actions contemplated by this Agreement, including the Reverse Split, the Stock Split and the CVR Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Contract</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, with respect to any Person, any written or oral agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, sublicense or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">DGCL</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the General Corporation Law of the State of Delaware.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> &nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Encumbrance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Enforceability Exceptions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (b) rules of law governing specific performance, injunctive relief and other equitable remedies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Entity</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any corporation (including any non-profit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Environmental Law</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any Law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">ERISA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Employee Retirement Income Security Act of 1974, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Exchange Act</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Securities Exchange Act of 1934, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Exchange Ratio</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, subject to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;1.5(h)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, the following ratio (rounded to four decimal places): the quotient obtained by dividing (a) the Company Merger Shares by (b) the Company Outstanding Shares, in which:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Aggregate Valuation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the sum of (i) the Company Valuation, plus (ii) the Parent Valuation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Allocation Percentage</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; the quotient (expressed as a percentage, with the percentage rounded to two decimal places) determined by dividing (i) the Company Valuation </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">by</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (ii) the Aggregate Valuation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Merger Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the product determined by multiplying (i) the Post-Closing Parent Shares </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">by</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (ii) the Company Allocation Percentage.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Outstanding Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the total number of shares of Company Capital Stock outstanding immediately prior to the Effective Time expressed on a fully-diluted and as-converted to Company Common Stock basis, calculated based on the treasury stock method and assuming, without limitation or duplication, (i) the exercise of all Company Options outstanding as of immediately prior to the Effective Time, (ii) the effectiveness of the Preferred Stock Conversion, the Convertible Note Conversion and the Stock Split, (iii) the Pre-Closing Financing and (iv) the issuance of shares of Company Capital Stock</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">in respect of all other outstanding options, restricted stock awards, warrants or rights to receive such shares, whether conditional or unconditional and including any outstanding options, warrants or rights triggered by or associated with the consummation of the Merger (but excluding any shares of Company Common Stock reserved for issuance other than with respect to outstanding Company Options under the Company Plan as of immediately prior to the Effective Time).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Company Valuation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the sum of (i) $94,000,000, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">plus</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (ii) the aggregate amount of gross proceeds received by the Company in the Pre-Closing Financing up to and including $50,000,000 (for the avoidance of doubt, the Company Valuation will not increase to the extent the Company raises gross proceeds in the Pre-Closing Financing greater than $50,000,000).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Allocation Percentage</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the quotient (expressed as a percentage, with the percentage rounded to two decimal places) determined by dividing (i) the Parent Valuation </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">by</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (ii) the Aggregate Valuation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Outstanding Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the total number of shares of Parent Common Stock outstanding immediately prior to the Effective Time expressed on a fully-diluted basis and as converted to Parent Common Stock basis, and (i) assuming, without limitation or duplication, (A) the settlement in shares of each Parent Option outstanding as of the Effective Time pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, solely to the extent such Parent Option will not be canceled at the Effective Time pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> or exercised prior thereto, (B) the issuance of Parent Common Stock in respect of all other options, warrants or rights to receive such shares that will be outstanding immediately after the Effective Time, including the Parent Warrants, and (C) for the avoidance of doubt, the effectiveness of the Reverse Split, and (ii) without regard to and excluding any Parent Option canceled at the Effective Time pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Valuation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the sum of (i) $8,000,000, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">plus </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(ii) the Parent Cash Amount, but only to the extent that the Parent Cash Amount is a negative number (in which case the Parent Valuation shall be reduced by the absolute value of the Parent Cash Amount).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;">&#xF0B7;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Post-Closing Parent Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the quotient determined by dividing (i) the Parent Outstanding Shares </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">by</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (ii) the Parent Allocation Percentage.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">GAAP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means generally accepted accounting principles and practices in effect from time to time within the United States applied consistently throughout the period involved.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Governmental Authorization</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any: (a) permit, license, certificate, franchise, permission, variance, exception, order, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Law; or (b) right under any Contract with any Governmental Body.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Governmental Body</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry,</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-5</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority); or (d) self-regulatory organization (including Nasdaq).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Hazardous Materials</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or by-products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">HSR Act</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Intellectual Property Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means and includes all past, present, and future rights of the following types, which may exist or be created, registered, applied for or to be applied for registration under the laws of any jurisdiction in the world: (a)&nbsp;rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, software, databases, and data; (b)&nbsp; trademarks, service marks, trade dress, logos, trade names, corporate names, brand names and other source identifiers, domain names and URLs and similar rights and any goodwill associated therewith; (c)&nbsp;rights associated with trade secrets, know how, inventions, invention disclosures, methods, processes, protocols, specifications, techniques and other forms of technology; (d)&nbsp;patents and industrial property rights; and (e)&nbsp;other similar proprietary rights in intellectual property of every kind and nature, including confidential information; (f)&nbsp;rights of privacy and publicity; and (g)&nbsp;all registrations, renewals, extensions, statutory invention registrations, provisionals, nonprovisionals, continuations, continuations-in-part, divisionals, reexaminations or reissues of, term extensions, supplementary protection certificates and applications for, any of the rights referred to in clauses &#x201C;(a)&#x201D; through &#x201C;(f)&#x201D; above (whether or not in tangible form and including all tangible embodiments of any of the foregoing, such as samples, studies and summaries), along with all rights to prosecute and perfect the same through administrative prosecution, registration, recordation or other administrative proceeding, and all causes of action and rights to sue or seek other remedies arising from or relating to the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">IRS</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the United States Internal Revenue Service.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Knowledge</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably be expected to know such fact in the ordinary course of the performance of such individual&#x2019;s employment responsibilities.&nbsp;&nbsp;Any Person that is an Entity shall have Knowledge if any officer or director of such Person as of the date such knowledge is imputed has Knowledge of such fact or other matter.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Law</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any federal, state, national, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of Nasdaq or the Financial Industry Regulatory Authority).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Legal Proceeding</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Merger Sub Board</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the board of directors of Merger Sub.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-6</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Nasdaq</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Nasdaq Stock Market, including the Nasdaq Capital Market or such other Nasdaq market on which shares of Parent Common Stock are then listed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Ordinary Course of Business</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its normal operations and consistent with its past practices.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Organizational Documents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, with respect to any Person (other than an individual), (a) the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> &nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Associate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any current or former employee, independent contractor, officer or director of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Balance Sheet</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the unaudited balance sheet of Parent as of March 31, 2019 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Balance Sheet Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), included in Parent&#x2019;s Report on Form 10-Q for the quarterly period ended March 31, 2019, as filed with the SEC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Board</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the board of directors of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Cash Amount</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, as of the applicable measurement date, (i) the sum of (without duplication) all Cash and Cash Equivalents, short-term investments, accrued investment interest receivable, and any prepaid refundable deposits listed on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 1.12(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> of the Parent Disclosure Schedule of Parent </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">less</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (ii) the sum of (without duplication) (A) Parent&#x2019;s accounts payable, accrued expenses, and debt, and (B) any Parent Transaction Expenses; in each case, as of such applicable date and determined in a manner consistent with the manner in which such items were historically determined and in accordance with GAAP and Parent&#x2019;s audited financial statements and the Parent Balance Sheet.&nbsp;&nbsp;For clarity, any consideration (i) actually received or to be received by Parent prior to the Anticipated Closing Date pursuant to signed purchase agreements in effect as of the Determination Date and not subject to any contingencies in connection with any Parent Financing or (ii) actually received prior to the Determination Date by Parent prior to the Determination Date in connection with any Permitted Disposition, net of the current fair value of all liabilities and obligations relating to such Permitted Disposition, shall be included in the Parent Cash Amount.&nbsp;&nbsp;Notwithstanding the foregoing, Parent Cash Amount shall not include any liabilities of Parent that are covered by the Gemcabene Funding (as defined in the CVR Agreement).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Change in Circumstance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means a change in circumstances neither known nor reasonably foreseeable by the Parent Board as of, or prior to, the date of this Agreement nor known nor reasonably foreseeable by any of the officers of Parent as of or prior to the date of this Agreement and (b) does not relate to (i) any Acquisition Proposal, (ii) any events, changes or circumstances relating to the Company or any of its Affiliates, (iii) clearance of the Merger under any applicable antitrust Laws or (iv) the mere fact that Parent meets or exceeds any internal or analysts&#x2019; published projections, forecasts, estimates or predictions of revenue, earnings or other financial or operating metrics for any period ending on or after the date hereof, or changes after the date of the Agreement in the market price or trading volume of Parent Common Stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Closing Price</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the volume weighted average closing trading price of a share of Parent Common Stock on Nasdaq for the five consecutive trading days ending five trading days immediately prior to the date upon which the Merger becomes effective.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-7</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Common Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Common Stock, $0.01 par value per share, of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Contract</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any Contract: (a) to which Parent is a party; (b) by which Parent or any Parent IP or any other asset of Parent is or may become bound or under which Parent has, or may become subject to, any obligation; or (c) under which Parent has or may acquire any right or interest.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> &nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent ERISA Affiliate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any corporation or trade or business (whether or not incorporated) which is (or at any relevant time was) treated with Parent or any of its Subsidiaries as a single employer within the meaning of Section 414 of the Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Financing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the sale and issuance of securities by Parent to the extent that the Company has consented in writing to such sale and issuance (such consent not to be unreasonably withheld, conditioned or delayed).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Fundamental Representations</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the representations and warranties of Parent and Merger Sub set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Sections&nbsp;3.1(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (Due Organization; Subsidiaries), </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">3.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (Authority; Binding Nature of Agreement), </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">3.6(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (Capitalization) and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">3.21</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (No Financial Advisors).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent IP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means all Intellectual Property Rights that are owned or purported to be owned by Parent or its Subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Material Adverse Effect</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any change, circumstance, condition, development, effect, event, occurrence, result or state of fact that, considered together with all other change, circumstance, condition, development, effect, event, occurrence, result or state of fact that have occurred prior to the date of determination of the occurrence of a Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Parent or ability to consummate the Contemplated Transactions; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, that none of the following shall be taken into account in determining whether there has been a Parent Material Adverse Effect: (a) general business or economic conditions affecting the industry in which Parent operates, (b) acts of war, armed hostilities or terrorism, (c) changes in financial, banking or securities markets, (d) the taking of any action required to be taken by this Agreement, (e) any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (f) the failure of Parent to meet internal or analysts&#x2019; expectations or projections or the results of operations of Parent; (g) any clinical trial programs or studies, including any adverse data, event or outcome arising out of or related to any such programs or studies; (h) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP); (h) continued losses from operations or decreases in cash balances of Parent&nbsp;or any of its Subsidiaries (j) resulting from the announcement of this Agreement or the pendency of the Contemplated Transactions; or (k) resulting from the taking of any action required to be taken by this Agreement, except in each case with respect to clauses (a) through (c), to the extent they disproportionately affect Parent relative to other similarly situated companies in the industries in which Parent operates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Options</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means options or other rights to purchase shares of Parent Common Stock issued by Parent.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-8</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Stock Plans</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, the Amended and Restated Parent 2015 Equity Incentive Plan, the Parent 2016 Inducement Plan, and the Parent 2016 Employee Stock Purchase Plan, in each case, as may be amended from time to time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Transaction Expenses</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; shall mean the sum of (a) the cash cost of any change of control payments or severance (including a reasonable estimate of payment or reimbursement for continued coverage under any employee benefit plan), termination or similar payments that are due or become due to any current or former employee, director or independent contractor of Parent upon the consummation of the Contemplated Transaction and that are unpaid, and (b) any costs, fees and expenses incurred by Parent, or for which Parent is liable, in connection with the negotiation preparation and execution of the Agreement and the consummation of the Contemplated Transactions (including in connection with any stockholder litigation relating to this Agreement or the Contemplated Transaction) and that are unpaid, including brokerage fees and commissions, finders&#x2019; fees or financial advisory fees, any fee and expenses of counsel or accountants payable by Parent and Parent&#x2019;s portion of the cost of the and the Nasdaq Fees, but expressly excluding (i) the Company&#x2019;s portion of the cost of the D&amp;O Tail Policy, and (ii) the employer portion of any and all withholding and other payroll Taxes arising from the issuance shares of Parent Common Stock upon the exercise of any Parent Option pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 5.5(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Triggering Event</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; shall be deemed to have occurred if: (a) Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation, shall have made a Parent Board Adverse Recommendation Change, (b) the Parent Board shall have failed to publicly reaffirm the Parent Board Recommendation within ten Business Days after the Company so requests in writing; (c) the Parent Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal; or (d) Parent shall have entered into any letter of intent or similar document relating to any Acquisition Proposal (other than a confidentiality agreement permitted pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section&nbsp;4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">); or (e) Parent has breached the provisions of </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;text-decoration:underline;">Section 4.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parent Warrants&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> means the warrants to purchase capital stock of Parent listed on </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Exhibit E</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; or &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Parties</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Company, Merger Sub and Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> &nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Permitted Encumbrance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means: (a) any liens for current Taxes not yet delinquent or for Taxes that are being contested in good faith and for which adequate reserves have been made on the Company Unaudited Interim Balance Sheet or the Parent Balance Sheet, as applicable; (b) minor liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets or properties subject thereto or materially impair the operations of the Company or any of its Subsidiaries or Parent, as applicable; (c) statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements; (d) deposits or pledges made in connection with, or to secure payment of, workers&#x2019; compensation, unemployment insurance or similar programs mandated by Law; (e) non-exclusive licenses of Intellectual Property Rights granted by the Company or any of its Subsidiaries or Parent, as applicable, in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the Intellectual Property Rights subject thereto; and (f) statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Person</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any individual, Entity or Governmental Body.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Pre-Closing Financing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the acquisition of Company securities consummated or to be consummated prior to the Closing with aggregate gross cash proceeds to the Company of at least</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-9</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">$24,240,000 (inclusive of amounts raised on or after May 30, 2019 but not including the Preferred Stock Conversion or Convertible Note Conversion) pursuant to the terms and conditions set forth in the Subscription Agreements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Proxy Statement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the proxy statement to be sent to Parent&#x2019;s stockholders in connection with the Parent Stockholders&#x2019; Meeting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Reference Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means July 23, 2019.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Registered IP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means all Intellectual Property Rights that are registered or issued under the authority of any Governmental Body, including all patents, registered copyrights, registered mask works, and registered trademarks, service marks and trade dress, and all applications for any of the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Registration Statement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the registration statement on Form S-4 (or any other applicable form under the Securities Act to register Parent Common Stock) to be filed with the SEC by Parent registering the public offering and sale of Parent Common Stock to all holders of Company Common Stock in the Merger unless such registration is not allowable under the Securities Act, as said registration statement may be amended prior to the time it is declared effective by the SEC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Representatives</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and representatives.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Restricted Cash</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any cash or cash equivalents that are unavailable for dividend or distribution as a result of the requirements of applicable Law or the dividend or distribution of which is subject to Tax, including any withholding or other similar Tax, or the dividend or distribution of which would produce other adverse Tax consequences for Parent or its Affiliates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Reverse Split</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means a reverse stock split of all outstanding shares of Parent Common Stock at a reverse stock split ratio in the range and at the time prior to Closing mutually agreed to by Parent and Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Sarbanes-Oxley Act</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Sarbanes-Oxley Act of 2002.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">SEC</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the United States Securities and Exchange Commission.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Securities Act</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Securities Act of 1933, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Series A Preferred Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; &nbsp;means the shares of the Series A Preferred Stock of the Company, par value $1.000000 per share.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Series B Preferred Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the shares of the Series B Preferred Stock of the Company, par value $1.000000 per share.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Stock Split</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means a stock split of all outstanding shares of Company Capital Stock at a stock split ratio of 10,000 to 1 or such range and at the time prior to Closing mutually agreed to by Parent and Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Stockholders&#x2019; Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Fourth Amended and Restated Stockholders&#x2019; Agreement, dated as of May 30, 2019, by and among the Company and its stockholders.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Subsequent Transaction</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 80% for these purposes).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">An entity shall be deemed to be a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Subsidiary</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; of a Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a) an amount of voting securities or other interests in such entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#x2019;s board of directors or other governing body, or (b) at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Subscription Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any preferred stock purchase agreement, as well as related investment agreements entered into by and among the Company and the Person(s) named therein (in each case, substantially in the forms entered into by the Company in connection with the Pre-Closing Financing prior to the date of this Agreement), pursuant to which such Person(s) have agreed to purchase the number of shares of Company&#x2019;s Series B Preferred Stock in such amounts and on such terms set forth therein in connection with the Pre-Closing Financing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Superior Offer</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to greater than 80% for these purposes) that: (a) was not obtained or made as a direct or indirect result of a breach of (or in violation of) this Agreement; and (b) is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant, as well as any written offer by the other Party to amend the terms of this Agreement, and following consultation with its outside legal counsel and outside financial advisors, and after taking into account all financial, legal, regulatory and other aspects of such Acquisition Proposal (including the financing terms and the ability of such third party to finance such Acquisition Proposal), would reasonably be expected to be consummated in accordance with its terms and would result in a transaction that is more favorable, from a financial point of view, to Parent&#x2019;s stockholders or the Company&#x2019;s stockholders, as applicable, than the terms of the Contemplated Transactions (after taking into account any revisions to the Contemplated Transactions offered by the other Party).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Takeover Statute</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any &#x201C;fair price,&#x201D; &#x201C;moratorium,&#x201D; &#x201C;control share acquisition&#x201D; or other similar anti-takeover Law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Tax</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any federal, state, local, foreign or other tax, including any income, capital gain, gross receipts, capital stock, profits, transfer, estimated, registration, stamp, premium, escheat, unclaimed property, customs duty, ad valorem, occupancy, occupation, alternative, add-on, windfall profits, value added, severance, property, business, production, sales, use, license, excise, franchise, employment, payroll, social security, disability, unemployment, workers&#x2019; compensation, national health insurance, withholding or other taxes, duties, fees, assessments or governmental charges, surtaxes or deficiencies thereof of any kind whatsoever, however denominated, and including any fine, penalty, addition to tax or interest imposed by a Governmental Body with respect thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Tax Return</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any return (including any information return), report, statement, declaration, estimate, schedule, notice, notification, form, election, certificate or other document, and any amendment or supplement to any of the foregoing, filed with or submitted to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">Treasury Regulations</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the United States Treasury regulations promulgated under the Code.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-11</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:11pt;">WARN Act</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Worker Adjustment Retraining and Notification Act of 1988, as amended, or any similar state or local plant closing mass layoff statute, rule or regulation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Each of the following terms is defined in the Section set forth opposite such term:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Term</font></p>
				</td>
				<td valign="bottom" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Section</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Accounting Firm</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.12(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Agreement</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Preamble</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Allocation Certificate</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.17(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Anti-Bribery Laws</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.23</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Anticipated Closing Date</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.12(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Business Associate Agreement</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.14(f)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Certificate of Merger</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Certifications</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.7(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Closing</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Closing Date</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Preamble</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Audited Financial Statements</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.21</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Benefit Plan</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.17(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Board Adverse Recommendation Change</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.2(d)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Board Recommendation</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.2(d)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Budget</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.2(b)(v)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Determination Notice</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.2(e)(i)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Disclosure Schedule</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Section 2</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Financial Statements</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.7(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Foreign Plan</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.17(n)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company In-bound License</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.12(d)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Interim Financial Statements</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.21</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Lock-Up Agreement</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Recitals</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Material Contract</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.13(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Out-bound License</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.12(d)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Permits</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.14(b)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Plan</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.6(c)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Preferred Stock</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.6(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Real Estate Leases</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.11</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Registered IP</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.12(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Series A Stockholder Matters</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.3(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Signatories</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Recitals</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Stock Certificate</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.7</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Stockholder Matters</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.2(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Stockholder Support Agreement</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Recitals</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Stockholder Written Consent</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Recitals</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Tax Counsel </font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.11(c)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Company Termination Fee</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.3(b)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Convertible Note Conversion</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.20</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Costs</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.7(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">CVR</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.6(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">CVR Agreement</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.6(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Determination Date</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.12(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">D&amp;O Indemnified Parties</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.7(a)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-12</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">D&amp;O Tail Policy</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.7(d)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Dispute Notice</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.12(b)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Dissenting Shares</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.9(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Drug Regulatory Agency</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.14(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">EDGAR</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.7(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Effective Time</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">End Date</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.1(b)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Exchange Agent</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.8(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Exchange Fund</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.8(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">FDA</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.14(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">FDCA</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.14(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">FLSA</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.17(p)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Gemcabene</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.22</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">HIPAA</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.14(f)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Information Statement</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.2(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Intended Tax Treatment</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.11(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Investor Agreements</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.22(b)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Liability</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.9</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Merger</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Recitals</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Merger Consideration</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.5(a)(ii)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Merger Sub</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Preamble</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Nasdaq Fees</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Nasdaq Listing Application</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Cash Calculation</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.12(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Cash Schedule</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.12(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Preamble</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Benefit Plan</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.17(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Board Adverse Recommendation Change</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.3(c)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Board Recommendation</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.3(c)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Budget</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.1(b)(v)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Determination Notice</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.3(d)(i)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Disclosure Schedule</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Section 3</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent In-bound License</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.12(d)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Lock-Up Agreement</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Recitals</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Material Contract</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.13</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Out-bound License</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.12(d)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Outstanding Shares Certificate</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.17(b)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Permits</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.14(b)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Real Estate Leases</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.11</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Registered IP</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.12(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent SEC Documents</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.7(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Signatories</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Recitals</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Stockholder Matters</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.3(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Stockholder Support Agreement</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Recitals</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Stockholders&#x2019; Meeting</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.3(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Tax Counsel</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.11(c)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent Termination Fee</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.3(c)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Permitted Alternative Agreement</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.1(k)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Permitted Disposition</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.22</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-13</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Pre-Closing Period</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">4.1(a)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Preferred Stock Conversion</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.20</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Required Company Stockholder Vote</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Required Parent Stockholder Vote</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">3.4</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Response Date</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.12(b)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Sensitive Data </font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">2.12(g)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Stockholder Notice</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">5.2(c)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Surviving Corporation</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">1.1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Third Party Expenses</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.3(d)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:387.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Willful Breach</font></p>
				</td>
				<td valign="top" style="width:18.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:63.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">9.2</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">A-14</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>3
<FILENAME>ex-2d2.htm
<DESCRIPTION>EX-2.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:41 AM-->
<html>
	<head>
		<title>
			gemp_Ex2_2
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">Exhibit 2.2</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CONTINGENT VALUE RIGHTS AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">This CONTINGENT VALUE RIGHTS AGREEMENT (this &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), dated as of --, 2019 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Effective Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), is entered into by and among Gemphire Therapeutics Inc., a Delaware corporation (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Parent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), Grand Rapids Holders&#x2019; Representative, LLC, as representative of the Holders (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Holders&#x2019; Representative</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), and Computershare Inc., as Rights Agent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">RECITALS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">WHEREAS, Parent, GR Merger Sub&nbsp;Inc., a Delaware corporation (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Sub</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), and NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), have entered into an Agreement and Plan of Merger and Reorganization, dated as of July 24, 2019 (as it may be amended or supplemented from time to time pursuant to the terms thereof, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Merger Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), pursuant to which Sub will merge with and into the Company, with the Company surviving the Merger as a subsidiary of Parent; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">WHEREAS, pursuant to the Merger Agreement, Parent has agreed to provide to the holders of record of Parent&#x2019;s common stock, par value $0.001 per share (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Parent Common Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), immediately prior to the Effective Time the right to receive certain contingent cash payments, on the terms and subject to the conditions hereinafter described;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">NOW, THEREFORE, in consideration of the foregoing and the consummation of the transactions referred to above, Parent and Rights Agent agree, for the equal and proportionate benefit of all Holders (as hereinafter defined), as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEFINITIONS; CERTAIN RULES OF CONSTRUCTION.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Capitalized terms used but not otherwise defined herein will have the meanings ascribed to them in the Merger Agreement. As used in this Agreement, the following terms will have the following meanings:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Acquiror</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; and &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Acquisition</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; have the respective meanings set forth in Section&nbsp;7.3(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Acting Holders</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, at the time of determination, Holders of at least a majority of the outstanding CVRs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Affiliate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, with respect to any Person, any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person.&nbsp; The term &#x201C;control&#x201D; (including the terms &#x201C;controlled by&#x201D; and &#x201C;under common control with&#x201D;) means the possession, directly or indirectly, of more than fifty percent (50%) of the voting securities entitled to vote for directors (or similar officials) of a Person or the possession, by contract or otherwise, of the authority to direct the management and policies of a Person.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Assignee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; has the meaning set forth in Section&nbsp;7.3(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Beijing SL</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; has the meaning set forth in Section&nbsp;4.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Beijing SL Transaction</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; has the meaning set forth in Section&nbsp;4.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Board of Directors</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the board of directors of Parent.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Board Resolution</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means a copy of a resolution certified by the secretary or an assistant secretary of Parent to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification, and delivered to the Rights Agent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Business Day</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any day other than a Saturday, Sunday or other day on which banks in New York, New York are authorized or obligated by Law to be closed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;Covenant End Date&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> has the meaning set forth in Section&nbsp;4.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVRs</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVR Payment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; has the meaning set forth in Section&nbsp;2.4(d).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVR Payment Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means a calendar quarter, prior to the expiration of the CVR Term, in which a Gemcabene Deal has closed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVR Payment Statement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, for a given CVR Payment Period during the CVR Term, a written statement of Parent, setting forth in reasonable detail, (a)&nbsp;Net Proceeds for such CVR Payment Period; (b)&nbsp;a description of the Gross Consideration received during such CVR Payment Period from a Gemcabene Deal, (d)&nbsp;a delineation and calculation of the Permitted Deductions applicable to such CVR Payment Period, and (e)&nbsp;to the extent that any Gross Consideration or Permitted Deduction is recorded in any currency other than United States dollars during such CVR Payment Period, the exchange rates used for conversion of such currency into United States dollars.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVR Register</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; has the meaning set forth in Section&nbsp;2.3(b).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVR Shortfall</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; has the meaning set forth in Section&nbsp;4.7(b).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVR Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the period beginning on the Closing and ending fifteen (15) years thereafter.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">DTC</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means The Depository Trust Company or any successor thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">FDA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; has the meaning set forth in Section&nbsp;4.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Gemcabene Deal</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any transaction (a)&nbsp;that is entered into during the period beginning on the Closing and ending ten (10)&nbsp;years thereafter and (b)&nbsp;pursuant to which Parent or its Affiliate grants, sells or otherwise transfers to a Third Party any rights to the Gemcabene Technology or any rights to research, develop or commercialize the Gemcabene Technology, including a license, option, or sale of assets with respect to the Gemcabene Technology.&nbsp; For clarity, the sale of all or substantially all of Parent&#x2019;s or an Affiliate&#x2019;s stock or assets (to the extent such asset sale includes assets unrelated to the Gemcabene Technology), or a merger, acquisition or similar transaction shall not be deemed a Gemcabene Deal.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;Gemcabene Funding&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> has the meaning set forth in Section&nbsp;4.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Gemcabene Technology</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any and all Intellectual Property Rights that are (a)&nbsp;owned or licensed by Parent or its Affiliates as of the Effective Date or during the term of this Agreement, but prior to the closing of any Acquisition and (b)&nbsp;related to or constituting forms of gemcabene&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">or any salt, hydrate, solvate, anhydrous form, or polymorph thereof, including the</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:11pt;">monocalcium salt Gemcabene calcium, which is also identified as CI-1027, PF-01430506, and/or PD-072953</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">, methods of using gemcabene, and methods of manufacturing gemcabene, including the targeting of known lipid metabolic pathways to lower levels of LDL&#8209;C, hsCRP and triglycerides.&nbsp; Notwithstanding the foregoing, Gemcabene Technology shall not include any Intellectual Property Rights owned or controlled by an Acquiror prior to the closing of an Acquisition or developed or acquired by such Acquiror subsequent to such closing independently of any activities of Parent and its Affiliates (excluding such Acquiror) related to Gemcabene Technology and without reliance on or use of any Gemcabene Technology (provided that the Acquiror establishes reasonable internal safeguards designed to ensure that such conditions of independence are satisfied). Such Intellectual Property Rights as of the date of this Agreement are as set forth on Exhibit A.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Governmental Entity</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any foreign or domestic arbitrator, court, nation, government, any state or other political subdivision thereof and an entity exercising executive, legislative, judicial regulatory or administrative functions of, or pertaining to, government.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Gross Consideration</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, after the retention of an aggregate amount equal to $500,000 by Parent or its Affiliates from the proceeds of a Gemcabene Deal or the Beijing SL Transaction, an amount equal to 80% of the following amounts: (a)&nbsp;all cash consideration paid by a Third Party to Parent or its Affiliates during the CVR Term in connection with any Gemcabene Deal or the Beijing SL Transaction (including royalty payments, but not including, in the case of the Beijing SL Transaction, the $2,500,000 upfront payment), </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">plus</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (b)&nbsp;with respect to any non-cash consideration received by Parent or its Affiliates from a Third Party during the CVR Term in connection with any Gemcabene Deal or the Beijing SL Transaction, all amounts received by Parent and its Affiliates for such non-cash consideration at the time such non-cash consideration is monetized by the Parent or its Affiliates (which amounts will be subject to payment to the Rights Agent when such non-cash consideration is monetized and such amounts are received by Parent or any of its Affiliates).&nbsp; If a Gemcabene Deal or Beijing SL Transaction also involves assets that are not related to Gemcabene Technology but are related to other proprietary technology, products or assets of Parent or its Affiliates, then the total consideration will be allocated between all such technology, products and assets, and only that consideration allocated to the Gemcabene Technology will be included in Gross Consideration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Holder</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means a Person in whose name a CVR is registered in the CVR Register at the applicable time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Holders&#x2019; Representative</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Holders&#x2019; Representative named in the first paragraph of this Agreement or any direct or indirect successor Holders&#x2019; Representative designated in accordance with Section&nbsp;6.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Independent Accountant</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means an independent certified public accounting firm of nationally recognized standing designated either (a)&nbsp;jointly by the Holders&#x2019; Representative and Parent, or (b)&nbsp;if the Holders&#x2019; Representative and Parent fail to make a designation, jointly by an independent public accounting firm selected by Parent and an independent public accounting firm selected by the Holders&#x2019; Representative.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Net Proceeds</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, for any CVR Payment Period, Gross Consideration </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">minus</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> Permitted Deductions. For clarity, to the extent Permitted Deductions exceed Gross Consideration for any CVR Payment Period, any excess Permitted Deductions shall be applied against Gross Consideration in subsequent CVR Payment Periods.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Officer&#x2019;s Certificate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means a certificate signed by the chief executive officer, president, chief financial officer, any vice president, the controller, the treasurer or the secretary, in each case of Parent, in his or her capacity as such an officer, and delivered to the Rights Agent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means each of Parent, the Rights Agent and Holders&#x2019; Representative.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Payment Amount</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means, with respect to each CVR Payment and each Holder, an amount equal to such CVR Payment </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">divided by</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> the total number of CVRs and then </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">multiplied by</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> the total number of CVRs held by such Holder as reflected on the CVR Register (rounded down to the nearest whole cent).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Permitted Deductions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the sum of: (i)&nbsp;any and all fees, milestone payments and royalties paid by Parent and its Affiliates to Pfizer pursuant to the Pfizer License Agreement with respect to the Gemcabene Technology that is subject to a Gemcabene Deal, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">plus</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (ii)&nbsp;all fees, milestones, royalties and other payments paid by Parent and its Affiliates to any other Third Party licensor in consideration for a license to such Third Party&#x2019;s patents that would be infringed, absent such license, by the practice of such Gemcabene Technology, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">plus</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (iii)&nbsp;all patent prosecution and maintenance costs, and drug product storage costs, incurred by Parent and its Affiliates with respect to the Gemcabene Technology, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">plus </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(iv)&nbsp;all out-of-pocket transaction costs incurred by Parent and its Affiliates to Third Parties for the negotiation, entry into and closing of a Gemcabene Deal, or any transaction described under (i) &#x2013; (iii) in this paragraph, including any broker fees, finder&#x2019;s fees, advisory fees, accountant or attorney&#x2019;s fees, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">plus</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (v) all fees and costs (including any amounts paid for indemnification) payable by Parent to the Rights Agent pursuant to this Agreement, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">plus </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">(vi) all fees and costs incurred by Parent and its Affiliates after the Closing in connection with the Beijing SL Transaction, including but not limited to those relating to insurance costs, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">plus</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (vii) all fees and costs incurred by Parent and its Affiliates to settle any claims relating to tail provisions under investment banking engagement letters entered into by Gemphire prior to the Closing, in each case to the extent such costs have been incurred during the CVR Term and are not reimbursed or paid to Parent or its Affiliate by a Third Party (including a Governmental Entity).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Permitted Transfer</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means a transfer of CVRs (a)&nbsp;upon death of a Holder by will or intestacy; (b)&nbsp;pursuant to a court order; (c)&nbsp;by operation of law (including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (d)&nbsp;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial owner and, if applicable, through an intermediary, to the extent allowable by DTC; or (e)&nbsp;pursuant to Section&nbsp;2.6.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Person</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any natural person, corporation, limited liability company, trust, unincorporated association, partnership, joint venture or other entity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Pfizer</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means Pfizer Inc.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Pfizer License Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means that certain Amended and Restated License Agreement between Pfizer and Parent, effective August 2, 2018.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Record Time</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; has the meaning set forth in Section&nbsp;2.3(e).</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Rights Agent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means the Rights Agent named in the first paragraph of this Agreement or any direct or indirect successor Rights Agent designated in accordance with the applicable provisions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Third Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; means any Person other than Parent, Rights Agent or their respective Affiliates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Valuation Expert</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D; has the meaning set forth in Section&nbsp;2.4(e).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">1.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rules&nbsp;of Construction</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; Except as otherwise explicitly specified to the contrary, (a)&nbsp;references to a Section&nbsp;means a Section&nbsp;of this Agreement unless another agreement is specified, (b)&nbsp;the word &#x201C;including&#x201D; (in its various forms) means &#x201C;including without limitation,&#x201D; (c)&nbsp;references to a particular statute or regulation include all rules&nbsp;and regulations thereunder and any successor statute, rules&nbsp;or regulation, in each case as amended or otherwise modified from time to time, (d)&nbsp;words in the singular or plural form include the plural and singular form, respectively, (e)&nbsp;references to a particular Person include such Person&#x2019;s successors and assigns to the extent not prohibited by this Agreement and (f)&nbsp;all references to dollars or &#x201C;$&#x201D; refer to United States dollars.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONTINGENT VALUE RIGHTS.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CVRs</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; The CVRs represent the rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement. The initial Holders will be the holders of Parent Common Stock as of immediately prior to the Effective Time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nontransferable</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Certificate; Registration; Registration of Transfer; Change of Address; CVR Distribution.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The CVRs will not be evidenced by a certificate or other instrument.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The Rights Agent will create and maintain a register (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVR Register</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) for the purpose of registering CVRs and transfers of CVRs as herein provided. The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from Parent. The CVR Register will initially show one position for Cede&nbsp;&amp; Co. representing all the shares of Parent Common Stock held by DTC on behalf of the street holders of the shares of Parent Common Stock held by such holders as of immediately prior to the Effective Time. The Rights Agent will have no responsibility whatsoever directly to the street name holders with respect to transfers of CVRs. With respect to any payments to be made under Section&nbsp;2.4(d)&nbsp;below, the Rights Agent will accomplish the payment to any former street name holders of shares of Company Common Stock by sending one lump payment to DTC. The Rights Agent will have no responsibilities whatsoever with regard to the distribution of payments by DTC to such street name holders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Subject to the restrictions on transferability set forth in Section&nbsp;2.2, every request made to transfer a CVR must be in writing and accompanied by a written instrument of transfer in form reasonably satisfactory to the Rights Agent pursuant to its guidelines, including a guaranty of signature by an &#x201C;eligible guarantor institution&#x201D; that is a member or participant in the Securities Transfer Agents Medallion Program, duly executed by the Holder thereof, the Holder&#x2019;s attorney duly authorized in writing, the Holder&#x2019;s personal representative or the Holder&#x2019;s survivor, and setting forth in reasonable</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">5</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form and the transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of Section&nbsp;2.2), register the transfer of the CVRs in the CVR Register. Parent and Rights Agent may require payment of a sum sufficient to cover any stamp or other tax or governmental charge that is imposed in connection with any such registration of transfer. The Rights Agent shall have no duty or obligation to take any action under any section of this Agreement that requires the payment by a Holder of a CVR of applicable taxes or charges unless and until the Rights Agent is satisfied that all such taxes or charges have been paid. All duly transferred CVRs registered in the CVR Register will be the valid obligations of Parent and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor.&nbsp; No transfer of a CVR will be valid until registered in the CVR Register.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">A Holder may make a written request to the Rights Agent to change such Holder&#x2019;s address of record in the CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written notice, the Rights Agent will, subject to its reasonable determination that the transfer instrument is in proper form, promptly record the change of address in the CVR Register.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent will provide written instructions to the Rights Agent for the distribution of CVRs to holders of Parent Common Stock as of immediately prior to the Effective Time (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Record Time</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;). Subject to the terms and conditions of this Agreement and Parent&#x2019;s prompt confirmation of the Effective Time, the Rights Agent shall effect the distribution of the CVRs, less any applicable tax withholding, to each holder of Parent Common Stock as of the Record Time by the mailing of a statement of holding reflecting such CVRs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CVR Payment and Related Procedures</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Subsequent to any Gemcabene Deal, within sixty (60) days after the end of any CVR Payment Period during the CVR Term, Parent shall deliver to the Holders&#x2019; Representative and Rights Agent a CVR Payment Statement for such CVR Payment Period.&nbsp; Concurrent with the delivery of each CVR Payment Statement, Parent shall pay the Rights Agent in U.S. dollars an amount equal to the Net Proceeds (if any) received with respect to the applicable CVR Payment Period.&nbsp; For clarity, to the extent that any non-cash consideration in Gross Consideration is monetized after the end of the CVR Term, Parent will include a description of such non-cash consideration in the CVR Payment Statement for the CVR Payment Period in which it is received, and will make the applicable payment to the Rights Agent upon monetization of such non-cash consideration (regardless of whether such monetization occurs after the end of the CVR Term).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Upon the Holders&#x2019; Representative&#x2019;s request after receipt of any statement under Section&nbsp;2.4(a), Parent shall promptly provide the Holders&#x2019; Representative with reasonable documentation to support its calculation of Net Proceeds (including any allocation applied when calculating the Gross Consideration component thereof and including its determination of the applicable fair market value(s)), and shall make its financial personnel reasonably available to the Holders&#x2019; Representative to discuss and answer the Holders&#x2019; Representative&#x2019;s questions regarding such calculations.&nbsp; If the Holders&#x2019; Representative does not agree with Parent&#x2019;s calculation, and the Holders&#x2019; Representative and Parent fail to agree on an alternative calculation within ten (10)&nbsp;Business Days after the Holders&#x2019; Representative requests documentation supporting Parent&#x2019;s calculation, then the Parent and the Holders&#x2019; Representative shall engage a mutually agreeable independent third party valuation expert (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Valuation Expert</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) to determine the applicable calculation.&nbsp; The determination of the Valuation Expert will be final and binding on the Parent, the Rights Agent, the Holders&#x2019; Representative and each Holder, unless the Parent and Holders&#x2019; Representative agree otherwise in writing.&nbsp; The Valuation Expert shall be</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">6</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">an investment banker or other Person experienced in the valuation of pharmaceutical businesses and products, who shall not have had any material business relationship with Parent or the Holders&#x2019; Representative in the thirty-six (36) months prior to appointment, unless Parent and the Holders&#x2019; Representative agree in writing to waive this requirement.&nbsp; If the Holders&#x2019; Representative and Parent fail to agree on a Valuation Expert within thirty (30) days after determining to seek a Valuation Expert, the Holders&#x2019; Representative and Parent shall each designate a valuation expert, and the two such experts shall select a Valuation Expert.&nbsp; The Valuation Expert selected shall be entitled to apply discounted cash flow models and such other valuation models as she or he determines are appropriate under the circumstances, together with any other valuation models as may be agreed by the Holders&#x2019; Representative and Parent.&nbsp; Within ten (10)&nbsp;Business Days after the selection of the Valuation Expert, each of Parent and the Holders&#x2019; Representative will deliver to the Valuation Expert a detailed written proposal setting forth its proposed calculation of the Net Proceeds and Parent will deliver to the Valuation Expert a copy of the applicable Third Party agreements.&nbsp; Parent and the Holders&#x2019; Representative will use reasonable efforts to cause the Valuation Expert to make a determination within thirty (30) days after receipt of the proposals.&nbsp; Following its determination, the Valuation Expert shall deliver to Parent and the Holders&#x2019; Representative a report of her or his determination, and within thirty (30) days after receipt of such report, Parent shall make the applicable payment to the Rights Agent.&nbsp; The fees charged by the Valuation Expert shall be borne fifty percent (50%) by the Holders (through deduction from the next one or more CVR Payments, including the CVR Payment evaluated by the Valuation Expert) and fifty percent (50%) by Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">All payments by Parent to the Rights Agent under this Agreement shall be made in U.S. dollars.&nbsp; The rate of exchange to be used in computing the amount of currency equivalent in U.S. dollars shall be made at the average of the closing exchange rates reported in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:11pt;">The Wall Street Journal</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> (U.S., Eastern Edition) for the ten (10) Business Days preceding the date of the CVR Payment Statement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The Rights Agent will promptly, and in any event within ten (10)&nbsp;Business Days after receipt of a CVR Payment Statement under Section&nbsp;2.4(a), send each Holder at its address set forth on the CVR Register a copy of such statement.&nbsp; If the Rights Agent also receives any payment under Section&nbsp;2.4(a)&nbsp;(each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVR Payment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), then within ten (10)&nbsp;Business Days after the receipt of each CVR Payment, the Rights Agent will also pay to each Holder, by check mailed to the address of each Holder as reflected in the CVR Register as of the close of business on the date of the receipt of the CVR Payment Statement, such Holder&#x2019;s Payment Amount.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent shall be entitled to deduct or withhold, or cause the Rights Agent to deduct or withhold, from any amount otherwise payable to a Holder pursuant to Section&nbsp;2.4(d)&nbsp;such amounts as may be required to be deducted or withheld therefrom under the Code, the Treasury Regulations thereunder, or any other applicable Tax Law, or as may be determined by Parent.&nbsp; Prior to making any such Tax withholdings or causing any such Tax withholdings to be made with respect to any Holder, Parent shall instruct the Rights Agent to solicit from such Holder an IRS Form&nbsp;W-9 or other applicable Tax form within a reasonable amount of time and such Holder shall promptly provide any necessary Tax forms (including an IRS Form&nbsp;W-9 or an applicable IRS Form&nbsp;W-8) in order to avoid or reduce such withholding amounts. To the extent such amounts are so deducted or withheld, such amounts shall be treated for all purposes under this Agreement as having been paid to the person to whom such amounts would otherwise have been paid, and prior to the 15th&nbsp;day of February&nbsp;in the year following any payment of such taxes by Parent or the Rights Agent, Parent shall deliver (or shall cause the Rights Agent to deliver) to the Person to whom such amounts would otherwise have been paid the original Form&nbsp;1099 or other reasonably acceptable evidence of such withholding.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Any portion of any CVR Payment that remains undistributed to the Holders six (6)&nbsp;months after the CVR Payment is received by the Rights Agent from the Parent, provided</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">7</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">that the Rights Agent has fully complied with Section&nbsp;2.4(d), will be delivered by the Rights Agent to Parent, upon demand, and any Holder will thereafter look only to Parent for payment of its share of such returned CVR Payment, without interest, but such Holder will have no greater rights against Parent than those accorded to general unsecured creditors of Parent under applicable law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Neither Parent nor the Rights Agent will be liable to any person in respect of any Payment Amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar law. If, despite Parent&#x2019;s and/or the Rights Agent&#x2019;s commercially reasonable efforts to deliver a Payment Amount to the applicable Holder, such Payment Amount has not been paid immediately prior to the date on which such Payment Amount would otherwise escheat to or become the property of any Governmental Entity, any such Payment Amount will, to the extent permitted by applicable law, become the property of Parent, free and clear of all claims or interest of any person previously entitled thereto. In addition to and not in limitation of any other indemnity obligation herein, Parent agrees to indemnify and hold harmless Rights Agent with respect to any liability, penalty, cost or expense Rights Agent may incur or be subject to in connection with transferring such property to Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">For the avoidance of doubt, as between Parent, Rights Agent and the Holders, Parent shall have sole responsibility for making all payments due pursuant to the Pfizer License Agreement. The CVR Payments shall be in addition to, and not in lieu of, any such payments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Voting, Dividends or Interest; No Equity or Ownership Interest in Parent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable on the CVRs to any Holder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The CVRs will not represent any equity or ownership interest in Parent or in any constituent company to the Merger.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Each Holder acknowledges and agrees to the appointment and authority of the Holders&#x2019; Representative to act as the exclusive representative, agent and attorney-in-fact of such Holder and all Holders as set forth in this Agreement. Each Holder agrees that such Holder will not challenge or contest any action, inaction, determination or decision of the Holders&#x2019; Representative or the authority or power of the Holders&#x2019; Representative and will not threaten, bring, commence, institute, maintain, prosecute or voluntarily aid any action, which challenges the validity of or seeks to enjoin the operation of any provision of this Agreement, including, without limitation, the provisions related to the authority of the Holders&#x2019; Representative to act on behalf of such Holder and all Holders as set forth in this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ability to Abandon CVR</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; A Holder may at any time, at such Holder&#x2019;s option, abandon all of such Holder&#x2019;s remaining rights in a CVR by transferring such CVR to Parent without consideration therefor.&nbsp; Nothing in this Agreement is intended to prohibit Parent or its Affiliates from offering to acquire CVRs for consideration in its sole discretion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THE RIGHTS AGENT.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Appointment of Rights Agents; Certain Duties and Responsibilities</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; The Parent hereby appoints the Rights Agent to act as agent for the Parent in accordance with the express terms and conditions hereof, and the Rights Agent hereby accepts such appointment.&nbsp;&nbsp;The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">8</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the extent of its willful misconduct, bad faith or gross negligence (in each case as determined by a final, non-appealable decision of a court of competent jurisdiction).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain Rights of Rights Agent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied covenants or obligations will be read into this Agreement against the Rights Agent. In addition:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent may rely and will be protected and held harmless by Parent in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it to be genuine and to have been signed or presented by the proper party or parties;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">whenever the Rights Agent will deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Rights Agent may rely upon an Officer&#x2019;s Certificate, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent shall, in the absence of bad faith, gross negligence or willful misconduct on its part (in each case as determined by a final, non-appealable decision of a court of competent jurisdiction), incur no liability and be held harmless by Parent for or in respect of any action taken, suffered or omitted to be taken by it under the provisions of this Agreement in reliance upon such certificate;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent may engage and consult with counsel of its selection and the advice of such counsel or any opinion of counsel will be full and complete authorization and protection and shall be held harmless by Parent in respect of any action taken, suffered or omitted by it hereunder in the absence of bad faith and in reliance thereon;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the permissive rights of the Rights Agent to do things enumerated in this Agreement will not be construed as a duty;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent will not be required to give any note or surety in respect of the execution of such powers or otherwise in respect of the premises;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent will have no liability and shall be held harmless by Parent in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution and delivery hereof by the Rights Agent and the enforceability of this Agreement against the Rights Agent assuming the due execution and delivery hereof by Parent); nor shall it be responsible for any breach by the Parent or any other Person of any covenant or condition contained in this Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent agrees to indemnify Rights Agent for, and hold Rights Agent harmless against, any loss, liability, damage, claim, judgment, fine, penalty, claim, demands, suits or expense (including the reasonable expenses and counsel fees and other disbursements) arising out of or in connection with Rights Agent&#x2019;s preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder, including the costs and expenses of defending Rights Agent against any claims, charges, demands, suits or loss, unless such loss has been determined by a final, non-appealable order of a court of competent jurisdiction to be a result of Rights Agent&#x2019;s gross negligence, bad faith or willful or intentional misconduct (in each case as determined by a final, non-appealable decision of a court of competent jurisdiction);</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">notwithstanding anything in this Agreement to the contrary, any liability of the Rights Agent under this Agreement will be limited to the amount of annual fees (but not reimbursed expenses) paid by the Parent to the Rights Agent during the twelve (12) months immediately preceding the event for which recovery from the Rights Agent is being sought;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">9</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent agrees to (i) pay the fees and expenses of the Rights Agent in connection with this Agreement as agreed upon in writing by the Rights Agent and Parent on or prior to the date hereof, and (ii) reimburse the Rights Agent for all taxes and governmental charges, reasonable expenses and other charges of any kind and nature incurred by the Rights Agent in the execution of this Agreement (other than taxes imposed on or measured by the Rights Agent&#x2019;s net income and franchise or similar taxes imposed on it). The Rights Agent will also be entitled to reimbursement from Parent for all reasonable and necessary out-of-pocket expenses paid or incurred by it in connection with the administration by the Rights Agent of its duties hereunder;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required or requested by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent shall not be answerable or accountable for any act, omission, default, neglect or misconduct of any such attorneys or agents or for any loss to the Parent, to the holders of the CVRs or any other Person resulting from any such act, omission, default, neglect or misconduct, absent gross negligence or bad faith in the selection and continued employment thereof (which gross negligence or bad faith must be determined by a final, non-appealable judgment of a court of competent jurisdiction);</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">unless otherwise specifically prohibited by the terms of this Agreement, the Rights Agent and any stockholder, affiliate, member, director, officer, agent, representative or employee of the Rights Agent may buy, sell or deal in any of the securities of the Parent or become pecuniarily interested in any transaction in which the Parent may be interested, or contract with or lend money to the Parent or otherwise act as fully and freely as though it were not the Rights Agent under this Agreement.&nbsp; Nothing herein shall preclude the Rights Agent or any such stockholder, affiliate, director, member, officer, agent, representative or employee from acting in any other capacity for the Parent or for any other Person;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent shall act hereunder solely as agent for the Parent and it shall not assume any obligations or relationship of agency or trust with any of the Holders or the Holder&#x2019;s Representative;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent shall not be deemed to have knowledge of any event of which it was supposed to receive notice thereof hereunder, and the Rights Agent shall be fully protected and shall incur no liability for failing to take action in connection therewith, unless and until it has received such notice in writing;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent shall not be liable for or by reason of, and shall be held harmless by Parent with respect to any of the statements of fact or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by the Parent only;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent shall not be liable for special, punitive, indirect, incidental or consequential loss or damages of any kind whatsoever (including, without limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action and no provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing that</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect to any action or default by the Parent, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon the Parent; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the provisions of this Section&nbsp;3.2 shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Rights Agent.&nbsp; The costs and expenses incurred in enforcing this right of indemnification shall be paid by the Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resignation and Removal; Appointment of Successor</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The Rights Agent may resign at any time by giving written notice thereof to Parent, specifying a date when such resignation will take effect, which notice will be sent at least thirty (30) days prior to the date so specified. Parent has the right to remove the Rights Agent at any time by notice specifying a date when such removal will take effect. Such notice of removal will be given by Parent to the Rights Agent, which notice will be sent at least thirty (30) days prior to the date so specified.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">If the Rights Agent provides notice of its intent to resign, is removed or becomes incapable of acting, Parent, by a Board Resolution, will as soon as is reasonably possible appoint a qualified successor Rights Agent who, unless otherwise consented to in writing by the Holders&#x2019; Representative, shall be a stock transfer agent of national reputation or the corporate trust department of a commercial bank. The successor Rights Agent so appointed will, forthwith upon its acceptance of such appointment in accordance with Section&nbsp;3.4, become the successor Rights Agent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent will give notice of each resignation and each removal of a Rights Agent and each appointment of a successor Rights Agent by mailing written notice of such event by first-class mail to the Holders as their names and addresses appear in the CVR Register. Each notice will include the name and address of the successor Rights Agent. If Parent fails to send such notice within ten (10) Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acceptance of Appointment by Successor</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; Every successor Rights Agent appointed hereunder will execute, acknowledge and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and thereupon such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring Rights Agent will execute and deliver an instrument transferring to the successor Rights Agent all the rights (except such rights of the predecessor Rights Agent which survive pursuant to Section&nbsp;3.3 of this Agreement), powers and trusts of the retiring Rights Agent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COVENANTS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;List of Holders</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; Parent will furnish or cause to be furnished to the Rights Agent in such form as Parent receives from Parent&#x2019;s transfer agent (or other agent performing similar services for Parent), the names and addresses of the Holders within ten (10) Business Days of the Effective Time.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">11</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; If any CVR Payment is due under Section&nbsp;2.4(a), Parent will deposit the CVR Payment with the Rights Agent for payment to the Holders in accordance with Section&nbsp;2.4(d).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development of Gemcabene Technology</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">. Following the Effective Time, Parent shall make or Parent shall cause the Company to make an amount available, up to and not to exceed $1,000,000 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Gemcabene Funding</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), to support the development of the Gemcabene Technology through the quarter ending March 31, 2020 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Covenant End Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp;&nbsp;The Gemcabene Funding will be allocated and spent based on the mutual agreement of Parent and the Holders&#x2019; Representative.&nbsp;&nbsp;Such amount shall be funded upon the execution by Parent of a license and collaboration agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Beijing SL Transaction&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">) with Beijing SL Pharmaceutical Co., Ltd. (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Beijing SL</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;), provided that such license and collaboration agreement with Beijing SL has been executed on terms acceptable to the Company prior to August 31, 2019, and the receipt by Parent of an upfront payment from Beijing SL in an amount not less than $2,500,000 to be paid by Beijing SL in accordance with the terms and conditions set forth in the license and collaboration agreement with Beijing SL. Following the Effective Time neither Parent nor the Company shall have any obligation to develop any Gemcabene Technology, or to expend any funds or efforts whatsoever with respect to the Gemcabene Technology, other than the provision of the Gemcabene Funding, which shall be used prior to the Covenant End Date to fund, to the extent such funds are sufficient therefor, (i) a toxicity study with respect to Gemcabene, (ii) a related submission to the Food and Drug Administration (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">FDA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) designed to result in the release of the partial clinical hold with respect to Gemcabene, (iii) preparation for an end-of-phase 2 meeting with the FDA, and (iv) consulting costs for up to four (4) former employees of Parent to support such activities. For the avoidance of doubt, following the Effective Time, neither the Company nor Parent has any obligation to provide further funding should the Gemcabene Funding not be sufficient to fund the matters set forth in (i) through (iv) in the previous sentence. Except as expressly set forth in this Section 4.3, Parent shall have no obligation to support the development of the Gemcabene Technology or to undertake any effort or expend any resource to divest or otherwise monetize the Gemcabene Technology or to maximize the likelihood or amount of any CVR Payment.&nbsp;&nbsp;Following the Covenant End Date, Parent may, at any time and in its sole and absolute discretion, discontinue any and all further efforts to develop, divest or otherwise monetize the Gemcabene Technology, upon a determination by the Board of Directors (as determined by a majority vote), it being understood and agreed that Parent has not promised or projected any CVR Payment and any such CVR Payment is speculative and may not occur.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Books and Records</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; Parent shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to enable the Holders and their consultants or professional advisors to confirm the applicable Payment Amount payable to each Holder hereunder in accordance with the terms specified in this Agreement.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">12</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audits</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Upon the written request of the Holders&#x2019; Representative provided to Parent not less than forty-five (45) days in advance (such request not to be made more than once in any twelve (12) month period), Parent shall permit, and shall cause its Affiliates to permit, the Independent Accountant to have access during normal business hours to such of the records of Parent or its Affiliates as may be reasonably necessary to determine the accuracy of the Net Proceeds reported by Parent.&nbsp; Parent shall, and shall cause its Affiliates to, furnish to the Independent Accountant such access, work papers and other documents and information reasonably necessary for the Independent Accountant to calculate and verify the Net Proceeds; provided that Parent may, and may cause its Affiliates to, redact documents and information not relevant for such calculation pursuant to this Section&nbsp;4.5.&nbsp; The Independent Accountant shall disclose to Parent and the Holders&#x2019; Representative any matters directly related to its findings to the extent reasonably necessary to verify the Net Proceeds.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">If the Independent Accountant concludes that a CVR Payment that was properly due was not paid to the Rights Agent, or that any CVR Payment made was in an amount less than the amount due, Parent shall pay the CVR Payment or underpayment thereof to the Rights Agent for further distribution to the Holders (such amount being the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">CVR Shortfall</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp; The CVR Shortfall shall be paid within ten (10)&nbsp;Business Days after the date the Independent Accountant delivers to Parent and the Holders&#x2019; Representative the Independent Accountant&#x2019;s written report.&nbsp; The decision of the Independent Accountant shall be final, conclusive and binding on Parent and the Holders, shall be non-appealable and shall not be subject to further review. The fees charged by the Independent Accountant shall be paid by the Holders&#x2019; Representative; provided, however, that if the Independent Accountant concludes that Parent has underreported or underpaid any CVR Payment by more than twenty percent (20%), the fees charged by such Independent Accountant shall be paid by Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Each Person seeking to receive information from Parent in connection with a review pursuant to this Section&nbsp;4.5 shall enter into, and shall cause its accounting firm to enter into, a reasonable and mutually satisfactory confidentiality agreement with Parent or any controlled Affiliate obligating such party to retain all such information disclosed to such party in confidence pursuant to such confidentiality agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENTS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments without Consent of Holders</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Without the consent of any Holders or the Holders&#x2019; Representative, Parent, when authorized by a Board Resolution, at any time and from time to time, and the Rights Agent may enter into one or more amendments hereto, solely to evidence the succession of another Person to Parent and the assumption by such successor of the covenants of Parent herein as provided in Section&nbsp;7.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Without the consent of any Holders, Parent, when authorized by a Board Resolution and the Rights Agent, in the Rights Agent&#x2019;s sole and absolute discretion, at any time and from time to time, may enter into one or more amendments hereto, solely for any of the following purposes:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:144pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">to evidence the succession of another Person as a successor Rights Agent and the assumption by such successor of the covenants and obligations of the Rights Agent herein;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:144pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">to add to the covenants of Parent such further covenants, restrictions, conditions or provisions as Parent and the Rights Agent consider to be for the protection of</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">13</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">the Holders; provided that, in each case, such provisions do not adversely affect the interests of the Holders;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:144pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">to cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision herein, or to make any other provisions with respect to matters or questions arising under this Agreement; provided that, in each case, such provisions do not adversely affect the interests of the Holders;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:144pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange Act;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:144pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">to reduce the number of CVRs, in the event any Holder agrees to renounce such Holder&#x2019;s rights under this Agreement in accordance with Section&nbsp;7.4 or to transfer such CVRs to Parent pursuant to Section&nbsp;2.6; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:144pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">any other amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition, elimination or change is adverse to the interests of the Holders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this Section&nbsp;5.1, Parent will mail (or cause the Rights Agent to mail) a notice thereof by first class mail to each Holder at its address as it appears on the CVR Register, setting forth such amendment.&nbsp; The failure to deliver such notice, or any defect in such notice, shall not impair or affect the validity of such amendment to this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments with Consent of Holders</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Subject to Section&nbsp;5.1 (which amendments pursuant to Section&nbsp;5.1 may be made without the consent of the Holders), with the consent of the Acting Holders, whether evidenced in writing or taken at a meeting of the Holders, Holders&#x2019; Representative, Parent, when authorized by a Board Resolution, and the Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, even if such addition, elimination or change is materially adverse to the interest of the Holders, including any amendment to effect any of the following:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:144pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">modify in a manner adverse to the Holders (A)&nbsp;any provision contained herein with respect to the termination of this Agreement or the CVRs, (B)&nbsp;the time for, and amount of, any payment to be made to the Holders pursuant to this Agreement, or (C)&nbsp;the definitions of Net Proceeds, including related definitions, such as Gross Consideration, Permitted Deductions, Gemcabene Deal, and Gemcabene Technology;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:144pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">reduce the number of CVRs (except as provided in Section&nbsp;5.1(b)(v)); or</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:144pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">modify any provisions of this Section&nbsp;5.2, except to increase the percentage of Holders from whom consent is required or to provide that certain provisions of this Agreement cannot be modified or waived without the consent of the Holder of each outstanding CVR affected thereby.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Promptly after the execution by Parent, the Holders&#x2019; Representative and the Rights Agent of any amendment pursuant to the provisions of this Section&nbsp;5.2, Parent will mail (or</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">14</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">cause the Rights Agent to mail) a notice thereof by first class mail to each Holder at its address as it appears on the CVR Register, setting forth such amendment.&nbsp; The failure to deliver such notice, or any defect in such notice, shall not impair or affect the validity of such amendment to this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Execution of Amendments</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; In executing any amendment permitted by this Section&nbsp;5, the Rights Agent will be entitled to receive, and will be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of such amendment is authorized or permitted by this Agreement. The Rights Agent may, but is not obligated to, enter into any such amendment that affects the Rights Agent&#x2019;s own rights, privileges, covenants or duties under this Agreement or otherwise.&nbsp; No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of Amendments</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; Upon the execution of any amendment under this Section&nbsp;5, this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HOLDERS&#x2019; REPRESENTATIVE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Appointment of Holders&#x2019; Representative</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; To the extent valid and binding under applicable law, the Holders&#x2019; Representative is hereby appointed, authorized and empowered to be the exclusive representative, agent and attorney-in-fact of each Holder, with full power of substitution, to make all decisions and determinations and to act (or not act) and execute, deliver and receive all agreements, documents, instruments and consents on behalf of and as agent for each Holder at any time in connection with, and that may be necessary or appropriate to accomplish the intent and implement the provisions of this Agreement and to facilitate the consummation of the transactions contemplated hereby, including without limitation for purposes of (i)&nbsp;negotiating and settling, on behalf of the Holders, any dispute that arises under this Agreement after the Effective Time, (ii)&nbsp;confirming the satisfaction of Parent&#x2019;s obligations under this Agreement and (iii)&nbsp;negotiating and settling matters with respect to the amounts to be paid to the Holders pursuant to this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authority</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; To the extent valid and binding under applicable law, the appointment of the Holders&#x2019; Representative by the Holders upon the Effective Time is coupled with an interest and may not be revoked in whole or in part (including, without limitation, upon the death or incapacity of any stockholder). Subject to the prior qualifications, such appointment shall be binding upon the heirs, executors, administrators, estates, personal representatives, officers, directors, security holders, successors and assigns of each Holder. To the extent valid and binding under applicable law, all decisions of the Holders&#x2019; Representative shall be final and binding on all Holders. Parent and the Rights Agent shall be entitled to rely upon, without independent investigation, any act, notice, instruction or communication from the Holders&#x2019; Representative and any document executed by the Holders&#x2019; Representative on behalf of any Holder and shall be fully protected in connection with any action or inaction taken or omitted to be taken in reliance thereon, absent willful misconduct by Parent or the Rights Agent (as such willful misconduct is determined by a final, non-appealable judgment of a court of competent jurisdiction). The Holders&#x2019; Representative shall not be responsible for any loss suffered by, or liability of any kind to, the Holders arising out of any act done or omitted by the Holders&#x2019; Representative in connection with the acceptance or administration of the Holders&#x2019; Representative&#x2019;s duties hereunder, unless such act or omission involves gross negligence or willful misconduct.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successor Holders&#x2019; Representative</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; The Holders&#x2019; Representative may be removed for any reason or no reason by written consent of the Acting Holders. In the event that the Holders&#x2019; Representative becomes unable to perform its responsibilities hereunder or resigns or is removed from such position, the Acting Holders shall be authorized to and shall select another representative to fill</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">15</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">such vacancy and such substituted representative shall be deemed to be the Holders&#x2019; Representative for all purposes of this Agreement. The newly-appointed Holders&#x2019; Representative shall notify Parent, the Rights Agent and any other appropriate Person in writing of its appointment, provide evidence that the Acting Holders approved such appointment and provide appropriate contact information for purposes of this Agreement. Parent and the Rights Agent shall be entitled to rely upon, without independent investigation, the identity and validity of such newly-appointed Holders&#x2019; Representative as set forth in such written notice. In the event that within 30 days after the Holders&#x2019; Representative becomes unable to perform its responsibilities hereunder or resigns or is removed from such position, no successor Holders&#x2019; Representative has been so selected, Parent shall cause the Rights Agent to notify the Person holding the largest quantity of the outstanding CVRs (and who is not Parent or, to the Rights Agent&#x2019;s actual knowledge, any Affiliate of Parent) that such Person is the successor Holders&#x2019; Representative, and such Person shall be the successor Holders&#x2019; Representative hereunder. If such Person notifies the Rights Agent in writing that such Person declines to serve, the Rights Agent shall forthwith notify the Person holding the next-largest quantity of the outstanding CVRs (and who is not Parent or, to the Rights Agent&#x2019;s actual knowledge, any Affiliate of Parent) that such next-largest-quantity Person is the successor Holders&#x2019; Representative, and such next-largest-quantity Person shall be the successor Holders&#x2019; Representative hereunder. (And so on, to the extent as may be necessary.) The Holders are intended third party beneficiaries of this Section&nbsp;6.3. If a successor Holders&#x2019; Representative is not appointed pursuant to the preceding procedure within 60 days after the Holders&#x2019; Representative becomes unable to perform its responsibilities hereunder or resigns or is removed from such position, Parent shall appoint a successor Holders&#x2019; Representative.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination of Duties and Obligations</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; The Holders&#x2019; Representative&#x2019;s duties and obligations under this Agreement shall survive until no CVRs remain outstanding or until this Agreement expires or is terminated pursuant to Section&nbsp;7.7(b), whichever is earlier.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OTHER PROVISIONS OF GENERAL APPLICATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices to Rights Agent, Parent and Holders&#x2019; Representative</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&nbsp;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&nbsp;upon delivery in the case of delivery by hand, or (c)&nbsp;on the date delivered if sent by email (with a written or electronic confirmation of delivery) prior to 5:00 p.m.&nbsp;Eastern time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">If to the Rights Agent, to it at:</font>
		</p>
		<p style="margin:0pt;text-indent:40.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Computershare Inc.</font>
		</p>
		<p style="margin:0pt;text-indent:40.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">150 Royall Street, 2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;font-size:6pt;top:-4pt;position:relative;line-height:100%">nd</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> Floor</font>
		</p>
		<p style="margin:0pt;text-indent:40.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Canton, MA 02021</font>
		</p>
		<p style="margin:0pt;text-indent:40.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Attn: Legal Department</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">With a copy to:</font>
		</p>
		<p style="margin:0pt;text-indent:40.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">If to Parent, to it at:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Gemphire Therapeutics Inc.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">177 Huntington Avenue, Suite 1700</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">16</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Boston, MA 02115</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40.5pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Attn: John L. Brooks, III, President</font>
		</p>
		<p style="margin:0pt 0pt 12pt 40.5pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Email: </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">With a copy to:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">One Financial Center</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Boston, MA 02111</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Attn: Megan N. Gates </font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Fax: 617-542-2241</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"> If to the Holders&#x2019; Representative, to:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Grand Rapids Holders&#x2019; Representative, LLC</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">650 Trade Centre Way</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Kalamazoo, MI 49002</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Attn: Phillip D. Torrence</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">With a copy to:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Honigman LLP</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">650 Trade Centre Way</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Suite 200</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Kalamazoo, MI 49002-0402<br />Attention: Phillip D. Torrence<br />Email: </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">The Rights Agent, Parent or the Holders&#x2019; Representative may specify a different address or electronic mail address by giving notice in accordance with this Section&nbsp;7.1.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice to Holders</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; Where this Agreement provides for notice to Holders, such notice will be sufficiently given (unless otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at the Holder&#x2019;s address as it appears in the CVR Register, not later than the latest date, and not earlier than the earliest date, if any, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder will affect the sufficiency of such notice with respect to other Holders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent Successors and Assigns; Merger of Rights Agent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Parent may not assign this Agreement without the prior written consent of the Holders&#x2019; Representative, provided that (a)&nbsp;Parent may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more direct or indirect wholly-owned subsidiaries of Parent (each, an &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Assignee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) provided that the Assignee agrees to assume and be bound by all of the terms of this Agreement; provided, however, that in connection with any assignment to an Assignee, Parent shall, and shall agree to, remain liable for the performance by such Assignee of all obligations of Parent hereunder, with such Assignee substituted for Parent under this Agreement, and (b)&nbsp;Parent may assign this Agreement in its entirety without the consent</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">17</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">of any other party to its successor in interest in connection with the sale of all or substantially all of its assets or of its stock, or in connection with a merger, acquisition or similar transaction (such successor in interest, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Acquiror</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;, and such transaction, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Acquisition</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;).&nbsp; This Agreement will be binding upon, inure to the benefit of and be enforceable by Parent&#x2019;s successors, acquirers and each Assignee. Each reference to &#x201C;Parent&#x201D; in this Agreement shall be deemed to include Parent&#x2019;s successors, acquirers and all Assignees.&nbsp; Each of Parent&#x2019;s successors, acquirers and assigns shall expressly assume by an instrument supplemental hereto, executed and delivered to the Rights Agent, the due and punctual payment of the CVR Payments and the due and punctual performance and observance of all of the covenants and obligations of this Agreement to be performed or observed by Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or any Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the Parties hereto, provided that such Person would be eligible for appointment as a successor Rights Agent under the provisions of the Agreement.&nbsp; The purchase of all or substantially all of the Rights Agent&#x2019;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this Section&nbsp;7.3(b).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Benefits of Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; Nothing in this Agreement, express or implied, will give to any Person (other than the Rights Agent, Parent, Parent&#x2019;s successors and assignees, and the Holders) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of the Rights Agent, Parent, Parent&#x2019;s successors and assignees, and the Holders. The rights of Holders are limited to those expressly provided in this Agreement and the Merger Agreement. Notwithstanding anything to the contrary contained herein, any Holder may agree to renounce, in whole or in part, such Holder&#x2019;s rights under this Agreement by written notice to the Rights Agent and Parent, which notice, if given, shall be irrevocable.&nbsp; In such event, such Holder&#x2019;s CVRs will not be included for determining the Payment Amounts to all other Holders. Further, for the avoidance of doubt, any decision by the Board of Directors to discontinue the pursuit of a Gemcabene Deal following the Covenant End Date shall be in the sole discretion of the Board of Directors, and shall not provide or give rise to a right of action to any Holder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable. The Parties further agree to replace such invalid or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable provision; provided, however, that if such excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to the Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts and Signature</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; This Agreement may be executed in two or more counterparts (including by electronic scan delivered by electronic mail), each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the Parties hereto and delivered to the other Party, it being understood that the Parties need not sign the same counterpart.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">18</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">This Agreement will expire and be of no force or effect, the Parties hereto will have no liability hereunder (other than with respect to monies due and owing by Parent to Rights Agent or any other rights of the Rights Agent which expressly survive the termination of this Agreement), and no additional payments will be required to be made, upon the later of (i) the conclusion of the CVR Term and (ii) the payment of the full amount of all CVR Payments to the Rights Agent and the payment of the full amount of all Payment Amounts to the Holders by the mailing by the Rights Agent of each applicable Payment Amount to each Holder at the address reflected in the CVR Register.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">This Agreement will terminate automatically upon any termination of the Merger Agreement prior to the Effective Time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Funds</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; All funds received by the Rights Agent under this Agreement that are to be distributed or applied by the Rights Agent in the performance of services hereunder (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">Funds</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">&#x201D;) shall be held by the Rights Agent as agent for the Parent and deposited in one or more bank accounts to be maintained by the Rights Agent in its name as agent for the Parent.&nbsp; Until paid pursuant to the terms of this Agreement, the Rights Agent will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1 billion or with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&#x2019;s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall have no responsibility or liability for any diminution of the Funds that may result from any deposit made by the Rights Agent in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or other Third Party.&nbsp; The Rights Agent may from time to time receive interest, dividends or other earnings in connection with such deposits.&nbsp; The Rights Agent shall not be obligated to pay such interest, dividends or earnings to the Parent, any Holder or any other party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">.&nbsp; Notwithstanding the reference to any other agreement hereunder, this Agreement contains the entire understanding of the Parties hereto and thereto with reference to the transactions and matters contemplated hereby and thereby and supersedes all prior agreements, written or oral, among the Parties with respect hereto and thereto. If and to the extent that any provision of this Agreement is inconsistent or conflicts with the Merger Agreement, this Agreement will govern and control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">7.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applicable Law; Jurisdiction.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws.&nbsp; In any action or proceeding between the Parties arising out of or relating to this Agreement, each Party: (a)&nbsp;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the foregoing courts has jurisdiction, the Superior Court of the State of Delaware; (b)&nbsp;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&nbsp;of this Section&nbsp;7.10; (c)&nbsp;waives any objection to laying venue in any such action or proceeding in such courts; (d)&nbsp;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party; (e)&nbsp;agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with Section&nbsp;7.1 of this Agreement; and (f)&nbsp;irrevocably and unconditionally waives the right to trial by jury.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">{Remainder of page&nbsp;intentionally left blank}</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">19</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">IN WITNESS WHEREOF, each of the Parties has caused this Contingent Value Rights Agreement to be executed on its behalf by its duly authorized officers as of the day and year first above written.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:51.22%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:51.22%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">COMPUTERSHARE INC.</font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">COMPUTERSHARE TRUST COMPANY, N.A.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:51.22%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;">GRAND RAPIDS HOLDERS&#x2019; REPRESENTATIVE, LLC</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Name:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:48.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.44%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Title:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.78%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">20</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Exhibit A</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Gemcabene Intellectual Property Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">21</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>4
<FILENAME>ex-2d3.htm
<DESCRIPTION>EX-2.3
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:42 AM-->
<html>
	<head>
		<title>
			gemp_Ex2_3
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit 2.3</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">VOTING AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This VOTING AGREEMENT (this &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) is entered into as of July __, 2019, among Gemphire Therapeutics Inc., a Delaware corporation (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Parent</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), and the undersigned stockholder (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Stockholder</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, as of the date hereof, the Stockholder is the sole record and beneficial owner of and has the sole power to vote (or to direct the voting of) the number of shares of common stock, par value $0.001 per share (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Common Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), of Parent, set forth opposite the Stockholder&#x2019;s name on </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Schedule I</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> hereto (such Common Stock together with any other shares of Parent (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) the voting power of which is acquired by such Stockholder during Voting Period (defined below), are collectively referred to herein as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Subject Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;);</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, the Company, Parent, and GR Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger Sub</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), are concurrently entering into an Agreement and Plan of Merger and Reorganization, dated on or about the date hereof (as amended from time to time, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), pursuant to which Merger Sub shall be merged with and into the Company, with the Company continuing as the surviving corporation thereafter (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;);</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, the adoption of the Merger Agreement and the transactions contemplated thereby requires the affirmative vote of the holders of a majority of the shares of Common Stock outstanding on the applicable record date and entitled to vote thereon; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, as an inducement to the Company&#x2019;s and Parent&#x2019;s willingness to enter into the Merger Agreement and consummate the transactions contemplated thereby, transactions from which the Stockholder believes it will derive substantial benefits through its ownership interest in the combined company, the Stockholder is entering into this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, the parties agree as follows:</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE I</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">DEFINITIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Capitalized Terms</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;For purposes of this Agreement, capitalized terms used and not defined herein shall have the respective meanings ascribed to them in the Merger Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE II</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">VOTING AGREEMENT AND IRREVOCABLE PROXY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Agreement to Vote</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder hereby agrees that, during the Voting Period, and at any duly called meeting of the stockholders of Parent (or any adjournment or postponement thereof), or in any other circumstances (including action by written consent of stockholders in lieu of a meeting) upon which a vote, adoption or other approval or consent with respect to the adoption of the Merger Agreement or the approval of the Merger and any of the transactions contemplated thereby is sought, the Stockholder shall, if a meeting is held, appear at the meeting, in person or by proxy, and shall provide a written consent or vote (or cause to be voted), in person or by proxy, all its Subject Shares, in each case (a) in favor of (i) any proposal to adopt and approve or reapprove the Merger Agreement and the transactions contemplated thereby, including without limitation (A) the amendment of Parent&#x2019;s certificate of incorporation to effect the Reverse Split, (B) the amendment to Parent&#x2019;s certificate of incorporation to change the name of Parent to &#x201C;NeuroBo Pharmaceuticals, Inc.&#x201D;, (C) the issuance of shares of Parent Common Stock to the Company&#x2019;s stockholders in connection with the Contemplated Transactions and the change of control of Parent resulting from the Merger pursuant to the Nasdaq rules, (D) the adoption and approval of the 2019 Plan, and (E) &nbsp;any other proposal in connection with, or related to, the consummation of the Merger for which the Parent Board has recommended that Parent&#x2019;s stockholders vote in favor and (ii) waiving any notice that may have</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">been or may be required relating to the Merger or any of the other transactions contemplated by the Merger Agreement and (b) against (i) any Acquisition Proposal and any action in furtherance of any such Acquisition Proposal, and (ii) any action, proposal, transaction or agreement that, to the knowledge of the Stockholder, would reasonably be expected to result in a material breach of any covenant, representation or warranty or any other obligation or agreement of the Stockholder under this Agreement.&nbsp;&nbsp;As used herein, the term &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Expiration Time</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean the earliest occurrence of (x) the Effective Time and (y) the date and time of the valid termination of the Merger Agreement in accordance with its terms, and the term &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Voting Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean such period of time between the date hereof and the Expiration Time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Grant of Irrevocable Proxy</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder hereby appoints Parent and any designee of Parent, and each of them individually, as the Stockholder&#x2019;s proxy, with full power of substitution and resubstitution, to vote, including by executing written consents, during the Voting Period with respect to any and all of the Subject Shares on the matters and in the manner specified in </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 2.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder shall take all further action or execute such other instruments as may be necessary to effectuate the intent of any such proxy.&nbsp;&nbsp;The Stockholder affirms that the irrevocable proxy given by it hereby with respect to the Merger Agreement and the transactions contemplated thereby is given to Parent by the Stockholder to secure the performance of the obligations of the Stockholder under this Agreement.&nbsp;&nbsp;It is agreed that Parent (and its officers on behalf of Parent) will use the irrevocable proxy that is granted by the Stockholder hereby only in accordance with applicable Laws and that, to the extent Parent (and its officers on behalf of Parent) uses such irrevocable proxy, it will only vote (or sign written consents in respect of) the Subject Shares subject to such irrevocable proxy with respect to the matters specified in, and in accordance with the provisions of, </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 2.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Nature of Irrevocable Proxy</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The proxy granted pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 2.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> to Parent by the Stockholder shall be irrevocable during the term of this Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall revoke any and all prior proxies or powers of attorney granted by the Stockholder and no subsequent proxy or power of attorney shall be given or written consent executed (and if given or executed, shall not be effective) by the Stockholder with respect thereto.&nbsp;&nbsp;The proxy that may be granted hereunder shall terminate upon the termination of this Agreement, but shall survive the death or incapacity of the Stockholder and any obligation of the Stockholder under this Agreement shall be binding upon the heirs, personal representatives and successors of the Stockholder.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE III</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">COVENANTS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Subject Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Stockholder agrees that (i) from the date hereof until the Effective Time, it shall not, and shall not commit or agree to, without the prior written consent of Parent and the Company, directly or indirectly, whether by merger, consolidation or otherwise, offer for sale, sell (including short sales), transfer, tender, pledge, encumber, assign or otherwise dispose of (including by gift or by operation of law) (collectively, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Transfer</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), or enter into any contract, option, derivative, hedging or other agreement or arrangement or understanding (including any profit-sharing arrangement) with respect to, or consent to or permit, a Transfer of, any or all of the Subject Shares or any interest therein; and (ii) during the Voting Period, it shall not, and shall not commit or agree to, without the prior written consent of Parent and the Company, (A) grant any proxies or powers of attorney with respect to any or all of the Subject Shares or agree to vote (or sign written consents in respect of) the Subject Shares on any matter or divest itself of any voting rights in the Subject Shares, or (B) take any action that would have the effect of preventing or disabling the Stockholder from performing its obligations under this Agreement.&nbsp;&nbsp;Notwithstanding the foregoing, the Stockholder may, at any time, Transfer its Subject Shares (1) by will or other testamentary document or by intestacy, (2) to any investment fund or other entity controlled or managed by the Stockholder, (3) to any member of the Stockholder&#x2019;s immediate family or (4) to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder or otherwise for estate planning purposes; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, that the applicable transferee shall have executed and delivered a voting agreement substantially identical to the Agreement.&nbsp;&nbsp;The Stockholder agrees that any Transfer of Subject Shares not permitted hereby shall be null and void and that any such prohibited Transfer shall be enjoined. If any voluntary or involuntary transfer of any Subject Shares covered hereby shall occur (including, but not limited to, a sale by the Stockholder&#x2019;s trustee in</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">bankruptcy, or a sale to a purchaser at any creditor&#x2019;s or court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee) shall take and hold such Subject Shares subject to all of the restrictions, liabilities and rights under this Agreement, which shall continue in full force and effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a stock dividend or distribution, or any change in the Subject Shares by reason of any stock dividend or distribution, split-up, recapitalization, combination, conversion, exchange of shares or the like, the term &#x201C;Subject Shares&#x201D; shall be deemed to refer to and include the Subject Shares as well as all such stock dividends and distributions and any securities into which or for which any or all of the Subject Shares may be changed or exchanged or which are received in such transaction.&nbsp;&nbsp;The Stockholder further agrees that, in the event Stockholder purchases or otherwise acquires beneficial or record ownership of or an interest in, or acquires the right to vote or share in the voting of, any additional Shares, in each case after the execution of this Agreement, the Stockholder shall deliver promptly to Parent and the Company written notice of such event, which notice shall state the number of additional Shares so acquired.&nbsp;&nbsp;The Stockholder agrees that any such additional Shares shall be subject to the terms of this Agreement, including all covenants, agreements, obligations, representations and warranties set forth herein as if those additional shares were owned by the Stockholder on the date of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Stockholder&#x2019;s Capacity</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;All agreements and understandings made herein shall be made solely in the Stockholder&#x2019;s capacity as a holder of the Subject Shares and not in any other capacity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Other Offers</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Except to the extent Parent is permitted to take such action pursuant to the Merger Agreement, neither the Stockholder (in the Stockholder&#x2019;s capacity as such), shall, nor shall the Stockholder authorize or permit any of its Representatives to, take any of the following actions: (a) solicit, initiate, knowingly encourage or knowingly facilitate an Acquisition Proposal, (b) furnish any non-public information regarding Parent to any Person in connection with or in response to an Acquisition Proposal, (c) engage in, enter into, continue or otherwise participate in any discussions or negotiations with any Person with respect to, or otherwise knowingly cooperate in any way with any Person (or any representative thereof) with respect to, any Acquisition Proposal, (d) approve, endorse or recommend or propose to approve, endorse or recommend, any Acquisition Proposal or (e) enter into any letter of intent or similar document or any Contract contemplating, approving, endorsing or recommending or proposing to approve, endorse or recommend, any Acquisition Transaction or accepting any Acquisition Proposal; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, however, that none of the foregoing restrictions shall apply to the Stockholder&#x2019;s and its Representatives&#x2019; interactions with Parent, Merger Sub, the Company and their respective subsidiaries and representatives.&nbsp;&nbsp;Without limiting the foregoing, it is understood that any violation of the foregoing restrictions by any Representatives of the Stockholder shall be deemed to be a breach of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 3.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> by the Stockholder.&nbsp;&nbsp;The Stockholder shall, and shall use reasonable best efforts to cause its Representatives to, immediately cease any and all existing discussions or negotiations with any Persons conducted heretofore with respect to any Acquisition Proposal.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Communications</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;During the Voting Period, the Stockholder shall not, and shall use its reasonable best efforts to cause its Representatives, if any, not to, directly or indirectly, make any press release, public announcement or other public communication that criticizes or disparages this Agreement or the Merger Agreement or any of the transactions contemplated hereby and thereby, without the prior written consent of Parent and the Company, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> that the foregoing shall not limit or affect any actions taken by the Stockholder (or any affiliated officer or director of Stockholder) that would be permitted to be taken by Stockholder pursuant to the Merger Agreement.&nbsp;&nbsp;The Stockholder hereby (a) consents to and authorizes the publication and disclosure by Parent, Merger Sub and the Company (including in any publicly filed documents relating to the Merger or any transaction contemplated by the Merger Agreement) of: (i) the Stockholder&#x2019;s identity; (ii) the Stockholder&#x2019;s beneficial ownership of the Subject Shares; (iii) this Agreement; and (iv) the nature of the Stockholder&#x2019;s commitments, arrangements and understandings under this Agreement, and any other information that Parent, Merger Sub or the Company determines to be necessary in any SEC disclosure document in connection with the Merger or any transactions contemplated by the Merger Agreement and (b) agrees as promptly as practicable to notify Parent, Merger Sub and the Company of any required corrections with respect to any written information supplied by the Stockholder specifically for use in any such disclosure document.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Voting Trusts</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder agrees that it will not, nor will it permit any entity under its control to, deposit any of its Subject Shares in a voting trust or subject any of its Subject Shares to any arrangement with respect to the voting of such Subject Shares other than as provided herein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Waiver of Appraisal Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder hereby irrevocably and unconditionally waives, and agrees not to assert, exercise or perfect (or attempt to exercise, assert or perfect) any rights of appraisal or rights to dissent from the Merger or quasi-appraisal rights that it may at any time have under applicable Laws, including Section 262 of the DGCL.&nbsp;&nbsp;The Stockholder agrees not to commence, join in, facilitate, assist or encourage, and agrees to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against Parent, Merger Sub, the Company or any of their respective successors, directors or officers, (a) challenging the validity, binding nature or enforceability of, or seeking to enjoin the operation of, this Agreement or the Merger Agreement, or (b) alleging a breach of any fiduciary duty of any Person in connection with the evaluation, negotiation, entry into or consummation of the Merger Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE IV</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Stockholder hereby represents and warrants to Parent as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Due Authorization, etc</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder is a natural person, corporation, limited partnership or limited liability company.&nbsp;&nbsp;If the Stockholder is a corporation, limited partnership or limited liability company, Stockholder is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, organized or constituted.&nbsp;&nbsp;The Stockholder has all necessary power and authority to execute and deliver this Agreement, perform the Stockholder&#x2019;s obligations hereunder and to consummate the transactions contemplated hereby.&nbsp;&nbsp;The execution and delivery of this Agreement, the performance of the Stockholder&#x2019;s obligations hereunder and the consummation of the transactions contemplated hereby by the Stockholder have been duly authorized by all necessary action on the part of the Stockholder and no other proceedings on the part of the Stockholder are necessary to authorize this Agreement, or to consummate the transactions contemplated hereby.&nbsp;&nbsp;This Agreement has been duly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by Parent and the Company) constitutes a valid and binding obligation of the Stockholder, enforceable against the Stockholder in accordance with its terms, except to the extent enforcement is limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors&#x2019; rights and by general equitable principles.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Ownership of Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Schedule I</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> hereto sets forth opposite the Stockholder&#x2019;s name the Shares over which the Stockholder has sole record and beneficial ownership as of the date hereof.&nbsp;&nbsp;As of the date hereof, the Stockholder is the lawful owner of the Shares denoted as being owned by the Stockholder on </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Schedule I</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> hereto, has the sole power to vote or cause to be voted such Shares and has the sole power to dispose of or cause to be disposed such Shares (other than, if Stockholder is a partnership or a limited liability company, the rights and interest of Persons that own partnership interests or units in Stockholder under the partnership agreement or operating agreement governing Stockholder and applicable partnership or limited liability company law, or if Stockholder is a married individual and resides in a state with community property laws, the community property interest of his or her spouse to the extent applicable under such community property laws, which spouse hereby consents to this Agreement by executing the spousal consent attached hereto).&nbsp;&nbsp;The Stockholder has, and will at all times up until the Expiration Time have, good and valid title to the Shares denoted as being owned by the Stockholder on </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Schedule I</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> hereto, free and clear of any and all pledges, mortgages, liens, charges, proxies, voting agreements, encumbrances, adverse claims, options, security interests and demands of any nature or kind whatsoever, other than (a) those created by this Agreement, or (b) those existing under applicable securities laws.&nbsp; Without limiting the generality of the foregoing, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Shares, and no Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of the Shares except as provided hereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">No Conflicts</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;(a) No filing with any Governmental Body, and no authorization, consent or approval of any other Person is necessary for the execution of this Agreement by the Stockholder and (b) none of the execution and delivery of this Agreement by the Stockholder, the performance of the Stockholder&#x2019;s obligations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">hereunder, the consummation by the Stockholder of the transactions contemplated hereby or compliance by the Stockholder with any of the provisions hereof shall (i) conflict with or result in any breach of the organizational documents of the Stockholder, (ii) result in, or give rise to, a violation or breach of or a default under any of the terms of any material contract, understanding, agreement or other instrument or obligation to which the Stockholder is a party or by which the Stockholder or any of the Subject Shares or its assets may be bound or (iii) violate any applicable order, writ, injunction, decree, judgment, statute, rule or regulation, except for any of the foregoing as would not reasonably be expected to impair the Stockholder&#x2019;s ability to perform its obligations under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Finder&#x2019;s Fees</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;No investment banker, broker, finder or other intermediary is entitled, whether directly or indirectly, to a fee, commission or other benefit from Parent, Merger Sub or the Company in respect of this Agreement based upon any Contract made by or on behalf of the Stockholder, solely in the Stockholder&#x2019;s capacity as a stockholder of Parent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Reliance</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#x2019;s own choosing.&nbsp;&nbsp;The Stockholder understands and acknowledges that Parent is entering into the Merger Agreement in reliance upon the Stockholder&#x2019;s execution, delivery and performance of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">No Litigation</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;As of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of the Stockholder, threatened against the Stockholder that would reasonably be expected to impair the ability of the Stockholder to perform its obligations hereunder or consummate the transactions contemplated hereby.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE V</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">TERMINATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement shall automatically terminate, and none of Parent, the Company or the Stockholder shall have any rights or obligations hereunder and this Agreement shall become null and void and have no effect upon the earliest to occur of: (a) the Effective Time; and (b) the valid termination of the Merger Agreement in accordance with its terms.&nbsp;&nbsp;The parties acknowledge that upon termination of this Agreement as permitted under and in accordance with the terms of this Agreement, &nbsp;Stockholder shall have no right to recover any claim with respect to any losses suffered by Stockholder in connection with such termination.&nbsp;&nbsp;Notwithstanding anything to the contrary herein, (i) nothing set forth in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section&nbsp;5.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall relieve Stockholder from liability for any breach of this Agreement prior to termination hereof, and (ii) the provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Article V</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and of </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Article VI</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall survive the termination of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE VI</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">MISCELLANEOUS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Further Actions</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Subject to the terms and conditions set forth in this Agreement, the Stockholder agrees to take any all actions and to do all things reasonably necessary to effectuate this Agreement.&nbsp;&nbsp;If the Stockholder is a married individual, his or her spouse shall deliver the spousal consent attached hereto unless such Stockholder can demonstrate to Parent&#x2019;s and the Company&#x2019;s reasonable satisfaction that his or her spouse does not have any community property interests in the Subject Shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Fees and Expenses</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Except as otherwise specifically provided herein, each party shall bear its own fees expenses in connection with this Agreement and the transactions contemplated hereby.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Amendments, Waivers, etc</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement may not be amended except by an instrument in writing signed by all the parties hereto and specifically referencing this Agreement.&nbsp;&nbsp;The failure of any party to assert any rights or remedies shall not constitute a waiver of such rights or remedies.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">5</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Notices</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Any notice, request, instruction or other document required to be given hereunder shall be sufficient if in writing, and sent by confirmed electronic mail transmission of a &#x201C;portable document format&#x201D; (&#x201C;.pdf&#x201D;) attachment (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> that any notice received by electronic mail transmission or otherwise at the addressee&#x2019;s location on any business day after 5:00 p.m. (addressee&#x2019;s local time) shall be deemed to have been received at 9:00 a.m.&nbsp;&nbsp;(addressee&#x2019;s local time) on the next business day), by reliable overnight delivery service (with proof of service), or hand delivery, addressed as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If to Parent, to</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Gemphire Therapeutics Inc.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">17199 N. Laurel Park Drive, Suite 401</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Livonia, MI 48152</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn: President</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Email: </font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">with a copy to (which shall not constitute notice):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Honigman LLP</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">650 Trade Centre Way, Suite 200</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Kalamazoo, MI 49002-0402</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Attention: Phillip D. Torrence</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Email: </font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If to the Company, to</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">NeuroBo Pharmaceuticals, Inc.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">177 Huntington Avenue, Suite 170</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Boston, MA 02115</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn: President</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Email: </font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">with a copy to (which shall not constitute notice):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">One Financial Center</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Boston, MA 02111</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Attention: William T. Whelan and Marc D. Mantell<br />Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If to the Stockholder, to the address or electronic mail address set forth on the signature pages hereto, or to such other Person or address as any party shall specify by written notice so given.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Interpretation; Construction</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Headings of the Articles and Sections of this Agreement are for convenience of the parties only, and shall be given no substantive or interpretive effect whatsoever.&nbsp;&nbsp;Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.&nbsp;&nbsp;As used in this Agreement, the words &#x201C;include&#x201D; and &#x201C;including,&#x201D; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#x201C;without limitation.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Severability</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.&nbsp;&nbsp;If any provision of this Agreement, or the application of such provision to any Person or any circumstance, is invalid or unenforceable (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">6</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application of such provision, in any other jurisdiction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Entire Agreement; Assignment</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement constitutes the entire agreement, and supersedes all other prior agreements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter hereof; &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &nbsp;that, as between the Company and Parent, to the extent of any conflict between the Merger Agreement and this Agreement, the terms of the Merger Agreement shall control and supersede any such conflicting terms.&nbsp; Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of the other parties, except that, without consent, each of Parent and the Company may assign all or any of its rights and obligations hereunder to any of its Affiliates that assume the rights and obligations of such party under the Merger Agreement.&nbsp; Subject to the preceding two sentences, this Agreement will be binding upon, inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns.&nbsp;&nbsp;Notwithstanding anything to the contrary set forth herein, the Stockholder agrees that this Agreement and the obligations hereunder shall be binding upon any Person to which record or beneficial ownership of the Stockholder&#x2019;s Subject Shares shall pass, whether by operation or law or otherwise, including the Stockholder&#x2019;s heirs, guardians, administrators or successors and assigns, and the Stockholder agrees to take all actions necessary to effect the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Governing Law</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;THIS AGREEMENT AND ALL QUESTIONS RELATING TO THE INTERPRETATION OR ENFORCEMENT OF THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAW OF THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF TO THE EXTENT THAT SUCH PRINCIPLES WOULD DIRECT A MATTER TO ANOTHER JURISDICTION.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Specific Performance</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder acknowledges that any breach of this Agreement would give rise to irreparable harm for which monetary damages would not be an adequate remedy and each of the Company and Parent shall be entitled to a decree of specific performance and to temporary, preliminary and permanent injunctive relief to prevent breaches or threatened breaches of any of the provisions of this Agreement, without the necessity of proving the inadequacy of monetary damages as a remedy, which shall be the sole and exclusive remedy for any such breach.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.10&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Submission to Jurisdiction</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The parties hereby irrevocably submit to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, or, if the Chancery Court declines jurisdiction, the United States District Court for the District of Delaware or the courts of the State of Delaware solely in respect of the interpretation and enforcement of the provisions of this Agreement and hereby waive, and agree not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in said courts or that the venue thereof may not be appropriate or that this Agreement may not be enforced in or by such courts, and the parties hereto irrevocably agree that all claims relating to such action, suit or proceeding shall be heard and determined in such courts.&nbsp;&nbsp;The parties hereby consent to and grant any such court jurisdiction over the person of such parties and, to the extent permitted by law, over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 6.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> or in such other manner as may be permitted by applicable Laws shall be valid and sufficient service thereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.11&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Waiver of Jury Trial</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.&nbsp;&nbsp;EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (a) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">7</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WAIVER, (b) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (c) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (d) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">SECTION 6.11</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.12&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Counterparts</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement may be executed in two or more counterparts (including by facsimile transmission or other means of electronic transmission, such as by electronic mail in &#x201C;pdf&#x201D; form), each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by facsimile or otherwise) to the other parties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">8</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">IN WITNESS WHEREOF, Parent, the Company and the Stockholder have caused this Agreement to be duly executed as of the day and year first above written.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">NEUROBO PHARMACEUTICALS, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">[STOCKHOLDER]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Address:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Electronic Mail Address:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt 270pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">[</font><font style="display:inline;font-style:italic;">Signature Page to Voting Agreement</font><font style="display:inline;">]</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SPOUSAL CONSENT</font>
		</p>
		<p style="margin:0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">I&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, spouse of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, having the legal capacity, power and authority to do so, hereby confirm that I have read and approve the foregoing the Voting Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;In consideration of the terms and conditions as set forth in the Agreement, I hereby appoint my spouse (regardless of whether or not my spouse remains as such) as my attorney in fact with respect to the exercise of any rights and obligations under the Agreement, and agree to be bound by the provisions of the Agreement insofar as I may have any rights or obligations in the Agreement under the community property laws of the State of California or similar laws relating to marital or community property.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:49.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.56%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.44%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.56%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.44%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.56%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.44%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.56%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.44%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">[</font><font style="display:inline;font-style:italic;">Signature Page to Voting Agreement</font><font style="display:inline;">]</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Schedule I</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;text-decoration:underline;">Ownership of Common Stock</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:8pt;">Name and Address of Stockholder</font></p>
				</td>
				<td valign="bottom" style="width:03.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:49.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:8pt;">Number of Shares of Common Stock</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:49.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:49.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:47.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:49.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">Schedule I-1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.4
<SEQUENCE>5
<FILENAME>ex-2d4.htm
<DESCRIPTION>EX-2.4
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:43 AM-->
<html>
	<head>
		<title>
			gemp_Ex2_4
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit 2.4</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">VOTING AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This VOTING AGREEMENT (this &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) is entered into as of July&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019, among NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), &nbsp;Gemphire Therapeutics Inc., a Delaware corporation (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Parent</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), and the undersigned stockholder (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Stockholder</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, as of the date hereof, the Stockholder is the sole record and beneficial owner of and has the sole power to vote (or to direct the voting of) the number of shares of common stock, par value $1.0000 per share (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Common Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), and&nbsp;&nbsp;the number of shares of preferred stock, par value $1.0000 per share (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Preferred Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) of the Company, set forth opposite the Stockholder&#x2019;s name on </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Schedule I</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> hereto (such Common Stock and Preferred Stock, together with any other shares of the Company (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) the voting power of which is acquired by such Stockholder during the Voting Period (defined below), are collectively referred to herein as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Subject Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;);</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, the Company, Parent, and GR Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger Sub</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), are concurrently entering into an Agreement and Plan of Merger and Reorganization, dated on or about the date hereof (as amended from time to time, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), pursuant to which Merger Sub shall be merged with and into the Company, with the Company continuing as the surviving corporation thereafter (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;);</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, the adoption of the Merger Agreement and the transactions contemplated thereby requires the written consent or affirmative vote of the holders of (a) (i) a majority of the shares of Common Stock and (ii) a majority of the shares of Preferred Stock, on an as-converted to Common Stock basis, in each case, outstanding on the record date for the Company Stockholder Written Consent and entitled to vote thereon, and (b) at least two-thirds of the outstanding shares of Preferred Stock, together as a single-class, on an as-converted to Common Stock basis; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">WHEREAS, as an inducement to the Company&#x2019;s and Parent&#x2019;s willingness to enter into the Merger Agreement and consummate the transactions contemplated thereby, transactions from which the Stockholder believes it will derive substantial benefits through its ownership interest in the Company, the Stockholder is entering into this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, the parties agree as follows:</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE I</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">DEFINITIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Capitalized Terms</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;For purposes of this Agreement, capitalized terms used and not defined herein shall have the respective meanings ascribed to them in the Merger Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE II</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">VOTING AGREEMENT AND IRREVOCABLE PROXY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Agreement to Vote</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Stockholder hereby agrees that, within five (5) business days after the Registration Statement becomes effective, the Stockholder shall execute and deliver, or cause to be executed and delivered, to the Company, a written consent in the form of </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> hereto (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Written Consent</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The Written Consent shall be coupled with an interest and shall be irrevocable.&nbsp;&nbsp;As used herein, the term &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Expiration Time</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean the earliest occurrence of (i) the Effective Time and (ii) the date and time of the valid termination of the Merger Agreement in accordance with its terms, and the term &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Voting Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean such period of time between the date hereof and the Expiration Time.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Stockholder hereby agrees that, during the Voting Period, and at any duly called meeting of the stockholders of the Company (or any adjournment or postponement thereof), or in any other circumstances (including action by written consent of stockholders in lieu of a meeting) upon which a vote, adoption or other approval or consent with respect to the adoption of the Merger Agreement or the approval of the Merger and any of the transactions contemplated thereby is sought, the Stockholder shall, if a meeting is held, appear at the meeting, in person or by proxy, and shall provide a written consent or vote (or cause to be voted), in person or by proxy, all its Subject Shares, in each case (i) in favor of (A) any proposal to adopt and approve or reapprove the Merger Agreement and the transactions contemplated thereby, including without limitation (1) adoption and approval of the Merger Agreement and the Contemplated Transactions, (2) acknowledgment that the approval given thereby is irrevocable and that the Stockholder is aware of the Stockholder&#x2019;s rights to demand appraisal for its shares pursuant to Section 262 of the DGCL, a true and correct copy of which will be attached thereto, and that the Stockholder has received and read a copy of Section 262 of the DGCL, (3) acknowledgment that by the Stockholder&#x2019;s approval of the Merger the Stockholder is not entitled to appraisal rights with respect to the Subject Shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of the Stockholder&#x2019;s capital stock under the DGCL, and (4) the Preferred Stock Conversion and the conversion of the Company Convertible Notes and (B) waiving any notice that may have been or may be required relating to the Merger or any of the other transactions contemplated by the Merger Agreement, and (ii) against (A) any Acquisition Proposal and (B) &nbsp;any action, proposal, transaction or agreement that, to the knowledge of the Stockholder, would reasonably be expected to result in a material breach of any covenant, representation or warranty or any other obligation or agreement of the Stockholder under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Grant of Irrevocable Proxy</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; The Stockholder hereby appoints the Company and any designee of the Company, and each of them individually, as the Stockholder&#x2019;s proxy, with full power of substitution and resubstitution, to vote, including by executing written consents, during the Voting Period with respect to any and all of the Subject Shares on the matters and in the manner specified in </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 2.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;">; provided, however, that the Stockholder&#x2019;s grant of the proxy contemplated by this </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 2.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall be effective with respect to </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 2.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> if, and only if, the Stockholder does not deliver the Written Consent after being given a reasonable opportunity to do so, or attempts to vote or consent in a manner inconsistent with the provisions of </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 2.1(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. The Stockholder shall take all further action or execute such other instruments as may be necessary to effectuate the intent of any such proxy.&nbsp;&nbsp;The Stockholder affirms that the irrevocable proxy given by it hereby with respect to the Merger Agreement and the transactions contemplated thereby is given to the Company by the Stockholder to secure the performance of the obligations of the Stockholder under this Agreement.&nbsp;&nbsp;It is agreed that the Company (and its officers on behalf of the Company) will use the irrevocable proxy that is granted by the Stockholder hereby only in accordance with applicable Laws and that, to the extent the Company (and its officers on behalf of the Company) uses such irrevocable proxy, it will only vote (or sign written consents in respect of) the Subject Shares subject to such irrevocable proxy with respect to the matters specified in, and in accordance with the provisions of, </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 2.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Nature of Irrevocable Proxy</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The proxy granted pursuant to </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 2.2</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> to the Company by the Stockholder shall be irrevocable during the term of this Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall revoke any and all prior proxies or powers of attorney granted by the Stockholder and no subsequent proxy or power of attorney shall be given or written consent executed (and if given or executed, shall not be effective) by the Stockholder with respect thereto.&nbsp;&nbsp;The proxy that may be granted hereunder shall terminate upon the termination of this Agreement, but shall survive the death or incapacity of the Stockholder and any obligation of the Stockholder under this Agreement shall be binding upon the heirs, personal representatives and successors of the Stockholder.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE III</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">COVENANTS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Subject Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Stockholder agrees that (i) from the date hereof until the Effective Time, it shall not, and shall not commit or agree to, without the prior written consent of Parent and the Company, directly or indirectly, whether by merger, consolidation or otherwise, offer for sale, sell (including short sales), transfer, tender, pledge,</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">encumber, assign or otherwise dispose of (including by gift or by operation of law) (collectively, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Transfer</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), or enter into any contract, option, derivative, hedging or other agreement or arrangement or understanding (including any profit-sharing arrangement) with respect to, or consent to or permit, a Transfer of, any or all of the Subject Shares or any interest therein; and (ii) during the Voting Period, it shall not, and shall not commit or agree to, without the prior written consent of Parent and the Company, (A) grant any proxies or powers of attorney with respect to any or all of the Subject Shares or agree to vote (or sign written consents in respect of) the Subject Shares on any matter or divest itself of any voting rights in the Subject Shares, or (B) take any action that would have the effect of preventing or disabling the Stockholder from performing its obligations under this Agreement.&nbsp;&nbsp;Notwithstanding the foregoing, the Stockholder may, at any time, Transfer its Subject Shares (1) by will or other testamentary document or by intestacy, (2) to any investment fund or other entity controlled or managed by the Stockholder, (3) to any member of the Stockholder&#x2019;s immediate family or (4) to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder or otherwise for estate planning purposes; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, that the applicable transferee shall have executed and delivered a voting agreement substantially identical to the Agreement.&nbsp;&nbsp;The Stockholder agrees that any Transfer of Subject Shares not permitted hereby shall be null and void and that any such prohibited Transfer shall be enjoined. If any voluntary or involuntary transfer of any Subject Shares covered hereby shall occur (including, but not limited to, a sale by the Stockholder&#x2019;s trustee in bankruptcy, or a sale to a purchaser at any creditor&#x2019;s or court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee) shall take and hold such Subject Shares subject to all of the restrictions, liabilities and rights under this Agreement, which shall continue in full force and effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a stock dividend or distribution, or any change in the Subject Shares by reason of any stock dividend or distribution, split-up, recapitalization, combination, conversion, exchange of shares or the like, the term &#x201C;Subject Shares&#x201D; shall be deemed to refer to and include the Subject Shares as well as all such stock dividends and distributions and any securities into which or for which any or all of the Subject Shares may be changed or exchanged or which are received in such transaction.&nbsp;&nbsp;The Stockholder further agrees that, in the event Stockholder purchases or otherwise acquires beneficial or record ownership of or an interest in, or acquires the right to vote or share in the voting of, any additional Shares, in each case after the execution of this Agreement, the Stockholder shall deliver promptly to the Company and Parent written notice of such event, which notice shall state the number of additional Shares so acquired.&nbsp;&nbsp;The Stockholder agrees that any such additional Shares shall be subject to the terms of this Agreement, including all covenants, agreements, obligations, representations and warranties set forth herein as if those additional shares were owned by the Stockholder on the date of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Stockholder&#x2019;s Capacity</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;All agreements and understandings made herein shall be made solely in the Stockholder&#x2019;s capacity as a holder of the Subject Shares and not in any other capacity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Other Offers</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Except to the extent the Company is permitted to take such action pursuant to the Merger Agreement, neither the Stockholder (in the Stockholder&#x2019;s capacity as such), shall, nor shall the Stockholder authorize or permit any of its Representatives to, take any of the following actions: (a) solicit, initiate, knowingly encourage or knowingly facilitate an Acquisition Proposal, (b) furnish any non-public information regarding the Company to any Person in connection with or in response to an Acquisition Proposal, (c) engage in, enter into, continue or otherwise participate in any discussions or negotiations with any Person with respect to, or otherwise knowingly cooperate in any way with any Person (or any representative thereof) with respect to, any Acquisition Proposal, (d) approve, endorse or recommend or propose to approve, endorse or recommend, any Acquisition Proposal or (e) enter into any letter of intent or similar document or any Contract contemplating, approving, endorsing or recommending or proposing to approve, endorse or recommend, any Acquisition Transaction or accepting any Acquisition Proposal; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, that none of the foregoing restrictions shall apply to the Stockholder&#x2019;s and its Representatives&#x2019; interactions with Parent, Merger Sub, the Company and their respective subsidiaries and representatives.&nbsp;&nbsp;Without limiting the foregoing, it is understood that any violation of the foregoing restrictions by any Representatives of the Stockholder shall be deemed to be a breach of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 3.3</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> by the Stockholder.&nbsp;&nbsp;The Stockholder shall, and shall use reasonable best efforts to cause its Representatives to, immediately cease any and all existing discussions or negotiations with any Persons conducted heretofore with respect to any Acquisition Proposal.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Communications</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;During the Voting Period, the Stockholder shall not, and shall use its reasonable best efforts to cause its Representatives, if any, not to, directly or indirectly, make any press release, public announcement or other public communication that criticizes or disparages this Agreement or the Merger Agreement or any of the transactions contemplated hereby and thereby, without the prior written consent of Parent and the Company, </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> that the foregoing shall not limit or affect any actions taken by the Stockholder (or any affiliated officer or director of Stockholder) that would be permitted to be taken by Stockholder pursuant to the Merger Agreement. The Stockholder hereby (a) consents to and authorizes the publication and disclosure by Parent, Merger Sub and the Company (including in any publicly filed documents relating to the Merger or any transaction contemplated by the Merger Agreement) of: (i) the Stockholder&#x2019;s identity; (ii) the Stockholder&#x2019;s beneficial ownership of the Subject Shares; (iii) this Agreement; and (iv) the nature of the Stockholder&#x2019;s commitments, arrangements and understandings under this Agreement, and any other information that Parent, Merger Sub or the Company determines to be necessary in any SEC disclosure document in connection with the Merger or any transactions contemplated by the Merger Agreement and (b) agrees as promptly as practicable to notify Parent, Merger Sub and the Company of any required corrections with respect to any written information supplied by the Stockholder specifically for use in any such disclosure document.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Voting Trusts</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder agrees that it will not, nor will it permit any entity under its control to, deposit any of its Subject Shares in a voting trust or subject any of its Subject Shares to any arrangement with respect to the voting of such Subject Shares other than as provided herein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Waiver of Appraisal Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder hereby irrevocably and unconditionally waives, and agrees not to assert, exercise or perfect (or attempt to exercise, assert or perfect) any rights of appraisal or rights to dissent from the Merger or quasi-appraisal rights that it may at any time have under applicable Laws, including Section 262 of the DGCL.&nbsp;&nbsp;The Stockholder agrees not to commence, join in, facilitate, assist or encourage, and agrees to take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against Parent, Merger Sub, the Company or any of their respective successors, directors or officers, (a) challenging the validity, binding nature or enforceability of, or seeking to enjoin the operation of, this Agreement or the Merger Agreement, or (b) alleging a breach of any fiduciary duty of any Person in connection with the evaluation, negotiation, entry into or consummation of the Merger Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE IV</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Stockholder hereby represents and warrants to the Company as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Due Authorization, etc</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder is a natural person, corporation, limited partnership or limited liability company.&nbsp;&nbsp;If the Stockholder is a corporation, limited partnership or limited liability company, Stockholder is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, organized or constituted. The Stockholder has all necessary power and authority to execute and deliver this Agreement, perform the Stockholder&#x2019;s obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement, the performance of the Stockholder&#x2019;s obligations hereunder and the consummation of the transactions contemplated hereby by the Stockholder have been duly authorized by all necessary action on the part of the Stockholder and no other proceedings on the part of the Stockholder are necessary to authorize this Agreement, or to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by Parent and the Company) constitutes a valid and binding obligation of the Stockholder, enforceable against the Stockholder in accordance with its terms, except to the extent enforcement is limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors&#x2019; rights and by general equitable principles.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Ownership of Shares</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Schedule I</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> hereto sets forth opposite the Stockholder&#x2019;s name the Shares over which the Stockholder has sole record and beneficial ownership as of the date hereof. As of the date hereof, the Stockholder is the lawful owner of the Shares denoted as being owned by the Stockholder on </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Schedule I</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> hereto, has the sole power to vote or cause to be voted such Shares and has the sole power to dispose of or cause to be disposed such Shares (other than, if Stockholder is a partnership or a limited liability company, the rights and</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">interest of Persons that own partnership interests or units in Stockholder under the partnership agreement or operating agreement governing Stockholder and applicable partnership or limited liability company law, or if Stockholder is a married individual and resides in a state with community property laws, the community property interest of his or her spouse to the extent applicable under such community property laws, which spouse hereby consents to this Agreement by executing the spousal consent attached hereto).&nbsp;&nbsp;The Stockholder has, and will at all times up until the Expiration Time have, good and valid title to the Shares denoted as being owned by the Stockholder on </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Schedule I</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> hereto, free and clear of any and all pledges, mortgages, liens, charges, proxies, voting agreements, encumbrances, adverse claims, options, security interests and demands of any nature or kind whatsoever, other than (a) those created by this Agreement, or (b) those existing under applicable securities laws. &nbsp;Without limiting the generality of the foregoing, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Shares, and no Shares are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of the Shares except as provided hereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">No Conflicts</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;(a) No filing with any Governmental Body, and no authorization, consent or approval of any other Person is necessary for the execution of this Agreement by the Stockholder and (b) none of the execution and delivery of this Agreement by the Stockholder, the performance of the Stockholder&#x2019;s obligations hereunder, the consummation by the Stockholder of the transactions contemplated hereby or compliance by the Stockholder with any of the provisions hereof shall (i) conflict with or result in any breach of the organizational documents of the Stockholder, (ii) result in, or give rise to, a violation or breach of or a default under any of the terms of any material contract, understanding, agreement or other instrument or obligation to which the Stockholder is a party or by which the Stockholder or any of the Subject Shares or its assets may be bound or (iii) violate any applicable order, writ, injunction, decree, judgment, statute, rule or regulation, except for any of the foregoing as would not reasonably be expected to impair the Stockholder&#x2019;s ability to perform its obligations under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Finder&#x2019;s Fees</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;No investment banker, broker, finder or other intermediary is entitled, whether directly or indirectly, to a fee, commission or other benefit from Parent, Merger Sub or the Company in respect of this Agreement based upon any Contract made by or on behalf of the Stockholder, solely in the Stockholder&#x2019;s capacity as a stockholder of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Reliance</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#x2019;s own choosing.&nbsp;&nbsp;The Stockholder understands and acknowledges that the Company is entering into the Merger Agreement in reliance upon the Stockholder&#x2019;s execution, delivery and performance of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">No Litigation</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;As of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of the Stockholder, threatened against the Stockholder that would reasonably be expected to impair the ability of the Stockholder to perform its obligations hereunder or consummate the transactions contemplated hereby.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE V</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">TERMINATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp; This Agreement shall automatically terminate, and none of Parent, the Company or the Stockholder shall have any rights or obligations hereunder and this Agreement shall become null and void and have no effect upon the earliest to occur of: (a) the Effective Time; and (b) the valid termination of the Merger Agreement in accordance with its terms.&nbsp;&nbsp;The parties acknowledge that upon termination of this Agreement as permitted under and in accordance with the terms of this Agreement, Stockholder shall have no right to recover any claim with respect to any losses suffered by Stockholder in connection with such termination.&nbsp;&nbsp;Notwithstanding anything to the contrary herein, (i) nothing set forth in this </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section&nbsp;5.1</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall relieve Stockholder from liability for any breach of this Agreement prior to termination hereof, and (ii) the provisions of this </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Article V</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and of </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Article VI</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> shall survive the termination of this Agreement.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">5</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ARTICLE VI</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">MISCELLANEOUS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Further Actions</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Subject to the terms and conditions set forth in this Agreement, the Stockholder agrees to take any all actions and to do all things reasonably necessary to effectuate this Agreement.&nbsp;&nbsp;If the Stockholder is a married individual, his or her spouse shall deliver the spousal consent attached hereto unless such Stockholder can demonstrate to Parent&#x2019;s and the Company&#x2019;s reasonable satisfaction that his or her spouse does not have any community property interests in the Subject Shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Fees and Expenses</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Except as otherwise specifically provided herein, each party shall bear its own fees and expenses in connection with this Agreement and the transactions contemplated hereby.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Amendments, Waivers, etc</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement may not be amended except by an instrument in writing signed by all the parties hereto and specifically referencing this Agreement.&nbsp;&nbsp;The failure of any party to assert any rights or remedies shall not constitute a waiver of such rights or remedies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Notices</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Any notice, request, instruction or other document required to be given hereunder shall be sufficient if in writing, and sent by confirmed electronic mail transmission of a &#x201C;portable document format&#x201D; (&#x201C;.pdf&#x201D;) attachment (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> that any notice received by electronic mail transmission or otherwise at the addressee&#x2019;s location on any business day after 5:00 p.m. (addressee&#x2019;s local time) shall be deemed to have been received at 9:00 a.m. (addressee&#x2019;s local time) on the next business day), by reliable overnight delivery service (with proof of service), or hand delivery, addressed as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If to the Company, to</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">NeuroBo Pharmaceuticals, Inc.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">177 Huntington Avenue, Suite 1700</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Boston, MA 02115</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn: President</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Email:&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">with a copy to (which shall not constitute notice):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">One Financial Center</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Boston, MA 02111</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Attention: William T. Whelan and Marc D. Mantell<br />Email:&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If to Parent, to</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Gemphire Therapeutics Inc.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">17199 N. Laurel Park Drive, Suite 401</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Livonia, MI 48152</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Attn:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;President</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Email:&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">with a copy to (which shall not constitute notice):</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Honigman LLP</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">650 Trade Centre Way, Suite 200</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Kalamazoo, MI 49002-0402</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">6</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Attention: Phillip D. Torrence</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Email: </font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If to the Stockholder, to the address or electronic mail address set forth on the signature pages hereto or to such other Person or address as any party shall specify by written notice so given.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Interpretation; Construction</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Headings of the Articles and Sections of this Agreement are for convenience of the parties only, and shall be given no substantive or interpretive effect whatsoever.&nbsp;&nbsp;Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.&nbsp;&nbsp;As used in this Agreement, the words &#x201C;include&#x201D; and &#x201C;including,&#x201D; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#x201C;without limitation.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Severability</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.&nbsp;&nbsp;If any provision of this Agreement, or the application of such provision to any Person or any circumstance, is invalid or unenforceable (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application of such provision, in any other jurisdiction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Entire Agreement; Assignment</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement constitutes the entire agreement, and supersedes all other prior agreements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter hereof; &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">however</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, that, as between the Company and Parent, to the extent of any conflict between the Merger Agreement and this Agreement, the terms of the Merger Agreement shall control and supersede any such conflicting terms.&nbsp;&nbsp;Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of the other parties, except that, without consent, each of Parent and the Company may assign all or any of its rights and obligations hereunder to any of its Affiliates that assume the rights and obligations of such party under the Merger Agreement.&nbsp;&nbsp;Subject to the preceding two sentences, this Agreement will be binding upon, inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns.&nbsp;&nbsp;Notwithstanding anything to the contrary set forth herein, the Stockholder agrees that this Agreement and the obligations hereunder shall be binding upon any Person to which record or beneficial ownership of the Stockholder&#x2019;s Subject Shares shall pass, whether by operation or law or otherwise, including the Stockholder&#x2019;s heirs, guardians, administrators or successors and assigns, and the Stockholder agrees to take all actions necessary to effect the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Governing Law</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;THIS AGREEMENT AND ALL QUESTIONS RELATING TO THE INTERPRETATION OR ENFORCEMENT OF THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED, CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAW OF THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF TO THE EXTENT THAT SUCH PRINCIPLES WOULD DIRECT A MATTER TO ANOTHER JURISDICTION.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Specific Performance</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Stockholder acknowledges that any breach of this Agreement would give rise to irreparable harm for which monetary damages would not be an adequate remedy and each of the Company and Parent shall be entitled to a decree of specific performance and to temporary, preliminary and permanent injunctive relief to prevent breaches or threatened breaches of any of the provisions of this Agreement, without the necessity of proving the inadequacy of monetary damages as a remedy, which shall be the sole and exclusive remedy for any such breach.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.10&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Submission to Jurisdiction</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The parties hereby irrevocably submit to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, or, if the Chancery Court declines jurisdiction, the United States District Court for the District of Delaware or the courts of the State of Delaware solely in respect of the interpretation and enforcement of the provisions of this Agreement and hereby waive, and</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">7</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">agree not to assert, as a defense in any action, suit or proceeding for the interpretation or enforcement hereof, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in said courts or that the venue thereof may not be appropriate or that this Agreement may not be enforced in or by such courts, and the parties hereto irrevocably agree that all claims relating to such action, suit or proceeding shall be heard and determined in such courts.&nbsp;&nbsp;The parties hereby consent to and grant any such court jurisdiction over the person of such parties and, to the extent permitted by law, over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 6.4</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> or in such other manner as may be permitted by applicable Laws shall be valid and sufficient service thereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.11&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Waiver of Jury Trial</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.&nbsp;&nbsp;EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (a) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (b) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (c) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (d) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">SECTION 6.11</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SECTION 6.12&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Counterparts</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. This Agreement may be executed in two or more counterparts (including by facsimile transmission or other means of electronic transmission, such as by electronic mail in &#x201C;pdf&#x201D; form), each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by facsimile or otherwise) to the other parties.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(Signature Page Follows)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">8</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">IN WITNESS WHEREOF, the Company, Parent and the Stockholder have caused this Agreement to be duly executed as of the day and year first above written.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">NEUROBO PHARMACEUTICALS, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">STOCKHOLDER</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Address:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Electronic Mail Address:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt 270pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">[</font><font style="display:inline;font-style:italic;">Signature Page to Voting Agreement</font><font style="display:inline;">]</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">SPOUSAL CONSENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">I&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, spouse of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, having the legal capacity, power and authority to do so, hereby confirm that I have read and approve the foregoing the Voting Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;In consideration of the terms and conditions as set forth in the Agreement, I hereby appoint my spouse (regardless of whether my spouse remains as such) as my attorney in fact with respect to the exercise of any rights and obligations under the Agreement, and agree to be bound by the provisions of the Agreement insofar as I may have any rights or obligations in the Agreement under the community property laws of the State of California or similar laws relating to marital or community property.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 252pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:49.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.56%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.44%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.56%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.44%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.56%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.44%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.56%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.44%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">[</font><font style="display:inline;font-style:italic;">Signature Page to Voting Agreement</font><font style="display:inline;">]</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit A</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;text-decoration:underline;">Written Consent</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">See attached.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">Exhibit A-1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Schedule I</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;text-decoration:underline;">Ownership of Shares</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Name and Address of Stockholder</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Number of Shares of Common Stock</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Number of Shares of Preferred Stock</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[</font><font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">]</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[</font><font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">]</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">[</font><font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">Schedule I-1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.5
<SEQUENCE>6
<FILENAME>ex-2d5.htm
<DESCRIPTION>EX-2.5
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:44 AM-->
<html>
	<head>
		<title>
			gemp_Ex2_5
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Exhibit 2.5</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Gemphire Therapeutics Inc.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">17199 N. Laurel Park Drive, Suite 401</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Livonia, MI 48152</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">NeuroBo Pharmaceuticals, Inc.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">177 Huntington Avenue, Suite 1700</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Boston, MA 02115</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Lock-Up Agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">July&nbsp;&nbsp;&nbsp;&nbsp;, 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">This Lock-Up Agreement (this &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) is executed in connection with the Agreement and Plan of Merger and Reorganization (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Merger Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) by and among Gemphire Therapeutics Inc. (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Parent</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), GR Merger Sub Inc. (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Merger Sub</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), and NeuroBo Pharmaceuticals, Inc. (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), dated as of July 24, 2019. Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Merger Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">In connection with, and as a material inducement to, each of the parties entering into the Merger Agreement and for other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned, by executing this Agreement, irrevocably agrees that, without the prior written consent of the Parent and the Company, during the period commencing at the Effective Time and continuing until the end of the Lock-Up Period (as hereinafter defined), the undersigned will not:&nbsp;&nbsp;(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of or lend, directly or indirectly, any shares of Parent Common Stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive Parent Common Stock (including without limitation, Parent Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) whether now owned or hereafter acquired (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Parent Securities</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;); (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Parent Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Parent Common Stock or such other securities, in cash or otherwise; (3) make any demand for or exercise any right with respect to, the registration of any Parent Common Stock or any security convertible into or exercisable or exchangeable for Parent Common Stock; (4) except for the Voting Agreement, dated as of the date hereof, by and among Parent, Merger Sub and the Company, &nbsp;grant any proxies or powers of attorney with respect to any Parent Securities, deposit any Parent Securities into a voting trust or enter into a voting agreement or similar arrangement or commitment with respect to any Parent Securities; or (5) publicly disclose the intention to do any of the foregoing (each of the foregoing restrictions, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Lock-Up Restrictions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Notwithstanding the terms of the foregoing paragraph, the Lock-Up Restrictions shall automatically terminate and cease to be effective on the date that is one-hundred and eighty (180) days after the Effective Time.&nbsp;&nbsp;The period during which the Lock-Up Restrictions apply to the Parent Securities shall be deemed the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Lock-Up Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; with respect thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">The undersigned agrees that the Lock-Up Restrictions preclude the undersigned from engaging in any hedging or other transaction with respect to any then-subject Parent Securities which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of such Parent Securities even if such Parent Securities would be disposed of by someone other than the undersigned.&nbsp;&nbsp;Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to such Parent Securities or with respect to any security that includes, relates to, or derives any significant part of its value from such Parent Securities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Notwithstanding the foregoing, the undersigned may transfer any of the Parent Securities (i) &nbsp;if the undersigned is a natural person, (1) to any person related to the undersigned by blood or adoption who is an immediate family member (not more remote than first cousin), or a family member by marriage or domestic partnership (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Family Member</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), (2) as a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">bona fide</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> gift or charitable contribution, (3) to any trust for the direct or indirect benefit of the undersigned or any Family Member of the undersigned, (4) to the undersigned&#x2019;s estate, following the death of the undersigned, by will, intestacy or other operation of law, (5) by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement, or (6) to any partnership, corporation or limited liability company which is controlled by the undersigned and/or by any Family Member of the undersigned; (ii) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (1) to another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or (2) as distributions or dividends of shares of Parent Common Stock or any security convertible into or exercisable for Parent Common Stock to limited partners, limited liability company members or stockholders of the undersigned or holders of similar equity interests in the undersigned, (iii) if the undersigned is a trust, to the beneficiary of such trust, (iv) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under above clauses (i) through (iii), (v) to Parent in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Exchange Act</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) upon a vesting event of the Parent Securities or upon the exercise of options or warrants to purchase Parent Common Stock on a &#x201C;cashless&#x201D; or &#x201C;net exercise&#x201D; basis or to cover tax withholding obligations of the undersigned in connection with such vesting or exercise (but for the avoidance of doubt, excluding all manners of exercise that would involve a sale in the open market of any securities relating to such options or warrants, whether to cover the applicable aggregate exercise price, withholding tax obligations or otherwise), (vi) to Parent in connection with the termination of employment or other termination of a service provider and pursuant to agreements in effect as of the Effective Time whereby Parent has the option to repurchase such shares or securities, (vii) acquired by the undersigned in open market transactions after the Effective Time, (viii) pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Parent&#x2019;s capital stock involving a change of control of the Parent, provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Parent</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Securities shall remain subject to the restrictions contained in this Agreement, or (ix) pursuant to an order of a court or regulatory agency; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, in the case of clauses (i)-(iv), that (A) such transfer shall not involve a disposition for value and (B) the transferee shall have executed and delivered a Lock-Up Agreement substantially identical with this Agreement with respect to the shares of Parent Common Stock or other securities so transferred; and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">further</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, in the case of clauses (i)-(vii), no filing by any party under Section 16(a) of the Exchange Act shall be required or shall be made voluntarily in connection with such transfer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">In addition, the foregoing restrictions shall not apply to (i) the exercise of stock options granted pursuant to equity incentive plans existing immediately following the Effective Time, including the &#x201C;net&#x201D; exercise of such options in accordance with their terms and the surrender of Parent Common Stock in lieu of payment in cash of the exercise price and any tax withholding obligations due as a result of such exercise (but for the avoidance of doubt, excluding all manners of exercise that would involve a sale in the open market of any securities relating to such options, whether to cover the applicable aggregate exercise price, withholding tax obligations or otherwise); </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> that it shall apply to any of the Parent Securities issued upon such exercise, (ii) conversion or exercise of warrants into Parent Common Stock or into any other security convertible into or exercisable for Parent Common Stock that are outstanding as of the Effective Time (but for the avoidance of doubt, excluding all manners of conversion or exercise that would involve a sale in the open market of any securities relating to such warrants, whether to cover the applicable aggregate exercise price, withholding tax obligations or otherwise); </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> that it shall apply to any of the Parent Securities issued upon such conversion or exercise; and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">further</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> that the recipient of any such Parent Common Stock agrees in writing with Parent to be bound by the terms of this Agreement, or (iii) the establishment of any contract, instruction or plan (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) that satisfies all of the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> that no sales of Parent Securities shall be made pursuant to such a Plan prior to the expiration of the Lock-Up Period, and such a Plan may only be established if no public announcement of the establishment or existence thereof and no filing with the Securities and Exchange Commission or other regulatory authority in respect thereof or transactions thereunder or contemplated thereby, by the undersigned, Parent or any other person, shall be required, and no such announcement or filing is made voluntarily, by the undersigned, Parent or any other person, prior to the expiration of the Lock-Up Period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Any attempted transfer in violation of this Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Agreement, and will not be recorded on the share register of Parent.&nbsp;&nbsp;In furtherance of the foregoing, Parent and its transfer agent and registrar are hereby authorized to decline to make any transfer of shares of Parent Common Stock if such transfer would constitute a violation or breach of this Agreement.&nbsp;&nbsp;Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#x2019;s ownership of Parent Common Stock:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement and that upon request, the undersigned will execute any additional documents reasonably necessary to ensure the validity or enforcement of this Agreement.&nbsp;&nbsp;All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">The undersigned understands that the undersigned shall be released from all obligations under this Agreement upon the earlier of (i) the expiration of the Lock-Up Period, and (ii) if the Merger Agreement is terminated prior to the Effective Time pursuant to its terms, upon the date of such termination.&nbsp;&nbsp;The undersigned understands that Parent, the Merger Sub and the Company are entering into the Merger Agreement in reliance upon this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Any and all remedies herein expressly conferred upon Parent and the Company will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity, and the exercise by Parent and/or the Company of any one remedy will not preclude the exercise of any other remedy.&nbsp;&nbsp;The undersigned agrees that irreparable damage would occur to Parent and the Company in the event that any provision of this Agreement were not performed in accordance with its specific terms or were otherwise breached.&nbsp;&nbsp;It is accordingly agreed the Parent and the Company shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which Parent and the Company are entitled at law or in equity, and the undersigned waives any bond, surety or other security that might be required of Parent or the Company with respect thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to the conflict of laws principles thereof.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">Signature Page Follows</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">This Agreement, and any certificates, documents, instruments and writings that are delivered pursuant hereto, constitutes the entire agreement and understanding of the Parent, the Company and the undersigned in respect of the subject matter hereof and supersedes all prior understandings, agreements or representations by or among the Parent, the Company and the undersigned, written or oral, to the extent they relate in any way to the subject matter hereof.&nbsp;&nbsp;This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.&nbsp;&nbsp;The exchange of a fully executed Agreement (in counterparts or otherwise) by Parent and the undersigned by facsimile or electronic transmission in .pdf format shall be sufficient to bind such parties to the terms and conditions of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:48.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Very truly yours,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Printed Name of Holder</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Signature</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.16%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.34%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:52.50%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.50%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:52.50%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Printed Name of Person Signing<br />(and indicate capacity of person signing if signing<br />as custodian, trustee, or on behalf of an entity)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">[</font><font style="display:inline;font-style:italic;font-size:12pt;">Lock-Up Agreement Signature Page</font><font style="display:inline;font-size:12pt;">]</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>ex-10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:45 AM-->
<html>
	<head>
		<title>
			gemp_Ex10_1
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EXHIBIT 10.1</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">FIRST AMENDMENT TO EMPLOYMENT AGREEMENT</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Amendment&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) is made effective as of the 24th&nbsp;day of July, 2019, by and between GEMPHIRE THERAPEUTICS INC., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Company&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) and STEVE GULLANS (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Executive&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">)</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">RECITALS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">The Company and the Executive entered into an Employment Agreement dated effective May 1, 2018 &nbsp;(the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Employment Agreement&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">).&nbsp;&nbsp;The Company and the Executive now wish to amend the Employment Agreement as provided herein.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">AGREEMENT</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">NOW, THEREFOR</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, in consideration of the foregoing and the terms and conditions set forth below, the parties agree as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADDITION OF A NEW SECTION 5(F) TO THE EMPLOYMENT AGREEMENT.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">A new Section 5(f) &nbsp;shall be added to the Employment Agreement to read as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company completes a Change in Control with NeuroBo Pharmaceuticals, Inc. (a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">&#x201C;NeuroBo Merger&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) and: (i) the Company elects not to extend the Employment Period beyond the Initial Term or at the end of any Renewal Term; (ii) the Executive effects a Termination for Good Reason; or (iii) the Company terminates the Executive&#x2019;s employment other than due to the Executive&#x2019;s death, a Termination for Cause or a Termination due to a Disability, then in lieu of the benefits payable to the Executive pursuant to Section 5(a) above, provided that the Executive signs and delivers the Release at least seven (7) days prior the effective date of the NeuroBo Merger and does not subsequently revoke the Release prior to the effective date of the NeuroBo Merger, the Executive shall be entitled to the following benefits:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all of the shares subject to the Executive&#x2019;s Restricted Stock Grant Notice and related Restricted Stock Agreement entered into by and between the Company and the Executive on July 24, 2019 shall fully vest on the effective date of the NeuroBo Merger and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay to the Executive:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in a lump sum in cash within thirty (30) days after the effective date of the NeuroBo Merger, an amount equal to $75,000, &nbsp;subject to a reduction for withholding tax owing on payment of the cash and as a result of the issuance or vesting of restricted stock; &nbsp;and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Unconditional Entitlements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">For clarity, if Executive becomes eligible to receive payment of benefits under this Section 5(f),</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">1</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;">Executive will no longer be eligible to receive any benefits pursuant to Sections 3(c) and 5(a).</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESTRICTED STOCK AWARD.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> &nbsp;In connection with the Executive entering into this Amendment, on the date of this Amendment, the Company shall issue to the Executive a restricted stock award for 300,000 shares of the Company&#x2019;s common stock pursuant to the terms and conditions of a Restricted Stock Grant Notice, Restricted Stock Agreement and the related attachments (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Restricted Stock Award&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SURRENDER OF OPTIONS.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> &nbsp;In consideration for the Executive&#x2019;s receipt of the Restricted Stock Award, by execution of this Amendment, the Executive does hereby irrevocably sell, assign and transfer to the Company all of the Executive&#x2019;s right, title and interest in and to all options to acquire shares of the Company&#x2019;s common stock currently held by the Executive (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Surrendered Options&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) free and clear of any mortgage, pledge, lien, encumbrance, charge, security, security interest or other claim against title, and hereby authorizes the secretary of the Company to reflect the cancellation and surrender of the Surrendered Options on the books and records of the Company with full power of substitution in the premises together with such other documents, certificates, affidavits and instruments as are required by this Amendment or reasonably required by the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 409A. </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">This Amendment and all transactions in connection therewith are intended to be exempt from or in compliance with Section&nbsp;409A&nbsp;of the Internal Revenue Code of 1986, as amended (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Section 409A</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), but under no circumstances shall the Company be liable for any tax, interest or penalty imposed on the employee or other detriment suffered by the employee under Section 409A or for any other adverse tax consequences to the employee resulting from this Amendment.</font>
		</p>
		<p style="margin:0pt;text-indent:72pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONSTRUCTION.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Unless otherwise defined herein, capitalized terms shall have the meanings set forth in the Employment Agreement.&nbsp;&nbsp;The terms of this Amendment amend and modify the Employment Agreement as if fully set forth in the Employment Agreement.&nbsp;&nbsp;If there is any conflict between the terms, conditions and obligations of this Amendment and the Employment Agreement, this Amendment&#x2019;s terms, conditions and obligations shall control.&nbsp;&nbsp;All other provisions of the Employment Agreement not specifically modified by this Amendment are preserved.&nbsp; This Amendment may be executed in counterparts (including via facsimile, &nbsp;.pdf or other electronic means of execution and delivery), each of which shall be deemed an original, and all of which together shall constitute one and the same document.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">SIGNATURES OF THE FOLLOWING PAGE</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Amendment effective as of the date first written above.</font>
		</p>
		<p style="margin:0pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">THE EXECUTIVE:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">THE COMPANY:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">/s/ STEVE GULLANS</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">/s/ PEDRO LICHTINGER</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">STEVE GULLANS</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Name:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Pedro Lichtinger</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Title:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Chair of the Compensation&nbsp;Committee</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">SIGNATURE PAGE TO</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">FIRST AMENDMENT TO EMPLOYMENT AGREEMENT</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>8
<FILENAME>ex-10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:46 AM-->
<html>
	<head>
		<title>
			gemp_Ex10_2
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Exhibit 10.2</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">FIRST AMENDMENT TO EMPLOYMENT AGREEMENT</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Amendment&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) is made effective as of the 24th&nbsp;day of July, 2019, by and between GEMPHIRE THERAPEUTICS INC., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Company&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) and CHARLES L. BISGAIER (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Executive&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">).</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">RECITALS</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">The Company and the Executive entered into an Employment Agreement dated effective April 15, 2016 &nbsp;(the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Employment Agreement&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">).&nbsp;&nbsp;The Company and the Executive now wish to amend the Employment Agreement as provided herein.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">AGREEMENT</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">NOW, THEREFOR</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, in consideration of the foregoing and the terms and conditions set forth below, the parties agree as follows:</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">ADDITION OF A NEW SECTION 5(F) TO THE EMPLOYMENT AGREEMENT.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">A new Section 5(f) &nbsp;shall be added to the Employment Agreement to read as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company completes a Change in Control with NeuroBo Pharmaceuticals, Inc. (a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">NeuroBo Merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) and: (i) the Company elects not to extend the Employment Period beyond the Initial Term or at the end of any Renewal Term; (ii) the Executive effects a Termination for Good Reason; or (iii) the Company terminates the Executive&#x2019;s employment other than due to the Executive&#x2019;s death, a Termination for Cause or a Termination due to a Disability, then in lieu of the benefits payable to the Executive pursuant to Section 5(a) above, provided that the Executive signs and delivers the Release at least seven (7) days prior the effective date of the NeuroBo Merger and does not subsequently revoke the Release prior to the effective date of the NeuroBo Merger, the Executive shall be entitled to the following benefits:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all of the shares subject to the Executive&#x2019;s Restricted Stock Grant Notice and related Restricted Stock Agreement entered into by and between the Company and the Executive on July 24, 2019 shall fully vest on the effective date of the NeuroBo Merger; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay to the Executive:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in a lump sum in cash within thirty (30) days after the effective date of the NeuroBo Merger, an amount equal to $330,000, &nbsp;subject to a reduction for withholding tax owing on payment of the cash and as a result of the issuance or vesting of restricted stock; &nbsp;and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 144pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Unconditional Entitlements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">For clarity, if Executive becomes eligible to receive payment of benefits under this Section 5(f), Executive will no longer be eligible to receive any benefits pursuant to Sections 3(c) and 5(a).&#x201D;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">RESTRICTED STOCK AWARD.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> &nbsp;In connection with the Executive entering into this Amendment, on the date of this Amendment, the Company shall issue to the Executive a restricted stock award for 100,000 shares of the Company&#x2019;s common stock pursuant to the terms and conditions of a Restricted Stock Grant Notice, Restricted Stock Agreement and the related attachments (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Restricted Stock Award&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">SECTION 409A. </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">This Amendment and all transactions in connection therewith are intended to be exempt from or in compliance with Section&nbsp;409A&nbsp;of the Internal Revenue Code of 1986, as amended (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Section 409A</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), but under no circumstances shall the Company be liable for any tax, interest or penalty imposed on the employee or other detriment suffered by the employee under Section 409A or for any other adverse tax consequences to the employee resulting from this Amendment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">CONSTRUCTION.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Unless otherwise defined herein, capitalized terms shall have the meanings set forth in the Employment Agreement.&nbsp;&nbsp;The terms of this Amendment amend and modify the Employment Agreement as if fully set forth in the Employment Agreement.&nbsp;&nbsp;If there is any conflict between the terms, conditions and obligations of this Amendment and the Employment Agreement, this Amendment&#x2019;s terms, conditions and obligations shall control.&nbsp;&nbsp;All other provisions of the Employment Agreement not specifically modified by this Amendment are preserved.&nbsp; This Amendment may be executed in counterparts (including via facsimile, &nbsp;.pdf or other electronic means of execution and delivery), each of which shall be deemed an original, and all of which together shall constitute one and the same document.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">SIGNATURES OF THE FOLLOWING PAGE</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Amendment effective as of the date first written above.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:49.88%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-weight:bold;font-size:12pt;">THE EXECUTIVE:</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-weight:bold;font-size:12pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:48.38%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-weight:bold;font-size:12pt;">THE COMPANY:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.88%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:48.38%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.88%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:48.38%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-weight:bold;font-size:12pt;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.88%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:42.46%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.88%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:42.46%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.88%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">/s/ CHARLES L. BISGAIER</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">By:</font></p>
				</td>
				<td valign="bottom" style="width:42.46%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">/s/ STEVE GULLANS</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.88%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-weight:bold;font-size:12pt;">CHARLES L. BISGAIER</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">Name:</font></p>
				</td>
				<td valign="bottom" style="width:42.46%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">Steven Gullans</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.88%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">Title:</font></p>
				</td>
				<td valign="bottom" style="width:42.46%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">SIGNATURE PAGE TO<br />FIRST AMENDMENT TO EMPLOYMENT AGREEMENT</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>9
<FILENAME>ex-10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:46 AM-->
<html>
	<head>
		<title>
			gemp_Ex10_3
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EXHIBIT 10.3</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">FIRST AMENDMENT TO EMPLOYMENT AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Amendment&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) is made effective as of the 24th&nbsp;day of July, 2019, by and between GEMPHIRE THERAPEUTICS INC., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Company&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) and SETH C. RENO (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Executive&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">RECITALS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">The Company and the Executive entered into an Employment Agreement dated effective April 15, 2016 &nbsp;(the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Employment Agreement&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">).&nbsp;&nbsp;The Company and the Executive now wish to amend the Employment Agreement as provided herein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">NOW, THEREFOR</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, in consideration of the foregoing and the terms and conditions set forth below, the parties agree as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">ADDITION OF A NEW SECTION 5(F) TO THE EMPLOYMENT AGREEMENT.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">A new Section 5(f) &nbsp;shall be added to the Employment Agreement to read as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Company completes a Change in Control with NeuroBo Pharmaceuticals, Inc. (a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">&#x201C;NeuroBo Merger&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">) and: (i) the Company elects not to extend the Employment Period beyond the Initial Term or at the end of any Renewal Term; (ii) the Executive effects a Termination for Good Reason; or (iii) the Company terminates the Executive&#x2019;s employment other than due to the Executive&#x2019;s death, a Termination for Cause or a Termination due to a Disability, then in lieu of the benefits payable to the Executive pursuant to Section 5(a) above, provided that the Executive signs and delivers the Release at least seven (7) days prior the effective date of the NeuroBo Merger and does not subsequently revoke the Release prior to the effective date of the NeuroBo Merger, the Executive shall be entitled to the following benefits:</font>
		</p>
		<p style="margin:0pt 0pt 5pt 36pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all of the shares subject to the Executive&#x2019;s Restricted Stock Grant Notice and related Restricted Stock Agreement entered into by and between the Company and the Executive on July 24, 2019 shall fully vest on the effective date of the NeuroBo Merger; and</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Company shall pay to the Executive:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in a lump sum in cash within thirty (30) days after the effective date of the NeuroBo Merger, an amount equal to $297,536, &nbsp;subject to a reduction for withholding tax owing on payment of the cash and as a result of the issuance or vesting of restricted stock; &nbsp;and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Unconditional Entitlements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">For clarity, if Executive becomes eligible to receive payment of benefits under this Section 5(f), Executive will no longer be eligible to receive any benefits pursuant to Sections 3(c) and 5(a).&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">RESTRICTED STOCK AWARD.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> &nbsp;In connection with the Executive entering into this Amendment, on the date of this Amendment, the Company shall issue to the Executive a restricted stock award for 100,000 shares of the Company&#x2019;s common stock pursuant to the terms and conditions of a Restricted Stock Grant Notice, Restricted Stock Agreement and the related attachments (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">&#x201C;Restricted Stock Award&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">SECTION 409A. </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">This Amendment and all transactions in connection therewith are intended to be exempt from or in compliance with Section&nbsp;409A&nbsp;of the Internal Revenue Code of 1986, as amended (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size:12pt;">Section 409A</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), but under no circumstances shall the Company be liable for any tax, interest or penalty imposed on the employee or other detriment suffered by the employee under Section 409A or for any other adverse tax consequences to the employee resulting from this Amendment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">CONSTRUCTION.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Unless otherwise defined herein, capitalized terms shall have the meanings set forth in the Employment Agreement.&nbsp;&nbsp;The terms of this Amendment amend and modify the Employment Agreement as if fully set forth in the Employment Agreement.&nbsp;&nbsp;If there is any conflict between the terms, conditions and obligations of this Amendment and the Employment Agreement, this Amendment&#x2019;s terms, conditions and obligations shall control.&nbsp;&nbsp;All other provisions of the Employment Agreement not specifically modified by this Amendment are preserved.&nbsp; This Amendment may be executed in counterparts (including via facsimile, &nbsp;.pdf or other electronic means of execution and delivery), each of which shall be deemed an original, and all of which together shall constitute one and the same document.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">SIGNATURES OF THE FOLLOWING PAGE</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Amendment effective as of the date first written above.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:39.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">THE EXECUTIVE:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">THE COMPANY:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">/s/ SETH C. RENO</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">/s/ STEVEN GULLANS</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">SETH C. RENO</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Name:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:39.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Steven Gullans</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Title:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:39.00%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">SIGNATURE PAGE TO</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">FIRST AMENDMENT TO EMPLOYMENT AGREEMENT</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>10
<FILENAME>ex-10d4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:47 AM-->
<html>
	<head>
		<title>
			gemp_Ex10_4
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt 0pt 18pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EXHIBIT 10.4</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GEMPHIRE THERAPEUTICS INC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">RESTRICTED STOCK GRANT NOTICE</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">GEMPHIRE THERAPEUTICS INC., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Company&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), pursuant to the Company&#x2019;s Amended and Restated 2015 Equity Incentive Plan (as amended to date, the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Plan&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), hereby awards to Participant as an inducement material to the Participant&#x2019;s entering into an amendment to Participant&#x2019;s employment agreement with the Company, the number of shares of the Company&#x2019;s Common Stock set forth below (this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Award&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). This Award is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Agreement attached to this Restricted Stock Grant Notice and the Plan, all of which are attached hereto and incorporated herein in their entirety.&nbsp;&nbsp;Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Restricted Stock Agreement.&nbsp;&nbsp;In the event of any conflict between the terms in the Award and the Plan, the terms of the Plan shall control.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:35.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 9.75pt;border-left:1pt none #D9D9D9 ;text-indent: -10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Participant:</font></p>
				</td>
				<td valign="bottom" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:35.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 9.75pt;border-left:1pt none #D9D9D9 ;text-indent: -10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date of Grant:</font></p>
				</td>
				<td valign="bottom" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">July ___, 2019&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:35.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 9.75pt;border-left:1pt none #D9D9D9 ;text-indent: -10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Vesting Commencement Date:</font></p>
				</td>
				<td valign="bottom" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Immediately prior to the effective time of the NeuroBo Merger (as defined below)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:35.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;border-left:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Number of Shares Subject to Award:</font></p>
				</td>
				<td valign="bottom" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:35.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 0pt 9.75pt;border-left:1pt none #D9D9D9 ;text-indent: -10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Consideration:</font></p>
				</td>
				<td valign="bottom" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:60.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Execution of an amendment to Participant&#x2019;s employment agreement dated as of the date hereof.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Vesting Schedule: &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The number of shares subject to this Award shall fully and completely vest automatically immediately prior to the effective time of any merger between the Company and NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;NeuroBo Merger&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">); provided that Participant has executed and delivered to the Company the Release and Waiver of Claims in the form of </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">EXHIBIT A</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> attached hereto (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Release and Waiver&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) and not subsequently revoked the Release and Waiver during the seven (7) day period following Participant&#x2019;s execution and delivery of.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Additional Terms/Acknowledgements:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The undersigned Participant acknowledges receipt of, and understands and agrees to, this Restricted Stock Grant Notice, the Restricted Stock Agreement, the Plan and the Release and Waiver.&nbsp;&nbsp;Participant further acknowledges that as of the Date of Grant, this Restricted Stock Grant Notice, the Restricted Stock Agreement, the Plan and the Release and Waiver set forth the entire understanding between Participant and the Company regarding the acquisition of the Common Stock pursuant to this Award specified above and supersede all prior oral and written agreements on that subject with the exception, if applicable,</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">of (i) the written employment agreement or offer letter agreement entered into between the Company and Participant specifying the terms that should govern this Award, and (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">By accepting this Award, Participant consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:45.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:44.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:45.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">PARTICIPANT:</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">THE COMPANY:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:45.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:45.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:45.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:45.00%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.84%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:44.16%;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:45.00%;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:45.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ATTACHMENTS</font><font style="display:inline;font-family:Times New Roman,Times,serif;">: &nbsp;Restricted Stock Agreement &nbsp;(</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">ATTACHMENT I</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), Amended and Restated 2015 Equity Incentive Plan (delivered separately) and Release and Waiver of Claims &nbsp;(</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">EXHIBIT A</font><font style="display:inline;font-family:Times New Roman,Times,serif;">).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">SIGNATURE PAGE TO RESTRICTED STOCK GRANT NOTICE</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">ATTACHMENT I</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GEMPHIRE THERAPEUTICS INC.</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">RESTRICTED STOCK AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Pursuant to the Restricted Stock Grant Notice (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Grant Notice&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) and this Restricted Stock Agreement (collectively, the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Award&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) and in consideration of your future services and you entering into an amendment to your employment agreement on the date hereof, &nbsp;Gemphire Therapeutics Inc., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Company&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) has awarded you (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Participant</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) a stock award pursuant to the Company&#x2019;s Amended and Restated 2015 Equity Incentive Plan (as amended to date, the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Plan&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) &nbsp;for the number of shares of the Company&#x2019;s Common Stock subject to the Award as indicated in the Grant Notice.&nbsp;&nbsp;Capitalized terms not explicitly defined in this Restricted Stock Agreement but defined in the Plan or the Grant Notice shall have the same definitions as in the Plan or the Grant Notice. The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The details of your Award are as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VESTING. &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Subject to the limitations contained herein, your Award will vest as provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NUMBER OF SHARES.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The number of shares subject to your Award may be adjusted from time to time for Capitalization Adjustments, as provided in the Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECURITIES LAWS COMPLIANCE.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">You may not be issued any shares under your Award unless the shares are either (i) then registered under the Securities Act or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.&nbsp;&nbsp;Your Award must also comply with other applicable laws and regulations governing the Award, and you will not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RIGHT OF REACQUISITION.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Company shall have the right to reacquire all or any part of the shares received pursuant to the Award (a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Reacquisition Right&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) that have not yet vested in accordance with the Vesting Schedule on the Grant Notice (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Unvested Shares&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) on the following terms and conditions:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Company, shall simultaneously, upon the earliest to occur of (A) the termination of your Continuous Service or (B) March 31, 2020 if the NeuroBo Merger has not been completed, &nbsp;automatically reacquire for no consideration (that is, for zero dollars ($0)) all of the Unvested Shares, unless the Company agrees to waive its Reacquisition Right as to some or all of the Unvested Shares; provided, however, if the termination of your Continuous</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Service results from the completion of the NeuroBo Merger prior to March 31, 2020 (a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;NeuroBo Termination&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) and you have delivered and not subsequently revoked the Release and Waiver, the Company shall not have any Reacquisition Right related to any NeuroBo Termination.&nbsp;&nbsp;Any such waiver shall be exercised by the Company by written notice to you or your representative (with a copy to Computershare Inc. &nbsp;(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Computershare&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">)) within ninety (90) days after the termination of your Continuous Service, and Computershare may then release to you the number of Unvested Shares not being reacquired by the Company. If the Company does not waive its Reacquisition Right as to all of the Unvested Shares, then upon such termination of your Continuous Service, Computershare shall transfer to the Company the number of shares the Company is reacquiring.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You shall, during the term of the Award, exercise all rights and privileges of a stockholder of the Company with respect to the shares subject to your Award.&nbsp;&nbsp;You shall be deemed to be the holder of the shares for purposes of receiving any dividends which may be paid with respect to such shares (which shall be subject to the same vesting and forfeiture restrictions as apply to the shares to which they relate) and for purposes of exercising any voting rights relating to such shares, even if some or all of such shares have not yet vested and been released from the Company&#x2019;s Reacquisition Right.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">If, from time to time, there is any stock dividend, stock split or other change in the character or amount of any of the outstanding stock of the Company the stock of which is subject to the provisions of the Award, then in such event any and all new, substituted or additional securities to which you are entitled by reason of your ownership of the shares acquired under the Award shall be immediately subject to the Reacquisition Right with the same force and effect as the shares subject to this Reacquisition Right immediately before such event.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">In addition to any other limitation on transfer created by applicable securities laws, you shall not sell, assign, hypothecate, donate, encumber, or otherwise dispose of any interest in the Common Stock while such shares of Common Stock are subject to the Reacquisition Right; provided, however, that an interest in such shares may be transferred pursuant to a qualified domestic relations order as defined in the Code or Title I of the Employee Retirement Income Security Act.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESTRICTIVE LEGENDS.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The shares issued under the Award shall be endorsed with appropriate legends determined by the Company, including the following legend:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201C;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN VESTING, FORFEITURE AND OTHER RESTRICTIONS ON TRANSFER SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR HIS OR HER PREDECESSOR IN INTEREST. A COPY OF SUCH AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY AND WILL BE FURNISHED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY BY THE HOLDER OF RECORD OF THE SHARES REPRESENTED BY THIS CERTIFICATE.&#x201D;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THE AWARD IS NOT AN EMPLOYMENT CONTRACT.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Award is not an employment or service contract, and nothing in the Award shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or on the part of the Company or an Affiliate to continue your employment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WITHHOLDING OBLIGATIONS.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">At the time the Award is made, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any amounts payable to you, and otherwise agree to make adequate provision for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the Award.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to instruct Computershare to remove the restrictions from such shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOTICES.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Any notices provided for in the Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The rights and obligations of the Company under the Award shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company&#x2019;s successors and assigns. Your rights and obligations under the Award may only be assigned with the prior written consent of the Board of Directors of the Company (or committee administrating the Plan) in its sole discretion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of the Award.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You acknowledge and agree that you have reviewed the Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting the Award and fully understand all provisions of the Award.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GOVERNING PLAN DOCUMENT.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of the Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">*****</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Restricted Stock Agreement shall be deemed to be signed by the Company and Participant upon the acceptance by the Participant of the Restricted Stock Grant Notice.</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;text-decoration:underline;">EXHIBIT A</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">RELEASE AND WAIVER OF CLAIMS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:12pt;">TO BE EXECUTED AT LEAST 7 DAYS PRIOR TO THE ANTICIPATED VESTING DATE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">In consideration of the payments and other benefits set forth in the Restricted Stock Agreement dated July ___, 2019 (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;color:#000000;">&#x201C;Restricted Stock Agreement&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">) entered into by and between me and GEMPHIRE THERAPEUTICS INC., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;color:#000000;">&#x201C;Company&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">) and my employment agreement (as amended) with the Company (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;color:#000000;">&#x201C;Employment Agreement&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">), I, _________, hereby furnish the Company, with the following release and waiver (this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;color:#000000;">&#x201C;Release and Waiver&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">).</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">In exchange for the consideration provided to me by the Restricted Stock Agreement and the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and completely release the Company and its current and former directors, officers, employees, stockholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns (collectively, the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;color:#000000;">&#x201C;Released Parties&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date that I sign this Release and Waiver (collectively, the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;color:#000000;">&#x201C;Released Claims&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">). The Released Claims include, but are not limited to: (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;which arise out of, result from, or occurred in connection with my employment by the Company or any of its affiliated entities, the termination of that employment relationship, any events occurring in the course of that employment, or any events occurring prior to the execution of this Release and Waiver; (b) for wrongful discharge, discrimination, harassment and/or retaliation; breach of contract, both express and implied; breach of a covenant of good faith and fair dealing, both express and implied; negligent or intentional infliction of emotional distress; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; slander, libel or invasion of privacy; violation of public policy; fraud, misrepresentation or conspiracy; and false imprisonment (duplicative); (c) (i) wrongful discharge of employment; any and all claims for wrongful discharge of employment, and/or (ii) violation of any federal, state or municipal statute relating to employment or employment discrimination, including, without limitation, (A) Title VII of the Civil Rights Act of 1964, as amended, (B) the Civil Rights Act of 1866, as amended, (C) the Civil Rights Act of 1991, as amended, (D) the Employee Retirement and Income Security Act of 1974, as amended, (E) the Age Discrimination in Employment Act of 1967, as amended (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;color:#000000;">&#x201C;ADEA&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">), including, without limitation, by the Older Workers&#x2019; Benefit Protection Act, as amended (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;color:#000000;">&#x201C;OWBPA&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">), (F) the OWBPA, (G) the Americans with Disabilities Act of 1990, as amended, (H) any applicable state Persons with Disabilities Civil Rights Act, as amended, and (I) any applicable state Whistleblowers Protection Act, as amended; (d) under Michigan common law or state statute including, but not limited to, those alleging wrongful discharge, express of implied breach of contract, negligence, invasion of privacy, intentional infliction of emotional distress, fraud, defamation, or violations of the Michigan Elliott-Larsen Civil Rights Act (ELCRA), Michigan Persons with Disabilities Civil Rights Act, Payment of Wages and Fringe Benefits Act, Michigan Whistleblowers&#x2019; Protection Act, Bullard-Plawecki Employee Right to Know Act, the Michigan Occupational Safety and Health Act, the Michigan Social Security Number Privacy Act, and the Michigan Internet Privacy Protection Act, all as amended together with all of their respective</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">EXHIBIT A-1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 3.8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">implementing regulations and/or any other federal, state, local or foreign law (statutory, regulatory or otherwise) that may be legally waived and released; (e) for back pay or other unpaid compensation; and/or (f) for attorneys&#x2019; fees and costs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">To the fullest extent permitted by law, I will not take any action that is contrary to the promises I have made in this Release and Waiver.&nbsp;&nbsp;I further represent that I have not filed any lawsuit, arbitration, or other claim against any of the Released Parties.&nbsp;&nbsp;I hereby states that I know of no violation of state, federal, or municipal law or regulation by any of the Released Parties, and knows of no ongoing or pending investigation, charge, or complaint by any agency charged with enforcement of state, federal, or municipal law or regulation.&nbsp;&nbsp;While nothing in this Release and Waiver prevents state or federal agencies from enforcing laws within their jurisdictions, I agree I shall not receive any individual monetary damages, recovery and/or relief of any type related to any released claim(s), whether pursued by me or any governmental agency, other person or group; provided that nothing in this Release and Waiver prevents me from participating in the whistleblower program maintained by the SEC and receiving a whistleblower award thereunder.&nbsp; I hereby agree that the release set forth in this Release and Waiver shall be and remain in effect in all respects as a complete general release as to the matters released.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Notwithstanding the foregoing, the following are not included in the Released Claims (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;color:#000000;">Excluded Claims</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">): (a)&nbsp;any rights or claims for indemnification I may have pursuant to any written indemnification agreement with the Company to which I am a party, the certificate of incorporation of the Company, bylaws of the Company, or any indemnification agreement with the Company, or under applicable law; (b)&nbsp;any rights or claims to unemployment compensation, funds accrued in my 401k account, or any vested equity or contingent value rights to which I may be entitled to receive under any agreement and plan of reorganization; (c)&nbsp;any rights that are not waivable as a matter of law; or (d)&nbsp;any claims arising after the day on which I sign this Release and Waiver. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against any of the Released Parties that are not included in the Released Claims.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company. I further acknowledge that I have been advised, that: (a)&nbsp;the release and waiver granted herein does not relate to claims which may arise after this Release and Waiver is executed; (b)&nbsp;I should consult with an attorney prior to executing this Release and Waiver; and (c)&nbsp;I have twenty-one (21)&nbsp;days from the date of termination of my employment with the Company or the date on which I received this Release and Waiver, whichever is later and not including such date (as applicable) in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier); (d)&nbsp;I have seven (7) days following the execution of this Release and Waiver, not counting the day on which I sign this Release and Waiver, to revoke my consent to this Release and Waiver; and (e)&nbsp;this Release and Waiver shall not be effective until the seven (7) day revocation period has expired without my having previously revoked this Release and Waiver.&nbsp;&nbsp;Any revocation must be personally delivered to the Company or, if mailed, postmarked, no later than the last day of the 7-day revocation period.&nbsp;&nbsp;The address for delivery of any such revocation shall be sent to Attn: Chairman of the Board, Gemphire Therapeutics Inc., 17199 N. Laurel Park Drive, Ste. 401</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">EXHIBIT A-2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 3.8pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Livonia, Michigan 48152 with a copy to Honigman LLP, Attn: Phillip D. Torrence, 650 Trade Centre Way, Suite 200, Kalamazoo, Michigan 49002.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">I acknowledge my continuing obligations under the Employment Agreement. Pursuant to the Employment Agreement and any of its applicable attachments I understand that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must immediately return all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control. I understand and agree that my right to the severance pay and vesting of any shares of the Company&#x2019;s common stock I am receiving in exchange for my agreement to the terms of this Release and Waiver is contingent upon my continued compliance with the Employment Agreement.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">This Release and Waiver constitutes the complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and Waiver may only be modified by a writing signed by both me and a duly authorized officer of the Company.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Dated:</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">EXHIBIT A-3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>11
<FILENAME>ex-10d5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:48 AM-->
<html>
	<head>
		<title>
			gemp_Ex10_5
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt 0pt 18pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EXHIBIT 10.5</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GEMPHIRE THERAPEUTICS INC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">RESTRICTED STOCK GRANT NOTICE</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">GEMPHIRE THERAPEUTICS INC., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Company&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), pursuant to the Company&#x2019;s Amended and Restated 2015 Equity Incentive Plan (as amended to date, the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Plan&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), hereby awards to Participant as an inducement to waiving the cash retainer payable to Participant for the remainder of 2019, the number of shares of the Company&#x2019;s Common Stock set forth below (this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Award&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">). This Award is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Agreement attached to this Restricted Stock Grant Notice and the Plan, all of which are attached hereto and incorporated herein in their entirety.&nbsp;&nbsp;Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Restricted Stock Agreement.&nbsp;&nbsp;In the event of any conflict between the terms in the Award and the Plan, the terms of the Plan shall control.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt 9.75pt;border-left:1pt none #D9D9D9 ;text-indent: -10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Participant:</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt 9.75pt;border-left:1pt none #D9D9D9 ;text-indent: -10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date of Grant:</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">July ___, 2019&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt 9.75pt;border-left:1pt none #D9D9D9 ;text-indent: -10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Vesting Commencement Date:</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Immediately prior to the effective time of the NeuroBo Merger (as defined below)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;border-left:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Number of Shares Subject to Award:</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt 9.75pt;border-left:1pt none #D9D9D9 ;text-indent: -10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Consideration:</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:63.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:1.5pt 1.5pt 1.5pt 1.5pt;">
					<p style="margin:0pt 0pt 3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Waiver of cash retainer payable to Participant for the remainder of 2019</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Vesting Schedule: &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The number of shares subject to this Award shall fully and completely vest automatically immediately prior to the effective time of any merger between the Company and NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;NeuroBo Merger&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Additional Terms/Acknowledgements:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> The undersigned Participant acknowledges receipt of, and understands and agrees to, this Restricted Stock Grant Notice, the Restricted Stock Agreement and the Plan.&nbsp;&nbsp;Participant further acknowledges that as of the Date of Grant, this Restricted Stock Grant Notice, the Restricted Stock Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition of the Common Stock pursuant to this Award specified above and supersede all prior oral and written agreements on that subject with the exception, if applicable, of (i) the written employment agreement or offer letter agreement entered into between the Company and Participant specifying the terms that</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">should govern this Award, and (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">By accepting this Award, Participant consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:256.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">PARTICIPANT:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:261.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">THE COMPANY:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:256.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:261.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:256.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:261.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:256.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:261.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:256.50pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:36.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:256.50pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:36.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Steven Gullans</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:256.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:36.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:225.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">ATTACHMENTS</font><font style="display:inline;font-family:Times New Roman,Times,serif;">: &nbsp;Restricted Stock Agreement (</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">ATTACHMENT I</font><font style="display:inline;font-family:Times New Roman,Times,serif;">), Amended and Restated 2015 Equity Incentive Plan (delivered separately) and Release and Waiver of Claims (</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">EXHIBIT A</font><font style="display:inline;font-family:Times New Roman,Times,serif;">).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">SIGNATURE PAGE TO RESTRICTED STOCK GRANT NOTICE</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">ATTACHMENT I</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GEMPHIRE THERAPEUTICS INC.</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN</font>
		</p>
		<p style="margin:0pt 0pt 18pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">RESTRICTED STOCK AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Pursuant to the Restricted Stock Grant Notice (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Grant Notice&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) and this Restricted Stock Agreement (collectively, the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Award&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) and in consideration of your future services and you waiving the cash retainer payable to you for the remainder of 2019, &nbsp;Gemphire Therapeutics Inc., a Delaware corporation (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Company&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) has awarded you (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Participant</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) a stock award pursuant to the Company&#x2019;s Amended and Restated 2015 Equity Incentive Plan (as amended to date, the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Plan&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) &nbsp;for the number of shares of the Company&#x2019;s Common Stock subject to the Award as indicated in the Grant Notice.&nbsp;&nbsp;Capitalized terms not explicitly defined in this Restricted Stock Agreement but defined in the Plan or the Grant Notice shall have the same definitions as in the Plan or the Grant Notice. The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The details of your Award are as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VESTING. &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> Subject to the limitations contained herein, your Award will vest as provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NUMBER OF SHARES.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The number of shares subject to your Award may be adjusted from time to time for Capitalization Adjustments, as provided in the Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECURITIES LAWS COMPLIANCE.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">You may not be issued any shares under your Award unless the shares are either (i) then registered under the Securities Act or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.&nbsp;&nbsp;Your Award must also comply with other applicable laws and regulations governing the Award, and you will not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RIGHT OF REACQUISITION.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Company shall have the right to reacquire all or any part of the shares received pursuant to the Award (a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Reacquisition Right&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) that have not yet vested in accordance with the Vesting Schedule on the Grant Notice (the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Unvested Shares&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) on the following terms and conditions:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Company, shall simultaneously, upon the earliest to occur of (A) the termination of your Continuous Service or (B) March 31, 2020 if the NeuroBo Merger has not been completed, &nbsp;automatically reacquire for no consideration (that is, for zero dollars ($0)) all of the Unvested Shares, unless the Company agrees to waive its Reacquisition Right as to some or all of the Unvested Shares; provided, however, if the termination of your Continuous</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Service results from the completion of the NeuroBo Merger prior to March 31, 2020 (a </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;NeuroBo Termination&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) and you have delivered and not subsequently revoked the Release and Waiver, the Company shall not have any Reacquisition Right related to any NeuroBo Termination.&nbsp;&nbsp;Any such waiver shall be exercised by the Company by written notice to you or your representative (with a copy to Computershare Inc. (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">&#x201C;Computershare&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">)) within ninety (90) days after the termination of your Continuous Service, and Computershare may then release to you the number of Unvested Shares not being reacquired by the Company. If the Company does not waive its Reacquisition Right as to all of the Unvested Shares, then upon such termination of your Continuous Service, Computershare shall transfer to the Company the number of shares the Company is reacquiring.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You shall, during the term of the Award, exercise all rights and privileges of a stockholder of the Company with respect to the shares deposited in escrow.&nbsp;&nbsp;You shall be deemed to be the holder of the shares for purposes of receiving any dividends which may be paid with respect to such shares (which shall be subject to the same vesting and forfeiture restrictions as apply to the shares to which they relate) and for purposes of exercising any voting rights relating to such shares, even if some or all of such shares have not yet vested and been released from the Company&#x2019;s Reacquisition Right.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">If, from time to time, there is any stock dividend, stock split or other change in the character or amount of any of the outstanding stock of the Company the stock of which is subject to the provisions of the Award, then in such event any and all new, substituted or additional securities to which you are entitled by reason of your ownership of the shares acquired under the Award shall be immediately subject to the Reacquisition Right with the same force and effect as the shares subject to this Reacquisition Right immediately before such event.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">In addition to any other limitation on transfer created by applicable securities laws, you shall not sell, assign, hypothecate, donate, encumber, or otherwise dispose of any interest in the Common Stock while such shares of Common Stock are subject to the Reacquisition Right; provided, however, that an interest in such shares may be transferred pursuant to a qualified domestic relations order as defined in the Code or Title I of the Employee Retirement Income Security Act.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESTRICTIVE LEGENDS.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The shares issued under the Award shall be endorsed with appropriate legends determined by the Company, including the following legend:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201C;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN VESTING, FORFEITURE AND OTHER RESTRICTIONS ON TRANSFER SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR HIS OR HER PREDECESSOR IN INTEREST. A COPY OF SUCH AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY AND WILL BE FURNISHED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY BY THE HOLDER OF RECORD OF THE SHARES REPRESENTED BY THIS CERTIFICATE.&#x201D;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THE AWARD IS NOT AN EMPLOYMENT CONTRACT.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Award is not an employment or service contract, and nothing in the Award shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or on the part of the Company or an Affiliate to continue your employment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WITHHOLDING OBLIGATIONS.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">At the time the Award is made, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any amounts payable to you, and otherwise agree to make adequate provision for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the Award.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to instruct Computershare to remove the restrictions from such shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOTICES.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Any notices provided for in the Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The rights and obligations of the Company under the Award shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company&#x2019;s successors and assigns. Your rights and obligations under the Award may only be assigned with the prior written consent of the Board of Directors of the Company (or committee administrating the Plan) in its sole discretion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of the Award.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You acknowledge and agree that you have reviewed the Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting the Award and fully understand all provisions of the Award.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GOVERNING PLAN DOCUMENT.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of the Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">*****</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Restricted Stock Agreement shall be deemed to be signed by the Company and Participant upon the acceptance by the Participant of the Restricted Stock Grant Notice.</font>
		</p>
		<p style="margin:0pt 0pt 18.1pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>12
<FILENAME>ex-10d6.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:50 AM-->
<html>
	<head>
		<title>
			gemp_Ex10_6
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">EXHIBIT 10.6</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii)</font>

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">LICENSE AND COLLABORATION AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">THIS LICENSE AND COLLABORATION AGREEMENT</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) is entered into as of July 23, 2019, (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Effective Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), by and between </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GEMPHIRE THERAPEUTICS INC.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, a Delaware corporation having an address at 17199 N Laurel Park Dr., Suite 401&nbsp;&nbsp;Livonia, MI 48152, United States (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">BEIJING SL PHARMACEUTICAL CO., LTD.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, a company organized under the laws of China, having an address at </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Bitongyuan Building 1, 69 Fushi Road, &nbsp;Beijing 100049, China </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;).&nbsp;&nbsp;Gemphire and Beijing SL may be referred to herein individually as a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; or collectively as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Parties</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">RECITALS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">WHEREAS</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, Gemphire, a biopharmaceutical company, owns or controls certain patents, know-how, and other intellectual property relating to its proprietary compound gemcabene, a lipid-lowering small molecule under development&nbsp;as an adjunctive therapy aimed at reducing the levels of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein and/or triglycerides;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">WHEREAS</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, Beijing SL, a pharmaceutical company, possesses substantial resources and expertise in the development and commercialization of pharmaceutical products; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">WHEREAS</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, Beijing SL desires to obtain from Gemphire an exclusive license to Develop and Commercialize the Licensed Products in the Beijing SL Territory (with each capitalized term as respectively defined below), and Gemphire is willing to grant such license to Beijing SL, all under the terms and conditions hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">NOW, THEREFORE</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Gemphire and Beijing SL hereby agree as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEFINITIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Active Ingredient</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any substance intended to be used in a pharmaceutical product that when used becomes an active ingredient of that product intended to exert a pharmacological, immunological or metabolic action with a view to restoring, correcting or modifying physiological functions (excluding formulation components such as coatings, stabilizers, excipients or solvents, adjuvants or controlled release technologies).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Adverse Risk</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any risk of an adverse effect on the Development, procurement or maintenance of Regulatory Approval, Manufacture or Commercialization of Licensed Products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Affiliate</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, with respect to any party, any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">1</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">such party, but for only so long as such control exists.&nbsp;&nbsp;As used in this Section 1.3, &#x201C;control&#x201D; means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance; or (b) direct or indirect beneficial ownership of more than fifty percent (50%) of the voting share capital or other equity interest in such entity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Alliance Manager</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 3.6.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Applicable Laws</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including MAAs) of or from any court, Regulatory Authority or governmental agency or authority having jurisdiction over or related to the subject item.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Auditor</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 9.4.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Development Work</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 4.2(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Indemnitee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 12.1.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 10.1(c)(ii).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Know-How</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all Know-How that Beijing SL or its Affiliate(s) Controls as of the Effective Date or during the Term that is necessary for the Research, Development, manufacture, use, importation, offer for sale or sale of any Compound or Licensed Product in the Field. Notwithstanding the foregoing, Beijing SL Know-How shall not include any Know-How Controlled by an entity that becomes an Affiliate of Beijing SL as a result of a Change of Control of Beijing SL, unless otherwise mutually agreed upon by the Parties. For clarity, any&nbsp;Beijing SL Know-How including such Know-How as will be obtained by Beijing SL or its Affiliates (other than the entity that becomes Affiliate of Beijing SL as a result of such Change of Control) shall not be affected by such Change of Control of Beijing SL and shall be handled in accordance with relevant provisions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Net Sales</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; shall mean the Net Sales of a Licensed Product by Beijing SL, its Affiliates and Sublicensees in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Patents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all Patents that Beijing SL or its Affiliate(s) Controls as of the Effective Date or during the Term that is necessary for the Research, Development, use, manufacturing, importation, offer for sale, or sale of any Compound or Licensed Product in the Field in the Gemphire Territory. Notwithstanding the foregoing, Beijing SL Patents shall not include any Patents Controlled by an entity that becomes an Affiliate of Beijing SL as a result of a Change of Control of Beijing SL, unless otherwise mutually agreed upon by the Parties. For clarity, any Beijing SL Patents including such Patents as will be obtained by Beijing SL or its Affiliates (other than the entity that becomes Affiliate of Beijing SL as a result of such Change of Control) shall not be affected by such Change of Control of Beijing SL and shall be handled in accordance with relevant provisions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Technology</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the Beijing SL Know-How and the Beijing SL Patents, including Beijing SL&#x2019;s interest in the Joint Inventions and Joint Patents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Territory</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, collectively, mainland China, Taiwan, Hong Kong and Macau (each a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Region</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Calendar Quarter</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means each respective period of three (3) consecutive months ending on March 31, June 30, September 30, and December 31.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Calendar Year</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means each respective period of twelve (12) consecutive months ending on December 31.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Change of Control</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, with respect to a Party: (1) a merger, reorganization, consolidation, or other transaction involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent more than fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization, consolidation, or other transaction; or (2) a person or entity, or group of persons or entities acting in concert, acquire more than fifty percent (50%) of the voting equity securities or management control of such Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Claim</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 12.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Clinical Supply Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 7.1(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Clinical Trial</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; or &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Clinical Trials</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, or Phase 4 Clinical Trial, as the context dictates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">CMO</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a contract manufacturing organization.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Combination Product</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means: (a) a Product that consists of the Compound and at least one other Active Ingredient that is not the Compound; or (b) any combination of a Product and another pharmaceutical product that contains at least one other Active Ingredient that is not the Compound, where such products are formulated together, or are not formulated together but are sold together as a single product and invoiced as one product.&nbsp;&nbsp;The other Active Ingredient(s) in clause (a) and the other pharmaceutical product(s) in clause (b) are each referred to as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Other Product(s)</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercial Supply Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 7.1(b).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercialization</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the conduct of all activities undertaken before and after Regulatory Approval relating to the promotion, sales, marketing, medical support, and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling, and delivering Licensed Products to customers) of Licensed Products in the Field, including sales force efforts, detailing, advertising, market research, market access (including price and reimbursement activities), medical education and information services, publication, scientific and medical affairs, advisory and collaborative activities with opinion leaders and professional societies including symposia, marketing, sales force training, and sales</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">3</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(including receiving, accepting and filling Licensed Product orders) and distribution.&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercialize</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; and &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercializing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; have the correlative meanings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercialization Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 6.2.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercially Reasonable Efforts</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, with respect to a Party and its obligations under this Agreement, those commercially reasonable efforts and resources consistent with the usual practices of a similarly situated company for the development and commercialization of a pharmaceutical product originating from its own research and development department without a royalty obligation to others, which is at a similar stage of research, development, or commercialization, taking into account that product&#x2019;s profile of efficacy and safety; proprietary position, including patent and regulatory exclusivity; regulatory status, including anticipated or approved labeling and anticipated or approved post-approval requirements; present and future market and commercial potential, including competitive market conditions (but not taking into account any payment owed to the other Party under this Agreement), and all other relevant factors, including technical, legal, scientific and/or medical factors.&nbsp;&nbsp;Commercially Reasonable Efforts requires that a Party at a minimum: (a) establish a plan to achieve objectives and assign specific responsibilities for the achievement of that plan and (b) make and implement decisions and allocate resources designed to advance progress with respect to such objectives.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Competing Product</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any product or compound, other than a Compound or Licensed Product, with functional group(s) in such product&#x2019;s or compound&#x2019;s chemical structure that is similar to a Compound or Licensed Product, that (a) reduces one or more of LDL-C, hsCRP and TGs as its primary mechanism of action, or (b) is targeted towards any Other Approved Indication.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Compound</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the compound known as gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Confidential Information</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all Know-How and other proprietary scientific, marketing, financial, or commercial information or data that is generated by or on behalf of a Party or its Affiliates or which one Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs, or formulae in relation to this Agreement; provided that all Gemphire Technology will be deemed Gemphire&#x2019;s Confidential Information, all Beijing SL Technology will be deemed Beijing SL&#x2019;s Confidential Information, and all Joint Inventions and Joint Patents will be deemed both Parties&#x2019; Confidential Information.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Confidentiality Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means that certain Mutual Confidentiality Agreement between Gemphire and Beijing SL dated as of October 26, 2018.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Control</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; or &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Controlled</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, with respect to any Know-How, Patents,&nbsp;&nbsp;other intellectual property rights or materials, the legal authority or right (whether by ownership, license, or otherwise, but without taking into account any rights granted by one Party to the other Party pursuant to this Agreement) of a Party to grant access, a license, or a sublicense of or under such Know-How, Patents, other intellectual property rights or materials to the other Party, or to</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">4</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">otherwise disclose proprietary or trade secret information to the other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Cover</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Covered</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; or &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Covering</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, with respect to a Patent and a product, such Patent would (absent a license thereunder or ownership thereof) be infringed by the manufacture, use or sale of such product, provided, however, that in determining whether a claim of a pending Patent application would be infringed, it shall be treated as if issued in the form then currently being prosecuted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">CRO</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a contract research organization.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Data</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any and all scientific, technical or safety data specifically pertaining to any Compound or Licensed Product that is generated by or on behalf of Gemphire, Beijing SL, and their respective Affiliates and sublicensees, including any and all, non-aggregated or aggregated, research, clinical pharmacology, pre-clinical, clinical, commercial, marketing, process development, manufacturing and other data or information, including investigator brochures and reports (both preliminary and final), statistical analyses, expert opinions and reports, and safety data, in each case generated from or related to research, testing, clinical studies or non-clinical studies of such Compound or Licensed Product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Development</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all development activities for any Compound or Licensed Product that are directed to obtaining Regulatory Approval(s) of such Licensed Product in the Field or lifecycle management of such Licensed Product in any country or Region in the world, including all preclinical GLP studies (including toxicology, pharmacokinetic and pharmacological studies), and clinical testing and studies of the Licensed Product; statistical analyses; clinical trial protocol design and development; the preparation, filing, and prosecution of any MAA for such Licensed Product; development activities directed to label expansion and/or obtaining Regulatory Approval for one or more additional indications following initial Regulatory Approval; development activities conducted after receipt of Regulatory Approval, including Phase 4 Clinical Trials; and all regulatory affairs related to any of the foregoing.&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Develop</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; and &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Developing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; have the correlative meanings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Development Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 4.2.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Development Work</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means Global Development Work or Beijing SL Development Work.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Disputed Matter</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 15.2.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Dollar</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">USD</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">United States Dollar</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; or &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">$</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the official currency of the United States of America.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">EMA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the European Medicines Agency or its successor.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Executive Officers</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the Chief Executive Officer of Gemphire and the Chief Executive Officer and President of Beijing SL Pharmaceuticals.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">5</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Export Control Laws</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all applicable U.S. laws and regulations relating to (a) sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the Export Administration Act of 1979, 24 U.S.C. &#xA7;&#xA7; 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. &#xA7;&#xA7; 1701-1706, the Trading with the Enemy Act, 50 U.S.C. &#xA7;&#xA7; 1 et. seq., the Arms Export Control Act, 22 U.S.C. &#xA7;&#xA7; 2778 and 2779, and the International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986, in each case, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">FCPA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.), as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">FDA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the U.S. Food and Drug Administration or its successor.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Field</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the treatment of any human disease.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">First Commercial Sale</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, on a Licensed Product-by-Licensed Product and Region-by-Region basis, the first sale of such Licensed Product in such Region by Beijing SL or its Affiliates or Sublicensees to a Third Party after Regulatory Approval for such Licensed Product has been obtained in such Region.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GAAP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as may be approved by a significant segment of the accounting profession in the United States, which are applicable to the circumstances as of the date of determination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GCP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the current clinical practice as set out in (i) ICH Harmonized Guidance on current Good Clinical Practice (CPMP/ICH/135/95), (ii) US Code of Federal Regulations, Title 21, Chapters 50, 54, 56, 58, 210, 211 and 312, as amended, and (iii) the equivalent law or regulation in any other applicable jurisdiction in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire Indemnitee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 12.2.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 10.1(c)(i).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire Know-How</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all Know-How that Gemphire or its Affiliates Controls as of the Effective Date or during the Term that is necessary for the Research, Development, use, manufacturing, importation, offer for sale, or sale of any Compound or Licensed Product in the Field in the Beijing SL Territory.&nbsp;&nbsp;Notwithstanding the foregoing, Gemphire Know-How shall not include any Know-How Controlled by an entity that becomes an Affiliate of Gemphire as a result of a Change of Control of Gemphire, unless otherwise mutually agreed upon by the Parties. For clarity, any Gemphire Know-How including such Know-How as will be obtained by Gemphire or its Affiliates (other than the entity that becomes Affiliate of Gemphire as a result of such Change of Control) shall not be affected by such Change of Control of Gemphire and shall be handled in accordance with relevant provisions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">6</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire Patents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all Patents in the Beijing SL Territory that Gemphire or its Affiliates Controls as of the Effective Date or during the Term that is necessary for the Research, Development, use, manufacturing, importation, offer for sale, or sale of any Compound or Licensed Product in the Field in the Beijing SL Territory.&nbsp;&nbsp;The Gemphire Patents include the Patents set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Notwithstanding the foregoing, Gemphire Patents shall not include any Patents Controlled by an entity that becomes an Affiliate of Gemphire as a result of a Change of Control of Gemphire, unless otherwise mutually agreed upon by the Parties. For clarity, any Gemphire Patents including such Patents as will be obtained by Gemphire or its Affiliates (other than the entity that becomes Affiliate of Gemphire as a result of such Change of Control) shall not be affected by such Change of Control of Gemphire and shall be handled in accordance with relevant provisions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire Technology</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the Gemphire Know-How and the Gemphire Patents, including Gemphire&#x2019;s interest in the Joint Inventions and Joint Patents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire Territory</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the world outside the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GLP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58, as amended, or the relevant foreign equivalent thereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Global Development Work</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 4.2(b).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Global Net Sales</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; shall mean the aggregate Net Sales of a Licensed Product by (a) Beijing SL, its Affiliates and Sublicensees, and (b) Gemphire, its Affiliates and their licensees, in the Beijing SL Territory and the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Global Study</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, as mutually agreed (in writing) to be conducted by the Parties, the Phase 3 Clinical Trial for HoFH or other Clinical Trials with Gemphire as the sponsor that is designed to include the enrollment of patients in both the Beijing SL Territory and the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GMP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the current minimum standards for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug as specified by applicable laws of the relevant countries or Regions at the time of manufacturing conducted in accordance with this Agreement, defined under (a) 21 C.F.R. Part 210 and 211, and (b) equivalent law or regulations in any other applicable jurisdiction in the Beijing SL Territory or the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Governmental Authority</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any national, international, federal, state, provincial, or local government, or political subdivision thereof, or any multinational organization, or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, regulatory, or taxing authority or power, or any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gross Sales</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the gross amount invoiced for the sale or other disposition of Licensed Product to a Third Party in a Region in the Beijing SL Territory by or on behalf of Beijing SL or its Affiliates or Sublicensees.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">7</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">HoFH</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means homozygous familial hypercholesterolemia.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">hsCRP</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means high-sensitivity C-reactive protein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">ICH</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the International Conference on Harmonization (of Technical Requirements for Registration of Pharmaceuticals for Human Use).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">IND</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means an investigational new drug application or equivalent application filed with the applicable Regulatory Authority, which application is required to commence human clinical trials in the applicable country or Region.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Indemnitee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 12.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Indemnitor</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 12.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Indication</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a separate and distinct disease, disorder, illness, or health condition and all of its associated signs, symptoms, stages, or progression (including precursor conditions), in each case for which a separate MAA may be filed.&nbsp;&nbsp;For clarity, subpopulations or patients with a primary disease or condition, however stratified (including stratification by stages or progression, particular combinations of symptoms associated with the primary disease or condition, prior treatment courses, response to prior treatment, family history, clinical history, phenotype, or other stratification) shall not be deemed to be separate &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Indications</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; for the purposes of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Injunctive Relief</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 15.3(b).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any inventions and/or discoveries, including processes, manufacture, composition of matter, Information, methods, assays, designs, protocols, and formulas, and improvements or modifications thereof, patentable or otherwise, that are generated, developed, conceived or reduced to practice (constructively or actually) by or on behalf of a Party or its Affiliates or their respective sublicensees (a) pursuant to activities conducted under this Agreement, or (b) in connection with the Development and Commercialization of Licensed Product, in each case of (a) and (b), including all rights, title and interest in and to the intellectual property rights therein and thereto; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">provided, however,</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> that Inventions shall exclude Data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Joint Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 10.1(c)(iii).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Joint Patents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any Patents that claim Joint Inventions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Joint Steering Committee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; or &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">JSC</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 3.1.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Know-How</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all technical information, know-how, Data, inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, expertise, technology, methods, including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, and analytical safety, non-clinical, and clinical data; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">provided, however,</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> that Know-How shall exclude Patents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">LDL-C</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means low-density lipoprotein cholesterol.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">8</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Licensed Product</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any pharmaceutical product comprising, as an Active Ingredient, a Compound, alone or in combination with one or more other Active Ingredients, in any form, presentation, formulation or dosage form, and for any mode of administration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Losses</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 12.1.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">MAA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a marketing authorization application or equivalent application, and all amendments and supplements thereto, filed with the applicable Regulatory Authority in any country or Region.&nbsp;&nbsp;For clarity, MAA does not include any application for Pricing and Reimbursement Approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">MAA Approval</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means approval of an MAA by the applicable Regulatory Authority for marketing and sale of a Licensed Product in the applicable country or Region, but excluding any Pricing and Reimbursement Approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Manufacture</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; and &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Manufacturing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; mean all manufacturing activities for any Compound or Licensed Product that are directed to manufacturing, processing, filling, finishing, packaging, labeling, quality control, quality assurance testing and release, post-marketing validation testing, inventory control and management, storing and transporting any Product, including oversight and management of vendors therefor.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Manufacturing Cost</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, with respect to a particular Compound or Licensed Product (whether as Active Ingredient or finished form) supplied by Gemphire pursuant to Section 7.1(a) or 7.1(b): (a) if Gemphire or its Affiliate Manufactures the applicable Compound or Licensed Product, the actual Manufacturing cost of such Compound or Licensed Product (as determined in accordance with U.S. GAAP consistently applied with its other products); or (b) if a Third Party Manufactures such Compound or Licensed Product, the actual transfer price paid by Gemphire or its Affiliate to such Third Party for the Manufacture of such Compound or Licensed Product without mark-up; in each case of (a) and (b), excluding the external costs of insurance and transportation, import and export Taxes and fees, and similar charges, for such Compound or Licensed Product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Manufacturing Technology Transfer Completion</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 7.2.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Medical Affairs</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; or &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Medical Affairs Activities</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means activities designed to ensure or improve appropriate medical use of, conduct medical education of, or further research regarding, a Licensed Product, including by way of example:&nbsp;&nbsp;(a) activities of medical scientific liaisons who, among their other functions, may: (i) conduct service-based medical activities including providing input and assistance with consultancy meetings, proposing investigators for clinical trials sponsored or co-sponsored by a Party or Affiliate, and providing input in the design of such trials and other research related activities; and/or (ii) deliver non-promotional communications and conduct non-promotional activities; (b) grants to support continuing medical education, symposia, or Third Party research related to such Licensed Product; (c) development, publication, and dissemination of publications relating to such Licensed Products; (d) medical information services provided in response to inquiries communicated via sales representatives or received by letter, phone call, or email; (e) conducting advisory board meetings, international</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">9</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">advisory board activities, or other consultant programs, including the engagement of key opinion leaders and health care professional in individual or group advisory and consulting arrangements; and (f) the evaluation of applications for support of investigator-initiated trials of a Licensed Product in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Net Sales</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the Gross Sales, less (1) sales returns, and allowances actually paid, granted or accrued, including trade, quantity and cash discounts, chargebacks, rebates, and customary trade discounts actually taken, and (2) to the extent recorded in the Gross Sales, outbound freight, value added tax, sales or use taxes, and custom or excise duties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">In the case of any sale of a Licensed Product which is not invoiced or is delivered before invoice, Net Sales shall be calculated at the time of shipment or when the Licensed Product is paid for, if paid for before shipment or invoice.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Upon any sale or other disposition of any Licensed Product for any consideration other than exclusively monetary consideration on bona fide arms&#x2019; length terms, then for purposes of calculating Net Sales under this Agreement, such Licensed Product shall be deemed to be sold at the fair market price of the relevant Licensed Product in the Region in which such sale or other disposition occurred.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Net Sales for a Licensed Product sold as part of a Combination Product in a Region shall be calculated as [**] of the Net Sales of the Combination Product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Unless otherwise specified herein, Net Sales shall be calculated in accordance with (and include the deductions as permitted by) U.S. GAAP generally and consistently applied.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">NMPA</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means China&#x2019;s National Medical Product Administration or its successor.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Other Approved Indication</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any Indication other than Indications for lowering levels of LDL-C, hsCRP or TGs that are supported by biomarkers, clinical outcomes or medical guidelines, that is approved by the JSC for further Development pursuant to the terms and conditions set forth in Section 4.2(c).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Other Product</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 1.22.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Patents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means (a) all patents, certificates of invention, applications for certificates of invention, priority patent filings, and patent applications (including provisional patent applications), (b) any renewals, divisions, or continuations (in whole or in part) of any of such patents, certificates of invention and patent applications, and any all patents or certificates of invention issuing thereon, and (c) any and all reissues, reexaminations, extensions, supplementary protection certificates, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Pfizer</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means Pfizer Inc., a Delaware corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Pfizer Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means that certain Amended and Restated License Agreement by and between Gemphire and Pfizer, dated as of August 2, 2018.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">10</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Pfizer Sublicense Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 2.6.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Pharmacovigilance Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 5.4.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.93&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Phase 1 Clinical Trial</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a clinical trial in any country or Region conducted in a small number of human volunteers designed or intended to establish an initial safety profile, pharmacodynamics, or pharmacokinetics of a Licensed Product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Phase 2 Clinical Trial</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a clinical trial of a Licensed Product in human patients in any country or Region designed or intended to determine initial efficacy and safety of such Licensed Product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.95&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Phase 3 Clinical Trial</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a pivotal clinical trial of a Licensed Product in human patients in any country or Region with a defined dose or a set of defined doses of a Licensed Product designed or intended to ascertain efficacy and safety of such Licensed Product for the purpose of submitting applications for Regulatory Approval to the competent Regulatory Authorities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.96&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Phase 4 Clinical Trial</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a product support clinical trial of a Licensed Product that is commenced after receipt of MAA Approval in the country or Region where such trial is conducted.&nbsp;&nbsp;Phase 4 Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and post-marketing surveillance trials.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.97&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Pricing and Reimbursement Approval</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, with respect to a Licensed Product, the approval, agreement, determination, or decision of any applicable Governmental Authority establishing the price or level of reimbursement for such Licensed Product, as required in a given country or Region prior to sale of such Licensed Product in such country or Region.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.98&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Product Infringement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 10.3(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.99&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Product Mark</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 10.6(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.100&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Product Materials</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 4.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.101&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Promotional Materials</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 6.4(c).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.102&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Public Official or Entity</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means (a) any officer, employee (including physicians, hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality, or subdivision of any government, military, or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital, or (b) any candidate for political office, any political party, or any official of a political party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.103&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Recall</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 5.5.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.104&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Region</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 1.14.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.105&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Registration Holder</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the holder of an MAA or the approval thereof.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">11</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.106&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Regulatory Approval</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, with respect to a country or Region, any and all approvals (including MAA Approval, and Pricing and Reimbursement Approval, if applicable), licenses, registrations, permits, notifications and authorizations (or waivers) of any Regulatory Authority that are necessary for the Manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of a Licensed Product in such country or Region.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.107&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Regulatory Authority</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of pharmaceutical products in a given jurisdiction, including the FDA and NMPA.&nbsp;&nbsp;For countries or Regions where Pricing and Reimbursement Approval is required, Regulatory Authority shall also include any Governmental Authority whose grant of Pricing and Reimbursement Approval of a Licensed Product is required.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.108&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Regulatory Exclusivity</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a pharmaceutical product other than Patents, including orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, or pediatric exclusivity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.109&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Regulatory Filing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications, and authorizations (or waivers) with respect to the testing, Development, Manufacture, or Commercialization of any Licensed Product made to or received from any Regulatory Authority in a given country or Region, including any INDs and MAAs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.110&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Regulatory Meeting</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 5.2.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.111&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Regulatory Transfer Completion</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 5.1(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.112&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Research</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means all non-clinical and non-GLP preclinical studies/activities of any Compound or Compound candidate including preliminary (non-GLP) toxicology and pharmacological studies, assay development, ADME and other research activities for evaluation of Compounds or Compound candidate or exploration of new Indications thereof.&nbsp;&nbsp;Regardless of the foregoing, Research activities will not include Development.&nbsp;&nbsp;For clarity, Research shall not include any research activities to discover, synthesize or design compounds which are not claimed or Covered by a Patent set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> unless the Parties agree in writing to include such research activities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.113&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Right of Reference</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the &#x201C;right of reference or use&#x201D; as defined in 21 C.F.R. &#xA7;314.3(b) and any equivalent regulation outside the U.S., as each may be amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.114&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Royalty Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 0.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.115&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Rules</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 15.3(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.116&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Safety Data</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means data related solely to any adverse drug experiences and serious adverse drug experience as such information is reportable to Regulatory Authorities.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">12</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Safety Data also includes &#x201C;adverse events&#x201D;, &#x201C;adverse drug reactions&#x201D;, and &#x201C;unexpected adverse drug reactions&#x201D; as defined in the ICH Harmonised Tripartite Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.117&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">SEC</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the U.S. Securities and Exchange Commission, or any successor entity or its foreign equivalent, as applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.118&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Sponsor</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means, with respect to a particular Clinical Trial, the person or entity that takes the ultimate responsibility for the initiation, performance, and management of, including financing or arranging the financing for, such Clinical Trial.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.119&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Step-In Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 10.2(d).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.120&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Subcommittee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any subcommittee established by the JSC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.121&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Sublicensee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means a Third Party to whom Beijing SL grants a sublicense to research, Develop, make, have made, use, sell, offer for sale, import, or otherwise Commercialize any Licensed Product in the Field in the Beijing SL Territory, beyond the mere right to purchase Licensed Products from Beijing SL and its Affiliates, and excluding wholesalers and full-service distributors that do not promote the sale of the Licensed Product, and other similar physical distributors.&nbsp;&nbsp;In no event shall Gemphire or any of its Affiliates be deemed a Sublicensee.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.122&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Sunshine Reporting Laws</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 5.6.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.123&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Technology Transfer Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 2.8.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.124&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; has the meaning set forth in Section 14.1.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.125&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">TGs</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means triglycerides.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.126&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Third Party</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means any entity other than Gemphire or Beijing SL or an Affiliate of Gemphire or Beijing SL.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.127&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">U.S.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means the United States of America, including its territories and possessions (including Puerto Rico).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.128&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Valid Claim</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; means (a) a claim of an issued and unexpired patent that has not been revoked or held unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal, and that has not been abandoned, disclaimed, denied, or admitted to be invalid or unenforceable through reissue, re-examination, or disclaimer or otherwise, or (b) a claim of a pending patent application that has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.129&nbsp;&nbsp;&nbsp;&#x201C;VAT&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> has the meaning set forth in Section 9.3(c).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.130&nbsp;&nbsp;&nbsp;&#x201C;Withholding Tax&#x201D;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> has the meaning set forth in Section 9.3(b)(i).</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">13</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">1.131&nbsp;&nbsp;&nbsp;&#x201C;Withholding Tax Action&#x201D; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">has the meaning set forth in Section 9.3(b)(ii).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GRANT OF LICENSES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License Grant to Beijing SL</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, Gemphire hereby grants to Beijing SL an exclusive (even as to Gemphire and its Affiliates, except as expressly set forth herein), royalty-bearing license, with the right to grant sublicenses in accordance with Section 2.2, under the Gemphire Technology, to Research, Develop, have Developed, make, have made, Manufacture, have Manufactured, use, have used, sell, have sold, offer for sale, import, and otherwise Commercialize and have Commercialized Licensed Products in the Field in the Beijing SL Territory. Gemphire confirms to Beijing SL, as of the Effective Date, Gemphire has received Pfizer&#x2019;s consent to the terms and conditions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beijing SL&#x2019;s Sublicensing Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall have the right to grant sublicenses under the license granted in Section 2.1 to its Affiliates and Third Parties, solely with the prior written consent of Gemphire.&nbsp;&nbsp;All such sublicenses shall be in writing and shall be subject to, and consistent with, the applicable terms and conditions of this Agreement and, to the extent applicable, the Pfizer Agreement (including without limitation those set forth in Section 2.6).&nbsp;&nbsp;Beijing SL shall ensure that each agreement with a Sublicensee grants Gemphire all rights with respect to Data, Inventions, and Regulatory Filings made or generated by such Sublicensee as if such Data, Inventions, and Regulatory Filings were made or generated by Beijing SL, including but not limited to any applicable Right of Reference.&nbsp;&nbsp;Beijing SL shall be responsible for the compliance of its Affiliates, Sublicensees, distributors, and subcontractors with the terms and conditions of this Agreement.&nbsp;&nbsp;Beijing SL shall provide a copy of any sublicense agreement to Gemphire within a reasonable period after execution of each sublicense granted to a Third Party hereunder, provided that Beijing SL may reasonably redact from such copy confidential financial terms and confidential terms that are not related to compliance with the terms and conditions of this Agreement. If any sublicense granted under this Agreement is not in English, then Beijing SL will also provide Gemphire with a certified English translation as soon as practicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reserved Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Gemphire hereby expressly reserves:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the right under the Gemphire Technology to exercise its rights and perform its obligations under this Agreement, whether directly or through one or more Affiliates, licensees or subcontractors, including, without limitation, the conduct of any Global Study in the Beijing SL Territory;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the right under the Gemphire Technology to Manufacture and have Manufactured the Compound or Licensed Product in the Beijing SL Territory, for Research, Development, use or Commercialization in the Gemphire Territory;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pursuant to the Pfizer Agreement, the right for Pfizer under the Gemphire Technology to use, import, Manufacture and have Manufactured the Compound or Licensed Product in the Beijing SL Territory for Pfizer&#x2019;s internal research purposes; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all rights to practice, and to grant licenses under, the Gemphire Technology outside of the scope of the license granted in Section 2.1, including the exclusive rights to practice</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">14</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">the Gemphire Patents and Gemphire Know-How (i) with respect to compounds and products other than Compounds and Licensed Products and (ii) with respect to Compounds and Licensed Products in the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL shall not, and will cause its Affiliates and Sublicensees not to, restrict or impede in any manner Gemphire&#x2019;s exercise of its reserved rights set forth in this Section 2.3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Gemphire hereby confirms to Beijing SL that gemcabene is the most effective compound or product in blood lipid regulation that has been developed or licensed by Gemphire as of the Effective Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License Granted to Gemphire</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, Beijing SL hereby grants to Gemphire and its Affiliates an exclusive (even as to Beijing SL and its Affiliates), royalty-free license, with the right to sublicense (through multiple tiers), under the Beijing SL Technology (a) to Research, Develop, use, sell, offer for sale, import, and otherwise Commercialize Licensed Products in the Gemphire Territory, and (b) to Manufacture or have Manufactured Licensed Products anywhere in the world for Gemphire and its Affiliates to Research, Develop, use, sell, offer for sale, import, and otherwise Commercialize Licensed Products in the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Implied Licenses; Negative Covenant</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How, or other intellectual property owned or controlled by the other Party.&nbsp;&nbsp;Neither Party shall, nor shall it permit any of its Affiliates or sublicensees to, practice any Patents or Know-How licensed to it by the other Party outside the scope of the licenses granted to it under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any rights granted to Beijing SL under this Agreement are Controlled by Gemphire pursuant to the Pfizer Agreement, (i) such rights are subject to the terms and conditions of the Pfizer Agreement, and (ii) Beijing SL agrees to comply with such terms and conditions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the generality of Section 2.6(a), with respect to any rights granted to Beijing SL under this Agreement that are Controlled by Gemphire pursuant to the Pfizer Agreement (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Pfizer Sublicense Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), the Parties hereby agree that:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL shall not assign any of its Pfizer Sublicense Rights without the prior written consent of Pfizer;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Pfizer is a third party beneficiary under Beijing SL&#x2019;s sublicense to the Pfizer Sublicense Rights, with the rights to enforce the applicable terms thereof;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL shall not have the rights to grant any further sublicenses to the Pfizer Sublicense Rights in contravention with the terms of the Pfizer Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">15</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing&#x2019;s SL&#x2019;s rights to any Pfizer Sublicense Rights shall terminate upon the termination of the Pfizer Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exclusivity. &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">During the Term, Beijing SL shall not, directly or indirectly (including through its Affiliate, Sublicensee or a Third Party), research, develop, manufacture or commercialize any Competing Product in the Beijing SL Territory or the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Technology Transfer</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Promptly following the Effective Date, the Parties shall agree to a technology transfer plan setting forth the process and schedule for Gemphire to transfer to Beijing SL all Gemphire Know-How Controlled by Gemphire as of the Effective Date that are necessary for Beijing SL to conduct its activities under the Development Plan in the Beijing SL Territory (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Technology Transfer Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), including any such pre-clinical and clinical Data necessary for obtaining Regulatory Approval of the Licensed Product in the Beijing SL Territory. Upon the Parties&#x2019; agreement to the Technology Transfer Plan, Gemphire shall provide Beijing SL with the Gemphire Know-How pursuant to the terms and conditions set forth therein, at Beijing SL&#x2019;s sole cost and expense. From time to time thereafter, Gemphire shall continue to transfer any additional Gemphire Know-How that was not previously provided to Beijing SL, at Beijing SL&#x2019;s sole cost and expense, and Beijing SL shall and shall cause its Affiliates and Sublicensees to transfer to Gemphire or its designee any Beijing SL Know-How related to the Compound or Licensed Product not previously provided to Gemphire, at Gemphire&#x2019;s sole cost and expense.&nbsp;&nbsp;Upon Beijing SL&#x2019;s reasonable request, and at Beijing SL&#x2019;s cost and expense, Gemphire shall provide Beijing SL with reasonable assistance in conducting the Beijing SL Development Work, including without limitation, consultation with respect to the submission of IND and NDA to the NMPA, the design and analysis of Phase 2 Clinical Trials and Phase 3 Clinical Trials, the end of Phase 2 meeting with the NMPA, and life cycle management for the Licensed Product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GOVERNANCE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint Steering Committee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Within thirty (30) days following the Effective Date, the Parties shall establish a joint steering committee (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Joint Steering Committee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D; or the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">JSC</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), composed at a minimum of three (3) members appointed by Gemphire and three (3) members appointed by Beijing SL who are fluent in English, to oversee and guide the strategic direction of the collaboration of the Parties under this Agreement. Additional members may be appointed to the JSC upon mutual agreement of the Parties. The JSC shall act as a joint consultative body and, to the extent expressly provided herein, a joint decision-making body.&nbsp;&nbsp;The JSC shall in particular:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;provide a forum for discussion of the Development and Commercialization of the Compound and Licensed Products in the Beijing SL Territory;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;coordinate and monitor the Development activities of the Parties under the Development Plan;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review and approve the Development Plan and any proposed material amendments thereto, and oversee implementation of the Development Plan;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;provide a forum for and facilitate communications between the Parties with respect to sharing of Development information and Data in accordance with Section 4.3;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">16</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review and approve protocols for Clinical Trial in the Beijing SL Territory (excluding any Global Study) and monitor the progress of such Clinical Trials in the Beijing SL Territory;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review Clinical Trial Data generated in the Beijing SL Territory and discuss whether progress to the next phase Clinical Trial is merited;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;monitor and coordinate pharmacovigilance and safety matters for Licensed Products worldwide;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;oversee and coordinate Medical Affairs Activities for Licensed Products in all Indications in the Beijing SL Territory;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review and approve the Commercialization Plan for the Beijing SL Territory, including proposed material amendments, and oversee implementation of the Commercialization Plan;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;review the Compound and Licensed Product manufacturing and supply requirements, strategy and performance;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;oversee and facilitate the Parties&#x2019; communications and activities with respect to publications under Section 13.4;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;establish joint subcommittees and delegate any of the JSC&#x2019;s authority herein to them as it deems necessary or advisable to oversee and direct Research, Development, Manufacture and Commercialization activities under this Agreement; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or allocated to it by the Parties&#x2019; written agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JSC Membership and Meetings</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Committee Members</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each JSC representative shall have appropriate knowledge and expertise and sufficient seniority and authority within the applicable Party to make decisions arising within the scope of the JSC&#x2019;s responsibilities.&nbsp;&nbsp;Each Party may replace its representatives on the JSC on written notice to the other Party, but each Party shall strive to maintain continuity in the representation of its JSC members.&nbsp;&nbsp;The JSC will be chaired by co-chairpersons designated by Gemphire and Beijing SL, respectively. The chairpersons shall prepare and circulate agendas to JSC members at least seven (7) days before each JSC meeting and shall direct the preparation of reasonably detailed minutes for each JSC meeting, which shall be circulated to JSC members within thirty (30) days after such meeting for comment and which shall be deemed approved when none of the JSC members have any further comments.&nbsp;&nbsp;The Parties shall determine their respective initial members of the JSC within thirty (30) days after the Effective Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Meetings</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The JSC shall hold meetings at such times as it elects to do so, but in no event shall meetings of the JSC be held less frequently than twice a year prior to obtaining</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">17</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">the First Commercial Sale of the Licensed Product in the Beijing SL Territory.&nbsp;&nbsp;The first JSC meeting shall be held within sixty (60) days after the Effective Date, at which meeting the dates for the first Calendar Year shall be set.&nbsp;&nbsp;JSC meetings may be held in person or by audio or video teleconference.&nbsp;&nbsp;In-person JSC meetings shall be held at locations agreed upon by the Parties.&nbsp; All JSC meetings will be held in English. Each Party shall be responsible for all of its own expenses of participating in any JSC meeting.&nbsp;&nbsp;No action taken at any JSC meeting shall be effective unless at least one (1) representative of each Party is participating.&nbsp;&nbsp;In addition, upon written notice to the other Party, either Party may request that a special </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">ad hoc</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> meeting of the JSC be convened for the purpose of resolving any disputes in connection with, or for the purpose of reviewing or making a decision pertaining to any material subject-matter within the responsibilities of the JSC, the review or resolution of which cannot be reasonably postponed until the following scheduled JSC meeting.&nbsp;&nbsp;Such ad hoc meeting shall be convened at such time as may be mutually agreed by the Parties, but no later than fifteen (15) days following the date of the request that such meeting be held.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Non-Member Attendance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend JSC meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party and obtain the other Party&#x2019;s approval for such Third Party to attend such meeting, which approval shall not be unreasonably withheld or delayed.&nbsp;&nbsp;Such Party shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decision-Making</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All decisions of the JSC shall be made by unanimous vote, with each Party&#x2019;s representatives collectively having one (1) vote.&nbsp;&nbsp;If after reasonable discussion and good faith consideration of each Party&#x2019;s view on a particular matter, the representatives of the Parties cannot reach an agreement as to such matter within fifteen (15) business days after such matter was brought to the JSC for resolution, then either Party at any time may refer such issue to the Executive Officers for resolution.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Executive Officers cannot resolve such matter within five (5) business days after such matter has been referred to them, then:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Gemphire shall have the final decision making authority, which shall be exercised in its reasonable discretion, with respect to (A) Global Development Work, (B) the protocols for Clinical Trails, including the selection of any CRO, site and principal investigator therefor, and (C) any regulatory matters relating to Licensed Products for which Gemphire is the Registration Holder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL shall have the final decision making authority, which shall be exercised in its reasonable discretion, with respect to (A) Commercialization, Medical Affairs and regulatory matters in the Beijing SL Territory, (B) Beijing SL Development Work, and (C) any regulatory matters relating to Licensed Products for which Beijing SL is the Registration Holder, in each case of (A), (B) and (C), to the extent consistent with the terms and conditions of this Agreement; provided, however, that (x) Gemphire shall have final decision</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">18</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">making authority with respect to Clinical Trial Protocols, and (y) Gemphire shall have the right to veto the conduct of any Clinical Trial in the Beijing SL Territory that it reasonably believes is an Adverse Risk to the Development or Commercialization of any Licensed Product in the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">For all matters except those where either Party shall have and can use the final decision making authority described in (i) and (ii) of this subsection, neither Party shall have the final decision making authority and such matters can only be decided by unanimous vote of the JSC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In case the JSC is unable to come to a unanimous decision and neither Party has final decision making authority with respect to a matter in dispute as described in Section 3.3(b)(iii) above, the Parties shall resolve such dispute through the dispute resolution methods described in Article 15 hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations on Authority</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The JSC shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.&nbsp;&nbsp;Without limiting the generality of the foregoing, the JSC will not have the power to amend this Agreement or determine or waive compliance with this Agreement, and no JSC decision may be in contravention of any terms and conditions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discontinuation of the JSC</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The activities to be performed by the JSC shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services.&nbsp;&nbsp;The JSC shall continue to exist until the Parties mutually agree to disband the JSC.&nbsp;&nbsp;Once the Parties mutually agree, the JSC shall have no further obligations under this Agreement and, thereafter, each Party shall designate a contact person for the exchange of information under this Agreement or such exchange of information shall be made through Alliance Managers, and decisions of the JSC shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alliance Managers</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Within twenty (20) days after the Effective Date, each Party shall appoint an employee of such Party with appropriate qualification and experience to act as the alliance manager for such Party (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Alliance Manager</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;).&nbsp;&nbsp;Each Alliance Manager shall be responsible for coordinating and managing processes and interfacing between the Parties on a day-to-day basis throughout the Term.&nbsp;&nbsp;The Alliance Manager will ensure communication to the JSC of all relevant matters raised at any Subcommittee, which shall be in English.&nbsp;&nbsp;Each Alliance Manager shall be permitted to attend meetings of the JSC or any Subcommittee, in each case as appropriate and as non-voting participants.&nbsp;&nbsp;The appointed Alliance Manager may also be a member of the JSC.&nbsp;&nbsp;The Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this Agreement and shall facilitate all such activities hereunder.&nbsp;&nbsp;Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party.&nbsp;&nbsp;Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager.&nbsp;&nbsp;Each Party shall bear its own costs of its Alliance Manager, which costs shall be excluded from the Parties&#x2019; respective Development and Manufacturing costs (including Cost of Goods) under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">19</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DEVELOPMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Overview</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, the Parties will collaborate with respect to the Development of Licensed Products and share the Data resulting from such collaboration as provided in this Article 4 to facilitate the Development of Licensed Products throughout the Beijing SL Territory and the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The Parties shall Develop Licensed Products with respect to the Beijing SL Territory pursuant to a comprehensive written Development plan (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Development Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), which shall be incorporated by reference as part of this Agreement.&nbsp;&nbsp;The Development Plan will include all Clinical Trials and other Development activities conducted in the Beijing SL Territory, including those conducted as part of Global Studies, and shall be subject to the approval of the JSC. As of the Effective Date, the current working draft of the initial Development Plan is attached hereto as </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">Exhibit B</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;&nbsp;Following the Effective Date, the JSC will meet to finalize the initial Development Plan, which shall be agreed to by the Parties not later than ninety (90) days following the Effective Date.&nbsp;&nbsp;Once finalized and agreed to by the Parties, the Development Plan may only be materially amended with the JSC&#x2019;s approval. If the terms of the Development Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Territory-Specific Development Work</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall be solely responsible, at its sole expense, for all Development activities that are conducted solely in Regions within the Beijing SL Territory but are not part of a Global Study, including all non-clinical and clinical studies, as necessary to obtain Regulatory Approval for Licensed Products in any Region in the Beijing SL Territory (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Development Work</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;). Beijing SL shall use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for Licensed Products in the Field in each Region in the Beijing SL Territory, including the timely achievement of the Development milestones set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">Exhibit C</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Without limiting the generality of the foregoing, Beijing SL shall use Commercially Reasonable Efforts to conduct its Development activities under and in accordance with the Development Plan, including without limitation the timeline set forth therein, to be performed reasonably and subject to the oversight of the JSC as set forth in Article 3.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Global Development Work</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. The Parties shall collaborate in good faith in the conduct of any Global Study (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Global Development Work</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;).&nbsp;&nbsp;Subject to Gemphire&#x2019;s final decision making authority pursuant to Section 3.3(b)(i), Beijing SL shall be solely responsible, at its sole expense, for all Global Development Work that are conducted solely in Regions within the Beijing SL Territory. Gemphire shall be solely responsible, at its sole expense, for all Global Development Work that are conducted solely in countries within the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Amendments</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;If Beijing SL wishes (i) to perform additional Development work, including the Development of a Licensed Product aimed at any Indication other than the levels of LDL-C, hsCRP or TGs, in the Beijing SL Territory, or (ii) to modify the Development work that is in process or planned in the Beijing SL Territory or pursuant to a Global Study, Beijing SL shall prepare a draft amendment to the Development Plan that reflects such additional work or modification and shall submit such draft amendment to the JSC for review and approval in accordance with Section 3.1(c).&nbsp;&nbsp;If the JSC approves such amendment, then the amended</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">20</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Development Plan shall become the then-current Development Plan and any such Indication for which Development is approved by the JSC shall be deemed an &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Other Approved Indication</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Data Exchange</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;With respect to all Development Work, each Party shall promptly provide the other Party with copies of all Data and Regulatory Materials related to the Compound or Licensed Products generated by or on behalf of such Party or its Affiliates or sublicensees in the performance of Development activities of the Compound or Licensed Products in their respective territories (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Product Materials</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) in English, including without limitation (i) at least Calendar Quarterly basis status reports on trial recruitment and other metrics consistent with the performing Party&#x2019;s internal reporting for clinical studies and Development activities, provided, however, that with respect to unexpected events that may impact safety and recruitment, each Party shall inform the other Party within forty-eight (48) hours after learning of such event, (ii) supporting documentation for such activity (e.g., protocols, CRFs, analysis plans, etc.), (iii) preliminary and final Data, and interim, preliminary, and final results and reports, and (iv) output from advisory committees and investigator meetings with respect to such activity.&nbsp;&nbsp;The Parties shall cooperate on a secure website to facilitate the sharing of reports, Data, and other information on a routine basis.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party shall Develop Licensed Products in compliance with all Applicable Laws, including good scientific and clinical practices under the Applicable Laws of the country or Region in which such activities are conducted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Records</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall maintain complete, current, and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities.&nbsp;&nbsp;Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes.&nbsp;&nbsp;Beijing SL shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and GMP).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Reports</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;At each regularly scheduled JSC meeting, each Party shall provide the JSC with regular reports in English detailing its Development activities for the Licensed Products under this Agreement, and the results of such activities.&nbsp;&nbsp;In addition, after the completion of any Clinical Trial or other study of the Licensed Products (a) by Beijing SL in the Beijing SL Territory, or (b) by Gemphire with respect to the Global Development Work, the Party responsible for the conduct of such Clinical Trial or study shall promptly provide the other Party with a data package in English consisting of, at a minimum, tables, lists, and figures, as well as any other Data specified in the Development Plan or otherwise agreed by the Parties.&nbsp;&nbsp;The Parties shall discuss the status, progress, and results of each Party&#x2019;s Development activities under this Agreement at such JSC meetings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of Subcontractors</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party may perform its Development activities under this Agreement through one or more subcontractors, provided that (a) such Party will remain responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself, (b) each subcontractor undertakes in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties pursuant to Article 13, and (c) each subcontractor agrees in writing</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">21</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">to assign all intellectual property developed in the course of performing any such work to such Party (or, in the event such assignment is not feasible, a license to such intellectual property with the right to sublicense to such other Party).&nbsp;&nbsp;The Parties may also subcontract work on terms other than those set forth in this Section 4.7 with the prior approval of the JSC. Notwithstanding the foregoing, Beijing SL shall (i) with respect to any CRO conducting any Global Development Work, ensure such CRO is qualified in the Beijing SL Territory and capable of producing Clinical Trial Data acceptable to the NMPA,&nbsp;&nbsp;the FDA and the EMA (and other applicable Regulatory Authorities in the Beijing SL Territory, the United States or the European Union); and (ii) ensure that any Clinical Trials conducted in the Beijing SL Territory, whether by itself or through a CRO, are conducted only at medical facilities that are qualified and registered with the NMPA or other Regulatory Authorities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REGULATORY ACTIVITIES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Responsibilities</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">General</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Subject to the terms and conditions of this Agreement, Beijing SL will be responsible, at its sole cost and expense, for the conduct of all regulatory activities required to obtain and maintain Regulatory Approval of Licensed Products in the Field in the Beijing SL Territory, including the preparation and submission of all Regulatory Materials and all communications and interactions with Regulatory Authorities, including the NMPA, as necessary to obtain and maintain Regulatory Approval for Licensed Products in any Region in the Beijing SL Territory. Beijing SL shall be responsible for filing each MAA in the Beijing SL Territory for each Licensed Product in its own name except that the MAA shall be filed in the name of Gemphire for mainland China.&nbsp;&nbsp;&nbsp;Without jeopardizing the approval of the MAA in the name of Gemphire, Beijing SL shall, as soon as possible after the Manufacturing Transfer, submit an MAA in its own name to the NMPA to market the Licensed Products as locally manufactured products in mainland China.&nbsp;&nbsp;Upon approval of such MAA in the name of Beijing SL, the MAA under the name of Gemphire shall be cancelled and all regulatory responsibilities for the Licensed Products in mainland China shall reside with Beijing SL (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Regulatory Transfer Completion</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;). The Development Plan shall include the regulatory strategy for obtaining Regulatory Approval of Licensed Products in the Beijing SL Territory.&nbsp;&nbsp;Beijing SL shall use Commercially Reasonable Efforts to carry out its regulatory obligations for Licensed Products pursuant to such strategy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Right of Reference</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant to Beijing SL</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Gemphire hereby grants to Beijing SL a Right of Reference to all Regulatory Filings submitted by or on behalf of Gemphire that pertain to any Compound or Licensed Product for the sole purpose of obtaining and maintaining Regulatory Approval of Licensed Products in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant to Gemphire</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Beijing SL hereby grants to Gemphire a Right of Reference to all Regulatory Filings submitted by or on behalf of Beijing SL or its Affiliates or Sublicensees that pertain to any Compound or Licensed Product for the sole purpose of obtaining and maintaining Regulatory Approval of Licensed Products in the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">22</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Regulatory Information Sharing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Beijing SL shall promptly provide Gemphire with copies of any Regulatory Filings prepared (including any drafts), submitted, or received by Beijing SL in the Beijing SL Territory pertaining to any Compound or Licensed Product, and Gemphire shall have the right to review and comment on drafts of such Regulatory Filings in English. Without limiting the generality of the foregoing, Beijing SL shall share with Gemphire the following communications and correspondence with any Regulatory Authority: (a) summary of contact reports Beijing SL receives concerning substantive conversations or substantive meetings in the Beijing SL Territory with the NMPA with respect to the Licensed Product or if contacts with those Regulatory Authorities are made orally, to be reduced in writing, (b) documents related to regulatory milestones and dates (e.g., submission, validations, agency review questions, and opinions, and their equivalent), and (c) IND annual reports and cover letters of all agency submissions relating to any Compound or Licensed Product.&nbsp; If any such communications and correspondence with Regulatory Authority is not in English, then Beijing SL will also provide Gemphire with a certified English translation as soon as practicable. Beijing SL shall use Commercially Reasonable Efforts to grant to Gemphire access and rights to use any such communications with any Regulatory Authority generated by or on behalf of any Sublicensee.&nbsp;&nbsp;If Beijing SL fails to obtain such access and rights from any Sublicensee, Beijing SL shall not have the right to grant access or rights to such Sublicensee to any Regulatory Filing or Right of Reference granted to Beijing SL by Gemphire pursuant to Section 5.1(b)(i).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings with Regulatory Authorities</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;On a current and ongoing basis, Beijing SL shall provide Gemphire with a list and schedule in English of any in-person meeting or material teleconference with the Regulatory Authorities (or related advisory committees) in the Beijing SL Territory planned for the next Calendar Quarter that relates to the Development of any Compound or Licensed Product under the Development Plan in the Beijing SL Territory (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Regulatory Meeting</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;).&nbsp;&nbsp;In addition, Beijing SL shall notify Gemphire as soon as reasonably possible if Beijing SL becomes aware of any additional Regulatory Meetings that become scheduled for such Calendar Quarter and will keep Gemphire informed of any significant interface or communication with any Regulatory Authority which might affect efforts to obtain Regulatory Approval for the Licensed Product in the Beijing SL Territory.&nbsp;&nbsp;Beijing SL shall be solely responsible for any communications with any Regulatory Authorities occurring or required in connection with performing its regulatory responsibilities set forth in this Article 5 with respect to any Licensed Product in the Beijing SL Territory. With respect to Regulatory Meetings for which Beijing SL is the responsible Party, Gemphire shall have the right to provide input in preparation for all such Regulatory Meetings and the right, but not the obligation, to have its representatives attend any such Regulatory Meetings.&nbsp;&nbsp;If Gemphire elects not to have its representatives attend such Regulatory Meetings, then Beijing SL will provide to Gemphire a written summary thereof in English promptly following such Regulatory Meetings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Inspections</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beijing SL shall permit all Regulatory Authorities in the Gemphire Territory to conduct inspections of Beijing SL, its Affiliates, and its Sublicensees and subcontractors (including Clinical Trial sites) relating to the Development of the Licensed Product under the Development Plan, and shall ensure that such Affiliates and Sublicensees and subcontractors permit such inspections.&nbsp;&nbsp;In addition, Beijing SL shall promptly notify Gemphire</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">23</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">of any such inspection and shall supply Gemphire with all information pertinent thereto.&nbsp;&nbsp;Gemphire shall have the right to have a representative attend any such inspection.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gemphire shall permit all Regulatory Authorities in the Beijing SL Territory to conduct inspections of Gemphire, its Affiliates, and its licensees and subcontractors (including Clinical Trial sites) relating to the Development of the Licensed Product under the Development Plan, and shall ensure that such Affiliates and licensees and subcontractors permit such inspections.&nbsp;&nbsp;In addition, Gemphire shall promptly notify Beijing SL of any such inspection and shall supply Beijing SL with all information pertinent thereto.&nbsp;&nbsp;Beijing SL shall have the right to have a representative attend any such inspection.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adverse Event Reporting; Pharmacovigilance Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;A reasonable time prior to the initiation of any Development work in the Beijing SL Territory, the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Licensed Products, such as Safety Data sharing, adverse events reporting, and safety signal and risk management (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Pharmacovigilance Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), which agreement shall be amended by the Parties from time to time as necessary to comply with any changes in Applicable Laws or any guidance received from Regulatory Authorities.&nbsp;&nbsp;Such procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under Applicable Laws (including, to the extent applicable, those obligations contained in ICH guidelines) to monitor patients&#x2019; safety.&nbsp;&nbsp;Gemphire shall maintain (either by itself or through a vendor engaged by Gemphire) the global safety database in English for the Licensed Products, and shall maintain such global safety database for so long as such Licensed Product is under Development or Commercialization by the Parties.&nbsp;&nbsp;The Parties will collaboratively agree on data cut points for periodic aggregate safety reports and Gemphire will author such reports; the Parties will jointly review and approve such reports before submission to worldwide Regulatory Authorities as required.&nbsp;&nbsp;Each Party shall bear their own costs associated with maintaining such database and preparing such reports.&nbsp;&nbsp;Gemphire shall ensure that Beijing SL is able to access the data from the global safety database in order to meet legal and regulatory obligations.&nbsp;&nbsp;Beijing SL shall be responsible for reporting to Gemphire in English all quality complaints, adverse events, and Safety Data related to the Licensed Products to any Regulatory Authorities in the Beijing SL Territory, and responding to safety issues and to all requests of Regulatory Authorities related to the Licensed Products under any MAA or Regulatory Approval for the Licensed Product held by Beijing SL and filed with such Regulatory Authorities in the Beijing SL Territory, in each case at its own cost.&nbsp;&nbsp;Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees, and sublicensees to comply with such obligations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recalls. &nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">In the event that a recall, withdrawal, or correction (including the dissemination of relevant information) of any Licensed Product (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Recall</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) in the Beijing SL Territory is required by a Regulatory Authority of competent jurisdiction, or if a Recall in the Beijing SL Territory is deemed advisable by Beijing SL, Beijing SL shall so notify Gemphire no later than forty-eight (48) hours in advance of the earlier of (a) initiation of a recall, withdrawal, or correction, or (b) the submission of plans for such an action to a Regulatory Authority.&nbsp;&nbsp;Upon such notification, the Parties shall promptly discuss the appropriate actions with respect to the Recall, provided that the Registration Holder for such Licensed Product in the applicable Region in the Beijing SL Territory at the time of such notification shall have final authority on deciding</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">24</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">such action, and the other Party shall not take any Recall action for such Licensed Product without the prior written approval of such Registration Holder.&nbsp;&nbsp;Beijing SL shall handle exclusively the organization and implementation of all Recalls of Licensed Products in the Beijing SL Territory, and be responsible for all costs and expenses in connection therewith, provided, however, Gemphire bear the costs and expenses of any Recall that occurs in the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sunshine Reporting Laws</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL acknowledges that Gemphire may be subject to federal, state, local, and international laws, regulations, and rules related to the tracking and reporting of payments and transfers of value provided to health care professionals, health care organizations, and other relevant individuals and entities (collectively, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Sunshine Reporting Laws</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), and agrees to provide Gemphire with all information regarding such payments or transfers of value by Beijing SL as necessary for Gemphire to comply in a timely manner with its reporting obligations under the Sunshine Reporting Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMMERCIALIZATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Subject to the terms and conditions of this Article 6, Beijing SL shall have the sole and exclusive responsibility, at its own expense, for all aspects of the Commercialization of the Licensed Products in the Beijing SL Territory, including (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating with applicable Governmental Authorities and other payors regarding the price and reimbursement status of the Licensed Products, (c) marketing and promotion, (d) booking sales and distribution and performance of related services, (e) handling all aspects of order processing, invoicing and collection, inventory and receivables, (f) providing customer support, including handling medical queries, and performing other related functions, and (g) conforming its practices and procedures to Applicable Laws relating to the promotion, sales and marketing, access, and distribution of the Licensed Products in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercialization Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;As soon as reasonably practicable, but no later than three (3) months after the first MAA for a Licensed Product is submitted in the Beijing SL Territory, Beijing SL shall prepare and present to the JSC for review and approval a plan for the Commercialization of such Licensed Product in the Beijing SL Territory, on a Region-by-Region basis (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercialization Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;). The Commercialization Plan shall consist of overall program of Commercialization for Licensed Products for each Indication, the key message, positioning and target physicians and patients for Commercializing such Licensed Products in each applicable Region.&nbsp;&nbsp;Beijing SL shall prepare a draft amendment to the Commercialization Plan on at least an annual basis following the First Commercial Sale of the Licensed Product in the Beijing SL Territory and present such draft amendment to the JSC for review and approval.&nbsp;&nbsp;Subject to the provisions of this Agreement and compliance with the Commercialization Plan, Beijing SL shall have full control and authority with respect to the day-to-day Commercialization of the Licensed Products and implementation of the Commercialization Plan in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diligence</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">General</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;During the Term, Beijing SL shall use Commercially Reasonable Efforts to Commercialize the Licensed Products for each and every Indication that has received Regulatory Approval in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">25</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Licensed Product Launch</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall launch the Licensed Product for each Indication that has received Regulatory Approval in the Beijing SL Territory as soon as reasonably possible following receipt of such Regulatory Approval.&nbsp;&nbsp;As applicable, Beijing SL shall obtain all Pricing and Reimbursement Approvals necessary to launch such Licensed Product for such Indication in a particular Region in the Beijing SL Territory as soon as reasonably possible following receipt of MAA Approval of such Licensed Product in such Region.&nbsp;&nbsp;Without limiting the generality of the foregoing, Beijing SL shall use Commercially Reasonable Efforts to launch the Licensed Product in each Region in the Beijing SL Territory within two (2) months after receiving Regulatory Approval of the Licensed Product for an Indication from the applicable Regulatory Authority in such Region.&nbsp;&nbsp;Thereafter, Beijing SL shall utilize Commercially Reasonable Efforts in the ongoing support for the Licensed Product in each Region in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercial Updates</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall update the JSC on an annual basis regarding its Commercialization activities with respect to the Licensed Products in the Beijing SL Territory.&nbsp;&nbsp;Each such update shall be in English and in a form to be agreed by the JSC and shall summarize Beijing SL&#x2019;s and its Affiliates&#x2019; and Sublicensees&#x2019; significant Commercialization activities with respect to the Licensed Products in the Beijing SL Territory, and shall contain at least such information at such level of detail reasonably required by Gemphire to determine Beijing SL&#x2019;s compliance with its diligence obligations set forth in this Section 6.3.&nbsp;&nbsp;Such updates shall include Beijing SL&#x2019;s sales activities, sales forecasts for at least the next three (3) years, marketing activities, and Medical Affairs Activities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Coordination of Commercialization Activities</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Generally</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The Parties, through the JSC (or any designated Subcommittee), shall update each other on Commercialization strategies for Licensed Products (e.g., for branding and messaging, international congresses, advisory boards) in their respective territories, and the Parties shall work together to identify and take advantage of any potential global strategies and messaging.&nbsp;&nbsp;The foregoing shall not be construed as requiring either Party to seek the other Party&#x2019;s consent in connection with such first Party establishing or implementing any sales, marketing, or medical affairs practices in such first Party&#x2019;s territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Pricing</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall keep Gemphire timely informed on the status of any application for Pricing and Reimbursement Approval or material updates to an existing Pricing and Reimbursement Approval in the Beijing SL Territory, including any discussion with a Regulatory Authority with respect thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Sharing of Promotional Materials</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall, at its own expense, prepare, develop, produce, or otherwise obtain and utilize sales, promotional, advertising, marketing, website, educational, and training materials (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Promotional Materials</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) to support its Commercialization activities in the Beijing SL Territory, and shall ensure that such Promotional Materials, as well as all information contained therein, comply with all Applicable Laws and are consistent with any Regulatory Approvals obtained for the Licensed Product in the applicable Region in the Beijing SL Territory.&nbsp;&nbsp;At Gemphire&#x2019;s request, Beijing SL shall share with Gemphire samples of and updates to Promotional Materials with respect to the Commercialization of Licensed Products.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">26</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical Affairs Activities</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Beijing SL shall be responsible for Medical Affairs Activities in the Beijing SL Territory in accordance with the medical affairs portion of the Development Plan, provided, however, that Gemphire shall have the right, but not the obligation, to also conduct Medical Affairs Activities in the Beijing SL Territory in global support of the Licensed Product, consistent with the medical affairs portion of the Development Plan and in coordination with Beijing SL.&nbsp;&nbsp;Beijing SL will not undertake Medical Affairs Activities in the Gemphire Territory without Gemphire&#x2019;s prior written consent to be given on a case-by-case basis.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diversion</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party hereby covenants and agrees that it and its Affiliates shall not, and it shall contractually obligate (and use Commercially Reasonable Efforts to enforce such contractual obligation) its sublicensees not to, directly or indirectly, promote, market, distribute, import, sell, or have sold any Licensed Product, including via the Internet or mail order, to any Third Party, or to any address or Internet Protocol address or the like, in the other Party&#x2019;s territory.&nbsp;&nbsp;Neither Party shall engage, nor permit its Affiliates and sublicensees to engage, in any advertising or promotional activities relating to any Licensed Product for use directed primarily to customers or other buyers or users of such Licensed Product located in any country or Region in the other Party&#x2019;s territory, or solicit orders from any prospective purchaser located in any country or Region in the other Party&#x2019;s territory.&nbsp;&nbsp;If a Party or its Affiliates or sublicensees receives any order for a Licensed Product for use from a prospective purchaser located in a country or Region in the other Party&#x2019;s territory, such Party shall immediately refer that order to such other Party and shall not accept any such orders.&nbsp;&nbsp;Neither Party shall, nor permit its Affiliates and sublicensees to, deliver or tender (or cause to be delivered or tendered) any Licensed Product for use in the other Party&#x2019;s territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MANUFACTURE AND SUPPLY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gemphire Manufacture and Supply</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Clinical Supply</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The Parties agree to reasonably cooperate to ensure that Beijing SL has a sufficient supply of Compound or Licensed Product to conduct its initial Clinical Trials for obtaining any Regulatory Approval in the Field in the Beijing SL Territory until the date of Regulatory Transfer Completion.&nbsp;&nbsp;No later than sixty (60) days following the Effective Date, the Parties shall negotiate in good faith and execute a clinical supply agreement incorporate&nbsp;&nbsp;the terms set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">Exhibit D-1</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> and other customary terms for clinical supply agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Clinical Supply Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;). Pursuant to the Clinical Supply Agreement, Beijing SL shall purchase from Gemphire, and Gemphire shall use Commercially Reasonable Efforts to supply to Beijing SL, the Compound or Licensed Product for Beijing SL to conduct any Clinical Trial in the Field in the Beijing SL Territory.&nbsp;&nbsp;For clarity, (i) Beijing SL shall not have the right to Manufacture or have Manufactured any Compound or Licensed Product for clinical use prior to the Manufacturing Technology Transfer Completion, and (ii) following Regulatory Transfer Completion for the first Licensed Product, Gemphire&#x2019;s clinical supply obligations under this Section 7.1(a) &nbsp;shall cease.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercial Supply</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. No later than twelve (12) months prior to the anticipated date of First Commercial Sale of the Licensed Product, the Parties shall negotiate in good faith a commercial supply agreement in accordance with the terms set forth in </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">Exhibit D-2</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercial Supply Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;). Pursuant to the Commercial Supply Agreement, Beijing</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">27</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">SL shall purchase from Gemphire, and Gemphire shall use Commercially Reasonable Efforts to supply to Beijing SL, the Compound or Licensed Product for Beijing SL to use for commercial purposes in the Field in the Beijing SL Territory.&nbsp;&nbsp;For clarity, (i) Beijing SL shall not have the right to Manufacture or have Manufactured any Compound or Licensed Product for commercial use prior to the Manufacturing Technology Transfer Completion, and (ii) following Regulatory Transfer Completion for a Licensed Product, Gemphire&#x2019;s commercial supply obligations under this Section 7.1(b) for such Licensed Product shall cease.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing Technology Transfer</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. As soon as practically feasible following the Effective Date, unless Gemphire in good faith identifies any Adverse Risks with respect thereto, Gemphire shall use Commercially Reasonable Efforts to transfer to Beijing SL its Manufacturing technology for the Compound and Licensed Products in accordance with a schedule to be agreed in writing in good faith by the Parties (the completion of such transfer, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Manufacturing Technology Transfer Completion</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;). Gemphire shall transfer to Beijing SL such documents and information, and through its CMO provide such technical assistance and support, necessary or reasonably useful for Beijing SL to Manufacture Compound or Licensed Product, to the extent Controlled by Gemphire as of such date. Beijing SL shall pay Gemphire&#x2019;s reasonable costs incurred in connection with providing such information or assistance pursuant to this Section 7.2, and such information or assistance shall be provided on a one-time basis, unless otherwise agreed by the Parties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Distribution</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL will be solely responsible for the distribution of Licensed Products in the Field in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brand Security and Anti-Counterfeiting</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The Parties will establish contacts for communication regarding brand security issues, and each Party shall reasonably cooperate with the other Party with respect thereto.&nbsp;&nbsp;Practices around these incidents will comply with Gemphire&#x2019;s then-current standards, where they define product security features, warehouse/cargo protection requirements, and response and communication process for such incidents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL PROVISIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upfront Payment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Within forty-five (45) days after the Effective Date, Beijing SL shall make a one-time, non-refundable, non-creditable upfront payment to Gemphire of Two Million Five Hundred Thousand Dollars ($2,500,000).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Milestone Payments</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Within thirty (30) days of the first achievement by a Licensed Product of a development milestone event set forth in the table below, whether by or on behalf of Beijing SL, its Affiliate or Sublicensees, Beijing SL shall pay to Gemphire the non-refundable, non-creditable payment(s) for the applicable milestone event.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:66.32%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Development Milestone Event</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:33.68%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Milestone Payment</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:66.32%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Upon submission of IND to the NMPA for a Licensed Product</font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:33.68%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:66.32%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Upon dosing of the first patient in a Phase 3 Clinical Trial of a Licensed Product in mainland China</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:33.68%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">28</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:66.32%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Upon NDA approval of a Licensed Product for a first Indication in the Beijing SL Territory</font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:33.68%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**]</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:66.32%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Upon NDA approval of a Licensed Product for each additional Indication (other than the first Indication) in the Beijing SL Territory</font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:33.68%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**]</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales Milestones Payments</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Within thirty (30) days following Beijing SL&#x2019;s receipt of Gemphire&#x2019;s notification of any sales milestone event set forth in the table below, Beijing SL shall pay to Gemphire the one-time, non-refundable, non-creditable payments for the applicable milestone event; in each case, where A is the cumulative Beijing SL Net Sales of all Licensed Products when the relevant sales milestone is achieved, and B is the cumulative Global Net Sales of all Licensed Products when the relevant sales milestone is achieved. For clarity, each payment in this Section 8.3 shall be payable once only upon first achievement of the applicable milestone event, regardless of the number of times such milestone is subsequently achieved.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:292.25pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Sales Milestone Event</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:175.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Milestone Payment</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:292.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Cumulative Global Net Sales exceed [**] </font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:175.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**] multiplied by A/B</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:292.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Cumulative Global Net Sales exceed [**] </font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:175.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**] multiplied by A/B</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;width:292.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Cumulative Global Net Sales exceed [**] </font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;width:175.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**] multiplied by A/B</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:292.25pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Cumulative Global Net Sales exceed [**]</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:175.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**]</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">multiplied by A/B</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalty Payments</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Royalty Rates</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Subject to the terms and conditions of this Section 8.4, within sixty &nbsp;(60) days after the end of each Calendar Quarter during the Royalty Term, Beijing SL shall pay to Gemphire non-creditable, non-refundable royalties on Beijing SL Net Sales in the Beijing SL Territory during such Calendar Quarter, as calculated by multiplying the applicable royalty rate by the corresponding amount of Beijing SL Net Sales in the Beijing SL Territory, as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:296.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Annual Beijing SL Net Sales of all Licensed Products in the Beijing SL Territory</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:170.75pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Royalty Rate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:296.75pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">For that portion of annual Beijing SL Net Sales less than or equal to [**]</font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:170.75pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**]%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">29</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;width:296.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">For that portion of annual Beijing SL Net Sales greater than [**] but less than or equal to [**]</font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;width:170.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**]%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt solid #000000 ;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:296.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">For that portion of annual Beijing SL Net Sales greater than [**]</font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt solid #000000 ;border-top:1pt solid #000000 ;border-right:1pt solid #000000 ;border-bottom:1pt solid #000000 ;width:170.75pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">[**]%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Royalty Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The term of the royalties payable under Section 8.4(a), on a Licensed Product-by-Licensed Product and Region-by-Region basis, shall commence on the First Commercial Sale of such Licensed Product in such Region and shall end upon the latest to occur of: (i) the date of expiration of Regulatory Exclusivity of such Licensed Product in such Region; (ii) the date of expiration or abandonment of the last Valid Claim of a Gemphire Patent or Joint Patent that Covers such Licensed Product in such Region; or (iii) five (5) years after such First Commercial Sale (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Royalty Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PAYMENT; RECORDS; AUDITS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment; Reports</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;All royalty payments due under Section 8.4 shall be accompanied by a report setting forth in English, on a Licensed Product-by-Licensed Product and Region-by-Region basis, Beijing SL Net Sales in the Beijing SL Territory in the applicable Calendar Quarter in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including, for each Region, the number of Licensed Products sold, the Gross Sales and Net Sales of Licensed Products, including the deductions from Gross Sales to arrive at Net Sales, the royalty payments payable, the method used to calculate the royalty, and the exchange rates used.&nbsp;&nbsp;Prior to the First Commercial Sale of a Licensed Product in the Beijing SL Territory, the Parties will agree on the form of royalty report.&nbsp;&nbsp;Beijing SL shall submit a single report for all Beijing SL Net Sales during each Calendar Quarter, but shall separately identify the Net Sales and other information applicable to each of Beijing SL, its Affiliates and Sublicensees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange Rate; Manner of Payment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;&nbsp;All payments hereunder shall be payable in U.S. Dollars.&nbsp;&nbsp;When conversion of Net Sales from any currency other than U.S. Dollars is required, such conversion shall be at the exchange rate equal to the conversion rate for the U.S. Dollar for the currency of the Region in which the applicable Net Sales were made as published by the </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:12pt;">Wall Street Journal</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">, Western U.S. Edition, averaged over the Calendar Quarter in which the applicable Net Sales were made.&nbsp;&nbsp;All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Gemphire, unless otherwise specified in writing by Gemphire.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Taxes on Income</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Except as otherwise provided in this Section 9.3, each Party will be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Withholding Taxes</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">30</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">If&nbsp;Beijing SL is required to make a payment to Gemphire that is subject to a deduction or withholding of income taxes by a governmental authority in the Beijing SL Territory, (excluding VAT as defined in Section 9.3(c)) (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Withholding Tax</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), then then in the case of any payments to be made by Beijing SL to Gemphire under this Agreement, Beijing SL (or its Affiliate paying to Gemphire on behalf of Beijing SL) will, in accordance with Applicable Laws, (A) deduct or withhold such Withholding Tax in the full amount required to be deducted or withheld from the amount due to Gemphire, (B) remit such Withholding Tax to the proper Governmental Authority when due, (C) furnish Gemphire with proof of payment of such Tax Withholding within thirty (30) days following the payment, and (D) pay to Gemphire the stated amount payable under this Agreement (after deducting any such Withholding Tax).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> If one Party (or a Party&#x2019;s assignees or successors) is required to make a payment to the other Party subject to a Withholding Tax, and if such Withholding Tax obligation arises as a result of any action taken by such required Party or its Affiliates or successors, including an assignment of this Agreement as permitted under Section 16.5, as a result of which (a) the payment arises in a territory other than the territory under the laws of which such required Party is organized, (b) there is a change in the tax residency of such required Party, or (c) the payments arise or are deemed to arise through a branch of such required Party in a territory other than the territory under the laws of which such required Party is organized and such action has the effect of increasing the amount of Withholding Tax (each, an &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Withholding Tax Action</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), then notwithstanding Section 9.3(b)(i), the payment by such required Party (in respect of which such Withholding Tax is required to be made) shall be increased by the amount necessary to ensure that the other Party receives an amount equal to the same amount that it would have received had no Withholding Tax Action occur.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">VAT</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. All payments due to Gemphire from Beijing SL pursuant to this Agreement shall be paid exclusive of, and without reduction for, any value-added tax (including any goods and services tax) (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">VAT</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) (which, if applicable, shall be payable by Beijing SL). Beijing SL shall be responsible for the payment of all VAT applicable to the transactions contemplated by this Agreement and shall file all applicable VAT tax returns. Gemphire shall cooperate, to the extent reasonably required, with the filing of any such VAT tax returns. Beijing SL shall indemnify Gemphire for any VAT imposed on Gemphire as a result of the transactions contemplated by this Agreement and if Gemphire directly pays any such VAT, Beijing SL shall promptly reimburse Gemphire for such VAT including all reasonable related costs. If Gemphire determines that it is required to report any such tax, Beijing SL shall promptly provide Gemphire</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">31</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">with applicable receipts and other documentation necessary or appropriate for such report. For clarity, this Section 9.3(c) is not intended to limit Beijing SL right to deduct VAT in determining Net Sales.&nbsp;&nbsp;Gemphire shall reimburse Beijing SL for any local surcharges imposed on VAT by deducting such amount from payments due to Gemphire.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Tax Cooperation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce withholding Taxes or similar obligations in respect of the milestone payments, royalty payments, and other payments made by Beijing SL to Gemphire under this Agreement.&nbsp;&nbsp;To the extent that Beijing SL is required by Applicable Laws to deduct and withhold Taxes on any payment to Gemphire, Beijing SL shall pay the amounts of such Taxes to the proper Governmental Authority in a timely manner and promptly transmit to Gemphire an official tax certificate or other evidence of such payment sufficient to enable Gemphire to claim such payment of Taxes.&nbsp;&nbsp;Gemphire shall provide Beijing SL any tax forms that may be reasonably necessary in order for Beijing SL to not withhold Taxes or to withhold Taxes at a reduced rate under an applicable bilateral income tax treaty, to the extent legally able to do so.&nbsp;&nbsp;Gemphire shall use reasonable efforts to provide any such tax forms to Beijing SL, including an IRS Form W-8BEN-E, in advance of the due date.&nbsp;&nbsp;Beijing SL shall provide Gemphire with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding Taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of Gemphire.&nbsp;&nbsp;Beijing SL shall use reasonable efforts to minimize any such Taxes required to be withheld on behalf of Gemphire by Beijing SL, its Affiliates or Sublicensees.&nbsp;&nbsp;Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Records; Audit</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp; Beijing SL shall keep, and shall cause its Affiliates and Sublicensees to keep, complete and accurate records in English pertaining to the Development, sale or other disposition of Licensed Products in the Beijing SL Territory in sufficient detail to permit Gemphire to confirm the accuracy of milestone and royalty payments due to it hereunder. Beijing SL will keep such books and records for at least five (5) years following the Calendar Year to which they pertain.&nbsp;&nbsp;Upon reasonable prior notice, such records shall be inspected during regular business hours at such place or places where such records are customarily kept by an independent certified public accountant (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Auditor</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) selected by Gemphire and reasonably acceptable to Beijing SL for the sole purpose of verifying for Gemphire the accuracy of the financial reports furnished by Beijing SL pursuant to this Agreement or of any payments made, or required to be made, by Beijing SL pursuant to this Agreement.&nbsp;&nbsp;Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit.&nbsp;&nbsp;Such audits may occur no more often than twice each Calendar Year and not more frequently than once with respect to records covering any specific period of time.&nbsp;&nbsp;Such auditor shall not disclose Beijing SL&#x2019;s Confidential Information to the Gemphire, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by Beijing SL or the amount of payments by Beijing SL under this Agreement.&nbsp;&nbsp;In the event that the final result of the inspection reveals an underpayment by Beijing SL, Beijing SL shall pay the amount owed, plus applicable interest pursuant to Section 9.5, to Gemphire within thirty (30) days after the Auditor&#x2019;s report.&nbsp;&nbsp;Gemphire shall bear the full cost of such audit unless such audit reveals an underpayment by Beijing SL that was more than [**]% of the amount that should have been paid by Beijing SL, in which case Beijing SL shall reimburse Gemphire for the costs for such audit.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">32</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Late Payments</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;In the event that any payment due under this Agreement is not paid when due in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from the date due at the annual interest rate of [**]% above the prime rate of interest as reported in the Wall Street Journal (or its successor publication) on the date payment is due; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate.&nbsp;&nbsp;The payment of such interest shall not limit the Party entitled to receive payment from exercising any other rights it may have as a consequence of the lateness of any payment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INTELLECTUAL PROPERTY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership; License Grant</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Data</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Gemphire shall solely own all Data generated by Gemphire.&nbsp;&nbsp;For clarity, all Data Controlled by Gemphire are included in the Gemphire Licensed Know-How and licensed to Beijing SL under Section 2.1. &nbsp;Beijing SL shall solely own all Data generated by Beijing SL in the Development of Licensed Products in the Field in the Beijing SL Territory. Beijing SL hereby grants to Gemphire an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, to use such Data generated and owned by Beijing SL for all purposes in the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Product Materials</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. &nbsp;Subject to the terms and conditions of this Agreement, each Party hereby grants to the other Party a fully-paid up, royalty-free license, with the right to grant sublicenses under multiple tiers, to use Product Materials generated and owned by such Party, for the Development, Manufacture (with respect to Beijing SL, solely to the extent applicable under Section 7.2) and Commercialization of the Compound and Licensed Product in the other Party&#x2019;s respective territory during the Term of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Inventorship of Inventions will be determined in accordance with the standards of inventorship and conception under U.S. patent laws.&nbsp;&nbsp;The Parties will work together to resolve any issues regarding inventorship or ownership of Inventions.&nbsp;&nbsp;Ownership of Inventions will be allocated as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gemphire Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Any Inventions generated, developed, conceived or reduced to practice (constructively or actually) solely by or on behalf of Gemphire, its Affiliates and their respective sublicensees, including their employees, agents and contractors (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) shall be solely and exclusively owned by Gemphire. For clarity, all Gemphire Inventions shall be included in the Gemphire Technology licensed to Beijing SL under Section 2.1, including any Patent rights therein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beijing SL Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Any Inventions generated, developed, conceived or reduced to practice (constructively or actually) solely by or on behalf of Beijing SL, its Affiliates and their respective sublicensees, including their employees, agents and contractors (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) shall be solely and exclusively owned by Beijing SL. Beijing SL shall promptly disclose in writing to Gemphire all Beijing SL Inventions. Beijing SL hereby grants &nbsp;Gemphire an irrevocable, perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses, under such Beijing SL Inventions for the Development, Manufacture and Commercialization of the Compound or Licensed Product in the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">33</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. &nbsp;Any Inventions generated, developed, conceived or reduced to practice (constructively or actually) jointly by or on behalf of Beijing SL and Gemphire, their Affiliates and respective sublicensees, including their employees, agents and contractors (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Joint Inventions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) shall be jointly owned by the Parties. Beijing SL hereby grants &nbsp;Gemphire an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, under its rights in such Joint &nbsp;Inventions for the Development, Manufacture and Commercialization of the Compound or Licensed Product in the Gemphire Territory. &nbsp;Gemphire hereby grants &nbsp;Beijing SL an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, under its rights in such Joint &nbsp;Inventions for the Development, Manufacture and Commercialization of the Compound or Licensed Product in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL&#x2019;s Affiliates, Sublicensees and Subcontractors</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall ensure that each of its Affiliates, sublicensees and subcontractors under this Agreement has a contractual obligation to disclose to Beijing SL all Data, Product Materials and Inventions generated, invented, discovered, developed, made or otherwise created by them or their employees, agents or independent contractors, and to provide sufficient rights with respect thereto, so that Beijing SL can comply with its obligations under Sections 10.1(a), &nbsp;10.1(b) and 10.1(c).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution and Maintenance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Definition</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. For the purpose of this Article 10, &#x201C;prosecution&#x201D; of Patents shall include, without limitation, all communication and other interaction with any patent office or patent authority having jurisdiction over a Patent application throughout the world in connection with any pre-grant proceedings and post-grant proceeding, including opposition proceedings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire Patents and Joint Patents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Except as set forth in Section 10.2(d), as between the Parties, Beijing SL shall have the first right (but not the obligation) to prepare, file, prosecute and maintain or abandon the Gemphire Patents and the Joint Patents in the Beijing SL Territory, at its sole cost and expense and using counsel reasonably acceptable to Gemphire. Beijing SL will use Commercially Reasonable Efforts to prepare, file, prosecute, defend and maintain all Gemphire Patents and Joint Patents in the Beijing SL Territory. Beijing SL shall provide Gemphire reasonable opportunity to review and comment on such prosecution efforts regarding the Gemphire Patents and Joint Patents, including, without limitation, (i) promptly providing Gemphire with copies of (and upon Gemphire&#x2019;s request, English translations of) all material communications from any patent authority in the Beijing SL Territory with respect thereto; (ii) providing Gemphire, for its review and comment, with drafts of (and upon Gemphire&#x2019;s request, English translations of) any material filings or responses to be made to such patent authorities in a reasonable amount of time in advance of submitting such filings or responses; and (iii) considering in good faith comments thereto provided by Gemphire in connection with the prosecution thereof.&nbsp;&nbsp;&nbsp;For clarity, Beijing SL shall not have any rights pursuant to this Agreement with respect to any Gemphire Patents in the Gemphire Territory (including any Step-In Rights relating thereto) and, as between the Parties, Gemphire shall have the sole right in its sole discretion to prepare, file, prosecute and maintain the Gemphire Patents and Joint Patents in the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">34</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Patents</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Except as set forth in Section 10.2(d), as between the Parties, Beijing SL shall have the sole right to prepare, file, prosecute and maintain or abandon the Beijing SL Patents, at its sole cost and expense and using counsel of its own choice. Beijing SL shall provide Gemphire reasonable opportunity to review and comment on such prosecution efforts regarding the Beijing SL Patents, including, without limitation, (i) promptly providing Gemphire with copies of (and upon Gemphire&#x2019;s request, English translations of) all material communications from any patent authority with respect thereto; (ii) providing Gemphire, for its review and comment, with drafts of (and upon Gemphire&#x2019;s request, English translations of) any material filings or responses to be made to such patent authorities in a reasonable amount of time in advance of submitting such filings or responses; and (iii) considering in good faith comments thereto provided by Gemphire in connection with the prosecution thereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Step-In Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. If Beijing SL elects to cease prosecution and/or maintenance of any Patent that it is responsible for prosecuting and maintain pursuant to this Section 10.2 on a Region-by-Region basis, it shall notify Gemphire in writing reasonably in advance of such due date.&nbsp;&nbsp;Gemphire shall have the right, but not the obligation, at its sole discretion and cost, to continue prosecution or maintenance of such Patent and in such Region (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Step-In Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), and Beijing SL shall transfer the applicable patent files to Gemphire or its designee and execute such documents and perform such acts at its own cost and expense as may be reasonably necessary to allow Gemphire to initiate or continue such filing, prosecution or maintenance.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Cooperation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party agrees to cooperate fully in the preparation, filing, prosecution, maintenance, and defense, if any, of Patents under this Section 10.2 and in the obtaining and maintenance of any patent term extensions and supplementary protection certificates and their equivalents, at its own cost (except as expressly set forth otherwise in this Article 10).&nbsp;&nbsp;Such cooperation includes (i) executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as enable the other Party to apply for and to prosecute patent applications in any country or Region as permitted by this Section 10.2; and (ii) promptly informing the other Party of any matters coming to such Party&#x2019;s attention that may affect the preparation, filing, prosecution, or maintenance of any such patent application and the obtaining of any patent term extensions or supplementary protection certificates or their equivalents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Enforcement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Notice</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party shall notify the other within fifteen (15) days of becoming aware of any alleged or threatened infringement by a Third Party of any Gemphire Patent or Joint Patent in the Beijing SL Territory, which infringement adversely affects or is reasonably expected to adversely affect any Licensed Product, including any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability, or non-infringement of any Gemphire Patent or Joint Patent (collectively, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Product Infringement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Enforcement Right</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Gemphire shall have the first right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate.&nbsp;&nbsp;If Gemphire (i) decides not to bring such legal action against a Product Infringement (the decision of which Gemphire shall inform Beijing SL promptly) or (ii)</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">35</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">otherwise fails to bring such legal action against a Product Infringement within ninety (90) days of first becoming aware of such Product Infringement, Beijing SL shall have the right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate after consultation with Gemphire.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Collaboration</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party&#x2019;s request and expense, including to be named in such action if required by Applicable Laws to pursue such action.&nbsp;&nbsp;The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party&#x2019;s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court.&nbsp;&nbsp;If Beijing SL is the enforcing Party, Beijing SL shall promptly provide Gemphire with English translations of all pleadings, discovery requests, and key documents filed with the court. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Expense and Recovery</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The enforcing Party shall be solely responsible for any cost and expenses incurred by such Party as a result of such enforcement action.&nbsp;&nbsp;If such Party recovers monetary damages in such enforcement action, such recovery shall be allocated first to the reimbursement of any expenses incurred by the enforcing Party in such enforcement action, second to the reimbursement of any expenses incurred by the other Party in such enforcement action, and any remaining amounts shall be allocated fifty percent (50%) to Gemphire and fifty percent (50%) to Beijing SL.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Infringement of Third Party Rights</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;If any Licensed Product used or sold by Beijing SL, its Affiliates, or Sublicensees becomes the subject of a Third Party&#x2019;s claim or assertion of infringement of any intellectual property rights in a jurisdiction within the Beijing SL Territory, Beijing SL shall promptly notify Gemphire and the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action and may, if appropriate, agree on and enter into a &#x201C;common interest agreement&#x201D; wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute.&nbsp;&nbsp;Absent any agreement to the contrary, and subject to claims for indemnification under Article 12, each Party may defend itself from any such Third Party claim at its own cost and expense; provided, however, that the provisions of Section 10.3 shall govern the right of Beijing SL to assert a counterclaim of infringement of any Gemphire Patents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patents Licensed From Third Parties</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party&#x2019;s rights under this Article 10 with respect to the prosecution and enforcement of any Gemphire Patent and Beijing SL Patent shall be subject to the rights (a) retained by any upstream licensor to prosecute and enforce such Patent Right, if such Patent Right is subject to an upstream license agreement; and (b) granted to any Third Party prior to such Patent Right becoming subject to the license grant under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trademarks</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Product Trademarks</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Subject to 10.6(b), each Party may develop and adopt trademarks, including trade names, trade dresses, branding, and logos, to be used for the Licensed Products (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Product Marks</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) in its own territory at its own cost and expense.&nbsp;&nbsp;Each</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">36</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Party shall own all Product Marks developed by such Party.&nbsp;&nbsp;Each Party shall be responsible for the registration, maintenance, defense, and enforcement of the Product Marks at its own cost and using counsel of its own choice in its respective territory.&nbsp;&nbsp;Beijing SL shall keep Gemphire informed of material progress with regard to the registration, prosecution, maintenance, and defense, if any, of any Product Marks in the Beijing SL Territory, including content, timing, and jurisdiction of the filing of such Product Marks in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Trademark License</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Gemphire hereby grants to Beijing SL an exclusive, royalty-free license to use Gemphire&#x2019;s Product Marks solely in connection with the Commercialization of Licensed Products in the Beijing SL Territory under this Agreement.&nbsp;&nbsp;For clarity, Beijing SL shall have the sole discretion on whether to use any such Product Marks in connection with the Commercialization of any Licensed Product in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mutual Representations and Warranties</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party represents and warrants to the other Party that, as of the Effective Date: (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof, (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action, (c) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a Party or by which it may be bound, nor violate any material law or regulation of any court, governmental body, or administrative or other agency having jurisdiction over it, and (d) it has the right to grant the licenses granted by it under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Covenants</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Employees, Consultants, and Contractors</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party covenants that it has obtained or will obtain written agreements from each of its employees, consultants, and contractors who perform Development activities pursuant to this Agreement, which agreements will obligate such persons to obligations of confidentiality and non-use and to assign (or, in the case of contractor, grant a license under) Inventions in a manner consistent with the provisions of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Debarment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party represents, warrants, and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or comparable laws in any country or Region other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with activities relating to any Licensed Product.&nbsp;&nbsp;In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party itself or its Affiliates or Sublicensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">37</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Compliance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL covenants as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">In the performance of its obligations under this Agreement, Beijing SL shall comply and shall cause its and its Affiliates&#x2019; employees and contractors to comply with all Applicable Laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL and its and its Affiliates&#x2019; employees and contractors shall not, in connection with the performance of their respective obligations under this Agreement, directly or indirectly through Third Parties, pay, promise, or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or Entity or other person for purpose of obtaining or retaining business for or with, or directing business to, any person, including, Beijing SL (and Beijing SL represents and warrants that as of the Effective Date, Beijing SL, and to its knowledge, its and its Affiliates&#x2019; employees and contractors, have not directly or indirectly promised, offered, or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift, or hospitality or other illegal or unethical benefit to a Public Official or Entity or any other person in connection with the performance of Beijing SL&#x2019;s obligations under this Agreement, and Beijing SL covenants that it and its Affiliates&#x2019; employees and contractors shall not, directly or indirectly, engage in any of the foregoing).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL and its Affiliates, and their respective employees and contractors, in connection with the performance of their respective obligations under this Agreement, shall not violate or cause the violation of the FCPA, Export Control Laws, or any other Applicable Laws, or otherwise cause any reputational harm to Gemphire.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL shall immediately notify Gemphire if Beijing SL has any information or suspicion that there may be a violation of the FCPA, Export Control Laws, or any other Applicable Laws in connection with the performance of this Agreement or the Development or Commercialization of any Licensed Product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">In connection with the performance of its obligations under this Agreement, Beijing SL shall comply and shall cause its and its Affiliates&#x2019; employees and contractors to comply with Beijing SL&#x2019;s own anti-corruption and anti-bribery policy, a copy of which has been provided to Gemphire prior to the Effective Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Gemphire will have the right, upon reasonable prior written notice and during Beijing SL&#x2019;s regular business hours, to conduct at its own cost and expenses inspections of and to audit Beijing SL&#x2019;s books and records in the event of a suspected violation or to ensure compliance with the representations, warranties, and covenants of this Section 11.2(c); provided, however, that in the absence of good cause for such inspections and audits, Gemphire shall exercise this right no more than annually.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL will cause its or its Affiliates&#x2019; personnel or others working under its direction or control to submit to periodic training that Beijing SL will provide on anti-corruption law compliance.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL will, at Gemphire&#x2019;s request, annually certify to Gemphire in writing Beijing SL&#x2019;s compliance, in connection with the performance of Beijing SL&#x2019;s</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">38</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">obligations under this Agreement, with the representations, warranties, or covenants in this Section 11.2(c), which certification shall be issued by Beijing SL&#x2019;s global commercial head or other appropriate officer for the Licensed Product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Gemphire shall have the right to suspend or terminate this Agreement in its entirety where there is a credible finding, after a reasonable investigation, that Beijing SL, its Affiliates or Sublicensees, in connection with performance of Beijing SL&#x2019;s obligations under this Agreement, has engaged in chronic or material violations of the FCPA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional Gemphire Representations, Warranties, and Covenants</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Gemphire represents, warrants, and covenants, as applicable, to Beijing SL that, as of the Effective Date:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gemphire has the right to grant all rights and licenses it purports to grant to Beijing SL with respect to the Gemphire Technology under this Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gemphire has not granted any liens or security interests on the Gemphire Technology;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gemphire has not as of the Effective Date, and will not during the Term, grant any right to any Third Party under the Gemphire Technology that would conflict with the rights granted to Beijing SL hereunder; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to Gemphire&#x2019;s knowledge, no Third Party is infringing or misappropriating or has materially infringed or misappropriated the Gemphire Technology in the Beijing SL Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional Beijing SL Representations, Warranties, and Covenants</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL represents, warrants, and covenants to Gemphire that, as of the Effective Date, Beijing SL has not granted, and will not grant during the Term, any right to any Third Party under the Beijing SL Technology that would conflict with the rights granted to Gemphire hereunder.&nbsp;&nbsp;Beijing SL further represents, warrants, and covenants to Gemphire that, as of the Effective Date, there are no Beijing SL Patents relating to the Compound or Licensed Product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclaimer</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Except as expressly set forth in this Agreement, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED &#x201C;AS IS&#x201D; AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.&nbsp;&nbsp;Without limiting the foregoing, (a) neither Party represents or warrants that any Data obtained from conducting Clinical Trials in one country or Region will comply with the laws and regulations of any other country or Region, (b) neither Party represents or warrants the success of any study or test conducted pursuant to this Agreement or the safety or usefulness for any purpose of the technology it provides hereunder, and (c) Gemphire does not represent and warrant that any of the Gemphire Patents will be issued, or the &#x201C;clinical hold&#x201D; by the FDA will be lifted.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">39</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by Gemphire</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Gemphire hereby agrees to defend, indemnify, and hold harmless Beijing SL and its Affiliates, and Sublicensees and their respective directors, officers, employees, and agents (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing SL Indemnitee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) from and against any and all liabilities, expenses, and losses including any product liability, personal injury, property damage, including reasonable legal expenses and attorneys&#x2019; fees (collectively, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Losses</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), to which any Beijing SL Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party to the extent such Losses arise out of or result from: (a) the Development or Commercialization of any Licensed Product by or on behalf of Gemphire or its Affiliates, (b) the negligence or willful misconduct of any Gemphire Indemnitee, or (c) the breach by Gemphire of any warranty, representation, covenant, or agreement made by Gemphire in this Agreement; except, in each case (a)-(c), to the extent such Losses arise out of any activities for which Beijing SL is obligated to indemnify any Gemphire Indemnitee(s) under Section 12.2.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by Beijing SL</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL hereby agrees to defend, indemnify, and hold harmless Gemphire, its Affiliates, and licensees (excluding Beijing SL or its Affiliates or Sublicensees) and their respective directors, officers, employees, and agents (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Gemphire Indemnitee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) from and against any and all Losses to which any Gemphire Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party to the extent such Losses arise out of: (a) the Development or Commercialization of any Licensed Product by or on behalf of Beijing SL or its Affiliates or Sublicensees, (b) the negligence or willful misconduct of any Beijing SL Indemnitee, or (c) the breach by Beijing SL of any warranty, representation, covenant, or agreement made by Beijing SL in this Agreement; except, in each case (a)-(c), to the extent such Losses arise out of any activities for which Gemphire is obligated to indemnify any Beijing SL Indemnitee(s) under Section 12.1.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">12.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Procedure</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;A party that intends to claim indemnification under this Article 12 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Indemnitee</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) shall promptly notify the indemnifying Party (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Indemnitor</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) in writing of any Third Party claim, demand, action, or other proceeding (each, a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Claim</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense or settlement thereof.&nbsp;&nbsp;The Indemnitee may participate at its expense in the Indemnitor&#x2019;s defense of and settlement negotiations for any Claim with counsel of the Indemnitee&#x2019;s own choice.&nbsp;&nbsp;The indemnity arrangement in this Article 12 shall not apply to amounts paid in settlement of any action with respect to a Claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed.&nbsp;&nbsp;The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this Article 12 if and to the extent the Indemnitor is actually prejudiced thereby.&nbsp;&nbsp;The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Claim covered by this indemnification.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">12.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party, at its own expense, for a period until five (5) years after expiration or termination of this Agreement, shall, to the extent such insurance is commercially available for purchase in the such Party&#x2019;s territory, maintain commercial general liability insurance, including public and product liability and other appropriate insurance (e.g., contractual</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">40</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">liability, bodily injury, property damage and personal injury coverage) (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term.&nbsp;&nbsp;Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request (to the extent such insurance is commercially available for purchase in the such Party&#x2019;s territory).&nbsp;&nbsp;It is understood that such insurance shall not be construed to create any limit of either Party&#x2019;s obligations or liabilities with respect to its indemnification obligations hereunder.&nbsp;&nbsp;In the event of use by either Party of subcontractors, sublicensees, or any Third Party in the performance of such Party&#x2019;s obligations under the Agreement, such Party shall ensure that its subcontractor, sublicensee, or Third Party has a proper and adequate general liability insurance to cover its risks with respect to the other Party for damages mentioned above.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">12.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation of Liability</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL (INCLUDING LOST PROFITS), OR PUNITIVE DAMAGES, IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, HOWEVER, THAT THIS SECTION 12.5 SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY&#x2019;S INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 12 OR DAMAGES AVAILABLE AS A RESULT OF A BREACH OF A PARTY&#x2019;S EXCLUSIVITY OBLIGATIONS UNDER SECTION 2.7 OR CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 13.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONFIDENTIALITY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential Information</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for ten (10) years thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Confidential Information of the other Party, and both Parties shall keep confidential and, subject to the remainder of this Article 13, shall not publish or otherwise disclose the terms of this Agreement.&nbsp;&nbsp;Each Party may use the other Party&#x2019;s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations under this Agreement.&nbsp;&nbsp;Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors, and other representatives do not disclose or make any unauthorized use of the Confidential Information of the other Party.&nbsp;&nbsp;Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">13.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exceptions</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The obligations of confidentiality and restrictions on use under Section 13.1 will not apply to any information that the receiving Party can prove by competent written evidence:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is at the time of disclosure, or thereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">41</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is disclosed to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is independently discovered or developed by the receiving Party without the use of or reference to the Confidential Information belonging to the disclosing Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">13.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized Disclosure</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;filing, prosecuting, or maintaining Patents as permitted by this Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Filings for Licensed Products that such Party has a license or right to Develop or Commercialize hereunder in a given country or Region;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prosecuting or defending litigation as permitted by this Agreement;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;complying with applicable court orders or governmental regulations, including regulations promulgated by securities exchanges, provided that any Party making such disclosure shall promptly notify such other Party of such order or regulation upon the receipt thereof, and provide reasonable assistance to such other Party in seeking confidential treatment of such Confidential Information;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure to its and its Affiliates&#x2019; employees, consultants, contractors, and agents, to its licensees and sublicensees, in each case on a need-to-know basis in connection with the Development or Commercialization of Licensed Products in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure to actual and bona fide potential investors, acquirors, licensees, and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, or collaboration, in each case under written obligations of confidentiality and non-use at least as stringent (except with respect to duration, which may be shorter as long as not less than three (3) years) as those herein, provided that if this Agreement is being disclosed the disclosing Party redacts the financial terms and other provisions of this Agreement that are not reasonably required to be disclosed in connection with such potential investment, acquisition, or collaboration, which redaction shall be prepared in consultation with the other Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#x2019;s Confidential Information pursuant to Section 13.3(c) or 13.3(d), it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use the same diligent efforts to secure confidential treatment of such Confidential Information as such Party would use to protect its own confidential information, but in no event less than reasonable</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">42</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">efforts.&nbsp;&nbsp;In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder.&nbsp;&nbsp;Any information disclosed pursuant to Section 13.3(c) or 13.3(d) shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Article 13.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">13.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Publications</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">. Before Beijing SL submits any material based on Beijing SL Development Work for publication or makes presentation of any such material, Beijing SL shall deliver a complete copy of the material proposed for disclosure to Gemphire at least thirty (30) days prior to any such submission for Gemphire&#x2019;s review and approval.&nbsp;&nbsp;If Gemphire notifies Beijing SL that the proposed publication or presentation (i) contains a Gemphire Invention or Joint Invention for which Gemphire desires to obtain patent protection, Beijing SL shall delay such publication or presentation for a reasonable period of time to permit the preparation and filing of a patent application for such invention, or (ii) contains any Confidential Information of Gemphire or represents an Adverse Risk, Beijing SL shall delete such Confidential Information from the proposed publication or presentation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">13.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Publicity; Public Disclosures</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The Parties agree to issue a joint press release substantially in the form attached to this Agreement as </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> no later than five (5) days after the Effective Date.&nbsp;&nbsp;It is understood that each Party may desire or be required to issue subsequent press releases relating to this Agreement or activities hereunder.&nbsp;&nbsp;The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of such press releases prior to the issuance thereof, to the extent practicable, provided that a Party may not unreasonably withhold, condition, or delay consent to such releases by more than five (5) business days, and that either Party may issue such press releases or make such disclosures as it determines, based on advice of counsel, is reasonably necessary to comply with Applicable Laws or for appropriate market disclosure.&nbsp;&nbsp;Each Party shall provide the other Party with advance notice of legally required disclosures to the extent practicable.&nbsp;&nbsp;The Parties will consult with each other on the provisions of this Agreement to be redacted in any filings required by Applicable Laws; provided that each Party shall have the right to make any such filing as it reasonably determines necessary under Applicable Laws.&nbsp;&nbsp;In addition, following the initial joint press release announcing this Agreement, either Party shall be free to disclose, without the other Party&#x2019;s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of the Agreement which have already been publicly disclosed in accordance with this Section 13.5.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">13.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior Confidentiality Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;As of the Effective Date, the terms of this Article 13 shall supersede the Confidentiality Agreement.&nbsp;&nbsp;Any information disclosed pursuant to the Confidentiality Agreement shall be deemed Confidential Information under this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">13.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equitable Relief</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use, or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 13.&nbsp;&nbsp;In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 13.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">43</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TERM AND TERMINATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">14.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;This Agreement shall commence on the Effective Date and shall continue until terminated as provided in this Article 14 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;).&nbsp;&nbsp;Notwithstanding anything herein, on a Licensed Product-by-Licensed Product and Region-by-Region basis, upon the expiration of the Royalty Term (but, for clarity, not upon the early termination of this Agreement), the licenses granted to Beijing SL in Section 2.1 shall be deemed to be perpetual, fully paid-up and royalty free with respect to such Licensed Product in such Region, and Gemphire will neither export the Compound or Licensed Product nor license that to any other party in the Beijing SL Territory after the expiration of the Royalty Term.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">14.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination for Cause</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Material Breach</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement and has not cured such breach to the reasonable satisfaction of the other Party within ninety &nbsp;(90) days (thirty (30) days with respect to any payment breach) after notice of such breach from the non-breaching Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Bankruptcy</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party shall have the right to terminate this Agreement immediately in its entirety upon thirty (30) days written notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee, or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation, or any other similar proceeding for the release of financially distressed debtors, or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within thirty (30) days after the commencement thereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Patent Challenge</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Gemphire shall have the right to terminate this Agreement immediately in its entirety upon written notice to Beijing SL if Beijing SL or any of its Affiliates or Sublicensees directly, or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Gemphire Patent, whether in the Beijing SL Territory or the Gemphire Territory.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">14.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effects of Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;In the event of any termination of this Agreement by either Party, the following subsections (a)-(h) shall apply.&nbsp;&nbsp;For clarity, during the pendency of any termination notice period, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Licenses</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;All licenses granted by Gemphire to Beijing SL will automatically terminate, including all sublicenses granted by Beijing SL to any Sublicensee.&nbsp;&nbsp;All licenses granted by Beijing SL to Gemphire shall survive such termination and shall automatically become worldwide.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Regulatory Materials; Data</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Within sixty &nbsp;(60) days after the effective date of such termination, Beijing SL shall transfer and assign to Gemphire, at Gemphire&#x2019;s cost, all</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">44</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Regulatory Filings, Regulatory Approvals for Licensed Products, all Data from all preclinical, non-clinical, and clinical studies of Licensed Products conducted by or on behalf of Beijing SL, its Affiliates, or Sublicensees, and all pharmacovigilance data (including all adverse event data) regarding Licensed Products.&nbsp;&nbsp;In addition, at Gemphire&#x2019;s request, Beijing SL shall provide Gemphire with reasonable assistance with any inquiries and correspondence with Regulatory Authorities regarding Licensed Products in the Beijing SL Territory, such assistance shall be limited to a period of six (6) months after such termination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Trademarks</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall transfer and assign to Gemphire, at Gemphire&#x2019;s cost, all Product Marks owned by Beijing SL.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Development Transfer and Wind-Down</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall, as directed by Gemphire, either transfer or wind-down any ongoing Development activities (including any Clinical Trials) of Beijing SL or its Affiliates and Sublicensees with respect to any Licensed Product in the Beijing SL Territory in an orderly fashion and in compliance with all Applicable Laws. Without limiting the generality of the foregoing, if Beijing SL or its Affiliates are conducting any Clinical Trials for any Licensed Product as of the effective date of such termination, then Gemphire may elect, on a Clinical Trial-by-Clinical Trial basis, for Beijing SL: (i) to fully cooperate, and cause its Affiliates fully cooperate, with Gemphire to transfer the conduct of such Clinical Trial to Gemphire or its designees, including without limitation (A) to continue to conduct such Clinical Trial, at Gemphire&#x2019;s cost, to enable such transfer to be completed without interruption of any such Clinical Trial, and (B) to assign to Gemphire all Regulatory Materials and written agreements related to such Clinical Trials; or (ii) to wind-down the conduct of any such Clinical Trial in an orderly manner, at Beijing SL&#x2019;s sole cost and expense, in accordance with accepted pharmaceutical industry norms and ethical practices.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Manufacturing Transfer</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;If the Manufacturing Technology Transfer Completion occurs prior to the effective date of such termination, to the extent permitted by Applicable Laws, Beijing SL shall transfer to Gemphire or its designee, at Gemphire&#x2019;s cost, all Know-How Controlled by Beijing SL that is necessary or reasonably useful for the Manufacture of Licensed Products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercialization Transfer and Wind-Down</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;If Beijing SL is Commercializing any Licensed Product in any Region in the Beijing SL Territory as of the effective date of such termination, then (i) until such time as all Regulatory Approvals with respect to such Licensed Product in such Region have been assigned and transferred to Gemphire, Beijing shall appoint Gemphire or its designee as its exclusive distributor of such Licensed Product in such Region and grant Gemphire or its designee the right to appoint sub-distributors, to the extent not prohibited by any written agreement between Beijing or any of its Affiliates and a Third Party, and (ii) Beijing SL shall, and shall cause its Affiliates and Sublicensees to, immediately discontinue all promotion, marketing, offering for sale, and servicing of Licensed Products and use of all Product Marks in the Beijing SL Territory.&nbsp;&nbsp;In addition, Beijing SL shall immediately deliver to Gemphire, at Gemphire&#x2019;s sole cost and expense, all existing Licensed Product-related samples, sales materials, catalogs, and literature in Beijing SL&#x2019;s or its Affiliates&#x2019; Control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Transition Assistance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Beijing SL shall use Commercially Reasonable Efforts to seek an orderly transition of the Development, Manufacture and Commercialization of</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">45</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Licensed Products in the Beijing SL Territory to Gemphire or its designee.&nbsp;&nbsp;Beijing SL shall, at Gemphire&#x2019;s cost, provide reasonable consultation and assistance for a period of no more than ninety (90) days after the effective date of termination for the purpose of transferring or transitioning to Gemphire all Beijing SL Know-How not already in Gemphire&#x2019;s possession and, at Gemphire&#x2019;s request, all then-existing commercial arrangements relating to the Licensed Products that Beijing SL is able, using Commercially Reasonable Efforts, to transfer or transition to Gemphire or its designee, in each case, to the extent reasonably necessary for Gemphire to continue the Development, Manufacture or Commercialization of Licensed Products in the Beijing SL Territory.&nbsp;&nbsp;If any such contract between Beijing SL and a Third Party is not assignable to Gemphire or its designee but is otherwise reasonably necessary for Gemphire to continue the Development, Manufacture&nbsp;&nbsp;or Commercialization of Licensed Products in the Beijing SL Territory, or if Beijing SL is performing such work for the Compound and Licensed Product itself (i.e. there is no contract to assign), then Beijing SL shall reasonably cooperate with Gemphire to negotiate for the continuation of such services for Gemphire from such entity, or Beijing SL shall continue to perform such work for Gemphire, as applicable, for a reasonable period (not to exceed twelve (12) months) after the effective date of termination at Gemphire&#x2019;s cost until Gemphire establishes an alternate, validated source of such services.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Remaining Inventories; Continued Supply</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Gemphire shall have the right, at its discretion, to purchase from Beijing SL any or all of the inventory of the Licensed Products held by Beijing SL as of the date of termination, at a cost equal to Beijing SL&#x2019;s fully burdened cost of goods for such inventory.&nbsp;&nbsp;Gemphire shall notify Beijing SL within sixty (60) days after the effective date of termination whether Gemphire elects to exercise such right. In the event Gemphire or its CMO is not able to Manufacture the Licensed Product for the Beijing SL Territory before the remaining inventory is exhausted, Beijing SL shall continue to supply the Licensed Product to Gemphire at Beijing SL&#x2019;s fully burdened cost of Manufacture.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">14.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential Information</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Upon expiration or termination of this Agreement in its entirety, except to the extent that a Party obtains or retains the right to use the other Party&#x2019;s Confidential Information, each Party shall promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party&#x2019;s possession or control containing Confidential Information of the other Party; provided that such Party may keep one copy of such materials for archival purposes only subject to continuing confidentiality obligations.&nbsp;&nbsp;All Regulatory Filings and Data assigned to Gemphire upon termination of this Agreement will be deemed Gemphire&#x2019;s Confidential Information and no longer Beijing SL&#x2019;s Confidential Information.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">14.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival.</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> &nbsp;Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination (including the rights to receive reimbursement for costs incurred prior to the effective date of such termination and payments accrued or due prior to the effective date of such termination).&nbsp;&nbsp;Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement: Articles 1, 9 (with respect to payment obligations accrued prior to such expiration or termination), 12, 13 (except for Section 13.4), 15 and 16, and Sections 10.1, 11.5, 14.3, 14.4, 14.5 and 14.6.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">14.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remedies</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The termination provisions of this Article 14 are in addition to any other relief and remedies available to either Party at law or in equity.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">46</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DISPUTE RESOLUTION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">15.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Objective</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The Parties recognize that disputes as to matters arising under or relating to this Agreement or either Party&#x2019;s rights and obligations hereunder may arise from time to time.&nbsp;&nbsp;It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation.&nbsp;&nbsp;To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 15 to resolve any such dispute if and when it arises.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Mediation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The Parties shall attempt to settle any dispute, controversy, or claim that arises out of, or relates to, any provision of the Agreement (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Disputed Matter</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) by first referring the Disputed Matter to the Executive Officers (or their respective designees having the authority to settle such Disputed Matter).&nbsp;&nbsp;Either Party may initiate such informal dispute resolution by sending written notice of the Disputed Matter to the other Party, and, within twenty (20) days after such notice, the Executive Officers (or their respective designees) shall meet for attempted resolution by good faith negotiations.&nbsp;&nbsp;If the Executive Officers (or their respective designees) are unable to resolve such dispute within thirty (30) days of their first meeting for such negotiations, either Party may seek to have such dispute resolved in accordance with Section 15.3 below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">15.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dispute Resolution</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Parties are unable to resolve a Disputed Matter using the process described in Section 15.2, subject to Section 15.3(c), a Party seeking further resolution of the Disputed Matter will submit the Disputed Matter to resolution by final and binding arbitration.&nbsp;&nbsp;Whenever a Party will decide to institute arbitration proceedings, it will give written notice to that effect to the other Party.&nbsp;&nbsp;Arbitration will be held in New York City, New York, USA, in the English language and administered by the International Chamber of Commerce pursuant to its ICC International Arbitration Rules then in effect (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Rules</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;), except as otherwise provided herein and applying the substantive law specified in Section 16.1.&nbsp;&nbsp;The arbitration will be conducted by a panel of three (3) arbitrators appointed in accordance with the Rules; provided that each Party will, within thirty (30) days after the institution of the arbitration proceedings, appoint an arbitrator, and such arbitrators will together, within thirty (30) days, select a third (3rd) arbitrator as the chairperson of the arbitration panel.&nbsp;&nbsp;Each arbitrator must have significant legal experience in the pharmaceutical industry.&nbsp;&nbsp;If the two (2) initial arbitrators are unable to select a third (3rd) arbitrator within such thirty (30) day period, the third (3rd) arbitrator will be appointed in accordance with Rules.&nbsp;&nbsp;After conducting any hearing and taking any evidence deemed appropriate for consideration, the arbitrators will be requested to render their opinion within thirty (30) days of the final arbitration hearing.&nbsp;&nbsp;No panel of arbitrators will have the power to award damages excluded pursuant to Section 12.5 under this Agreement and any arbitral award that purports to award such damages is expressly prohibited and void ab initio.&nbsp;&nbsp;Decisions of the panel of arbitrators that conform to the terms of this Section 15.3 will be final and binding on the Parties and judgment on the award so rendered may be entered in any court of competent jurisdiction.&nbsp;&nbsp;The losing Party, as determined by the panel of arbitrators, will pay all of the ICC administrative costs and fees of the arbitration and the fees and costs of the arbitrators, and the arbitrators will be directed to provide for payment or reimbursement of such fees and costs by the losing Party.&nbsp;&nbsp;If the panel of arbitrators determines that there is no losing Party, the Parties will each bear one-half of those</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">47</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">costs and fees and the arbitrators&#x2019; award will so provide.&nbsp;&nbsp;Notwithstanding the foregoing, each Party shall bear its own attorneys&#x2019; fees, expert or witness fees, and any other fees and costs, and no such fees or costs will be shifted to the other Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the terms of and procedures set forth in Section 15.2 or 15.3(a), any applications, motions, or orders to show cause seeking temporary restraining orders, preliminary injunctions, or other similar preliminary or temporary legal or equitable relief (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Injunctive Relief</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&#x201D;) concerning a Disputed Matter (including Disputed Matters arising out of a potential or actual breach of the confidentiality and non-use provisions in Article 13) may immediately be brought in the first instance and without invocation or exhaustion of the procedures set forth in subsection (a) for hearing and resolution in and by any court of competent jurisdiction.&nbsp;&nbsp;Alternatively, a Party seeking Injunctive Relief may immediately institute arbitral proceedings without invocation or exhaustion of the procedures set forth in subsection (a), and any such Injunctive Relief proceedings will be administered by the ICC pursuant to its ICC emergency arbitration procedures then in effect and applying the substantive law specified in Section 16.1.&nbsp;&nbsp;In either event, once the Injunctive Relief proceedings have been conducted and a decision rendered thereon by the court or arbitral forum, the Parties shall, if the Disputed Matter is not finally resolved by Injunctive Relief, proceed to resolve the Disputed Matter in accordance with the terms of Section 15.2 and 15.3(a).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, this Section 15.3 shall not apply to any dispute, controversy, or claim that concerns (i) the validity, enforceability, or infringement of a patent, trademark, or copyright; or (ii) any antitrust, anti-monopoly, or competition law or regulation, whether or not statutory.&nbsp;&nbsp;Disputes regarding the foregoing shall be brought in a court of competent jurisdiction in which such patent or trademark or copyright was granted or arose, or in which such law or regulation applies, in each case as applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GENERAL PROVISIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;This Agreement, and all questions regarding the existence, validity, interpretation, breach, or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement; Modification</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;This Agreement, including the exhibits, is both a final expression of the Parties&#x2019; agreement and a complete and exclusive statement with respect to all of its terms.&nbsp;&nbsp;This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written, or otherwise, concerning any and all matters contained herein.&nbsp;&nbsp;This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Relationship Between the Parties</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The Parties&#x2019; relationship, as established by this Agreement, is solely that of independent contractors.&nbsp;&nbsp;This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties.&nbsp;&nbsp;Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">48</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Waiver</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance.&nbsp;&nbsp;Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that either Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#x2019;s consent:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">in connection with the transfer or sale of all or substantially all of the business or assets of such Party relating to the Compound and Licensed Products to a Third Party, whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets, or otherwise; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate, and provided further that if the entity to which this Agreement is assigned ceases to be an Affiliate of the assigning Party, the Agreement shall be automatically assigned back to the assigning Party or its successor.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties specified above, and the name of a Party appearing herein will be deemed to include the name of such Party&#x2019;s successors and permitted assigns to the extent necessary to carry out the intent of this Section 16.5.&nbsp;&nbsp;Any assignment not in accordance with this Section 16.5 shall be null and void.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement.&nbsp;&nbsp;All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable, or illegal part.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Any notice to be given under this Agreement must be in writing and delivered either in person, by (a) air mail (postage prepaid) requiring return receipt, (b) overnight courier, or (c) facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party may designate by prior written notice to the other in accordance with this Section 16.7.&nbsp;&nbsp;Notice shall be deemed sufficiently given for all purposes upon the earliest of:&nbsp;&nbsp;(i) the date of actual receipt, (ii) if air mailed, five (5) days after the date of postmark, (iii) if delivered by overnight courier, the next day the overnight courier regularly</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">49</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">makes deliveries, or (iv) if sent by facsimile, the date of confirmation of receipt if during the recipient&#x2019;s normal business hours, otherwise the next business day.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">If to Beijing SL, notices must be addressed to:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Beijing SL Pharma Pharmaceuticals Co., LTD.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Bitongyuan Building 1, 69 Fushi Road</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Beijing 100049, China</font>
		</p>
		<p style="margin:0pt 0pt 6pt 108pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Attention: Dr. Mingbo Xu</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">If to Gemphire, notices must be addressed to:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Gemphire Therapeutics Inc.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">17199 N Laurel Park Dr., Suite 401&nbsp;<br />Livonia, MI 48152</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">United States</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Attention: Dr. Steve Gullans</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Force Majeure</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement&nbsp;&nbsp;by reason of any event beyond such Party&#x2019;s reasonable control including Acts of God, fire, flood, explosion, earthquake, pandemic flu, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, or any other event similar to those enumerated above.&nbsp;&nbsp;Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur and uses reasonable efforts to overcome such event.&nbsp;&nbsp;Notice of a Party&#x2019;s failure or delay in performance due to force majeure must be given to the other Party within ten (10) days after its occurrence.&nbsp;&nbsp;All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure.&nbsp;&nbsp;In no event shall any Party be required to prevent or settle any labor disturbance or dispute.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interpretation</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction.&nbsp;&nbsp;All references in this Agreement to the singular shall include the plural where applicable.&nbsp;&nbsp;Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections, and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection.&nbsp;&nbsp;The word &#x201C;including&#x201D; and similar words means including without limitation.&nbsp;&nbsp;The word &#x201C;or&#x201D; means &#x201C;and/or&#x201D; unless the context dictates otherwise because the subjects of the conjunction are, or are intended to be, mutually exclusive.&nbsp;&nbsp;The words &#x201C;herein&#x201D;, &#x201C;hereof&#x201D;, and &#x201C;hereunder&#x201D; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision.&nbsp;&nbsp;All references to days in this Agreement mean calendar days, unless otherwise specified.&nbsp;&nbsp;Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.&nbsp;&nbsp;This Agreement</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">50</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">has been prepared in the English language and the English language shall control its interpretation.&nbsp;&nbsp;In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">16.10&nbsp;&nbsp;&nbsp;Counterparts; Electronic or Facsimile Signatures</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">.&nbsp;&nbsp;This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.&nbsp;&nbsp;This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">{SIGNATURE PAGE FOLLOWS}</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">51</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">IN WITNESS WHEREOF,</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> the Parties hereto have caused this </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">LICENSE AND COLLABORATION AGREEMENT</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> to be executed and entered into by their duly authorized representatives as of the Effective Date.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">GEMPHIRE THERAPEUTICS INC.</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">BEIJING SL PHARMACEUTICAL CO., LTD.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">By:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:43.00%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">/s/ STEVEN GULLANS</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">/s/ MINGBO XU</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:43.00%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Name:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:43.00%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Steven Gullans</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Name:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"> Mingbo Xu</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:43.00%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Title:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:43.00%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">CEO &amp; President</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.00%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.00%;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Title:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:43.00%;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">CEO &amp; President</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">List of Exhibits:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:81.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:459.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Exhibit A:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:459.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Selected Gemphire Patents</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Exhibit B:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:459.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Development Plan</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Exhibit C:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:459.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Development Milestones</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Exhibit D-1:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:459.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Clinical Supply Agreement Terms</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Exhibit D-2:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:459.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Commercial Supply Agreement Terms</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:81.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Exhibit E:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:459.00pt;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">Press Release</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-size:14pt;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">53</font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>13
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:51 AM-->
<html>
	<head>
		<title>
			gemp_Ex99_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;border-bottom:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-weight:normal;font-style:italic;">Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo&#x2019;s Clinical-Stage Pipeline</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-weight:normal;font-style:italic;">NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain Indications</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-weight:normal;font-style:italic;">NeuroBo Recently Received Aggregate Gross Proceeds of $24.24 Million in Series B Financing</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-weight:normal;font-style:italic;">Gemphire Out-Licenses Gemcabene to Beijing SL Pharmaceutical Co. for Chinese Market</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-align:center;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-weight:normal;font-style:italic;">Companies to Host Conference Call at 8:30 a.m. ET on July 25, 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Livonia, MI and Boston, MA, July 24, 2019</font><font style="display:inline;">&#x2014;Gemphire Therapeutics Inc. (Gemphire) (Nasdaq: GEMP), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of dyslipidemia as well as nonalcoholic fatty liver disease, and NeuroBo Pharmaceuticals, Inc. (NeuroBo), a privately-held clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases today jointly announced that they have entered into a definitive agreement whereby NeuroBo will merge with a wholly-owned subsidiary of Gemphire in an all-stock transaction. Upon completion of the merger, Gemphire will change its name to NeuroBo Pharmaceuticals, Inc., and plans to change its ticker symbol on the Nasdaq Capital Market to &#x201C;NRBO.&#x201D; The merged company will focus on the development of NeuroBo&#x2019;s clinical-stage drug candidates for the treatment of neurodegenerative diseases.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">NeuroBo is focused on the development of a treatment for diabetic neuropathic pain (DNP), with its lead drug candidate, NB-01, in Phase 3 clinical development as a first-line, disease-modifying therapy. NeuroBo&#x2019;s second drug candidate, NB-02, is in development for the treatment of neurodegenerative diseases associated with the pathological dysfunction of the amyloid-beta and tau proteins in the human brain, which include Alzheimer&#x2019;s disease and tauopathies. NeuroBo believes that leveraging the therapeutic properties of its natural product-based platform will drive a paradigm shift in the treatment of DNP and other neurodegenerative diseases where drug safety combined with efficacy is a strong unmet need.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">NeuroBo licensed NB-01 from Korean pharmaceutical company Dong-A ST. NB-01 has successfully completed Korean and U.S. Phase 2 proof-of-concept clinical trials, showing that NB-01 provided significant relief of diabetic neuropathic pain with minimal side effects, compared to placebo. Phase 3 clinical trials are expected to begin in the fourth quarter of 2019. NeuroBo acquired NB-02 outright from Dong-A ST.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&#x201C;We are excited about the opportunities and resources that will become available to NeuroBo and its therapeutic pipeline as a result of the merger,&#x201D; explained John L. Brooks III, president and chief executive officer, NeuroBo Pharmaceuticals. &#x201C;As we move towards developing both NB-01 and NB-02, we believe that having shares publicly traded on Nasdaq will provide greater opportunity to advance our therapeutic pipeline and corporate strategy.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Today, Gemphire also announced that the company has signed an out-licensing partnership with Beijing SL Pharmaceutical Co. Ltd. to advance its drug candidate, gemcabene, into the Chinese market. This partnership is expected to provide an upfront gross payment of $2.5 million to Gemphire and back end milestone and royalty payments to the combined company if certain development and commercialization milestones are met.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&#x201C;NeuroBo represents an ideal merger partner for us,&#x201D; stated Dr. Steve Gullans, president and chief executive officer of Gemphire. &#x201C;NeuroBo has a compelling Phase 3 program with NB-01 in diabetic neuropathic pain and a strong team to advance its pipeline. We evaluated numerous potential merger partners and recognized that NeuroBo has a solid base of investors and the potential to deliver significant value based on its pipeline </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;">assets. The NeuroBo merger complements our partnership with Beijing SL Pharmaceutical Co., and together, these relationships will enable us to continue to advance gemcabene toward a Food and Drug Administration (FDA) partial clinical hold decision and potentially lead to a beneficial outcome for Gemphire shareholders who will hold contingent value rights.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">About the Proposed Merger Transaction</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">On a pro forma basis and based upon the number of shares of Gemphire common stock to be issued in the merger, the pre-merger Gemphire shareholders will own approximately 4.06% of the post-merger combined company and the pre-merger NeuroBo investors will own approximately 95.94% of the post-merger combined company on a fully-diluted basis. The actual allocation will be subject to adjustment based on Gemphire&#x2019;s net cash balance at the time of the closing of the merger as well as any additional Series B capital above the minimum required amount and up to a total of $50 million that NeuroBo may secure at or before the closing of the merger. The transaction has been approved by the board of directors of both companies. The merger is expected to close in the second half of 2019, subject to the approval of the stockholders of each company, as well as other customary closing conditions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In addition, Gemphire stockholders of record as of immediately prior to the effective time of the merger will receive non-transferable contingent value rights (CVRs) entitling the holders to receive in the aggregate, after the retention of $500,000 by the combined company and certain other permitted deductions, 80% of the net proceeds, if any, received during the 15-year period following the merger from transactions entered into during the 10-year period following the merger involving the sale or license of gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Ladenburg Thalmann &amp; Co. Inc. is acting as financial advisor to Gemphire for the transaction and Consilium Partners Inc. is acting as financial advisor to NeuroBo for the transaction. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is serving as legal counsel to NeuroBo. &nbsp;Honigman LLP is serving as legal counsel to Gemphire.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Management and Organization</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Following the merger, John L. Brooks III will be appointed to serve as the post-merger combined company&#x2019;s president and chief executive officer. The board of directors for the post-merger combined company will be comprised of six directors, one of whom will be Steve Gullans, Ph.D., Gemphire&#x2019;s current president and chief executive officer and member of the Gemphire board of directors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Conference Call</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Gemphire and NeuroBo will host a conference call at 8:30 a.m. ET on July 25, 2019 to discuss the proposed merger transaction. The conference call may be accessed by dialing 877-451-6152 for U.S. callers and 201-389-0879 for international callers at least five minutes prior to the start of the call and providing the passcode 13693096. Additionally, the live, listen-only webcast of the conference call can be accessed by visiting the investors and media section of the Gemphire website at www.gemphire.com, or the investors and media section of the NeuroBo website at www.neurobopharma.com. A webcast replay will be available on the investors and media sections of the Gemphire website for all interested parties following the call and will be archived and available for 90 days.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">About NeuroBo Pharmaceuticals</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">NeuroBo Pharmaceuticals Inc. is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. The company&#x2019;s novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-01 is a natural product candidate that restores nerve growth factor levels in pre-clinical models of pain. In Phase 2 clinical trials, NB-01 has shown efficacy comparable to existing therapies and a superior safety profile. The Phase 3 program with NB-01 is expected to begin in Q4 of 2019, studying diabetic neuropathic pain patients in the U.S. and a number of other countries. NeuroBo&#x2019;s IND-ready second drug candidate, NB-02, focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals, based in Boston, MA, was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;">School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based research into ethical medicines.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">About Gemphire</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate, gemcabene, as an add-on to the standard of care, especially with statins that will benefit patients, physicians, and payers. Gemphire&#x2019;s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, hypertriglyceridemia and fatty liver disease, including Familial Hypercholesterolemia (FH), Severe Hypertriglyceridemia (SHTG), Non-alcoholic Steatohepatitis (NASH)/Non-alcoholic Fatty Liver Disease (NAFLD) and Atherosclerotic Cardiovascular Disease (ASCVD). Two Phase 2b trials supporting hypercholesterolemia and one Phase 2b trial in SHTG were recently completed under NCT02722408, NCT02634151 and NCT02944383, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Important Additional Information Will be Filed with the SEC</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In connection with the proposed transaction between Gemphire and NeuroBo, the parties intend to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a combined proxy statement/prospectus/information statement. INVESTORS AND STOCKHOLDERS OF GEMPHIRE AND NEUROBO ARE URGED TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GEMPHIRE, NEUROBO, THE PROPOSED MERGER AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemphire with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemphire with the SEC by written request to: Gemphire Therapeutics Inc., 17199 N. Laurel Park Drive, Suite 401, Livonia, MI, 48152, Attention: Corporate Secretary. Investors and stockholders are urged to read the proxy statement/prospectus/information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">No Offer or Solicitation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">This communication shall not constitute an offer to sell, the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Participants in the Solicitation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Gemphire, and its directors and executive officers, and NeuroBo, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from the stockholders of Gemphire in connection with the proposed merger. Information regarding the special interests of these directors and executive officers in the proposed merger will be included in the proxy statement/prospectus/information statement referred to above. Additional information about Gemphire&#x2019;s directors and executive officers is included in Gemphire&#x2019;s Annual Report on Form 10-K for the year that ended December 31, 2018, filed with the SEC on March 18, 2019. These documents are available free of charge at the SEC website (www.sec.gov) and from the Corporate Secretary of Gemphire at the address above.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Forward Looking Statements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;">limited to, statements regarding the proposed merger and other contemplated transactions (including statements relating to satisfaction of the conditions to and consummation of the proposed merger, the expected ownership of the combined company and the ability of the combined company to raise additional capital to complete its clinical programs and opportunities relating to or resulting from the merger), and statements regarding the nature, potential approval and commercial success of NeuroBo&#x2019;s clinical programs and pipeline, the effects of having shares of capital stock traded on the Nasdaq Capital Market, NeuroBo&#x2019;s and the post-merger combined company&#x2019;s financial resources and cash expenditures, the ability of Gemphire or the post-merger combined company to advance gemcabene through the FDA partial clinical hold and Gemphire&#x2019;s or the post-merger combined company&#x2019;s potential receipt of payments pursuant to the Beijing SL Pharmaceuticals licensing partnership. Forward-looking statements are usually identified by the use of words such as &#x201C;believes,&#x201D; &#x201C;anticipates,&#x201D; &#x201C;expects,&#x201D; &#x201C;intends,&#x201D; &#x201C;plans,&#x201D; &#x201C;ideal,&#x201D; &#x201C;may,&#x201D; &#x201C;potential,&#x201D; &#x201C;will,&#x201D; &#x201C;could&#x201D; and similar expressions. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors and risks. These factors, risks and uncertainties include, but are not limited to: risks relating to the completion of the merger, including the need for stockholder approval and the satisfaction of closing conditions; risks that the conditions to the milestone and royalty payments pursuant to the licensing partnership with Beijing SL Pharmaceutical Co. may not be met; risks related to Gemphire&#x2019;s ability to correctly estimate and manage its operating expenses and its expenses associated with the proposed merger pending closing; the cash balances of the combined company following the closing of the merger; the ability of Gemphire to remain listed on the Nasdaq Capital Market; the risk that as a result of adjustments to the exchange ratio, Gemphire shareholders or NeuroBo stockholders could own more or less of the combined company than is currently anticipated; the risk that the conditions to payment under the CVRs will not be met and that the CVRs may otherwise never deliver any value to Gemphire stockholders; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger; the success and timing of regulatory submissions and pre-clinical and clinical trials; regulatory requirements or developments; changes to clinical trial designs and regulatory pathways; changes in capital resource requirements; and other factors discussed in the "Risk Factors" section of Gemphire&#x2019;s most recent annual report, subsequent quarterly reports and in other filings Gemphire makes with the SEC from time to time. Risks and uncertainties related to NeuroBo that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: NeuroBo&#x2019;s plans to develop and commercialize its product candidates; the timing of completion of NeuroBo&#x2019;s planned clinical trials; the timing of the availability of data from NeuroBo&#x2019;s clinical trials; NeuroBo&#x2019;s plans to research, develop and commercialize its current and future product candidates; NeuroBo&#x2019;s ability to successfully collaborate with existing collaborators or enter into new collaborations and to fulfill its obligations under any such collaboration agreements; the clinical utility, potential benefits and market acceptance of NeuroBo&#x2019;s product candidates; NeuroBo&#x2019;s commercialization, marketing and manufacturing capabilities and strategy; NeuroBo&#x2019;s ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to NeuroBo&#x2019;s competitors and its industry; the impact of government laws and regulations; NeuroBo&#x2019;s ability to protect its intellectual property position; and NeuroBo&#x2019;s estimates regarding future revenue, expenses, capital requirements and need for additional financing following the proposed transaction. In addition, the forward-looking statements included in this press release represent Gemphire&#x2019;s and NeuroBo&#x2019;s views as of the date hereof. Gemphire and NeuroBo anticipate that subsequent events and developments will cause their respective views to change. However, while Gemphire and NeuroBo may elect to update these forward-looking statements at some point in the future, Gemphire and NeuroBo specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Gemphire&#x2019;s or NeuroBo&#x2019;s views as of any date subsequent to the date hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Gemphire Contact:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Ashley Robinson<br />LifeSci Advisors LLC<br />(617) 535-7742</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">NeuroBo Contact:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Nicole Franklin<br />Racepoint Global<br /></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;">(617) 624-3264<br />nfranklin@racepointglobal.com</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>14
<FILENAME>ex-99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:52 AM-->
<html>
	<head>
		<title>
			gemp_Ex99_2
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Exhibit 99.2</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Gemphire Therapeutics Inc. / NeuroBo Pharmaceuticals, Inc.&nbsp;&nbsp;&#x2013; Joint Conference Call Script</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">OPERATOR:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Good morning ladies and gentlemen, and thank you for joining us for the </font><font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Gemphire / NeuroBo Pharmaceuticals </font><font style="display:inline;font-family:Calibri;font-size:11pt;">joint conference call to discuss the proposed merger of Gemphire with NeuroBo Pharmaceuticals, as was announced in a press release yesterday afternoon.&nbsp;&nbsp;I would now like to turn the call over to Steve Gullans, Chief Executive Officer of Gemphire.&nbsp;&nbsp;Please go ahead sir.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">STEVE:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Thank you, operator, and thank you all for joining us today.&nbsp;&nbsp;Joining me today is John L. Brooks III, Chief Executive Officer of NeuroBo.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Before we begin, we advise that certain remarks that are made during this call will include remarks about future expectations, plans and prospects for NeuroBo and Gemphire, which constitute forward-looking statements for the purpose of the Safe Harbor provisions under applicable federal securities laws.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">These forward-looking statements include, without limitation, statements regarding the completion of the transaction, the combined company&#x2019;s expected cash position, Gemphire&#x2019;s and NeuroBo&#x2019;s expectations with respect to future performance, the nature, strategy and focus of the combined company, the contingent value rights for Gemphire stockholders and the potential development timeline of the combined company&#x2019;s product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expected, including the risk that the conditions to the closing of the transaction are not satisfied and uncertainties as to the timing of the consummation of the transaction, risks related to Gemphire&#x2019;s ability to correctly estimate and manage its operating expenses and its expenses associated with the proposed merger pending closing; the risk that the conditions to payment under the CVRs will not be met and that the CVRs may otherwise never deliver any value to Gemphire stockholders; the cash balances of the combined company following the closing of the merger; and risks related to the combined company&#x2019;s development and commercialization of its product candidates.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Investors and security holders are urged to read the proxy statement, prospectus, information statement, and other relevant materials when they become available before making any voting or investment decision with respect to the merger. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus, meeting the requirements of Section 10 of the Securities Act of 1933 as amended.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">STEVE:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">I am very excited to announce that, following an extensive and thorough review of strategic alternatives, Gemphire and NeuroBo have agreed to merge, creating a leading neurodegenerative disease company.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">As you may recall, at the end of last year, we announced the initiation of a process to evaluate a range of strategic alternatives for Gemphire. After a comprehensive review of these options, we are confident that this proposed merger provides the best path forward for both companies, and that it will deliver future value to Gemphire shareholders.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">While John Brooks, NeuroBo&#x2019;s CEO and President, will provide more information shortly, let me offer a quick introduction to NeuroBo. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders affecting millions of patients worldwide. The current drug pipeline is based on natural products with a strong potential to deliver efficacy with an excellent safety profile. NeuroBo is developing an oral therapeutic to treat diabetic neuropathic pain (DNP) with its lead product candidate, NB-01. NeuroBo believes NB-01 has the potential to become a first-line, disease modifying treatment for DNP. NeuroBo also believes that NB-01 could find application in treating a range of other neuropathic conditions, including chemotherapy-induced peripheral neuropathy and post-traumatic peripheral neuropathy.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">NeuroBo&#x2019;s second product candidate, NB-02, which is IND ready, has the potential to treat symptoms of cognitive impairment and to modify the disease progression associated with other neurodegenerative diseases related to dysfunction of the Amyloid beta and Tau proteins, which are linked to Alzheimer&#x2019;s disease. NeuroBo believes that its pipeline has the potential to drive a paradigm shift in the treatment of DNP, peripheral neuropathy, and other neurodegenerative diseases.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">In our view, the combined company will benefit not only from the value of NeuroBo&#x2019;s compelling late-stage pipeline, but also from its dedicated leadership team, with highly relevant scientific, clinical, regulatory and commercial expertise. I want to recognize and thank the employees and shareholders of Gemphire whose support has enabled the transformative transaction we announced yesterday afternoon.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">The combined company will take the name of NeuroBo Pharmaceuticals and will be led by John as Chief Executive Officer. John will now share more about the exciting therapies being developed at NeuroBo and the company&#x2019;s path forward.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">John:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Thanks, Steve, and thank you to everyone who has joined this morning. I am equally excited to discuss this announcement and to share details about the merged company. To accompany my remarks, I will be referencing a brief presentation, which you can access on either NeuroBo&#x2019;s or Gemphire&#x2019;s website; it has also been filed with an 8-K with the SEC. Please reference slide 4 for a NeuroBo summary.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">NeuroBo was established in July 2017 to advance the two clinical stage assets that Steve described that were originally developed by the South Korean pharmaceutical company Dong-A ST Co., Ltd. (&#x201C;Dong-A&#x201D;). NB-01 has been in-licensed by NeuroBo from Dong-A with exclusive worldwide rights except for South Korea. NB-01 has successfully completed two Phase 2 proof-of-concept clinical trials, and we intend to initiate the Phase 3 clinical program in Q4 2019.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">NB-02 was acquired outright as an asset from Dong-A by NeuroBo, and we have full worldwide commercial rights.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">The foundation of NeuroBo&#x2019;s current platform is to address multi-pathway diseases such as neuropathic pain, with multi-component natural drug mixtures that address these pathways. Diseases related to neuropathy and neurodegeneration are caused by multiple mechanisms, some of which are still being fully elucidated. By targeting the reduction of general inflammation and neuro-inflammation, reducing advanced glycation end-products which are implicated in neuropathy, and elevating levels of a key neurotrophin called nerve growth factor (NGF), we believe our multi-component drug approach can harness the synergy of targeting these different underlying mechanisms while deriving the benefit of minimal adverse events.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Before I describe these programs in a bit more detail, I want to thank our outstanding team, shown on slide 5, our Scientific Advisory Board, shown on slide 6, and our investors whose continued support has enabled us to reach this important milestone.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Let me start by telling you about our lead product candidate, NB-01 and the target market. The global neuropathic pain market is currently estimated to grow to more than $7.1 billion by 2026. This is reflected on slides 7 and 8. Diabetic Neuropathic Pain (DNP) occurs in up to 22% of all patients with diabetes. Additional indications such as chemotherapy-induced and post-traumatic neuropathic pain may constitute an additional 20% of the market. As is shown on slide 9, our pipeline reflects these future indications. In the U.S., there are currently only three FDA-approved treatments for DNP although other drugs such as opioids are also used for alleviation of pain symptoms. The market is characterized by significant unmet need, as more than 50% of patients do not adequately respond to current first-line therapies, as these patients experience significant side effects with these existing approved drugs. As you can see in slides 10 and 11, side effects are a major problem for the currently prescribed drugs on the market. NeuroBo expects that NB-01 could potentially offer efficacious pain alleviation with minimal side effects, and it could be the first disease-modifying therapy by impacting the underlying disease mechanisms.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">NB-01, NeuroBo&#x2019;s lead drug candidate is a novel, therapeutic that has generated compelling data on efficacy and safety in a 128-subject US based, placebo-controlled Phase 2 clinical trial. See slide 12. This trial showed a dose related, statistically significant advantage over placebo in improved pain scores for patients with diabetic neuropathic pain. As a result, FDA suggested the advancement of the 300mg and 600mg doses to Phase 3.&nbsp;&nbsp;NeuroBo is working with Syneos Health, a global contract research organization, to conduct NB-01&#x2019;s Phase 3 development program, as is shown on slide 13.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">In extensive preclinical studies, performed in mice and rats, NB-01 has shown multiple mechanistic and therapeutic effects as can be seen on slide 14. NB-01 addresses a range of mechanisms that contribute to neuropathic pain and nerve degeneration in diabetic and other peripheral neuropathies. These</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">include a decrease in key inflammatory markers, restoration of NGF to normal levels, and reduction of advanced glycation end products. Inflammation is a central factor in pain generation and other peripheral neuro-degenerative diseases. NB-01 reduced levels of TNF-&#x3B1; and IL-6, both of which are pro-inflammatory substances. NB-01 also reduced AGEs, which are present in high levels and implicated in diabetic complications. AGE inhibitors have been clinically tested as potential treatments for such complications. NB-01 also restored the neurotrophin NGF, which is involved in nerve growth, maintenance and repair. The efficacy of NB-01 has been shown conclusively in animal models and we will be looking to demonstrate this in humans, as we progress in the course of the Phase 3 trial. We believe NB-01 has the potential to be a new first-line disease-modifying approach for treating DNP.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">I&#x2019;d like to shift gears now and tell you about our other natural drug candidate. The second drug under development is NB-02, which has shown considerable promise in improving cognition and as a neuroprotective agent in pre-clinical studies, demonstrating a multi-modal mechanism of action including inhibition of tau phosphorylation, acetylcholinesterase (AChE) inhibition, inhibition of amyloid beta toxicity and plaque formation, and anti-inflammatory effects. NeuroBo intends to further leverage the benefits of tau modulation by the drug in conjunction with the other pathway effects to explore the treatment of certain tauopathy indications. The drug has demonstrated an excellent safety profile in IND-enabling studies, and is IND ready.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">I am confident this proposed transaction as shown on slide 15 will provide immediate advantages for our clinical pipeline while also facilitating the growth and enhancement of our operations and capabilities. NeuroBo has a solid Intellectual Property position as is shown on slide 16. The long-term value creating potential of the merged company is demonstrated by the support of our strong investor syndicate, which has invested $41 million to date in NeuroBo. Our latest financing is expected to advance the further development, potential approval, and commercialization of NB-01 and NB-02. The total cash balance of the combined company following the closing of the merger and the financing is expected to be approximately $17 million (based on the amount closed in our Series B financing prior to signing the merger agreement and assuming the Merger closes by the end of the third quarter of 2019), which is expected to carry us through key milestones across our programs.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">I&#x2019;d now like to turn the call back over to Steve.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Steve:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Thank you, John</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">I'd like to share a few of the details of the proposed transaction. On slide 17, the high-level terms of the merger are delineated. The merger is structured as a stock-for-stock transaction and is expected to close in the second half of 2019, subject to the approval of Gemphire and NeuroBo shareholders, as well as other customary conditions.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Upon closing of the transaction, the merged company will operate under the name NeuroBo Pharmaceuticals and is expected to trade on the Nasdaq under the ticker symbol NRBO.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">On a pro forma basis and based upon the number of shares of Gemphire common stock to be issued in the merger, current Gemphire shareholders will own approximately 4.06% of the combined company and current NeuroBo investors will own approximately 95.94% of the combined company on a fully-</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">diluted basis. The actual allocation will be subject to adjustment based on Gemphire's net cash balance at closing of the merger as well as any additional Series B capital above the minimum required amount and up to a total of $50 million, that NeuroBo may secure at or before the closing of the merger.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">In addition, as part of the transaction the Gemphire shareholders will receive non-transferrable contingent value rights (CVRs), entitling them to receive 80% of the net proceeds over $500,000 from the grant, sale or transfer of rights to gemcabene during the term of the CVRs, subject to certain other permitted deductions.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Following the merger, John L. Brooks III will assume the leadership role as President and CEO of NeuroBo and I will become one of 6 members of the combined company's Board of Directors.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">The proposed merger has been approved by the boards of directors of both companies.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">At Gemphire, we are very excited about the proposed merger and look forward to working closely with John and his team to build a successful merged company.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">I am sure many of you have additional questions regarding the merger. To address many of these questions we are providing a FAQ document about the merger which addresses many topics that may be on your mind, which has been filed with an 8-K with the SEC.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Thanks everyone for joining us on today's call. We are very excited about the proposed merger of Gemphire and NeuroBo, as I hope we conveyed to you today.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">If you have any additional questions, please reach out to either company through our respective liaisons listed at the end of the press release.&nbsp;&nbsp;We look forward to dialogue, and to keeping you informed of our progress.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">-------------------------</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-style:italic;">Additional Information and Where You Can Find It</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">In connection with the proposed merger transaction described in this communication, Gemphire and NeuroBo intend to file relevant materials with the Securities and Exchange Commission, or the SEC, including a registration statement on Form&nbsp;S-4 that will contain a proxy statement/prospectus/information statement. </font><font style="display:inline;font-family:Calibri;font-weight:bold;font-style:italic;">Investors and security holders of Gemphire and NeuroBo are urged to read these materials carefully and in their entirety when they become available because they will contain important information about Gemphire, NeuroBo and the proposed merger</font><font style="display:inline;font-family:Calibri;">. The proxy statement, prospectus, information statement and other relevant materials (when they become available), and any other documents filed by Gemphire with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Gemphire by directing a written request to: Gemphire Therapeutics&nbsp;Inc., 17199 N. Laurel Park Drive, Suite 401, Livonia, Michigan 48152, Attention: Corporate Secretary.&nbsp; Investors and security holders are urged to read the proxy statement, prospectus, information statement and other relevant materials when they become available before making any voting or investment decision with respect to the proposed merger.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-style:italic;">No Offer or Solicitation</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-style:italic;">Participants in Solicitation</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">Gemphire and its directors and executive officers and NeuroBo and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Gemphire in connection with the proposed merger. Information regarding the special interests of these directors and executive officers in the proposed merger will be included in the proxy statement/prospectus/information statement referred to above. Additional information regarding the directors and executive officers of Gemphire is also included in Gemphire&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 18, 2019. These documents are available free of charge at the SEC web site (www.sec.gov) and from the Corporate Secretary of Gemphire at the address above.</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>15
<FILENAME>ex-99d3.htm
<DESCRIPTION>EX-99.3
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:54 AM-->
<html>
	<head>
		<title>
			gemp_Ex99_3
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Exhibit 99.3</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g001.gif" style="width: 6.794544in; height: 5.1in" alt="New Microsoft Word Document_slide001.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">NeuroBo Pharmaceuticals &amp; Gemphire Therapeutics Merger Building a pipeline of treatment candidates for neurodegenerative diseases that affect millions of patients worldwide Novel Treatment Candidates for Neurodegenerative Conditions July 2019</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g002.gif" style="width: 6.781219in; height: 5.09in" alt="New Microsoft Word Document_slide002.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">Disclaimer Forward-Looking Statements&#x2014;All statements in this presentation other than statements of historical facts, including statements regarding the proposed transaction and other contemplated transactions, expected future results of operations and financial position of NeuroBo, its business or strategy, the clinical development of its product candidates and its objectives for future operations, are forward-looking statements. The words &#x201C;anticipates,&#x201D; &#x201C;believes,&#x201D; &#x201C;plans,&#x201D; &#x201C;expects,&#x201D; &#x201C;projects,&#x201D; &#x201C;future,&#x201D; &#x201C;intends,&#x201D; &#x201C;may,&#x201D; &#x201C;will,&#x201D; &#x201C;should,&#x201D; &#x201C;could,&#x201D; &#x201C;estimates,&#x201D; &#x201C;predicts,&#x201D; &#x201C;potential,&#x201D; &#x201C;continue,&#x201D; &#x201C;guidance,&#x201D; and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements are based on expectations and involve risks, uncertainties and assumptions, including, without limitation: the risk that conditions to closing the proposed transaction are not satisfied, risks related to Gemphire&#x2019;s ability to correctly estimate and manage its expenses, the risk that as a result of adjustments to the exchange ratio, Gemphire stockholders or NeuroBo stockholders could own more or less of the combined company than anticipated, the risk that the conditions to payment under the CVRs will not be met and that the CVRs may otherwise never deliver any value to Gemphire stockholders, risks related to the timing of completion of and availability of data from NeuroBo&#x2019;s planned clinical trials, the clinical utility, potential benefits and market acceptance of NeuroBo&#x2019;s product candidates, developments relating to NeuroBo&#x2019;s competitors and its industry, the impact of government laws and regulations, NeuroBo&#x2019;s ability to protect its intellectual property position, the strength of NeuroBo&#x2019;s intellectual property portfolio, the strength of NeuroBo&#x2019;s financial position, and changes in NeuroBo&#x2019;s capital resource requirements. Consequently, actual results may differ materially from those expressed or implied in the statements. New risks emerge from time to time and it is not possible to predict all such factors. Forward-looking statements included in this presentation are based on information available to Gemphire and NeuroBo as of the date of this presentation. Neither Gemphire nor NeuroBo undertakes any obligation to update such forward- looking statements to reflect events or circumstances after the date of this presentation. Market and Statistical Data&#x2014;This presentation contains estimates and other statistical data made by independent parties and by NeuroBo relating to market size and growth and other data about NeuroBo&#x2019;s industry. This data involves assumptions and limitations, and you are cautioned not to give undue weight to such estimates and statistical data. Neither Gemphire, NeuroBo nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. 2</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g003.gif" style="width: 6.821187in; height: 5.12in" alt="New Microsoft Word Document_slide003.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">Additional Information and Where You Can Find It Important Additional Information Will be Filed with the SEC. In connection with the proposed transaction, Gemphire intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus/information statement. GEMPHIRE URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GEMPHIRE, NEUROBO, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and stockholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemphire with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemphire with the SEC by written request to Gemphire Therapeutics Inc., 17199 N. Laurel Park Drive, Suite 401, Livonia, MI 48152, Attention: Corporate Secretary. Investors and stockholders are urged to read the proxy statement/prospectus/information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction. Participants in the Solicitation&#x2014;Gemphire and NeuroBo, and each of their respective directors and executive officers and certain of their other members of management and employees, may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about Gemphire&#x2019;s directors and executive officers is included in Gemphire&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 18, 2019. Additional information regarding these persons and their interests in the transaction will be included in the proxy statement relating to the transaction when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above. No Offer or Solicitation&#x2014;This presentation shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. 3</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g004.gif" style="width: 6.847834in; height: 5.14in" alt="New Microsoft Word Document_slide004.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">NeuroBo Summary NB-01, the lead drug candidate, is Phase 3-ready in Diabetic Neuropathic Pain (DNP). Additional pain indications and a second IND-ready drug candidate in neurodegenerative disease, NB-02, are being developed. Robust Drug Pipeline Large Market DNP estimated to affect up to 22% of all patients with diabetes and is projected to represent a global market of $7.1 billion by 2026 (GlobalData, 2018). Differentiation NeuroBo drug candidates are based on natural product sources, shown to be efficacious with favorable safety profiles, and have potential disease-modifying properties. Intellectual Property Strong IP portfolio consists of composition, method of use, and processes for both drug candidates NB-01 and NB-02. Financing, Management Strong financial position with Series B financing yielding gross proceeds of $24 million closed in July 2019 and additional investor discussions are ongoing. Management team with 150+ years combined experience in drug development, innovation, and corporate strategy. 4</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g005.gif" style="width: 6.821187in; height: 5.12in" alt="New Microsoft Word Document_slide005.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">The NeuroBo Management Team Mark Versavel, MD, PhD, MBA Chief Medical Officer John L. Brooks III, MSBA, BBA President &amp; CEO Experienced biotech, device, and healthcare executive Senior medical and clinical drug development experience Nandan Padukone, PhD Senior Vice President, Business Development Experienced executive in innovation and venture development Nicola Shannon, RegN.,BA Vice President, Clinical Operations Experienced senior executive in clinical operations 5</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g006.gif" style="width: 6.781219in; height: 5.09in" alt="New Microsoft Word Document_slide006.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">Roy Freeman, MD Founder and Chair of SAB Scientific Advisory Board Members Robert H. Dworkin, Ph.D. Leading Clinician in Neuropathy Bob Rappaport, MD Regulatory Expert Professor at Harvard Medical School and Physician at Beth Israel Leahy Health Former Division Director of Anesthesia, Analgesia and Addiction Products at FDA Renowned global leader in the treatment and prevention of chronic neuropathic and musculoskeletal pain Additional SAB Members Being Recruited 6</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g007.gif" style="width: 6.821187in; height: 5.12in" alt="New Microsoft Word Document_slide007.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">Diabetic Neuropathic Pain (DNP) arises due to hyperglycemia and other diabetes-related factors. Up to 22% of all patients with diabetes suffer from DNP Most common pain symptoms are reported to be numbness, tingling, burning, sharp, and dull ache, which are often localized to the extremities, impacting the feet and hands (Cakici et al., 2016) Current treatment options are efficacious in less than 50% of patients Only three approved therapies for the treatment of DNP: Lyrica (pregabalin), Cymbalta (duloxetine), and Nucynta ER (tapentadol) Outside of these drugs, the market consists of off-label use and generic medications Key treatment needs: Minimal side effects with pain alleviation Disease modification with nerve regeneration Diabetic Neuropathic Pain Background 7 GlobalData PharmaPoint: Painful Diabetic Neuropathy, 2018</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g008.gif" style="width: 6.83451in; height: 5.13in" alt="New Microsoft Word Document_slide008.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">~10.8M ~5.5M ~$7.1B (~3.4M U.S.) (~1.9M U.S.) (~$4.8B U.S.) Prevalent Population Total Diagnosed and Treated Population Market Sales Diabetic Neuropathic Pain Market Overview 2018 DNP Global Market: ~8.4M ~4M ~$3.6B (~2.4M U.S.) (~1.2M U.S.) (~$2.6B U.S.) Prevalent Population Total Diagnosed and Treated Population Market Sales Projected 2026 DNP Global Market: 8 GlobalData PharmaPoint: Painful Diabetic Neuropathy, 2018</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g009.gif" style="width: 6.821187in; height: 5.12in" alt="New Microsoft Word Document_slide009.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">Disease Indication Current Stage of Development Discovery Preclinical Phase 1 Phase 2 Phase 3 NB-01 Diabetic Neuropathic Pain (DNP) Chemotherapy-induced Neuropathic Pain Post-traumatic Neuropathic Pain Diabetic Neuropathy NB-02 Alzheimer&#x2019;s Disease Tauopathies Development Pipeline In Neuropathic Pain and Neurodegenerative Disease 9</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g010.gif" style="width: 6.83451in; height: 5.13in" alt="New Microsoft Word Document_slide010.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">50% Responder Rates: NB-01 Shows Equivalent Efficacy to Approved Drugs Despite Higher Placebo Effect in Phase 2 Study NB-01 Duloxetine Pregabalin 10 Moore et al, 2009; Lunn et al, 2014 0 10 20 30 40 50 60 PGB-Placebo PGB-300mg DLX-Placebo DLX-120mg NB-01 Placebo NB-01-600mg Percentage of 50% Responders</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g011.gif" style="width: 6.767897in; height: 5.08in" alt="New Microsoft Word Document_slide011.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">Adverse Events of NB-01 from Phase 2 Studies Observed within 2-3% of Placebo Safety data compiled from two Phase 2 studies (US and Korea) Average incidence of AEs over Placebo of Approved Treatments for DNP 11 Range: 15-30% 0% 5% 10% 15% 20% 25% 30% 35% Constipation Sinusitis Headache Back pain Placebo NB-01</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g012.gif" style="width: 6.807865in; height: 5.11in" alt="New Microsoft Word Document_slide012.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">&#x2022; &#x2022; Change from Baseline in NRS Score 0.5 1.5 2.5 3.5 0 1 2 3 4 5 6 7 8 9 10 11 12 Weeks * * * * * * * * * * NRS: 11-point numeric rating scale * &lt;0.05, &#x2217;&#x2217; &lt;0.01 NB-01 300mg NB-01 600mg Placebo 16 US sites, 128 subjects, 3 doses vs. placebo (600mg and 300mg doses shown here) ClinicalTrials.gov NCT01822925 Two End of Phase 2 meetings completed with the U.S. Food &amp; Drug Administration (FDA) 300mg and 600mg suggested by FDA for advancement to Ph 3 Trial NB-01 Improved Pain Scores in US Phase 2 Study of DNP 12</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g013.gif" style="width: 6.887801in; height: 5.17in" alt="New Microsoft Word Document_slide013.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">2019 2020 2021 2022 2023 Three Phase 3 Studies in DNP Powered For Efficacy and Safety NB-01 ANCHOR Study: North American Pivotal Study N=717; 2 doses &#x2013; 300mg and 600mg daily vs. placebo Primary endpoint: Change from baseline to week 12 in the weekly mean of the average daily pain score measured by the PI-NRS , an 11-point numerical scale NB-01 BELAY Study: OUS Pivotal Study Same as Anchor Study performed OUS NB-01 CLIMB Study: Extension Safety Study, All Patients 12-month long-term safety extension study; n= ~1100-1200 Disease modification: Blood samples assayed for AGEs, inflammatory markers; potential skin biopsies for assay of nerve growth Submit NDA CSR NB-01-301 (NA) ANCHOR start-up NB-01-302 (OUS) BELAY CSR Interim analysis results @ 240 pts NB-01-303 (Ext.) CLIMB 13</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g014.gif" style="width: 6.887801in; height: 5.17in" alt="New Microsoft Word Document_slide014.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">Potential Synergistic Disease-Modifying Action on Underlying Pathways in Rodent Models Reverses inflammation, decreases advanced glycation end-products, and restores nerve growth factor as shown in preclinical models of diabetes Elevation of Nerve Growth Factor (NGF) Reduction of Advanced Glycation End-products Anti-Inflammatory 14 TNF-&#xF061; Reduction NGF Elevation Note: DA-9801 = NB-01 AGE Reduction</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g015.gif" style="width: 6.847834in; height: 5.14in" alt="New Microsoft Word Document_slide015.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">Summary Planned merger of NeuroBo Pharmaceuticals and Gemphire Therapeutics NeuroBo has a strong team, a late-stage clinical candidate (NB-01), and a recent $24M investment of capital NB-01 targets diabetic neuropathic pain (DNP); NB-01 Phase 3 clinical trial in DNP expected to begin this year Post-merger John L. Brooks, III, will become CEO of the combined company and Steve Gullans will join the Board of Directors Gemphire shareholders will receive contingent value rights for gemcabene 15</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g016.gif" style="width: 6.794543in; height: 5.1in" alt="New Microsoft Word Document_slide016.gif"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">Intellectual Property Portfolio (with current year of expiration) Granted patents in US, EU, and Asia on combination of plant species for drug composition &#x2013; 2027 Granted patents in EU, Asia, and allowance in US for composition and use in peripheral neuropathy - 2031 Patents being prosecuted on drug applications in neurodegenerative disease - 2031 NB-01 Drug Mixture Composition Peripheral Neuropathy Patents in prosecution for US, EU and Asia on composition for treating degenerative neurological disease including Alzheimer&#x2019;s &#x2013; 2035 Patents in prosecution in US, EU, and Asia on method for treating neurological disease including Alzheimer&#x2019;s - 2035 NB-02 Drug Mixture Composition Neuro-degenerative disease 16</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:92.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:92.30%;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"><img src="ex-99d3g017.jpg" style="width: 6.772222in; height: 5.048611in" alt="Picture 19"></font></p>
				</td>
				<td valign="top" style="width:07.70%;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;color:#FFFFFF;font-size:1pt;">High Level Terms and Conditions of NeuroBo-Gemphire Merger Definitive agreement for all-stock merger announced on July 24, 2019 Expected to be completed 2H 2019; shares of common stock of post-merger combined company expected to trade on Nasdaq under new symbol NRBO Requires NeuroBo and Gemphire stockholder approval among other customary closing conditions Pre-closing financing by NeuroBo of approximately $24 million On a pro forma basis, current Gemphire stockholders will own 4.06% of the post-merger company and current NeuroBo investors will own 95.94% of the post-merger company (subject to adjustment based on Gemphire&#x2019;s net cash balance and the amount of additional financing proceeds received by NeuroBo above the minimum required amount and up to and including $50 million) Gemphire stockholders to receive contingent value rights (CVRs) entitling them to certain cash payments in the event the gemcabene assets are sold or licensed during the CVR period Post-Merger Leadership: John L. Brooks, III, President &amp; CEO of NeuroBo Post-Merger Board of Directors will be 6 directors, including Steve Gullans, Ph.D., Gemphire&#x2019;s current President &amp; CEO The transaction has been approved by the Board of Directors of both companies 17</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>16
<FILENAME>ex-99d4.htm
<DESCRIPTION>EX-99.4
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.3.0.107-->
<!--Created on: 7/25/2019 4:35:55 AM-->
<html>
	<head>
		<title>
			gemp_Ex99_4
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Exhibit 99.4</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Filed by Gemphire Therapeutics&nbsp;Inc. pursuant to<br />Rule&nbsp;425 under the Securities Act of 1933, as amended<br />and deemed filed pursuant to Rule&nbsp;14a-12<br />under the Securities Exchange Act of 1934, as amended<br /></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;">Subject Company: Gemphire Therapeutics&nbsp;Inc.<br />Subject Company&#x2019;s SEC File No.: 001-37809</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Date: July 25, 2019</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;"><img src="ex-99d4g001.jpg" style="width: 2.155981in; height: 1.239428in" alt="Picture 1"></font></p>
				</td>
				<td valign="bottom" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;"><img src="ex-99d4g002.jpg" style="width: 3.426655in; height: 1.14569in" alt="Picture 3"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Gemphire Therapeutics and NeuroBo Pharmaceuticals Merger</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Frequently Asked Questions</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">What is being announced today?</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Gemphire Therapeutics Inc. (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Gemphire</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) announced that it entered into an Agreement and Plan of Merger and Reorganization (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) on July 24, 2019 with NeuroBo Pharmaceuticals, Inc. (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">NeuroBo</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) and GR Merger Sub Inc., a newly-formed, wholly owned subsidiary of Gemphire (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger Sub</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The Merger Agreement contains the terms and conditions of the proposed merger of Gemphire and NeuroBo. Under the Merger Agreement, Merger Sub will merge with and into NeuroBo, with NeuroBo surviving as a wholly-owned subsidiary of Gemphire. This transaction is referred to as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&#x201D;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Today, Gemphire also announced that it has signed an out-licensing partnership with Beijing SL Pharmaceutical Co., Ltd. (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Beijing SL</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) to advance its drug candidate, gemcabene, into the Chinese market (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Beijing SL License Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). This partnership is expected to provide an upfront gross payment of $2.5 million and may provide future milestone and royalty payments to Gemphire if the conditions to such payments are met.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Who is NeuroBo?</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">NeuroBo is a privately-held clinical-stage biotechnology company focused on novel therapies for neurodegenerative diseases. &nbsp;NeuroBo is focused on the development of a treatment for diabetic neuropathic pain (DNP), with its lead drug candidate, NB-01, in Phase 3 clinical development as a first-line therapy. NeuroBo&#x2019;s second drug candidate, NB-02, is in development for the treatment of neurodegenerative diseases associated with the pathological dysfunction of the amyloid-beta and tau proteins in the human brain, which include Alzheimer&#x2019;s disease and tauopathies. NeuroBo believes that leveraging the therapeutic properties of its natural product-based platform will drive a paradigm shift in the treatment of DNP and other neurodegenerative diseases where drug safety combined with efficacy is a strong unmet need.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">NB-01 has been in-licensed by NeuroBo from Korean pharmaceutical company, Dong-A ST. NB-01 has successfully completed Korean and US Phase 2 proof-of-concept clinical trials, showing that NB-01 provided significant relief of diabetic neuropathic pain with minimal side effects compared to placebo. Phase 3 clinical trials of NB-01 are expected to begin in the fourth quarter of 2019. NB-02 was acquired outright from Dong-A by NeuroBo.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">How would the merger affect Gemphire shareholders?</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Gemphire shareholders:&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">1) will maintain equity interests </font><font style="display:inline;font-family:Times New Roman,Times,serif;">in the combined company as described below and </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">2) will receive contingent value rights (CVRs) </font><font style="display:inline;font-family:Times New Roman,Times,serif;">entitling them to receive certain future potential cash payments from the grant, sale or transfer of rights to gemcabene, if any, as described below.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">1) Equity Interests in the Combined Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">:&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">At the effective time of the Merger (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Effective Time</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), each share of NeuroBo&#x2019;s common stock immediately prior to the Effective Time (including shares of NeuroBo&#x2019;s common stock issued in connection with the conversion of NeuroBo&#x2019;s outstanding preferred stock and convertible notes and excluding certain shares to be canceled pursuant to the Merger Agreement and dissenting shares) will be converted into the right to receive shares of Gemphire&#x2019;s common stock at the exchange ratio, and each outstanding NeuroBo stock option that has not previously been exercised prior to the Effective Time will be assumed by Gemphire.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Under the exchange ratio formula in the Merger Agreement, upon the closing of the Merger, on a pro forma basis and based upon the number of shares of Gemphire Common Stock expected to be issued in the Merger, current Gemphire securityholders are expected to own approximately 4.06% of the combined company and current NeuroBo securityholders are expected to own approximately 95.94% of the combined company, on a fully-diluted basis and assuming that Gemphire has the minimum Parent Cash Amount (as described below) allowable under the Merger Agreement and that NeuroBo raises the minimum required amount in the Pre-Closing Financing (as described below). The ownership percentages are subject to adjustment to the extent that Gemphire&#x2019;s Parent Cash Amount (as defined in the Merger Agreement) at the Effective Time is negative or to reflect aggregate gross proceeds received by NeuroBo in its Pre-Closing Financing before the closing of the Merger above the minimum required amount and up to and including $50 million.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Prior to signing the Merger Agreement, NeuroBo has signed subscription agreements with investors for a Series B Preferred Stock equity financing for gross proceeds of approximately $24.24 million and may enter into additional subscription agreements and receive additional proceeds between signing and closing of the Merger (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Pre-Closing Financing</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">2) Contingent Value Rights:</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp;Further, at the Effective Time, Gemphire, Grand Rapids Holders&#x2019; Representative, LLC, as representative of the Gemphire stockholders prior to the Effective Time, and Computershare Inc., as the Rights Agent, will enter into a Contingent Value Rights Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">CVR Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). Pursuant to the Merger Agreement and the CVR Agreement, Gemphire stockholders of record as of immediately prior to the Effective Time will receive one contingent value right (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">CVR</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) for each share of Gemphire Common Stock held, entitling such holders to receive in the aggregate, 80% of any net proceeds (following the post-Merger combined company&#x2019;s prior retention of an aggregate of $500,000 and less certain other permitted deductions) received during the 15-year period after the closing (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">CVR Term</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) from the grant, sale or transfer of rights to Gemphire&#x2019;s product candidate gemcabene (other than a grant, sale or transfer of rights involving a sale or disposition of the post-Merger combined company) that is entered into during the 10-year period after the closing or pursuant to the Beijing SL License Agreement (but not including the $2.5 million upfront gross payment payable thereunder). Under the CVR Agreement, the combined company agreed to commit $1 million to support the further development of gemcabene through the quarter ending March 31, 2020, to be funded following execution of the Beijing SL License Agreement and the receipt by Gemphire of the $2.5 million upfront gross payment payable thereunder. The CVRs are not transferable, except in certain limited circumstances, will not be certificated or evidenced by any instrument, will not accrue interest and will not be registered with the SEC or listed for trading on any exchange.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">After the Merger, will NeuroBo continue the development of gemcabene?</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">As described above, in the CVR Agreement, the combined company will commit certain resources to continue Gemphire&#x2019;s ongoing activities with gemcabene directed at addressing the FDA partial clinical hold that limits human studies of gemcabene to 6 months or less. As announced previously, Gemphire is currently conducting preclinical studies requested by the FDA to provide additional information regarding the safety of gemcabene. These activities, including conducting a study of gemcabene in PPAR-alpha knockout mice, remain on target to be submitted to the FDA in the fourth quarter of this year. Activities thereafter will depend on the decision made by the FDA at that time and will be determined by the combined company&#x2019;s board of directors and management. A key consideration will be coordinating with Beijing SL who will be working to develop gemcabene for the Chinese market.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">What is required to close the Merger?</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of Gemphire and NeuroBo, the continued listing of Gemphire&#x2019;s Common Stock on the Nasdaq Capital Market, the conversion of all NeuroBo preferred stock and NeuroBo convertible notes into NeuroBo common stock</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">and satisfaction by Gemphire of a minimum Parent&nbsp;Cash Amount of negative $3 million at closing.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Concurrently with the execution of the Merger Agreement, the executive officers and directors and certain other stockholders of Gemphire entered into voting agreements with NeuroBo and Gemphire relating to the Merger covering approximately 26% of the outstanding capital stock of Gemphire, as of date of the Merger Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Gemphire Voting Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The Gemphire Voting Agreements provide, among other things, that the stockholders who are parties to the Gemphire Voting Agreements will vote all of the shares held by them in favor of the Gemphire Stockholder Matters and against any competing acquisition proposals. The Gemphire Voting Agreements also place certain restrictions on the transfer of the shares of Gemphire held by the respective signatories thereto.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of NeuroBo entered into voting agreements with Gemphire and NeuroBo covering approximately 90% of the outstanding capital stock of NeuroBo as of the date of the Merger Agreement (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">NeuroBo Voting Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">,&#x201D; and together with Gemphire Voting Agreements, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Voting Agreements</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). The NeuroBo Voting Agreements provide, among other things, that the directors, officers and securityholders party to the NeuroBo Voting Agreements will vote all of the shares of NeuroBo held by them in favor of the adoption of the Merger Agreement, the approval of the Merger and the other transactions contemplated by the Merger Agreement and against any competing acquisition proposals.&nbsp;&nbsp;The NeuroBo Voting Agreements also place certain restrictions on the transfer of the shares of NeuroBo held by the respective signatories thereto.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">What will happen to Gemphire if the Merger doesn&#x2019;t close?</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If, for any reason, the Merger does not close, the Gemphire board of directors may elect to dissolve and liquidate its assets. If Gemphire were able to secure additional capital to provide it with necessary financial resources, it may alternatively attempt to sell or otherwise dispose of the various assets of the company, pursue another strategic transaction like the Merger or continue to operate the business of Gemphire. &nbsp;Gemphire expects that it would be difficult to secure financing in a timely manner, on favorable terms or at all. If Gemphire decides to dissolve and liquidate its assets, Gemphire would be required to pay all of its debts and contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurances as to the amount or timing of available cash left, if any, to distribute to stockholders after paying the debts and other obligations of Gemphire and setting aside funds for reserves.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Why are the two companies proposing to merge?</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">NeuroBo and Gemphire believe that the Merger will result in a clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases. Gemphire is announcing the Merger following a thorough review of strategic alternatives and believes the Merger is in the best interest of Gemphire&#x2019;s stockholders.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For a discussion of Gemphire&#x2019;s and NeuroBo&#x2019;s reasons for the Merger, please proxy statement / prospectus / information statement Gemphire intends to file with the SEC. See &#x201C;Additional Information and Where You Can Find It&#x201D; below.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Why is Gemphire entering into a license and collaboration agreement with Beijing SL?</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Gemphire believes that the Beijing SL License Agreement, together with the CVR Agreement, has the potential to benefit Gemphire stockholders through their rights to receive contingent cash payments pursuant to the CVR Agreement described above in the event gemcabene is sold or licensed or if future milestone and royalty payments become payable under the Beijing SL License Agreement during the CVR Term. Beijing SL is focused on the potential value of gemcabene for the Chinese community where dyslipidemias including familial hypercholesterolemia and severe hypertriglyceridemia are a very large unmet need and where the population is known to be naturally statin-resistant.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">When will the Merger close?</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Merger is expected to close in the second half of 2019, subject to the approval of the stockholders of each company, as well as other customary closing conditions. See &#x201C;What is required to close the Merger?&#x201D; above.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">What will the combined company be called?</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Upon completion of the Merger, Gemphire will change its name to NeuroBo Pharmaceuticals, Inc. and plans to change its ticker symbol on the Nasdaq Capital Market to &#x201C;NRBO&#x201D;.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Who will lead the combined company after the Merger?</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">John L. Brooks, III will be appointed to serve as the post-Merger combined company&#x2019;s President and Chief Executive Officer. The board of directors for the post-Merger combined company will be comprised of six directors, including Steven Gullans, Ph.D., Gemphire&#x2019;s current President and Chief Executive Officer and member of the Gemphire board of directors.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Forward-Looking Statements</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Gemphire, &nbsp;NeuroBo, Beijing SL, the proposed Merger, the CVR Agreement, the Beijing SL License Agreement and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Gemphire and NeuroBo, as well as assumptions made by, and information currently available to, management of Gemphire and NeuroBo. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#x201C;may,&#x201D; &#x201C;will,&#x201D; &#x201C;should,&#x201D; &#x201C;would,&#x201D; &#x201C;expect,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;plan,&#x201D; &#x201C;likely,&#x201D; &#x201C;believe,&#x201D; &#x201C;estimate,&#x201D; &#x201C;project,&#x201D; &#x201C;intend,&#x201D; and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the conditions to the closing of the proposed Merger are not satisfied, including the failure to obtain stockholder approval for the proposed Merger in a timely manner or at all; uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Gemphire and NeuroBo to consummate the Merger; risks related to Gemphire&#x2019;s ability to correctly estimate and manage its operating expenses and its expenses associated with the proposed Merger pending closing; risks related to Gemphire&#x2019;s continued listing on the Nasdaq Capital Market; risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger; the risk that as a result of adjustments to the Exchange Ratio, Gemphire stockholders or NeuroBo stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Gemphire common stock relative to the Exchange Ratio; the risk that the conditions to payment under the CVRs will be not be met and that the CVRs may otherwise never deliver any value to Gemphire stockholders; risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results; the ability of Gemphire or NeuroBo to protect their respective intellectual property rights; competitive responses to the Merger and changes in expected or existing competition; unexpected costs, charges or expenses resulting from the proposed Merger; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger; the success and timing of regulatory submissions and pre-clinical and clinical trials; regulatory requirements or developments; changes to clinical trial designs and regulatory pathways; changes in capital resource requirements; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Gemphire&#x2019;s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. Gemphire can give no assurance that the conditions to the Merger will be satisfied. Except as required by applicable law, Gemphire undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Additional Information and Where You Can Find It</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In connection with the proposed merger transaction described in this communication, Gemphire and NeuroBo intend to file relevant materials with the Securities and Exchange Commission, or the SEC, including a registration statement on Form&nbsp;S-4 that will contain a proxy statement/prospectus/information statement. </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Investors and security holders of Gemphire and NeuroBo are urged to read these materials carefully and in their entirety when they become available because they will contain important information about Gemphire, &nbsp;NeuroBo and the proposed merger</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. The proxy statement, prospectus, information statement and other relevant materials (when they become available), and any other documents filed by Gemphire with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Gemphire by directing a written request to: Gemphire Therapeutics&nbsp;Inc., 17199 N. Laurel Park Drive, Suite 401, Livonia, Michigan 48152, Attention: Corporate Secretary.&nbsp; Investors and security holders are urged to read the proxy statement, prospectus, information statement and other relevant materials when they become available before making any voting or investment decision with respect to the proposed merger.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">No Offer or Solicitation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">Participants in Solicitation</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Gemphire and its directors and executive officers and NeuroBo and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Gemphire in connection with the proposed merger. Information regarding the special interests of these directors and executive officers in the proposed merger will be included in the proxy statement/prospectus/information statement referred to above. Additional information regarding the directors and executive officers of Gemphire is also included in Gemphire&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 18, 2019. These documents are available free of charge at the SEC web site (www.sec.gov) and from the Corporate Secretary of Gemphire at the address above.</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-size:12pt;">5</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex-99d3g001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g001.gif
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M\_/T]?;V^?7]_?[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
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MSHY0&"W<($Z,,6U=5.J"Y*:)+D(UPVW+6X?Q"#825Q5O=CS%XE#<U7:[^*J
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M&W1(QY$<,7H'W&F$:KNV?KDE<B"@[=&=5WB'=+2:=[ FQRN7! L=%2I&7(A
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M:]%TC= H<J0]I1>049=\P 8\)5%AP:UGZX=,I,%+J$1TO<VNDU>QF8<F A[
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MMLV&S:.BJ>R'>3 L0J@&R;Q-D:H&_"L_( K1:AB_2K#BJB2W:)@_2<P&Z=W
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M7%C$*&5265UT>S_Q<6L&<E41>%!QI-:XC7VX16'C^\K31]\!$*;1)>QA#_8
M',"A&^"@&Q#9D.%A'^#A#5@ 'AK3AGMXCR%6 G^"&^[7B#<K?61A=LL#M-Z'
M9"W4$&8A&K0!';1!&B940V]!M1;X927!<.SA\[#7%SG"[VC0#%]0H%R-/BGK
MVA@K\LX"C'VY(ARSCG<Y0UYT:5RM>T]"\NXD!2,,!+,M[;#(F-%.BWN9,VXD
MF'QB(4[X*,+$?2VB]6K0F,<$DWWI'#0E?7UTQ;HR+L A#Q[Y'O_@@ / 04XB
M&1[X81PZ8 ].MQCWH1OV *S<F3''3DF0Z3N^0SS*IYK8%#W.0YO00QI6><)N
MX93C)X%OM6&PX>J"V7*=*A_6(6X<#4\!I3+J81WD837W =;NH:1A J5E32GS
M =8<C6[*;9RKIB/*(?Q04D=&)FDC;$\%-G N,+K*H1H&T!VR5M06HATF#6[F
MIASZ!R7[H1W.(2LU J4%MH/B9M*R>JQ?JA^VK?DLN%S806ZJ 5F/&?"R;1Z0
M58_5&AV:CR@OUH9 C?& >(458JH,H["ZE"\&.2/NH1ON02'@ 058X!X$:+'E
M9 \X8!P"&YCV  [N<Z$-<NUT!%T@6LW_[J6T ?A];B$:(%$;<B%#P^VC@Q<U
MSP&YD!F8,'82=F$2H $:)J$:V.&.NA8:T.$%\^$;4K,".T(:)F&X84I$,#82
M)D&Y1V$4I.$;?@2I8&@2NB)U^B$;(J$:S#@LHON]F'IP)F%_H&$7* :L&2T2
M&F:W=7L4Z*D &P(:7 J(J"$GD&(>X)MA=J$2>/L;WJIFT&$4V '7!N74H$&Y
M=^$;:KH$&<6[J\&9XR(L1J$=I,0,,9:ZJ0$:J!O#/=M&I<_B,CMRIJJ>86(<
M*!DA++L;%D4>PH$?'AL.+KG$3Q A]$&A0[P@FUJ8.!E=Q@>:RF,6(!2UI:%W
M=^&5_27<*N$6_\[;<'XD*7FV'J1A%])AF-X:&G3!';HO(]P!<*VH(32ABF"B
M9=!!0ZL!'X91(:A\%]K.'=HA':IA$DPRS!W"+08UNC1A$ "*<%F$RBMA%]Y"
MA!<"8RLAO_*$':H!0&"J(9:;F*H-SK,UIJ"ATJ:Y&JHA9<*J5ZUZ%ZH![L3F
M+OL!'2KAP!W/I[*AM^-.T:GA.*3YSY-H%]IA:_JA'&0=IEP('[ !&C#*'="!
M&C9JQX')4Q9CR0A1)R!C8F&"A^V0!5  H!'B'AJ[&_CYX.Y*G?T!V[-=W_R\
M5.12'L8AIFU<V&W4:H0)'78.7<JG5<O',W?A&NXO&W;!76'V%L9K5_\7+T=A
M&(NDP;Z;.1TT(45(;1YVH1RZ_(5\MW_F@LJ=:!?21LKS8;8"I/"J81?J88,P
M H: [;AZ F.5;L+YZ?'8P8FD(=-Q'2S00;O#I&?N"(M2?>(]4-]?*!M&@0IQ
M2QJ^$YRIPAU&(47TNW)K?1)FW2?W(>5]1+]_ B<$-ZS1P8F.=]3*H1*.NE2H
M/-,C3^G'O7S]+72ZU F5-(S!@0/VH,;\P1Y8X VD71YT/'ND?>+:_DBS7>WY
M(<<50MJE?1_4/B[TP1Z:ZBE0AX8O8A_V  7&04[TX?!+(GO8FA_NGMQ=+E@8
MY2?4X8 [$SR(_/(E%-[+*;=GH<DS%-A<R^K_%L^D<72 )!Y$-V04&-W=>/ZH
M:/@;'+X&+ZO@W4'EM1@A&-XHUJX<A+[E&V(76ME ? (= AZ[*/REL*@:TN2
MN=Q[<Y^J*5?,LV9-&I<AOD$3O )'7@@;,AWR:Z;V <H$PT(33%UM<A^I5M-Z
MV5SYP?2X9#*[V6$H4]\:SCEIL_YJ[U!S"IH850=: (*?OX$$"_K;EZ=#.(/^
MP''H-@Y<-SCP"L(#!VY/MWWWNKT!-VY/GGO^X'7K!G(/''DE][! V2T.N'W\
M]NW3AW$BO'TA]]CSQP\>G'#\.H+X" ^>RH7\^(U#&4Y<4W[A0(;3QS"KUJU<
MNWK]"C:LV+%BFQ(4_RAP8+Y\]=RERR9MURY<L^K6W76-6[EJNRK-NG6KTBYI
MU;*AHY>/7S^T:(&2)=NOGC1H]?H-C+RK6N6!_/*YDX8N7[_1_?)ET^1NJVEI
M[O))DU8Y;5JUUJ3E<UPZ&[1VG-.N9E<-&CNVTJA]KI98JSMHV?*QBU8NN4%^
MZ30UM\S9\=2!^[)5<F=Y]-3M_G*CQEX^7S5I^+:ZV]6\=W:@Z#2Q ]K8GSOK
MHN>/QX]?/^U,$EI]Z:!G4#[UL3/;=,3M@DYL9C7X6(467H@AAOB\\D>'H=!#
M888BEG6.'Z'88Q97\(#  CT%%?4&"B#Q]!!WW>PASSY[H' //SON,<XX</_<
M XX:X]BT1P=["'0/"R" TV,W(,#3E#Q[S+3B1BLN>=".%?$CY3A-W?,&"RSM
MHQ,_&=W#TQ[[V /DB'+.26>=8<V6(F/IL>56-ME<4YLTUZ"##ERO$>9G.NW4
M(YU\#(4HIT"2P3::/\[!EQAC]8QR#3N>?FK-+JG-=]ERV>S3#SH$WG;69:[!
M1M,^GKU6CVQJP>7.<>Y\LPL[DF&SV*.I3L).9.MM-M^PZ.!G:V\"F58).NVP
M,^VB" )E&C3@G54/-L@Y9E _[DQR78K@IFH?N *A.YRST\G663:C,"J99EKU
M4XXF[00;8E/L2*-)-8>M96?!!A]\%CE^^/%'*.__( RQ/_>$XL<Y7@G4S4/F
M^C,.!RQ0Z2,'1^IH)D\HN"D/"BB,; \X3]JD(PABJLF!FP-E#$Y)+"QYSXYB
MABD0/"?OXX\];[Q!DC_A/&13-RLW)1%-*NTC3S=)1XQUUEH_^FYGI;%53UON
MA)TK.V./O1:KSFZLM63:TIL.-*.T@Z=G?4&CB32CC*)+)9K, VFJJ!0;&6'U
M".M:+NE0FTXYKZ63W(3YY!MV.;IH@VF]C7)K>&GFZ)LI8PH2VR"\!9DVB":[
M0"/-)*-\<]M_IOUM&5KJP38=0?O!KAVXY9E#+*G^E$-L[6<QAN<^]4"#W%JX
M7HMMO@SZ[I_R< U6#J.0_V[-O=;\*+QP(^]LW[V%"H?27E=%L1#"3@7M$P<'
M.0<5 AQ-@P#11+&PZ9#5-@D-!WTT947VXX<^X&"FINP##@J11XR"M!2JH:"
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MEFWIEB:4DIYFE35V5V]IEW>)EWFIEUSQ/8#0,#^QEX$IF(-)F(6I-:[4(>3
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M]_L+Q\"^^[L,QT#  ]R_ PS !(P,!'P,P,# #.S !!S!#+S #US!#$P+"DS
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M T!S2Q\ 2[?T Y?M1N?L71]P7V=S-"^  T?V-,_U!+CT-3?P82?P_QYP-X>
M6=^ 6I]U".#S$T@!;T>!%$ !%5"!</\ 00=V1A]P8/=OTR9PS7YW!S@ !2"
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M< M<< $#T5''KK?.AUI=<@]2SQUY$MDK\X#3\7? VW+2!'!.\&VP@GQRU_E
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MSRJ]1\R<_=5^.LF"%93)3 =-R'IN =<"&!"R&*SLFA[R$(=0R]H$DNP%*4)
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M6!$\4B2UAFO,P+_USO!%CC?AQFT$3_ @C_0P1QIA![RPF3W5C+UD4)#@!]E
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MW-[M522^C486[ML>2A*UG$K _6&VA(SQW4:*!$]<]5G#Y6()J<4J0:(D<EF
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MC_!&762H_]TPU'*=A*P(#EA!!@2)@879*5H?#@5F<@4OUD+3_F6@;[RK3IA
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M]L3J8,(<Z9I9%FB!%?BM.;=K6W"SD#&  A#/)WU2\Y"*"-@4<@RFB[)J%%+
M;7FK!7EPD\Q:RWV@/]$3PS@TN";,A)QS/UM E.1$LYJ+Q<WG F0Q.&:Q%\\N
M]L6J1R#O4/AC15<T1!430D6$1'>-ITCCJ+&<.^(=:YJ7JW%12D-W=/\;CN 4
M%&A;Q[B0+$[V(6OT5!8J-4OB'J3R19X.)ZOP <T2!HA-6%#9WG1N\B;[['B#
MLNZI2K.(ADP"WVL  2JW41O-@%67*DX27[8@4)S56+;D1B;QW-+1R'$WB<J)
MF7%;[TL+J_%"I93QY_A5Y5RS8Q]3Z6AZ+7WVR*M:K01)#&+58F)6*+O(1;16
M &(3KL)]DOYUQV/2BY+\SP.X0/Y4"7 ](&:VG)^%;&@WR?IDI6$65XZG-ND&
M 0MC(^I6%@HAP B08 F"XQ?/+I$#"$092I?ZXTC "(_"(TB@(@R"; \1"+#:
MKH2/])W\Q$E(K*OML4NS5!.F=,=^+$88-X#_4-ZW9'>V;!MJ!.=>\'3*[@5X
MNPI??)A0#X9@J+=0^<$B1R=3ZRDH-[7//K6*:9X,[/>T='JH8@MYDBKO]#>
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MR$$X=YE(]1@RMC+)4)],9+',10&+Q4$3B. L4I8R>73IUF%-X'&/J[P)&;"
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MQ$:P?09"($&5'_^QM_81(/M!C=X',_X1<(&0"-'8J#Z ?\>)-*L*M2=RTQA
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MP@$$#!9,<"#B0 0("!YP,##C 2MH"@P8X$! PX$&*2XPL."  00L$2R :='
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M]BC<J,H;*/>VSXWLZ+4YJHBZ[7*X<V$@!A:  0Z\I&\S/<X%D].W,^$_-;$
M"U E1DH6/(&P!322LAD!$\B"6(@'?[ '+G  =5H)-? P.O^C!Q"PN,Z!H((@
M !P8,**K'^ BBY;HC&DPN0!XC)60D97;@ *@,+6(@ =A (MPBF01 #7 N5%#
MMCH+!P4@ '3;N#28E"R@ #HY.J40E-@ )P[@IZK("74[ !&@NJ^P.FCY.,A0
M"[CP0I1SC(*(#;:XJ26SB04Y*2EC0Y9:.Y;JB_M[%]89N_#SG3SA.S+;J3';
ME[U+,\'+0Z="*L](*L0S1*=J*CDKM6X81,V(@#W;AWV0 \S;@1OR&+,B-)!Q
M#B!:J^8( ^EPM)JACN- O9DQC^.P-/'0M-9[O30"$. (M5+C!]F;O7.8CUL,
MFD1H#EWL TCKCQRH(0!9HZ3ABP;_N:T!6H#C0[Y2NX>N2HPVH$5_D(<(&(E"
M4;=3JI#K4Q&+N!/'J" 8R:G\L;N+4!OTXY'TTYM#4BZR4X!R2XSA0RGJ2BD+
MD#?ONB4RP:XOF9Q\PZXT<9.WDQHCX9JRP)0%O)%AFH L$ =DNP<N@(!!<0@U
MN =DLP<0$("*FPLO?+""2$A)H9UK*8W(XZ:2JS-P  !O\IR0N$"64T"0R) %
M494// !P&#5YZ(8\F(8)Y+,X$(":<  K0,([X (+,#IA*:@-@("L@XMJXII%
MF0D1<((@J+KW^8H02+PAJQ'(R!:4M!'U8B>.8BYN++L"(LLI>ZEU0:"7^@NU
ME*GJ4T>R_P/++]S## J8/9R1GMJ@T$ SO12\0_3+US@\T C,SGC$4K,'-3"8
MC+B R:,S?)B#%JA$\E .M0J$YN@BSXN.]!!%Y,BA4^2\2\NTNG(]5_R]WXL]
M4QLM;U!-;_@&<8B'(/0'?$"%00 :2'@L7>3%U$,CTIPU&2#&X5N0#-& 7FL\
M<#!.<!"'<;B'4@N'@%N#:)2'QT-#DM+&[=,M$E'*DCC#L2._!ODD[Q229N.;
M4'(V#',V$%D0E#J[ F'/%\ !\.J26!K 64*3[:J!&<  .,&5@-.V&@FR)6L0
M+H ^?VC("9@O@7""<P M> B'#K"X!PO!SG" ?_(X\--.A\ ,5_]HP6_!B)%H
MC 9  RM 279"@ I@I)B<BA(@3CN# P!PT3=83CIC1(<B03P0"AE[  L0EC0@
M.@@ O(U2'J:TE0/8,:KKL:]8H1I\BVZY"'N)D>^SE"9=C$-ROT]YD+,[%\"@
MQ[4\R[1<RP2:*?3J+7HABX@ J@H:,PT",]/X.POBH#([LQ_]RSGU2P)0Q%(3
MATJJ"!%8T7UXS!M*CA_2Q.90M$0 A$"H3,M4CS[XQ$5[M%$DF9LIHE)4Q>]X
M/1MPQ?\P&AD@A0'%!S)H@,LS$ 9X 1N8AFCT!V\(A/J A$3@Q.=(/>+PCQPP
M&@#IS1C U0*Y+$&"AR#LAN>!'@0H@6[_0-5[<(*<:(,!C0=J[)R:2!(F*2DE
M,<]IT0BXR;H%I+MQT8B]$9<@\5:]2;D:V4Y9>0FFB;LI*T 7P %<&L#]ZX$K
M $#MXC<<> %=_:/S&BDO\T(01  NB%$*Y)[349$.< A%N<B%JI>">)AKR1-A
MF90,> @FS:1-F0P!($DZ,TF45$F5%  '"-'%L L(J<&!H !YB8@2T$D"!0$7
M-:H5#8< &  $@( M\ (\Z)4&T5%L$I\)@$+4, FHF)6:D( 2R,(>DR@)2 T;
MB=*UL!>F!3ELG9Z,LPAYN1 H>P%219<7:(&TY-J6@D.^R!RR2X#JJ[8SY)>Y
M]!<T[9<U%3,._SK;T9B1R*!3I1K,.5T\7]N'/3 J)Y.!=Z"\.:B!2/.8M(J.
M1'B$1T@$1+!,SVL.*IB"\P!%2#6/ZK@922T.'8B",@@#F6FB)KH!'=B!*A!=
M)BC-6@60&N#4:)3$%E@CU(6!&KH!QJ0S<O !04@$05"TYDC41#!<1J""*. .
MR2I--:*UF$*0X1RU:0B  C  J6A>!*!)4[.#GCR YZNS91V)" "!%#B!Z1.Y
M(U$2IU, <L**%/B ?W$;3H&+C1" "-"Q%C,R,$L;RHB $E !$_@ @4#'"!B!
M%,!?&!0EN3  !1B!'8N?$4 2"(G'+,&R&1@",#"#+XA7R=&!?>3',O_I 3#X
M@B_0 @W8"P>BP_WIMADQ" (8.!"4R#IKR/B*L1-(R@ 0@)'@2@.XEV9B%F@1
MH8B=623,@A1BEOA1@&XA *02@%@PN9-D)Z-R)BY( S3P@&ZBNY+BC:=0% Y@
M %<)IQ7EASTXR0%@@1_T!T84@ ?( C/(@TGIG@L0%C,8E@L(/_Q),)1T'9PX
M80Y0 !0( J^8J!/PBJMBF\[(J4L)9$OJ%A2<4C2L$Q8QH*S]TC?LTJYE0P1Q
MUH(KV_Z9##";RSYD4Z *LS]$L[SKNZ'Z#*&:V[J=6ZQB/%*+AQ+PJA>0@2)8
MASK#!SH(7$$EU%8XAWFP!WN@AW.@AD?H@\O_Y*)@]H9R. =C_@3V**)0.&9R
M\.74FX)/^(9S.(=O2.97B =>/H=1& Z3H0-O. =YN =ZB(=SF 8R*$T:"I Z
MB$9\6(/>J%6QT@%Q&#5OJ($^2-0^.-1 $ 5PI@=>[F5J.(-6'-Y9JS6P1=XZ
M^]677!4#L /8W(, :(EDK;/HY  W (=XF"IXZ 8GH##640D2V(-P6*U[V.AP
M*"T1G!$N.,YPL(,#@(-QT*\]F( 1Z 9P" >4'@ )R(-PT&AY&(<]*(&QC8"%
MRR^.5@-G:[8#.(&1+NF3S@,2J-I1Y0L&6()IX*Q_EH=U\ 8\L)PO09,SR0$P
M@(9S^&=[B =QV(,A_P!A1#J F_X&XU2!;G$ #NAIG';IB%@#Y!S0?1"'<%#K
M&,L"<(CK<.B&$5BG(0:!/ "'IX8'<,B##JB6D!L H(B%<)!I>; '_>H&-1 _
M]1V B_4'D]2,@1B!GLXODV;0/$!LA> -!I 7=2NIG("GMQZU>W@# $ !QN.'
M/ " $1RP.T@#''@ "+ "G<V"#*@)N,FSB%B4N*AM _" 9<$*+7R?$.A9ROZ,
M!+O*>XF;.URNUS(6>?$J H*R*,-:1W:I]7:7_,20<P/!^ :@3*9O"L)+H#K;
M.!4J$1HJ_3YEIC)EP"R-N_VU;J@ &MJ./JT#&WH.43B'?O U>GB%($*$<_]
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M_+!?W4;FT0,@M -$00!H_ZSHA?RU9H2*'7F"E)T]>$"!D3"(-!="1/>'<!B
M% !C!IV]<#C5MG^#!UN#D4>^<2"!1ZJ2+)^]?A"'+[@W*QB%G">U>]"#\PHG
M,,8'-0" I8Q>&06  ]@#Y.N&^,*# :6'92,(.T#\7XL'%I!0 I@&?H!PDG<%
M;QH #EBP(^X,+I![V'\"F,A!ZEDH*]X)*1R(;H#-8O7\ 0#*.[C1!R!!+]!V
M ]1\35':!(CA\LDDG+ )HFT"9NFQ[N4M=(]8STBP]#=D/'F@22:W#.$-##"@
M],9W]59+*R,0>!F[N0&( P<<(!"8X "!A 0Z*&SHL.$ !PHC$AA0D8#$BPXL
M)O\<X)$C1HL<+6[\:/(DRI0J5[)LZ?(ES)0=QOFKN<\5O9HUS^W0P:-//)W\
MZ-3PTZ</I'DZ_?6S)^_>4GRC?/@X2F6=4%(V?/+PP8/:4G$P;O#XNI3?4G_[
MUC"H >5<6GYRXX*;\2+&BPIU]@GMYNHOX&[G\ EUQ:!%C1LW=%"!&Q=M6G%1
M%%.^D=C&#1N:812!M[0;  ,(%"A 0, )39UK R PL(9PVGWRY/%=&FZ 0 0/
MPIUU2CMM+ $"![BIK39N'@ AY FU.1MRS;G^[LG3ES9<A($#1J2.[MNX/WY[
M#I0N[<JZT'OV^IV=YB('_#/VSLX&3X^+ 8$'/#"OB4__30##"03.9Z'M$5Y:
M.G4#P0EX&"</" *(Q$5_<]US#WC^C-.!1P>\ 95JL^4DE#PH?"1 -TN! X!'
M!! 8W3WCA#/.;SJ%<P$#"HC6&@((<+! CP;D)U (W:45SQL !+#!%GC@P486
M$."PQ19>.%%"CUD>8$ ""!QT $H&<' 0EPD,B0 *3:2)0@IMIJ!""AQ^5!)N
M*54$9H>XX=DAGOH=4)! #OSYP)^Y^8G  A14P$ %C>;UPJ.01II7!8]6VBBF
MC2I* 04/"#J00 J &JB?I0KT$*H=.=2BJA.95!%)%[5X4D<?U6K1GC'I^I(#
M$N[Z*[ ?=+=/'=Y YX\K.U#1_P=6T7FB Q^) $).5*Y( 04=YT 7#Q4^= M4
M5C64Q<,4/'@CE%AD[?!*@O2(\XT\Y\30 @S&"A6/*VNTX4I_T1EV:1W')IC@
M/=.\T%8-,F VS;'RN$(''?R>Y4IBE2FF66::(=%L3=UH0$(0032Q1!Z.Z01/
M! *(ID:&X\ !@@=M>*:3/"'HJ0:(:DU3 @<@J#%S3>-4U&L<&=XC#CCPP ,"
M ";T6Q,\;7P0PAX9\M--%A_\O%3-7 Y@AW'W[%%"!R"TT>\^X0A7FA-/Q[-'
M%ESH ;0_\FR1@PY6B,.U'D($P8:1X7R*0 =H ZA?0><J", !7+@"#FQJ=;-'
M-VI,L/]!'F%_(.$!$? &8S<JA* &.,;Q$X>$#KP(=1Y<A!!"+*:_(2$! *2H
MTXK"J9#S.BH((( 56[ABG#U+>.GCGSL"F26@7!@9'3@E* F!%7?@<<<6&S#I
MA1=;S+" :']F:>:>8 IH  %")D#^GRD$H4*:;K)9 JPKE?]1G^7[^:6I@.I'
MZ $(U:,_+8!1%<! IA@%*09$JE*2@A0"*Q7!1EF@ ITJR  #:"@O"02 _ -4
MJD+X$)'4KU83N=4)34*GB]2/5K!J(;!B*,,9LF0"PZK#%Y2B$WHXP@> X-@^
MZ*"#HSRB'H5!C YN$ 4@DH('W:*"#FM""ACL8%SF@HY8Q+7_@VFD11YR8  #
M@- %!E;A:><(0@'26( ET T>/\ 4V 8F1WYXXP>'J0%>9""%I\&##"UP00UJ
M4 :.U4T*%JN,9FI@ RC0[1[QD,<CGR(P?^Q!93UJ0^3\ 8\.     @! &XRS
M#RX(YP!J^ 8\:-.-  3@=P+(W,DV J:B+>4>J - !UCP.Q2X;01*"D $]J8B
M ;0R +2LR3U(*1 WA ,>]\#''CKYNP <2"?B6!L"7,$U+@2@  UH !F>Y@H7
MN, 3D=M''KZY@ (((2C(Q(] )F"XT/CI=I)CW $$D(*<V2,$2HK(!.X0.7F<
M0  5P9EJHME) '#@<S4!1T(4L(=Q_\3C'O2X0Q:RL(&$&"DY'A$ %W''(@.$
M$G?$!)X5!M"-=8!C#V[ 0 &$%*3E96D!'"B !/:0LZ6@LY,.8%(>\N %'# I
M#=T;P@5\="8&M,9,"?"52?))@/6Q;P ><%,0V"0_F]G/5OA#B8#JI*?^F:I4
M!2& ;@P(QDM-RH&0<B!;,R57"SX  6/M8%GU!$ _H2HC&7G(7UD($9"X:B2P
MRHB=O"J25]V*AHY][(E80B?<>,!D_1"B-,#SC:I$,8A#[$,KMF4$<56E#ZZ
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MIS"$(#&LK%HTV6BKQ*"#A2RV9ZCJJ"*. B0 6A![L AS\'04AX@B/^J@@T
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M$BB MV%<-[0%RWF%$?K#.6!&%<V<#4@!>L4%3\G#V"C9C@C >]4$A C'IWP
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M3/H)L0E*0<1D?S)$0W"(LTD@1/@D1?AD86G@K"R6K6#9!S:6"(;IK^A' 6'
M#P"!8D3!,DHE)'3")K1#5.2,# (A(A#2>-X#&5#1$BV%OU%&P0G<6FJ&6YY#
M7-[%7!8!O^D!7N9%#,P !@PJ!>B6%^Z#&N@6 \E ( 72#=#-."2F!C!F 23&
M:Y7%$M9$/ A!#>B ;15<#F#&Q>P (76#;C4 &*F1&B'* CQ 72& ==9-RO")
M:T8';$:  ^Q!)JE%C(2#<<0#!_B*@17B1R($<,YB@'1@F]W&DI$=>GJ9:"2
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M0-Q;C@ "8$")*=S<\H .L*>\) ;N\H!EEM=F*HC"7>X#^1H&<$JPN<:RIHR
M!&MX6%U%M,%.P4,WP$$)"$ 3Y S*6., &%C4<8ZQ95V_:&. ,!D!=(/@^8/:
MJ"N3G0!ZKD%VYL%5KL,TM,'UOH%QC,/OF-(Y<0$^:9 #]!W>=2<.[&&+48XK
M^(4")_ >M ;C]0L_O,'1#=#GR,4J^1D7'%D*'%TL/L@); _=Q )#U0J8C.-
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MP P82>TIB0&PDNIIM&@TGE 8W0:EA@4#0(]0@.7M4 F$GVM$CCU 619L@9&
M0RM=X B P^2T01,0"D(AD]$! /5D 4:O&8JH""#^21K]UP!< !?$@CC$ WB\
M@PCLR(XP%5,I@$*K-&LP0*"P)^YHS\L.'Z*(*%GGXY:L#QCG3T6JB46J@,B4
M@ <(A'"\7Q>#%9_<U8V:REV5%;&9,0/IVAJW@!JS51L/8+#_C7&F%427F JR
ME0K7=L!?X?&JI!!A5;8)<2F6OI"K*(1!6412(K((A@K<LF5MC<LC4P%Z[8,D
M=P)58H)X"H40+<L<PD/C4D8-1 PIE$$2W  -4(8;M@ J[P#=A,-A4%?F;IRA
M-MQ>UM(8<6X,,,!QJ<8<_/!?&L=_& "C*(SKWO9.C4-,+<!I^1@#.)RK?M=2
MZ $<*D;!_:X=QF W-( V:S,W<W,W4TJGL,&<R4.SX@:HH;/5"< 'I'8;>%)^
M&( 7QD/*_([W2IV?V#,R9=Y V-77J4T!L.]RVH27'<"%3\>$28B0&''0[*\$
MS#31&L#M0%<X2  \AL66"$1,K<$>_\!!$X@ \X@ W>3!T?U)*4+CCL!G<,DG
MR)*S/_03HV5!/-),A$S$,>T#/#2! %CL.""8-69!&LR,7!1HZAUH:"# "*A!
M'NR!-ZQ!TFV %># D1,B!HC)6--4:^"O:DCP 3#5 61 &NQA>,3"!FR$CN C
M4Y:H0OJ90<RU?Q* "ESQJ*% FKBU O"/%V^:^XF5@#1X6952J_E/EN!7CYPQ
MHQC0D#802KHQDA)*U28@DPX;3.9&E.:QJF/I8J'M4&ZI"74V#($I:(=I B3F
M>+NJ%)AV'WA+G:H&FU*"(4!"(E"#)!)+#7B+)Y@L/XB7;4D!M?##/<R#-U0&
M[)[#Y;KN8?]:T^K*@"NO+A;F!1DP^S@0@6 ?#!FTD0A4X2Z+DAM<  D(@1$8
M@114016XPFM/@P!48=LL!3PL07'+ !E@7#P4 7!;3&9FS")A<V%:1JMJAF9T
M,SAGX?&NP;)R$AC[-XLLQVL^GFZ,'CQ, /?.LYP@Q*E,ZX,?W49\W3>DCJZZ
M[X7![P!P0>0P(Z@A@ @8";D*1)OI ^K@EWO9)8M@DFK$@6B(2@EXQCXX4@.7
MA@<0$CBHS)8@P)EWC$R]9\[@ PL,;$0/5(0XP 0X"&1<38(+@ >,WCAL!)2G
MGD=T #3DS#Z 8U&+5  IJXU @#=9 1I8@+E6V=6/QO#%['L^S3C_?(!H%, #
M;$$WK.P]Q$('[*/X9 E3#=HZ<<"?= GY>%HIX88!7%7\7'$3J G\9%I5S0I'
MDB->%VVI,)D8JSYIO&U3'@P"J=60#BFG"!#65GJI\ _OIWK7HHJ4+EMEY^2S
M=>F,OA"ML J7FL1G?U2MLT2F/>1!%- /*))ME<4CE]:R($)JI^ B0 (D"$(?
M<&6"!%&R=PO&W8,KE$$4E($WF(ZSWP![TE$52 $93,.QBH/"X84K(S= Q(CQ
M8N ,;_X0(H3G:LX<5_(2^MN7QP""!17L[$O(3QZ\>!\_TKNG,:*\)Q474.@6
MT5\\A@[C1>3GJD"-&S=JV+BA\Z8-GT9B_R;LUJ!&T1P^D?JD 4/&BPH4VN!+
M*,]#@ ,##ASX &\C'  #/'!-.*[$@ =-NI%$**^#@ ,"XN1+"*_M +L)LI:@
ME_">"@$#$#@XX"IB. $"'CQP<"*H/WUJW)J F##<B ,*N(#C%W$< 0-9G4Q&
M>*];FS9[&ON3AP(  0_C2N8I\<&)YH3XW%1$@ !<1'Q[5(3@DI9E-P %#A1P
MLC<AN#A[\ESM(G7MAP #'&P0YSM<GC=YQFU&R"\/@ !Y?.\A(*!#'-$(]P#@
M,$! 6O'@ +@EG'!?MR8+<$ C#=C& R< W1 P8($%=DL0@94V@F>/..R8)A[Q
M_,$PPW#4V*TB!/\;M,A!!#APL,3/#N#@,P,22  !$51(0<84FD"!QA1*R"HK
M SY+P*X?[;IJ/1]UU!&K(J\R\D@'4$2RR"-U5& W!BBH@,H*L*P2 P9><,JI
M"KS$4DP**) R*[SP0C)-!+)2X,PBTR1 SCGII+.#.N4<8$Z[\-R3 #T)< !0
M/_4LE,]#$?W3T/4&!1)11R&-5-))*:WTKP'27 "#&("X:0<>HIC"!U&IZ*./
M0P!!9!W^/-$AD$0",=4'4>QA:1\Z:O!!5T:8&X\>>.C1\!P:6K#I!D^H&^^>
M>.[9#!\,Q2F @:;V0V@<!+A\8=,N7^A"K(CT44LH PHHH((%,F)))G[_-!S/
M%1Y%).(<=?<1-\-O7BC6V*3X-6)5H1AHP:>=;,@)*1IHD &&&"AP0ZUX%'!+
MQPF^Y2>.ZPB <*IPPGEOM!(DCD,MNOXZP$>L5!"MK[\$.V":POY*# ')$GI,
M  0BV"ZB>,(1QV/5VM)Q#W'YJ5?=/0(08#TX[HEHGX[DT1 <^CS<0T..Y&G:
MGV>% D W$;[-4*.I#5 C67L^N-0!-;3FSVC.(DB:A??V&0><<=KN^B\ [$,(
MOP$,*"%LCL8YA]F([%'C0 -*Y&#!!@\PP(G4$,+'7G_Z67<<$$#<C<$0/73P
MPP0CUY''!$IH8L845 AB1A$.8-/D!#X[,L@?_Z_""BN)KW)+=R-CUQ$!*($7
MWLG+L'V* 2NOQ*"%+<6TL@(,QB03 3/-/+[E-(]_X,@^[02_3P?NS)/.0O,T
M5,\(  52T?35Y_//]]=3M-+[\<\?_ZPX8( !3G6R RGP@ =4,*"I$&@J1LR#
M/W70@:Y\<*H^^, ;&MI''7+E P..(F\98@D\NA PGO#@&^WB2S?:%@[_$:1:
M_A#' K@T$&[%H )D")NZ,@0.!90K)>BZW'A,*)%N\$A!"WA  ;CP+QR.)QQ
M8( +/-63I!C,"!7K1DV20K"D)$P@%9##PSS0)*U4+ Y?&0 7?L87T>RC#0#
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MBRH5>8"<1E QK]C% '&@G$).@Z%N^ X.(ZM+DNR2,KZHX#J*(0 P,6<8!S1
M,2<0C3[6<#,%1" /O=K(.-3P2%?X[BH>V$/4<&B/;G @/[P[0!Z*B9!]@$.3
M" JD$SRYD76HX0UJ,8XS$1 :=<$C 0%@6T+L 8)%_^JN#? (XC[$P=K#V"4"
MX+@<:5+ E:+=PPL >,LCP_$59SXA'"0Q83SR(  B>NYZI&2<AP+ !7'\4"(2
MVD 6-%.T;@3@0"4:T0(,P !L?:Y!/,H*B4I7) 2@  5-<%V-5"<C-^V(QDDB
M0#N3Y+M\TO-X!H 2\9B$.[?XN)XGOMY W\H\AHII>6,Z%P4"N1LX4;1( )VH
MCCA:IPYL%$\.X&BCV(?2^4$J?22=WYC/7#](*:VE,'6SI-HD@A@,; >?LJD&
M=76(4^DY$( (Q"&H<0YO?,,;5:C!IZ;  UU-P0^?^,8WPN&-0M= T0@LH"O(
M$0]ZV,,>[PB''EX0,)L(]O\F-3 "*7QF#WF<8P]!*  0ND%H<.Q!6EV: S@D
M/6MIR9"&O(X! [HPC7$PRQ[Q$,<>FD"N KR53%WP!JZAW0UH2[H;WG#%'I90
ME60^ ,H&E5)X73$.>6S:V*YP@K0$QI,;&&$G,D!880M;A&E$&AS?L$/ :-I8
MPS(E!@EU-K2G@0!2*D!*"G!%., A;=;@3@7=@(<\5'WLJC0<'+C>0^^&4_%P
M3(-1?,K*"*2=\&Y,P+_V3( =$.Z-[B@8D"^2]K.[<0($&2 S#Y<'S_;P   \
MH>(53S"6LY*"/8A;U?(81S=8$(#\B#$O>PC'P^\ACW64Q@";#%$@1S!T9AE[
M#Q'_ $ *IFT'JX3("0Y7-3S$D0?ZZ+7GRST,/>GS :=#O2/@8,, FGLI>Z(\
M'F?OAAH   "G]RP<=_C1'1*.<*^4S$%NZ(:XLV8/>(1C#R7P&H(6I*!O<X"4
M',"+ AP/]7M(GO)9V, &/H.:<'# ZB7VG\!%U*!N)NA$)49Q!VHD(W/&&$>D
M8_H!/$,[O.".QT5VDC^!/#SB#<](L@L>>*_T%"PUN<G4>PH%/G=B*NL135/6
M443YAR<NBS_+7TXS^KPLO_@Y:CU*Z[C[UO]F^>?OQ!2( 4T#*\ H%' *4S"@
M'_;L$!(!$?9LJ7B@!EJ@!62 TGQ T1R0@'!"!B3PT/",_ZF82@=N( FDH J2
MP 82\ 46\"9$$"EB8 : @ A^8 &6;84:H%RD)6 ((M1@;X5>8 9B4%NZ2,08
M@ 1*( A$($'*!0&JY/JP1 4YC(A>L 4"Q@6]QJTH@$JH)#$>QP 48 1*H 1@
M)PBGQ08$B]0(1@(1!F$DL 4$KERX! ;>K0;>;2E@@-\$HM] C%R6Z=N&)VDX
MS+GH(P)*( 0\:ND^XS  T78"SSS,Z #8)RL(X"TXK+D XWH2H  6<>P00&9X
MY X/!+P,P)U*  4\0 #,0\$$@,.2QKER1VDZ( 3X4.D^,1&=I.H"P .NT ,F
M:>G 2Z#8Q)T^H 3:HKDBQQ4/I+L "&Y!+D,$4* $U"MI5B04 R]I@N1D6"8+
MLL +N. $-@ "<.=]L(( 0  566\53P :O2 +K.!]/#'P6(9-D(-'.$ $OG$+
MK. (X45$%J!$1&R''FPW, #$!& #MD -V* -II$:LV ">B<$1" 4X[$B&. >
M&83$0L=#9F]%#D $4D=&6FQU<@0O6#%R$M&=W G'SJ1D:HS*G.])4"0PG 0P
M#.#*C R&GE#ZHH<(R<2(I,SY(*IXH(1[).I(_Q* H\9O?+KL?/J$OLQ'_4H*
M??C$_<9,3]B,/EAJ_J#R1UPJ2"YCIHK 4W9@_TC%_W*J#_Q,S_3,5)B*![JP
MSARP 0F(+,G2+#]%5Y9JJ70% D40*W<  T?0)R3PU_S'?UI@()C'?P:"AIQB
M+[/%2[ID4Z9G(/:2E!@S^K+D^K O= (F!A2P6&"@ 1JRH*", 1[@ F"(,VE2
MX"('6[@$#-6-U&Q  A4&#,?P+U^ *="PJA!F!E3S#1$3,LFD KCM ;ZM%XD/
MM0#1QSZ#D2+'+ISO2.;K&I.$GH@L AP@,)XSD%;R,P I,:(L=(Q,^PZCEE+R
M[8B//NAC% -13G[/=/\ \3!,+)"NLT'<)!,OI2)B!PECAPZ5B8B(Z$E<ZD_2
M1%#L @).#QK%T?3X4W>D\CQ=:@*V8 N\X ZV8 .PXR_.DRJ3PT-XI *LP I,
M+$0<$B)WHYM^;;>L( OZ,1S+R1VA1,$^1$48YQ[E41Z+:$5!Y#/8I")YKT92
M!W9:<4=Z\DV6<_N>C\J^\_>&A_F.Y\@L@C"'D$J@;#<>0/N:]"9[E**(A,K*
MYR?+CTZ\3'P$A:1"JGWHQWW.[%#.3_VB<BK;#$C,%%),9J P0 8Z)?\&J(!&
MI2L1"%;Z(!'$4E3.,BWYE( ^Q<YL2M%N"H(,B%3Z-"U1LV#P4C6;(B_?4 ;_
MWE @;G"&;G && H'!>)_M(5ZJ&]Z*. "J@?[9G(!%% &"J8H)'!4#4I4GQ#*
M\&I4&W)Y0- TYU*P"HM15;-+I@=+-D4@VE "W9 @(G7)P,0"K ^O)E$Q#!'Y
M6#%(K/-9[2DK%.-V..!]CN=(K',2M35VGE5FDC4P&B20@H=-$$ G@8<J-[*.
M;NQ1 *5$V&G[R!5YGI1)4P1PLHG$1,QS'N?YR!6?!O2>A.1'[LD_ 31!K6 #
M^/,I)\4*TL +\  /T, :]Z1:J=(6%X0" D0++$(%&S+VKN=C%81T&&"@&'9!
M\X -%#1!ZPE&E2E?,6]CMXE<NLEQ'.0B:31UFD %_SH QVA'2DW,1Y_D6E4,
M,(J,0(U/Q0ANH) ,R1:D-V7'7+]OGHZVGYQD*+4L3ZPTR[*T3M2G*.'OHTR*
MS R%S?XD3:/2S=KD >Y/!,VR_WC __RO#\* IP[AS_I,+.,2+:F @)@*+?U4
M+?\T+0>U;_W@;>.R;_<VT=:28,20*?(R+V^PW[JDBP*36V8 3&8(,:FGWZS$
M^J1O"&'R5<O$?R0P-5%5!J"0V\C$H%175%."56=22VJ3!HSE+AE5("!5(*A'
M2WKU_F) !C @LOIM6'6W OHMH2"3-PE.RBCJ.0_ .ELDRH 4R[X'*YXS7+6U
M.M6S6[]U$MLD.Z55^_9)2?^N(@)T='YX#%[%5UK91'K=Y$D5H$F-9YLLXMLZ
MECVOAT=9TBX&]  @  >L(!Q%M$$%)<S8#U(<( W2@ WP( VVP%'ZU\BN9WD"
MQ H:0$3R54-K4G:P0@&R0T#RX&$;U@NV  )0!"M0Q  (H !FCCYAUO9HC_;@
MTR+2:?=H9!.;@#A5^"U,YF=G!VCA+GV?1'9*LIZ(-G:,CX@O [S6DWEM4DW>
M]5KE28@URGRJ],O*9VNW%GP2]OSP9%'LHBE_I,SBKXS/]J6N(G[7ML[V;__2
MDJA\  !-I6X!P50" 7$+2$X?L$\#URP/]<X2+=$@:%0:4'']] MO]W<C-3 9
M65C_8Y!Z+K<&*^!RP<1XIX=+$&I7/14#JD1T\6IDV]0GBJ(&F@(T5]=54Q>O
M$B-V7Y5Z9M7=U.T&CN)Q<U=WOZ23>=5XCS>A='=;>/EX:2BA*("3/7-YS00E
M[:E)$T!^MS=V$J!E$E%1S#=*F32;U#-9GU5;M=4ZG6F)HY5--A(14:M]$%&%
MZ^AVHC1*U^3$_,F?HNR8:_%>6[1IKV=#YW.>TK=E!$6/KH)@HW& !Q)(!I0
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M!9;=8/ESG[$Q?;9 @?$@#])@H0]%,$CD,V!H$C=@HBT [ D*AI9?Q)QD M#
M"QCXH[? #+:@ 483P<6HQ%(41.XW1/_4D5R;:0&<H G&2:9U#Z6_KTET4J=3
MS+KA+C".!)FAQ)]($8AAO,B@=OB C_\!XL" ! <$#BAX\ !!@@<[$.@P8(!#
M A0K5AQ@T6('!Q8Q9B3@D0!'C X\8HQ(\21(D"A-1CR)DN5+F#-KVKR)<X #
M 3,/.'#0(,:-&SMX&(TRQ0<5I7V:(NJ3J,_3IE2J^KC*PT=6K7Z4&M5J-*S8
ML4:+[CB[8^A9M6?+2C'ZUBS:H3ELT) !XT6,%WPKO)C!%X/>&!4P$.;[HL+>
MPHPQ5*#@N,+CR10J6[YL>0$%!C)DW*@!ND:,!0H0F'Z@8 &#!PM84WCP #,%
MTQ1:OZ[L-T;_C,XT:-CX#;RS[MW#'5-0H* @ @+*$5R6[!B#]!C2IQLV+#G[
M:]:ED:=><($TZN3+DQ=4Z!/! 0*F$3QH#S\^[-:PW3\X\%Z]>^7GF9]'R-Q!
M K(DT'H@]5?0@>L59,!_!R#08$$$.6B: PJ9=EYRW<47WP(+P/<A:1P^6) "
M/R&0D(/\D7@ !1M8D446362Q!8P3]*131#Y%-$$::7B1QQUH;%#3 0TJ( (1
M3JC1A1G00..%&D[\H $#'X*HGWKX6?'C'7BPX44:9F#0W@$<:,G@@P888!H'
M;#* 98@<FL8FFP<H4$(303210@I-E(!"$R@H0%"$_ZWYWX0J+GH>_YH,6GC>
M  8<A.)! JB74(HJ*OJ?IN=-J&.GZ V4*44&+30A0P(*E!(!-V8T446QQOJ1
M2+76&D%'(;TDTTHQS:1K3L)&Q--+Q0X;44D./&"!"SD495124UC5!R"'.!4(
M5-?V8=5525$A%E9B51%6%$>1]18/4JQ%5%I#O3M4$FBM918/\\)K%PQY <;7
M7G\)IEAQTB4&'6'914>!9 DO+%MMF'$66F<R,%!:>QZF]L %F\4VFV;.-6Q;
MPH;M)K%O-_PFG S#44==!:QI":D#I\%&P06265"8=(7I9EUU&&A<&6S>@7=!
MQ@Q<0+$"[R5P'T+GY8= :2^[UY[#K=%7W_]]]]F''Z,)8F200!&$>B!&!I1=
MX*()&+!VHRMJF0 "D&:9(']91LUA:1YZ&+6(\#UHWP/+^N2UHW)#8,46*\28
MA156$&E0IC1ET24>=VP!P4P)B(!"%VO(X4;H>3QI!^ASK"&E""%JQAZ) EB!
MAA=W!!EF&C\@<.9Y$1KJI@%N7FG E<+/"2&;=!X@0A,J")HGGW^6\"EZ7D]/
M_:&KBBK0I*'J7KV#F8+::0**'D3 I FNG5 "+T6>OD\4T?K^K1=9Q)'\&:%4
M$J\#Y/IK_KZF!"R3%(L#R"J@ 975@ ; ( <Z",L4IL"#I/B@*4TY1"(2$8@+
M1J4J2_%6N,"%E:K_D&4LYA++7-+B+GA]YF0U@!<*VS6OL^3@!G6Q"[\JP*_$
MK(Q@A\E9=K*#,^W8+&$-8%AE-'.9!52  38(30UL$ .*M><]\_%0T!@ ,HXY
M)S96'!G)>&.#D]E 92O3#0,>\QKS>$HY-,.-9&)@ >I<9V?5*0S#+F8;#-3,
M,O6Y&XDZ=*4X.0<!K3G-LF #FX(T#3^.4A"K6$6^]63*:07:']@TA:K_. IP
M;B-<<SA)/-,(KV)Z(V0@*P0!"VQ@ Q!8)$'F%C=-4B B$DB<%[A HRUL 0<Z
M(A^P7+6%-+ !#WE(@Q5*XBH5J.$-;IA#Z-RP!CL\J0[-;&;IY/ $##  _TZ<
M', &T)"%8>;!"UL 9YT@I"4VG<E0Z'23* -Y2N+9"7EZ<D(3^-0G/T'/2&GJ
M7O?F^4=(49*2)8F4/YWVDO&E2'T&K62*KD?)A5+2?K6"'T7?5[^+Z*16NP+)
M2 P(K&,!$( @S8D I*< !L! +>7RP;<HV(=K83 JB=@6MY:2E0A&*Z=: 9=8
M(#C"<MDK+490BPIG")S>]$:%,2PJO=XU1AGHA0$\T\L+L*.8Z!SLAWI,F,(L
M\]7+8!$S,FABQ&) Q2E:3#,<<UC07H/$06)&,+J16&?L\ILRRE&/%;@ ANI6
M$ O)##]MU5ET>C9'-%Y 8ZPA6E\A@[3%CC5H\O\A9'M2@]F]B;(^RW*/S&0F
M-\)MTE01&5O:"A0@ Y4*;/[Q'8/<Z;8(Z<=-K6O.VM"DGSMQ"$X,, "<L&0Q
M^#!K SC8@ 4:(%!/JF>PC4*3 S:PA1B14Y?';(EU([(!'WD)#\8D@#+;T(8W
MR&$.S S=')Z$ASDX<[W-7$,3R/37!^B2#=L-TS$M5 !T&@I1_#12?/*[@/R*
MTK+Q6=,Z.5 ">PK*"2@(E*! <"A#L:A1*=JD)BGT5Q0U-&V3+,A)):PVGB"$
M(0--U$ 0,@ !B,_#O;240K9' -.*9"(2^8A%8?60B^J*HRS1Z/]:)1.;]$H
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M8MC#<HH2(%!Y<Z02?&'C($48/T$7$D3843Q6;BIQ736!CU 89%.)$PI  X=
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M,L42@UG&!!(0H.&25]+9X7,TVT. _A!PX@FBG_!Q-MXJXXVUU@ATK3>HX;4
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M," $0.L! 1/(9.82D@&1I"CH0@T5W[44 PA BUK<PZ1J8H\2S*8 !2C*%$M
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M"+MD6CS."$%:Q$Y_" >X3!J3R1R3>)WI6B9Y,(%K3)9DL8H1L+'U/+YU$![
MF #TT\Z#A >^68P0Z#M\.,AS@($::,[@4$'E$(?(2 H/$,9]L$C@D(?' RD"
MZ(;%,\!D>@/H"8QX9#\ F)Z;.8"(5+.,? (6?4<M2E'@*#-14@ 9Q4<U"P&-
M0  W,+H5I0=]"(YQ. $'V"6$PHNBP(N&W(,EG3T5$  'B !AA <6P#EY\((T
M8,#ULKZMRP>A^ ;_;QJ/?DRFFNB'?E#!.!,\1&%/90)&H)&G$A#&9KE07/.(
M']#)V5O/F@B''TG+)MBG?HJ0*W**@,(:3)7+NB#3P.#!A'HH#2-')Y0H%(F=
M(W0CAVH,$-$0D#I,Q$0,4B75P>@ <.LV)<E"D^(V<<M5)%F>E4H>* G#F,(2
M%3& !["! [*3** "CFL3[+D$2X %8S"&3N@$UH1-06#-/T@@VVP3V(3-L<K#
M;95#/JP3=*4&#B2%.]JC/IB"K=*!B7.AI0.5*BB[:;@M/V4Y3VC7/BB'$3T'
M5Q"P]=.?;K #F0R./2@ MV  5 R.>U RF>P\>6 "2)2"_10'/7"#Z=.?_S@8
MD*/H(ILXAVYA@/H\2'Z@AP>\AR8(  5 Q]GK!CB @V[ N<T0 )]H)<JID,J)
MQKJSKHKH.0S@"KEHT* ,!SU8@W_4'QM%#%W<!W#( SA86F",F1  R&22!YH(
M3AUH.&;:@S906D.5AQ$0I0FPL7=,KF\$CG"0"J9X Z,;ASQX@^E;IG'X@"C)
MO9C<40X $@[XT7<,&"<(AW,PNG@8AW'H!BWBQB,- %>* Z-KNSV8V)@D) 0
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M^(BZDP<A:PMLQ#L=(IAA](  X*$'J&Z'G W 9?\F$-C1((F%O0V,6\Y=%@@
M!F@!%V@!&*"!(N@".W %%K0/ XB .^:'=>PVC1XF6#8-5%9E+5(!G!OF';V9
M $ .FX!4Q&C(:=C1XC" _\;(V2" !Q!&?@"E=#( ;EPF)#T 9/Z_TH#D1E(!
M><"'P^V&5\-GENN&%,C(HO  -C@!*[ R@4:#@<;R+,\E*P"F9MD#!SA3#Q
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M--R"%C)HT%A"#R<^.PQJZ.#A0RO1<S5X].G#]N:Y%BUJV+ AXT47?#CW/2F
MX <\H:08V+BQXX:-N?[ &2BPH,">H'0+'$" P,X^LD\,9-:,((@\G/RZY<FC
M)\^>/."$@A-PX$"$!Z$3:)[M ,'LV95QR@MA  $%"A<P5+A0@;!0.P$0+"A.
MH1OLX0K$"1T7)S5KUIUOPO/_((! B=(X]P@P,!R! @4/*C"('L2-*W#P[@WE
M%^>Y@PGKA.8!P "].7# 'MD1$ !U.,&3!QS<L6:>/_>@(,   RQXTQX"#GB
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M<@%$X-5NJ"A=O5+1C1)DH0_D%7C$R@P;,GF//8@'  ):\UXS(SN<=&/Q!4*
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MRK.<G[D12[A6,+ ,P 3P&Q>Y*VF6T6F:T;DHP ]00;\V0L4Q0A@ ;' Q0B/
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MA4!N//\RU*.= %V%R"[[V0%T0 ?)PQ>7S0#<*6^@=$%1LXK02@0<-)FIC83
M0TLIZIP%B3VH@ !<@)W B("DR_]!97XX[YX- !?05>N\0PE$3[$2 (D," +T
M"O;>R%.268!<B H<JSRP  NT@1NX 0";AN^D3*OJ"5ENA5DZ4"SL 32, ]D,
M!3S4-T-?B 1@=Y!PC#T CWH<0!.,15 D:_0PJV!MFTWC8&%Y@ []U 8;RQ09
M ! MY;="=;18IA,EEF;.6Y0+M11=>;=(=182 !9F5@H3G!-5 !(P@BALM11,
M@6V6P12( 2!8W",\9\>EA,.F7'6]!,1T@A!C[,,A$D:\-7/_Q?40 PQT881T
MP8+ 6$,R*(,Q0,(BX-'=^0 94 ,S"W(XN($G"^T,R( <"'CK_&<)"$;380!
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M#Q!TY(A 01YQ]O;Q\\?O'KP]'@ (,'#_X,"# P@..(!)TR9,G0/R4*PXKD,
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M?;J+A0LU[H@%_\)8\I.'0G"\N ,//!Z,!1H\H.D0&G'@F0HV%C[HAC'&P!&
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M  $&*H@AAAEFD$&&&6" (88*2, V#SOL(".+"A9H"@-R,?CA!Q)$$$$C!C#
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M#!8E/I4J3G "%M9(AC%TQ8E-R"H1AZ "#VY@ QI4JV ,:,"]"O8":YUK!C2
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M[BX0 @$0#N'XD'$B)W(*J. 0$($9^Q,1#B$,#B$1$&%3'@'_$CS%[EYL!VS
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M[T41  8"P?\0((%&$^K,OJEJ730K*.T&J, ':FDB)7)F=& B:^D%ED8!N,\
MM])-.](CF;0H:X<ESV,!Y:LI.K3G5I(HY"MN/:VDW*_38*K7HF@QLPO52))I
MY#9.>&H .F <]N% \"$.A**BZ.INUJ<H=_*B]'1K!+< &]!8F1+['E D=>N,
MJ*.M\)#:Z$323HZN>,U8,T)I[@77R)(!UX)-GY51G4@"V!* X$ .X !Y 20/
M=M N/\3?]FT:^!*"0 O@ BX-KG>#1F(PS<DU5.(RC -/L,C4.@*-5.<!Q(_7
MP 5(> @%B@2XR- #NM34EJM,N'5,LE5:JZAV:,X#TW0.]5<TS>7_\8! !GX
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M*3M_\>R<6NY29?_L?.6&,V$3.FGN;C&2V.Z',U80,C;O_*"#^T! B7C#-&E
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MD29%&.&SS908^08=^91X& ]4\#YE$:RX#^[ZB676!B08C/.S7O<3B[7X"WQ
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MF;[W<S*P99]R/H"G_ 3Y.L,5BEA1P5$&&1IIHGU2E*,.)3^#2.HHD3H@ E[
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MTP5L4(;J(<((&%@?FPP5)P#BB4X,6)0"[J>(*^QOBC4T%*(@);]%-?50.U2
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M"/\5'&( "(U0AJ9P"JO "IX@!DD 35) !8V0":>0"GQC3DFG=/0A3I%#AXW
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M@B%2EHC&\630B640+643[AP,?=$/7;XX)]$Y-]'"X:U91CP,902B"(H]T -
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M]P;@SC7<$ CP.OH&,,"_\;K+SCL)Q_,.P@,2:# !"5L[P#OQ.!0ONP#I.T"
M!$P<0+[_YALP10+:@_'"!J\S #L.:@3/ 0(?7/"]  UH[SH$_T0HH8DFBCRR
M"11^0 $%)U!8X005O$@#&FCPP#)+*Z^<PPTYW+#C2S?TF(::::I!LYHSJX$F
MEECN@'/+-J>9QLU8H-F##2=>JP &&FH ] 9 == !T!H*+530&G"P HU&K=@
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MA-.+-][P @\VW>Q&G>B'APQ\ID^!JL$-%&@H'@"J@8<"% P:X()&.0I2AD,
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M/LV04P/A(ALS;6G+S0+*!K?8@-@V/$B$#:II31$OP 9/X8$,5M-.YF2. C"
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M,5D#-T T)TT#-;C(-HB^2W,JBXP3\L$2-I"#-%"$+:V!'> ^0A&4DP04#&"
M5Y,Z=\V-!VB"+?]@@SS  ^OC@B9X*P_(%> 9@#@-EE[IOX\2-@&U4Q5M-CW%
M4Y]DG(X-,LTS//E3MFB#6E[)(!SY#VNX!FM(!85@5'NQB'M;(['T%G1!%[0D
M02TR%]N:RSWB5#^BF*>H@IX +GICP3AZHWU#A(*!B9\("E9E52J( C'H"?$5
M7_ ].(T1I$+JPAV0&:\P F7Q"L;<@60Y3,G\&$1:PE$J@OU]7\V$+&%-BS*@
M BD  AH0 OAJ7R4<I;S @&<-&C2\I0NP)9O;.34LC_*@ ?#%@/)0@'-EIJ71
MC#XH)OLH#8+JX-?00V<RIMKP#*^)#:J3C0Z+@M(1,0/1&PPH#BJP 0;_R)N,
M^D;F6+&#K0'!$4>.0APH&P#S[-F,Y0 .4-#O: \*$(SJ@,_S[(8 Z#]^&A#6
M00 )(.$@Z,_SA(=NZ(8"/<]Q>+L#& %X>-APZ 8VMF)B:;(!Z(!8*-GSO(<G
MD-@.(0 '/<]XJ,9[B,]I^+4:RI#K(,K,H13#41U*2<>\ H]?(ZP5O8XT&T4G
MV]RI=#,/.($-\B!-01(>)0(CR8(MN)*<&EN91((-<( "2$0&> +CDP,XF(,C
MM67X89\ZV!\]J 8\<+ZEJMM?%N8U^.4NR*GRL3XS2 ,TL %#62!$Z;Z4K $8
M:('L9 !WA1OF. '=VS3*M3XU6($)($H];;88_V+*]RBI%WW&IO65&G$ 7IG=
MU(65'UH04_'3&]*.8COG\ "6/OT/V9V/0^4$T9H(>GE!C! W2"TW**I4Y&TW
MBL WZY6C&GS>B9$MY@T#, ($,#()O)P)'$08A?%>H'@*>7M+Y-(*AK,*CUG@
M')B+QEPNQMRN[5I"0OJ")/2*'#B"(K !9#6"9"F#,_@$3X"L(4H9*>#I&6A"
M0JJNA"L"&? +QO"+#*@ "*8 "" :K'9-QJ!6!?B!GSM7KHE-UHB!*) :A?5#
M_%@-T%"P@=H/)7O7XOR:W5" '5@$&OA#YPP.;R**&]C$-OL.OF$Q%[,!&\
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M@I1#0BBX:??=:62E\Y\.(LVTI)39<[5@"_A*5J8^)1PHN0:.)0C..6LE&@7
M )"Q@0<;C=# &OTP#0P8UT3@ 0QXX65".N-786?2#<>E5PISC0>P@46X@>-\
MSM,HL2DP E:7D,*9QX*5 4I4H'5"Q#@##R6&6' G %?@AWW ASU(J0%H@WO8
MAWT A^8 " :N_/GCUPW FGO[\,$;,># @0$>QNW;9X^+@(<)#BA0@,!)GCW=
M5!B 2  <07YM##P81_ >BP $!.PAZ&]/@ $#NA'<U\VEOWM< D TL(<?P3T
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M2UB^$J"'/* "-K!!#FYP@T=68"R[JPH!!B .F\0! #,9&C_V4#0W<*QA!E
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M,L&THSK"$' P!$3-4(9,R,''%W6$1:%VAK=-0A&$0(,B1(JWE)H4;S_H*22
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M"H0#Q_"#/'3#BG5,,0U/>_A'@613T]PCV@'(1%[-5_B16H -V*$3UI0:2*H
M1X99VHCD \H3"D#@"4Q?]/&3WNA.?F+? O1-GP).0?DIMJ" 0ZT!;$Q4^JF!
M"GB AWUIUB1EY]P!YX .I<E "TQE5?:-U1$C 3P 6:K Z^ 3$:C !+B% _#+
MW'F [* :3['IW4S JST YD#'4B' J:[BIJ&@>\A>8-K'7S8/5QP;5Y#'(N%E
M!U_6!8,L6Z__UD4RP(+W9((-AH^)R%5<;9O\1&;]S BW!<*1Y-N0.-:3Y%6-
MK(^)X,B\Y8@7!M!A'="E$-!HAD$9]$$8R"MFU>N4B$D/_$B_@0ELCF&:E&&:
M3-;"?<&BR)8-C5#'04'%*2RA[%#*X< ,!,&A','(N:$>SI 4@ &D2,$2V%8-
M%<$/2&<4_8 06*<1:<H47 IF!4H/[(!W'J)XQJP$2, #@!$&W  /)$'4*8 '
M5,MV#<NTS&Q'8*)E4  -H"(BV  F%LMY,2TM(4#J"&B<%10%+ (4E,N AMU6
M'-@#V  $W< #^,>7)MH %,L+% $9T $IR,%45@ "U-V'ANA29-+F_V5C3AR
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M@!XHA#]XPR/)0 P Q3[$ 5'@G=[-[0 0*</<C.#M@0%<  8PP!Q4:3<,#3X
M3?1,\  8;D& 0P3_$(6SZ#()_*,_X,/H140J*87G:1,!\-@^9D])"!4  $
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MGAC7H0S!#%6<#BGL#LW0PT)L$ 0!#M30$6RV'^X0%(!!PD%*:AUL=$JG!H@
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M-,>PZ'O2S6QS6XL"8( A)T(8Q$!2JU'3=@N*%91EO!=EQ$ DS$!EG,6M*16
MI$5;Q  /^  44,"5$Y4*Q-@^3 .D> ,NQ4.0TL?D=@R-"< 3!%D_B*Z)<F,
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M , -'72=W46 TFUX QQ.G>I2>\  "L! #&20!%)0PQO3F ,"A*.@!TU'#6U
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M$F;5$MQ2$ A-!BK ?\5,$'&3LQH+L #3,&LGJ7+V+MWC,&V0V:9M3MKC 4+
MJ[Y*3;JJ0YA'1;1U!<[P#3+S_P0F "^WQ^7 V(3.%4XJ49MT1# *E@L- "Z*
MI'T6)Z=:%3Y&H-?>(%_3T'Y.X$H0)=O2[ " 9-D"C@%?!(GCX$LD0%,B8 1*
MY 2P]7D^P$)0JTH>(PY+2X"O(WI+".:X$XSS)(0FX/7&>(RO,[,=H*!7MA*M
M,(%/HQ01FZN?LV%%[3Y84+0-5G?RDQ6ASA7# !"4(KN*A0H0(4&YA5N&1;YV
MA5>@15Q\(+9OY9$AE!@UM(RN15?0J!LQ-(VN)>T((ALYU"! - J,XBE$F90-
MXNZB( P6S!$B(1+"\1OE=@R<%!UC&2,>;",8(B5D&2/^5@GDNPCV\<-PX@=,
M0,1*P/]C&B:3E%1)2^\+R(#T?)1C\K'&8*\GM%3!A\;W%O('CD!>3F4<E843
MKL$:+.$+*N J<B8L/)<LRJ*8INSXG*\L%*"83))V^8(!;" 0%J$E3[++( MK
M( -X#Z "Q@#\(@2<3H-\J&2F1X,">J"5,V"S"=K(':#]WL,O[=B<+#4&\,\&
MHM+ZU),Z/C,"/H!Z"    ( U8^#5&(!\UC.CC X5=VUW%* '9+43W+(2*$$0
M;H &9  &9. %*( "K(PF9S*NY+ GG9.(&],X&R6IH,W:#'TIW^D#2@""E%.I
MA[ (MY4+U$!_,C,$.F#])D"$L3I\ZNU3,5$S J.%U;5(AAANX$R]K!^K6<V2
M7M6P22:]#=:@?T;@0G*32%R8"Z\$XCCE1>X #]@ #RY.4Y(3@E($K9R5Y"X(
MY7)+0J)W D[@Y;@ YK)@!8C YD9@ T8@A AE S!;L[N]LW^./GWG;:1S,.[\
MW,\=KN<DM7%V,QC_,(/X,^JR&54 P59FQ>S\LUVH8.W<B%>\SNMTL;>[KEIB
M!4*7)=\WU)*[UFN!)8VF0%>@4<"JFVP%C%S6]N*?X@OJ1>,!C/!<-!*<3KP3
M#.V>0B-BV1S7^T8E1@LFKR'D^\7FFPB(( B(U 2F=$I1Z9>%H,0Z0@O @'+-
M-I2*P,-^ )6&9G-[ DM](F<*\@>N.544H1*:X1HNO!)RH&8XG +,.!(]?&G*
MP@/20IB.B7:-B<K<(@:B8%EZ ,_[E##H64/ [#)RX NNV(I_&&-+^P&,H)4U
M@(PW>X-4-G<<,[1]=>2L;'OQSW\5)#OD,W*BZFDZFB?0[([7LSIN4/ =_Z4
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MI>5L[TRS/]F<YL]\IC,4O9L8%+$WO3DT<(^0Z12XHSHH@&$V.0"#XF"#!-E
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M,L3?,89;-&=BLV@D((X)^Z<-;XXP!+\1:90S:2-U:4&@:;0C.PN84IX&:D/
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M\K %-<PC"RK+Q&Q),8JM!RUC4,0,MC,T8(J,(,XAWD$H8A""/( ",7A(0V2
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M0@G\B5 @"4(4H41;9921G5U@/(B$$3D$,8,0,VB@08 7 'A!!AYP&*($&5R
MP0^I)7&#:320<,$%"D@ HXPPQOBB B_&*($'"B@0P8P*/.  D$!>$ ,-.?B
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M'C7!"3T%M0+2V>YT)IYR.DO6 E&]\ (,6#FJE:%:9675"P>+Q3$":Y'-0,*
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M29!'">@1:14P6B[QZ (RR$$/0"B()?4 "XE(!!:BP(@9B&DF0 23 W:[D*0
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MO=,><<$6\%';S1TX]O]7?W&!KV2!"K! %J3 "01>! 3>!$Q+3GS !\ 3/)U
M",!9ADW7*9[32SR-Y'W+:(4+_A4:HM&2Y9E2!71-#=S #?" 'RC):[W6DHB0
M50S4CJ&% CC!ZX%*[.'!+KG!&L"!&AA$DR79P1"4H@U$080,DH5,E"G$0AB
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M:FQG$=B _2!0Q5E<!%D<C40+CWQL!47+!9D6)8(<R9 B O2 -5A#,E!"&.1
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M#3PG#M2/B"!B@2A   T08@/!#&" CDP<>.:R96,<(\8(R'U<R79);XEQE]S
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M!SIP 046P)L%=&XWQ33FGMF0!VBL80T735U(0UK2!8C =2!]'9A!)*)W=OD
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MUV#7Z9RN=0NW/P: J_ZF)KK*>;IY//\5@)SEH K(60VN1'BQ)'BO9,3)"MG
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M$(-,1F$0HP#$#&:PA5' 83&000Q&.4K*2(PJ*%O(14@UE:1T[ 4=@65'.,(
M#C#@+('A@,@D0A&5H0PBB&F9,&<3 2XHTES=(H7.=O:9S)B$*4Z)"A.A$AA4
MHH8E4-E+!L+B%;" I2LER(O@-E(:E*0%-Z098Q:XD 5=Q;!L1K-:W\IF&JID
M!C"BH0U@4+.7O#B@;HU1V 4<0YF?F>1G!AT:9Q B&K;DQF\0O6=:8K.XR#D
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MM!Y J1O<0 ,WE)033]5$#,2NEIDB0$-7I2IG<>"B$?_80 X4$8DQ9(&.;9Q
M"'3UEA-X-XQI0,,*C!5&[RIK6;=Z%G8#,05:6<L!)FC#'>* QW'U$0[Y.F8;
MV%"'0K+K6_1JI'[W]0&8L,PEEIR,*2G0$8-E4I,5<)@,9$ #&DSXA#'HY /8
M,AN64"0!"^@8 S#0L1#?L@"WA HJ6P,1VEB$4P*P26'<YK)APB0G?URF&_!@
MAZ'(P0D?.\G0>O:4!40E(E8S@"Y7;+6K)&0$6S&!5[C9!!60H)Q666C?<'.
MMV3!"UQH@JX(U\QYSI.<&N%,FD%SS7PZT6^AL4MC(& !Q]R-P0)AP 5(LH"?
M/8 !"V4;/7/CE(.P#0&KX67_2TA&48<TI#8<U0M']V)2RP5G"6]8PF^2((?)
M9:X*Q^%3Z%RJ4^FT#G6H/IUW=KI3T=4N/;5+PE"-(*#AY:YV[3&0?7QGZZC*
M^@A0O<]R&-A"*)G)JT78ZH6LIR#N">$(.:!K7=\JAC*0S]KD.Y$8O@ %%N6
M1=UFD8< I(6[AN^M;T7#6[.0O1IY2+"&1:QAAR0D,L1/"8U50O4PA*$@5$E+
M'N 2P+GDI<T^:7E@$JT(-#!;#2Q\35<5 @UP,'$<_$"U*7PA59=C)A$,BE"T
MI2&D'+6H13E  C2X@1%H<(%%[; #HCGBID:5 !&LE '#?>ZJILCSQ;AE M.-
M!!JL_^#&[-)J6;QJYPG*V,XTCA%8Z&VCM2*0@4/LH /6<N,)PN6M;W5=7-K:
MKWX#R2YVI4N1 =X)OM0^@9K<9#8/L0D""#"0!7B@) 0C*&4L8($8P*#"-+"!
M#2H,@U%FL@(Q>$$%#O(QD,2@(RW 0 L8\'A9>H0I&MN(DEFLZ)6HC"$1 8P
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MFA0#,Q!XZJB.-X %AF )EV )@J #-;"D+2 #3=H",3"/'D$!1"85$"&**9,
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MD.EHFY@N NJ:A' JB**.0JHI(*B.N@@DOAY)*RCF&CLLLPLSR^RULJ)J+:W
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MEI_@5 )=X:H)>VP""1#PJ4]-V,(5QA@"%N"J486JPPL@P0:R,(1G;6# [**
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M^/" ;&R1^;+<$.@>(PU'(\6!#(  "F@ "Q Q)R7=**4A*I4A:T'<_Q_ QR?
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M_\IG$S97I&U)O?:]_)+&17NA 4(EU$*M<S(9$^[UWE6B:9P.A-Z_:41@,AX
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M!G*['Q#?/OX$[MO_'K#_@'X)*,  !@56D  "'!R P (**' !@006B($(#"C
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MZ4I8RI(5-F !"E#0@4$X$\QRV 4G2.A#;R(1I.PRJ0[AB8@$)*" )) !#6S
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M#BY/ME4''%S'&Y3 7HF/7RT&!@P,#TB!#!0677T/AIC/$.Z5];0'7L%;OL7
M#V#  B1( -7/@CR=AV# #W3=LCB+GJP'P D07@TAOMT(%5T '$((:&F6PTU<
M(1%2$=!!'>SA'FK0'MI!:J76$%2 #-CA<CT0BUA RVV RF4!$6R !L ACES
MD\"<!926!M0<F:P)EBU!%3"8LD3(FY3(@]Q)$=W(8N@)D@A=!F0 #F3!=FT
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M>DI.Y90:=2C>'4L?M0H6...MO!$6Q%T@(((B'((/\, -T)V!;>,?:6,?R0)
ML?]@X^!5F +H*+:,B.&!VDY)2ZRQ0)F,&#M>4KI\BQRHBQKX03V&TA*<4K^L
M$B[5"^?EV.41)! 8SNDIY$!N7L(T#,84&0T($^M]C,<46J&9@$,*@3E!&1-4
M@1+@7ISF$,RT64AH!$=0Y)Q]!/5Y1#B=9)FI)$G,Q$J&1,[(Y$2<S5.6P @\
M*K<(P=2< :66P1>  3]I 1/T69\9BE**7_0EF?G9Y-O@!55\1=S4S0@D5%M4
MQE9&FEMPY53,0 Y$0N,(AB-XI$.HY<C8A08$S@>LU&28&DPA8 2 C@,< $V-
MCEMPP".=!DI]QF$ 2&1 !N:HU6D6YK&Z10@(CPJP@+?_,E56<8$NI,%Q.!4J
MS($7T$%E3H(6;( ##,#L3%NU^6 .7L=H0L]H!B%N I;Y8$#FQ14#].L:#A!@
MF=L4KL<!")"B8 "G4 CIZ D)^=O]Y!LP5BBGS$!S$1Q[*(B>* @'!!!CZ,D1
M)=:+?$FS\ ]V:@H1!*++?B<?&H&"V:B"S:@,.-@,P$ ,X( %S$ ,6 !AT:)L
M64!P88 0I D7*$$7U&>:) L?B6>!'%#0_:<"Y"7!#:@#]&>!;D#264 &3$ $
M],G3'9%=-&BD]!"_\5L+M,!]?LJG>!VH@,I[R2VR.*V-V@"L8 $60.-^S=$8
MA $/[(#@#EB-<F/?U>S>66,._QP8X6'+-]H%(W$ W_!-A@EIMRC>AWU+OF@N
M/&H2/:J8DRXI/F;>O5RIP@@DC@FD02IDQ4@,$21DPY1ID7$,$'#,F2+9^Y%,
M1BA!$3 $EC&!%'2!0& J&/!%-D4,S^SIS@!JHI+3FX69F0T!2S@!2X0D\PE?
M$$!?39H 3HZ !TQE$61!2G0!&'3!2[ $T<P$^,T9/$T$V3B%J(:,69PIFY(%
M0M5-2FGE 6KE5M[%###3%T0"-.Q"&DB!0_!N$8#%R)# $K7ECLK48UP&9%R&
M PCKL?[-3(4.8B2(M<2:QUS L*H;^+"&",?.YJQ.!'R MZK N"[FMYH@%T@"
M*KPP<__, 2KHP0G0A1:D@9Z901"H  Z&U5AAFW><U5B)5?.(56F6L%J%EU\A
M0 SL0!50 0\ 06%%UKH!R/\L;&Q"(6[$FVDT5[W9CX)4EG?!3W/]@(;2 ! (
MRP]\"((("!<3W+^5K-%],0'A2(PLT(0P@!VVK'?"+!_2@1'\4=[A'2+#UXQ&
M6!D:B,@U0#-%$)DL!-.N27@2R\R*T<Z]R:+,#P%=CFSX"8Y(  3$8M(Q76Q%
M70 )T:/XXF)-*"S?Y]?%K0PD3*A@:(:"BJC<YWCBK=Y>02"\D=S=D8 -V X8
M 8'IG1X%7J=8(S8&RS@J4N2"P$0%3EHTW36GQ0<8GB*1@!/_;**9J$$7B',7
MM,OCD1(]EA+EW6/G79X_$N0[=^G#0,R7ABGG<2E%;JG&S  0_(#M^C/()-/9
M*)G'4&011*DYN1@94-E!:*KNO:Y(V R;>9E&Y$Q%$&K8 (V@?@2:I=F@"A^<
M<:]-=B^W1,5$3'*:- 03.('R[83RM;2?9A>H/L6AB"K(2 6;TAG(E("ILFJD
M9=1:Q&4&8( &_*\@'<&E&B3,'&V:7N50#\Y.R05O(,9=_@UGR-0$0* %)U4$
M3(MI5(461:P3_Q4'=F#L<,8'E,!SN/!BLD *N/!S.$(T=(&S.1L7>((G ,$!
M_(8'$($9. (TN((>S($/*L\/;L=A_]MK#_9@"*#FNADA$$C!%%3!#F! 75D/
MMYTAMUG/;*9B7AT  Q2G%BZ(:@H(H/"F+4Z*&&IH&]<2(7T(%\9VR)*&'9=L
MT1% 9566<RT7;\? $O0A=PKR'AK!W<77-9:*(O<1#-B @SD8(>W<!6@ S\X<
M#B&7%G"B$'2=@MU=L"28ST9MA9QB@$I  MS;O1$<=L6B!5R  _3)O:4&>F4+
MUY%AIX0V@UTH?H^1:6"C@N7R<V\*8RW+W^V #^BMW@J"&/A*&/A #[SH,:>*
M,NO1#'@W)F>CL%@8AIV7-4L1WVRX-:=?(W5+AY'+$\B!XI4)*54!E#XIE.)+
MC)VNEA+DZ_^:1A#0.#WGF,( T\,(F3"Y[Z*%!<@LV4-1I.&D29Q2TS210160
MP3D]Q/5RV3M1G_->=-,\+YN!4YHA)4-8Q)@IZE.,-+>(P%.0Q9H1 4I[-$NZ
M]#I%.448BDQ_S$"E#4T#VL=,Q=U,U-]H5%QP%/N1P/\F$P9LQ0A4(!#0C&F4
M!9,1CJ\.3@;H.:EYCEVF6E6[ZE9+P*#K5 6(=6Z,]6*HVVEJS@@N!UPW)F.6
M0308!W.X-0I\ .B0P2A406[DQ@"@0!ZX C10PS3@01Y01[Z")J_[^A'_.FA.
M#_APFV<?NP)$,14LNQ$L2G)V&VUD-L=&!L=F=H)0H-MVD7*:MM3_W90!A=&G
ML'$??0J%D%!J!-#$3FUJ9%')GO>ZJU>%-%>!"$'&U8$<!#+,%O(AA^BH+"XB
MO]<-N, VVFAY1A@C/PD&S, 22!(.=>2:C*'3ZM&P#$LC-U>#Y$G1)6=F:SR>
M"$HS;1<$3(#5.DA\CR*%WB?*RRW=*O(- $&-UJVR1.UR1<ABF4H/%#@6A('>
MMNB U9BJ%'(14+BF:"P6]O8@R<"$0Q@-2',BG6,Y3NZ&RT6'>T"E,!*VC(FW
M%&G-8=*2=GVYU&.ZI!B+]4O8Q?A 'N3J]O-^:VD0^-+I!5/M9L26>DP_H^FB
M%LZ0MSU#J$R2$^] H._QONZ;C1E%S)F<_UVY2B+^T&C!/S7!FT6$$^3,J$KE
M0?W ">!]1Q27$RA!F5^YS:2DV(0%4TX$^8T-FZ)-6*@>G)F%78! J[JJ6G1%
M4?]Y6ZY%6M@%68@>HC.9FH)X!HS 7V[&9]BEJW)&!>_O2D'&LW[UJ_5F;3#&
MJ5'&9'2 6@\/"[3UM[HU"S\'&7"")'!!JJ- "5A&:!# $'R"(XQ !,P.\JR!
M&]B!'KC"-$R#*^PZ#GJF9R)Q=\ !&P@A0$1(,)!@P0@*$DC@H$ $$!Y4J$B)
M@3 !0@44!RIPD&#AQ8P5!58DB* B!AE 9&!0P&'DQ0478<*\P""&#!DT;.3,
MB1+# @X,?JX$JO\ @8(1"Q8@>*G@P@4%2UTR8""B*%*D%Q9(!3+'#M<Z=NJ$
M%2O6B,X:-VS4.&L#+=J<-73JA '#!@P:,&38M0)C2)<E2[ITJ>+7KQ(9,VK:
MM$GCIHP8CR''P("!@5,%!!2$%%EQ88>+%S:$#FT!@@,./J6*D,I <6O7B5VW
MKG%29Q(;0(KDM&FC=0P&&![3C*%:=5,,,VSLZ+%\N9$;18KDR/T\1T[&D(%+
MCOP#,HP9AV?0$#&>/'D/XQ6<3^]! GOW[MO'YU">8?F&3IXL4:-?C9R_:M1X
MHPH!WY"C"CD03%#!*JJ0(HDD>-CA0=N2  *("BW$$$,@@BC"P@\SO!#_-P^A
M*X((((2P4(@99OC!12%<_*%%#7[0@,86@\CQ!R"46(())L  0XHJP"!#R"ZT
M6$()(H80@H@EBG"2""%R'&*(((8@(@@MM]SRRBR)8%)+,8EPX@@EG!ABR1[!
MG/+$,',,@@022JBS!!."*"$()Z84@D\N<QS32B:SQ"%.$_",,X@?%L433PT0
MU2 ((2BE5,L?Z#3/ P\ZB*"#]D3  %,:-9AAO$X[.(\\$H!P(D5,21#!1A(T
MH#56#4;X(+T('.B@UUX]!;8# B(HUM@..HT ,PXDV+$$(,;C  $.!.H@@9 $
M*O;:"#Y 085OP0U7!6]38,%<%); 1)4NP"V!_]-BB>6 @!'H^,2) 29XHXTV
MW&AC#3?LT&,4:*AQ10\[]MT7#H43;F-AAQ-^&(XX&H9##0\.^.@@;3$J2($?
MDH"("B,P^$BDS*Y5X  )+,K,(P4>$ @FCFBZ308&-JLHII>)2D"$"TS"*0D9
M;'/K9JD68D"!J:Q:0 2G*ZOL@@J:>MJGI9?.RNJJG>!JCJ_D^&JL.CRIHRRU
MUD(K;;;B<BLNZ^JB 0<K7$C"R"Z8^(L,+<BH0@D: &\L<,8.NVZ&[";#X&>6
M)0")(IXCR,""T'#8( ,)#GI*-:EBVTT&WF;K7#&U9%!+I\]OLUFQQ"1+G#@&
MG+[J@:9B"*\Z&V@(#_^GG'*S(3<:)-,  ^&!*[YX%L%S# ;[YA/A/ F<WS35
M]^*+#SY5I[+/OA+PVR^P[^5(8L #Y=C/0 71#W_"!R^T04.41#P)Q/EQ$S&)
M$GF$3D4488QQ41G_)ZD:+6H&0>"0$)2@A!\QH0IDD$*0R  DO"5P240H0@7#
MY"0O8<E*7?(2F 85)BME:0A.2*":S)2E)9DH3( *@@GN1 )$Z4E1K0)"F!A%
MPR8$2DM9HM(+@8@G1@G148AR5)PJI2,YD2!7SFN/IR80*A)@@ 0RFI,((N !
M3V71/G-RT9PT(((Y47%XM=) !D2 Q@E,X%C%\I6OW!BL"22+ !WHB B>Y2+_
M$4C 6MDRUD!80@ .>,!;+ "7(0^I D.R( 7@<H(C.'&&;Z'@ ]B"E[*N5851
MD.$)#8-8PN)@!U),8QK0($4>V. &?46,8:R$P\(H]LI^M2$%UR+(XT"RF<>)
M@ 91 $08I@ $EF&&6#')G )8YH&+;.QE@+Q(#-I7LHI( #-0V1E,$  T^+$%
M"#?P9EIL,I[LK69SOZ',;Z1RSJFD)E2O6R<#NB:'4"+(#G8(V]C*DA.W50<M
MU<G!#6['%K>])2XYL (-E%"%)9!!;TNH M]P\#:=X&1P-8E,XB9S 0H(9"$?
ML0AF)">:#9!& NDT26Q )SK9V"1T-0""Z>!B&R!8_Z<WOAG.5)K2%&MFYB#&
ML5'M:H><F?+.!D( G/&$]YCL/.8[X9D!7F;0//N\1YD=V..FVD.]3<%'!!R8
MSR#/ Y2GB?,^3NB"$]00&#F\00T':FN!UB"'+LB5? @Z$(.J0"'VB2A$(/+0
M_%P$H@K]M7XC0I&%8L0H1OV/438:X*(@"YT$,D$)6@ #$[3 ("U(00M:6-.2
M>&1!)VF0AQR\DJ)&V,,QF59-2DBM"%O8PD7ML$YXTE.=\N2$/?DI3[955([P
MY";@!D%202B@HP3X Q- :@/&K523*+78,'[@ UC]P)RJ:"L-7$"+R!*(>^PS
M@A*0!XUB%*,9,U"K-*YQCO];Y-4;C<6K.A)+61&@%@>L"H02[ B++.G40#RE
M,T**"Y'F4N2W$'G@)S@B$Y)X @I&X*L#"(18$R[6A = A$^\ F$/\R0<UM &
M-N1!#ZX@)1[R0+%5>OB3^YHEOQSF!C>HH7$'(4BU;)FYCEH$ T:8 B"H (4?
M+!,FQTS/SHS\78^4]',5NAI,.J( STP3)E;[3>FZF01O:ADM1UL-T$R*SLE,
M9<SN3$TZR=DU.X2RGESIBE?LB1*)NFV@;.'G0&\' X-&]*%]VUL# P.&W^GS
MFW7.G6.X<QR,-L4CG+%(!! 0@0= 8'*CV4 #)O.8V,#%=&D)G4U:(+J46BAT
M-"#_$0TL]!T1/*:<"[#,?'SB ,PP$VB9UC3@3/TV%B6N=8GC3E!SYYW#9"]:
MX\EJ5AER;.O!QWI>)?9%M#<>#-0),-][T%J3L(0"R35!<;5K^O+*OO5]2$,5
M<@+] GNAP4+G?O6C0:6 L",9R0A&!XR1"10;IQ$-X8(]\M%"F6"DRR8P3"P4
M898XU$$F=0E.6VHA"0<5\1(.(0M)J* *R>3P%_HVAT"DX9Z<D$/?PO $0%24
M">;TPA]L0+F/==3*\5W 2?7IY-,=@8UJ18(9V&H\F_*4=U,5WJFV$XSJQ2X)
M,O !]B+KC0[((KPZ, $"$(L $UC(U3$0;R#$BJ?V94FU_T* @B84N,#B"I>Y
MG% &3&"B"R$HEM/C:RSZ3OT 3G#%*UPA,5<VC"LEI@8TIH$'A+$5E&V@6+_Z
M%8?#PS@%QKJ,SDYV2X0HRR)"D,(A&$$%:+DL/8Q["LN0"1/&@?XBC6/ 3&TS
MY(L,<F<B6'T'%@![J%V@)MV\01(DE/LNHQFCO1^S.2DC3C&K1G%24;,<YB '
M.[A!^6_FBAR D!C>O,TM=6:;#0*J3QQ< 0=% (-@NE"D+I!!,$O('> $^L\;
M[$#]<?F<38":N*:PK" )0, !E@D!RE5N Q70].@^1RU>:C9,1Z5: YQ*QR90
M M<0BT56K=46XB X8&4B<&.*)?^GRDAX6 35/D<(;  ' "<&B,=&@&.*1 4X
M%N,F'+"KR&,^KH<A4N78MFK9XJ/87&]3NJH^HHU[N* + &0_^D.AY$JM#F2N
MOFU!)L1],J1"-@2PY VQR TWA(!$1F1%4"2Q%,M%9$X+B^L'J*0(K 0,^\U'
M@ 2SEB"S*&B%PD0)6,B#4$NUXD2U5NM+F.1,7.L.VR2VJ 1.$"4(FJ )AHB&
M/D[E<&N_2@!29$B&@$B&#A%19.B(($7EC,@$#&52*H52X@0'O@ ,>D (<B[G
ML A5VL@#0 "/M >K<#"-Q(A6S&A61("])N!7DJ53>F589G$EIJ6K1B"QL"B^
M/*,$Q,[_"1:)[!#L"53@"19)D9J #"0!$\A B_X(P.1.628L 3J@D^[.%3JL
MQ5J)"]1 843)%4S)#(+@&STIEF8I\=P Q)0)F1QO8ZP1<G8& T*&$?I "GY@
M*91F]) )]/PQ)MHQ]C!@_8P "':*(5R"*)PB*Q:RG&IB_2"2!R#D]F;#]XRG
M>'KM9FXF^'R#,L8L!I9@#KRF*Y:OGI3/:W[ UIAJ+NJB):G/!;+O VT )KG/
M"(SD;@".;\P/<& @H@!*_2 R!YSC!O()" +G,.3OR."QOB:MTC; !5S@!6#C
MI4KG!M#FI:R2-PQ0*UFJI5!B!N(M1DY@ TJ@ KK*JR(P 98E_\J,10+<TC@R
M#3%TY]!P;==\KP)24C+D<@/# WJ@)WJJASVRR@.XB]FRZ'I0,0*LAS[08ZPN
M0(Q^ *V^9S(=JC\49*ZJP-O(9S,GQ'Z8L GI)S0]9$,PQ( 0"PL9JW\8909H
MQ NA*P>FI B60$U\)+/^#$IF\X+TT(+BY$NP1 [CI EP $RPY(-4"X6.H(22
M<TW@!$Y^8(=<*$^D<T^4"^7RY ?V"SNQ$^5*@$X@I4[H9$ZL4[EP;HG$LTHL
M$1.%  K&8 P4 0VP  <PQ;R@412WR(ZB;3Q P*MZKKQ:L>B0;@30R"W9X^>"
M!8[Z*%FHA0#.8T?T:S_1$@10P F$D?\%O$616, 8#>D)C/$8RZX+'@$3$$$$
MMN7&ML6^HC$!2B!A]. 5ID$/X. -7JF5VH %4L5.W,4#2D +S, 11L$5\""5
M(,8-#F\=B91?W$ %..^:W/(@6&9C2.\I@* *J  1J. &5(("F.(IV&,!-N4E
MHO2:G(8&)F0J5B(F+,,IL,)J7.TQB:/VUF\'I& '=B!")$0K60-QC$<X)B,E
M,(HF,FV=DL">3))0FT_Y$.0' !4C(0-Y;F*B=D<GW&9N#@H)R.\F@R3\DN0P
MP*.@<D '_HG]=L";2+5WB@!P6"0&+. "&&?^'F!V,, "7  ':/4 T0:FX$(W
M/@TE4L(UM%+_=58G!KZ(!#;@!#Y@!& Q%K4E6V(F[HKE 20 5D-%!($-56F
M.Q"#!*@&:$)%>$A ,L #>1CC/+!J,+=J!@L4%=4U/HI%,+6(/3J#4]RT/!1'
M!';$K";3!Q$$,/PC?8P0?<+M?4BSKRSD6<;C0TYD-#&DJ"S$@.0-"SD$1_Y'
M1RZQ4BRHWWY$2?(F2?YB#2T("); 3X@S4*KDM+(D#CE(MNB04/#PM?(04,JD
MX:03AE!. [J39O/DMN:D.^F$9T= O+S39FG6$1.1%9$H/;7 /2-A$B)!$<8
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M":@@$02A!XS% \RV;.-K(3[@#13O8=Q@#UZ!PSYI8=0@)+Y.+:=,+0E@1?/
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M?(4!*5"A"DDSEM.P4K!(]@LJ(HC6N#02 R"T &E)T):WMK6M&R2!7.>2%KF
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M(40@,:YHH;C8<_]= !F6D8M8D@)U(Q898 ,]0"988 /Y* )>!E[&N)<>,!)
MEH[IF"?1F%_XY8QPX 1S00)D$ ITD 0<0"*'LJ IYS0*$$;E&'?XI:31V(Q.
M(&6K(@1@, FCH F.  9" &&$Y&"(]&O.4@1ET B?< A%@!4/$&:2=P$_, 6
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M*<>-2,%RL 469M=!BC-;W#B,]+%6^JJV#0.+_\5F&:_X7! WC"(P R0:"(<
M!4-DF3>E8&!9=8\Z'\R8CG%@!X-+N'-PHW"P!E21(A>P!)_P"5W@C2PA451!
M4W_1!3>JI'9GHX7K=5I' E#V%S@ !HXP"J@P"66  Z&++!S%40DI20Q >#$
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M1&S=RF K2I0B,(AE &3)DBY=JI#I(H>,VRIRY,254X9NW2ITYM(A4R4)D")
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M2[27_TZBC 2<V%H04)PY39XE)9W15',Y[1J2-6^$FRNC"4V&TC2@:&4$4%M
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M"/SKAM(TH(>4*$0#>W!*CL*Q03T\#B7@4  0JO")T(VC!,%C26&T9Y0-A2-
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M E_;@@6_0(H-A8 #-,0."'Q38]^,10$<_]BQ?[N1 !"(8T-O((  4.":.'!
M!5O:PXXY4%]]P(&'V&.!$[0ICS<X!PXG1 $*KAL.%'@ !"&X;C=VG =^@$,
M ^@ ?CT@@ -D>!\;/J0X7'"#*XR"?F78<QD8<09$,$(,=  5#'#0@W/PXQM'
ML,$-SC /[(["%6"$1QW<X(8NH$A&?;R1-RA0!Z=P=P9V0"0&3JF//!   0O8
M@S[BT0012!(!![H)/\Z1A"7X=Q^N4,,<NO -X\G!"4ZPPSA*-X<U",_' E!
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M2"4< ICC&BP "029&RQ !23@.%S  KS7.&B !53 2KB" 80@/CR! 2P  R#
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M8&/ZM9+,8$!]Y0$'1)=:N(*+KHFZ544>>" &,$"4WL.K%1N+NFADL$D\=@,
M#(0"#!@Z2 ,ZW,LWE$/!>O\#HLT#&8Q!4ZP!!>  !N!  RQ $*C!'MRH4ZP!
M,]Z/&R! !<0!>YQ,$%QIPPG2/7!!M>G#DKKH1,D#',S!3P+EL!AE_ZR!R_T3
MQF1 !EC I<+#"6S !J1 "JB!/=Q#'O!</DQ#'4'#*%RI*TA!_OW $CA!C+[4
MV+6!>Y!07<*#"!% *_)&'J3$ 1S RDC 6\H#"H3 GK#  !#$!!3;8*I!SXG#
M-+S!!%S854F5!$P VNR>8V$5!5).4B5!73$!$_B=0^#)R@!4WF(58>GM!(3
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MWV16W4RGW_!-\F(G9RE?=%+6X'26\I[->#*VX53?[EW >:8@Q45$0W >#="
M#8 ?:U?_Q.F5'VUI!$K8&GZNA#VX@GUHCO!,PQ)\1!G<1#?=P$;?0Q<H8P4
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MW,,9C$$\Z(,>F $9Z48>H(!_N4((-/_!P'S 7(2  %PM6R; 6\*#VG# U0D
MV(J#!Z4,39U="*# #:L  0RU!Q@UVSK "%1L3.T3QTMU9*N-X_I30X",$0PN
M$TB!%MB5X0H!4TF55$55W24>2[,TY*(U6B_>6O--[O+-4#_U4W=U:,Q #O!
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M@'DAT$TW!G""O4''31\(GAH( ([=3.!3'>!)'@XP)U-QB4MVZI($1A"E/5U
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MP>#!#BI@CB#-]1),'GA#!$K@!US,Q8"@#CC0">[)\9QO!_- P-#/'NQ #NQ
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M0[]K#9P +_3 %7!40;*0DN8@"&A@Q[H !Y#@"YSQ3,] #\Q #-700&T")XP
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M3(!XCT91A(9M;))1" !*YO-(/L).SI<#YD0^EXLWB4#_"_:3"%PL0$N <BZ
MIZ D>J?S? F ?TEN!*IO;=1@#=1@"0Z6 ADBP%! @?>1!1!6#9[ "2(B@H]P
M28N0=XV0EZ0D?8$26O(D D!G01\ JO9UCJ  "8"  51#_L(' Y!P3_9D-)NP
M?)) *-9 #A2D01QM#O""DO*@0;H *(#7*80 @9  "GK@"W(@!UB%#,OP"I3X
M"KB.#,DP"G( !F(@@UX7!Q9O4G$ "E)H%$0H74G!,B%$A8+,,L&@JF8@7V8
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MP IF0 (":D_:*0.<PHWHJZ#V!"?M) ,FZT^48"B8@& (A7NN2 0DI5*&UD[
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M 9> _=$!8']DT&&&''*8T4453""1!!),0%0A$A@>4401.6Q8A!!% -&7$$$
M041>0?P@A(I##-$7#D,$$41?0Q Q(XDRIKB5""60T*.//OX() E EF!"$"T2
M$6.2-OZ0(Q E<%4""%2*4"4(9WG0 9989GD6E2-(6<(()93)(PD\CEDFF3R2
M.8('):3@A!I=K%&GG7;.808=:10HQQIJL*#&$X,.^D.9)1SZPZ(E. &$$TDX
ML<2DCCHAXP\DL/\9I@=OCD#F#T-@B 048$ AA1%0 BD"D5)R!8*K'KSZ:IE
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M'/\@PWKTT6"#$.YQCPTV9(0JD"%  BJ#' 3D"?]4H8'^\02#^L.@*C!(#F0
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MV] ,+5<[,D=SOG-SOB,:HZ$*JH )^H9G*>%94% $1@AKZN0P$\,LR$("PI$
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M40!8*!=8G?NY@7 (@Z$(@V%R%PVZH?NAJ%=+O,V@#-:@#)OPNOO2HL[0B;N
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M@^M(89(]H8D+:XB3&IZ @CCL80TB $&<&*6&/>Q!#1(4 1SPT0T.E. -+/
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M*:"#''$%+Z"#<>"':N"+=MB'=NB&.E"U<P@+6%P'4C #<7 Y5ZB!2:B['@#
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MX\+1"0DZ'83(&^8HCNHXPSD=LT/ULCEMLAIRH?$0L_H 9"6[C_'X<D.>#@[
M0S*4PSID#RU7 $>-  -)H@OHY"6"LP=I(HBP&P_AD%*V 50&D5!- A$I(W$
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M.(!P]H  #<Q #S?Z00X^I@4;@$&<R<0#';JQ#E?001SRH,:O7%$K/2@!"4@
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M/,##0>2 *]@#S3G1"&% <20$#NC!/:S'.L##.+@9";A(G)5A.&A4/.!#-V2
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M"3[, SW@PSF000X$@B(8),@)8L_5&'G<PSS8 SYX@QF( <-XPQ5@@=GE@S?
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M0FH -PK!'$Q#!I7AD[D(03 'GWJ#.'3#&G0!HO[ )05;'S;!'H@#..1!!EC
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M"BTI-'5##LP !G3!>F  Z!1!#NP-#CRA_%C #'3HLNK-'-S#-TR 0FB !6S
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M2J !F9EK7C%20A*8<C$;80E'.^)1"82DHB$%B2 Q"TF11L"D)E%)1SSDH0B
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M'^9@")! (JZE^Q[5<F:2]=:!'NRZ6DK+*(X   'I![I 'N#AGDT 'N2A"41
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M0\0%AN0*=.0/9F8'&>0$_]-% F'U(?<0#ADP!U/V SD%9.&P ;FQ#_UU!E5
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M$'_U-H>UEB![5PIA-F##>(+>$01!SAU  'OC 3SA-Z 7>I]U-#&0LZ=7%4(
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M?9&TSE\\:I@TC<(D29)N>=_.S<L^#8<C?.)P@#DC#QZ.'EK.Q-MW3IP]>O+
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MHPTV%R(80:Z%06<1O)9$*G81C6@T2?=,<@0PO:Z(XBQT#,KT1'S"M?I\092
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MR9:4!DPPOS&K)?CZ.D=(A-'EG^;[/>AE/J&,.U8 52=22J5$2LX+CQEKOD?
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M'2A=&-BU!"I1(HA%S"36A-J=702L#-V5C%+DA"OY1-L9T\SDQ(O=4HNU&%'
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M$)Z*Q*W*3;8?K% 1>SS7QDW"<PV"%7W<%5*(8T(/39Y*JE0)N@"1=RE)M&@
M_TC '.F0DPQ!$3A)E)Q !E# :<IA' )=?=D7T0T2(ED!%/B7#<"76Q B(<:
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M^"4/\30H]U"(368I$N5JKPR1$G51KQ'+KK0*=N'1_0FKH4A+H?#/Y)8  Z&
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M0<P:C_( KAD$<IKW=9I+:6:8WS\M]H_V:*372$6ZCWK$K5=E\O<.6W<-@1*
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MGD"2_P[PN::+DKY$WP0C93I)N3KI PPNX-!+:>Q" K8+X)#&X$8 !9Q@X9Q
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M3[96BRT*$D&=(KF*JXZ ZV16AD'GPB[XJ 2BRV8H,@'E#05"( ,;Z;J6"S!
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M(Z K."DN"*!$_^UB@/5M@/D- A/88D6210M08UV4O1XN1KG@)=MK@KM @M7
MX0 J4I@JH!JJ@&PGH9[R1X(@2:RR1<HP9X7D:@!J2) 'AEW8H,IP=ER84F@8
MH4Q@#IR6A_7 #I[6:7_8#3@8@ :*H$X@4L2.SL263/:R;KFG;N?6S S3[\X6
M#@2Q3A,SS.Z.B>_4?C(QBH-J,/VD[;Z8 R!U4.BG; -W<-'KSIP$<;?6[ @N
M?-"$SWYL!*JV"'' GW*D""M/(F(D<G;H5?YJA/BJA*)%A3YM]HAS5ZL!KW !
M%WB36)=Q&:.EDF]7^';7=TG-6?D@>*4U>+.1L:X5'??E/<'/M* ->?_C\SYA
MHHS -8P.="DJIAU_0B_RD_SX,2EB(K8$]!]I^8[.5V,V,H 5E+B0>2X,TBP$
M< ("]@!30))2 $,M4@7R]_^$RW^Q*V8^-&(#(P$Z-$11U$3+N40;3YH?V# <
MC@7:JYT?+I9<TN$T6 3K.>N,;*"0[/$02DC*L(!T5H55&%.&!WG8-@1.8 ).
M  TEA: <]W$/RG&Q9JDNXVH>:@7N( _B( Z.]FGC $LRVFCA( Z>  U!H 30
MT*+:M.L&EZ4W$:/NYWG*K&SY]DXDU7R ZJ7 ]HLMT8KA@*2.ZNX.NFV+*E#7
M.*@<L8OI9(S[\GW^=GY@&GIL6C/AF/'BF*K_"Q<$$#&KMQKL]@R 3*,$BB2$
M8R=',E=<CN!RWV:"Q. *,DBMSHKW) UUXXK3B!,7@I%9)'D0#"%8>\\0B*5V
M!X$0A-40*('4/%GX-/F3@S>4Q1-:^Z /;H);45D^P>];5?FR>]G[E$( I!=[
MN5>7IRTJX)66Y;4^&[1>V2*Y#(E?S:V1!*F/U,W\9CN9(X P"M:2"%::)8E^
ML.NUE:N1<"M$M:(KOODCSQE%(=:<2511"G E#6,%*%@EN4"Z09""KYMCL[L)
MELP#1D!10* -(TIY(O?J/)A2!DB@?.S''JI0EVP-/: $%&6\O^?(U+N^1^"A
MV "C-UJD[4"C]V!/_[A.?Q!73CUQ>EXZIULZ;CNJ$J5:INQ$4&^*J<L8?W2Z
M;_.63[1'[>BD!!+Z!-JV;1=S#V-:;L,8??QT,O$42M(X4OF0IKJ6RN*8J.D0
M3C'J3UQJ I_L4;0.4GS,Q_K9-$E1" !Y" 8M@1K(\W Q@X(%6HXE$F0OACHM
MKVV!%H)U=IEQ$OXZDWLOKA&[U' W.@E!^$!YS+OQL?L@)HI"LJ^O>3$[/KM(
ME4T+8,#U)Y!M74.+M-(O_; W*5*K'V$K*&)K>B.&M@V4)T3&?4NFC@!08QIT
MV<9M *698!%PMQ6CTE5 DT;TF!M0N++"D90KG.$WFYTD9B V8I]$, XU1?]'
MDDY0@+H-8R4YE@6D&T9GG6/G^>'4X&#A<.P6=WEZG*#4FZ'O&:DJBE ?:M6[
M3ME!@+V_1TV26*&9!WZP1*-#.J,]&DL 7*2UA^ST1VNI),%'_*C%EA(7?%*3
M&@4PO$L($]Q=:DT@]Z V8*@3U4[!UB\S2E%Q:C!_NGO$Q*EYBHF-FDHFL#/;
MU,:S>G_@4.S"[M?;,("()%-Z=%,.J,9.-2-X):Q^SU5+R%AV\3=!C=-F:!;Z
MFEAMX:])WJ^+I1E]5Q &>[!)3<S%G+']('AMK0^@=;*!3<YMPLV1S5S3+R:V
M-]MX'A]!^_QVHI7953\-X)>]%V-8*R#GS[:V K7_^Q5?T3>9XT( 69MF")8B
MOSXQ[%=#1U2;\^VW.;WL@RO43S0N"AB[G$1_05)_")A$3=1)0J!%-5:=*>.=
M6?*=7W3A9GT%#E91S"['%47*"O^>/X!)(.51#B['#]'@Y?*-]<?=<9QYW%O:
MW^ .[D"CM>3SN21MYW#<WUC<Z79L(1Q/K(RCV(Q.T8?>IY@#U)U+-#RH)@#$
M/SP+3B +V!;A3;SNEGA1(1/N /[,SOC?G9@37?I)$#>.#[<3SXY-Z@</#Y=1
M$*Z[]VQY!NH#>NPRBH1%^#AS(R('/ 4*0'?U,@A;U*KW(F$2%!EV)[G+,WG^
M>^_E][H9"WOE9;[4>@\@$2@)(D1HD"!!? @2XH/PX,% _X$.)$!PX("#BA@S
M'AA0<<  !PDJAN08$B-'C"4'A$S@\0 !EB-AJMRX,@%,BS!K?K3)LZ3$E1)%
M&K 9]&7-GC8C(.VY4RE/IT83.%V:(&K4I1%>$B 0H2N!#B%2I."BHJQ9%2M8
ME$W!0NU9%611?,BJU*E2#A$<#.!*-^O+KEX!2P7<=3#@#A$0(^ZZF+%BQHDC
M*^XPH8/E$"C:MGW"@O/FSJ#;JN'\1,UFSBA >.BP^D,'$!U<JW[]P0,($!\^
MP%;-V[9MUK M!P\1G+7EXR$HAYBP?/F)$+DGH(!S!X[UZ];C8+?^YKCW[[>_
M"^<@'CQY\2#.'S^OOOSQ].7;N__O(!_]?/?3M^O?_@:%]Q  ;G#""5D,6. )
M$U1VWX+U648>!_ U2)]X*+RQWWXHU*=>9IIUV%:&$BXHHG>NN1;;B9:M]MI[
MQ>F6&VVVY9;;"!_0:.,(.(Y 0@DF:!"$"40((:000^"@A158C*'D08HH,H@B
M@CPYR""15!G)))7,LHLA4W:)1I=1=BFFF(1P6="4E$PY4)0.A6F000/Y0<A!
M#+6YR$$7:511GGD&E=%))&U$$J""<F2H2"BI5)5+3$FDDD<Y.7H33S]1F@ '
M)7' P4]!+=4I55C9]!=2=57%$U=5U87J5!)E1:I?$9RPPEHIF)796[BZI0(*
M(=15JEW_73E 6&"^\M457E(U-NRRDC4KV6.*3> !9).%H,)I+)A&VF>@;:OM
M$VFQD-I]Q7E@8HHB%J<@;2MZD%QE(# G[W,A;) ;"]95MP=U>62G'7;^E5?<
MB /35[!W#XXX7XCML><=;!HZZ"#$]T%HX847OE'<!A,82& 6!0I(G,+BU9=>
M@_#%AS (&.N787 -@^#AS"<SN'!Q!Z=KG&4)\NS!S\+E9JZYN:DV @@V?E#"
MC#F6P*,)))@0Q-1!$'D$%%=DK20:@BBB9)-..BE(E8M\.277#GTI"-=4CNFV
MF)%PJ2:;!\UMT$(+'92W() 8!(D@!U#4IYX^=8321H=K!-1)_S09^NCBC.[E
M*$@\/0H2HI9:ZE*G(FD.ZN=/+674Z#W1=96I2'&%*JD#1( 9KF:Q4.M9;NGZ
M1 HE>)#48+LSJ_JR> %FK%(=))N8\8=1JRS/B*W;F'$J=B"!NRH\X1EIGG6X
M;?;::I9:]#M'_QN+XHU_F7@ELN9!9<O%"V"]RS$W('754;=?O]P%E_-X-J?\
M'<,J&Y%Z$A9 ]_@/8>\QF,DX4*&6Z><._GE7QPJT I"%#$$V$Y'#-.B_ S;0
M@=9A@:;B([.9=>@V$:O8_MYS+N%\IX6[69$+A?8:U1#M9TE;VHV:UC0-2,T$
M/Z :#H9P!"U<X0M'%$/6L*!$)3EQ#/]>@U+6!#'%NM4-3F\:TYFFM,4WM2E,
M:VJ(0^KDD+\=1",(N)R?&"<20AGN)"QY8Z)0XI/'$64F,F')3AZEJ)D8X"4'
M,,"FCO*IGP@2D#915.>00KG/0455KJ+*ZE#%E0-,)2E_^< )SI*"%<P.=J!4
M00D08Q.01%)5F/2=KR(0/,(DI3"$^4IDF*6@Y"VF,HDYC@2@]9]K>8@SW?N,
M]<*E&2ZT95<Q#,ZY8',N\04'?,Y+3OI<V!SF;*":S['7"N"P+_LYD 4KY"#!
MW ,A#4IL0B3,8,DTE;.3I2>&KV%G!RX&PNN\H3D"^AC(*DB@]@F09/]4&<OJ
M"0<1(O ])O3_WCL!RM"''<=$YG,>;%:CHI\-S3<VE!&-:J31'(V@!#L"J0E&
M^@.I36T(*"7B$*UPI"\@\0ICT%K69DK3F6+A"ES# A4'<04XM0E,89H3W:SX
M13HAA ]D_-O?$N  BB!*3X<#E!M'\J<\0>J-C". 1 0@$JT2@(^*6HE'6I<3
MU!$%*(DDR@$P12FV9FHIC?S<ZD"'E;_\I75;D<KOF/-)6[UE5K";G5P TZK=
M+64QJ0I,*YEU&,.PTI;+LDSR)."L:!TGE]Z1C+588,R9=78TV\)6N$PSLH9^
M!U[N28YR;I,@>G4,?O5BCA?N0%MN/A [_8%0.05&+O(<T#X3:^AN_^.CVY*1
MRX#\8PT'?K9<W;Z3@=DA:!S4@)L!Z=."*S@!QU1KVI5Y]YSH7-@'00@BW9J7
M@0G]$#N'ZT)R.A2Y\*VA>!3DFM:\IC5 (YJ,.*H;C];HHSL:*0E*"D234HUJ
M0Q#2$8Z !"U  0Q?,.(7>I #*UQ!!UG#<$VQ$ B=!N(A@OAP4:WHTR]>X2&!
MX$.*D8K4HJ+1(HDS24:H&A1 Q;&/,F:<'BNU%4X=12]Z491>)K>H2AT%*1(9
M2D@(H&30D154J]/+4_ABE*F<CB@1>+*H^'JML@ 6+6CI*PJ^K!9Q@2#+PG)5
M89+URM )YLW&HO)C><=8R,S2SK-<365P*?_97$X@,<ZCZ*TXFUYAF@8TAP[7
MN':FF_;*!CF0/LZZELDS>3FG8P/*YW-H6YWZM4R$X0PO>X^+S@W*)T3AY:UP
M:[9.^HC N9JR: =$\&H0O%H-=M#/OZ[SKSC<<P0;V !V]UF@Y03T?\ %[\+*
MDY]ZOLR=$$I/H<55W%,;D#V_G4^HVPL6X9@K1;C1#3/W2VZ.?I1&)=!1"300
MM:A)C4<D"$*\@S # P=)"#DX @Z,I&\KY$ '+@CX%01^X9IJ^ HW#03"3WSB
MGPI"IP>!N$,@LF(6(Y7B#MF31BXR9(W@V%$P[@@<9_(GD+,QJT/IHUCMR$>0
M/$JKD>+Q66MB9-3_;22N/?G4J=K\.;>:RG0]7G,$/H "7'FRK[7R).W6LIR\
M *9U=FESU'FGU[[@92O'(I9CAM7*Q]AR,7U^S+0FDTM 4V9GL=EL:+AEFD.O
M/5N:"5=I%;9"[J(H02# 9PBLBZ !R9;3M:U?-W$;L&6GFD$0\VUW2ZW.]11L
M@,H>X,!>76OF<D $Z7GUY:?3:XS%X?-V8$$)""0K"X*,0,RIF+61[2!4ISIE
M%!NO \M[7O06^F609_SAU[-X;GN'OL>AZ(G2)[3]]@9'JE':C9SF[@'/^\#0
MC[X0JB:$?0?\^E9P00YR<&& 9QC#&KXIASL<8BQ W/Q4;)/"4^P#'P1"_P<6
M5S'&!?& C#C53U&5<1U;DA+'&2Z._V=CF",Y>I03D&* *Z%5.F=D/W$5@91(
MB\14924Z1M8ZBG(5<U4JI*(Z3$5TG;069B$6'^AE*U!TN!("TX)7P4)64R<5
MCI5*CA5+@!$\@[$JP!-9=]9GS0)VS.,\9/<P'$)HW'(:P#0S;M<6(R-- _-H
MYP,>D%8BNY$@[W--FF9=64!;>Q!XWJ0?&B,QX?$PH_9=[Y%""N-<W%9<] %
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MZJR/Q#I)*#&RFNLD;6+2S2X=\M(@BY#4DJ T94+[(2X=NO(AAQJ22*(X*YH
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MG@*R4Y[;R@\$WU//\I#'ZWUVL_BJMQ__M-VY_X(1S%SU\BS ./J#'3 9528
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M=>RLM/N8#9@ &]R 35,.81D+7^H_-)./R\B-"= ["1#" 1  51M"OW, "(
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MDQ*]F!J;+RS)*-FVG(0;.'DP@9B;,]I(,'G*G>JCV2.3W;NC=_,]DDA5$ON
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" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex-99d3g002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g002.gif
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M^O3Z_/[^_LS,S        "'_"TY%5%-#05!%,BXP P$!   A^00!  #] "P
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M=O.$!LL$K7PP>_ %="Q&+-1"5L1-=KN$]=L'$Q1+S&3)FD0WSG0P_%-+!Z/
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M6H#P!/#<!W.%![#I!-A>_;9C&@8''0]N?K#OW>YR[X5PYQ[?U]YP!Y"';S"
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MQ&%@UUSG$WK=FZ?<-,IH#::1RK9@$3@ 1:P&@*72:RT$0%PC1%_S3?91][Q
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MS8S<$T!\DV?@%3]^WQP<&)  G,&#!&H99$" 044&#UP5@&>06P%P\A@82-
M00)^K0[(XP>.P"R# VGE.^"*WP,%+PEN(_#-(+@"W!S61)"/WX(&_P;A$:!%
M2X "BPRV.90IRZ#,5M\(1-VGX*A!6@3 .6#@T$&"6CL-[D/P@!^W!@H5P',E
M8(%%![,@(BT0T2'+B&=YMD5@0(&# FP9=(57P"6X!P@((."6CY4!! P6$(#'
M:FA0>06H?OOY( '1A[5>I>2WU8%#>0T*(&B0X,"^608V\L.<E"J_J4$?F\9:
M2R?/V[GK+C[P]!7@H"N5!AWN,+D!E_R^PDM*J^: IP[ )6!ED#-1;F@;=.77
M0,' @K4.$'8PH"#[@PN?RD+0VN "_@91(JHBAURQK*X!OO&)KP)5HF4! P9P
M()_PY"N@@8%H"DJ6 E1BA:$""B(O)?$XRO^JK806:NBY?!(HX"E6B&H%@ ;V
MX>>5SOB1Q8#S+K-(%O9J["NO^9YZX!6T'@K,(1U5:F"!&A>C"C/?$!BOK9T4
M-*@![RIJP &5M%2 J&\&Z+$BEQPL@( ']GG% )7V2:"U*;&*BI]:0AK@0H=F
MT:BJ UJ1*<2JJEQ2(P;^JXBINA*#R@$%@G1SN2TG*W0@69*Z;KT$Y)G)H.).
MA'"!W)XKU=1344U5U559]:V6C< )*1]7#LA')@94XDVW!58"K2I:P$E-I>E8
M'*^5-WNJ11X$6OF4@,D(6JF6??(YJ]D2[62E5H.^(<[$',%RY5FB2#I)M4ZO
M96D606L2DQ\,6>+_[LX![#2(M!K]ZZD 6G2R4QY:2)7)2G7/ VK3(%OAL"RB
M\N%J.GX6<P6<B*HEP!5:/$**EF^BO9*OGO(Z2\4%$(!GGTX14XPQ>&JQE1L#
M'-AF %F(D@6L#7.3Q94H>^6FP-R^^D;8U>3D$R*B*LOG.(D8$%C?W@QBT"L$
MS^-)1^1P72NM6KH%Z[G/0H3'@5H,Z*U3!^"QSB"\M(ON%3]7HD4>$ODI[TJ>
M9JN1Q2\)RN<R>?99K+Z;!-\Z5DBI_.^DSJ9\R!6B:$'0)SO=E(<;GN1YA5X'
M#/@FGSB;+OK=![C9L$-.M>Y/3&:Y?79B:JTUE0'$VXIJ&PM;LA%N!THV_\#*
M.[]!"<Q79/&+GY^3/4_>H)]C4K>;H)-R++78PFX ;HPW%TQP8B(+\<)7 W8;
MS%NY_NV-9&IM 5[K; LH>6090--^0:;Y@$%76]^A!PS(![,:ET6ZO+P+8(\B
M"DM8H1*9;<-OX[E4/@QP+1;ARE/\* XXHO(O^K2*@QWTX <](QMPP(,!"=B'
MS5YE@ ; (RP *$A"/,>Y;<@E*T-K7[$.<AAP? ,!<4% A@JVCP.L\"NS@,?M
M!M4^"Q* %3M<CCP48!9:0 @<K7B6//""@'T$B#P%V 8X&A" F'CJ47J;R3X8
M<(!:U (! 3 8@ RPC7T8!2E*B5,"N &/!Q1 2?\RV0L\W@*/\]CI+#LC6VL<
M$(!7P.-(+8MB@ARPDZ\ ["R86@XXP+&  XCM %]<0  ^!C$FRL,Y6V&(7 *@
M/I7- BN+Y,8!6%&+F5D. 0+ Y&$$&4$(HDTT7]0A#\64&M,4QB&:VP8I"\"A
MI>WJ)']T  "@UJL'[+ D^2#3*["(+-V,15P PXLLG/,<_F$O(8#<$3RLJ"RU
M84<SGWF /'P"GF]$<6Y6TI9YT))(3(FK909XW'*T\P  T.0!!YB,#.4R@#42
M8)&O2&50&IF/]=6(&P-PA3R^D0 !8&\O!JG<.!GYK+=\Y!5T.=Z^Y.*125+&
MA D#6/Q>$2<K%0QCLT"E9D%FH2EV+O)V#X#'92CC$5D P*<8HTG"7F4S66"E
M%2P#T6<2*)II9I13"TC -S(J "49Q'G\_$8# ."2A$PFC=S@A@("D*#H/,2G
MP#0-/Q9F$(2Z0J%CE4=&,,A0<+CBH0-B22ONZD7X?<LW"5! @F ##G8%Y9OP
M^,IX&"" ?8XKBGE\ %C*"!W 9A*4_$C  CY2MKH9X%6:&V.(BF,SN9U%IR!T
M_^UK7\O& QP@ 5'Y1GQ*9QDY*:!9M8B-/,PY6YRZ"QR2\0T#,D0+!,Q6 8I=
M0&^X@0">6%%"E1G,E_IBW+4M]P"@A=A;"@,6<"A )!?AU"L68!IY<&Z("&C9
M ES2"AKY1@%462]M(_G&MAC@ (ZQ$CS,LA)-'@ !\OI3 FB# -M*-RVIF>T*
MX4H8X1[P003F3C[X-Y@'$&4;M*%M!D,B&P4')1^1=$5T500?VJ;G* ^H'H"Y
M4Z#E,@ >)1:)>&I[)^YBEQ5K"@]0E!L?[\XBO:MIP._@\:#/DF9BG)(K6]9K
M&084^#E!-H!WY9&96="B/4_VC75]EX\.JR@H@)QMCO])2. #V%<!\F+C1B(Y
MGEIX^+#^"Q%ZQX2 AC1 PO>C5GWY<9N2.& !X[E=R:(L7&H5J+N\E4Y\OO$
M_E#&,@KP$,#PN#8Q)=DR?HXN;1'5- RKV24_]>(K&'"R@LXV4&@,47$]!V;L
M LDA;2*P"C/'8'A8^D@*F.V&1S=;0!%E%L+>\#XBV5ON'E; EB$)F;U2&HAE
M1H4)X(YO.<7# AR@+-_X:;V"W%UHLV*^$&/O_59"WN46!,,$N/("FB5IWS3
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M#H);R:M97DD!4E5H::MHF^?&U.9B!T H^0=GO^$K!.!"?*T .J= HFA-2BP
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M5X1/(IQE("B_!0R,.F#("L KC:[_(FXCP,WH WC@$#@ 5V ;Z=WP& 38!HX
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MGQ*1EL#>"=27#Z<(/!04+5[O/>@#;>:SP "O;*,IHGL?< !;W& 542L9M96
MUP<@M8\"WDJD-4CI/>175(\K$)0L!7C-0&JU\!E1/@L_#MY$ P!;0 % )>2
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M?EDVVR  U",Y7;$-!6"4&E(=7$$+V,(-<B$W_<$B((,S?+,-8-(5*F.$K2
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MGX7X?K*0O^:7H Y1P31QM%\U"W"# $-<%>E!II\300[LLV-Q2EZ1P'IC  /
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MTXFC)0<:UEQ63Y%!EO$FL@#208$L:)D0!Q :$N(*8,K<;C$=.",\2_39#4
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MX@"OL1$4LXBL!BP@6Q>"S0(:X !%3D0>8'RA5+BQ$J,L((E9D<<"U%@Q+A9
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M6)D%QJICPI>$+%NXU>6/%OEX0*\28!SVW @!3MEH A0P"^<P1"[ZW*5S#I.
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M,CB>4@  8!@O)#T6VZ8"("@#T*1T:3F3H 5Y\*ZL*[H#S#!:L!@,H04!2/\
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M,I9]D6TXRZ" /B/MUS9!+ CA!F=+.Q-,K/&L5@'5M&:=JU:%G2ID#^STTI
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MB-2Y!0YU<![$GXWY0"BA>)M]! \#:-E&"X_#?2-/AS!Q=Z1!_''F';,L':!
M3=,%**QLOMFFYIY1TF)878+N*5V@1IX+K' 3"MICH 1.=IG""S?TB@$+)# D
M/PTT18L!"B!   (.('   2M]8\ WKL'F,,0$.+!? 1F?&5L"""A@ &P])?4
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MF)AR,=&#.0 1>AJU9-$%=81&R$/AN89OM Y^R)=W82$?,1@*EA0K],XW:46
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M FRZ2)8"&OK&@,_6 FHU5P)X)9_:U$/ )EITC6D6G0R0A1L"-E*IH<S"DX6
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M(6JC(+@AW @M9[2B %+"PG"'95I%64@G@'@EDF"PH8 H;MC#;K[C:<X+/A*
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MM0T,8( #G,'CRGP%$"#/ YGJ1!9'!(Z'TVJ)\BO0E,VB"!:; G!3GXL/"(
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MK6I78XI+H#46NM7I5>&*HA2G2$5NI0HE?2G7!Z4%&'"\8@$>S(?!.F.8E"A
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ME4NL.C\4LIDSM7  .-PW$01\(V[RBXP!*(0M0*F8Q?.%J'-V"%%&P0F""D8
MG.HS&AGI);!T]JIZW'0 P0Y%>&19T*.@^ K,S(1WK#X/=P)66=GM<#$\6@LD
M4;L/!R#+-$;!+$I,R$154AE L VWN%L;R%TF "1[NJD"9)'?2C7J%;*0=;Q\
MRU^,$$B&"5B93CK<BOC!=RG6<46QQ;+M !PUE\IJ:'10*)B1U.)?KV#_!0'>
M,K@&V),XT4R +*QTDKJR0A;: <>7#RX ]"Y& =P(Y(@E* L%..^3):F%5QA
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M("@-P!E0=A"&TQ'&I_\O*R0=*^95I+$ LT!#?:029"<+(L*%\[-(&3$?-/=
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M*8(= C<_EWN+KU!V.U1/(L$98/E%Y9I1#D"Y.>&%<BE3[LI3^GM'\XL;D30
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MADY3'5A&)0 KIAKN$U9)"V:CZBLGP:\3E9L2%5;L5!^!E27PS#6RIO M$TT
M\!;6'O'WC5H 74%H8TGJ^>79@6%XDR4QPYT,A#HFBC)XDP^UL9]RF_78L1;M
M40L%-!BNP,K;Z7+<0$DJ?DQX9"'R$J\L)"G4,F=JD8%9,CD_*38$6K*J'Q82
M1C0"$ #W@BC'54X__S(_M;9QM3,>M)WL.DBA$DW2 T5!/C)P2;?B;X(4U";@
M;%3_N843&7H3P1T;(#-HJT0;*:=TT20RUH\2K:)Z!(HT )'/@"M^!1\@X$:@
M5L&"^Q(("/"@80*)_+X1V";+@+R"\ C0HE4 GBR1!4/"8R6  8,&"09P.\"J
MH+P% Q"T^L90YTZ>/7W^!!I4Z%"&\ HL<-7*E:N%\A!$+-B@ 4,&"VH)>+!T
MZ3=6"?+QRQ<3;*V# UQ]&]! JZMM_,"Y4D @ <>>^Q8P 'NS8$)NK@:P2MKJ
M%3R==POF0T#08BN7#/:Q,EM <=$"L_CQ+=CJ0+Z0"EC-.N" GRL#7QFV(L!
M\,>Q#@X0D*7SFP$$#F0M2+!/YZN-_.094+"6%K^1# @<_P!7BT!.?@X2\-.<
M3UZ!5SH3MN6W3P%>!:)UHE8MZR.MY06W%0#'-VPK\P2X^9[5P$"!;>N)&QC.
M;\%4?KSS<1/ @;7Z0N"K?"CBAY4"L^.FJP$J NL ]G@CC#CJ="*)HZX,E! M
M!@)CBR%P4ENKJ0,$D,FHV&;*AZ6.*J/)@ 9>884 >+@I@#D%G9*IH.X\^E"K
MA1CZ33%P$ A-E@8VPZP6D68IR3?)>@)G@.H.V\>5 N1!#3"E!E.@(LTX^J:
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M6BP)'C3)CTX<4 #_6;!I>]S(AP(.\*T#V*PP)1.@?&9!1IMUQ3<)F(OF#I"
M;5QD9IO1(BUJP0"5\&,6 T#881"@ " F( "#*0 #:D&2R8QF ++8Q@-LLC.]
MT84\#R"+\1"(+U;D"% +H(4#!J" !!4(,0EP%VI>0<8M\B-L1!IE*4_9' /(
M0B,#N)%[FD,=WKRM4+C4TD(2@(!:W"T["N"/1C0DF5HL #V0,A""7F$6>"@
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M<.L6C*@VK@= *I3 <=.H%<!&3BDL21H@CR1RM!9:RF,4I3M=>.UC%EBS2CY
MJQMP," ^%$D  [!S+ZPUX#VS8(73'A"SEF2+(__Y> 76Q.L;QH3W/4YIY5ZV
M@Y*)=1=/ X.D T8&'<5H=S@ 3D #\"2+]%YF 2OUU4U*R+M@Y@,>+5G *UXQ
MV0LG@#F,PXUW65&=;3  DJZ@Y<.&]IGEZJ3"#*$%;B"[CWS(PIYKU$T[:T,C
M3]+.D[L]#%P2K*,5,80;(9[% ZJCX@\M%S/P^-P"E(2GBRI %CFF")2Q(Y@!
M#A4L0F; >VCA8WX\(#;=50 XP.&<VHRL%@EPP#Y8EJT!R\,Y^ELBXBP#7_E"
M&"PV#F\MM'LRMS!@.(!6\&BN)(\&M$46">C.%[DQX8+(PL??0-,KKKJ/VPS-
M76#Q8I A_0!:, !/@)/_Q3<:0!@59QDL#.@5D>!R@'S6 F/@>  D19:@%;V8
MTI_+]8.S0^K1F?K"82SRP\K+N]$Y!\ZL;DE.9I$T87\9:P_(X7J-M>K/%!M/
MN(9D*+?15^(<A &O(+>JPXVH4!=DVJ,L<K/#S9$7BXT!']9NG"UBX@2@V"T-
MR">ZY:%J9I<8TK/0S2P@"<D&S,(TFSQX\CK"9@'[IB5BIO:0^.SJ;ON*?:P0
MV+W+K6N.;*/% &XR1]9,\A'FL<I7IF[,92X4&HM0)_OX( ,014NP[(S&FLN3
M='9"8XE+!V/YH&)=G';SU/*\(4S7'*MP#O2A2SP[R9.':7;&<Z)G1X19]PFB
M_YY^<ZOOO.D2[SK&DH<\GH@]3U;W.MS!KANK82D[>0*[YD[X]CS=G.U>[SO5
M>TZOM3M=<TL_C-_A?BBGT?+O^Y!Z\@H_=J?+XA6Z 92@$+7XLMO<[D6G);I\
M4G.XN_WN@3^] Q90<[XG'NI-KXOI <_XG9B^Z*<?^V%\+GFQ@Q[UAS+\X'\_
M?-P+__"GY[KLD??WG>3P)YM/;=!Y;ONU\\3W#?$][[=>>]G/W/O?'\I*%@_^
MP\@B^.1'?_K5#_Y:*"!*ZX=__&-.G@8P!@',7K]U!^Q]!RA@_/('P  4P $D
MP (T0*( B0-4P 5DP.F:!55JP B,OWVH(@9@!?R3P/\G8J,,Y, .], /!,$0
M%,$1),$2-$$G^K\35,$59,$6=,$7A,$8E,$9I,$:M,$;Q,$<U,$=Y,$>],$?
M!,(@%,(A),(B-,(C1,(D5,(E#+K2XT'F [^!8Y7:&\"?X[XGZKX1S,+X@\+4
M2D$HLL*@Z$)XV<*X$XHQG!<T7+_>2SXFC!?(@R(U# HY P=6Z<*?VSGI.#\W
M1!4/VPEN@!\=K*=/FSG202B=V(;WJ"<_@[_V&S!7\+)YD06=&T%YH(6O@$0
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M2KJ0ASKD2D39AG)R-S-Y3,54&'#H25I EGV@J;W,#IH"A^BXN:\DR\XDS(Z
MAV/42KGL2M\XS<8L"B BRWVHP[OD+F2)RL/8(ZU4O6-<3>*XHKW43*8TR&VH
M&HZ0S8&CA6_XBD(1F7RPS)FX(MXY3=\02]><"=A4.>#B';1L2Z0D#W_DJ*@L
M@&9,SCQ!2YY;3'@HI]OTC:#\"ID!BV^P37M2SC YSX9(CN34C8JY(!&!-.5,
M@%:XSX[@2E)D2GR#R]%!3FY(GJ\LF )9S,QR@.%2SK?43UP%O4NZO%#<["VP
M^$H&;;[3+,V.($ZR9$_?4,[9;$JW0$JLJ\J98$S(9#0#&$T4O37".$W4[,ZD
MQ"SU7$VQ])B=>1RQ<D@'5;O-Y#FCB+4Q0:"702"QG!)A29OVW/_0&ZPG ]#&
M=2PC!#" ]'**%:F% ]@@;0I36N,35R06VI",#_(.^2 ,K8()09H/<S0(K'F-
M!V" UUB ]Y(/+F4 CC"Q C" ;R 66ENMG="2 YBDG&@%)#D;F"&.B=)&]B =
M!$B KW&+<;I40B.2!5!3VFDH 5@ WGF, ) ,HQBGU[@2TD"24;TY5@6.4Z,-
M+,V)5X"TUX"U RB ^_.D 4C50&P%Q]@&X#J ;<3%Q.%2+],2!$"24SD,9)41
M1!$C+ET PNB_!+C3/"6 />V/2=)&;AU69DT-HK*G^:B.BW0:"S0/ PB 416C
M<2( !: W,P4JMR#6.?U#9D6 H\BZH>'_4H32K@ (%' X@/?X!B31QMA8@ GQ
MUJ,BC&W0UW%]!0&8'?BBC4(BC%HP 'I=1NT2@(&5"VSE(Y7!4N!R,UH#I?B2
M#EC1QJ&2F9T*1%P)$'DH(WA5UI(%6 806'-T&V81&D.=G?TT5$+9B2N]5%>0
M,T_E4MH))'MZ#?9 F5WE4@2PKKE(B5,EITR=5;D1FG(E@.JH)TLU@,G:BP,(
M@#23AXE*UBF$%$@S /9AG(C5.4VKD%:HUO J5@-@# ,XQ$PUU-@ *$$J /@Y
M#Y5 %EH0TZB8BD;%UFTM.45EUK<)'C-%"'X(U$$]C ;8V8L8)[X]'J-!DC_5
MB4_J1.>$O"YE_X@%6#V/X)IR.4U[NE2RO4'7L$Q[+*$#4$X$FH5]I)C=48^T
M@H?1^C#M@!_XP@A[E(??$(#AN,@J48 [2AI::@#C"5BYJ9B%"*?_0%T%,)YO
M$)H_!4D*$L>O=4Y(2Y  .(NVK(PR0X[@&4](R3I7T#GX[0]N98C$ 23E\*Q(
M(A*]Y:WBE97SB UX@#/K(-\C80N )6#_<X53@J^GDH>$B U:Z"+G!*M<VX=M
MZ")Y@ >P(HFVF(VS -C9")9*"QUNP \$NL1O"(W>@1SM @#K5:P&OKPRD0DT
M01[2G8[[F]&Q*H\RF1;2X @'$( K>QS+6("ARI+=<=X[FA^=$"UZ>__AC55.
M,3K-"RD3K<2-NE*0>G*C4]),U$63'/JA Q$- 28.=$*BY2+@*>4)HR (YZW#
M%*+ LR&=)J(% '  [S5)X:*8YP7B@^A$%+(9[>BM>?+>?J,QU_@=UM"<NZ ?
M,UEBL>Q2=J-)-4&.&MLBUU!.+!*(0247D4B(CL01!*BER[$0B;J_&ON(?-C5
M.M0B>2 )/+DN9"$-PC":^B@4KFD%!RX3]KC('/JD;QB1/;L)>9 +L7R-M&3D
M%GE>3LN15T#?_SA$4YE"=R29,@L ASMBQ-C3X!4 ^1Q;=BL0[DW.G0D8BQ!5
M)R8F*+$U@NT1_R'%,D, E5M?5&T%5@A64/+_E6:JY1M$Y?C,O(;8#MX-(O=(
MB"%12A$I@/Q #+^13$NUG$$J1V-1G*C(#4\J#T 9CF=BWZ;="[. 2=V%%J7Y
M3B(B28T2B$9[S+'])-.JJUZ%Z11+(LLE)@S6">9:1]3RE2WII5J R3UB%=J2
M%'@ S=Y]B]Y(E<5!(.98%4<J'NR(':R!R6VHF5LNE1(F9(SQWKR!CM(PL83;
MG53^:KHX" N+RK@1@+2,TI-XED;=&2&F9P.YE=,$AUAZFV*VZ"F,RAOQBTM$
MW>!9CNF(C2SVB!49N .1";F>ZQR-27$2C9^&R<1!(!\::Y[81[WV$SLS * V
MN8O.G\PHD.(QM#MB_RJ7(,0&(*9 2I,160BQ3 Z%6LQK.:2\\ Z^J)BJB1C)
MK<G#(.;<01J=.X"*T!7&_IQ^SCIUX6C"GHCE\E^D?ARH,FV&VHB'IHJ,5BJS
M+A"[5NNV, SAF8XK60#_0^X1@1@@^MICP1;1..I*BQ+#T)>;&8B+4.CER&V8
M=)F:L3JW3&BELJNJ3J&=Z262-#)#X1:/  X$^-A+#)ZT:,J37,'#UHE)80CG
M&.C>S:9;Y.V+^+"I>9GM:)16J+\UHJ"$W&N=:(#5\Z22N)NPB&<*02>3B"!F
MQ59S5&V,X0M32=+*\(C!958) <G7^!I$@90!T-N=86Z#*) '(&_<6<>&CO_,
M"Q. <6+6YZUPJD7Q)K\.>'(31M$+3+&EW8'J'%%RIR  2V76!F!D8W%6[> /
MAJB- T*/BS1A'!W/T<!NG7F?25(  >BG:L(5/,DUH6D3DOT*?/0-4-$J;\WK
M.Z\EZU#:A[A$ ?JK.AS9JJ+OFYL>5Z!)/==&2/)S?BC@!A  ?1TE?N&=A/#'
M@3;Q6N(D*A\E5OE.T?X*64   @"L@1, XVJBJ" F9_(.U^[60BK6V8ZN;/8>
M1W$/:3;U@J6,>'-+-9D+2M>5LU89JAU)NVEH82^(J@ 4,!UK38NI)3*6 I .
MOH$.9X6.)H^./1^EM5YQ*%O=]<UF3]H( ,'25+7_O*42=?96]W@O"/@VI+!(
M8) IDV^09EI+56Z(\:)=WY9,=YJU"2I'JL6Z[.M\K^Y(*M2I#D[K6TZ[]0*P
M'( &[E?8AEL)^#U%^2?EBTS_JP\K$X>.<U:HF5= X:IP"T>WE"FD<XVV\^$H
M8(/8B(:?FDODX,-\'=-X'L)Q^-VM9.FHI-/\#UE:S]]Y@%"?B9HVL3)K\L,0
M((YV;W(1T^3]!A#U[P&B!1TWB;<QR2YG:O38ZS%GCJE&*K+_FRAI[ZK F*KQ
M:I36&( WIZ/^'$"Y-VK^\UZSD<PB#5?4F>;X]:V!DPGMR4;'#L1"C&<<N%9&
M^8+\C<*FCVA_(0)>;'X__PC"]]Y,+V!]N:/%Y%'+-L@+:?55^9SD'3BSIQBX
MAX[MMLS/?"7Z%H]/2W%LJ0C7+I1^S)(MX?;4Q8MD_Z.FSKJ[1O(D@J^3+S#5
M/<CV^!O%49!]0%Z"OP_,'%EL^5- %^PZM$RN*!OJ3NYX!KCD$?P$,/W_@)Q_
MT0S+6,F 3Q-U"AA$X1]X (A7!_+QVY?  ;]6 _DQY#>+ +B""ACP>Z" 8#X#
MKKX1J,5P&X%O#[G)DP=OFSP%#1HVA$=@%K]O!;@Q5)B/@8*2^;YQV]>0HRN6
ML@C0Y">0EH&B+H,R9"6 %C]XX':V$@"3)=:L6K=R[>KU*U<'"*;**O"MP=A\
MM/\&O,J'@(%)!0/@<2.:+\&"D@P$?&N83X$">/ED#8 *DJB\ P)>\0-7P*-1
M _)8-EC <%8!>%$+0'558-N^;P80*D#(3]Y;>?M>S6Q8BX"L?/ 4(-C':B%+
MES ='/BV;YL!6:P2:*XUH-9P>/M>0V;XP(#OUZTJ7F29[X #V9P9EI7W.K8\
MG 09UHT-#@$KD. 5),CG"L'DNC3=3I\5H)5L!"LM_C;K/,%J'36&P ,RX0>.
M ;@Y]%D^W!0@RU"UY(-@ _LT0-&"FL&SG2L!R+(/-P:T @X!C.7S0 "TR&/
M5;1 Q,]?!##@4T-E]>7  CYE] HW \ 4G@#<. :9*Y+_M43 =/FT L LUS'&
M#TC?K,C*A)_QLT!.2AHPVP/\=!B;3*PL!2.*4"VP0#[?Y1->8 <T4-(" T2T
M35$,943ED R](IF+3::48T,N1N0E OD(U!='LLC4TP+PL2269@ITV5A'LPQ
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M#VM>EP!G.>H! S"<UAHC.9F=*C%7J<66=&@SN/R$ $F!Q_5Z1L5J 4]R]VM
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M!M29E.$!=58T[17\B6R@S=;*H9=':#<#]Q7FVY,\2 1LE3%@U)MN&Y"Q\@!
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M99"(CG(*#O8P_\*PNG3)_]"45+22$=>P]B3&_"RR2^ 3U*@S27$P%5^P6R@
MVLDR/QBM50,.*]=RB7 *^)[C$Q>$>' .*W07=UP>@H3*]MU=5#H88,M'U28$
M;"0EAEB$1<1.?^+S1=BIZY$*-PP%VDD%2CCU*R!0 XT&?,2<Z=T=$4>>24A?
MS;5-1F3_RUU3=;PEP/F2+%YS52IGQ6V$$L7E Y;4-E=%KFED3D8]:F!PBFUO
MAR'U3;9.]A"&KD<D\!EEA4 4B6;\CRPD)>NJ<YVBR<3@]=?5=$1,L#L7 %61
MR,/]XHDH"Z?<66(\29 JHLLN\ET@;(NL<Z;N(&_B5E?_5&FS1HX$Z69<A4$$
M\%FW:7]^QVE@H*",X!0. ,<6BN(V1:'@A&^3B/)TG@,\7E9,=(6*BNEM@U-(
M*6P\A$=H&3>$^$>S;X;M$VX%A[H@J50TM)W>2FH+"<-^<+W=19=P>,B D,LF
M"T9<<,)X$E7GFH[=Q?I4!',2A H/;!<^T'@<A"J&"I1LB[G\_R;58LM=4!$4
M71>Z7+5'J M"@ 1,G$A[!&F2(= XEU$:#505OLW2R,,".&*]T(2\Z;CFGDV*
MQ+4T]VE?='$G_X4I @>T.09:KDEWBLQ:HEK%'HL X(=LCS=) 3I(S <"I'#;
M] B&_!!98D6P:,:TB"2J-'=,')YC, 43.K5,P/ MST_<KAY3*"YO1,1YU.6^
M7 >D#[K4?*)&LP9O$=*O;'A#(P@">$EKR/D+S[)IB$:O\RFR6S@Y[>?1+@RI
M<\3C6$@>:AC'8&:YM,W45JYE@ 0M@$A< @[Z2$P+0<GA&3NFV,_@L (+"<98
M=<T^G"VJ5$8\,D77C7/ISGET?*B"K_^SB.[@K?181EG2X4"%N0).R<2N:AB'
M+$R)V07IBVZ:!:7S:TQE0\OY0-Q&@PSGV]2&9K-= P1[0DCAX<+$"<KS62^K
MLT9-MDC-(97,R^>?T:Q[GWI$-W_-@PQY0=0F8XB'ORBBU'A&7]2"$F.%>R+(
MJ>C=I=2NG<.1071)VTW&-Z F%#:%MRQ/ #!%N45&N-FHGCB*F.M6QRQ QA!$
M50 :^%BF\$ )(QZ/LB%GU>2)*G:);80AT< $P46:E\@(3M!-=II&$_,N>X A
M23F&U$#R,0UA-Q= 4)9(0N1+[-3% 7 #8(]*T'@,W206 0$0):FD)NUUHQ?$
MTWQ#68@/^9[_8Z:WAEL$Q4.H!&U4QUU<WB-.#MUHQBOT#[J'KIT#D )T^B+C
MM"/B:(ECO6>(#]!FRN3PS*33?CAO/MHKVR'Q!31=3Z-<?N$[U"@V"KV'!_:0
MC)#$H#GC\].?!O:+_X8 6XA*).TH "'C?"T$0+U1A@"H<5SB1-+L_#[P-D 0
M2(#   -^\!086'   3A^#_F!,U" 5KX%"AE^@_@P7ZL"!A 4(+! 8[X'!18D
M,% KWX%7#QTHR,>OE@&'"P@@N/A@G[P#LQ[2*@!O6P%P\@R\?.BJ@ (%!93R
MVW=R04):_&8-2 "/&\,%!1K,G&4@08(#M7S*.GB@ ;R?08U.14FP_Q:_5@AF
M>E2@$D'/!G,/<(-'\>$W! <8'% @+Q\"!QN+:N3WZD ^>"H9($@ 3F)=< 58
M(2R(H"'$;P6V<72 4B5: VI7,V#PE-5D 8NW>06;3][%!0@(U-[(2D#864V?
MNMH8L0#J5PCD257P@)_A [ZC+]>^G7MW[]_!AQ??'1Y:?O)HP7O(32.X;?OR
MF8=(=-_#;9+ES7JU;2:_?+1HJ:\P]F1A:3[]^%N.J)GB4X\?]A[:AQM99''(
MOUIFZ4^J;5Z9A;/4(+S0P6]>H<4]#=>3!1[W!+SO/%I>00M"] +<:,(5N8%H
M&POAT<] [=![11;)($MMOA\?@L?$!U_93_] B-Q[2!X#]]EQO0XYJT5 V;8+
M\L?_*K+R//F^H9";^D(L[+V(J-S&06Z:S%%*&&G)#DHCJ^0100U9A"B^#M6+
MS\Z-\N'P/B/_G"50\]($1TL_:P%41.W^3.^;',6<,CMN4..NO"?A])#%2^=\
MA3W\(JU3NS(=JG30C7H4DAL-JQ32H2I'E'/*F19H@$,#"W5PUUWY$5,J$H=<
M+CY7DKTPPX/VA)+"6]TL#*UJQYQ)0B$=[+/66J*\4%)!#W2EHJ6$D_)'^EYT
M1=$+-]42/7<=Y$@^_SCT$-] Z92'U/B>C35!_V#DAAL+(4+OT3)?^>9)TRID
MMUC)E(SQU?$PSEA5XXTY[MCCCT$.6>212299R95*3EGEE5D&+Q]P8D*QY9DQ
M7N QFG&F>1]6KLK9YY^!#EKHH8DNVFB0'1C  9F/;MKI\;Z9R,BG<6X@7:JQ
MCA">A[/NVO_KK\$.6VRCN6)Z[+-]EA!AM$.&YV*VX8Y;[KGIKMONN_'.6^^]
M^>[;[[\!#USPP0DOW/##$4]<\<49;]SQQR&/7/+)*:_<\LLQG[P_;J;V#KVW
M.0:GE59 +WF?);G+9Z;/1Y9'%E;D[/B;1T-F'?7M:B&2H_1H:N]1L\.3YQ56
M=/=35>[@$Z\65F;ANN/\UN:F+I(GI%"6@;?;9Y;.Q_NO7I9G=YY0WK>)73O.
M,99>6=S-7ZY\C/M[_^/97P2==?&\=[F^\E0G'U'Q008\[^1C?^?:CI(T])^U
MA6QYV_O?RL!1H[MM(RS\8$4# +@1< 1&9/EX2EMPAI2H*,L!=?G_Q@&*YS%7
M#$ !T^L8*_ B,FXT)!\&4,YV6M**Y8 # :E)P&->(1-P,.![XV$%"]M7& *X
MD(1,[,XV"'" &X9L&P%8#$0:D("2-2  !O B 1@ NGS\<&.?Z5G+7&$  1ZD
M $!Q '6X\X &8,P!"0 5 V2V#P;HD#MD% \M'% ?!LSQ8S#,AV%2^! >)K$[
MX"# &3W% (W0 CJ#<2-UX"')E'V#B!B#1P,T4@L$%!$BM2@ D>311NKEQ!4.
M>,PG&1FR5E0&;[.<"3Q("9$G[0,>:_0D 8"2,Q%ZZI%2 4<&-:8 @X ,ALB$
MWS&'J4L_'8"/N@3'3!! '<OP@Q8$6*!X_QR3O8@LD3N?">9W7F& 7':LB@&8
M8A9+EAEYS#,K(US.*Z8(GB?!HY@S2^,:^0D47'9''NN,8P(TE,:+N6TY3U(
M(</S@+[P@TL;>Y(A]W%-Y&E4/&;\#C<(D*.7\;*8# 5I+#UV'(-N!Z2I&>E&
MGE0+ A!I,&H9V2N&<A[U?(, W!O9/^]V0@$\0$EJ^88K:C$;$\6$=.=I!2Y;
M08L&*, 5V:'@ I@%27FX8@$,D(5E&G ;F^IHJ@^PT#8<L( ':&0?,6+%=, A
M"V7*:1:RX*H#-!)-;J35K/D@3@)J 8^G2F46#,!J=.01U:DV59>T,.Q@5V@
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M4$AMZB25V &TM!L\</**?,2$)EII!0,&D,T'#. EI[G/<EFQ[-IPB@&O6$
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M 3V-FE>/J)PZ]@?8S/_.1P.2S0!N3(>;%Y=%TJY"1EG8,)T0U6 ""O!5!@@
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M7@$ 3GD;!@!VTHDR(R,]5[*':.':4NL @H,6]N)EZ'<6WU)I6J6GEP.D>?H
MU*.'(\Y=QG0;A+H58LP *-,:MX&>KZ=XCQ0BEEA*I6(U0EHU<?<XIS)GK]DN
M $"+J$W.Z'B,#D#K/H)H;?CB-AJ=W^O@-DL E".C >ES77>VIN]JG-/_EIJK
M;5FG@[BG_[G6F-WCF@V)4W)LZ_1Q($QK )+T'7]BLA/5;!'9(*1P@RYKZVIA
MZVAAQ[!8;N67=*:*05@R2E<BJ02:C%*V0$P/EV9K(P*NJD 9&4UOKMNK !Y
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M5 K.TSZG3,MAB:'X,X-6N\(*P."XTA4MPO(JM:X,"." =E5?71 \KS3  .>
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ME06F/:F2E;$"QP$Y][&[#J^H S@J 9XJ "G!PY?P^,9)8=+!LFKI &_B!P-
M:-H$S/4 WR"8K/[5Q $8 %(RI2EQ^;$ !#BTA@;(6RA9@;:9("0?"E! U!Z6
M$&-F+IG"/.L"\@$.4AHV 0QXIXUN]=JJGC>QBRU ! ^(G 4TX)"D^\:CH@5*
MYE]4LK.4+-Q6DB/983X,EJ)<;M(80$X&*!<\K).'//%&2:J>-"+."NG$$%"
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M8L)1,[,T\>(*L<0*%S(2&1A"!C +W+!!)893K\!F?_=*7:4Q->8PVV!7$N,
M8D$6!$,=!%!"6G83_/ *U>< U]=U ]-D"! H"^ BC!$6;2<0\J0Q#Z   V!
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M5LI)T>)UX,H(./Y$)@ TH#):2:4G+S.G?0SQ&TK<BVA>(<<SBJ9CGC' CPS
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M17^)1I_S0V?QMU09&\(+(L^EL=+V_U!TVTQU4?]SS^ 6I7*.5)^((X/ICGB
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MPR9^W(2)52M-1" HK+)@,'=.LQ!(^\DZIK"-/J&RVBNV(0 #K.0 !)@=[A9
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M#H%K/R_Q&9WD7,!$RC/@;X!PJ >H"2@[%U '(""W*Q5(NK84T/*:SI4N?,
M^"A!^\%U/&)3T#8N\F(E>9.U#7UD8\?R@%"-KA7;D)$,E4P?62I%J$X%S(0K
M3!U<I<ZRIUHF2ERAV?^*P,\IVI&UC$0KD=$HF-3DG?2T"L57&@U&%A$ZDUS%
MYK:23E<>29Q-:\0C#Q0[@&Q,$>[JI,IGE,B85^QL !K?++UDUK!-)P$.ZS*'
M7:8 C&KP)'1CSUT+3HNM?*:;UK)G329QJ2I5XYF9<<'CBN;0F:'[W3C'>89+
MW@@  %]!R-00,(O^4$E!1T*P?QL@DO[,HC0ZX8J-2 /+ES<1D$=9HGS0YC4:
MLRV'HZ.2AQBPI=,DM7<"9$5Y5H.?@"FEK!0IJP,$$*6O)L";PW3< !P@DKW)
M@Z?,0PH\;CY?@?4G0#WO'8SP3&GV]LE0R1, E<IN$HJ<Y")&ZU&>3P/!KZS_
MK'61"B1PU+2=3;$2@_AIG ,(WA6CP9(W=#F4 PC91]\D>DX8Y#!2!MH*#@YU
M:&7YQCYH4=^1"&RS&C'-C,6F':$<(*J71\Z6O"4N)\F# :R9Z1)7L@\VHTA@
M6YH9R5U2JO0D0/A.MTB*)'(;IB0M(O$22@*\'1[K=#[K(VMM#04V_5>'J'DR
M096M(463S[BB*R;IHXEFL?/2% O8,\3H^G!/'L$@F^]>(V_[$A4J5G"(X*#1
M22P):AD$WFB$YUA;0S&8I;R"J-'5M,S4/OB$UB53/CA  ]#"3!C0NGU*]"7&
MNP%2%6U9 <#)V&G$ I1-$X'# 12'\@C,6G#(9P@+_WFXQ#/1R&V<!/KA$0>B
M$:!1B3PDP ,H#L_]WP"4S)9H2BI%S@VMU/@0$0.<5\=1814VA6UA!0 (BVL@
M (?%CD\ %5ZMW*29R3)M#%>$EP&H(0'L7!FF"[TYSD/ SF/X'(:!U[D90(\@
M40$D58\\WNF4E9CT8438S$UH4"L( (TD%T(X"J(5@ (P'5YE1T3Q@W( %9X0
MHCY5XB]Q&(S<$"6)24OT"=0,$D8IEBLDHO MAR<-A#HED?^HDE&("6Y V4<D
M!-*L&!7-2,\-DX5TS(SXAT8@P%]MAO\TGDC\H1MNC.(I'=2<87R(A99M8A>N
MA"/*F?GDGE%,TLS8B/\DG?_5G-2<W$0I$M?]1 I3!8!KS1?L\%,#X-1\F<_6
M)=@OS04L+D  J*%O,4>"/40]_M% F0J>7-1':%"H5=^6A4>\0&)LI,4"AA@X
MT.,!T!OXC0X#O!I,#85:55WX.)C %&*ZM$0+=N%\W0J5R(*0P$.O+)$]01K)
M)$5%+!7[T%!%7N30 .!H[89BW,0!(*&9#49YQ8ZJO20Z%8 #P$XP>11=44DW
M$8<:GAL#!*2?""$L*0 _X1&_'$#5&!>\D2 @G2!$4B-SK 4!,$#6%8=C+)Q,
M>*'!),!+K2$'EDKX&$6+"*&I5"7R8*"I@!88D65-Y@,B(L K(D4J)8I86$<#
MO)H%5IFB%3+_9F-^PZN@Q+T@1G4($W*0!2N4&I6 B\FX BMTAD30PBN(IBP(
M1<ATYF<R!66^PA\EQZL0"@:!D4APP^>I$"M<G I!QC982XVP FU:A"O(&N?(
MP@,2#2NLY@IM4"NTPEC$'!C1$-6\@F\Z)P7)0F7:H@/0@F?2T#8HY]^(BKX(
MU@,*8\))% +40BN\0HM$"5R,5GLXCBM<3(!(T'G*FDAHBTM<B$1PIZQYT0/\
M58WT!)%(D'LFV&FRHJBT@F=BT&PV!VHN476FIT8@9X+]C0_5@IKLV$?,0H#N
M)H%>"W!>#&BRYA(MQ*'0PHE!Z._(PRMX)J94HH/6B3!AT#:(YBL@_XCBQ:B]
M-$78]>8[#2ADO";1(,:]>%]WPD/,W2=O6$MVL.<&4<GAM,+%B8YG#&1]U(*,
MH@0W=*9W5N(K/,!J2BA20$?ZE1KGS()M(D>9XJ8J+0 -%:>4=H:+2A5BS*8K
M/"8S:JAQDAUJZJ9&I&B?)HB9YH9PS,)L+@]TV"9B9(=_^N@2=4;I_<Z1>I+H
MG!=T;!&31JA&>"DMN"BFG!=EZBC1V*AH,H;CL&C,-063VJE3\&:F7BF<9N1Y
M1BC1;-$VV"EOVNEC@@3R-&:O^NJO FNP/D6B#&153$2$_8PKX4NC#H2M":L$
M8>:S7D4K\ G,2>NU8NO/-%ZVT@)Y9JM41/]1W4W=MY)KT*A5N:)KNJKKNE;B
MY/',6G@KSYQ/,#V%*WS7M>X#Z;%KR*Q$UHGBO@(LL!)AMEY2P%:)F,P7!QHL
MP+8"W"WLPT)LQ+ZKX?A,C- 2D1RH1HRHQ 8K?Q3J%')LR *-EHBLM+;-R>%I
MR5[K_JELR[KLR\)LS,KLS-)LS=KLS>)LSNKLSO)LS_KLSP)MT KMT!)MT1KM
MT2)MTBKMTC)MTSKMTT)MU$KMTDH/R#:FU5(%2(AF7$FL2(!$RN(7UDK%X8"M
M+=6%!&5KA%3B%MU+>HYIBU2AV#I%:(AM:*RMW";'*\P"WOK,: 69T+8&+=$M
MT* 85Y0F5<P:4S3_!\\,[M0ZKBT-5L96(3>LWU5HB"_)U+\:[#ZP1XT5*WY]
M@^96!;%RG&Y\A5W K;#:#;6>!*<IP#>P B498,=1KN0VQ6=)+I4Y1MERS@'P
MH>WVS%^>B!T&;:KPK53@+M PC&MLK%,X6I4HP%]!!3RPBT$$S.-B[RQYS?'N
M5TI9A7\E@'A ![TN[!\JQ^="KBE9Q?ER7.<(2U-):]*1;-)H"@19'F-V557
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M58)]^0S(XI?O@"M^L@0T<-!0P#8%%RE"=) @'S]:!,#QDV=@_Q9$<+-:,1#
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M:''@]QK=+6":VYA7M1*P#:5**C6OJ,4" C +CHAD*2%J0"QG21%N'- \FD&
M:-0'S0$<KJ?7^J8#;AF BVRF>KVSB>UJL8V+UDZM+DG83&IRDYPPX #<>&D
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M<#5?,V,IHDP!!L X#-,]$"  M(>)>%2_ B-)X$%926RE+J< ^J9IH\)Y^K4
M7 %_4C; M$DAN,Q4+@5C>,==K.7!X,YV<L/\_(H?S!,Y( SN_(A"D4/65FJZ
M8FO"'"-8Z$UW$N!24(UW\N(P;4QA#6 O',AC"^"LF"@N2J-@OV6?5HI8,&5G
M]P(L^0XWC()5]V)BWJ=>\_6F#.!2\I5D5%0!LJL6OH$R<J-$8,A:#* !#H5!
M;-$ TE8!$.(P:X,;E+7"+G(I"HI9P")J@R4XTJ-;N^0;2.,C%*!42M=7.ZD
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MY8XX) &@"<TXU7MAA$*D\YR1)K/*UWQ'Z0&(I'Z<@K*0!ARFPB<\HBN8> &
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MX' J73W]?'A7+G(C'S"F)K2W(4KS.2[8]!$^X=/F,X#NQ";BG3HQRJ2Q 0
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M._E*S/B1,#BQ9M[U'&6)R^X<$B,!TS!1(/,K/)Y5T&YB',,Y$F8!MO(81 B
MD?+($  MLA F'@0#&RC+(PHP<^7&T3NSS61LP5>=:#&AQL)A?4\=12U!(R3(
MRJ[_<=$+44#!2FX3(1%^_+]R&<@APC8M0434R#A5RA])N'H3N2\ O"-X0K!;
MG5W]R\V2<<G^"[6C3;:N@!)%DT9IF%Y9=1=0T22>P2H1*[S!(LZ[&A]B40N
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M;JD;149&"_R=S[T]C_J1USO9'9%!AA,F1GRQ'.^!,)*3A6Y!U2D/-_<\?JT
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M@8%0W2<! !9G<("B"S(J(P2VVZ: MDFEI8 #:%Q@ &IEK:4 P&5I(&];-0J
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M %8T90 "T"%8Y"*+!"!T*/Q@Q0,&>H#NQ:AE"%  1DSH%G@T@* -$(M1Y,$
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M[0$4L!T*_U,!"MC8/AS U%FDKJA870!4V+L  Y3EGPAHP "<"1%H=L4!!&6
M8^H[T;A8<XP6@4=$#[B 5LQUM U-ZP-4A%:$,@ >%;WH-T)L@+K1@@ @'?]C
M<!4 4?YMM!5%74APJ*P\Z5KDN%QA18([&F$$O)4@<28 6PM[  ;(+F(-"$ K
M"D2 ;:CRE;M)P *L=-^$TJ< 2&M% 6;QC7_"8Q8!8, V9#& %JE5-)&F169T
M+ \%_"X?#\$C*S)# *0Q0 !M<<  P,>4!!"-TY&CRNWX8]E\".]( \CK-@1P
MN8,T@#&O_(8LFOD- 1S %7XE2 8MM@\5>=DNKRC 63Y,BU=D41;%SD@!EKV
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MW_[Z"MGWP0,!#\TWXJP)_P],;L=]8+LW+>B71FZXO!6U4U'0+'. CCX@C_G
M-FUXB)3(<N.[DJ;T^RZ=:58,FQ:P&XAG@IQO*2=@ *_8!@8@@$ Q )SR/'
MO:S+H:MAF5K8A@30( "Z';]@,WXC"%J0G ,""6[@,RWS%HW0+'GXAHT0'ZBX
M.L1Y!0-H"#K)!WA#&N'!" 6@%@;P(WYP  3 (!R4N!TCDUHC+@+XAIGZ)*20
M!SRB&P60.,P9 +\R'K=+  *BL!@3@)8B$P68.Z9PA:!9 ,DC('A(@ 8P(:YH
ME3D*JJ[P.LP@-(GPJP9( ,,Y'F'3G5X"!P)BPPHQG\5)07D(,,-H!154*T/1
MB/]6>Q\OHP]".R!9B!VL^Z1"RS."< 4M&KW8N;3C.@ "<"'#@420$)E],+D6
MX@:*P\,"D(=>\HN6N3H%." O;  X/#FWH(\J:AGB>KX#$(NK6X N_$+848^
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MDNB^;4@>C^B^@-0RYR [];F,[CL^B1&)@@ :>(A(5P@ A&JH]=$X OB,OQF
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M KBM5_+5JQ#*( WAKC@H5A! ZF$FOZK)9"&_C)Y3B$GFQ"B DB4N?EMFA!N
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M;_X\^O3JU[-O[_X]_/CRY].O;_\^_OSZ]_,_OZ"  0CT9L "#1C RC<*!*!
M+:X<,% K!C2P@ $VU6*  @X8\, V!@S@0%@$O6(  PP8\ HX4OU4 #C@()"
M P<H(,\V!"# 0 (#R +/ @$P,& ##A# BF,=*F#@ OG  R")*R6$  (.O$@8
M D\1<,"&\BAP@ ,)'/!0 6$=R8\#!23 0 $(*,  E@C-(F&9$WGX $X%,*#A
M@_ 8<, "JSD@D@$P-NDBC @L(,\W)&J8)$L)1+F C@EJ)DN//\K_8V*7 BYI
M@(1=*7#:8@+<B  !B6TCHX8-.$E; 7T>((!-#QC@0 ,$,) /*Z+.PD^$#9BX
M:TBMV(FF*_# E< K?O$#3@(!- ".::,6D)@"#_#SI@-"$JD8 236Z@H_L@S
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MN;-<9&A+8]F]/L21U1@L=_OX2/221QL!-(" L*K%[@S E0.,CR-VJA%H'I"
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M,,."/K"<SC&_\UP0Q4>D3-+&1 2 *$@2!1I'AK&@Z.12-)-5N ,,0 'P8,4
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M2"7-@E!>3,U8)9FY@E+6A_B BSP@"'T\@ Y93'1<9K!(E$#I1]30HT2F)3@
MVGD@)C^X0E.B1RC=9J:=1]=4S!^EQSNYARM0IGEP%<4HIWO@_^9]6.;4+!<:
MZMB8_90B]1]1& <\;.=V, "%I=\2?<-!?M:L_2/*R$97Y)*K)0\\;)E?@43S
MI$Z)&(2.2)BG[4U!C)% (L4,<8.?L5Y@4AT.MF?XI$Y[>AM!^"5!&!%)85A[
M?8/ ?,3:"0AX<(.KK>1Y'1=(0.9BX>>RA 6-V.-MP .-%.B'DDQ)^&>(K-MV
M2*9X/A;*/(4]YD,K<07Z#<5 R-4V2!]+;,,WK,1VVJ2)WH9_DI2,&@?)H8R(
M?I- P--]&@=_FN"1OM=0H.2R^&@%^J<*3DW"".A'X%=[JF")0@V$XJ<\R-LW
MA*>(WD257N!]*M5V7FB/]D:72::G*9_'I1A ^'@G@4*-BOZ%]_T=^$'HEB9*
M"_T%43P6AK6"YGQ?_\DI51)._QG'/ZVI+:WGVU@E=L)#E\R0>.)GQ^GI$EGH
MD (JC:3I/PTIR>$H#$W3PJ#.E(I:J8AG2?RH8O3@]-'?-/F:CPY,:MB2AP8I
MEL)0D=;2Q^QJJRY9N=W$GR8$B4Z3A K97&YGF+)GHBX1?OD98#8$4B@+L(8(
M."#_ZQ7&R&%QC]JX"P=Q"FG0W #,@G<*1=95!+.5TE$HR'-A')04@%EYE[P=
M  %4$<Y "0(04TB(RW4X*U4"P-OI2[JRD48!0 ) "P.@7+J*#JQ)Q3>P$4$Y
MWO:QS,"FI8+RD&@1A+SUWY9$Q:$<TFG0")3X*TG"!^<PF!8)6:O Q (8#52T
M;"05A@+,R^WQ ]( 2/JY7L#0!@=Q$&DP[,".W-*QR9YP SP@0  <P-[,:YJ$
M:P$L2%),[#Z,2"DY3FZJR0&T"@T&V]':1(+@G5[>"):<CI8HK$?<W;Q0'J_0
M6=..+=6*A, >0"3A2KH^ -C,ZX:D7@#\ZX\%A:_,2P&T_P*;7)5?K!T'D>TL
M#,#*JEPIN0VS0(D!Z),\,%L"7"W=>,E5?40MK-P@Q:.^!,C@1H=F  :&C*W<
MI2V4! 5D^BNEI>[ 0M2_#,D^S,+12D6\A>5):&R$#&S*4N[MW:Q(N!Z.T4;+
M#LG48)9D#M/!!4K!'9R9>!H!"(!9)4B^,B1!L(("?)T>Q8C5#,2E1"X\SE[@
MS9=(G&S1@@2&"=G!X5<Y_04"O)9W&<TK&,K8TB2S.-T-38V70 EI0&;/SLJ7
M(AW?\I#_ZBM,,,M##O#@<)!AL)JYC.VMB,O*;F3/SHOH7,O1$D#=E:X"8 X"
M  #5SH)AMEXI$8X(O_!<0F'TO/\)3-1"_AY7HGA$U#( JP7 OEU* RP=X+*:
M7)H$7]F0C2(5/ 8D >S*(*W2&+5( 0R&Z1#L>\$%B:#(3Y3;A>QHHE@+B2V%
M".T#SGS,*P#-PHC5K/XKHE!/HG %5<H6RX0([/2@%NE;Q :DB.50_7FGYL#.
M#*O'Y,IL !R%9+A-6]&-/%B$1O+*(?\3\=#1$V_'F31R]/"(J@ &D0S3WV$0
M<X!*Q=$9Y^PH+5 MRBRN$2/$;TV.0&2L#\>90!B;9"Y Q%I$ O#(+;="J>#4
M-ZR=W-2(1VB40*;+GT"FFH%*NOAP ]B+14RL[]C@/VTN7ID$/"Z)Z)@8I'@;
MK!V%*TC_3F%\#(9Q!8[4GY3\:*(M3N#@"J,T9/BDC-$PD#P YMX<0 NYR #T
M((D)I&2 9HS 1& TA+CL: *,U-X]B ,<<HM>%@K1@H"@$^"2D]8QFY5\%,&X
MUM0$S.C,2-2TS_CBU\^<*8B 7.>DV&5-!89EFBRPD96 2];8C5F9Q ![F0"
M!2L  )U\3U#X+@J9CM$TP$,[ *&-CD&SPI<P!0",%+/(%FXM1\Z$Q"*[ A"O
M&PD#;<0:2ZQ%3>8<]-X% $I7-8Y\S# MQE1+1MW9<JXU0%9?,E?#)6[,5[P1
M74B<L$=TF_AHG88$I(_X6720!L[D$I?DTL]$;?L,7T=&X=W=_]E:Y<V/CE.X
MJ@FKB26;V(D(DLA07,A-2:]:X!<X3&[=]1VYB9)81HAY%@4"#,!PL=--./:%
M_% /87"(<0B)JE;"3<M[?L/'C%-[FDLU.0GLQ./YX%=/Z @_-,QDD6A$6!2U
M4FLN,3< ZI?,VLXLC=RX/0#Q0.VJU#%!=$G4 %?>N,)0B LM&,@K_#+8G-ME
M]QV $80[V1EG?UINUJ4#)$WTK 2#ODN.9AVW (LM^6I/M<)2B4B$]2:B(,4V
M& H&J]E,1] 8N<)VA C:&,90C*]D-("WH:]D+4E0Q-:(S53*D ;[?4.V,4W2
M+(D#7/;BPDX0TV"!IUL!6 N./*[*K/]9N(RLZL@0GNU#?1<W0JD0EOGGY,Y%
M7;)EOUQX0>@WRN02-R ,4MC@B:&3 I27YMR3#\>F>=&("6[G-Z!5^FDVJ[D8
MC@0@4M!"%;/:S(3X(472W;V,AAK:!"+%I_&-[+VJ?('W-DQN[V#8;,#1FKTK
M5'?R3$4-H/516=R0#;U">$_:CM_3K@V)?Y99HIU-R.03XTT:EB5Z+>PX.M6=
M<3L&Z5B2M>@V2!& 34)1;"P-SE0&E7$#/6_)04C@%-:WKUP14=C:&GUNTACU
M2L#:GL $^IB)HV2=22L&LQV< -3=N$4O2@QYJM-,"29(F*AV:;YPOTS40" S
MC1I MX F^NS_2LGL. S1W.=F6LB.TD82T^8Y74T7MW=G')3,E\'AG;SC7<1*
MDH:&;U3IM_%81 '82"2)[TK4<93\A  <W(O@&&#T>U6BDXV8RX946?A6R3L=
M],%]2&Y6TF\Q.E,0#&26A'XS'I1M/&C<>(JD1@_U)LA1NVPA\RY%?+Z5R0"P
M' R1BJ- B:JL- %4<;Y1S[(X.57YE2.1QENH>]TULTB,2\U33VD6P  < .?>
MW8O(3W'[,&VO)M[4Z73_981UT]2KV"S40L'O[5M*E%.1U8MKSL>S</76%=RT
M/'410+\ M&RI#BOD35'JHP4/0)?SV\\HBR EA,3E")'(S$>\FKI'_])\U]D0
M,93+13VHH0[?U +8.UTIO18&&0<[=72*]&U42X_JB-.R+LDVT$+8!_M<0/-H
M;4/8MZPLG P\M95)H\_H%[RYE-)<U,VM@4NGU_(>]4GO>HGHVN1^J?9?9X8%
MEY*>=0P!T)X5QLAR"(W<8%A/D/"/_HR9[SJZ<<E,_%(R0NVPPY.\>=N2)$NR
MAY*&K>4,+0".AUBX2HZPS )^C<EKE[&P/@"L8'3*H)GM"$4843] Y'.0@%^K
M _+X)7Q% %Y"?O ,-,BG ,$V>/ *R.+78,%# PRXP=LV8!NX;R=1ICP)+E_"
M603 .625H&6^ ZWV)7CP4!Z\6@I@RD30DO^?@Z$Z$]8BL$U>4V[RP/6DE>
M. 0/\C7]!FY;@6\)62'@IS3F@P*THB9PP,^5@98.%NP;N,\ES)ET;;9R"(X
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M6D>(%@.V<453_792X/N6Q8>H_(_A6A4V=%?DM3P)YB6- XI/0J,>W?0)*@7
M2>T.P T$P*8H&X+7!3&800VNZ 'T*LIR")2=6JR.,@D82BN&M9&U[*,!!WG9
M 19@@ 5@+@$$"(ZN"+  RK"*00D)F&X I  36O O#AB  2IU -U0"CVT*( "
M*(. N*C'<*V8GE5:]Y&N+0 _ 6-.PRB2 '! *P$-2( )Y>&*%+J* &TD0&_
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M2$RBH ZO?) 9Z8O&N4,27.SX^1SHBY(%S1=E]46-O<]9#[NCX-%S5^R]%:W
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M%" X:DH!&B#5,H4H;*(VN $^<M%-7%$6%@ KX,&*&&#P1&\?:,&,%L"6"F
M'$ >>HM 6F$6-$866F)QQ$D66L%TT"D &" FMH&O'(#H:L$59$%CM@'U:I$H
MM@$^$J 56J*X.G$;I"9T6"$_QH*O6*$S&"  $N#K]H$8K2HF5 ,SLJ0\&$ C
MP '26-$-6^%K'. K5'$6*,,5C"Y+Y*?^X*$3'6 61A&5U$@C?I$VW"H4N:$!
MO(L56,$ I#%Z&, 5H$C^ND,6_R"1%N3F&BE1P""-%1K 4&J.,CYQ9AP(>1Z@
M$UGR+R9R 6:!862A 1A PE8RI&!&-&:!KYSR= 8 *_+A%3*1 =SO)C,Q$GOG
M 2"M%>KF(Z%H\,8B%%M&Z@Y  !K KM3#%!-C%W%C%5OQ_!(B%L^,%6CQ68#Q
M7?2R.[!&?8!QNLCL(:%(&]WD%2*G%=9Q 5X!+V9!AQ;B*5DA,;[A 1J"%BCC
M'#O'\@R-%=:1%1Y 521346#D>B3$%2ZQ(;8A%),#)=^/%F?R,3Z2(EG" 0(
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MHJ( 5'0Q2$,>*,(56,%/"V)^K@*D;"CH%(@B&@(#JU0!KO1#K .>[H1 &_)
MWW0P;,KK:N$EF>-4+),!4BH"150!1%)=W,1O2-1$491/5)1%G_(U]&2,ZB@S
M^294%@"[CF@!9'-#JM U'8BSCJCO!-4V#&1=8ZC/7,%/V\)=+E46%B,^7H$N
M0P*&O-%2 L@3V4( %.!$:09R$J(M $-0L:HJ;$06U@2>'*8K'  G^09/*!.-
MOM/9JG%6PNLCZ.(E3(Q/O4,HOV1[_X@#>?0B1U;$,>9,15&Q=OA4+L0H0 D
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M2GLJ1LA-< J\,A]+LB2@@ ,8?@-.:'ZA!B!FK92'6#XILB*2/-\\$!9VS"E
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M[K+40@ 'P/%6S&( (XLZ,? X0 )P366S?)H5M>8'HQTP;:?0I#2_N6?I,L6
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M P"'/I$0^R!-*;$2>K%TSK: !2$=%?(7QP&4F483\+ 9%W$ Z!)] ', Q-<
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M8$8BR1LJ)!*,9K%IJ*J<&.B7-H&!0_% 5<AJ&I$<C 95N$JA.)B3L'LOT-0
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M!U#-R(.)AQ()5D"V0SLB!4 YH02[\F"WR!PO39*'-=0.!B$ YB&  M((-S(
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MG+6I]?(H$G,],6PT;S@' ' G?_3@ #R=J"P=7E<K?XLUQ8B-W(8S30KLU2T
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MWSZ;,[\9> ".&X(%1P$X ,?9%;\%#?C-F@S/0/C>!>!Q*S!+'C?V40E ;87
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M<IQNF975"OA9F2MK]ZVWB!_MRD\"^$[D^6:-^JL MZEF-;O<2L;ZP+S ?B/
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MRA:>X^14<DMMZE.C6G\E24![W8FPWGQC'TQ"VC'W 1(#N&4; YZCTN9$@ 5
MTR'R>/_%?J*R*I"\* %->I1_<8*@E9CDD@Q$$=/\J+=;C5 B^X@>T@0%KMC8
M]C8YG 4,@5;&K\@#;]A5P$.X(DANE' U"@R8;0A*X:<=;0"$Y==4<M?0 1AK
M@<<A(ZVM]J78;%!+5'D  P04E]1>!6=3LLH(:X+K!7 U1 65DTI:\39V.\D
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M'9A"*E2T%1Q!(KP#TO8O$GAK>^(J=(9 )^"#.NR!!NSE7_H!/H@#$.3".'\
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L%MQPQ1V7W'+-/1?==-5=E]UVW7V7LF\)A9?>>NV]%]]\]=V77P[E!2D@ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex-99d3g003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g003.gif
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MN!R,O1:3OQ:9NAF0OPBAO1:COB2"MB2$NR**O2J#M"J"NRB*M"J*O2>6NS:
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M^_3T]/'W^_3Y_/[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
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MY+,GXG4G[2.'Y#5M@F)M%G%MJO<H>\AM!N5ZX$9?YS9 ^?50F.)0"D43#=5
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M@Y7SKO$#/\ISNN=+ALR#KLA3/,_;K6&0/-'SAW,@!,4[/=0#KGY@A/Q3O!7
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M;WY9<_[1VGK7EVW@Y7WQ4*PM^JZMA%6!&"?*2=OO/:R_%_SO2&,'.2:$+@C
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M/!RQZCYO'<]#ARZ  ?3G2\3"QQ;L*S3G+*"S51JQ[1J  VS#_"I >>9I*RP
M BQ >28J*\QQ^5;P/FSS^L[#(;,NIH*J/;?"[M*O6+X"\#K J-(R]$*E+#C
M!8\NJ)[PAT[L59[N,1^J*XYG>3K_@  \ "TL0 /3 BM\["L @ -/J>\6[S8T
M0 'T<@$00!*/L@. PRB_ C<8J5@*M5XR0(U^ QA_0]-L;&%VZUW& TC_+GW2
MJ%X^  #HIP,LP#[$@@"$YC8\=3\P;QLG )RB*.C&0@&TZ<!B]2L,0&&ZKY0:
M:-(*0%<;Z#>H\#:\[@&T<?K. XJJ*RW0-0/, O[6+T 7YBL4+S>TPH;&0_)R
M0Z+NY0,P-2/'PRN4LE0.@/'ZI8CF;1L7 #CD;2??Y[OZ X]RIELWP#:T @%8
M9BLP-0[/)KZRPBPT-RVH;3D?[7XJ[S94K%TR+RU4K  <:!;#I0, 0&$**3CD
M\CX4=6J^__8"Q+9KUA9*O\(\S$( )$!F#\"YCK)C'G=(XV>*L@(M3&;ROD)8
M CAFJNA-J*RI&@#93O.C7NE>RS6MRL(YBR@X", !R$(6BRQ=IZ61VJ8LH"I9
M&L W@ /Y;D.!QL(L,'8\$&Z_&L L1'@\@,, 5/B%&X3IFNH!;*X_7#3QTL(\
M\/,V[ ,#P.<V.,  =*<^_^H^/$  "#?^[B4 QP)#(\!LQD( M"Y@E[4 Z"DX
M.( !0'CRSL.$3_8V*&\_).I"3^E4LB@W"&E]$X!CLL)3@T-@#W<K-PTM#$!5
M?P.%LX(L)&HK<$.!LN<#",!"/\#$YNT# /JOPB@"T )#%P!F\O\U%G-LHD+P
MQEJE*Y M-UPI-Y1K@I]NU')IU$:L%FMF = "C'OV *"JD(ILN>[L(COL95MX
M8-/V/NBYW!(FV0ZY 1SHQHIE S!V4]?H>!-QDG<Y0\.I*RPY+;2" %CE:LL"
M+2!  &R#G+O":#\U+]XY5(KZ56;HV%KEE#8GB:)U?"+Z/!2 ?H*J >2H9?:#
MB)_K GBKSJIE#S<$_,H"C@-V@/)NGGIKWK9I7'-E<4LS;E^HI'Y#ONJY:W+O
MK0,K6H,H8O.E8L_[7=9[TK8IPA/$A?:Y *0G0$.EPA?F/MS[-KS[A19F \PI
M\7+#V*;GV+Y"84.E>Z[[:SXU+0SIQL[_0LL3Q'V2<+QN*:375LB6JUW>>O$:
MA)X3 ((7@ *X*NH>K2$_M:FV@@'0J*32=7?^NGN2KS^@Y3[D<I#BMF\K=MB7
M\?$20'F>.(,.J +H[Z@F@,T7Q"SPLP"@JF54[P$ ZN=^PSZL[TUP::LJ]& J
M-D'H;'I^PT 7@#OO+(QW<J[J.X,JJS\D@*.RY;N&=C-+^]BJ9:*&>-(3O!(;
M-D$$/4'0PL$? -FZIRN,K66:KL\C+<87!(\FY0,80-:V^]A.)=*OM\>2^\K.
M;U+*>>./?B>/\C<X/$&<,)B2Z4;[O>6;:CR\J]4G9<E;,UY>KX4*0">#@RP4
MJ^5__="GNR.3_S%<NGR0;BI/TVB%9G;8GVNY?K_<QBW[$GZ0&GY#=.N4Q,+R
MOBA -$@P;]^\!0O #7CE;Q^"!?[\M4+0;YX!!Q"_$9CU3< LB \0['N%8!['
MA0T=[-L7ST KB/XJRO+'X, \?^ (Q/*GH(&_> 5>%>168)8K N 8'F U#RC$
M60*V<2/@*MX^;C9?9M6ZE6M7KU_!ALTZ:P W?PX4.#WJTX#,D5A?&=A&]"6#
M!3\7PC2PL)\L!@H0"'"YH*=/C?T27,RZ0(""!0D"7&15$^*KFCSK]G3P$"<M
M?W/!S2J %.:!5M\*;(/8ZH#*60T "WC@CW#66&MKW]1(N^<L M\@[O\S+56U
MOU@&XNGVV&_!Q7VQ&"1 $$ G;'^HN4DUZP^Q \M8$V>=AR!6*P7]:'NGG-X?
M@MFLL?I[D/8C FX"#"#0+SCK_5CQ $Q..%?.2D"^  [0SX "C +.GZ$<A(B!
M!KA!P)4#P"'/GP1<\BVY"\%3#*)M"#!+--+LJF@ !!(<X*&L]H%HGFT:$$"G
M@^;),<=^]DF  :U4\JJ!D"K*BY;?7B*Q.(B.=+ A5L IP#-_7#'@.>0@6H !
MI@C0+S &' @IJWAV&XH;$AWLQ[W.(*HROGD.D.65YAA [9LH/7,@@1AS^\FC
MEZJ,$:T8B^0HO_U<>BD6DB"*I0"#7D0S. 3_H"Q@.YQFR<T?60B(AQ8#"% J
M1U"]'("!OUYZP,"7F-(IHRG]H06V! 3X455"#R#PE0((2" HGUIYS  !OG$T
MN9>$<XFE6<C\<R8%X#1RK:T<6$^6!QX@@ '$!/"RUZ$\ZU&Q"PLZ0">&#' %
MN]4FLFR?5PTK@$4$!BB,K>I^A*F &WO:!C\O!7#%%4;59 5>GU+KAQ4""E!
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M);4A7436(Y^UP&DI!U!,/!8 JP>%$D@6*M"F2M3_J 9\HR5M(E96-E< ERC
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M$!R8)9\")6WS"F(BE260 G211< V\R#  &$7%83: P9L\\T" =!BUP+?<',
M 6X58)]8 SV$W $,<-/59@-U]MDW"@0@D$BO& #:*P;%,PM;X!3@ #>O",";
M*PU9-<L\M!0@2U@-Q&/93#L9@%PL1/I#RP!-MM+0CP_$P\U=Y#$65$L#]2C+
MB*^<MT \LCPWSS8&B#@/7*L!2=A=#X+W0$.-Z00;;5W%LF1$._V599(V$I!F
M3F,EL&!!-;YHVU'[^)377I4U>&9N_KS$GC\,8"32@P?$\LTV]$V*U'8I&07;
M6:.ZQ&26D($H #C5?6F4=U@"H-8  '19-)T#O*&HD@)X@:/  G8MVT!N"&'&
M4#^!?;8  N#$\TH &#6@T2R>BGJ82 ^0.$]7O(ETGFWQG N.3 ,%U@J8!HRV
M%BW@&+"@E<M1!7#  @],_W#!47US )7SU/2>*P;*I0![X"2@$ -C]>/*>P8X
M )H__5A\X +O(3 3*V;.XM\!"Q@*SG=R[95  @QM,_$W [UR6'$&&?7 @K,D
M<%,\"0@TRWLL,= 2B!0M_)[+/P/U"@,$*7!  @ML-P_.G"4P<J@B&7O3*R12
M%S%!"%SH2@,I7?I5J0+2$HNS S4PW<(&O-?*JR)QLT !!1"0P$S[,$" WWX3
M0"HX#!A@0 $*U.@*CD9-K% #8YFM4)CO,1"/73--7, !#0P-&-47 1TF./LL
MT+9D-G-#]0+9&M@/20@HL!MJ(L6B &A9'7 V*XAM0S4#/OD3]S[[.&! \(BU
M0O^  ^ @@%EA52/MK%U7Q<( 8K3X9X"':LDM45S^:-?\QC>Y@G@\B]_%D,T.
M$# =+5SW],W'1256;F$1S:,<_[3"(3]9"$:$=A65L*)IK+B)Y08R/58AC%40
M%!GP4%,8S-@O:/BAB?E>U#>_(<!K26D%J8S"C;N!HV<N"=SR"@ _TK&"  L2
MR0(C@AN!#*XHK9":9 SU(JJI+"(R,MI,OG&<FRV@'_-8@$$D4[4&.& T)L-2
M 4=BIA=Q+0$,P)I*$H  KB$ -1'<'?#NU3G<X>0 -HL'X@P&QSC*<8YTG(?J
M/ 8FH!QE'@::1TKX6*J\( 60*B$,:.;1L7GDY6'4>5C_/PS92.J\:A^'U!58
M0,/$4O4Q+_V@I$O D9)^0 DHF93+(2NSCTQZDCH?ZEBI,)G(/JI.>9K<HZY*
M29V.C5(IC^3&-Q*)R& B4B5@NB,$&^!*2>:R5)-<9%WZR U0)A(YI?1C).M"
M$ [Y\0$). HX?K-,E20SCR_*CO) <CY,?A.4 WFD1ZQ9ET56<Y;3-.8JTVD4
M44:S/1[AS"^5N0]+LM(^SY0+[5Q)3H]U;)5V9.2GN*%'0E)GD'H#RS<3R:Y$
MOFJ81]'G/YERSUZ!DI8%#>@_ 1G09*X2ERB]"2[9A<I205*AXJS+'2,STIN0
M%)A[S(L?77F>!GY4F8%DYZ<._XJ8?4F)CDQMJE.?"M6H2G6J5*UJ4F;1-JLR
MI2RL$!(!+F>PA[B"&^S+JE;/BM:TJG6M4UW)!P.V#UF<))ELK:M=[XK7O.JU
MJ16U:S]DL46'Q;$?L=CB_O:*V,0J=K$$8P4) ]9$BC%VLI2MK&4OB]FF4-*A
M<-QL9C\+VM!*M:\"(ZEH3XO:U*IVM:QMK6M?"]O8RG:VM*VM;6^+V]SJ=K>\
M[:UO?PO<X$:%M,(MKG'G&!G.5C9>\]!C4N($Q*8V5[=@<E![XI47YK)RG.PD
M#',?UCF1N@0H4/*N1%?C79_V*AX5C<<[O;LMND:&9GJS(W:]N]%4&3.?EDSI
M>@/JT/_F!C1>\%4GAGP'7^]&]$/[)0AAD -/N:2*H$IQKT49&=X!QY>X=>'&
M/EV2W?N^JI=#;8\O$^E<._(Q'AAV+I@@NMZ^*C)>X95IB)%#'0+'=X\>=FX\
M[SO3A\(8*8]4,"$'7!GSLDN@-J4Q77-,X+S\\I&NG&Z1@4R[#U'X4U%6KVRY
MHMP7F=6ILY@4+<K%5F[H;K@-D 7OPCP]N#!U'[&(R .R2+"_VDPIZ?(Q4\$1
M"PZ3A0&&,T K0-,  12. (Q."RL$@&?W&( P<RI< 1#PE4M]D!94D@A&YJ$
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M#L"7HY2E 9592P,XLPV^727^S4V =>X^@+B V@#$_T8#*L4 ". 2"L!T&S$
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M$7<_@F>^&'=:8RXN,A#08V\\F8^<4A=7(Q$(($I4LV>-]T52DR4D!(_LT17
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M92E->4I4IE*5JV1E*UU)R4):)I:OI&449UE+)]X2EW74Y2Y9.8L&#*L?K7@
MM+;A@"W)0D\-8"8S#==,!NB)%8TC$3,=P(IM2*\56#P(+1S N&U69AZQ:$"]
M9G'(6[D".JS@_TY%8N$ )+*BF=>DA>OD&<UE?L-$T&Q K;@Q3:R\8B^T(!=>
M!#J5?KRB%7V;Q<L\YH XFNAG>2GF/AG@@ >\@H"N:4U""SJ=![1S'^K$9S3A
M*0M7$(\5\V%F2?<"CI!2J9G]=,6UW+G,:#) .BI#8F$<,E,]O6*8$;G7/%EQ
M3HR5E)G?F 4^9QH+9SV/%;J*Q8) ^@J*&N6@>6%G0EO:S(C$ J"Y6^E1\.F
MEC(DINY<$#C0NLP&.  <KDCI5,1JJX3B\P&QD HM^,F NCZM%0L(3CN?=J$%
M,*4BW'# ;>R*S*$X54_<G,HW',!-67R4K-P:IF;G\0"A?(,5&S41*U^^95D]
M-78F&*/CTQQ04@84TR.O:.9>^PI4!CCV::X@;"L,VQ+9@M2F!)6>+*#3 *3N
MHQ5PC68<+0)4/?%5L169Q6WB0:*2RE6ASIO%6)4+*FXT((X$I9$KI'.OUG[#
MH?^^1-H# ! 8+@E  ,SJ!P, D!&J$!8! = 1 [8A"P$H8 $,@(X_ ^P M")
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MU3,HJ\B^C*@[T#N5^#&5?G@-%G27-W$2M^,[!O *I%@R@Z NY\.+B=B'CUB
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M-:X(L?;'$];5C 5.J-@79'7P'VN^MEM HEEOZ&8U7%GJN1L J/"4 X ROUS
M093 JZ[ON-%J/^%!IG1P?]P'2U2S)Z3%_8R277/P9MQ,(U.UUXU53 X+$Q<
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M  4 1@$+.(@#XJ8C;7WI,+#JQ^) =;7A$8HGWRB ]IA" %&=KX0_D5U16@$
M =!O:[F;4 'P11!P&* !!1@0JO_VL0\% ,  T#F9WP0W*W^T0@ $H)\_3&=
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M("V6^!BSU0B'IR2.\9BH+[]!<BMXG)"UH',Y< 4F  &0YDP-$@_D]=)&!CM
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M$$U!T(W8E)D/G1+ '=/Y($!5G,UG?%@\H)OA<,?7B!<X5-U .%>UX5I!?(,
M?,DWN,\!>*$RQ8-! F19,  $:5?#E([4%- "#(8LQ C7:(W6E%P\/!JOT-LV
M1$IZV-P\6&0%6F#_43A +UU3DP$D0!9%NG73?27;-\Q"O>1%FP7B/,C*+ #D
M-\";QA4$%WH<D=E3S6G-4Y$<3N;D&WUD2!:%&3D -TQA :0'4W9AS=VB5;R"
M9IC12/&<R"#&*#*=5>HDZX72TC6=22$.-V!3 ]2(&2' 51#28M249OQ41A+?
M-[B5ZQ78**Z) )C*-^"=/)86D=%9"N97"+*A/PC-%,(=,S)F*0K !('=3^@;
MK-A:H[$7)<)$.Y*4.&+8D)Q/6#1C68S0*7VB-+'; PB% B"5*EZ7/\@"%:&8
M$:%? >R#+!S -@R/8P(6*&Z&KW7)$0%2T 2C7*:(L^"F+*EA[!4'/.F0_^T9
M!*%I%@2:S:90YV,@ &GIT7$D%C,*DW692@,T *SUPUGMC;)<YP&H8;4)XEQZ
MEC.>#[[4(_/X$==,VP (!6X. "A]G ,1D$,ZEAKVF7[&DC,^A@'@3W&PW3>4
M9D$0)BLL0+141C854&C]SC%!4DIFRF,8CF:LET.XU5;.'C^5&( ,GT 8'H )
MQ/GH)<B5R3P:478<5UHRTGSY&U02V<@PF$*\HE--6+:DU7\69802A'45%FB
MD3/ED?5M5 76U]]0Z%L.2$)R7.X($OT)Q68)SNED"\6\4BM #1[A"B-:A<2
MP\AHWSPP ,Y\')V5G(1LS:5<YIJ.%O'AYW4J0/]Z<9!*0=P&N113S"!JS@3?
MT$>.0E1*U<@\& TF+>3% $!MZE%VK(NHH(IH\94#!$#'.2JM"&(K/IER1A,M
MK=*@68L6H59TI=6)^8VLT08,X4IK=8K[Z6K/Y=YKC%  <)K\B5<L8 @XS&JA
M)8#(((#KN:=O&D " *@;$:5 R *R6IL[5J<5WA1B!JAO"D"G-F?@%5@V?5P2
M><4"9)Z-;&M8K I7/16OO=_MO1+!S8V^>$6C0DEB]5&H(!.Z36>%FJC.D%=#
M+0?6D!,H?MVUU5Z6S9'JU""AIA'SG)#@A!,^Q6K#*( VZ4MDT%P@#=4S_4=-
ME8P/O0V1F0YQ[!/)N=__="FA0;RJ=C"L9Q7 R0Z J$CI<PH:LRJ7QR[%/GC3
MC )C>O3#.O7=6_)4Q3I WU@B,TI-8-JL^"!1(EH=7L8@QN)+9E(8$WV<'[;B
MLSS&-YY'#6J6!='&QN(>*]B=7I#*K.Q=J'%*@T&J2^C+ KC(T;REN35C ;C-
MN/:5N2Z>#267Y[BK,^%:;_Y$#MZ5G:U1 P! 6!"1D(+9 SA+*]0D KR&^_@)
MU80,KE;HA6Y2Q=C42_'2<SD5-*;,^I2GC>@/ ^PMY_I+K<Y+Y\@=KJ07$F5>
MZ9G%HTBHM_8M*[ "Y= /?<(M '0-'K[.*MV- A0-(?F.GJ4CD!AHC=147\H2
M_U@2A,31[-/&V@,(C%X6S**,C_N\X00UC*X,;)=^EW@]A:_U;!(1A?/,U/UJ
MA2M<+#ZY7P79S0/=[_@ RASBY@%JAE."B6YZ!19]4BL<:NY$#N$PB[)LI6XZ
M@'@LRE+0W\H.W9'RDRL(@ 3=+R4YV!ZJ&1(%@%M8$A5A<-8H+)A]H]XV$@BQ
MW2>)&P&XQ?,&, -,C0"<I_M@38/5964-6K7*F5&(U&5^# "\3SQ(#'4HBO9(
MR]=-B]98L/XF*)28G:.Z#2U("H\T"[?\)G&XD+TRB^><DIX1'@X%P%4MSOUN
M#(G>[4LP7$;J+7ALP\S$VH TQ@T]0!C-0RND!\2LWO]A/$ \S )[,-WJY3%X
M4 7"N6F*'/*$9,8^"#)")*T=NP)Y_. K@%>W !H<N=RPQ<69Z$5P^4DBR^S8
M5$>&N&QL4/+2@<DL,,!H;?(C=7)<*)M8F"$MN,(WA')I36I@F*&9  8W.(#/
MF/)A%/-/_+%P?+*.. <RPV=2S(*?Q(,K,$L#7//KS$SU?&$B)T32QDOU;$.-
MO$(U5W-8A%66V4:*V(:#+)TEYQ%7%,4K:$4@Y]$\L )1B(<Z-T .*Y=D1/)C
M^$6*3(<Z[UQQT$(M[S$H@\<W.$!Z4(7/3/1RX A\.H!(;D8L, L#</1*V>M6
M1'.*E/0KY5U"5_-"FT5FT"QJ*Q01/V_7*WQT2-,S0GQ3O"S +6_%-S< B%"S
M0@-D1O=%-Q^$/4/SD-#"4)ST/MP%<P &/[O*66S* A"%)8<68O0631..+'@.
M4L.12^<H*UCTD^3H.Y<MS@1R(;,%..PR8RQT.FOT*\CD'/_'A*K@]"K;M5[;
MM8W4A$"A!&#G=47@M=^I"5]/1&%#A&!'Q.TI(T\@MD+@JXU$=DXP]D-,=D-<
M=E]S=F=[]F>#=FB_SA?>K=")]FFC=FJK]FJS=FN[]FO#=FS+]FS3=FW;]FWC
M=F[K]F[S=F_[]F\#=W +]W 3=W$;]W$C=W(K]W(S=W,[]W-#=W0S!$C)A5P
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M$F"P3[4! 0JX-3@@FMM;N@8BSD-.<L%"AC@KUKPIL["_;4U]:F^E #Q7ECK
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MTV^G[9;=AP&';QH G$UM4J" ;WQ&N2& $6)@ %I^51.A63"J\3.)G4Z(H.)
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MA8P#0&_8_Y@I$%!^\Z,AGH5XC&,AM0A8VRETM3 B/CF2]"( >4=ESH.;/]@
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M=)XK ;3(&CV:L !#TMS0'IU%@#-& ]P0S,K<P($_5I"S+JQ\F>JK6(W]+6A
MVE^L @1Q%XY*>4#O! @L*F@0S\ LTOT4/#BZ@,$L 0AH A_MKZ=FM?,2;'7L
MM6#K>00,8#Y=O+[]^_CSZ]_/OS_^?AO-0PL"!^SC2H'[0,3-/.89MH!*!'BT
MSSX;O8+3-P3$E>!6_P(1U$\\&R%@E$$;E>7/-@D05)UB&-*2$6<MCF4 *_-\
MLP\XKPS@RDK7N;>- [F5]\TV!UT$3BSS3)>5 4:Q!LX\X%#8R@"O.'#:@?NT
MDIM+VQUH7 'Q7-2B+& F).)%0$9&"YBT4 E./ZT80&&&#2'6@ *+:72 8B\>
M%4^4W[ "6CP$7!=+A/'L V0_1*+50 (7W?A-=6()AYAQ2H%#0*5O>8: AS7Y
MTU5D8QTP48T#A&8 GZUUB%0"A1E9 *=5;9C0JA<Y&6<\A<6SX&3%K<1BAHWR
M%*$KP=$R2T:J/<J66^XAY!)##WRZ3S_@;%31140^&=2?%'YF4:0H^?.-3__^
M)+!==_U$%M@K9;)5X%'"BDGG-@4@Z]I1M B@F3_])("8 I?>F"U6,6TGJEMD
MC4NH+&>EY166<*$)660@QBIJ @J8=0 #"WQ8P'5J17988J0Q1M #"BR'TDIB
M33@I::X:&:%H]C'PJ9\&*'P1LZ4Z@$ \#BQP ,FYG=0*H1ZUNY%.)2F9<F.X
M1<8<TY%R$Z9.785)&L&1(L *D7%]->E+D<:R#; 7,9"BV!)'UBA9IU&XKW]X
MYZWWWGHKU,J$0N\#+SC5;6=@ !8].@]>"H0YBT]0FTMGP%MM0^4^\[@=SYDG
M'A35 UG:5EX!"<0S3U+S/,Z90@LDFN,VLL &8 '_K\0S@%WS-# 0:[+L$X\"
MK2/0P#RY0[: 70G:!<Y<1QZ UKE:QB5OEM#Z W=;-Q9 XSP.@$EFF"X9]=C/
M8+ZBD4H'*(5A[PT\R-HL-R+0.J[^.'E45YP1.0M'KO3#2IE7*9!!:-$/613*
M=P+K2:6ZDQ.E,"Y1C]N&A4#5I0+LBU IV0<K B +L+ *'$2*Q5M(1ZJL**!Q
M^XC% *Z3@.&113&J,\@K,*<XMAVE'PLHW3PVJ"J2[+ U!A$A.,2&H5?,@TAX
MPEZT=,.0C(AP'L>+Q[8PHA&Z]0,XWYC=N"23DI7$!6WFH\6-#N  Z$$I?24I
MSP :=[H#A"E)!&" QDS2_P "O.))WVB% +;B"I9@ZP"L.)>&X+8PS!E@:#L$
M$[Y44ZUGO:5(]=N4[X"'&I'\2@ 6Z<E/XL09!A!G=)7*R?FJ)IE69"<!47I<
MC[@U@ 9L!!P/*,!&M!>/6@:&($1R)906 $DQH>LB#D%,+"P3)N7H9BLYC-*:
M9@&UPDCM*(=""RF9(QQ4[D.5Y9&*SXZB@ SM@TRA^=CB^IA' ]B(3-M(2A:)
MU+^%Q.U$LA2*\_IQE2WR[9[XS*?>X 6=L+C'>:THP F-MA45IN@;!$I  4 7
MBQ29RP :RLM%^IB  QR@)0D8D3F%,H"A**8GER'0=?[BFMB$QP ,@:(!%&"J
M/_\5(*07S<K_^HD06L T+JZXW3<+<$BC$6X!*S6 =QQJ',BX0@&1H9P_7I$;
MX$#'.OZ0A1L3DH!Q/2!D&''C$$T%/, D*$(.(,X^DE+1!(2(3X"A5P*""I5]
M,&  K>"&11< /$0>8%9C%>@!$*"M'GGR(SN+S646FD*B+F [1'*>21Y  +H"
M=8:9^5E:D=7/!Y$&H9>946'T2!T$5.HO8:(H @P@QHS6YQME56A<G')2Q5#V
M (T3"@$0$![$')4@WX"-"5,")](1:!OI4<PVTNH0&@&5I:T[2H(L HZ+9F<K
MBB+=93CC5-H2-9M4.<!/)LI!^R22IP0P#4%R1[J59NO_ -)2P'J.>JM#KE4L
M<E6-EI8*F=PB1*;218#TQE)1@CC@?%+\2480 ([:\.1HE^4I-UJ!U?"9JZR$
MQ<YQXA,?CRAD  7(<(;7XY27OG2[RC5MKC I.=&U JE920!#4 O; C@@A3L3
MCNCHI> 3+T?%#\[LB]$D@/N21F<G/8U-!]N_S 65(?$ ZEJ'AQ>CG#@R<N7,
M[^0CU#3J\\I8SO)1OC$+6>SK&Z&AIRR 6TN <:,E"8$=-PH#I4A%B2<E 5!3
MO/8D-T?FB&<NR8J8XC4HE5! 7H[5/F 7&I6,;!NS\!K N$P+1<=#65Y["YJY
M#-PWI5EM#/)QF]MLI#?N"QQS_QZ+I552$D[?"&--B5*=!30IKP%HS'J^RYL[
M0PNUQ>J(:(G'G/U<GD9GA=$>FG69$[(O <TBB\2FE]>&E,9!0\QW8:IS5MXL
MYTG=;2RP4TU6ML&-&Y5ZUJ!.M)&LW)EE\;H\J;ZLN;,6BR=Y.E(V&K=)@"WO
M:=]Y&V@Y(J:#%6R,N9H;L*87Q#AMDB<A6M'&F>I]P%%K7RN7*< %&+B_?2NS
MS,(UIQ9ULC,^[W47YT\:M_>B0\.@@I.;X<3[=*D1'>_Z/#H6XC;2-V:>&JUU
M9ANQ*'1]CDHJ"I5$VL,F-;8A%O+R(-Q()%?YT-=\OR"1II9<1C9/E+4O9TO=
MV=VNMYNI9WW$9VOYZV /N]CS22E]"F;L:$^[VM?.]K:[_>W^$1 AT^Y!N-L]
M[/'PR]WY VH3[?WO@ _\VY,$XGOF?;^"3[SB%\_XQJO]<;%5>Y)6Z?C*'T46
M#ICCXLTW/,M[_O..3Y0^/Z1YT)O^]*A/_=B]S?:OE%#U@O^0Y<\-^]K;_O:X
MS[WN=\_[WOO^]\ /OO"'3_SB&__XR$^^\O^7S_SF.__YT(^^]*=/_>I;__K8
MS[[VMV_\>2"I@#ZNSRS"GY!8')U>KRC]/ K#%+3/ O'%P5Q6VHUVIKS^/K20
MWN+$#HX.XF?_]_$-H:0W[T<:!8@W^Q</2*(W"]8 #P _W.(*K2"!$C@+L1(/
M5>( "\@?\O=\WG=M?.,BQ5% :'& ZV<N [@WWZ1M6G:"=O<-_W(?VU!X]_1-
M(&@? %<?3%%Z6)9":"&"1Z(QWG=^?6-^Q0&#]\=]8L)7U&0?7/)QA7(?^[
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M5'K>F!^BIUR[Z(S?J#%D<C=RJ#':*(4361^1@2SQ>!2'$9'809&10AH+^4+
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M9M$0L+)SYW-Y(O1T:+D :_8 X*$9X.  ;^0 E1(+#V"@Y>$ /?(*#\":\=
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M?<00)2-%VRN@:T$1WO$_C38 3]&K'=&=:80LZ[<  / 3.I%;'@&)MT@O T
MKJ 3]=FQZQN#ZKJ& U$9M ,<VZ$R_:"N.@$3Q2<+/6(0\ ,W/"(XJG$H(%(
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MEATSIB0=$CF1G(<N+#'I,0 1,5NO5Q@?HJV4K#O?D"VW5/]-$OEQKW G!D
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M#0I^<U!R7X(%8PVT],=-0%,$K0IR(\#_+6)<?PP,B'WI8*(_5B'1%IRW=MN
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MH+:!]:8:0(%6'C#  &(/F[!" U[;!P$$G'/I%0"LY": A0IR!0">M@G@UU8
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M.(,9W9=864"SNOHA?RITYW%%4ES1E6W(KQ7_;&L(7APPBPX9Y'JL0$]!"O@
M !+K&ZW(")R2\HJNR*1E&?G& ]"SCUE!"2C5>P6-Z/< !3!@@ ZDCP(( HX'
M)"46H)$+!AO2"LX@D(1?:<4V6#&/;PQ0),3BA@YA=$-7M! B&.Q4/ZH7D_%U
MI!^RD)\#D-B !3S$?GO#GPA=$@\"U,4_,'I%^&HSQ9DTH(6SB(E,K.*6!&A1
M-PUP !ZI=2V-N!%*$73)++K3/?AMSU!7>D!<L(<N&BHR+X=Y %"PYQX:2C*
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MB?U4V2%%U$.1$=19$Y"04;X1+,-XN5D0@*)+BOHJ4*@Q"3IUB6V[C,RHMME
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M< O RPA:& Q:^X_] (@$"E[M\_>M03Q_"A6"6[ @7JM7"N<UX.9O'BL%"1R
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MM)NE6 F6]X*$-WJL-JW"_^,1E=XA\?13PI<!B]H1M^<OK37!)8<!,,4#R+=
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M<3-"@%(6MX]9;(QM$S&: A* O\ =[2N08YT""# JX?#N ?W@QO&.QIOA((
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M$:F;*5H2D<@J03C.@RNTB"L#VB<+A>:1%0UB*4()H)X#_#&@T@% 1"TJ4E<
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MCA&3*0L- ,!")2AZ[/*>3_.\1C+<1 @_0R"\[R @C?$>0]F$KSWP;CM:KSS
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ML(@<89;QVN8U!02E+J/N2&NDVC5L="<!BK3V0K1DL(E8'\ P; ,MX(A)T>D
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M@@"QN,8:P #O +]K'8!$H."5@P*A/\8C+9SR/,8(6P5(X(K! *.R_ )6,%C
M@04Q11LHH'*>@P.N6A5HY4^!;W# A1NH6"!JOP0.'D=V56"!/UJJ'0AXM9P
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M0I^UDD!BJPU TF.C(CS+/ >D:AYVLN"6Y*F8N9)  ,Y:MRLXV#*PY;/S@&.
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M[D<+T+XI+4G7)K]OS"XA#M /P10TD-;!*#2O,(#/?',4!^1E>CF9_X=?9J(
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MB8#&N8EI<7BR^&=78B<[_A7 *<U\9@"B>:-I5A-DP#S1ML#QBJ$(P'L)F-$
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M/F,D.H)&OQ.,*$D1(6A5!R  ;"43M!  >C89^OB#40$9[^."I-1?"",N!3
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MU+AF49%Y/  !!S"0/_YT'%:XIQ^S@-YP9I$]5@2@=!-:  (,H !NS(,! 3C
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MQDRUHS]N4%9.^6H.+0H CF\4((BO*("1,NB ;;S(?0Q9ZW!5LPU26M4 UR0
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MSB$*N(P@@BK1XFB0D6;M?@8K"P$$2P&T I<", 96C'%2;BO>1I?ZZBH:0G(
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M:9$P)(B^(Z#_ "G!@EBQ-]F4@3 YTK'%'!J !@!%^0J^\.J38S0>!-"763"
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M1H=X!>S,3NW$SFTP@+T[RMN2+-SDAFO+D4C<1;AJ$6F,DW I1D?LAW>,FUC
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MF>JF\8B)8(!(_S^,W;QS@A#8CA!D& K9E./3B$BGO%F(W;Q:3Y\)C%N)W5F
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M)]OH:V6/8AK4C*1C![ K(1.2$VY =!\/N>4 S/*P,:HKL>"(JT[V,8L&."0
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M\ L N<+-J.,+Q<LKF$55! F 55T)60E'J V^7,1J6M:9Z=UX#!K_F+1"]#S
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M@$.6_@0A2R8]G_/!\+,_SP();N\=(4LY=TY98HF8 !A'>F)]O8+4%(D!<(-
M#P_[071:[')"+TE(X1J_:(5"7R&Q_,D*[4-4770Y=\T*O;,\/_\T-Y#R]B%
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M"\3)U$"E1L \C ;S5G&@82<!A !:_KX5<-7OP %P_EX1 %=PFS\$!;[% W>
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M38JM7L'29&4;8\OD)I:9'B) 72FMM1"_(P5@!=T!#IQE@ &FVF8 C&.Y,Y8
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M2U5RMAE"-R  "7MB<\7R#6>51K[Y)28MKJ-B^:Y*@-_Q8D$B' ^ 1E$6OE2
M ,0E,S5.-=N/08M:=+@ XE%DR[FA7%=%_0T3)BPU#8'* P)0$CB_5*Y4P].Q
M"*!B+_];T3,& /A\FSHD>PTR+?$FYBSD2]_[%"1B9]['MJ6FW8;O R[&#._*
M6>[*!"+@;SH4W"QB.SYN5(8!.A'E+!J0D7T$"0')JY!>Q!<=M73N/4/1R"P^
MB!4PBF\K58FM 5BA$ZW\RB]%OHHLA-:/Q@0=E>%#  (2<)0MVEL!)9D'&&'.
MBGD\9X_U'2B'%[)QZ%'*W#6.Q5J=HO*CS3>:]7G >^>A%YC#$T@$P%E<5L(
M8VY#?+$]4&X6KX"%4&_JB)=%;'$6D7B4$N8/V$<_.$)VQ/Q&O@G0]1Z[:  8
M@O&7EQE24Z(YO@-,A2<)>!+,NECS@2#)S0[(B*FGOA5SJXO_Z38Q9P"A3):<
M4R4!6VD% ^Y"_* C>"GJBN9";B(?5D#I<V3O*/6_80"))^! GY]Z*U*5=NLH
MQ"0)TA%GJ@XWG!V 4$Q/2 ),LP\'$,!'% F$0(V=VDD!"J  ON<!;H3F$@(!
M(H(!^N,5.@/-CF)!%H\[LB)1O.P;BLPT% #'N$%\@@Y>EBZVQ@Y]E"(\K.<
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M4;#JD1C?4;N@AAQ!2#UN\1H5,6J&L1A?2A5M(IAX"AR-Q9<21B!942VXB19
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M5Y%%G\[4.;@A;;/Q<M$Q?@GW&YPV%F=7>SYU9F;E>3_7<LN7 :X"4G0",A*
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M\G6==B)M1T2U5H7D/#4! F!G^D(_,)CX#L:;X=E[/NN$UT)96V$!?/H5!$
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M9_)RV1^IVC7GN%U/1]"#1,K(>!",CP)@1P6 BX1M0! '0=S#6U\&2B9*"!<
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MS#,8_XNO@%.A/[.4N.4"@H75F@&N6-7//OML PZ7,"50XU*V/<4:4R\>1(L
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MG!)[NXTL*3'83SP**Z#FN"$5EEX#GETYU%7[;A./8V:)-!.(><&DZ9/Q)(
M;0G)ZH^"6$N87DQV'<16TPAE2V:>!0ST(T=Q@N- T4HBR0 "VP290*,*,JB
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M2M-#"\E<]2K@4$!^%  5G_R)*P0H@ *ZLX\&?%2.M@.L AB4I0Q6CP&-LM=
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M/(8 T@,E$;4QRR,EQ,$@D 6+_TP8.R41 $^H96+#B3+R2EYB%[S1$_3Q$O/
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M=E'(' $AG@>&K-&Q%6( LZ&&@P;2 @+3"'$E9PQ12L+=P644I6D<M5,2:F;
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M])C_VD>MQ9N"Z)M$4<0N 6<)Z/%'/2%R %@?#P!'TH(HG0BY)E]A6=>F-B/
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MRE:1K@!&R"&ER'/_8D>; B@@6@EPRRP"D&=#'6 !BTE( 1R49]L6AC<'",
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M8&:?AROH<DNVCWWP4X')-ETA ,?Q\$&KM.>C&% ^!.!N0R*D!0.\*=AY-"
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M<H\$D 57.!,YE)G](H#_5DB3$YFS3M$>%1&T!=@'N_"C!;BU5GB N<@(!4
M6>&*CR$ !VB(LC$2!> 6R;&5'/F,6'B P+ ZACA%6:"9;UA%P1"35E@3Q!D
M@@##$0.U,_H4U+,RG&J5!@"ID1  G6F%TWN%!LC&/\$20=LLEK!&]YL%O;N5
M3T$2!\!%6J00!$@.\K@RB)D676P4 Q@+>-E% 7FF-^$&T> &A.PR J"(R3L<
M-3DCT?N( 7 +B^ &RF,%, R)5PF6\-@&KSD,,%0<AI'&R2BF,>D3UF@%6> -
M7XD'!Q"  G*%WX"9%&&%5]R'YJ 0!0" <-,RKSB]I&JGIYB'82Q) L 2Y&
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M  ,LH"^T.$ \HJ4 !!R  "/13 'T4@#:+:@LKS   Q, CI 8('T$D,4\$A"
M QR%?X%9@$Z2AX# $"!R#1"@ 0IPE <00"\&T)]C K.^5OBC%6M;B ,6@)$#
M(("!1PD?$I.HQ"5"+%K3V@<#Q/+"#<YB ++8AP&.0Z?K!8 !WYB'+ @PBWUP
MPP#;*P!7XH'_ .(0@"YO$1@M"@".>10  0ET@ 'F00LK6F< M//A[AS8E*Q\
MXP!<V0=6,#( NM!"C,A98SP*T+YX)*"%?C$ 74(HHP<$H#3?* "1B/*_5RSR
M&VU$C@%B$:WV]8,5!V ;$V,IRUG2<E']8( !6L&-DV115@K07R]S)$=N"."(
M@-D1.)QB -S-@C>?5$ LON@L.<[# "/)40N=IR7 ^,,5"(A* 7P2C_\E4W20
M(6.=_(''6;"3-\EK3/(<M(]D<D,6@O'' PZP305\,D/[6&,_$N  $<F/%@)P
M!3M=(0 AU;*A#GWH0[U2@ $@8!O@<.1"&J" > 1SB]P8@%I^B90%50A ,7K1
MWS840  ",,!K<4Q@*E4B1XWNB!5__&8K7HFGG,(0 9<#J3\84%*$U*<5RL/(
M48=#1 440(@/4$!-*WK*A8@T%@AD0-AB(8#L$)6A$/TJ6,/_RKC=#6@;101'
M,/VQF&I>,XS7(X!:N+F0TP$F2_-4T3?F&0L"/. FLQA<-9^S15?Z1*/=]&D\
M:2*+O<;B?_EL"5S5N;8S@2-VZ1114ELAQO\Q@';:S"@_T0B2 PPT'@?@'UWH
MI#FEH4ZLKGTM;+'FQ#,%<!Y3W$<5&1:9>8!# 0-XJUKH-$:_Q8).A*'D5PQP
M%-/V]2,O#:Q,P;$- L3B<A'LX=H^Z8I!.L"H$J'?*[\Q@%G,YX/(^:5IXX(^
M2P)1I]-- #X#<,5^I4:4^XC% ([H (KR,B[[X-\<<Q?; 1.XP#M3X?JXTEOU
M2;(L@C. 8!!8QL9HAGP&Z D$ X, YLTY(((KY!A&[!BM#!U0)T9=(0*$*)6+
MC"\P&RVD8!8C8@04P".LB" 1JS(+"&='IS3!8&*P\E_UK:\Z.60P>A1YS1P1
MD<9B:>3K#"SE*5,Y9:+CGGLF5[F/B$YSE=M'7K?4Y2]=V2=D/%WJ-MB/.;HG
MS(ZA'&\[PS'CT4*<V_M?F.-!BPI=V4':V^66/T+G 55NG'_^DN2H!Q)I?D3/
MLFOSX:HLZ4E3NM*6OC2F,ZWI37.ZTY[^-*A#+>I1D[K4ICXUJE.MZE6SNM6N
M?C6L8RWK6=.ZUK:^-:YSK>M=\[K7OOXUL(,M_^QA$[O8QCXVLI.M[&4SN]G.
M?C:THRWM:5.[VJ$>U9;J]39K$^U+V[[TH^(EIDC/>A8-X)AF,F2E>+B"* P8
M(Y<3\PW#*,"K[9I'N^M#F"F!IC* ^TB$6K2LW65F+NZR+6(.@YB[$ <I(Z(8
MB"_%HE9P)EP/MY)!)+*5;LV#<.Z:YT("7I"G@?Q>^UA0?Q+0OD657%SISE&2
M757R6"SYW@TWCI2X89..4RF!YVG7+-#[KO]Z!^7D[HS'NV47Q]I;4CP/2907
MQPH N,T]N;S2-VC<7080P,C[2-\KP,&;A\ +B@5P "L6,  >2LD5>8S' J+^
M$0>,).O_/E("LO3N@_^_J $#*$ #&M *M%:\AP_XMKT:\K16R*@?#CB.N!@@
M(RMQ Z[[."VW;LEV>;FBZB)QS//2EO=[;6, XOEH \B[J*$</4Z8_RRWD'21
MIR)>49&T\>:1<I6+_"M0">#**QK0^DUU4)7O,N@#MK%'!ZC;2HB$?+@:.<>T
M6DKSJ)00XU@1@ $\AZVRZCB@OA[ZN0Y +)%DBFG)(JL$[NA/39N4S]T3M;Z4
M7MWETEW\Q9;'?ORO5_WOS$70R3;L2%,XB'<A1Y?PG*R41<<-7V;41Z.E$O_Y
MQ/LAQ__U"I?D7X?@7U\T1>I4B]+P7__U X#YG^XDQ@:"B09FX+5XX(XT  /_
M*$U?1$W\51[V',"TZ$K^N<?_I9^Q[* ,ZF 'QA\4C5[3"""7M$6D'.",#,BA
M=%Q;A(D'2LD4AIP<W==E(=V7A$D%]D,^1<X%PE^M$"$.XI-/80;X]0H ;DD)
M/I72H$T:7@K[4<O_@4,!*$0%0B%(=,@!K)S3Q)\I,8S2;$G^18T(MDG\7<X'
M 0H4ME]F[" =Z@Z G9P<J6 "1LV7G%^70*(*?J"62%\U0=_Z1>&9>,T\]*'2
M+!/_C2$L(8TKX9)$5!,/<4<1*< 1^84 -%]0/<\"! #@]6+7S1-V( "./,"&
M'("=G%P1_5YF-$ ^=<U'?%1J+(2>E<5T%)%PN,(K_\$=D#B/ %6%2% 2 )A/
M-T'&A5V/ 01  KB$@KU09$C$=+ " S% Q#D?!%J= Z1/ M!%; Q'+=ZB/YS+
M,'+%/"Q /A6081"13=#" JU1A_C0-^8( [@2::E. 02  LR1-^+@?0V  .C/
MXRT$>*A/=07D _#& 6#?3A11 ^@$8+R0-84&=A"10MC@Y>5>\ 50+C&@\Z08
M76@? >0@WA$1D9@%$27(>C0 A*$'+4"&M( 1 7PD2KB"&HWCY!00$+E"&:EC
M,GDC/5++,1J 1NR#QBP !NDB0VA8:@A. *Q1.I)06JY035*'N3A75&X4OC&0
M NBB9BSC97S# A016MQD0/]^TTTXQ3Q6!3@8Y-GMB-]PI?,$$$=VACRF6-1Q
M#39V2&76&W+<84"R'9(0T9,5$%!JQ#62#RU D2^.B+JL1?H\I8@XXP'T85],
MAT+.0]8%@#51RT',)@]!D4VA)F:,9 )XQ%ZI8[FT)5WXA_IPQ71T6 Z&A"_R
MD-C-9DLB!6 644O-R"LL(U<TTA=1GU$B %(VP +(T$=HWP PQX69946YQ0(<
M92L6C3RB50S*8@_5F%T40)2] @%$''Y]0[\,1+]$1P@I #>850/T@V\]P"NT
MA7^^PC>P @&D9@.Q L. B0,(0%;4&34>P(_, HAV4Q[9X5'<&.5@QSS 13^0
MDBK_Q9&$RL( ;!<-04Y*(M(^<DW>;0.'TD(8-9<MW6-GUAAF I"*89)A_-!"
M"%4K3"A_TE$!=$2T_,@!F00Q&D^-Y>?Q!% \Q$(7;0,IE4:'I:8KH-$W*-0V
M4!("Y)7*85.3N@)U^0-)Z5(#9"&#>M$!\5 #!$#RL<(B,2B" F8>V23FI2>?
M;D,KY)<ZF9%+&  X?-*YW<0G#<1>48XD(4^4QE?RM4(QG>+&"(XJQ6=>L:B+
M1D4>988""!\-H4X#(  M3(<"M(7;R4ZB'L4!E%]*R<]--%*31JA,R! X:%;N
M_)4KG&D!; ,WM*4KW*)M85(WU9C.':M?R9!=O-*4<L,!_Y%%&<+>C+S0J\;G
M_ C  2!4KSA &TFG R"JHN;3\;1JY*P1EMK8'8I&P$220F!52TC2-_BGC\H/
M_=!C""W -[S%VNP16BC'/%U8[$A2#P5  VR#*W!?HX%H[%P8&)6?U[""<DVH
M &A. \5"2OF82CC0F5)791RKBXC1/H21A!I5@JJC*S!4@<X10FR#69'-EB"&
M=)5A\K3LWX B]=&/ ]1377)2 Y!=75Q8,A4 D9Z3:5'%C@EEUKA2CE@16WE?
M9_1A>B252H 4%AW'N&)$A0[(7GW# FG+&H'$+V'1Y$U*CQ2  ,14\K!(&.WK
M*YDH';$=.#RH O35=$F$\60&./\@0-BXW8"DY'0)2>6]:C$!$7PY"I@(:=Z*
MY. $43>)$:'=A)!UAD/RE4BVT8"\ G_V1EXE4S6A!6[66("B:N'J%#=4!3IY
MA'DN1%8$E1 MZ3=M[D6IVSX@1.E*1*N6A;WF2"R2$G#]4^[=7V=8T^U1(RCU
M0Z&FYZF*"#<0%D>$D_)>;;KDE309EEKY;3I=D/# !8GB)@$\J.14J%_ [G1=
MT8BN161]A$9IB0,@EDX)3I8L1@)14KH*0.'UD#Y=7G02[DWLE2S\3U7L%>K@
MFZ.29V&2&49=5#0!#V9<T.R=:BB>WX 05Z^ Z!>9;@&02"[%@R-)'C[Y6#3)
MPOY)2V;_G$UG:%;'B99RD*AY[!6[5>(_">7<=NTWV*&](6MF3-<8I8M59*&<
M+L".O(38Z-3X_$E][.\:&11 +J]8T,EG+!*8$(7F@,,&U4?'#:YL_"<=05].
M^429H@379@8+3RYFS8/H[A)W3._4&J92;H,U[>Y'',9-D!+@^.<&Q=3EC<0K
MC% 1-5!*A<UA9NE".(^G7HJ6Z)':3:AA.D:%OL+=HBQ&?43?PB]!](,LO 0"
MV(_^#4@J)59GA/!T-<:&T(+DP6 KO[+D/4?OMBU'"58+66X\,,#?V8?F#M22
MME0(<P0A(X !U(D*4Q1?B%<=%=':-?&,I"J),J K8,4!!(!'_W06[9(%"Y-$
M'O&$\S9?_ P #KKD[4:26$ $41C  %26Y6WS(B= 66"15L:O/P@48=Y$9ZG)
M K2M]!E.UHY$\E 4WM"46@U4*H\RZ^K?/A@4!C&0Q+K'- >&-?N# T/6Z_P3
MD"9/PISJ7_U/,1<1 K#4=,F=*S6%9V;4X[J'WS75B;9E$<40-["P/Q=Q8_2#
MM(A7TUDP/B4 95C3-\0M2,^H7ZDS>9KO+?Z2'7(%5O4#8CB<_.1P76Q( A1
M"PWO#,^O6X"4-EZ$30.I/&J)*>W95/5*OE7S&(6MV"9C&7*S&^L30^11-1$
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MP&4852X;X0(0_O1!G^B6O3[-])9 NBW'0Q@)2>?-Y]"XTHXX'@#PT(Y-I/K
MX0(0 '6$-%!0\9&/A!=*4KE41ZO?A!TO0"L$QARA-D@T (>^1-=QB5(^0(?E
M]24?Q5^A?E]M\D55%)RRPFJP/D8(0-RE9$#2_MFM!61O".))^_)"]RT+T?+O
M/C0NJ?7+_V.LTI$L%[^YH@5OG$LP+W]E=JF/0;-!"2PNM8)R" ! L/+72H"#
M>0D>^/N&($$K!0:V^5O0P)\_< 5F5:SHH "K!QW]-6!0<5Z!6/$,*'#E ,&
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M]E_?-*W!0P0D%AMRP\Q6$#WOERK)8?HAHJY_^4SNWQIV5ZXV=458/PH S0T
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M>!$Q0<AXXRD(T)96 Z3^6,VU&KG!7W_<&BPTP&J6 @-^!X(S6WH?T(O<YBT
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M%O&P7K7B08 ':,R"R&+DZBP8QJX<(&(G<<I ^G&1F+1)74^:AR W:  $R4(
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MPPQC(\.AT6>CG;;:(X5L1!)(($'JGD]4>0<EH1ASCT+W]"&!!1Y8$-9KL6T
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M9%,"I#Z80RAD@?P@P1 PXA$H :E@ 0=>P;1 P00$4!]( W>XH%.:Y2C*D4Q
MY2_L076%&[@9P1R$@B9<@:E00 #I 2=4@TR>95]RY$UJPR]0 A9@@11(P2"@
MPB5<015< 1[TP2T\@SMH0"0H^F5EUEZ![,,4F<,Q'(,VF(,Q&$-GNL,\:*1E
EFN9&4N9IJN9JLF9KNN9KPF;AE69IQF9MVN9MXN:&T69'! 0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex-99d3g004.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g004.gif
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M^O'S]_3V^?;X^O[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
M    /@-O @ (_P#)D!$C1J#!@P@+'E28D.% @0K'D)$(D2%%@V,*2AQ3YN 6
M@Q\%CMD2,F29+2?)H!2(LJ/*DF52JHQ)YJ3-F"1QEOD2D^?.GD##_.1)](O1
MHV&,EA%ZM.E1,TZ_>#&:]$N8J4>G>DFZU:@7K5NO7@6[]6N8LV+3A@$3%HS;
MMV^]Q(5+M^[;+G;IXG7;)<J:*$[6K $SF#"8+H,#$U9,Q0D5P4XB!WXL^#$5
MRI;77-9LN3/GS%2F4$ESF0H:*Z6MG+Z,>C45U%-$IT%-I0IK*[*MH-9MI4KO
M*K:!_Y[R^S=PW\:K3/'-?/GQY\>=5\$"' N(*M>G@Z .8OOU[=:]A_]' 0(%
M%A3DTZM?C[[]!_0?/+1'(7^^??LF3)PP,3\_"O_\H9 "@ *BEU^  _Z7@H F
MI'!""@,^V&"$$$Z8@@@09JAAAA-BF*&''V9( H0D#"$BA":F8&*)**; XH@F
M#@&CBB24.$2,,N9X(XTWQFACCT#:*"20-XY Y!!&]ICD$$+T*$22-@K1))!-
M3OEDE4XR.<0,0A#1I)=#>$D$DUV6*::84A*A9I=J$C&#EVRBV>:<<:XY9YLR
MN*EFGD3P.:>?:KX9 Q$$%6KH0 5)8>BBC!J:D1AC9!0II(]&:NFE&9%$J:26
M;B'&%EI\2I"F6XPDJJ:1>OHIJ9Z2]!*H'Y'_)*NLK[9ZTJQ:S/K%K+R.M,6N
M8^S*ZZ_$ZGK4KR=)16Q4S#*+5591@2755U\9]02UV&;[U1/<LG6M%U%H"RZX
MW';Q1!11</L$&.%&YH6Y8#B!+F" /2'OO/)&9J\37D@6&6"1]25O8Y$1+%D7
M_C;61!-4=-&$8P@W7-IE#(O6Q11=3$P%PQIG/'%LEXD&<FBA$2=R;"B#K'+*
M:*",VW*Q*3<%"###_-W,- -G\W?=8===SSS_W-T'/G>'WL_D(2TTTBA\\/,'
M)G A] =.4^TT>2?01[4'\7F0GP=@>[TU?V ?2)_7!IH0]M<'YC?@@&W'?: (
M<HM 0MUTYZVW"'SO_]TWWR;4:/>() !^X> U%MYWX8(G[OCCC$<.>8TCC.!X
MY91;GCCFE5O>.>>>?R[Z"#-47OH(3Z*.NI12C@#$E4"@_KJ4L;-N.^NNWP[$
M[+?3WCOK,DC))1 RH![\\3(@G[P0,LRP?/+0 S$#\<E+3SWTV&??? PS=#]#
MHP41A"BBX#,JA1:/+CHII)M.:JFCF*9:**F?YGJIJJ*>NNK^LXZ::ZNP&I8
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M2F ] FA#O>H'3#@U1#L %F #2WA%N2(X0VM"N>*',H1"<E,&V\M#97 V07S
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MVA_]VU]]U;?]V9]]TS>&RQ^&;8 '!'6L*M_[Q4]N47" 5*@M>+ %/]@!&IB
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M#U@1"@G4P).W$#&+=@ !PI###@O8PS55P0!:^:/3R9;4C1>#'MK_'J8?CIQ
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M^&#G$&%]#5 4B@7HSA_PJ/":K+C(?B0A!RE4!<1R59:("7#4-\SU1-0147[
M8P*&RRL-6+N'IVET (WW!^YR,H]EMF\>]O.'+F@/$58T@%;-]P&KC!$!ZBG&
M4>0V3#EL, $,Q S>P&VWN^VO__S(FT$9$(IW&5?1Z-M[,5T#< ,%#0"N1(WF
M[8$=])X$V(&Y] ,_5.#0B$.'280V#(!D1<21/1Q%J,UU =T$3%P&]8 /Y$/
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M)O?'_T4?CPR@0DKP1(1"  2?'4, $B1!$B!!7?@ TT;$[4V O,C7QX%DV4[
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M466 M.-2Y62VUNX5++WY%DL0MOVI98$WS>KGEK)OKB5EKO#)(8F@)U=KO53
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M/QB6F4NF+R( \\<[T" 4%YS#/LU)YE'J)P&2@25_S]1*,1;PB1P<%"J?_V"
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M@ 2(%?$<Z*<<.8# 'C \ <9!)8(554@X+*R7!M@!%'MHP 306(\)V $GH6C
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MI\R5H=0K@X8/1!O (_TA%4XT3Z."%3)H\P1'$") B,C!%02A)1= 1D=4]1I
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MRA JU $V?>!OUO!4X %1\$$'?" Q>E'_@J5V3.9 3.F%CI.3 4EA ;9!:6B
M&RC%M4)X BQ4<$L8#\B%8/E!;J8TOVBA9FYF)K/B#Q: %O !)]:+<]P3)S06
M*A2GH\WQ/F6HP/ I%02@&M?&'[L:=A_4AK X*_;A[M1I3>T$'_@P3O.!3%W7
MH_K!73&%[L+834N*C&FTP3HV% 9@3^8 ;-4P MS!97J@'![+/]M696"(%W=
M7?]0'G B1\V65([!E"LEJ*1B1(N6%Y_T7R?XS1('C_T!4"U93-R1' X&L@^6
M3R/(%J:F 71L@"- '0C7D!]W']3!><*!#DHTH6B@!L(A,68SOXK[EBE0<4:J
MK7UY&QH@"=0!_UQ^@&17=RK6@X7!8A_6.2SV 0EBUP BU9E+PBUOUR'BERH8
M!DBRXATV,Y(N:WBBXA=*R2& 5RJ<Y%V(XZ$'Z3/3X"'D[3,CY"1@1"OR(1:
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M?CK4PA9-X>Q@X5?U""+!!/\UV*'-'H+TLX\=&C[H'4W%^!#.5W;H@$]-=N1
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M9BC39%Y?IDZ>*D=H/Z5+/(]V!!?>LQXV^(-7^C$'&T *'P,KU[LBL"M!-&
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M!V.6"@U  W.@ PVP)]="%?;7 !/0(V26 SV0 _O5 !92(P.0@"S! "!!#@W
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M@B0,4ZB6!0+XRQ\[!@"%%59(\8.& =!JK"*4Q-KCK&[(.6@E=28 :1X#&VA
MOG)HJ*$8<EB)0( B_:DGAP%Z(.RP?O9HH,0<!-#*GR2ZZH@<"'C01IQ0(A@@
MH7[P&$"084:90$T9%5+'A@F&*6>8"7RHQY4@RU'G%B!C7#&',?<@R)]P)/#!
M&/\:&,"IF)2J):MPPMEC@+EP1!">_W)&D4  J<IL@$!__MO#0E4:F&-,A4@9
MH!M_RI'@DX[P.0JQ81;0Y:D!;NI'D#W["V6 /2:ZA=1MS)3 ''^N32BM.1I(
MI< #I?)H 3Q*/3)5<B28X!9SM/'AT\).Y=// 2XZ-PEMR*DE A\X&I4DA4Q"
M:9\YW$J2J:O"8; C;AI (IQXCOD!58[^"R6<L8;J2! !( !6(7$FD$"7<I#9
M8:3#^($030'V*(PKHE()DIQR:H&@VGYR'(6<;J"]*B>0Y-DFX0CD^X0!4OK+
ME;%Z?#C3P5-O2FD.9.8310)1YO/ZZ[20B$ #RTIKS[/RTE9;A1?>42B?<\X9
MYYIG?$&DA?_65"#@$87H88V 26![(;/:_+'G!3?R48B?>_*A)Q_#E-$[.G^6
MTUNWRIDC /-Q6,@;D;>SX_MMQ_-17"%+UL;L;-;/8Z\]#":@ 2BP^SE" OP>
M@V>/""*88()/B/*'G"0@Z)T&5@S#QZ?>.4C0'WY4F: !"7961R%=)B#XH0B*
MK,<.!GS?(X>5R)SC!IZBKG8J?DXU%]H&(&C ]Q]JP<NQ823X5B%X?)+ W4]X
MI5L3@ \-!*&E9?E#7O.K@2 *-95/V.@Q\S"3^'; L_$)L#!:BI\/6$&#K/EC
M'I^@001T(#U]'68;4NO='.13#S/)+@>LN(.BQH($&0DB!P(<1@[_C$<^[05K
M N;J!RL(* $D[&$CP_.![VK@@UODP \*0=2>_+&/4)A, A'8 T<.\T'YJ(,&
MC,G+^J92# D4XTT3>-[R>N<N00AP'X*87P3F, H;7.\6$5!C1]1A!PA4;XB&
MZ8?TC.<#.^B@( ]AT19MT*5ZD# ".2 %C";2#U=,  ($1()\NB6!D% E M_:
M7>]\%XJPD&.('2DD 6M @U'X*1R8LD&^\&$''PA/@1&P0Z 6J,D<[&\J\[C#
M_"8POI7DJ0=$P<<G3,E++Y:R=Q, A?!<L44.&%!+6:.@*2401X648PZF'*1"
M&/6\QXBB 60$6SL;(YD(8*!LI&G=>E1W_T_,$. T"E$&"UC0 N9TYC)[@TT:
M9E.X=PQNH)+H&QH2IQ!]T,,>]GA'/B::#+TE)W,9=<YE* >.YZ@ =(9C P$8
MVK>)TD.B]L@')?!93YB"YG7H(4#LXM-.?LP! [E+#3F*@8QR!"H?/M7&(EE9
MCF)H@R=3@8<VL"2C>I#C=%<DAR[[X5-R\*,<7CR,.H(:SNL=!B8"A$=_@%:.
M>@3JG>70I5C*<8QCJ"-0\#B&H?IQ50W68QO%4,<^JCH54B0-,E?%DE:]Z%6U
MJ@,9VJB'5HFR#WGT8QYLA0<7([-7<8Q)JTGUBCS(,1%UR+4CK(*J4^4QU+#@
M=2KJ.(8V\#&/S_\J!!_;&$8XPE(.VOE#'=L(JV[A^E7$1/62Y#!J/[:*&)B,
M2;5B4<=/@2L6G]H6'U^=+J\*0XYA%!4QK-W&:Y^+CW 48QL:W,<\)(O6%Z5H
MM$[-*F"DVI&A6I4<QM"&:*%'W,.\U1C7FZ[PY,$-H+"*??@5:WBYH4$58=6P
M_/-D8>)5V*D8M[6]%90QB@$4?I!#@,9%AC&>>U_Z<M5+=D"G8TSA ':Z4\5I
MF0P&"E >F.)3QFP3#S!"(U#7P 8->BM</MJ0SUCLIC?V4 @FT'#D-+S@R"]@
MCD8MIP(G:PYSX' !9JSCCWR4=*3\0 0:TH!D)5?YGC&MYV7:DP'9-=C_:_Q
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M!540-X*)FF&I!75#L&ZC!08@-[#Y@UWYM@5@14)3AX@80AJ(D7C,29V\-%#
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M0-D';: %H.<5?# &5]C7<!B9KT?+@L]\TSNQN.:V?H@B C(9#,B !"C]!$
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MY0Q,6<,:SMATIH&1*4YCZA>>*H0U/Q7J73IS4X\$YJC_1?WI3VE*5,X,U:=
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MV<YL!O.6Z7QG-^.YSX'N,I?#C.= NSG1;4:TH@5=@ 2$-R$[6,I6]L$@#MB
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M!ER@"?K@#XY@":*@#X[?$ +A$>;<$19 <T7 '-2#4^3#'+ (#5)A%6X2($B
M!#Y',=  Z?0@$H*AS1EA&)J@")*AS#'=&+;?_95@ 4S,!" @4SQ)E%AA'=KA
M).W!#3J)'2C$!9SA'Z(A(/Z@&0;B'ZHA&D;=(:I? B2$#R0(4^ &'=[A)%+B
MI-B@%C9'-W0A#PKB$2IB)P)A(H+B*.;?$HH$I?$)#%;B*K+BE4 @)C)'*BA$
M I B&7[@)];BS!4B+O_F(A@FP%\H"22J8BL28S$2"2!@ "P"1S_PX01X7R^"
MH2A"XS1B(,]1X\<I0",^(9@,HS&JDM9YXY3D018ZASSTP 3P8/A=XP;RXCJV
MXQEFX#5BP-6)V%',80SNA#JP@BKPHRJX0C',@T[L0RW40C[D(RN(6#'T(S_6
M@C%LXUGL T[( T*B!3^ HS_4@RN$@YM<9%'TPRWLP1Z( SZHPAX( CR,6$<V
MA45NQ3P, RNX C>423]H@RNP0C'81DZ0PR<(0C%L2#^,0APF8"V$9#T>Q3:X
M@FUD)#>@13]8B#^0 RN@Y%@8Y%GP0RT4 YL\93E(Y58,PRW<!%+F9%%\94?_
M1N2#^ $Y-H<ZV 4&<-PZLB-<RB4'!N T%B -,"68B D^ZH17,$ #1$ #+, "
M'&!.P,,$#( J[,0P#( KX- <!$ #0  $-(!@MJ!9Y$,HT ).' ,#U,)9E,,>
M=(-6D,, D$)/A*91DD4M+, $M. GQ!02J,-6R(,@'$-<B,,>S.93:(,.0( -
MT$"25*4\S$$#T$ --, /E -.J$,.)($@P&%.: -6<(4KQ%0/N*!1A$(#9 4Y
M0$#JE$4\]"1.U,( :(-8\ ,I*.99U ,-V %.U(,@4-HM+ !?JHD/[(!!A@($
M+&=1\(,/Y,!3.L4M?(* 2@<6*N-OE ,-1$ &]-]<_Q8BA'(@U.FBA/[A!1Q$
M=A*%CQ2%5P@".8#H-JC"!#2 +N#$80H =>:$5SAF/Q1G,8 H.83#* Q #CRD
M6)!# XR"1-Y"?Y:%*S1 7LI%8O8$*PR AHH%'XI#/T1%#L"#2NK" *"B6NRG
M:A[%/.0 #6C#/LC#)RS *^"$(#2 *]0#/MR"!,R!A;C"!,RF(/B A;CH'HP8
M'Y(#2S(%*$3 <N;HCIH%,BP  JK#+=RH5L1#! A"4P[#<FC# 'RF/]P" V1E
M @)H1';#+8REF_B #YQE4^3##OB 2I[%'CQ @O(&.6RBA0JA_J%J^ZTJ&1;@
M!)PG-T[A4# FCN3$-DB C?_ZPSP(! ,DP:8RIF/ZPQQ$P&[FQ!X,P&V:23W4
MPYEDR#PT:TZ$0P. 0E4*:#[<Q#[4PZ;B0[0*)+-6)4Z00K*62;=NJD[@PSST
M0XZNYTX@25KE1+J>JYG@@SS@PX;40Q+00(6H PW, 3GU"+3V";,*Z*."94\
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M&.4QS,$$<  2",4M(";'7JH_:(,/Q"I4^@!8X(,=J (I_V2I#^A"FH0"]])
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M.$B G.Z#_?:GJ1ZJ+BS E.8$8Z)B.#! Q<T#<BIK/+3XH/K#$;^Y-2OL'C2
MLA(%/.PN.&\YD>*V(-A #O0 .>@X7!C%/X]N/XQKBR+!#J T/OC O^($/O"
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M 23 9'0P CB !D8E!VYD'ORE 2:C 0:695S"30[6@]K5)?:  S[D&'I$>Y#
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M&J #65U %E)I'6(!)=H!MS%;( >B'0H!*0B L-<!&%B8 &AV'(C8'TJ7 %@
MVV6G'0BA@5I@'$YBMLW"#40;=87U!736?25!*!"!ME6"'@#^966''M0@AZ7E
M I2UI4BT)9;WI=A\ >Y''"!@ @10/@X''UH#FUR=7JO;4*ZH/G( 1K5!1F#P
M%A9@.;RC1_9A&>V@ > #'^; B8[F,9AN:?!!N5?%&!; #T2#E(/()/!A!V@
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M@7X'D8^:'+"[-H%B%*Z @ ]>9#L:Z$96_QD>6;!7.W^X8@!J(: _BH$H&.4
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M#LDP">T&$2_0+N_2$>95).NP$YLD+;QU$.-0#=A0@B.H1C'H#\QP,1UG2AG
M,I.7)_XE,WE2:0SP8L-@!Q-P>N3  +LD#Q!P(;;  $DP#+;  P- '1:'!Q.
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M4$.*L8=K,7H3<@Q2PE]K\GSYH(F", >"((HT92 _8&X4 WC^]&$PE3@G@[8
M=$B-FG40<+@C[)$HA ,JZG<]!":-JN"*&X(ICQ5TFD(6\G"0GZ@+1F5E]B-Y
M Q@K@/   O\8EJJ2#DQ4  BH;2_ 6@S8$=4U#LI5+E\TA!,S#N]& (^@$X2@
M6RS #!X(7!#! B#C BC#7#&A+GPT%KY57?WR E_D"^O&7NX67@<1<#X($\^
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MF2KR4)[F:0>$_ EM5^2JONK.#0@.0-WT30-,[N3:_R;>&(BL6<[ENK[KQ3W
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M%B8\%@ZB?3@"]7S'M;<P!TZR,XR##[<0G)_@SLAX"WA@![5P3ML "G9 D]I
M$1)&5$BBDZH@ ")B)-UCG:U_G!Y%FT_V/G/@!\80XR!R!Y.2&4G -!^%-$DP
M& QQ)JK 3X2<2XR#*4/#;!T:]]B?_8T\]_^Q;M]W_T1['_[B[]L"O/*L6<"
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M(YURE!/]B2Q7N<NC60"+3V#:<#E23@HED*E7O5 F_. 'J\X/?IC0ZEJW>J'
M?D*MEWWK9C_AUO,1]K2SO>UB1_O8KYYVN7/=ZUMW^]O)+G:^3YWK?1\[/]9N
M=:R7W?!X[SO;L:YWLM_=[WD/_./#_O>V!W[P7X<\XAE?]<77O>N3S[SD-[_W
MRJN=[7+7_-O_43_USG_]\YAW>^03?W; FQ[TL=?\ZN>>==<O?O.\YSK:3V]U
M?/!#,*\ UCZ@FQ@#(/WH2,^VTJE( -1PR,J=IL 1E$ '.B!A#MVGPQR\+_[O
M(R'\YN<^F[@??O5[W_Q*^#[YOZ^$.HP?"77H?OGI4'\VW3__X.>_[UN_]A,_
M.H"_\U._[;._.B"_[L,_^]._ DP_ 0R_-<F_]XN_\3/ _!,_!O0^!^1 __M
M\PO ]0L_\/N^)&# ^CO!\ M ]!M![H- %$0_]AM -B$_#$3 ^0M!&=2_$'Q
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M;UM*'3E.7[LU["F !#C&"-  4N!-GJ/.ZK3.ZQ268MB0(7%$!"B [S0  B@
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M?N,Z;N,WIN,YAF/GVN,Z9HL\]N,[UN,\EF,Z_F-!=HE#OF-"MN-"[N,^5N1
MWN-$1N0VIF1(%N1%?F1';F1,]N1.WF1+EF0\7@I%9N1()N509N-)?N149F16
M?N5!UN16]N13;F53GF50'F5*CF5>SN6;Q65:!N1@*8;O,M3@5 #BK!K)_R
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M0A_W,:_V4\=V,/_U6MCV2J^%D(@E6<L.H3NY221R:3'R*5* IL,IN^@'/)"
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M Q1L=-,G!. #<I!C'Z]#W_] Q+$^?]1#!Q#IQSZ22K^#X*$!NNA'STQ#T0;
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M!D9=YF61N,5C6 E+X $&Y"%#D ,#I/^81D4A1M&9C8!5/^ #4[ 96UX;20T
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M5H=S1(##H[M;M( +5/T+N,#5MX#,I_;+JT#5NP +O 4!L$ :_[!!&KR 6[#
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ML;$P_.H %<[RQQY$V&!C$$22\>LQ-;I2HY!"TN"* $D*LD>-RU0P9")^W""
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MY0]ZC(PPOCA7&@C @G$41!8$0(1"Q@&J7ZC@!1_[32\Z0P U$(0?YP#).%S
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MCR#Z48[XC*E!B45R8^_KM @(8 )WZ(8$^F:04)P8(:J(@!URS($(T&*;,I;
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MTE1HP 8@SP8\I=)4(0!4R[F<2P<"!"*5E%3'U"+] <YD*6MV8UERP.: 14W
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MVI8*)@';B;+58,= _2#A TCO3=!##4B,$D&O_N"S P3<$ 3GA+G6N5F^53[
MA[[^_NO/)Q%HX%!E!D=DD4#]\)-//OR<R,\B$)DDD$J+9?7.2S$M@A%D!\BB
M<#64_ *2/\ L1A1*1R&EPB(]^C,.)K'D!#-7;2FCUV)>N5663 J?_W/-46.5
MU4;)XT#RR#7"94P2R"AA<XT:*N#ESU4/(?)R/M=40W,_ECQ$P&$P*\:88U)#
M--ED!T^4 &;<Z=L/'A* MMD^VM3"BC$7^KH-JRB%8]S?M;BBC:(#D;/-R_AH
MX[<ZVQ@^SS9[<[;-+<;UHXTKM22.4.3X;./*+7X+A \RM6S^\D'[@%Y+X0-]
M'H]LCPM4#C<GUC-,Z&OZ6HSFY/03C^LHD3.X-B7+,SOIQV@>CK>XNZ)+/<B_
M#,\PK-3234*("[=XXYRCI(TNOX=#97?9&\1/WP/!<XONJF$IFS8,$M1/.(,;
M8S@\DJ.8>RVIE<,YP-7C%K3 WT <9[A]+/\/=0B11_^:=\!;L&(8\JC?FR"H
M,-8)#T/#*(:B]I&#X" D%0S01CB@MSM\<&-W& &=*Y+GCWQL8TWUT,:%ZA>X
M1;5/=/3;QN"&$3L,^4 7!NF'"PMGM^K(PX:OTT9]9F4]O0&NB-PHGS^Z\3LA
MW0\?Z1L=.3 XD'WT[A;? ]A!6D$!0)AQC0=92 0*L+:U)2PA[7A$1"CF#UF
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MAP^DB>5^D&-ORS:<JM\]XQU;. )@SO54V3SH70L9WT2V-Z)O79FJQCDA>'C
M@).I#1I02YBUL(%Q!-$#<AM$'A/ 4;Y\0 ,&N8(&VL1S.)HT*Q_P>%:H"L4M
MO$60<M" %76N!0U8]0>TPGOF$J:KG_]=?6%8^SO$1=:WD \&\)T;.>@420"'
M!NY@SQP<F;5@ #*(^8=,X4,>^IH'!\*5KSG8X$+YF ?*\=R- ;#<'_.87SGX
M]&)YN/O*@I  J^IA;)K+G<#9M>L$- !'H6=8Q3XGL]J(KO<?IXV_N41Z$?%
M 70;)'+Y*,<MAL%"M(1#%[?(XJ($,8!1E"\>Q;B%_%ZWC7K@CHPO(\=H_/>^
M$\'#&+>X!3<4-8\)W*'4W;@%,O!!AXS[8XDE4_<P/.]NWU?>6\C^_3!RV ]Q
MY(+T] O'+<3W]8',X_7J&(8N4J/N6QR#U/#H_.<)(H_.UVX KOA;:M0AHSUH
MHQR,(XC=YI'_/@.%OAZL9Z*XG+]]_:&<'.3(AS8\/SG(LSB0IS#.=WP$ 3@*
M!'P%,0^LMWU-5 ^UQW])  &VD!I?=#O_1X#E]GO?-W<?N%6L9G=X%WB_Q6:3
MT7<FUFO[96LE>&: ]Q"7D1F[%&.TL!FW, &?, $<P!#NPB@,@2F?<"&DP!P1
M, <]<@O: 0$]$!_;, &@T ,0,  +L <7L@<-L"&"X ][H'O^4 L<( $*T@#4
M-BNUXFR-HBH PB"J$ &YT0^D(!VV<6T"L0^ AAE[L"9U&(<-,"H"P0\+02(0
M@"^S 801\ DE8Q X^ FFL0 <4%:8 1P,P@^L@!FVX0/P,PPU$!T<_[ '#,!R
M^) #X:(*$C C-$ +27(BR[%^$Q!M/R((2! !S#$']5$/4')A/8 =H],/2? #
MV"&'5((K4!( G^ /XO =J2(!H] C8X($<Q"&C^(WNJ =$> #Q4(.$]!V ^ #
M<S  &_()_; '6Z<>4<B#-'!R,1*'$= #\ ."[=A,\N9E$Z!S+K@VMY:"A59K
M*4:/@@:#P 5LFS%GN!!]OC$CK" /WH$<[R(AK  /Y(!Y08(/H\ >5*<-U!@.
M\' , 1([VK AH<!_=K  1#0;#6 ,]7 HNA<.#> #Y'"0=O!D9#<!6$<0F*<*
M\! .<Q  .< @1 @AVM  H0 /\W +8R@0H/_0'.4 #[30 (+0&*XP )^@#O.@
M#3DP :DQE :I#JJP (9RA36I#LO2&LKQ7_YS"Q=6C>4@" ( &DYI!Q=Y"Q)0
M*:V2 XQ3E@' <K02+KCSE/'0;6VH,#Z0 _A #C^I&K$H".30#9@W=D8Y"NI
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M_$ .C@NCZPH0\/KY(UC0X$&$!>'!2]C0X4.($25.I%C1XD6,&35NY-BQ%05
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MQT#KY;%^>TSC&_U(0P!N3XP U-X*PV=&-6*/@%;)C#:20*\)3  #&;A  A*
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MV:%\-;N%/#Z"'G788 +N^D0 J">LB8"B 4$IAP]881_>[<,&/GA+2:"GC@:
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M$=U)==R=E1IF=:WC6C_R( 'RXF4?Y6"%1?(T#S[UK@$#])]AE5:N/T%O(;:
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MB9H\V$+&+<Q3G!M4',,G^$ #[%9]N)M,^-4*]0,0N1W X1O!+ #:+8D$X '
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M'92BA*:+/*A#$H17/" <^*+$LB3!&M%"$JP,.0S<!.@'*"-;"#-O57A&24Q
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MDT/Y56R##RAYE,,U!LS8D:.B$[]XEWOYE[=XC!\?'>= C5]-S."XE=-4$D"
M#X B%[TUC#5-:ZIYG=OYG=-8DN-Y-I6#F>_YGY\K/- YH-\%IY1BD7]-V!@
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M X(?5!TF C38@^)*<A!5,( '-MC##TI'I>?T $HT"-UE1B8:?. N"7NP00T
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MT=1CC>H JS](<G5\X$,>MXB #>81#S[L(?KZP0\JXSR2"(C>; YVY=T6$-Z
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M?=HH51_"#P2 !EQA&XI(.RHB!R* %;9!<25@W.C#4QYM[R3@"B'K)K2A%FA
M (JO0.1UJ6C@%HJ!,I(3LB:%%?Y 4N[ .CZ! 3RE&)J"'!2&!HK_H1QT8870
M#]&T$R ] P\:8!2V@14F *HH:.[@ 7AJ81N:$5S]8?/F(!S(@15J8#PZ@UPU
MI2$Q-QQP\;#X]W.W08Q&]S*0@ -8+1PD  #HJJ@$08-=!P\GXCD^ 7G9MLSX
M@08*4R(LP@:*P1R& 0D8( +8AQ5^L50MC1]P)Q2VP17D]V$1%"$?8ALLN&*G
M1X-;1P(:3:]V H1= 5!%PYLD9X@%X1,LHQQ\X%A-UHH/0A0@0-YJB]Z<H@"\
MUBR6)A8F@8PG 1'4@"H(X&8? ;S8(% D06LP0;!\4BG]@1Y\<@/_@A_48.!\
M8APVZ0?]81Q<P-_&]&K5F&?3<DQE 97 _Q@KXC0'2#,H\$ "<N%M2D('(B D
M?LH<<N ;+T,5:D"3:4 5B$P;K$<")$ .#Z(<QBP7=P#-C*$'@D<"?"!>R$'2
M<C$'T.R4]P;L (T6;& "]$>2*=+"PB$)]D9 XL5^J6PBT&04*M(V HD<["!X
MP(Z&N&%Q]D#0[& Q0@$Y(J(>!F5O1L%9#@(0YH#5:($&&D! 2,@^\"$5=H #
M?& @G!,B\"$4<G$<_>46:J!\<H 4:B$'=,@6&C3/:.!FQED" BAB*.H: Z4;
MDCD"=B E6")ZSL>>/V$'+"/9OL<@>KFA_9= 7$&8SV</2%, ?8#5_"&'[<45
M-$ #SN=R?X!B*/^B'CYAF)D*RZSO#K8O%VQ@;P2Z%FP@.DCH.[5A? _B^1J:
M!D@!61AC#Y* C^(7D52!IL_G[&[A1?_E$QJ:.7X*%P$ZJSMW4:OMBF/40;:8
MMN1!;R3 D7<4 S7PE+I&C0,%*:5"C=GT2:DB%OY"N51 :/.!#:RFCO<8#:1F
M2IGA&1B[L:LA%KYK*\'AEE1@EJY6*H#A())!#5(0*QLYKJD"YN**+BD ,+F0
M <*A'L*A'!1E'EYT'LBA&]IM'\A!'%1:';:!'/AH'\J!M5LCG?ZWI7L['%1M
M*<B!&XP[,.JA-7H[N4DC^2@"'PPB'HI[X=2!&\J!CR+1(.YOV'+U(>#_H;B5
M*$?P09+GX7_WH1^@1XE:>Q]NS'?0^B'06[N7(AS"(3GZ81X<(A_D05'\^SS4
M(1P\.D=D[#S(0;7U>S'$>[>/%L"/5AT>/!]\6QUFHQX07+F7HMWT.T?R 1Y*
M5![8&RC$NQRVS\ GXL+)(;_E(4_ZV[451< ?,[K%><,9MX_DP?D"=+^!HA_$
M6[GS0<?G(:5"G-=L/*U-UB@0:=XFY(M#6RLD"0JGPD3N^B"0,FM<8!TV^[B^
MIA\&F0#JV!_R6BIF%N!> $D/8BU$J05<B0 "&1MNR6K3V 4!CLRQ(9.<7"L:
M+)+S @,FC N7\\@#7= 'R1@F(/6NR6P'7=$7_YW1&]W1?\*04G;>=L I' G/
MK^(E,Y JIOQFQ=P'IW(# R466A AL(&0"> %SN$@KF&3C%*0"=FZDJ$:9(%H
MMY+5JT)*GR&5I,(%5!W'#L(20/O2P7;/Z128*&P!OO/1EYW9X4]R0,$.F*JK
MF9W:J]W:K[UG0N&03G(';-32+UUI!"O*I6+*U0 $K7PJ"$&QWR$6'D$6 J4=
MC.O+SZ,:%N$1HK8?V)A)"4,9"*$-MI(?J%(% OG6J4*S[1@3*($)R5RPT!C<
M'WD"W)5%*-G/(X)10!7;,]YDX2%B=B ),%/C0U[D1W[D30$"E)R+]<9E'[XJ
M7K(>\)C<3<3<#P),J_]"$NC1! 5^WB]#L1]B!=621_EA,61!E&R]Y1G^7 I;
M*MP8(9ZALEE>*B#Y"GF\#FR.Y*]^T /M3K&>Z[O>ZQEP1MW-K5OVVZ%>!6*!
M'_*A'5Y E^ "#=XA[0L!E0QA![^P&HCVE(3V'1"A&K:$NJBB!3"!9Y,+$^Y<
M!61!Z'6]*M)@Y 2K#<ITEOSA$<R^*D:[V(>B122@XK^>\SO?\S\?]*V])&F4
MTE>>\E7@!=S #=B !=K^ %J #=R@#>8KC5F@#1"!$A:A#6YIY_FM!0I!$AZ!
M]5'I!0S!:0UAW*4"#63?X:OBNBCA$=S@E@X^L$]_*F(N!\ ;*.I PD+?^[\)
M'_S#7_QGRR@Z_X'T*]WZZYH 7!\NR$)+N<8JA);?P$O8U=\JM'24ZEIGV8!G
M?P$@5 @<2+"@P8,($RHT6 "#!!OR_$F<2+&BQ'YX)-BRR+&CQX\@0XH<2;*D
M29+]3JI<R;*ERY<P5::,2;.FS9LX:8IR0"IGQ7@])&!82+2H484'DBI=RO3
MT82()-)#\[0JPC:3**&3R ^1U:]@"1YPF&.>R7YT,*B:!T\=O+9OW<*=*U<N
M/'?JV,YMJS>ONK_QZ,8=++AP7;R!]^:-.^^ONL!U"4<V3!COXL)O[_YM++DS
M7\^9XZ7SZSFR.G>02ZLN;+EO8[M\':>F3'MR:\9_,\<&7'OU9,=]"?_KQLNY
M]V?,F3?_]NR.[7+CMC?CANV7]_/KG1]+WZV[^F/H;;&'OSQY.&GCS7'#$^0
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MC8!K12M=Z<;VNLE][FMSRUK@-E>WJ@RN=8_J6]'^-@=^T 8<-\O>]KH7L_V
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M:^&P!V-I!]ZHE(+@63F0 X* I/C "G][#*%0KQHI0@V0!*-0#Y_ "BE1#()
M#I^5 WL H_6@N#R0 W.0E/TP"LM(!SG0 ZKPJ/- "CN0 TA0HOY #GNP#1<Q
M#'90N#Z0"@)9#P,Z/J2@"L60!'PINQ)1#ZJ !'S)"F5)NZ\[![)[E*K@#]S@
M P/ N?/0#;4[$=NP!SV@ W9@NQ*A"Y_PH3I@N$@J$>JP!XQ9"W8 H?T "K1
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M0BRW2: Z_+ '*SD*22 !#" (%3$/J4#)@I +&XJ3_D *;ND#H2"W2&#.=C
M>Z *H3 !#0!%*#J@G] # GR\2=  >Y *2;#0._DRKM  /D *J:#0G3B4!!J.
M/@ !=<D*2;   SP//O"5HX"I=B \Y0!VHT *<^F*0UF4Y8#.NXL/))R+PT"3
MW4P#$)"+GS  -( $GR"W]ES%-5"4K-,# ## @[F,_U"IE-;K!]R$SA.0!*#P
M P -1^I R:,0#M#,.B":!*FP!PTP!P()#ZM$ Z);#PHL//PPUF4=N0(Y#SU
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M.&:CU#L6/&U73.:H,A_4L4&5YU(IIEU_%OJTY9PF,*C4K+(?)C".YB*%-@E
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M7%[F@V/B*U[R2,F%%DB.EYTN' ,@Y3 6T#Q=#( 6&SF,/T QN%2N__ BKIB
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MD!ER4B&8O1BJANOJ"SQ\( #$;,08#;",BE[V YJX<'D.8>JFOEH9":A('32
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MQ[@M\7PX[T3'[;"CZ,2';). \Y!'VZ2L>L3'_\NBS\7*S=QDCP*0@-<#S>_
M@[913_"HAR2 @"38@^&1Q0)]3L5X1@>5T FET J-D' @K">T@0AH,H<(AQQ@
M@-2ST#P:@!_8@UM+@L)T"%8RT21H "1('PM%FNW02.6$K0C0  ,@D/ST&K&)
M3?SDT?T4TDI3@>?C 8[JK#FH/ADUBGFP1A_ &=-D4CFZA5J0TBG%TBS5TKXJ
MAU&8@R3XA'-T"'A(.A^141;;@R3 @UH(4'ZXA32U U<(T"VUCNV@E.@4O0B@
M .$;/OJ,M'FD-!ZMSR'=3PR8P!B-$)"[)#IEU$9UU$>%5.^\TDCU3$K%CNT
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MA6L;.GEIY%M0A=OH!UJ0Z*WX \ZB",P0F=NXGA+#BD]X'OJ="_K-B9FRCG
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M06F1%#7.!,)A@[BAK3N;[!(2FB01?LI'39D+3F_0,@<=@+@A#?!!-^Y#R1H
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MV3QRT "'[R$)#J5DDQO- QM@;10ST]^"Q3P ;L"COMP@49:ZX]3@E*I4\I@
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M2O3#';C;R0A !*@"-]3"!/0 EGC&\87" NR!-FS#<3!>0X",+G##?\!,Q$4
M*X1#,?C  K2.<0P "7(#?*#@,#0 $B"#-M@! Z"2*BS 'VQ#."3/=PG/ /A
M,6S#65D<V%#9,S5 #KB"#]3"#D1 @&#.!(#"*(2"&*J".;W71R@3,]& ,S&8
M?F"$?RQ @/B</V"3/^ #$C1 *G###)X-AVT$'F2<9M! #=@"-]!">_3#,3"
MR13A'!C#-GS""$:$WXT"-X2#W[%8/)%".!S#''S9@@B"-AA##P@ [P34C\V.
M01D)VS4$!.1 += "#?^XF42\@CT=PS#H%X90"ASZBP\(P %]A&A$P">$82B,
M0BJHACK0  T,@PG2FT<4@P#X#T8]$CD,@S*NHC^(PYEI0SD, PW20''D5,S<
M"3[X@ 3$("M,@ #4V1V05#GHH)W00I8$32IL@RW00 #\&7JXBC8<PP\,0-JU
MWD-Q3C@<$D)TPP30P"UL8$(22>YMQ,MQ!BL(@""0 SFP0@W8T[?8P,XAGT?Z
MPUM)T$?.!P]H0*F=FO.I$/0A1#_<6E',A%'8T%CX1/?A6L2(GQKT13^L@S+(
M@EWT Q 10+R8RTR\GS\0@@J@P4T6A5#HQ6U-FVJA%DT$H+P,H$:XI$QTV[?_
M>-\"=J5O<0RZ.<9PJ40=4,:[!5,.%,0<U$TYT #G:8LJ3$ #1(#;I)<H%L0$
M?$*&D,,<% 3(K!,^A(),10 '@()#]<,MU$#J),$GA$R6C ('X*4@')Y@V((-
M^*4?B$RQ+*&)U( \18 .#%XH1$#JD&9!Y$"%V-CB@40H..9L_("F:$,K]4//
M( 0LBH,_Q(,-"(M_(8DZ(-5I[DT!S<&]",(.;--J_ !>_@&6;,,$3 \_L (-
MX.4GL$\]9!1=UF7! >=,U8)&Y(-@DB8@V %P-(I;"@;#I9=_26 M4,T W !@
M&LE8"0(\J08'GL]&J(( ,$I'I*,$E&9!T$#=; .<_]!E*I@3H#VGC4%4020!
MAJ&%=$; CA@C#<2&=.;/+419JMP!!$BH?Z68F9CC!-2 '0Q##D@0/ "G!H1"
M#XQ0/Z1C06"2#V17#>#G,=#  @C"/O@ 'H1&)35H;.@2#4#///1 @5PG7=:
M#]R"'? 2)6'=2!*?*$" *43I?&PA!B!+\^D$8CS?4BP"4"A&MFQ+M[P09ZD
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M@B"H0LIT@RT@IS;<PGULQRC\ 2G@YWS<PB<(@BL@2:6;79#N0S&$ K-C3??
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M8/<P:+Q\S$/&LP(VSH,MZ%0X['QP%(,VJ!2':$,/+$2#U&_W//_\,?!J#_I
MH?"G0GSW;B150@Q >S,4J;25*3BXE8[:L: Z3*BZA;NZ[_\^QN0S'UTJ'F!
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M?^J0P$P9T53S)!6!=CNZ",I!: \.^DQB@J\0$HX&1(A7M J@.?17*G^40P(
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ML$"BY;/H13&:42QA0))]HMZ8,/ ^#,7/3_;L"3Y^AQ!NK,I/'!!=/<SSB5"
M8A0B ][K!I #01A#=A*:0*<"Z9-P#.!&F/&G3[2Q@&D*0H%6[$X]=C  &__L
M01<'"0<#['B5@@#P<0OQAS@T,  ??*(8LIM'#Z2ZAUN :5G[V(<.>D _A/A/
M'C@#5H86<!1X<$6GM^CI5?"QC5N, E *Q-==_>$'FH2"L9\P3QDK,X ?)F0
MP$IC3U.(TDOV9*APX<QD53$ GNC%*L>XHC]8I$=25#- /O CCOS21CSDP"J"
MN&0B^V8,5@@B!P*@X#PD<(>>[*,'/2C7/L*A"U7@80(0F)L6FU>.VR1$ $F8
M*2A X8,%',,?ID3(".W0$[\,PY4_F"ECD3" ;V+DA_AB2"1%YYAY_ <A(K,#
M8T,QBKE )["W2 6@:- I52Q@9@*B0<M8-%"?L(C_@G_X04G*@5)<%<M,GX!
M&>7#U=5"%D/D(.5WN>H/G[5SGGNDKSIJ40M:3(P6MZB%"O\I"AL1])]0Y4A"
M%:JDANZ8>R_X!3. S(Q"#(D006:&+UZ@424OV:(L0,.2"X"![332>6.B@$@=
M$UHU14"6-;,?<6_; &,T9 *N@5$2?@ *.Y7C$Z=9RS>[^U-_X S."(FE/TY5
M3I_XY8L,DH"I6*N.5.R@<L7QQS:4BB'IJ)!7T.F&((*6T[O"8Q0\: !J6&$G
M)(AD3IOM"6#F03;N(B1!!5+'****NSYGJ#<QV::<\55.2 T%1DA  L&T&D>?
M#"I@E %G!. QIR3XI!L-NH +3F!<BP4 :V-6\<OFN&$L$4O6)TEPW(R&\<@Y
M-T ;<Z(@;O%1D C88 Z0@N2XCJL1.X6#*)*T0V_(L0]+\LT_N'EA#FKM R0D
M@2&@_BXOC3@R."T&1OKV07>D@\ 'ZC*2X97O!(!)$ '0.B(^$)L_D-$#U/A@
M#S7@0*=BC<4?\!"U#5!G3_C1@R34PP>A8%$MMA&BIS"@0*&X< )[FHH&= -'
MXO@PAO*8\AXT!K40*&1K2TCCGL@XJ_]*#Q./)H#0'">)QSQ601KHX1-@#,D7
M/K''DYD<=K%?B0W*V/J2.:H#,%%O#E?&$4GK*4M\U&#82$&7'6@+-!_PK%#]
MJ,=(DD;)<(PB A_O+@?XXY=I(OIJ(7<,XWW"5+XX]2,JXI K4M*-#AU]@:HI
MR ]SV<*DB8H;A,]FX/-!#E9D7D!^3#DW4?X#;HH:*WG]"$OPH?H)1&"R$J/!
M,.#AJ#E( .2L/5KA^EZ/O\XRE3[)97?FD,V>;+4?/-"!7!-TE$\,0!P^&06!
M_=$Y/:F7L]*V(F*)^]H9Q1:(GQC&!"IR"P(Q*$[DX$M2*0C?X>; N!F,P"W4
M820^RQ]0HJ?_A@HW+B94^BX?>.;PP&2$XFO\C,&5VLA1[&5O[D>%X*2%ZL&E
M, 2XC$96^J7O\,%S)L &@,^M+BLATB1 ?L '6D:Z<,,Q0F$"AD$"CH$?<F /
M0"' GN**+.P@E*DG=&ZR'*,;/JP>;H$A0.EG[L '[ZC/!,33G YZI,?IG"<>
MJB,#<&P%%JKJ&DH%T"#K>F(=D@Q(7. <?((>U(  QNX-X5!))L$>_$$9F(RC
M<@#&PF1,RN3M6C#N3DH'DLZ")D"=[* !6B@W?J"-6"$)&DD0=B[.ON)S8+ G
M0F'96%#/>J+36F8><J"IN$U/DF=7*LMW>J P6B]SF@^,=.F_>NH0_]5A&$;Q
M/2K+'S;-*OY 9CBK <*K%AA@U#".6N8,"2#K^V8F+FJG(72G^)C0C?0((6Y"
M$/XHV]0I@]0H+'HJG :"EH!1$ +@*"!C!BEI([Z"#FB CAB@S@1(C\(! C(&
M(;9A -1/1K[E&>U $(5HSGZ&'(EP@G8I O-!W3HD I^IE@;,GT)! ' C'M_Q
M(T!A#OC#W_P! GL",HJ!'"# #HB.%(CQ?A0.SP;@O2;@@AX.8%Q)'/EA#VHB
M0=1)'CA@ O@#352)'T("P4P.0R@G"6K@*Y@*X$S+3&P..O!@)XFPEF;$P]3)
M/^P'C"2@(G@-G)S+4QS(Z9@."YT'JB*  O^Z\ O!T'NPSD4(P0T)@ WDRA_N
M(0V<A #<<$K6,BV!I"V51"TQ"BZIA"[-QRY5H!H0@AE4 "_'IP R0)+6KLKP
M@ )6[2K0I(4 $2&$C6]0B?>P0CR.(1ZVP0>Z11\%H1SF 2IX2%98(7\N41#(
M01U.9>] 4A-WA0%$LQQ$IJF:KUCF@!S@(1Q^8 (&(K0R4QU6BX+\P@Z4IT$8
MH"+PY1/4 1Z,(8CZ81M\0S;9S39UB%G$A3O481N0@ '&S!8P$:\THS?)81ZV
M87"HC!R$HASJH1OL@ %TS?%HIC5>C#6)RC'PH35HP7A$)C:20/KJ"]@6: )H
MH!:TH2 B93TAP!7_U,$]$4<GZ6@!ZBS:GE%D/D$;:J&WADY/]L (QZ^-]&0!
M9J6+?F9::J$>Y*$60.=&] \:AZ(?YH$#;( ;\,$]JTD>]L45M('P!.!JQF0
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M<$DI1H,:2" "J7#///" XQCO(3V"L($=!C" 6PRC 0O-\(LGP($(X('&G>"
M( P\  C0PB?:_] !? W\47^H(PD+CG&#@R+BU6TC H+(08P78(?H'60;-VB
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M#S\@></P5*$P:3[A"I8F9TD&3 D8 )YV$,7P7^40#[4  0)0*7 G 8P'#Z&
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M9W(GA@R8!$,<F$:-FAJF; !BCYTBR-K  %",M,07?N)1#!'0 ^8AHIT@#_A
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M;K"# 1";4%B 3R '1EJ &B@G71B )-B&<D@%6G22"-"!P[L%&YB N2"'!F@
M.V"%6\B'$T1"=5"%!O@#BW"(8RB'6Z@9S]@&*50%YDB"!NB,<AB%!4"1>O"<
M5(@3<J@!&QC_!G48!AJH >';A@80!')0!U9@@#WX#SMH@%MH$SP8 !M #GC0
MA@&8@QC2!A]@  L)AQR@@6-P#',4A&X@AU 8 'WQ!UU8@#G8!G(0A 48@"WQ
MG)L1! D0ODY<R>?+ABP0 S(8 R801 TR&^[[!GTPHX0!@?&#NG3@ATJ(";IY
MGE6A@_<+@B)H*NY:*K_)-UU@2:A,G?[!@/_[B%JP@_UYA0$('67TB\>X1W^
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L( 7]XL *8C"#&MP@!SOHP0^",(0)^QM=+BC"$Z(PA2I<(0M;Z,(7:C @ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex-99d3g005.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g005.gif
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M^?7Z^_GV]OO\]O[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
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MH(Y2VNCXD)I*::6/8BIII:":CVD:FZZ:Z::+RGHKJ*F":K^K_/>O5*U3H94
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MTF4HP39LY&-LUJ4HQI9ZZ/-Z>E@HT29>GH)LG*)/,P%>X+5>_F,K S1?!!1
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M BKD3!VD+7U(2K%%P49@2:\E LO-216X4=2[P+I4RI]#A[ -0B)$R1E4@2%
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MPD(\@B($K@] L1030HXZ[A64@SXL H2 ,0^ <916 0[T0GK$0R%?Z.;B3:0
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MHO\1&/9P+OW2%]ZQXWSAY'[Q%$*  Q@S S)  QCS T) !$)@!$B %$O !$B
M*%-!%FYA&J^GG/ A&V!R%4XA&4<@!$+@ S;  U23,3F@,C.S! 8!"]_0%JHA
M'/+A]ZBGW^0O_WZ3&R.N_H)N[>+._AKNZ##Q$/WM&OB.Z9B.\*0NY8"A$J<N
M'J5S'1L0ZA+P'@=#"=,-!G>O(4"/'[P0'N8AW20RW=;!V#B/]0[J_192]<X3
M/>^A^<#N!>LSWM1/'?21@Y3((U8C'^ZA)''2!N=A'@J4_3!2_5CR0;4A"C7N
M%TUS"TQ %&;!&HQM'CHP/=$MWXQC%D8@,TO!$\1 %$S_81!$014U80R9<BJ!
MT0VO4A;>4"JG<A7(DA9T% ^_S_NJT W+CT:;,15H41%O01K",@[/+P_-[P!O
M 1B^SR[#$AH/$/RZ<B^7]/S.4@\73RN=X4@'$!C.<A84$S8Y( ,XP ,\(#95
M<T25,3./TA-2(19\(1L^16[&8O;R@1MNX0I/81!(0#4K4P1(8 0^H /.U#'1
M5 ,>,P-:TP-&H!2PL!:TH1[:ZQJ!4_[<+E,CKN?P[C@1[NZL83FI 1JL 1AL
MH?P.T_R: 54KD>/Z;ND840#G<0!E3DRG\$MCCO&P4SH5KQX/T#L% SR?S00Y
M3_>BZ^MP;_- 4-V:S]F2$-UB_Q ^02GV#&+S\H%#T8U#8^\#$?38VB$',3(E
MPY4GYW,CX3-=$R);<U ?8?#8/)3]3C(<HC *[ZXE+^X6I%(816$S9^$F21+9
M)O#R\H(6D%$52T$3B!)%18$,5<$VI])&FS)BWQ J;;3\S.\.N5(J3?,IV] J
M:W1)M5)'P0\QL;1'G91+SQ+\HK1*[;)DCQ1)D50K 7,>.PX:SC(41Z Q'1,V
MU;1-W71$3< 33F$59$$:$LYNA&]/B2$6Q% 31B U59,V-<$8-P #T#0#+H !
M+N ",*!KO19-0Z $)M4:VF$W&5)NWJ%3>6Y3@]/NA%-4Z4X<YP]G^3 6'E85
MTG 5!_\!%4RA,\L2 &$5Y&@56)TT+<&4.P^0.^DQ90M/.X4U,-J!'?3Q0SG/
MN<@S]O3!"Z]-6@5R'^OM/2$EN@X*/B42(BVU\@HR7N5M7#.R A<210+TDS"0
M(O,Q7&&PVDH2)572)7U7"E,5;TU!$TC@!#(4)_>SWH[#8"_4%$R!%:%7*2'V
M#<G/1MWP>FLT#F$T#NW0%J"T#J623$] 4E&A:-&P8MVP*Z/4&<!/*[?TY)HT
M+N<255V6%@Y3+UGV+@'3&?:7?E/VZ9S!>VU!%C1A,1GS GHV3=DT:D=T1$]
M15V!%IRA&NZ4;C:OWV1!%6:2!#X@:E7S!%"A:D?  S8 33G_X&NWE@%46 $4
M@&O9]!A/@5+9@0=O3VY\<_Y^+CBS453W3^ZR(>"JP2^YLA:  57K,(/]MA0&
M811+L3)-<0M,P0UK ? "L>EJ]1:(P1:0]!:^]$N/E"X!\QT7U^7N%QAP]N0(
M4TP7;^:0E# C%S#:(1RB-2+-R_)&;_HJ+ST_UW/!=1_Y<3=C-Y#A4Q_BV$'G
M5=X\=-WDU5XIMQI=[_?0%51L-PD/5-R&D%Y3LB5_=^GT%0U% 5"--QN0MW/3
MC<EJHA9H<A"<=QA;<2E?5$@E-F+#-RHM]@V;="MC%!A+87Q7\17+<$ZMT [+
MKQ:H$"RKE"RY$B^UE(L/TT?/3V3Y_S#\[C<:578NW=?D4"Z+]U 61&$Q%=6$
M&5-09;,4E5$3HO@901-?,H(U"-D:?M%$^U5H)W-\-6$0MB S4Q-1U;0QNU:%
M&2!KUQ1258%.J^$613=NXB_O<KCM] \XU^[AV"X;4JX69*$JUQ +70%D78$H
M3P ,-"$92: 4&=@4$Y89SP_D D\ '5</@4$:[O?DG(&:5WJFN5BF3TZ-4]89
MWO@O0K+>EHTWKY7U-._8;%<];Q!TW?/W!()TKS4?VD$;I($.Y[ *[? SM4&.
MV8\&EZT>XABK89!:'8CWW((&;[>2/W!W'523094:@E<53$$,1. $9$&4!1(B
MZZTG_6(6,O]S8<OW%/26#6V3>RL6& D[? 4[EI&9F&EA%4SA%"+8--70%6,2
M%3S!:".X"FG!&0F3F*-:_.C0*V_Y /$0#U=V#DDV+FEZI?GW  .8@$,@ S
M S@ @6$S!%QS;-]4*,4@BL_/&BJ87D )7=;6%YQ6##WA!(*64..4*,5 $TS
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M$L'#@ZUB(NQ "ZB %D5F G;1 441 E;(:"5@%X0F)SZQ/9)S%[FE774G.1\
M*L_"$Y(3@1(V%K?P#NWUA^I!/^8V3\XW;O\S7^B"&3)1?6UR$!\@!F)  HIQ
M)0S!$,U!<,LQ""9@_PKH=PK/1'#8QCN^H@J&XR=_\A 2\7 ,!VFFU#>!,XWU
M1R;/R"4FEFO\  \@<T8U!&,J BLNZ"(Y17(Z)2*SL!Q[XC,FT#S,,3AI5R:.
MPH$],C9ITUIK]1X[P@XL<U/YT _XP [A  ]>=!7^H8 A)R+M$(-31X,QV%:'
M$@O+,0M;!S5>YS+P W8^:'9E5V>#%(0?F1%]QB>-!4R.R"QX6'?&,868E%!I
M00*](09))3V^8B&T!A$(9R:I@$MW@2P(P  AD J<EDJQ55*/!Q(TX2%R6!(\
M:3VM]GF1A"^G0@NJ4HI/8A_Z0 VJ\$#^=8B>>%D%584FH!,KV6RB,BK>]/]-
MG0A!<!)D0&$L")  VV-)"50*#\%M5[D>X59/^ -]Y>**YR9NZ%)+#Q(<P'$"
M(I!^6V *89)(?A4FJW APG% L7 AY;40#7$D:*%I:$)PS'AV8W)(TVA*9&=V
M@G4FAP22U;AP^O>'0^>-+38RQA53^\$B.A8S .A#(0,/M> SF>4);R$71Q8T
MA$)"M*09.S>0[Z$.H\$-#,D-8",W[> ?VL -(N-57(&0[^&!]/$?\F$CX: C
M4W=6T,DC:.,,R=4F2=(R& D@?W@\@R(XU0AIHJ,WS3@F&;@0IO"5QL$LY!.5
MM(=!57A)"W0"@Q!7=X(4!C4(;M$<$\<ELK!ZN:3_  A0  5 ;2:P"A-!.M]1
M,1U1)I^T$F^8-''(>77H;'?X>8PSE8M1E=; #7I9&2G2#A/9>@"#4) T,,\C
M!O8"2;>':,YR 1O0 5L@7GNQ%[JU8&@1DTM8B1:: (7Q<L0R E%4@C)*&7RI
MBJF8BO>4&6DC"PN!"M*#4+M22B/Y-WT62J\Q')+9$(U&- IA%F  <\GHF<L8
M1>B42';VD8-T9T(8FH!#.('EFCQX(RRV<?QA(NYU(EJT0[R9#S45([QF%L%)
M-'XU<)BS)UM8*-'A#$\%AV=C#=FP(ROV(N' 5MH (]O@'B^((_'!#4H#1# 5
M%?RPFRP(,S?&G>.Y<P_Y_YQ1)T<98YFE$ O6\']VI9$5QY%D)X]%F$A^2G8D
M5 N*,SU#E5WDLUN^1'L+%H&\LP7YPCOYTBL"UB]XLBO*(7B<Q6=IADL,@  &
M()<(@ $G8&$KP2BL,SHCBC1R%(=IXY1K^2DJ*95^ASFQ4 N>$:-8.AE?<0NF
M< )'4B\*E0$8( *,>41)!$E"(:5$P2QA& +$03M(>H>X<QAB8"L9E"]TP@$+
M8  % )2BXH@_<0)+40TFF)T*2Q7QQ:6"R;/EUHK[4TN*!"$V-P);X#D>I%&I
MF9-6DHQK@FT.L0IS<0JN826E(%$B, AATB;+B"72^%=?"[9\"H06H9K46*C[
MM_]TD+JHR6>;.90/!IB;WLE#!J(-$QF,6L*,3OL6>/.#S[HEZ 5JQ32#-+AS
MYI!Q_R$S[< C\-!T+U:KW @?X0 W(9> . )UA/NK88:>R85MQ6I7\Z%'/.B#
M5D(F'SF-9Q<+I<59IY0\P:&RV94!*DM)<'))K*<OO",OC/9W_=)H"'HGQ"%@
MFA2,KD 2R=5G13([?Z$ T+( Z9,*&W(+TBI%D_(1SN +T<%D<1@2J3 "WJ0L
M*NIJE.0\A8 *K@ ,Q "C.+L5)[(-:59!2'$"93E^5[(0CU04N!<G0)&(AQBR
M2:I;AE$"RR4]IC 7)/ !'W !"'  @L$ 0_$3(; 8HHC_5^I[%5J*BCT+F!G\
ML_L3)&2A<DE4K:EP$5Q8'9N32.[B9SBCC HAIWCB6?WD*T5U3LI(83\(MC>,
MPW^EM*=[MLK'D HH,EG67OIAF^18(%\&'^[@"]:7(6?B"I+9)GMK$,%(2F/J
M2$]$:UCB$2 !#=50#3N7(X>K,F65@-M G4T71%X!5EMS4TXG'Y8+=6B5(_ !
MK"+$6,0JJV_VGCQ8#:3+FO)(C1Y&2'KJ"L#A"EM0+,J"K6@):P&EN_42<P8:
MK@5EKOV2)^Y(KEAH"JIP$='KP:KP2+FD>!G B2&P"M)1.B;4A2<!#$$2*:V%
MC]/:O7Z1I"HI*G41@5,BPLX0B3SM0,&O@@^UT%\G<$"#,#L@( :S0CB&ET3V
M(DE!47>D++)\\1,@0!1;<$#"$8R!)PH7E$OAPQ?<%%DED JSH W\\<N606Y;
MVJ7[PQG$0$1^QBLF\!:%4"@N82@EH;2Q$+UBT4%NBB6G8$"H\$D0<1N.> (*
M<2:'PXQALC>#_!"1J7:#DL.#\S<]_VQZW(FH+],T4[:H)M@?973$\H& (K>/
M$CK#_54KO@*_!H500V7-< (&A0 HA$),3(89V;!6:,52+;@/^K R-Z6X\Z%5
M!8DRVSF03.-F,?,Q."*>9R5#W*D-U8 I%5%D22(R;W93R?IM?8RZ"D>-@85>
M:N?$*BP&&?"NXB.EN:,614L;291]S*.[CHP4RS4OZ<<\W[I<_(8Y=HJ!L^ *
MP4$"N707X(, %[ %LN H(T4Q'S$3,]$HQ$!+T<N]:LD7X-M++X<8$9)SO9S.
M4^%MW&"9\Q(<.A$"6S 6;X4\UL=Z0?:Z3>A-VC6QV"H4=N)H?9(X?0(PXI4
MX8Q[0E$*KO] #4WSV55Q&8'9/^S\&:/AI?IT$X;#GV+ $*L@>=8!$X(,$1NQ
MT,T!(5G2)K=A6EOB"A5"%(VYVA0V=A%]GX/ET!/]-^W]-WZK)=50BM")J"WX
MT;5Y(C.VD !"'[JZ#L"@"@E!PP05+PHE29'C ;I307XM'G"(-O]CC^9@N"Y#
M,OY0U L9'RP2'U+A'R"3<6VLX4UMN-R (Z]Z5E--?:YPU5OW,G@$&:+KQYL3
MDGUCG)S3C*;D9[%P BQ+ /#:P(@V5-VJ"73JCD?2*T<B8">01 /6: 9$+W =
M33]C0!ABIY\V0$4B;:*"ULB2 2* "H\''A'C:9/M.B Q"Z<@ M[_Y+^V/+#N
MZ*(ZY\O%715:N0KN^!9QMXBJ, O6&QTF 1$#O@4QJ6"^AX>\%%F10Q1_=Y-X
M.K369!?4S '2UC@:6@M72N?\I]R;/B[H @W D%R2V<TFD(Q]3A/=40L"Q*>D
ML]U7\J J#1P>)@O8!DD)K3=;VQQ8HMZZONOJG26\OMX53=\\*$1S_(TU)%,?
M]U7DR)N/&FX+P;=F41?&1BQTE]EV<J"BP.>*4A->W,7_\Y LQ;A?5")O]G_U
M82!8MIU@0U5D_,9@8^*6^\,@(YY3K1* W>*?.R)\'"8V+C@>Z7!MU^]]9B&:
M@ $%$  "8 #;!%F*AKOQ$B^],A>_DB=N_Z()P(8<1.8KY?IK@S 7P%(E(=5V
MV(=[W<,3BSB4X;$=YO$=TR%;, $,M' *(V#REQVPB%Y9?G>7.:>/7%W<]6 +
MJW<*.%,*O/.\-YV]K<6Y/A.34,@XD*-W1%6RGXDA#I$*'J]]M@<4Q,:2&6(-
M/I_..JO!G.[.^0,D:9-<"C$(#7914^0HJ)XVAI1(SU$1H90A.;.A_?4KC5E"
MFB(&D\Y4$<VU$4V_]/OKO?[KA__0:M?>JS#LAOJ<B$K4[+2VZ#Q33=+L.":(
M; (HI6 7M/._E'48S!,TA&=K,9$T$CYU(#/N7N1S!K+4C-LT+0(/^,%E,#(C
M:N3L[:%B:7MQW/\PU=(P0%>/Q_]QK"T&9S+.-Z4[\( E\&(R:2'   ) _0(0
MI5'8K4DE474M')JT7#[S+P?J,W%U0']'S)JDS;O8C!I5$:,]:(^(/IF6'9,G
M$B>Q,"@AV;Y "]P+^L8"$ PN9"#(@8,'#R-"C"A1XL2I5;.H5=/6SM]%C!DU
M;N38T>-'D!OW^>/'SUPL4Q!7G3KQ<-:MB=:L5:-&S9<M6JM2B1)%0F&($ B%
M(A118L11$B1$I4QUZE0JJ%%3F=(DAH0(@P89<LC 0:&I6+?R\<,X,N19M&G1
MMI/9UNW;M]K@SJ4K4ZY=:]*HW<JY:E5/3;-F$2,F[68M6[5N$:-52U;_+,@O
M:\62ZG<59*<\ER:N56LEPD&I(%]N^C359<NI5:]>'>NR:]BQ94.&7$WM;=P:
MVW%KU_L=/'CXYNG;1Q8COWXD^>W+5P\XO';/X>4#WIN:3E2N5 WR<&$! PP'
M17Q82**$F%*F3*5R%6L68E_$G!&#6;.M-FW;N.WG'3T?OGSTX2<?ZJ9S+I]]
M!/1''WSV&8FZWMH)YQT G\.G.N@BU-"="-G91IN])DO%$T]<L28XZ:3#)S<6
MU;K./<%BI,T]&&&D1<;+7'EL"PX4(""   0P8 $.@EJH!!),4-*$$T018PM-
MJI)R"U&6%.,$3: 4Y00Q1/&DRBI-^#)+44HY_^VU]SH#II995$%ED! ((BBA
M+591[)9;.K,E,<YLP1-/8/"D)E!G:#DE! P$8D"@"P;JRB /@&+(H5)4><F:
MBEK4=%./^M&F*=1*B\46:J#!]%2:<(K%E57>-,&GGV)-:LDF17'JUJ:D@BHS
M$T;X0*@23/" H(7JE,6BBY+C=%D6X;FOKE.AE:F:NN2Z"R]MJHGOEEG\BJ64
M$U!!3)KY?,&SLYIP>HPV6WS)*=?31IM*,U%<X=,U$C8@ 977_"KM3,L 9FW@
MUKQ%;4;:4+.-688OVJV_Z((C<*22_*&88@(OE.Z=WU"$)QS*4E%%%E%"\ Z\
M@X 2@2$H/8GJ-5IL<?\&&%ND";0^3/'3+QP/>>L8GGH"+#"X"_$IJ1^RD",I
MGW=Z8X>==O"YL!Y\G/O--PTSC' _$/.,!96J9-'FG8Q3I+IAAJN)+$891XOH
M1EKB%DRV64S1P  !!"! ;P4N*/*HAAI2LB4H31!#$T^:A%(,)4E(',LNMZSR
M\,'1*_.44IZRS#T_JZFF4%=2*2%.\$; ,I8[;]D3,9S>:ZRS6YRYQ9>:9J<E
M%9,O8& !W1LM*"M)&SK!E%5HN:6:;9!%>_FS^-''%HADL8Q?XRF*5J80:9%%
M.U1,X6F0EDY 4LPN-1%ED$$R-TVJI]IWZLN?(CVAE!" )^$R;1QD?G^/V)+_
M]G^Z7 LN K0&,)RQ)^EA1A.K^%.II'&N6@"#&NH:35BDX1FIM$<5E#F%9@9Q
MBEG0HE HV4 (1(&:4#E%8/[2"<%4XQIOP<9@%8PA;1;&OQ;MAAT\@P[1]+><
MLI"%.<U)4<0TUHYJ0,44K"I!!A85GD@M9 1B6HKF8".+U,$D3Z2*"7[RPPYS
M]*>'P '0T/"A#^J,A209Z0>$VO$TX!1(:M+I#3S8H;7H1.A#$YS%U\3@B5B<
MB$$:LU ^<-@BM=DHA#="6 C3)(M90'(5[>E6!PY0@+P!R0!^.\@(?$*"Q9E
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MM*,'&H_<L$:(*#,_65B#:O\I&M$@N_.-6(.R<'/DW 0CBV7'K4:Q$$$!1&N
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M )(+/&F,ET"N4W PF;&>4]&N/ &&7PI#%,.B,*0Y%[.I4=J"_WLJ/]'HHU3
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MYBFZAFW;3)Y;BQ(,(  %*  #./ !6QW2-5,9,J\&+";,EM0XODD83)9)C9I
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M"*W8<N)KAPQLQ:B0@V9'!G]A7*%'-0C1("!05:_,#B%2-3L0A#& E!@D[)1
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MF:I1I'%HU*D)M @9A,KEIQ3Z7?$SGVK=(#BJYQXA:TM"/,%*EZ.<NP+R Q_
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MY<TST"3=>.9N#M"&1=26%'FGO^M+G =.+O)#*%";"H# &DZ(2* Y) A0($X
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M_#*%=G$&:3B+)[D/JR@+!02&D%*5_#*YEI.;A9&IQ-"$0IBGG1NCT.@,FN,
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MBMYXGCJ$'GZPA@\R-UJ)#W<BEN\K!)D2@Q$R 1"<-WL3L&<4%I6PG_K9-XR
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M'2*!GJ /-<*=:!(@_<@3[ NF>0F<')7_)0>$!EDX!<C4KLFD%$KA)O,AED&
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MLBR6-P++-YRN:%=XGD>O]J$(XVX9:C+VBE -1:NX!JM(P!&O.!+PE9=F@ U
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M6$LMT +!0SA80RR40 :HZQ;&+X=RK[P6Z04W%-890 8@QG-X6*RTCT5@A./
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M1P(>+F!I^*5@7)&/;&@6[<-?!NDU>0\7K2+_%U\$0F $;PY@ *;' %2$ T8
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M6J]&58! 08*T#"YDX. A! E3L6SY_ZI%*U8L6;/Z3ER*L9;(4UM*A$A  *R
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M6&,0"_B50#H@K('$R4;%:M((25@L@C0' PRH30="$+Y2N.(AV9J%72JR%(J
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M_R)?%#R\39MQ3_+<1,N/X22&[_A;Y?YBW.)LTH(!(N *&J$<3>([%T!=P)0
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MC_-71O9W(.16-/Q':ZE1%N[F-1YP G=5"Z%7(QR0  ;P%OBF)@PP  NP :5
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MB]21Y@ J_!.8\! .[T"H 80VP. -VL%XI_(.>8>)I2)3<?^S#Q)D*Y-B*_7
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MSJ1QT_0<%H<?.FO /3&C[50Y='23*X(Y.YHAU6 H)%(4IQ<BKJ )(1!H_W$
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M"E)3AO]?]LY4T^4V,8!!6>!D4S4G!((I@B%BE %@7*L!,J2G' WRO#B7H0T
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M$3Y8@((+'L!!!R;(HDTK"DPHH80/#D! C!T^*("--^(H0  V1N@BCC3VF&,
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ML#-3/'(]=CR%*K9SR%/,(A;!"24'%C#&#:SB%K:0!3%J\<@1)"<$):B:)L1
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MA)(LR.M(B"B4X(-F1"HWQ(> P$.QU9\VG.I:+$PLX&7"7&NRQL6UGL#A>
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MZSL08L-> #\L+0"4PAZ.@-X.J.[VK?I&R;$"P.]PK0BP!8_MV(>U@S@(16(
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M<9XQ &P!6UQK!O3N")BLSEJM-63 D)22W/I#*(N X50# EP 4-2M*_3#"!"
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MX /7/FSX$H )C(".Y&K<!D!($[H_A ,N8\ )B.UUI[K>>D+<-FZE&X"/ <
M++D_Z$/:]G0VQ,+37A0J>+4G-"S+QO\Y "P JT.M/W@O!P!(N2, >?KQ=GEU
MN'(#+B^ "&CLF_:#O.M>O7.#F+0\ =PW6]C"S-K"_%SK*=?#LQ( + U)KG8U
MR_8I !S LV_C>$-\"-3\^D2N-IS"%I?\=;MW!D 6S)?RS/L#URK N!)]]GWN
M F3?8 OX 53#2JA9*K2#-<Q"N+8#9HANW:J"/]BQ/[C"X>;#X[ZI4</VM6KX
M.<\L (![/:BL-/1[L<["LP[K!?@T/"3OL : "+2GH1>O/]S"L]:PU0Z] (Q
M+=2B6O!S &" L ; "<R6-2@ ]0H C&Y#00"WQ8: 6CQNYM7PJW)#*@_K )2"
M6DQOI(G^*+__Q><:P*KPL0#G72DH+Y#.EC9$=M%J  "LZ4'O"&POM!L'"+M3
MP[1I@]C* EM ? 8L],>["OMVM0%4P[E*K)=>*]C+=#K[0Z5K IV?OUOL[Z-#
M+N0J?OMO[V7Y@B/7PCX A#8% $[Y&P$@0[M\JP(0T ;O0  . 0Q0\\<O X 2
MVMK-HI;/7TA_\!  6-5/%( +_+81 '!+9$Q_\QB8/&# V@("J (H@#?RQ $
M0P6<V.?OQ%"E  2L$ID* (-\VES2DBF3Y-*A"ZSYJ[= *P %U4+FXP#@A+]5
M !"TN_H6KK]; !;<,F"R%  1_MK5DM9OV\!8_LYRT.=/A%Y_L0 D_W!+30
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M1Z:ZP@^JA28C)> '/BI&G0!0Z!0#$( V9!&5Z^PC(P59R[;\80NVM(,?-2'
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M0"(Q6FMLO._[XH(_&DE8;$U(DF(Z_(7^]($GO&4T0@ >%DHJMJ$ YD<; F
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M,8Y*H,@2P!,20$4:TBJX80$,P!;Z 1@P(#(&( 38(8D\$FT@D#T2H$X,H!1
M@@0"P!1B@AH, .:PXB")HTJ< I;F;_YB3\TN$*'R@1J*R1JHX2>X@1A :!MF
MX8O> 1CH1S86A!^J@1K*9BJ;,GBHH1H6K"\\HAV)01UBXK)BP1;>HR-JP1S@
M@1JJL!VH(1.C9!9FP1JX1396\00P8,&<DGL 0 -9B30Z4#&4CFG$)P .I!:V
M:B <,DI6D",&X@+N4?IBPAH*Y@#_7"( G&)4I,=U;F%6HD($[F)*XN3?),PJ
MQ"TDRNTG6BH %D H%A(*?X),_,IG8J<VY0Q!:N*CM$$H="<UR()EM.I5.(D
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M ,+YB7IEE]*YKD-"'!XG+2[D %:0:6#B6O[:75T*+O!!0"X$2D9G(OK9@0#
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M46)4"PJ0.V0C1JL@,@J0 $BB"NS"#^J29P6@ +%2"[R*& <1"_+*6D"1 0G
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M#U:7 >XB"OVP:VD4:!$2%&BW#<<A$:@ 4EB3 +H1,H)C=HJS6):Q%"X4;<1
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M<0K#="T+T0^BH #O_\FJL:W4F=:"^WLE"3 (3TF),]5\2+44?[0/&<PC2SH
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M0W?^EN&43YAV?OG9#@=.<8H,". 4_ C)JTR"D@.L!$S*@0=;[H.!!:P"21Z
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MT6OP!K$TC1R#@0>,I1F8TYG3R>Z;-' P+D!505TEM6)CC!DHA$%C*]6X2"S
MUN[+!R?H5G(D)<I(L20;A&NX!EC-#'>8@>][!3$5,WB8-\O0!RPXT^W2A2C0
M12?DRLI0T*1X!Z$#AV;MNUH#Q(^]RRW*&>KR,H0=JU>( 88A,?/4C(V9TGV9
M![9Z@5[CS8>X*XU-58H1ICKZM<Z3*RY3O!D --0 F!)K G#(A_L2P%=("@%L
M02>[,M,2.G-P B2+!QB;&'C @B;KUT]2L$6\!G"XI(>@,(:1R8APK%RBT]JR
M!REHLE7CVA=8_S0]&\RPC( 7P-N\E;+L*S<\O#!PM2.\"@T@O#'*N--<<AE9
M UPAH[L<4U;A4HV=$;I\*(1=L+M"J)$-$Z/0F"YX0$%$O(:!BX==H(RW4D*Z
MTX<X&@U?(+W0O89]>P+#X+;6B <9B,UD<X>)TPR.XSKN>@6O"\#\C(UX2PI#
MN+?(>]N]4SM5TQAOB+B=I!APJ ?,P(;[$M;2:+66F0=R+!EA(X;20)J-T0=O
M*(WD&5_P98SOQ8:1L0?, (?034US%2W7B =OJ)F==(UQG-^L)%]BP,-L H>;
MR1ES*(08P#-_6!C+^[B]+,/^%4J- ;2%V5[16B]1V0=O2,@9F%G.G/^M*)"'
MCSVLS^JUA["RN%HXF",:B&L,4I4(W\JET'V95./2)R#%>* 'F?2RU:JTVC/@
MU*VM!DY+H.$M2@JV--U$!(H';,"]@HD"] O<S#!B8KO5A'K(TC#']2W#0I
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M RDWC5,?[^A//+G_*5%"KK",0AO-@QCE#48!!V0NA()H:-0:!J[G+ZQ\ 2O
ML5&.-@0U4J"E.4YDP%QQRFV-*>DN((@0>)%%"A<4"Z."ZA7FO)08,2V@/V;B
MG!-=Y"&$ZU4\KM(:3::J=+0$QR%GN*E>9-0;*ZWA1 <41EW4QYLE(M5PS.$$
M*5 Q M$R1Q.&,@\H1&$]S"'7=RHH!4S*H!!>G&"0IH84N4:!K079&3CD8IEY
M#.()\<A'%*+ H7T80@)/+4BAC.(A+$S&0;V(1^+T(B2C)(FM2 G-N6#ADY)8
M!C6!XRD\F&:0S\G ,OJ0PH16YS;&.$8?4!@*9?(3UN$2M[C&/2YRK>($_SHE
MM[G.?:ZT[).BJ?@E8KR*QRM,!0_6.&%V9D2?4U(VB,&0B"RZ^%X\H0,<>\Q*
M-"<BI0*U\SO*3JTC%+28%(8RQZ'-XQ4P05:\).3>6S%55S![A7KX(07.0BD*
MO9B-J?SQ(Z^0%'MBK%-VH7N0,'9-"@N. DY8N4'L^,4F,Y =%)I@*M0DKS%1
M&.H+S)74* !,2%C0A9;.2:CSG JX1-5%TF:4&$/H@@N+)%H48 $=B1GD'5&(
M 9$_!!-L9 5[[ML+%B"B"S2U-@91P#&;_/$.LR0(;@#C*A0^*UL+Z_1&8GL%
M*T 3P<:\HRS -;"&\ZSG/?,Y3O4@6)\#+>CB<O]5%_,8703\4@\L ,D>[R@$
M#**HI1B8JG.M@2L7*,0<O[ "-_" QVVB)<Q])HV3V'T!@'"5HL&,)1Y.B,(4
M45-?4MT7</S81])Z,8]X=!HFI>9'?U_0! [9JB#WXZ1;#BQ#N1B:UY0.3S[F
M(1=#-69329J!)=T!:1EKV!RL*(0AP"UN6-CCP<#9'2ML\Y9"2,$0V_21$P_V
ME54!91?16LZ)O!>@:[!B4_LX+U $Z+T4Q6/+4B@$S#)7""PP*,,(,<<KG&@(
M<_DB(D!YL%X*[N%"1%'A^>W%=%^(H4>:EPNZ]J\F7_$];!C"I_I*"#%>H1R
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M@Q--ACL@8L"XX8 4QPXMQ'<=%UY0(N-L5QP*VB%*U/_F"0CH*40.6LP5P8D
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MT' ,-R54.I+*Q0LQ1-B>;$H\V.E#3I*]^:/%1*#VY4,^4,S$81(P>D/'\5Z
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M#C,E2 B$$S :%W B%TJM9A!'1;V#'0>(THXJ4$ '67[GV]US2Y[_VTQ,AD"
MQ%6.5LJ$%R/_3K7@S7B1!8@YAQ1$K,7*A6:Q#0@^ZH(Z4:H\M,<0A$U8QG;9
MR(-"-,K ,*&X\E<<,',TJ$+P%/88FA/QPS /1#%;;[K\8?'HRZL!QW5F\QC:
M"P>[L* X(<7D3"+M]>K@QL4:D<K PZ_<F3+-UHW)P$\@A100C_(I*7JT&7;
M!0.!E1"5*V%4$!>0DLK4 V'_'O$*-!>(* 6'CVXX83X4(;/MS'6\PXF%+RS
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M&&0E=V)XBR@8'HI(*D.:&"R>)F Q9X:%]'G")T)?:3#.44DM529B8+B)E;_
M<F*LH(:B\"2<9%BQD!DJ(T:&09JH# O!#')GAB@NVH4RL,3R!Q:;#HI+HT+_
MS +*K93TB0**'LV100I]\N*"2G#Z4HJZ>:*H="5S$I6!.FSD.N@:*9B:K+)J
M,\/)W(0<U6<0T4(K#=Q8P<&".A/Q,O4@*E-"V#6%7V*8'E8&5HJIEA@>M>+U
M&*8TRC@O-MCCCT$.6>2122[Y3:KL\X>>:UJ;JBH9#!'NA8DMNR:>?08A]K57
M>GEGAEBIT@C<29WHT) H)GMH'RR@P-&<'4V.>N2:;LJIY7E<!4JH@WR9U1L9
MHB#F0QA@.8C<",:B2")PKAGD!6![D<"JL,8RQPDG>O&&*D,**JM'GQT]J)"H
M@.3B!2C8TFO,M.") F\,W][X($,BV,H@?@J!X15O_XAQ HJOXIHW"D4#?<$W
MNV1XCQ49^)4!4']8J8IS*&9(6>K;V]2W"6+ \:4)+"3'/2:-A2_>^..13UYY
M.+V)H9#!]HE=HZ]CIFJBA :!/BZFQ#7H&AAVZ11X?\R)8E9SVK6WQVMDF(%T
M?W9Y(3A_W(DBBN"7S]^@P_9<KL=Y!K$0>&!A%P<A1A3L\ZX9S, )NE"8+IR
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MH(Z#3-5Y]J%3)" Z?"@&-$(4@\)1AA$B9@"#C 0*;(U..T-:'(4+(NAC#TU
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MCD7*K5?ZF&.XI(192(G#C?&B'^B!'LC!&!Y!$0)A#^2@LBO[#N3@#MY@L]V
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M\$ /&!RS,;O2-WL(AN -AL -5F -@B$>IMB745NN9IFBL2[#266JC.HB] '
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M22%JC'RTSF"U"7VP$]V+(QCJU&.]5J1JQ!M3)%F!#&4XS4 (5SUXS]0TAGY
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M:JG&!29O<B=G\EWPAI'Q"RH7R,SP:F23R;H3:[:0IRK7<C#WQ]K;-9);C&"
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M?5"$-TB$#%8&0!C+,A@&P6B$-J"#%1B#.6@!<^T'1DB!/DT!%L@%,1E0$,3
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M@LP#GWR,YAVDZ'3&+@;JEY=RJZ<L@2T*2-:E"N0=,X/_*SO:=\N^WGH@P(#
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MA ?V!RVJ)&N@JZ1.&@_!0^N0!W%EVVKT2SYXPRYP9':U SS4 X1 B)&&HB_
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M.X2#-5!#!<L"*LB>SYY2* &M*O!>+7! "*AQ"'2 !MB"*8A5]PZDV5I#*8Q
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M8A_ZB(4)2L&-F=G"!)X(1T'Z\:ZJ*>2)7I*=M):C"0'N1YF4HQED_Y0$O72
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MQ"=^& ,0<!C#(/+AQV*;>RCR8,0:RM"'2T?V!I*] 7V=_,;+ZN"_N<C%(JS
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M=VCL=SS7:</0LSW0O#WPP-T JSQSO4_\>'P,R* <RJ+,'.@0/"X;K@:*",&
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)_<_?_*01$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex-99d3g006.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g006.gif
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M^O7\_/CX]OS[]?[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
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M"S]8F=?8EF=OL?FY/_K*ZG\$G0I!'=I0L*P!V@I5(%>R#1=B6:N_%\76?]=
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MT&1N]F',"NZ#-<E!8@8K.-$1W;*"N_QE5G=XTD6HPQ_^ .<2UR&Z[KQSA?O
M9G_NHL%RKK 1 #U,9@0YQL(XKS\\[. SUS/'GZ;!KMNY908'XYTZ)@(2..Q2
M<4":!D68PQSJ, <D(,'8-)!Q2/7A:1H<@1SF9'>)]^S,&H^9P:>&Z"X63 1\
MMYK \L SI8^A#V'J0QA&*/6JV[D/<7SC&^0XLCT-06<6G\/_X=_ L* 7C AG
M6MSAO*[GJ/.L:4<;>LS6=J?'OS%?>D;\G]_P=AW.00]XO.,=O25QA17N44PS
MV CO#N>32]W@80]SXA5&=$4/K?-WNMS?FR7'$4!MS6=OW)OT$ <SOG$.EB^S
M'O2H1]>?"8^LDP/D_J '/?117'_H@QS?$ >;]T&//NM<'_>=NSX(WG8WPW@7
M7X?FU]E.38LS0QRW9J>O&5R',1O"G%AG!CD6RHL2W_CN:=_GY?$N^&W6H_!;
M%[LT]>%QLWOS\L751\/A\?6TAU[SYNSV@NL \CDO>,K<?$?9S[Y,>KQ=Z^<8
MO-?3/DQZP)W7'C<',=GM;G(*G=(__Z8!QXG/>"(D^-[<1'[PGYGV^X[>^.+$
M[L/!J>\*W[@>Y##\[HD)#X?/_.JM]P?[X^[,WG_#\.]P^M/Y&O4%SZ'DR_R&
M70@&8=BV93H'1)B#(S "(U #03"R99*'6:N#06"S<S"$!#2"(ZB#74"\84*$
M<4,$>CB&/CB"(C@".Q"&8F*&.B"U&*L#0UBH8*B#&5RN-Z.P!4.".K"#Y9)!
M'?P_8F(&05"#!3R".4 $3GL\.V P-5@&->@_)"2^-S,W)( P7S,U?UB&&:P#
ME%LF?3"$&>R#Y/O .NB# J0'8; #)# "%5.#/CB&S!M!)"A!)+ ##I0F71 W
M0R '0U# .?^0P#J0/MX3A!G\@PZ4KI@#.?+C-VI:!D%(0!,$1"@TN#0L A6C
M0V$8/'J0P%WX!CO(0#O8M@.<@P54 SU4,B(P@G* M_[S-"*0-G^ N6_[@P8[
M-6;X@U$T BH4AJYC!CO0P883P@RL@S>L!UZH P5$ D$ NF%*-1I0+A(T03L(
MAGT2APM$1FED,WB0P&#PACKX1/*"AP\LP0STPP?4O\*JLC%# D-8!JXSIVX<
MN04S@ETH)G@@M0L#0#R;M'WK@R9S/CY A"+(,R(H I0[!C)#.CM8J$/8-T#3
MMWW+LR[KLV^S-&+:!6]#2/]3IV)C,$&@!T$H-2[LPHFT-RHL,6O_$SD:F#UG
MBD4:^(.%RK0C*#FZB[02*TAK@@<=^[1)ZX-E](>)0[=3)$@$[+\.] 8C4#!!
MR*V67,F.:T5M<R9]0 2$B\<Y8+%]"$BDL[<BT(5B K@%ZP/&Z[_D(P>Q)+-Q
M,S&?%#UVFP/%0P*@.S1TJST:*+1]$ :,+#$C0(3!TS@BN,!(.P+JFK0&LP/^
M&J:'=,6<&[,B@$%G6H: 0\A"7"9X<$(BF+4&D[$PB\<E*[IS'"QJ&[HYZ(/A
MTCY_*$MUM(,Y$,AV^ZXT6S"%'*9S$,L8ZP,U<\GY<KX@*P([Z /%G#=D"+*A
M*X(^6*C:(P) "X821+HB*#= 8\AOB[!C_Z!*=$O#2;.#[4*GHR."+CN&U7S%
M9;+"Q:O-P:3+89K%;^M,#V.P5<NT1ANF[EP\0T"$/J!*F2PF+[3)<!-(!2O,
M90)*I%,P&0/)]>PP.MNY;8H]2D.$8-B%!OU"&-.%;[+""D."!)2W_UN&^NR#
M6VRPMQRFK_PV.J,!04"[4_PVWFQ!5%3+;V++98"T[1RF >V#>EO$87+1!8.U
MWMRWV\/"*",",M1'@G2P/K"#_:0!'HU+>1M/OULF<0BX'ZW-$C.$>M3'U11(
MQU//X30$0^B#U9P#P_1,P:([K;0W(W!#:U+/:(L[>%"\:%NH.Y,]MINS"C,$
M>-"'=SC//WNF5O^D 28D.&8@M15#NR#<4;CS0#I;AGV0!W- 3$0@A]+3SN]R
ML0_;!:XC!W:K47(B!^N;-]=$Q1_T5") A'?0!S[3RBQ;AM5TO \5RR\U3Q/C
ML'T RG0;IKNDPJ*KL0 5!GA8+[-$A&("RF]C1V'@!2Q45=Y30G2#0F=*T)K<
M-[VTIF\(U$J5AV\0,Y>\+T20.B1(U'W01J+[4,A$@F! !EU8KE15,"0X!GK8
MAV^8S4U;170CAV1U/'@0RUTX!ALC/G8S@F!0.W%HU1G+UU(+07WXAB<]@G75
MA_#\@V(B/P9#!'C8AW=(4ULSNA*+V'TP!S$SL]@45UY8!D18N61]1:D&- +1
M+, P_PTL>I#!?=S*7V55'%Q&3:P#0=C%^ LX.RBN- O0)MM4!5M5YR,"'OU)
M'*W(B20"%F-(IJO5X!3)NJNS'NU(EEO!/C"$9I.F7/7+99K+5;51I/M.>TTZ
MM$M66D77Z%NF]MRV 0U,R2,F<7B'3,341 /4_@.Z8/U.?W"QHARF;T!*&O#:
M<&I62:.S(G,F[819CZ6X82*[8T"&:!*&?<LR$!55:?K/0/0'9JC/%14GMN2S
MUZR';Q!($#O(\B.VOVU88T*&!ENUU56P.C#,GF,PKRV'>YRO-KU.9"VUY3H'
M)U1)[(1%J4-;?X!3*:._5A6&<Q FK+-3E34L>3B&+_S;,?\S@BQ+T%"CO^"S
MQ]=,K^L]AW> !W@XAV1MRE:,LP(ET&%:VO-]IKDLNH$=VL-%U,/<-Y&<.Y>C
M!_.-,,UE,%KU!\6+7W&:RT*;T!N351/[O_8L.<2D-*L%,&?B/Y64.VP[SHNU
MO6TRSE6K/?;%+V^#M1FT@]3$2&YE7+%D/F=Z2!J(4"HCAY#5Q_)$NQMTSRXT
MWY2E![%,Q56,,7F(7$V;KJ(<6!BNM^@+WYJK6\#]V@4+W*-S1CO+V?M:NN%=
M)EV8M"GC2)<,7_"=, ;#WG?(.1YSI@'%P3Y A&4P1.<MK&H-AC]831K QV)+
M2G2:,/Y,K[,%MW +-Z2,,?(2.@?_4T7PW+>CQ5$Y*[7W1;JG7=RB95IW8H87
M#<P!%(9=:,%"0]I3HSP&*]9A&K6DO-. (\ZTE<=0?#%)2\9O4,'5_ ,,'K/;
M^\\#]8<$G5)]2%9\A#WAE;G6HP?L(DF+/0?HFP-><UTD)KYE, 1*M+<:!5$F
M.]YT]4GG.V$G8TNL>]$U!LM]*%T8GM-VP^-P:["7](=\I5/Y)<BB SC^O-VQ
M729A",Y?'>*3W>;5K(/M<DUEE29FN,%C-L+D0^._>@?[8P9>TP?IW+%WTSAA
M)J<M=N/T@M^!'#H/[6,/!>3T+5H& S;T3.<&(UKC_*Z)U--W8N)!VT=08[M6
MSMI#%B>@_V2R(=ZYF/P_<A $X8TT$L[<20M<^F4P5L;1SARF=>N_?J9*HA5<
M1-RFO64P0$O)O#76CHQ--MXW#7RQ*]3;@+-8WE,S_R4FMM5G:"Y*?:"^U+0]
M:Z9%"P90(7/%A2KH0.R'01CDR=1'V/2')#VU(.8X&B7/*'-5.)7@;6(&^G36
M.4C9?<XK65W#CJ:_9"T"1]-<!4M="*S RGSC_43!8T"VY!(&9+NO3$."/[;(
MA///#R-D!DN&90+G #8Z/_NN;#XU>0@]:>)9'SUF$SMMR94FXQ3)5+6] 85=
M<1I0(TA9AMN%6S0V_HPNOP4UL9M3(D YH.1@>F-=M_S!<&+*L__+M"/%6;ZE
MMWUS/-EU16' N%R%87J0:N E6YEUIGI00A6-UWG[3S\#-._.LJZ5[/A&-F%X
M0-N68D7FX'FFY68$ZAY687_P[C^H[/B.[V7865*K@]7>!V;0A3Y(,!@;T?P#
M;+=B8J64IBU&10XSAYR;-ZZM65W@+[Q.<-,47NR%P.!S/H@^S 839(HN4(*L
MR"%&Y'&N58QU2CL0A#<,)ZUE3C5  A\OMQ<5YL@%VJB<[D1+1Y4DM<"MNAF^
MNW-X-V]E!FUE,.;#:S7P27DP[))3;JR=8\LDV=4^Q,4KS1NN/'\P[YR.2NV\
ML:/&L!ZN49[-:V?*M HV0-\] LW>)I[_1K?H(G)Y(Z]KSC)P_N\N;%[11CK,
M56N"C##]/F?%_B:2%H?5M/"QTUZI%CM]D(?2\SQD, 1X5K\)ERLX_K:(-4!L
M^]VV$[.A+28G?<+XN\?TDF78SL=8R[(4YS1%K,CCKDAE:TA$OV#_7.O@53 U
M*$  KNG.W=&:LSF;@P<:3;>6].ME0@:$@VKP'+1V>VZ6]H=S<$0J!%X^Y[%G
M UJVVP?<G2_E?FYA_S88$TER$H>__5+62SMS^'1Y7&">1+P,+?9W(_54?B94
MS[)Y'G$4!MM;D\IGY=R=;L5??F6I UMA"N(L2TF96Z9@$$T'?,_5Q-PN9^O7
M/&<3*[IO\%TL_X^_43;V9;)G'%^U=_!=M^[;VCR"*37 @'-X4<^K>ICN'PTN
M1]1*'H5/33.$2*:^X<5K6M;:.3B&<NC%,U<^NQ4G152XN1S-8%C(0KYH!9OQ
MI UX>4.$8]!6!3L"K'WX!3/Y;;+7L"9W= L&9MB%%X;A9?K9,>L#[3M%F42[
M5O3+;[@Y8<@Y6CYBRT2V3P\VA5/W<#K;GE6GE@2W<9O!.7CP!?L#MC.')Y5&
MWU+,VX.Y=%T&>3A JD1NXI-J[<-PRU0N0[!V5,QJ;VKXZ)H'LZ3N;Q[;JG-%
M9C@'80@X, [FCD_DZG;C^6I&2MN%9<!X&*MT72BU86SAV5RU>3;Q8?^J_ ]S
MU)O3!565<)Q?*X"%2(1,2@S#SVP?,XN//\>>+TW\- 6D>[QC-Q7_7\YN6GMS
MU0W&5:0C6JB-L-.$MGU#!#&?2Q(%"'\"!PI$1(,(C3[Z_(F;0P0AD2(/YQ0Y
M&(R@OWV&:!PD(@RCOS\<CWP3R$P-1QI&YB!!J/(8P5T54T(\J&O?P(TJ2X+T
M1Z_.08Z"</;$*.X(1Y<IEQ*9(X[@,B1,EPI:Z+-/T"(L([I$)!#>'(YU\H$4
M9L3EPX@.B1@Q5S0C5AISY G<B+ (,X''@EX4* XHQR)'9A9!1/383*\Y#QK)
M^S4L#3M6=QTL C1M2J<#X<4].#BE('J/.=K_(4O0;$<D+#/S?.OZ->S8LF?3
MKFW[-N[<NG?S[NW[-V]Q?8PL37D$T3N,]! A9=KGJ<!SD.W4&_C.4/.4102=
M&ZBO#T(DW07NHWP09G0[2\7[TTEDV>&4NPBZ=RSP&_CBQZV"A >8"'H]?=,<
M7B9=%I@@QR!%1%]02217<AB)1 1) S%3QTPTS1$@><?4H11'<P1#5%V50=?3
M+F@M(YLXQ!5'$X6"M$8>,WUD.!(BH@WT%U-S\ *8':+) UD=.A*T3S!2&;>+
M030<0<Y;^\0U!SP""9.4&E7N<\Q#-'PT$'X@TH"$+OPAT]5 &G'4F'5A$2&9
M0.8AL8P@&1)1AS<8_YE3IWZ&T#5:0OR1)XQ#Q=UI'W")*KHHHXTZ^BBDD4I*
M4#W,Z/)''YD:PHLX)![Y#2)_V-&'(<<8Z8\^PNRRRS&>ZL-,J'W\@0@S@OJS
M3#"\"'/J-\'X"N5 Y^R2Z1^\+/3-+KZ.YP\YP21[HC_,)!O,L@+1@XPAQ"+R
MC:T$P2.,L[N^5<\QTY[XSBZ8EJJ//,[R BQ!]("[RXH@X9KLGU\=8PBFI%);
M%#S[9BH(+]6:-&V513'S8!T)P_:ML\Y.ZRXRXG3[%:R8"K++-YY&EZZL_TH;
MC+CZ'.,KAQB!FBDBWNPC3J[!G&JOL\=8]4[$K0K4+"_!P*LOOWULW"E!YYSD
MRC%!S$0<H3_D)JLS0^'20X_ ?_P+4J6QSOI-=0/5,R_4>@J3K1U_E.KPI&FK
MO3;;;;O]-J/Z[(.3QT753=O<P-V=J-R3]AUIWK(%CILN*2DVZ3Y=NS;WWK4U
MKO?BCR=*-VR#Z_8WW)EKOCGGG7O^.>BABZZH/J5'-1*BHZN^.NNMN_XZ[+'+
M/COMH ?3AQW9_:%X[;W[_COPP0N./SSQQ?]N'FO&*[\\\\T[_SSTT<.^I1%%
M"-9'ZM)KOSWWW7O_/?C$T_,-,\R(PWOXZ:N_/OOMN_\^_/'+/S_]]=M_/_[Y
MZ[\___W[_S\  RC  1*P@ 8\( (3J, %,K"!#GP@!",HP0E2L((6O" &,ZC!
M#7*P@Q[\( A#*,(1DK"$)CPA"E.HPA6RL(4N?/\A#&,HPQG2L(8VO"$.<T@_
M>IR#'/DJBC[>00ZT>8L<YL")/HQX,7_TD(B*@L<0WT(/<'S#&]]PXE?(00Y;
MT4.+6NSA.99HK1Z2@VG^$"(YSC&SW0C1C)&"ASF,Z$5XB!$C^HCC&GD#12]J
M\1UU;)06L6B;<YQ#D#H\)/N. 0A E,DU]#@$(%(V$$4>HDK? ,0@@*4/9?!$
M'Y#DA:,>"0A0"@B2?O #)FUF1UTL,F6*7"0L 7$(9NSMDHML)*IX 4ME_(8?
MNL1EI/2ARU@.8A"'F-%;X#$(0&1O-YZ,)2:-2<NT/9.43%1E;:J)R&V^+Q^'
M.&4F7:-,/U@3(\?PPR#_XN&/2X;S'KSP R]1=8A!E%-1CR1G3\@!"'0>PI1^
M2)D^3WF(4YT3G<5<)BKC"1)OG!*5$1KG*17:&UWX 9B1HN@B#PK.GP%LF1+M
MC3X&@<J#BA25WS!-,'5!3Y/(\H\]\20^N2E3]5VRH?4DCT!"^D\[Z@6=5;IC
M&/T!CWT&"(YK=.E;;'6/;][4'^\<Q#?HH8]OB/00]R#(.U'IAQD5](KP@ =5
M_7"(BS&CH7YP3$WW^=$Z2HZBC41J3U":T]=0=!#F^.H[E+'/IMKQ'>_(HV[N
M>8AWP,.OBJPH/P@"U]P(,6'O'&MB"1+9GB!1I'R=*6:AEP^*'J*NIYHJ+W2A
M_PQR+#- [SB&+MYUSD&(QAS'X,57=5E1V.Y#&;QH#3^^P8M=\$(95XT.+TRE
M6UV8:B#TL&UJCQ$AF#:UK@Y31FJ--$Y=?',7_#DG('ZV"W1>S!N+9&I/$:H,
M).J6M]P2R#V.<8P>[O88=%2&>2=3T=.:5V6[O:U5-OFN;Q#W'O?0+2^"Z\:!
M/)4_]]2%=Y![#+=8Z[50,MF"X1':=Q&$'!..8V_K!E,$>^>;AS -/!2,MGU8
M6!>[4$;"J%8PVRKWM>#(J6U+HM^2*$.DH\R33[R1VH(IMKS'(&U,,RMDZ9E#
MI,>H*:(."T[+[JRD&44G/7*+2BV:-;LZ):4P]]G0P?\FEJ&#8&5#&TD/BFI5
MK,FYYWQ @MU#'#F/WH7J4Y>%77#0XQY=9+* 4*E+UOK#K2*-IY+UO)#I.ED7
M9#XE3/2Q74PVE)D"R4>@1[D0>E1UGX.0\"FU'$Z,[*.NYM"'G?5Z5FMMM]'Q
M?(=:A2I2E6H:6%35M(>/NNH*SUJHWVPH5">I98%6Z1U5%2B0T7-E>5;4'[?>
MYWS&O.M!*%34X-SKD*,-/>R2X\!6":@NOE%C1*,*HT>6+9^_,66J[5.T=/PF
MAPMZ8EZLNG0U939_3;K.18[VL+Q<:I"]Y4],OHL_^N#L/0(:(.P:<YZKIH=<
M!^)EO697F8#8-B]K>MO#?H/_'^.,9+S1R<FJ+H3,V5;&-P>1'(E_X[!YNJ=8
M@VM+%'\#DI+TQR[VV<]Y+I(7O\7NM]'IEJ'"4]4UM_ I00E3>,MVK" 9>G!?
M6U(9/Y63G!4-D'7AC6,P^>*I50:E8XIF5%EVJB'_L3]P3HZ8#Z([ 3V$-[QA
MRLM*N^V_P[<N$OM.0+S8J5.^#[3/ >UN0YD?#,VN4(F:4_!.=R'\P&Y)&+K3
M>8^ZB^1(K,")S5<)^Q.5 8J\-\6J(V68U:R'J#M(F+%(<GR3D^@,:UZV.U"!
MN#4?6=<%6<2]^*=6:>[ 4KPRA"G6A?R[HONXI\COH^=J_[5;_#ATYWF1''SS
M(K$A_XTD$T6:EW$:?</,$OP9.7[TRF?Z$+F/_N+U"8B2/#5"MLV]KS6?V'$*
M&[S,%TB!?6)9LHR3EXA'%9#9[O;]ST[BA13]3N6#ZOU6UL&$+=G'4XG&WT%)
M^AV#\X%70.&8/YB#X/T=3P04+_'#?Z$60CD@3*5948S/,9@2((P'=C&#$,T=
M3W >QGU#R8G4I?5$6677.Z5619V#]"%=@(6</A2@0(##*>'8:E4)P E$^H%2
MR 48+WA8#X+75QQ;9WW#;V%$75E1%1W66%&?$N;=/JV(PV&96[W*W<&?YH'$
M/< @:ED:O,C>CLF6S7!6M["?<1G9X!4;<Y&AT?'<(2CAK/\]5HIU'?\%XN]D
M52R!$Q&6H3^<(3[55&LDX#K)6_K%TQTRHE6PWU2-H=[U'#Q\DRRY(=?EF[5H
M&[R8C%JYWK'!TBG%7=B-(=XM'D9X&3F(6S'!4_W!%"89W)?1@SS0X2-NE4!P
M7@S"H;5TG8T=U#P-U+ -A(65E*"!A&<-Q.&9%,]%TT&!$@[V7-:!8;&Q(+#L
MPV-URX&ABG>9F? 95#'-4^ZA6]TTX!PNWAW>$RD]U54%U$')$CWQPW;QF4\X
MH2#VH^RD'S4N4D3970PR"Y-A(-TXX@(&GCN"%ZJY(I+YPT)>WZBIWA;Y8#)Z
M2ZVU(B\I7C1ATCX!0G)06X757$__L& AA>3XU5^?B14\^-=7B88</B+=A5?M
M^51TT.'330T\Q(-H9.-DZ4-AZ=8R!1\5<A=!=-4X&4L/JM%5/21,^"#?E4E$
M\IU5;9_O^4,^9!6'D4-$]2 ]%%^?R9*.D ,G">6?;0:>,5?I.&'\-:"=">5+
M$N1X'*$_WB7LL""*?144M1O#V4R6C=(^NN1469HEC9[\D5/I#%OO99)0UI4?
MB1O@91\\;=BQ"-X=@L2B*9\0851)Y.,0^56(M9(_<!X\>5&\.=I"C1Y,0=DX
MK<AJ/9BA\=),VA)/#&%+1E+I9%5)D.28B=9@!@C('8().I0SGIX7>0,,FL/Q
ME2$Y&!J40_ <;2Z3-;E58A[3.Q2=K!6;M=P:+UW9L716E6"7,N0#/#Q=)!*%
M3NF":)25'\Q',I9?Z7!6E9">+D!)39F*[H$B7O;_)^@T)A'9WIBA4C\))"F)
MFC$A%)]Y%^ -W2%LD1.FU3PEE$!,9";RTMP%6$D)'9YAQ#6.E)892T#54]99
M54&A4DBFHIMA4G=P)4/RTCN$''4%H:HMGNS=)DYBE"S=VB[(9!)R8DG<T^7!
MH(8JYG&B*"J24V+5U"'L @PFQT/RDE3V7B.9)DC*7+>L)T&\VTB6FTKMGC_(
M R=.:,]%(E81**OA4V:^TDK)7I.&7'+TWHXRFO[YIYVZ#0X.@B11E9XR"RMA
M$G3UJ4]0';_56"6M4S$!RRN-W[\)YGW\J5A-$Z)NVCG,T_3]J9[^TGPZ*D@\
MYS)%$R^(1HWEFCEA$CDP_P-)%5,G"A*?XF<QP2@Z[LR?RM)Y/1*S-=FFZ=6A
MZE)O911[*N.L>M^DL1*'/*= TA,6L5M11I.P6@@DW=+C69REVIJ@.I6DH0K(
M&9,WJ%Z6LI*Q)&4Q)=H(6IHN.,PY!.OW;>(@(,JY9I1MK=2_K103/6LCJ1TL
MW>=F8"I\R>N=]NOF]* \=,OO255.!9)/$.QF?,,Y[(-0YA<]T%%.@=7"^@3$
M>L<[?$.U*=97H90N6@4/I5$^"*6.3 U@H0I88:R1R.5+?17#PL/#ZN+#LI4\
MZ C 5B(\D(@^G /*>DO%ABD]J*?+6DO07BPY>$S.8JR@Q&Q?!=+>R.7,ZF+/
M&I!7+ ;59E3LU!A8T";174'L=EF4<44MJBAM%BGL9)$'6&7L0,RLK211&:&*
M'UE+P$HMVOK$U*YM+/[4S/JKWNXM_(C2?8)5A_*MX [N3!&B@G(4X2:NXM;0
M)E%7/_$"@RVNY$ZN#"WF8E$NYF:NYFXNYW:NYWXNZ(:NZ(XNZ9:NZ9XNZJ:N
MZJXNZ[:NZ[XN[,;_KNS.[O[U P5)#NT>$#^D0S?TKN_V+CMT SL,+_$.K^]N
M@^\&;S>L@^]R0S<@+_!V0SHH;_ J[^_^+C>$0^\B[S9P S= [_6&K^^& SJ(
M[^^";_=*+^]6+_46KSNT@SNX SNT0SNP@_P.;_WB;_'N+__J;__F+_[2;_'F
M;_W6;]ER3S\$+^\F;_O";_S&KSW [_#R[C9L@S58PS:PPP&#!$Y$5C\DUC[P
M@^WR S_D PE_, F7<#Z8L J+,(DDENUB1 Q#(T@D%@GW!C_@1#_D PJO, FS
ML#^4< E_, NGL ^;<#[@PQ'S@Q+?P_R^CP8>\0JO\#WD0Q4+L09><15/_[$&
M1K$5=S$5"_$]8/$/I[ 9&W$B&O$9J[$9LS +7W$4D_ 8<[$*C[$==[$=?S$7
M^Y<5A_$<F_ 6>[$7*_$4Z_$\?'$>%[()MT\^N (ID$(IN$(I3+(K5+(KP (F
M9S(LE,(H=/(C4_(DCP(G=W(G3W(D6S(J2W(D3_(C0_(CDW(HA,(GA (LD_(H
MM#(IE/(ML_(KM[(M=[(HQ+(HG,(I7_(K&#,FUP(LU,(M4(,SWP(T/P,T3W,M
M5',U+W,F,[,U*_,U;_,M,/,W:W,X@S,T@S,Y5S,[@(\[U,(QEX(FLW,M%$,U
M5,,%S_,SVP([3S(HQ, +N$ ,U$+"_; )XX,[Y/\#_.;#\#XP\;YO <<O =-O
M.ZR#_?HPPYJQ5KJ#/;QO_.9#_.8P"&N@._!#_-X&&;O#/2CT_FKT Z_T_<;O
M/,2O]2(O\;8#\ 8O+-R"^_1#-WPO\G[O3E=P[WZO4#^O3_>T3SOO3C_O]2)U
M^&KO[SIU]/9N.BPP5/ON DNO\&)U-U1U^'KO]G:O\U9P]XHU3X=U3P-U4(?U
M\XXU48OU6+LU3[\U7%=P7%=P.C"R).=U,5MR-BOS)N<R)*^R7I<"8'LR)5?R
M*] "*@MV):\R8>=R+$<V+8\"+=.R*.3R+5/V+7_R*,=R)TMV'D3")VR!)6C"
M)U V*52R)K_",H.S,[__-C5 <S%,<VO[=3+7]C;C]C97\SAKLSG[MC6'<S>
M3S[$-C>#\S)/\S.\]C=_,R:7PBF(@B:\ '5_PBW(50D3,$>S]$&?M#WX< F[
M0P@;,3Y\=T%+<16_;S=D0S6$<S)C<%0_;S8(;SLL,FTH,OR>-/VNM$BS-$N?
M=$)O-$TGKT.[0TUW R:[#S^LM5N+]5HK-5 WN(.C-?>BK_ER]57_KO5&[X9;
M=587[_$N]?9^=85+N(0S>(,K-8,7=8DW>#:8^(M7L#;$N%NG,_LTLEZG,C*W
M-B:[@B@?=C&'<BB7\E[S=5X?^2D3-BQ7]F=7MF>/@BAX\BY#LBB  BT_,BUK
M_P(6R( _]S-UOP ,Q$ ,;,$HN,(KU (M=#,T4\,%L_DS3W-O7S,M+#,^\[@U
MX[,WQSEOG_-N;[.->X\[&#<L7+(R7_(FO\(T&_<SV *CL_,KC,(,D+8E '2:
M] ,1D[ ^V' *]\,<F_0#KS#\VL/\XN\# Z\[K(,V/#,LC (_R\ 6Q( +H( +
M@$(D/[(F6,(,7#DL4,.?SX85A_1V4[$B:V4\0/#]!KM!?[I!KP-0)W3_LO;[
M?+6*NS6*1SB$C_B#<V]2FZ^&AV^'L^^'3_#R2J_Q"F^'AV^$FW@%T[BZI_N$
MIWNUM[N\F[@U]'KZ-+(I-[:1LS:/JW)@.[8JJ[(I#_^\CA>\F5OR*-=R9(/"
M+,<R*+SR+U<Y93MY+%O""[0 =7.Y#,S #$1"'LA #$2"*+A"->,Y,U,#/;<Y
M;,=V.9>\-2=W-\<\;_=V.=-\G(=S<]O[]KB#+<!".Y?"F6<SRL]S/<_S+2SZ
MH(?"#,C "_PS683W/61T'[NQ02^T25/O2K.#M</T]@)#*82"Q:- "YR "90
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MZ([PP8(6U*NQ6,T7L0NY8C[@B40Q[FF/D[03IE"SW].8"5-V5.,5,V#  13
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MRIGK0JK.H"'<IQ('TQ+*5#BM5=)/C&(J.K)..N;+IDSMON HC6 A%$YK7%[
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M'C[FL4ZB&VX!%-Q.!1GS]ZA),G5&JV)-.I."J4*+2,4I!F7 $@8)C_IK/V;
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MJ,^/%\D/DO2M>$0YSE,QQ3QSBU>P0A25*04P'/^TH'SXPTL3:M VL( =!!R
M.>IB0(=>9J(3U6R#*ZJ9SG2VLQ!N(1*1 %(>:J2)&AG-:!<C4I040QCV3$Q
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M[H /7_(@PY8F1;14)F$--N>+3K3_85CD;"U1D 1)%^>'?NB7#<QC*=468;<
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MHBNT\!>TAVKCB5##XSK'HSR$HG%)II"U*2@V04HT)8M/)DRPMAG'L2QG%P-
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MXA<44Q@5XTAC99.SXSJY 14$\PJ+:36H\ JLX1UY91NO,;J1R7,&>R@-J:N
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M+5-!IMG<;Y6MBX].[Q61S/PMZ3)1%UI(8/B:/V0T+8[I.CCK5PU9P1)[;N[
MD?69$^.0>Z_N$P:1B6J1ZD?4)H0]FQGK1]O@VRU_$?E@5F0%[! ?5B^XV!)#
M'L;^;S4$&(/Q4V_<O;3I//*^.+S_03ZHY[/7(LN=A)'O\PH"9R",M5POLO=J
MOB(N0@I%ENY_)=X>38OJ_AU7;O42@=*&EN]=WM)?/H$-..9=WEMFMRP#S].F
MS%@Z8R CI!DC) -O3D]#+9Y=CUV?V#2NX%,C33Y4 6'M^"Y&.@,("&B 1@*W
MEALH05,#90V/6XMH^#J2N%.P8,R+;Q&<6^E6M/SUFH4V?Y3Z%[-0 WWPX]FS
M#1ZK3A!Q?WYJ.E/,^Q-@<2?X9IPH%5_OYKO3><7U9MC'C-CXS-BQ4XA6(^RT
M@Y."Q9-,@W"X(F16 1#<K W<1K!@P8'6J%FKEHUAM5O4JE4KEM#A-F[;"E+C
MJ)#:K8@?_R."K%725DE8MV"-"D4JE(P6+V3,F"%#QHL7,7+&X"F#E"U;$SUZ
MY"@R)$B.2(LN/5I4H<=V_J1.I5K5ZE6L6;5NY=JU:K$#!0Z,#5M [%BS9-4B
M0*NV+%FV<,.Z33L6 0(&)E"@.(&BQ=^8.'G*C $C1B0L/&/,C%'34JA/H$"%
M"C7*<JE2EBMG'D4*<RE7GS&/ @WKI*UBU:QUZX;.U:@M,K:,>K'@K@(%"!*\
MJ+5ZW3;6U6K9NK5:H\)LVR#6<O4*UO/GSX!N\UK=^G7LV:NRX]Z-^W?P[L"/
M9R<>?#OPW8"SUMB^8/+CV[(M_9A296E7L&J!;#@_:<BE@%N''?_YK&G/0/FH
M*28;;KH1R4#?U.O&F@$)7(\U[[QCIYU[W/&0'0Q#%''$;AH,\4(,V=%N119;
MM"X?5SP3;4;..+/LQM$P<V5'5_:KY970=O3,LEI@V1$6:AHL4#6'$!Q(-84:
M2FA*A@PZ:$IH  3IEI+VNT6ZD[KDLDA70LELBQ=.4#.P%UQXP9)/%/.I)&JF
MX:@8.YG:<B0 Z?,30**H4=%%0@O5CIJYYJJKK;,83;11M]B*JRVZSD) @1%.
M4(&OO_P"+"<9='IAKT[_RBFG+2+9PA)-1*&,%-)& P4+RT0113/*/F$5BU!H
MFFR4'A<RD+5:7*),$Q+NLNU2!!; (IO_$ 5B$CZ'J,EF/BZ=>ZY+E*@S]%MP
MLR./._/&)=?<<=ES#Z&$XB-*)5A>"0FZE"22LJAJ_*1&HW%8$XA*C?*M9CV(
M^'-(/> &!E$CUKI;1T,//<Q'/!(K/M%?]C+>9M!P._;X*GQ>*X44DD4+[;,;
M8[511]#RNX6X(IFS9!182M$O1OV25"]0:[)1+5^)GH1ORHV8['D@D&2)L3/0
M7D%)V^'@)<G'YVX,Y8464"C!A,!@T"0VK/\"-JB!)/IO3Z7X=$K?I0*E)JJ/
MX_Z6FK3$JGM12MU*=*U']9Y4+;$4V'HOPOWR"R>L^2*!A!%(V'IQO0XW; 8L
M(ODD%%=C!855_Y8P_Z0FG%I0X2\7LG:!)S-K66B]6TKYY!-28A!A+-SN8LL$
M6.3+:)NB*FJ2(Z"YI'=+Z*R1^_B/T4-W>>:_>]@]!(]K%T&1Z(4E7ZF%?9*:
M_0I>2#6&64MNJ.0<$EBC=9;;CZ'U$.)NV!3)C=B=B2FV^'X)*X8;>?X)O><U
MDI5L1BHC30%3EAD=[0@HMG@&-5:BB>?TJ!; HA-PKO$1X@#C&5[ZB)>FU"2"
M0,1>"KD%D$"A"2QDK04R^)PF+E>9'@%E6V,2'I HDX<8=$HOB .,"?32@BW4
M8B(_*PI2MO01)(J$;4![RE,6PI']]4^*7D%46>SV%D5EL6YD@107L?^XMP-,
MRBS-(L$)3'""K!FN4WLI 0E$( (&*& !<&3 &QDP@JV92C"1T01E4(&%+>0!
M,I^(1.),X$82^#"1/G2!##1AB5($A3W4<$4>/C&*%N0FC)?2) )B (SC=# D
M3^*/1(0WPRX]QUM39"5V^*&\YBVO7.1!V+H.!"5V%4-X1=(/2'HYDHEPY$>J
M4TG0K'2@CZ@&>,"#UD:X9 MK 4<Y"G-'_L SC_EE\V$@PE_%4(2A*+92G%N!
MT0%E))J4X4AE,\K/<V#6'"[%L%BUH 62''(+5V !A9H0)&4H ZQZ"<5\$-H/
M$N,YBIN4#G)^.6-,6%B*+CG'1R<!$BTH<PG_+(2N!2<@0:<6B<86C )*P3R*
M$9-BE"0^,9AV<N(3/7(+CHU3IE)!E-W,<L6;ZDUO9^%I%]'2J)S^]  +*(&:
M2+47HYK1C0Q8@ +B>)O<X(8!4VW<#P5CB4OD812/C$2H9K#1-K[QC2,8@0BV
MQK48"!)8SYBD*T#Q.A383JYW*0 #2#$@"$$I(4,\FKY*(CSCS52P5^G'+-$U
M2\,N#V&UW!E!(%2V^KRBGLQ)"6@BDJ]B4(,X*E$=$CT2L ,A[19 $PGX?$84
M*)FO(ML8!S?#XR%[S*\\U4Q1;6W;37 .5K=3N4>-<(3 =*J31@G,#RU*(MF(
MH%)>O?P(*62 U,BE_S$FK3I%0!D2S7>]C#FE> E8RZC4-IX1!2\(17XDNJ4B
MV8PED<!AZ'(X@C/&MP6GZ\U#BIBV)!JQ3_AR*6GI ]/=CK.F5@PJ3P''14A=
MT8L]W6E=%I!(PQ7.C(=T8U-Q@YL$Y :J4A5!&3OE@AE$@C(S6$R;TE16.HJU
MPT4=KTW**R_C4(,4D5"5"38YU]NT@!HCD@_0?&:MCA!%.OHI4F #K%M8A@<\
M%8IE>C F35NRJVS<@H[+@D7"!FZV;1ZYUNJN]9"" @@6"^+=GO!EC<P^0S7<
M&%##ON,.6'[(/+BE<XJ./-A\V"B=>@YN<-E)+Z<5"4BO>(:15.(T6I2"Q/^C
MXDM\02J32-",3B2TUE,*]C(CG0(4.51AJ0SW0QDPC<A J87-7L,J&,0D!KQR
M 85WZ )+P$+-_OW/2=-F4I4.45AL$]2=65G3G-HTBU],L+#S=NQ'Y90!B03I
M4<_H.#>J>,4H9NH"YOC&C_H%!EL(!2ADX*8VM< $)2#K".ZX.,/M9#&I@Z9&
MJ*'HQ9Q  6&TB^T6D  &A,(XM<3>1"Y+6I*\0ENJ]/5@FPS+)#,/0])<K/3V
MJA!ZHB2"]BF.$NM#Y,X"CZ]Z98B/^@0M@W+K>R0)2C/C]UKS?*C.=0YGP:=8
M3G7^=F67\2T[FZ,?C ,)-+:(EP/S4Z:MPB!L)K[_B0ST*8KF>$E@%6&?-4BB
M$E>( A21(+%A;-(82-9,$U@+-2DP7A+09(;$6V!38P83&"". D"9#9Y!U?;?
M7>L5R#SC2$Q=+K<JVM1N!%"4WF^J]P$$>XLX/79=[E@"3_6ET8H\)![%BW84
M')+%)SAK44$J \E\XMNB.FI?3&63&;PP,F9R6C4R0HU3:&(&,##!O.,R5]R<
M !;_VMYE4[JG,$GT.4:^.RL+RYV$ET>6;S:7QB046HUTN1C<DK@$.SNF?*'D
M2$<,"?9&+LR 6DL]1[1X,:1SQ)XQ2$.O%7ZY5AXB;I+([KWG'\S-R>>9Y^@R
M/#K2MIH3(U*\PA:A:1TIN$(S"EU9#)J8@3RX.IQ8%:3KI:.QD@ZBA=<(!4UX
MJP)$G% C$Z#H!8NRA-EP!2XQKE*#%0 ,,<0AL=(1E:QY@4@H!?JHACS1DR)Z
M0:< H8?K"!IL.?8+EUOX.QU\B[\3*@-#L"T"0K];% 4H(T\A'!_B*,A)0C8)
MG<ACDZSQH224B<GXG"T0%<01C#81P$ORC-< A5&0%VOA!FH8!2RHB1.0E+NH
M-PU;@$\8F)ZI-;,1B?T($YS;EMS_N4'?"[YQ*9?$4BS&"ABAD![N$;2_@HZ_
MNKC>*$2,P[F_FAK;,YLMF8_W, J/$S1WZ@A<\@X_S*;OT! 12;_S\PX]E")^
M>(W+V+,#4L5U.AD>@85ZVI&1\3]:( 51*#7,^*?,>"M6833%6R&:V99]:1+@
MR ;A\2?+>"O-&XR]* 65,$;0*!8PM!G=8PG20"'%D(D9P)H)TPL8"(4Y;!L7
MM#A<HQ(JT;CML<%2))1] +; JXN[Z<$AS!MX_,&R>$<"(("SP!0?^@O%,P'X
MBK9L\Y0T*AS$0<*&PH(7"@7VP@(7.)VSVPLWD0%+$ 7/,!(84AT&*<-4@8$2
M0 !+N0W;_\D-$H %;2 E):(T[J&A>,%#6."]=3R>X//#)CL7X?O$6F(7C> &
MGRD&!W0.DC 2F_FK#1*XE]RE5"*R1J2X4N(/H2"II1P9TM@1#[27Y!B_-XL8
M$/E$41S%$+&'F$0>& F@ D(9/J,Y=+(Y'M$Y_R.-"9J!'=F,XRH%44"3,Y*)
MQ"A!4" %,3F.B9@/GK.,!Z2,L$N@EW@!FA$XS  %I&L:Z+#&4K")S;.$T,LA
MCMH:%QB%)]K,S;RUMU.B8#)'H:B2A'B;L R7 8/'GU*P+R*P1=E!'KPI?<0B
MP1$OZ*(PQJFJ-B(K%4,\<7O"O]"+*0P]TG )34BUTTD<4C&5&/\ 0V#1.8B2
MDEOHE8PR ;80BS7$C3#*C03  H9XALQZ&2WA$RZ!.I>$R=/T&#YD'CY<3W5Y
MK"\#GOT;RL@"RE&K!51PFFG@I7;B)3R,&2]1BJ3(%Y\1#JK!0Y*9/T2,B'89
M#ZVD):]4O_2,FWP02K-$F57,T *2$5EL&0 J$U*@!5&(@<X(!2"IA5@H$TW(
M(?("05?)%3,I!5K@B/F DB)Q2^XBC>?0LY'I%11P@?(R$I;XN79Z!5"@"1QJ
M))W8@IHH#">,@>N!+$V\DY*2PY.J$W,4%AGT#W6<T.P -KTC,!\,4RM:S0*#
MS0'@.RXJ0L7[Q\590H"$HV7)C3F*G,+_B<(?BH'+"3M2V#0]BKQQ,S=L<X%6
M<8X@Z0V'L(4CA0D12 "_4</<0 %7\ _A(!NC0"_ILQ[T]%)#Z8>:)(\_+#YU
M89@$60@'S!D'BD6)@PZ@/+2D\Y)5)3(:$B8/"KD?J:=M^1%<R;]'#+(+D1^5
MZX[[V<H1(581Z5).91%^,)+_&Z#16"<,32>2D<4=84L07 D8N 32> 49+;50
ML(3%8 E=B<#Y@PQKK(R6T \ ! 6><XF6<0G-D(P\F(%>#+7G ))G^(2'-)W(
M0Z.>X(GDS$+4$2(H";*B>(;Q1!LS2XTF^J!S!+!D;9&:>L<=U$>S& !*P5C5
M+-,RO1LN4M.S_W@PQ0-4)2R!#JNPVI&4.1HO<>.:POFA%HB!#:PG4OB$Q E.
M'Q(!:YNJ#D,!&2@%;@7:T>J9Z6P3$^BP$9@WN!#)2UD 39#$+VD( Z4: "63
MDG"%:HC8CA&/]?Q4!W6R0+PNB- RIYLXX6D.I\F9'S%*YD,)*CN2I.@LZY.^
M^I,LYN@V4+ 9,^N(]NB&;9JMK136#%&_8JV8]=-:98T7'J&1/O,M=1*@EFD9
MEN ,6 B%5>N51T(%(>T5<)4-G6"AS@B-/$ ,8,F,(=&$2&!7J?R_04JH^7(3
M34 A2?L16' !W""J5$.!YHR3;1Q 3L.)&7#&<]0X6[M4_"HEH.&X!?]\E\-%
M7"K2P8L5-L'K.XY--L%K%DU"BWP,(Q&PT[V00A]J(Q*((Z=BJML8@1>P64 ]
M0L(YG9EQ#A,R#"?T(7.KH\7IE!CPPGHQD#*4KD\8T06X,6;!BTCE0".!!5G@
M)2"Y/_KK4%;(#&IPWD[M0_(KEZY5,G9X'EL2F)6D"%H]4+35C\TZX%YZ1%@=
MDU0*LX@PB>5K/@;FD7.*F=YIB&^:K3F+4(M!5@FNCGR@K 9&IS[[K0UE7%/3
M#,O(3\1X 2SPB1T1A4L0%50HA18@@9UX3MB( 8BB!>(Y!9903%E,110@@1D8
M@1:8%12P!"P !9PCA6TT%1%SR!E@B9GX!'W_"K%MU"<5+!O_&J+@&4^#2HH&
M\I.!&*B7 HGFW6&MR,'H+0"*W<%X#%-Y9#"QR(N-TH $8(OM10"S^B'#,2,U
M.22==:JR8BJG$H&8'14U\3Q -94^(M(5#16<0$)S>[ S'@6=B 2ORQFIE6(T
M^@17X!X4N#%Z:Y:FT@#$O)$$K0RK46:K&0510"%;0&07Z8>N33GGN4GN6(<D
MH\F</! [L;ZHM<0=1<1:D(ZUE-7R[)+)"E#F>[HO26?_7-S.(9)12E[@:*WQ
M4!Z+Z<HZ.V1I[HH*-2\'[-!G945HS1$$2B ;"07]B(',86CFL&4W*05M< 44
M$(%P>XU' H47X$N0_T!8YG NB.+/SFB=HS4!!F@!5[ $KG&AL'L)55D,,+3<
M&1@2?[($#40,BGR%*76I.@&X*S6I+<DLIZ"2G^GC6O#G?ZX*189>+8+>'Y1>
MV2P -1TJ$B#(UDL4!=ADONAJ0%4DGG6\-T*\$TC."-.A/,4"4;"9FAD%-+Y"
MK#E(RM/=$]+ /76:H'DWK $%#@0)4%@ [%Q#3L(-%+B<7_$GQ(8,O+V<R-@<
M3:B%I5Z1W[/)PZ+)F[0'#.8F);D2[$&OD3 2YQB9_'!;_\Q5&OJKMA63\L0]
M8O*15#H9XYP9).$(^2#&\7,'S(8E' Y%.XML[.CA@2/H((Z5LD1+LR0-5/\@
M:#/9JEO)#.)XA5& @5!S!6MPA2D6 9\UDIDHA1< A5LHAF* &5E0M)_@'B'U
M/]?A"7T:!6]+7QAR'1G(@[>BC!U)X_S0C%WAIQQZ;/+AM3\I7@ /,J,IHC!1
M:M_V![IA9*HV"WW,QZI63:@^"XN=WNYMJ(U2VK!(  @CE0F#G-QD-C;Z4<'0
M"9T C![2-A%C:^XBI,$@<<F,#7W" J][0+TM&U=X ;C\D?(BA1&@MV$621+0
MA%,H:-/-#'1-[$$*!<@^<.RX8 PVK#^$,V&%LM(\B5F%N@1]3EYR[>$@-6Z!
M9QIRYQ,^I9$0DZO]XD_@MI>$!HD8&M;:D':0+<'_W>U09/(7\<\%/IG&)6[&
MY7.F.9E28(5G+EV^7@F8(84(#))=W(S,B(Q2(%%;VU',F87]$$K+\,(OCKD=
M>1W1F/$^@BB52% 4:B$D@2R/R!>WX;6T">1=$]M@.AM:Z 8[SXH$MUA]#+P#
MP/6PP'6G9K".G4U-/H&R$LY&)8LB3$*_4*I$6D*6+4BL60Q.Z[0>.@%0 4,'
MW,4SA.6<F!P-5"O[6 F;69"!>'0U=H5]$@7KE)1ZLQV,9N9_>O?)@-%NZS84
M6O)9[PIJ-A?+/A?QL.8'W9#O@)XAXKDO]Z64Z4^,^VCMJL/41F&/8T3]@ :W
MI<.@9-:1F;HMH.Z-L 8E_V$R&U:Y$'D8W.I*4=3A>Y>*?!AH(BWH QHN(J81
MV(85#GR-DE"[EP&-6) %B_?0UWAF;[L%:+BT$BJ32"!2/0]=>B'HXG++>,$,
M(^E"I8P7M[Z<4P &TFRIW@EDM$$I[J-!E6K!D>@@6#!PWZ:;!F=DUQS"1^;!
MM,?.HG*CLSHD!F"+K1[(<5L<HR+(\1JZ$@.,'S5Q-<D)XOPYEE"]19.3Q8@T
M5G %+0:)T*@O8^R5,*Q9BB2%N%K#[82J!SOE4^G\%C\541D,5SAYKYC)YOD0
M?7<RO[23IP-0+ED9QD]*,8&9I'R.>EIM__0E__0X(]JLJ3$26*F<W.DQ^-B8
MK/]\4#HW7-+?"GZ@76:-^2$IR\^@5I>7?I,I826OF3+_[@W*EFI=&I?HT\YL
M/@ABCL4-H&K%.0;V$25W5;8VD\>O,M85P[*14CT1:H75+ 5!]5U3(H"X=8O:
M+5NU8+WJYF\APX8.'T*,*'$BQ8H6'5(C,*# 1@(<"Q0X\#$DR)('1)I,"5(D
MR@4G4)B(&?.$B1$+%"A@0,+$2Q0T2^Q\V<+%"Q0P4;1(JK3%"Z4OFBI%&F,&
MJ%"E8+DB-0H4EADQ9,AX 19L'DVB7+FJ=>M@VFK9K-4*]>D5+%*?+(4BA>(D
M KX($.#$J9/GB<*%?1HU_'(F4A.D+D*.+'DRY8;\VK'_RZQY,SMWFCU[[BQ:
M-.C,]C*OZ]9MF[5JU BN/:A6(*Q2HVZ[@@6KUL%7I7ZCA45+]VY7KXS3W0UK
M(-;EMXCKYLU;(/6"MF@?M(TECRO5W*Q94]T-=69WYLUG%J]^_7CV[L6SJRQ_
M/OW(_+#FQN_J]^_;H_@#6,I^_/UGFX&ED(*@@L9)%XINK@PTT'2Q'8=*<+"T
M@M]K&Q[TG"NBG$+00;L--^)Q: D8W2VOC")0+;3LIYM5MUP%'2T6?@+*+-4\
M QXUU5BSX6NNO4;=AA%61\TTK07IEI!(QK9;?/51665EU!3@T48@;;3E2"N5
M!"9)*&V$TDH)E$"3"8G%1 (#_SB)$)-1<\II5%)SPL034DT1!<-3,3S5U E,
M?07*?[GM1XI<,\P@PU=CR6 )*+^1V%PQX-%RFUJO?*+)*'J=Y)<"?_V5DP@[
MF5""3(D9MB9B>98PBI6STEI9:*%Q]EEYN?+:&:ZKL=8:;+;80HM S]@"RVVD
MH#6<;K]I=9N _=T6BK4)(NJ*+01%-^*#N<UFI$#%J&70LYK,D!"PVZBF6;OG
MH?=>N^RT6Z^\XME3J[[[2L1/+8A^RU^T!_*'(H']'2CM?PF6\DHMU-2BU6Y
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M:+B@,67NZ^RNC$)'B.!J\T6M5T3S+CKZD.]NS42;Q-LBVQ9QSAZ=:;#AEYS
M#4P-\BGE@6(1BE-$2@@[HKY>7P^GB#\Q%VKYADX9SR=<Q2O(P+EME2?3&P(D
M@ ;( "F<@L LBVOY#?TZB#;3QP [==[N"BW70KN6DU]*!V^$ZE577E;DG%R
M H/=W)3YL\4=AWS*P"U%BP47Q"A8PEE@=1/>D#3'RS6S60S_!RY35T8^2!:
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MA4T(LL%J,&G_)J[0#TKR$(/:E (+,:!2)$"AHAG0!@NU"8E 7 $*5]@B=:]
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M4/,F/);27>32$;_C'7_S+"GQ1H3%!1"C)T""0Y.%5+U$ND0# >5P:VSP!E6
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M:E-F "!*E6H%:Y2K5Z%D@)HA0\:,_Q@RMD32A"74*%*C0H&*E"<2#!0F4+A
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M#;G*U1;=_ 8M6^RB+)NRG.A\SSG4L:6]SK>REI5'7O5"CR[)HSZ;*2!]"F"
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M+ #465EL[76OQXJHG>VA(&[?>8 9%/:W2MF'_Y]P\K-^]BF$1%,A"H'FN<#
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MD\N1*)IK#4$S0\UIKIY+-$;"OYV[/V31L%%P"4@K.CC2A$@8E!DH+2QHB[;
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MB8\,*P'%43F%^D_<,PL[NT_UJXK+:?\_DCT06,5* Z7*6B7%^ML&:!B%%F
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M;"C*A'K:_,2SQXG_(O5[Y>%2X*Z(9>PV"MSPV@)--.49P5I]GUK 8$'\L@4
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M?K,LZE3DL? L[WY#K!8;JT" VSX!%P 5++"$E^P1()''O@">B)LA$ECX%V6
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M$ZS4O8LKV5C65C[5@FTY9SBW^Q=_>*2CFREG.<<QGV\.H !+W (%QLN.BE[
MF5ID(UB_ M8/]^:*&(PB;$523[U<H0%NT3*2 ,*D87)I/M\5QGT'@Y4OX?<^
MA_VQF">AAD0P!B*,_>]#(&LA_@(8,JMMK)E/*N !1) N[VR'95FT! H,,!"I
M!*=?K%* "504@QA,3C :V,P+8@"+;?!%)M4(!0D2H*03IO\P2RV\6C.9-*6J
M.>EI73(F0E.RCYOTA:'96Q-M:,,K4L3@!#1SW[\6\S;U"60!FH"%$^]VE6SD
MK5BV>,4GL*")/$1B+60)122P  I2A.(3,F!E$VF3J<9UZB>WL&()V"9'M]&1
M;;])F*HFLZH[ZA%6<*1A0J,JDD F"S;"*I:R@&@-;%PE%".H'<#"6AS=@:>2
M)#@.8IY"'#B*8 O3D$&YC)<N40!C&]=0S:]NH=-MD)17HV@!":B!)GSMQ1[M
MH$8+]).?.Y&O,!8@:OEP.4=,!K-]3K5LPR3HU(392JI_W,<MIMG,C'5,1/K[
M7\;\EZ6/?0QC!)A9*)-'JQ61<0'_&UF5)@5CL,',*@9;6.<+OLJ =(KR!9^H
M15^H1P(-($!I3%N2/Z.;I8(^5TDA"U'5H.K9A.)0C6ITTZ!Z(8M/M& $CFE8
M@0 &E8$%AB BL,0KE$4V8UD%B,C:VTE#L049S& M6TA4#&0 "IY]PA6H9%SC
MB&2OG]2"%'"-2D85HX%>HNJHJ"J('?$8&?8U]07;E6H@32<;0;[+34ZD#2G,
M6TNQ*H8P9$W.\)CC.U0IH 0SH 8HRJ6"$\3@%MTHBJ_RBA6BF,X5HX K T+!
M#I[,A!OJX0LIMM6?V]GRED/%9&*PW*]?8M:H1OUE9S]<PXDI4TNI[1":J:F_
M_:D6M:(M_^"3"B""> 98E"OC;PL0$+7V!08Y"]# C;+S A?0:D<F<($+1(DN
M4%QO&]IX!6!]9L)]8@V%!;UM":/&3Q1:*+K:%7,Q-V4F[?'0GM0 1BU*@91M
MH?= PV'L>I7H7DV\8G5:G>^Q\%8HVSSC%E[!P@I\NTX9R  +HW!%:VR#X+'I
MI&AI*HKL>@/'"/\G6IC-XU(W=T=75<;#H#8F/P2)51%C]5C9.+<KM@5)"C:V
M?,FQEHZ&=\G$3! !LWH!-4BAG73Z.#6GI!N^JF$+6,!%ORZP: OXZCCUN(,=
MU6@!8P/&K?5:.<MZ\ATOEZ)9&B-,8<!LM?R^+3K[48R9 MS2,T+S!R)_#E#E
M'2J91QC0@KX5-X$Q0($"*C2CFMUH.R@*]';*2X+8<@<%,7#%-M81#6>A2,_/
M+2&G.6U=%[(<(OWLYZ?_15[#;FS*NS)I$S7R^P(3J+O"!=HY<!9@@<7^#C(E
ML(2[B'45H!3K*KHFUK!<0XM1S*"+I2B%*VB1[-L$Q>NDCHDU;%&*/$!\5'C"
M3X7-WMZD8GASG,NCM[5NPWZ\)C:YP:JNL6(+G%.;XK-L\5)(4()*FO4X-U/K
M8A*@@N3!XA4G*-=G>&4+Z-T"&&[:!J\H)9=(C%V;@EUXP[LQ"J7TAY9MRR7T
M 7TYIXC  O1&KS O*\S(T]BH(==\Q.Q7VO&/%KL><GD V3Q-@T97YL0F=@RX
M(TH4%%&%@\F/-M$UN>S\=D>TLO-VQ !G/,,X  -28 <"B-,XG1#57)?581I%
M_V!(E5R==$U$YH'?UHV:V.#+5C28# #6GOC2@02'\SD202C "8B"@<W&-) -
MW<D&;KP.#,;)+9P2*>15; #1D!$)7W%@D:1)*95")"06,#U2\P'',&T;Y>$6
M4V7; 5P@!HH.YW5>B6D%5PS*L<B <U#<Y;B-^4R+"*Q><N@.<MB(J3  L941
M+& '*,Q&:C@/; A*+< %3544 VA "VS!"]C">CP9.S0<-;R 6BU6).&)GA0'
M]>%29$7%SF76EV76QQ4AQSG5]T7AK9#90DB)R;5<1P3 =9'6:(W(:FF,"C4$
M W20%OT6.\63=YA 5)0( N1)S^D(=UB')7S@T F@)_\ED"B]PC;\1='E''1M
M6M2M7S]1C2A63=5 H25RS4+A1-?IQ ^)W0EDRYT8"*LLE2/6#A*>8 LD#K 8
MB[D!!4FUSFU0@PS.ABO 0"04V!FYABV(HU LFS3^($^4QQ9 W#D]4F-$B]DY
M%>4U81,N(3,V(\24#B$ER[*0%&[@3364 @G8!Q)=62])TNZ\WEDU!>21P"B
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M#]47-4"#+<R.";!2D5(#+*  $^D4#QI>7FP*-;S"=3AH^UQ4?'+9$FI;:[8
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MN5HC'1V(4BVA'4FBN_9D-L7 6\!"E#YON0%*-;B"SY" 2K7 "?"7^9C GY[
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M"$Y9&&@>W-SM_PW/_U$.0?"(<1C=#'@H\23*)YR%*+1MX8B"*$3"7H?"#(A
M"4V=R)!(1@P4U5%$BEI=UT97 &@T?9N$/90 SF(CME6LMC&,8GJN9&!V%.<5
ML7 L4)2"\82""XQ G4R+)>B;BZ'"T>A,T'V'";P *6#*0_EN#?Y5&U^6\+I*
M'.]HQ=(Q;\<X1P,?ZKJ@5I3WVA"GG2+&ZR4W]36W2K/TA%&8#%B%K\#T"9"O
MIFQ#\&:CN"C8[]5$>CS9L<A"4L">E7$A3NXD>DH+F#HV?)\A/U;D>ROP32XP
MF1\3R.1RR6"P4U(PU+#<RK$08N=R0P0 VII%%I4%X,%4_'$'>-"*,__/2(X@
MQPG  *2,\ NP12B0 K!_Q?+05**4122(@#AOFM2,^&WAY=146@6R:CIONDBT
MPQM5!FY?M#QWW&-[N0)4!^"] I C2['@AC5 9#K)P C,P'2:  S0Y%- ,7;<
M'E>*D@(!8#J%LJ9$XP_YVBBX0!O#<R.NCQP;;L6..;6?1$=W\A4B4MT<DGBN
M^5F=[')[ZDJ3(5K!GG"TH37  BW0!AD50P_^Q%M"-F1K=^%9PUZPPS@\6;W<
MPB?8*:R5)^KAI)XL>@BZJT;)<LV<]\[+\MM0M6+;]RZSJH3XLJC?I]F:[?EE
MX@F8Q:,8Z.!\@AZJRVPECV(%FEO2'PH4CEG__"FE#-BO?P4HT$4>D( N+\W5
MM6I$D"+C.J!_K]:T4WL[C "V9QB8NV9UY5&77]8)KGNXYQ7/UEU/E +EE$^>
M9O:SF "2_Y5QR(#M&1TH@,(MPD#\E4L,Q!>;\!6-"I',$#RH#@B.C[Y P#BU
M=S3>X*LXK@G-BK&4-3=3R'GL)R)S#Z>=X@A_Y&PHH.09=?PHS---J#QB9:H"
MO,"0<4I-K$.A+UDGF3>CGX\BAJP7UM&.9XY43WI\GS=CS'?"B\36?C6+EAD$
M<TS9>FU7JQ]3"K,FI[:+%(Y'R@ ,M$7RT)D^$HA]) 99C\*?!E[!70) @!H%
M"LNG4:5"D2A0X$##_P,,&3X<L)!B1883"V <T' A1HH>.T[4&,-?29,G4:94
MN9)E2Y<O8;YT)P(! H<V;=YTN)/CSH@U@0:MJ4 !T)T)1L@HY0I6TUJW;E&3
M2LV:U%(C;))H$2,A"A0B1"QX\2H/@P4D2(TR<>+$"TVE2I$*I6F+)1DRMD0B
M]>J6M6W<K%6C9LM5J!=%#P M6C3HSL8-<_*4/-FABYB7,6?6O-DDOVW4JE65
MFBVT-;_;MG6#14*$61$D8,>&#9;U:["O1[".74)V;K +S"H844HPK*A4;Z7N
MAKI:MUHM2&A0L* %5>7=V&77GKU;ME$CP#(0[UK#>/.MQ;<.;YY!>/33B8?&
M)[I OG@%[!G<QZ\??WX%M3@+4, !6[HEHP$(& "D A)4\$ %(0Q 00DSJM C
MD3!T$$,++WQ00010&&644/*0P1)11-$DAA<BL403&5YX88883LB)(<2F ZZ%
M4)9BJA987B$%E%! V4*33T()Y9,2%NJ)HX\J>JC)**642,J-*JQH0XP">('_
MP"_!#-.?F1)++++(?.(I(IYJ*E,HH=C40"E77G$**FJ>F8J:4D1(3 &V9&CA
MA%)D$.$$%$A 80038D !BTA@<W045^(*Y2"X]K+%EE?HO"4;TZBYI;##S'P3
MIS8AJVG-)M-4D[("6A!3UEDOXR<;JDP3K#1KLD$-M830RTVVVHBE33=A23!A
MV-A^"XX$6*J"I1:_J*G%UVQ(@V:;44AP#87DN@E7.W?8<8=<=K8!Y@7WSDL/
M/_34:V\\=M'S3[[%B,K/O_[<Y3=>?6&A5>"!J6E00XL43-##" >0\. L+3PP
M8@=#@A+"B1!H8114E-3$15!F@"&&2+#P.(\77V  _[("@'LHO1%<N-2IIEPA
M110ED[0TH2FE9%4DB#KJ&6B(L.P(8J,1SHBD@9ENNAV:T&P335<=6A-54Q$@
M*@&I'3*  1E(8<I.J(J9BA02$&! JZ_$TX U$](B80$18*@E!@9*B*$%%S01
M<92P7_E1VJBJF>:65Y:J13!11R$U55-U>G*R52F;S,NF,9_5,]"D I6:3WU%
M+8;?%D#6MV5O6S8V98>MUZP3IJVE%%B6"SST;023"@773*"='7&QV^[W;4J)
MKC7@WNWO7_9<-R^^K.6CKS[V^.NO>OO$ S#S[3F[A8 $%=;P9P@?#*#! !PF
MP&*(M]1(?(DO5E"!%_X.!?\++)*T"R]+8I!!$Y)GT (%W$@!;FM(>T:  JZ4
MHDZU<"#-Y$*D) VD! :@B$^&II$#:'!*%[S2Q-CW,Z5QCX0$LD>?3E4Y)SUD
M,CAY'$Z(<K6K?2UL3GG*<4)5BA8D4$8P>L$)7. "!IB@!+P9 2@T80(EOD"!
M,; $CWP$%5L\!333J$;N9 <*4M!B4Z-H04ZPYL)4J;!J+"3C0V)50C5J9G.Y
MHDII0M>-8K2@62/(#;):QQH\JHX$=IS->(B" FN)JAKLL(8KBG$[P=2"&J$P
MB]I<$2Y)BNM<[.#&,];UF^;U"U[]XI>[ZB4?Z-WK/M?[I+Y R9^ K9&5*RD8
MA-3_!\+Q,4Q"#B.?1N!'L2W!+R3N&\#\0B&7&,Q@1'D!Q2= 88DMA"P2>1 @
M0Q"0@ 6<0 3W 4\"/\' IDA+6J\84<YT9H(-\LR,N!QG!]?4LYZYCT/M5-#E
M6AG/EK"C3Y Y8^5^XJ879DUJJ$H,#<4F+2I:I04*'-(G\A")+>Q(4*6(A'B.
MR"T1,#0&H$"%*QQX)Z@<)W=2*5LM7%$R'I&"5&&<FCTGET[*3 U6\G2I2OKQ
M&=!\RC0U]95SJ!D6!;RFCZJ[#6YZRD?9U(L^+Z#*K7Y'#5(L9QM^"<Q@''@"
M:8H@%),,7KFX@XU7F& ]ITS/)C_9/.!(CY3YPIXIO0K(_^R]5)ZWN-CW#N8@
MN-YR0O$;GSMQ23&)\9)\!V  5T;QB9)]HIE",N8G9O "&6 !!3?QF@G:0X(3
MC&"(6)C=*^HD4%B(")PC:BR#5H7.<7)D(D*K$ NS=*%93FQI;'4M/=ET3S.N
M$*6GJLG62C5#L 6T%IH*E2MD$ ,DD2*"HK#$;QA%@A(8!BPM$ 5L^#:[&VXT
MHWKR:)YN48L@?:)_CL-:F>P9&95&Q(/XY$@:7?O2S>WJBKV*(RQXHU.>\O&G
M>^2CLFZ#O 7$ %?4R$XU/G&+<*"FIM4 J2M&H9\M6'5<Y-K&,[9PS7FU:Y/Q
M6IZ\Z@6O4L(GAJ5$I?*8-V'LB?]GE>E5(S4:]KXM-<A#!JMKAQX6U[S>]6$B
MD$$P1^&B/,Q (*/ @@PB4:2["-&V0$7!"UK0 AD8Q!4!W29<.*LS%"  03RS
MR)6AA-JB64R7[#1: %IK8GD^3;;W]"<8'Y/;F]AX=DVAQ0UM<0I-!!,N=2Y%
MBKX"&_J@P!6:>$T++&&"%F!!%%&D;D;O))5;%*,8MY@B+"@U"AF@0 $O5+-C
MR@01R:CTI&I"KYA;Z9F:VO1VX>(6:^AC1][X=#:R637K4+>>^VRA+Z8Q%S20
M"(QT;.-650%IV%X G!A<!SOFTLXV7('?UE#6D\C[*2=%#&UY ;*L^?+P*3.L
MUO%H#]3_W/,>C6>9H8S4DF'O,YHN]PH2+V/(KS<6T?TB8:EOSB@/((N!"8)R
M'T2MI2TR(.:0EN)F;E(J+0*1RY1+J^DLK?,B%Q2MPE.;6O)]!)[=9B5L7V7>
M,I[),48QDSX=\M>]<-.!A-$FI98"Y1%9H@4DG2AK&-""5Z" 47II,Z(=B.A$
M2^49FA(<@C_AW=RF$-.;IEH+U51QBY?0,U=LJFENEYIM?")9S+9OZXPEU-7U
M$3WT84 D^E*-;9@K%HB=P2T,20UH.+#)2Y%;"[(A2>&Y W>1T !X0#GAYOU+
M/1>^37O6H]-J3R^M[:I>B9?>-+=>;&+A/E#Z4DQ7U<HRW;Y<_TB" E" $?#8
M4IJ8@<Y$E*(5^9O2I[I/MPQU A.XQ;@'">@K:,&IN(SH(%Y$ (.<%"6/;'#+
MD\\@C/DJDC GGH3V4%GDC)[2R+G0MN%-\WYO/D609I8I36Y[I5Y@ A>(X 6P
MP$)[=H2"%LQ % &W8<Y_I//C%.,9V85T*4;D./!ZO./W5"D96TK\$NZ#UZ,>
M]=-Y+0;^2&VTSC9H@S=6+5D4L#<>:0$20 -"07&HH1O(A10T 0MF0 ;0KAJR
M"Z,0AU)$P 2:0URVHQNL8>9J \0HS%_FI:O@!2P8@S'XJ3[0"MOV)3VX3?\$
MIA@8+\8R1'S.!T&J;'T>))>";V$:Y/\ 2F &ADN")B@4+ &9@BO8]"EKD$>)
M0G %7B2;F@Q(:(;@)D@N7H#*/(AG1.C*/NB"'$_<UF< AD\',8?,RLQ5K*8*
M2Z6VN*8A]JN&NBEL?JX+K0_^L. %Y*9TN"I$=FB8!,+\!"KG&M'1VF\JH.)'
M4"X48J#2'@>\YK",4.J,/@T.FT;41FU7FJI7YFA1PH( %S"/L@XVE @V$I!9
MCH<H1& 4&,F_[F$;D.C'%.L6NJ%:8 $8-FMV$J(7PD'NVJ$=T*4:-,&.,BS;
MVN6KI@WPPL+"^H6R8G &1ZEZD$<%P6JM0)%6O@V6-J1"YBIARBU^&(3Q>HE+
M.$1A8LE"OD?_";' 142$+B:(]N;BWNP)FFYO.@SES[8@1BQA8YPLY6@/_@XC
M2CIH'G=O:"CB>^(Q(MGIKD!+06 @'+>G'8Y/A>ZOT^:/Z&X"S79B?DCAR>:,
MF[9);-IN'W]H!DI@.EI A[3B\P[""QWQ_'IKT:*B)R<1%BKE$MFDGS1Q<JID
M$SE"Z3225CR#P/R/IOP"%E2OCR+K%7L#/ QP=5A'6:Q2 ?'.+!*@!$K!@:C!
M7&[!$AYE"[8@!F(@.6[AR<+F%C2!%,+A=ZX*76!AAT2 V:)Q[Z+Q/%(Q\ !/
M ^A#*$CIPU1PVIKE/')P*;\$Q80P(J%D'<4GQ<8MQ<*G0=3G!S=S_[7447T2
MY !0P&-ZS!*>"/ZB3!0ND;R@Z2:4:P2VPA)7#U.XB5,HQ5+@PA(5H+1ZYGLN
M[R-B:3,G$ITDDL8R@L4PY T=4U8P#BEI2R? "-/2K"'F)^4\1A1:89L@;9MD
M;Q0\)E#H)P1#H048  4L8060Q/5FAN30;R<W*E0<3;M0(?XP4<W\"9]\LU7*
M[!.74TQ$T2E+,3#\@EN4B+)>@RN'15AN0UA@30%A35GX<L\P"A:V(1_8P16V
MX"X6ZRY>H"\@K?J80E3N,CMPA^J^LAOU+MJ>[9$ KT4!;VX$;R@&SSQ0U$7Y
M;CK8 _'Z4T @LV'FBLO 1_)JR6&,ICB+5/\(#\8W@=!@1)-_M"BPD@3^="8*
MIPPGFB0^#F":DB5&9F &E"B;;N[]Y.)21B$&%L W?=,B>K-)AA,BBQ0Y)2Y\
MWFE'!88CRZM*[M1-K2R=-,TC"R!CCND3"JT+FR*SOE 0[X(\&0 !7H 4H$/U
MW$(@K$\[M1/]-NI2L^M'4B&P7B !CM(H.1&NX-'AR,NT\#3_Z%1,^._IH,Z-
M2F,&%% ]^,B/%!19E*@KMRZ4,D:@*+ ;2"&A-)077< X.(7MI&4"[9([MJ$6
M%&4O^4XQF>?"V@,X7E :=4HQ\&5ZT*I:06D!NA$]&C-5-<-[R TYPZTS4XS<
M-"3S,$).0;-]SB?_)(IS !# !6:@9&K/(/3QF(C,*/XTFO(C!$W *[9B!ER
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M+&$:&%NC80$   !] H"W \ 27((?3@  9$! LJ$U$-LDW$$! & 43((=$
MQ)8E:@&X?YNW&8"T9V44 & !*/LD0@$ 2""W78(=#@"[>;L ;,$?KAL!")LE
MVL&Y>SN["8"N-9H==L4OV@$F1"V\6<($!917V@&M$\^\2X(?!+2_2Z(= B,;
M\F$?#&E7N@'!6[H%>#O#>1L!5)M 8D##,QR_P_&Z>7MIW&$!>/L "!O#07P
M0,'"*_H5 (  8*$X1   "J ; OJK]Z&X9\ ?NKHS7,*[&6"Y2\(=ICL4HCN]
MJWLEKCL 7&$P9(     %8%PE$%R2O7L!78S<'YRC&E+BRM$; /CK%D:A  #
M!/CANE5\DE>BN0' J)ZA%!@   [ &C3Z$^I*0A2 %& \'T2  %S!)4X@\B0$
M 4+ARL4L'4:[):R!]WZ\)%[@0TA[%!"$2$V@P_]G^@4 0 $P108&H,H5W24^
M_  N!2YTO)6*.LA1@L0!H,C]P1JH' #@VQ\X'0$<-A1N/ !T5*-EO,U+0L8'
MH,/;@100I4,3W 3BW+1=8;FK@1!1X!4D&1]&X>P:Y1-NO !B ,^9>[JANR3&
MO,E5XKH'@+O]8;P)X#-B +]O(09&09*MP=TEN=BAHT.;VA5BH!8^X02\Z;O=
M@=ICP,^I8=W'Y!,^8>H&UJ_](=Q-XL,1P!W>N]T9!<Q1 LZ5O"2V(;TM 1]8
M/:(_/  >=[IYW27@7,2QG 1FW%L7(+T#P.3UCYX"0--5HAJR6P3N84SJ?,:S
MP1] H;>! P%^&P&X7:;_,?P$^F&?,5P!$)L=2&%%2J&_^>$50J'#]Z$60N$6
M4(+310"O]V&SJJ$4VM(?VJ$42!86;KXDTF$47"#L)QG!M@$6ALD:^ $6%$O3
M\Z$6 F@&:D&M[8&XNL$57N 3Y+XE:D%"$N0:_*$4[)S65YR\FYJ>TGS4(=H5
M[#P;C.W6=9P=4!Y] &  H)NX9QQ!>%L&MM<6T)P ?OO'YWOQ R#G>=OD\\&Y
M6Z#D2@'-Q3TE"K_<36(;T-P5;B$ :AW#"X"T9Z#*);P$@+OS/Q\%%A\ #.+5
MU\$2<#Q@/H&\]Z$;//;V?IL L'XEI)NZ2R(?F%\!(+[S'^*W%2"^F=NY/Z$S
M_YB?!#H^HF7@U=DAC;L!Q2LN'WB-P?TA]@$"0"E^V;CQ\X<PH3\1 %K,PY=O
M6P( )_HAS,?-6C=\"/NQ:^>O739V^Q#R^^B/W4B%_MQML\;NH+^3[OQUVU93
M(;]N&BTBO,?NGCMN[:@1"  K'TN%U0(  % @F[]J YP.L.8O%  $&]N].M!0
MYM*Q9,N:/8LVK=JU;-&V & BW[Z3#$D<W,;@Z5,&V_R] $""8[N)I%C& ,"@
M&[O%\?SM(P% @=-/[$SH#?!"*;>\3@-LZ6=/ >(!3Q&8( W@ %9^AP$X!1#*
MWS8" T2@/C#-;*VM(P3Z0P$WP %V_M[:3:CU0+>VS/^;.W_>_%5I!0K !HCM
M3T;J5]G^%JCF[P0  J[2?0HP@%H^AB_8U2IPU9WH J1<6?N+H!;(A/+U^@=0
M6%FP #! 7PBQ U8H\@5P2W\ O+(> *[X,\-VV1Q& 'CB!?")*]V, L "YY&'
MD%9V;5,  ")80PU8,92%(& RQ  9 "_XLYN-W;Q"VBLL]?>)0G\MH!1T1AZ)
MI%H5,C#/10S-@- ^KC! &P*A--E?"[81T!Y+_/1V(T+X0&;"0;6(0%L!)&!%
M#0(DD)+  %8>U.*;",@YRD'\E*+   ,4T )QK@#ZR0$#* !+0M:@4$  @!HX
M2@$OG,8  D\-\()8+#5UJ&__I(2('E:@;+6?/Z,JEV2JJJZ*I'<FH%#"1 ,D
MR@]D"[CBBFAEWA(  5CQBJI"APEWP $&R.!//Y!A]LDV6BEP2RV63OC7"-0,
M.L M]BR0FBNPI$A *;4D:%.EI6PS9$0I*E#+MP!88I8M "2P14/M]!F*<,15
M*Y9T5[$*<,#/#0C5:R+4<M!@L"$$Y#[BH9 P8=M4Y<HVU>0U2G\O(@0BD3^*
MAH ((C/@5(!D[59@0NQ8&MM?GU#3JXVS%="-.Q-A=R\ GS@,F$P@!N#4QOY\
MTG,W*?I87$,P@N5? "8LMQL!?;G#[2@?ZRQLB/<(S'778QUV@ R6S&!"  H8
M6 II_PN0', ,_.3#;0 ,H$" C9KNTQL)MD2;!VFQI6,I"2V A8(_Q0!=@ B<
M^5@+XHJ[EN@M5:% ]\(@_DF"I:K9)-H!)*3( '%$HW< "GE!%4-)8S4E*0 N
M[//6"P3X:FID.?G#*X->[\[[D7^Y]I33MI345 "U(-1X -7DDU=LA[6P5&NS
M^WDCWCW[P[S.[K3S?(RN;"^>)1K/U%OAM0*P<3O<L%,-?D.E.&$_XH5Y<F2P
MF W+H:\$@,"^@!6)(P*!IW<$Y)IT"D -:D & =1 B-$ <+R96"93XMD8/Q@"
MBEM<RD].B41_K,:Q$ 'P(J()!3].V VPF&PL TH90KB1HO]2!) $EK#1 1B@
M%1/8)$6)2I9EH <<^H%(+PL@SM  ,((=,J@D?W$!C"QE@E%(T19%&M!PL)>7
M%;9$-$&*$G!&H*D"BA$ZVOE/0XC3GQ>X Q]:R5 ^1$."FGPJ*@IY3-,(Y *0
MM(,4H5"*5A; #Y@!0 ;\< =P[,*K=Q72,F5REBOZH0_@0.]GKMB):)!5(01L
M@Q_5 $N0ZH44=KC#&HU"6%E85PJS;:-/I*"-5$:E@%(),H)CK*4MDR:"9X@B
M12W(B16-R(ZC904P[!!-#X44(FML8YE&A,S&4C@>!""@;B*@!FD*@ !# 0 %
M'YP)9)"U#^!L[!8GF"9I$#"4HS3_,&GT&\MN-)D I]D(6,0QCEA* 14#W7*?
MT4D-<;H!LN6LS#?8>Q+/4&"1#\)L *.H1;M@,8Z<F:QC870'RU2F0MWT2I^N
M(% #5R8G!I%@ (1)B:5D6-!!\DR(KHD!%TO4,Q0%8)U_@1Y98@1"EKP3C1B[
M&G9,.DA^"C4MVCG )T(1BAB I07]@)GR#@26@7 +.]"D9;(8@@ 46&H  TD(
M/V[Q"1.LRQU.':!T^J?! &#%'QU%9TAJ(8.1;M,?($+ ?K1C G<P!%D(^0L)
M_%%#!N3$:#,U"\P0&*=\+< 6?A+55NR1$*=:=:B49=5?RN2/5-K-'[* RG)D
M<Y1$H8@ __FRZU+^(H(1)@LR4 +J"4(!"E"$ A94L1$H+'';6E - %;+!V2"
MQ ]Q^L,HF*E%75VB3H3$3J-V!8Y32J'!_OGE>HYQ08AN5]GL+D4Z5_3'_<(2
M7,08))6Z$T\!BM&/_3$(IREIP0NXT1^4^N-37-%4-Z$*H);@"KO>A=PR20%%
MF;S%=J/*YTR PQ=\N )HQZL@<B+3CHX>H"]$(\$^"%N,F=0T)/M52(RTB+RM
M\)2W-BD%+/J1QF7>PC+?T:\K2J5=?FJ' 0"\'#:>L5&$M,-2I'AC?E,"%J0E
M!$PVZ4T"!E@91Y$ ,@H@*WH,M)L"L(-7 _BL%=MAC04(QP2B*?]<7;=V1!&T
MHWD)T8X(^$$T,#JP4>LD"Z>V 1Q+O8 J*7L69!'2T7_%>,]&>HL.L>?<1&DC
M19]XFR92LYQ^ "=%?#6,BE2[D'>9Q)D<FP$U;+8P>H!"$]:8AVAZ6P*L_09]
MPUQ 38[;C:. !W:N:TDMJ*C3K;ACB 6BIS^L*P+%?*AN/^5SC"5L1'[\)0 ^
M:E%JM&RC?/##,@0H )4HXD<"D4 T"A"E:":$D.\B0+Y;7-B!>#P5/TE%(8US
M356>HH"U^D,Z#>F'+9Q2 ID8^P"2L5MX&]VQ>_A6:6GN!V&?T5>E66, 4O-P
M1I>RFRO"C<1G;4=_T/,:AB)D8@,8H*__;3EC .)3>=RH6P^)FQ1NA<D:R?5J
M;VQ:C12)F:Y;P0H^FRQ(;(-( ?EX-P01,BK!7M9_7H:*5%C=@F5OLR3[AEZ%
M94)86USDA)M"SX?T4K%0U<ZT(;$,C2^.=;9<5B;;L)0"EG/H (Q !$X!14+V
MYYHV(S.U++%>%[T+M!:TH"H^T@JF@).>>U3-FU@+[XND$X 8R"!%P^GX4Y,&
M/:K0+-;HK"T@HTL<ZQ(K1<3,NG9OL0 2&-$F7,[,<%%P  (HH(\SF8$"2*'4
M [3@L_D(Q0(*4#JLN*,%"Z!E.P9W &[G P4*$'([3H HV8A@!)^-+ ,6L  %
M9/X3Q4^)"1:0_RAV !_;"*&&5@>P  4AQ/0Y?84"6J 46S" !-O(5>K800*^
ME$@!9L=+ =0=DA- ?RS48, )0(*/%\S_%G-S1SY:0!W4(0(O< M(1P(BH$^6
M1T#:40 Q, ,S\ )@46U"UWNUT!NFYF/T00V6L0 PY@]$%D( 8':CHDG= !D)
MX&21T2Z6\B*)Q "V  N6XC; 80+LT"9S-40E\ RD0!H3LF <<@LQP&#^4"_'
M81-@$0G5@&8,D%,(P2G=T!3CD0T30SMM] (S$ .<07T*R(5+,0,'T$ZO($V%
M<0^B$$_\<PH -% BP%\E4CJ0-C@FPP^C@ ! @P"C8!'YH D' #0,D/\H]W "
M!S A_. "!P!"2A4;^1 #C9( H" "Z=8-#*  XS9X\-)U!9" N.,F[N .)'
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M ]T ,P1@7"U@"9_%*P1P"Z/0 LQG$K#P B_P"MMP5+,6(L7P"8Q9*OQ0"S&
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M"]-6)/,4<3%?(H0[3.,:L7$-M($5KE WK]$"$)$7)4!Y \"/,'5F*10 B7P
M(!LC*K<]ED(K,F"K)T <G\( 6S.XQZ,5") B=B$ME_$"6W-89/_W%"- '- )
M/*EQ"XFDMQ&B )1' #YB9DIQ#V06G\"!@-T F7 $0(44CH5D$MJXBP>!P(<W
M$^XP#Q91GI8A Q/*#^UPH.2Y=#>ZSDM!)N0LT,1Q0F)Q0GDHCJJU#ZZ(B];X
M$SN1KCLZ#]PR \JF;*K3#65S*6ITA.D1<-"30H!2-R'R68-2&A-A4Z5 >0&
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M!634RMN"7\>$_MJ9=.5O,P-^[ [:TI@;A7T %/@JIQ/Z06H; @ (2:-[2/]
MH+Y;2 J'GQ$4]"<P!=R1C[)7_.%J 7X"0X"P;MC9;8 !JFG'-A%(>86H:O*Q
M[3L/ 5A 0Z1Z$B&X P+@SY^<_D.JG1[Y6\DCMRH48;SR2LF'JPS7.L@MBT3
M;@;=-()%+W:HD2T;C41LIQ2)8JC%+K5NT2L=?V0$@$8,-62+@%$&.*"S[?+4
M<\^D["(@,9]D(.P5O4JII90I120L)Q+6(F VC?+:J9L! *A&HRY',4&V6_PY
MH:%( 2A0HQAJXF>A O!T9\9\1'A3J8X0B&'666G#BZ$#+O6G%H' ;.S&CDZ
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M6/?R& D>@+8$ *%O*S4 !G1JTQL(0 !%0J&8 ;R ! 4@1=$*4)\+/3<II2!
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M>T !W@H%$R" ^NB'$B"  Q !%VB\%Q!4I-@2RWB! _"G 8 :O,@03[,&VSD
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MB<]<^K$% V"S  J BO0/T()YN.A-(O\8@#)Y-5#C=":8"5" "1;P=]B6QE+
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M:%>,_$A"J!\*3,S)5 ,"1"/3'( VD 4!=-M E D#U()JB<>:J)\*K(ICM$
M),"/!$#]^<: F!)(.I-#II\"%(@[+!Y"\$/XB0 *L&(,()$E%,";_Y#  "R,
M>0Q("20  NS-% K$+ S ,_B#92S GM%?%MV" @" ")#"//22HI$;"1R1O[3&
MJNS12K B Y "W V4W^1#7'C+JO@;-6@D"DB-,OWD -#2!%50O@U(89" -3H&
M/X#"4:H Q9S, D'2G@7 ).6#B] 2T52( YH1UDS/ B3 "+ BM(0$TY# """
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M*9<"!=EPS7@NC<Q#W 9."5S>LODL56U)[YV)$>LM08"&FAH'2-3C,V#)%A2
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M\H@:M51&KV*G !D(^C34H-I!  5^BERI&R21XM37JTYEYY4!-/6G&@1F8*"
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M1?H(4@W_ @B+(,]NP3YJ 8!(^&,?J6V-/];<9H+ PA*^DS).N#V /U81 >O
ME&4) IL'W0?"*^CV?OC! /$Y) :M@1"$K?RQ%[ S!@H80(-DPQIW?%)!P3W!
MC_643#L.4Z7^, $#+%> W5Y,0YKP\,!/(HK\DN!C+? -MN],D!EX[=F6P!0!
M)-0-Y2X@!K8X#@JF^HH/GB046QT6+$*A8 #D"T+J,_K.':*V'HN Q/P0-$I.
M10W$M8Z8\31!#%M0=[0#.7^T0I9#?KW'%]V#'R[@;@O,1A!TDYIS75<  ("M
MP;JW8,3Y.NUL2%4>,PKMW7-+V.-9,P"$3)<R+FA-<@F @L<K_[<:QHXPINZ,
M&GA/=TU%QR ".!T L?M#!M>V* OQL8 15 D!\$9CE8,<O&H'D.6C8+D_*%T[
M$=!\P*C6LT\4G ]ZDA$?Q>>Y3<CG,O>>A_$+SY?18U.?J\D&6 0=$]7+PWZ#
MJN8H99*-JOI!$1D$X%)\[9FYEA92D!I] -A*HE+*)TB YH9ER;; \QPB#_9L
M^QS"49YA'_)!/C+%(63 :]1N2L0E.;H!%$2  (+D-UB#'ZX/)4!A %*)7,8,
MC/)E9:3/'XX.IZBAD1;@!'*OVB;/),PH36HA ':+! + !(;0!%  !=3ML51D
MGWA+NQKF13:M%+K&BB0$W60MCA2$!?^5#4A,X 2&T BMP]5F8U22"N-BX]ET
MY$@.8 A/X 10P 66"#].1C7:H5VXL M-;QOL@:(< D+RI5E>CT &[%KX[7XD
M:/QPCP"V)+>L,!]H[4B$CR#N80%,H/C"X=L"" #4C;I"BH50JE1\D-0NIB,B
MJ11 ZP&-90$8 ,?BS57P3/KV(1(RI%F2A2!< 0#4+S6TR;+V@1K<R1WP@0%0
M:5@4($E"00%VJ<1@8*-HSQ9I"A]4BXSZ@000 #JLX0#>9N9J+A3VX1GFBR#6
MH9%H9^!(AC@BQ"%DD" .[!6(<6ZL1!^X01,"0.E(T,Y@<!M&H1VR[KIN:1LD
MRL[ 3MG&;DO_W(&AJ&&ECH2@4JM7Z@J%B"Y)^*IF>HIM=B0);661FA"-7B0?
M8"<?RN05/":D2H3;3* ;-L,'\^543,,=LF$S=! TV"^'3B !8&?)P 6BE"5@
M$&<@^.$$1* 4"J D&I'FE 6$MB$\%$"X%NG.@(79,.13R@=J&(!)_O$"&Y+Y
MS-%DI,W;(/'6UJ@6:\$2F:T??/ 9*+)$3K+L(,P?8&$ 2,V,J&\!\,$'K^4>
M<>H496+ = 1JLHL:5N9:9-"FN@<B9JRBQB0?6LKT1 [9!(@!1F$4&BF=J &M
M2,$50.87<NQ]"$ $7N$5^"H@'8)\7J 61J%C9,, M3%Y["H&HG  _W3O <DQ
M)2R0(# 0.M@A 1C@ -[C$Q  (?1!&PA@"_B-1DZF0[CD!0R@&W(K'2!$1_@!
M!CZ-]?Z2[(XD*2]KGV9$X,P((2X"G)0-W4 M-4LIC@:@4_(!T"X2\0I"(X-I
M_-)H :@C &3-SL3NBP  MJP.% )F'V8  2C#)3U#[0+2&@H@29XMFP2& +Z%
M':SL.,#G)@&0IMS!!-;IH5  0/K0VYH2@1Z* :##MH2E&!@.]W1O&P[@!([C
M.[<2);+.G@94$\#AV_;!U*Q#5AKB2$C -:PN/P8L%'7,'U1  >R!.'?2C)SL
M+FN"0Y[F%DS :8[0(5RAE0IJ1D2@!9Y!%/]B(!_ 2?K<(12*4$I<8TE%R$D7
M2:X4@$GU84>@R!]>X45&(!*JX05@,"%F0 $8P 1<H1:**]6&Q&1:0%/<X1,6
M0 %>H!2B]$AA$R5D$_<<$$1&X#BD2 % (10.YL90( $LA!0&P 2ZC@#R([<"
MY=A&H11F1!ZC\QP=,'FR2P9<(>1<92!,B 3(J+J0:@0.)H;RQ@0F:*]^ZBA@
M@<I((=*6D+T&,7D8(%?<H8EB8!0^"X?0K41.!@%$E>I^L" \J 66=;E,2P%>
MC3-4*_AV\QAC2R\UZ0!D8%)%]&2@<UBX15E'8 !PB Y1@&$P-+D*H 5Z@[I<
M@0 8(!1R+\N8\!#_92 1>VX 2" 47N"6.N(148(=<',&3FD!W.L2?3"=1J$
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M9(8@2*$T0&CH\F%0(0LEO'EH 1K?5#DKMB$4.J)$4=8C2* ZER*8$OF':Z$
M\)DKN:0=CA;H_.9*_,$:BDZ>3>)FDP;HCD,^\J$=^E=2^M>@()$?2F !DX<?
M3AJ-U&N/!,6@LDD^UD-GAZ,^5B]Y0H<E[B%T8G98JT>G&0:@VV:@_XV. )XV
MR)):H+,97/9.):(Z>?!-0 * F.T*(;0/0*8Y[^*H(M4YI[4YIXF8H*$B!I"N
M)ANF% BY*-@,KG.8ZMH!YPK94A=@4G.9.AC*!/(G7YCH6[9!P9"2&KZ(D$2
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M(@!^NURA'0Z@H6=@5E2$$@F"%@;@_PHJ!!W9G6:@T \0I6#$S2)D&U:_W0(
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M.]U0XXH)6^&4XB@4"F9"/P91=B%'^I (XHHAKKCAG'36F6$[![ST'0 3F5
M*3"^TD( MPA(H$'5#) <6Y\8E!AV'+50 #MYY6'?=0[6F V.!/CF@EAU#3 #
M1Q%MPX]D_H!"X7IO$97//5VZ0D*8HQ#:$0D,[//, #,9--^:=@8K[+!&O4#
M*%>ZPH!*D8FPF0FG572106DM&@!S#!SJX#9CD2#"=,6Q4X!W!O_59(T[!\3
M$7'B.3H I$;EHX!S^8C P&;$N9)H?@9U<ZQR%G$4PZ3Y)."<H^S4B^0^[E#S
M"8(3R:>8ONTL^="/P!*K\<9%-=CQ4WD,L%%1D0!PP&T''&!9.S+<)L( ._IT
M\*ZM^?-) =E84\!%#<X0P#5%O:#3?;:=W! #*]5"0LH**#  5SR)^= ]"+3
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M(OP8Q0&RB@!0O"4NEK@: CCJ* 6XKV,E4->Z%%" K+Z +OG80F'#:L17((
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M@:LW<BDH)R-X%!YH$"?8>].G?K7E;-H$@[U'@:Z73<]6?#;XA% 8A7)$(OM
M(E:8322"#[SW&[ GA=$&@%Q7%&W"A$;H,4$H@M"FA+)U&3^X@L;GADX(A&RR
M-4H1A"7B@B_HA7JXAWR8(;#  ( 8B RP&]: *X%( B$6("V@:7T8<B7WB'E8
M%%NX?458B0TR@G&H>K#'@OM#ASTX@#C8B%]X=5-!(T#W0H6&(44R&S0BBKD7
M"@!@ BV0&;.8'Q6Q )FA#0(,$ !O512W4 "YY8K_(#>!1XB&'Y-\D!B&*IB#
MD:B,2)B)F8B$SJ9UPAAMI4 05+$/,] "@/<4A,143+$-1Z44G=$KL0$+(["
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M?@Z)@JN'@W;9@LSXDTR!E3XHE\T8E/XHD.69$@Q0 F!R) .B(,.CD4-G'9:
M#__LD"4O("D,4! 7ZDB20@+ND!AWHRHKD90K(8\(@)B=@D4(H  O@ *=\A9.
MZ0Z2\@JDL20B\ (,$#I1N0#ST$;S^ +!U7S$9ALRD _5T*(9.E=<H95$T0($
MD! OD%8/P0\ST"F(V19(40H$H#A+ Q\F, #T:)_V!8M&<Q4#1A'P>!0,,)5H
M00":X"&)T0)@2::C8Y2":80*N2)C*(V<UY=K*')PHGW:U)\(.92^IY-$B0(
M$ I&1U0O\!8Y(4DML)%XU"C\]1V:IDL7 @L$8$8#<#>A0#?XH%@)LP#%!1&?
MQ&(/)VXK80(;^BD1\R,Q<%<GH"52.7JF477]X!5O&@K_I-$R#Q>3V &=00,
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ME%UIMO3KSD2Y#P*,$1KK#Q#$TDY#7":  (UR#RTP )[VM2MQ#\:B  M0 %N
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MRG=D#0<P.P:1#C)0 "[ N]7'US<?^((_^/<#OP;!W8W  MW=WA[@"(G_ 2P
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M T@B>21##2?)[41'(ND'KX*24R =G73:![,$]XEA!%=<&06! Z#Q!Z]]MD&
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M2@?=#7W#<IM\[&$'$D9\'M1$#1DQL+Q^:O&Q%M'R&86 !0)KYY,#2ED(KWQ
M(4"!6O+)IQ0#%*"FO%H2., 5=\*^I8!(K-HG&Q-&KY(?=DA(M;-MD+=D'8;8
M:8$ %[;AQYU1#%@@E%%"<2$\6 Y7MF3"QR>_?///5[GOA?*)Q')'%F$ACQE<
M"044%CJ ) 86/%AD9A;4\8Q%[E$+5Y3"<U5R!RQV! Q^=&-'M=A;/&!1"E?
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MMF]<C-H21K%4-UFJTS?:TX@J&":Y/4[24XP@34 J*'%:T6J8!51 !2V  17
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M31Y/K)!'-?E (\H**^A!2BBC2 @#BP ^(\HLV!B3R@JSL ,##'F $DH>4-R
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MUQ1@/Q!<9YT$ABA+*F# 'N#$. "#*,3#1+R#[PT#^-S $XK.  95/#21^#F
M*G0%X8@*\B675I!-R35 H2V&9@#7SW&%W5!&'K3:FNW)7^3!&989V,E73N74
M3[%&?)U&0<6#$EB!S-&?)12-&0)5'\D?)L)?3Q5B4-F#)J0=!6J"@-T:@5&@
M)QC8@!48*4(8 Q+8L='_1C]D( 9PCT34 WI< !0@S#X0 P9P@ (%R'T@"S^
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M6!8#C?G#BV7 E*E8.HT0/F(82A1C/9S#"FR C"5(*F3 $U3H<8*1,2B.I&3
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M2#A<@S6P23%&TC940S@D(6V<;MV% S;DNS".%FV,A)&$PU7CH#64S#QPPS9
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M>NHUE,NTK-ZPH6'9+E:^R]JNZ)1982FE:T,SWNRNE[V$1:Q5K/&+7YS""A0
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M%V3/S 3)'M8P'5!P!0$Q$#M$\GS$'A9/']Y.OGRM!AV0U'S0'Q3O!Z<B'I)
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MXZ>N'%X\#N2 "]  #MA@#=8@#.Y@)P*A"[X ><%X9H-@&/IA&'8 4ZE:H7E
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GYD8_"M*0WL:C(BVI24\JEXOF$Z4L;:E+/Z+2<+YTIC2M*6T" @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex-99d3g007.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g007.gif
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MXJ&JRZ"RQZ.US*:XSJFZSZ:YT*R]TJB_V+&^TY+*V9/"Y)K&YI[(YY;6XJ_
MU*C'VJK2W[/#U;;%V+G&UKC'V;O(U[W+W*7,Z*?-Z*;;Y:??ZJ_6YJ[4Z:K;
MZ;;.Y;W'XKK*Y++2YK/4[+G7Z;W:[KGDZ\//W<70W\G2W]34U,+/X,;2X</9
MYL'<[\K5X\[8Y<_:Z,3>\-+;YM7>Z=C?Z<OB\LCF\=;A[-OC[-/F]-+M\M;H
M]=[F\-SK]N#G[N+H[^GIZ>7K\N3K]>/O^.GN].;Q^.WQ]>[T^NKY^O'T]_#U
M^_;X^_[^_LS,S        "'_"TY%5%-#05!%,BXP P$!   A^00!  #] "P
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M6)!KA%Y'&)'$N=JR>^ZYY:HKKQ;O7K'NN_2^J^^^5Q311!%& 'R%7^<6X1O
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M*DLVCX1TVIAGDS2.=.9)[4N;@#:G&UA9HG0XZ1B".;M*E5/ O=EH*$B"LY3
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M>\=WV^3P:2OQYYE=J/J>&9_Q[B1/K@J&=>ML-KS]Y]/]^TF3^X.3 54_)2]
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M0XLXH3PT0G!&51T$0Z $(]70=/TVU'6Y>A!B>:N'IB4#9^2X0Q-8?U4NFQT
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M:7[@A4(&P-<B6I$# 4(@1]AJ!VEX!6HMM#&XL^]-98@[+4(NM.:-T=8EA$(
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M7AP\0&RS1V\8#P?!^/$3Y\!!C%:V9.5+.)%BQ8GH! " L<]B1X\?05($!0"
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M(0M/T %.^=I7#UK'*X3HK@=]L*(5][ "\N0C*POD!WN^8H\>2 A<,'$:8AS
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M6A1@;:MK"5U=9"C^$D9R[!%R<%5K+73\"'G[8D$T[88L 4=RS*@!7HMU>,(
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M"+L# 6 /)("'J23&:(*"(?:'O+SJM?AA#+GN\7;G9:*$:'B@'S>J 8[L"56
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M =EV!O*@(E-D8"=-,B@CZUAB0 Z8E@[(20XX(B:MHP$N:I80H"9-9-Z>8[:
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M$CI\"#%BQ'<R'*3Z)DZBQH?;&M#)Q\\=BQ[Q-IH\^7"8@T .W=4!= ^E3(>
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M)4*N"2HF&Z(0*4@MAK>(_+"+O(9U!Q4S*9<*JJF7X1B#MN46K:9U#S%%,*H
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M=CJL7-X,O[U5<(HANO#&7W ZRS"5@U9)SR5.[:#/N9CZ<  5I]PA)08%$$
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M +=Z2 X(&(@*6% ;'M A&&@[>,]]_O-_066<4:ZN$['Q\/>P(-T;X[)/(>0
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M*P*==#S7>,5SB< D]#('>J__DNH\VWQH=^[&_W/:X(U[,'<:YG+:X': X*%
M02I^_/;M&2@GGT%4 _?LX^=-A0('M@SR&_="00-C_,Z]0-! %D9; WW<X\=I
M(">,XE@H\&%O7YV!?[S%XQ</G3V#]^1PW+2MISMW/3$B36J0GD 'WS &:Z"
M3L1\=1 H@&@0I (5XOB]1+#B&D9C#BIZY/=G("N#Z&(H8#'.H*R!,,X9W$=G
MX"I^/PLH.(4QGH^!FY0B3JQX,3]T @3 B,AX,F7$H   \+2X;@.I/7(J755
M\]L>] [2X9%S;S#4#88EM2>G(S]C*AKT"!3LG&2#[F*H3IRP->)S+&*\2RI.
M!8_DJ J00FKR#U)O#?^HZN2A J_!?'0<I#7XIX&PCR]BN%.^0D9RT=$QTG1
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M#=0143P\3-W==T]A] <"K37]=%*V3ETUJ77(AUA=_R0AA<X*S1EDS!\\L."
M S$$6&*!![:"@'T&-3@L8K:,6  ",>P1'H((:!9S6K:.&J(<VQ6I0%HJMFS0
M."J8)M&+D@%2 "U*/1?=;YGS@W.[_/3QVE9_P(2 "CZTXF=2]]1"!^ .,*>
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M.@C$*;C@..R?#DJ42?F.RS5 *AR%-_\4!BU%10-L0D[L S&P(=D$@P/(P#5
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M8Z0H#O$C=X@FO)P%8- !CPDD$B9%@0Q$ 0B&213 0I*:FRU/B=P#)YQH$#D
M)R#,E95*$%VD%YU2@FQD;Y@-_VU7.")  >Q!@]Q6BI2I];&D^0%;FU(&L0UF
M&_E,.J&"#X@;*<A!?(F#@[(A'=@"/YV#E?^R(0]PPNQ\0QWP@ ^$&2C]@0R<
M1Q_$EP+6@8?(P!^X6$GX  $9@QQHE_Z10D30PQ_LP7%199FA@ASHC!P*CTD%
M@@HR3NCL@R?(07EA1%UX C'XP'%@*E+0PRKT@-3X "K0PS#( 2U-VB(-@P^L
MCAJIJF*,0U\5JB<<Y37\C>#%PYE"33X$0I B16Z6R"KTC\^85*_6G1SP@!R
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M'G10R2I.61 @I4.D^A#''G<\08 .UL)T;IMXSO$DUE1URN>\0-"QQYYMXE"
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M#'XGY <J?- 2J@2##C%800SZL#"JV$(.,6!!#.BP%HX,Z$7BD(,LQ+$''?9
M%O= !R>RZ*(ZI4(.VVC%#+2HAR9"9!,Q9,%_:'&U=Z3"!WKT 2I(,HY@X6D^
M-?+!*CX5AU:,HP]9Y$$@_Y*UCRM>T >V$ 8F$4(,X#2 !W(0CHQD(0PY!!*-
MVIN%!5D@@T"$ZW*!X$&!>L!$@L0#%7GLP2F2Q8]WP%"&J&!5&%F )Q$J9!N
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M'FVSBG+9\E@?\BU]HC<#EOHL&/"K3#QBN!Q;-, 'ACY(,(A*D-<JH Z5V8=
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M8Y8F&%$+O%00J__%=@=S0:^T$-O0!RM8<.+!>.7E"0VP!S7'#Y.G<F7',YQ
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MTP4\A;;4F9:-B/E,%8'#)CR>@B]2E@IA#UER1M80#-$'F8(U=WVP"NH3/2M
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MCDN.^VSQ&-A 12!W+]_QX/'NY5"B18T>19I4Z5*F33=F(P!@QCZG58VJ @#
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MKZ.PJ090C<<D9HB@3>G:--B2CF_@6 .9Z3E--G\5I*L[A6 0CG.(I82A U3
M#:3P%RFVWS]:7.[J*PNBAV_ E*>DBIBXJ9QZS-\=BG7SA,[#I*=JEO\QIH/4
MW"85"!4$NX<Z"*IX8)D>J .F/:*V+,%B8,Z>X#39>@G"2BL"$N5.FS(73"X4
MA@AAD*;MM0CBPIE\ $M9(&I\\R-JW=B\] \K/N9W,*\/C"ZHRLFQCA>A2:!8
MV1^B$(<8,-#J.X]/BM<U<=Q?KMW^]&6.6(4"X(3X"@G#S#[&"R2G/FCXVL?@
MM6;3[5%^P*82-%6*7,61BRI-MHAM.(4Z@*B0<*D46UXI10"R,89SAN?!R"P
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M;RGO*J C<Q."P@6W!1.7LG.!&$[=O8 ^=B!Y&4Y1!5_+SWEP)!&TSW:>R.%
M T@YY X/"JP@SD"V))@:09L$1\I#Z-3'PCG\X*1 #.*X\\Z([\1#3T'WH!.,
M)[,E6$N*X]BRR6S!2>70IVT*#G1.?2L(-% Q#B@PATRD!$>'.#*%QEM#WZ@
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M GU]>,&X7.N#F?(C'GUX4F]VJEP'#(,?@&"!J6\RQ'/F1!@:V8<LDNT %<2
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M95:F95ZF;P";8&+F7:9;8>GENZ4E9XXF:=)E3\AE:::F:JXF:[;F9:8" A3
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MWU!F$SF KYDE;!Y@#USJ!AE#'ZQ?A^U=N^4>(!PK6Q)#'Q L7AJLQ$H$.O3
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MI$\UM1;^1,Z-Y,.;Y$8&.D M: 0] ,?-Q942B<G)U]'O&F3XD@+@GT*5[P1
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M?4)G!<K,&%8@!B*C<)KBI&1$*@0FS="!!S!BRL9C#[(C>Q3"\O@!RTY'SAH
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M%DPB-65!A7@ 1$I$&HUB=NY!1&JS--<(D.X.,?,C?F *^@I+ 7K !WQ@+%E
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M@]C1<W2 FMRD\BBZ%W*,(KV<<%\KC2I@-O#Q#60=%K:>4FQ0!QW(?:M8Z'3
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MLH9N$Z_2RD#BF!]_:("&P,.#^8IE!<7FQS8$UX"63N@K=%AS*M8L$9DR<9.
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MM52O=A:A2C<WJG$/P? "!6"AF.$U'.A&;S:99H03FW![[Q K?$</O^4) I'
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MXQ.R"GW0QVY!W![K>W1V8B1Q(/SP#D3WX7O H+1@W3?) M:P"I!.!_"+%/3
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MF?;)^.K9--=;H5,4^#JI:QSH(=V9:E%@C\+&4>'9B_^$J3OA;1R@HW"%9E&
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M0(?@0P#PZ3YY0X?6<H#>4HAXB ,%\ 252R(5:  ARY[L.J-O\/^_%9 *8VD
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M"-846X4"0&!:0@>O_R"U9FWIL48(6T@_RFP7%)K&M-XJ?ZF(?)CI*A(''T"
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M\)+!A3RP8RXBLO*"*)X>* :%1X>:099.IITM^_*"L%4G=)V>N(=KD*<8+@C
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MB4]CH 8I4D59X?" !ND@$._Q1)>(D%7YN <(G>C#(4K$@4!,XQ>UR*IL$$
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M@AF_XP\%8-$^ ('_ $"0-AX2HD-N\I$*!'CB@EAU@!P,8X_*!.(X^]B&#Q!
MGG$ NP<'OP<V1/VG5"B $T[9)@\<P$IC0SWJE43V_ZI95G)*R+&PRXA/-H&
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MGN"@$2( E!B#H6C&4DA5 SC&.;# YYF.,;1"(-1!4)B$ XI>5K':VQW$'R!
MO:P ;A3$E  "H 2'3,@!*="4"1KB(1X01:D@JTS7-76>&A;$?GR(WQ%*$6+.
M'_#@>!Q1$,:56BR()6(.*0A$'6!@0=2=2&#&'TIA2@P14UVA2V0A5AG:<A1A
M' 3"/OQ('3"0H^A<Y$W>%O; "/9%$!X%HYQ" PZ$;<PAS5U0<,0>07B='OH
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M0.R#:2  #8&IKSB ,J&#JQ5 I9#>#OT@*6@("\#&\Z#AI9*I3KX7L*G 3;#
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MSX$>>$(P]*U"G,.I=&;ISBY!P$,LQ$$*), !Z+,!Z',_^_,_^[, Y#- $S1
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M87/V8Q]V8SLV9ANVA84V9C<V9J/V:1-V:7_V9J?V9E_V:Z/V:L. 9KLV9\.
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M,X_H@-J%$_VQ]UC;"\QIE(%4F4BD(-8]Z,P"/=AH1_\^GCYJH5= ]/^M@2\
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M#^W0I5NL$'+FJ\G'?I5\O$WQP'6 =Q=+P3+XKK?K>_&@#5%6S/5PM-"U9N.
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M:VB3%5\\$'&>0)I:* =T4*UHJA//&XQ:.(ZZ:B8R_ )WX- ?O&OCY68PX -
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MEINI^I P0YQ#$9$XUN8H43I6G0U5);8RW[2U8 W!XLP$) 09Q$ A^B#&>/8
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M!1+H>->V]-P]4%D?M)BU[$%R<<H:$40\V$(@_X2([,"8PVU+RB'9,AV),;@
M\%B=G8Q+#UB:WU7'$8*7JJS<^O18("R1'*3#$O' ,T#*,+S8D5W6"N5&M<3
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MN  @",.RR.OMTEP,; (QW$(?C,L/:,P]4-KD])X>L&?_$.ST>=$$Q]KY)2S
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MP A,'0PWF, /SL[ -$P; %-XPI*UL(,SO.$4V\4>?PGP9$Z,S@<OYL,&AO"
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M41 *<? (G7 ,\[ )[; +FY ,W9 0W] #]] !_ZQBDAB  AU1V[C- ;N"%@(
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M02%S6=WU7>$U7DM3P>(A$IC ",* "2C56K%53[.51RV@2[OU A9!%$HA7'7
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M!VX@=P=X>W%6",B!316YEFWYEK7"'*: ")( "@[!$C !$P8ADR-X"7(AE#5
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M*L>G)EK@S1HN\$Y#^ &* X1(FCA#!P.L08]'#@0]]$#_1YL(DA]>P> >O!)
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MQ!XLH,D6K0$T>"1.$YSP4 KH$<LZ]HXA#N&5"W9B2%PT\XI<<T<^AJ'8.AQ
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MD5[%J$<R4,@J8F!O=E>7NON0@:=)C/&,:YS$_5+'&IH%AY'_KH$(1*A"%8Y
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M0G5"-O!A_WRQ#S!D@B0&)'$@ _,!6OQ@#)R $,;P,FER%:NH"300",BG.9]
M"YQ@#Q=C>PL3!W0P-PJ!#E,5",. 3?-# [@@1W,P!Y\0#']0D62B!TEU$G_@
M'<&P<+2@.:H@"YHT"SCCAZ*'"@3Q#9#$*YK#"K$0$@!6C\0&*W. "P,!"K3@
M#E3I)#&R*4%@#?GP!TBI$:  B./U90'""<& ..* #9K@%C;)#\6@20)!/WK
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%?!$0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex-99d3g008.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g008.gif
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M^?;X^OCW^?[^_LS,S    "'_"TY%5%-#05!%,BXP P$!   A^00!  #^ "P
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MP)*4JAQK6<\*(+06Z*VN6&LM\:K65M1B+6QA"UWDX@L&-\A!=$DF7OD"8;E
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M]MT;@FU?KT& Z!7<0_#B$$!"V.VAF+$(Q8J#5)8<(G)CR9&#- 82&G2/T"^
MF'[A HB+'I=[9'A!NG2/V#U<L'Z1.W;NR+=]N]"=.PAPW;2+YR;^^S=RY<S1
M/(>.QDQTZM6M7X^>IOH9[=3/H.G^_,QW\."Y0^^>AGL:]NS!NV\?OSV:]?"U
MDTD3IOY[^>SQU\</O_8$))#  =,(D(PQ$L2OC ;)*".-""=$L(P)R8#0P0PA
M?-!""1VT<,$Q/K2P1!-/1#'%$[5 40LMQDBQ"Q7+8+$,&4OL(D<+=92Q1QY[
MM'&++K3XT<8;?<PQ2267]&+)')O_S/$+-92<,LHJNX#2"S6^P%++)[O@LDDM
ML\02S";5\.*+A]9D,TTQ'U)SS3@?0K/-.>%DLR$WU]03SX<ZB!/-+TCPPH-!
MO2#A"YH439301A$UM%! &R5AIYIV&K0#$C;=U%)*.04U5%%');544T<5@E,C
M0%V5A%9!E6M3$%8M(E97-PUB4R/DRI6$7D58-==<@1765V.)!2L(94405MEF
MG35V62.<I?;9:J_U]=I=K^66V]:ZO9:T:X%P]EMPJ27W7'.3<&$X9]M-PMWA
M7(B7767MI5?9%Y)XP=W<GM@WMWCI)1BX8@Y&.&&%%V:X88<?AOC@82*FN.*$
M)[8X8XTW_^:X8X\;;J;BD"$>F>&03UZXY)&;4;D88XQ!>&67%6:YF)(/EAEF
MFW<>&69C>HY99YAK'GKFF7U&N9F?72:Z9J5Y_OGII5E&VN6AHU[Z99N5#GGJ
MEZFV^>J?7_9Y[*RY-COLL:E6VNQGN$8;FF701OOGN<ENF^MCFCEF[:^-0:;N
MO\U6&AECE/'EF+X--QL9QATWO)G(#:?\&,<!!QP9RXVQ7'-D;LE&<<L7=_R8
M94:'_&7(.[^\=,A;9]WUU9GIO'-C>@'\&-PU5[ST7E[O171D@O^==\-UM_ST
MU6/G/7CC7X?>>.1=KWWYYX^Y1O/L?7>\EMJSQ[Z6:SH?WW-DMO8/W_'QKQG_
M&&J.J<5S]*_Q_GWOSS]?<6KBQUYQ^MV/W_^R=XU]]*,?!3Q@ A5HP 4BL( (
M9* !'QC!"$*0@A;$( 45:,$$<E""&@1A""\H0A*6T(0G1&$*5;A"%IZ0'Q1\
M80ME*,,8SM"&*O3@#76X0Q[VT(<_!&(0A?C#&JJPB$?L1Q$9J$03,C&&3$QB
M":$8P2D.T8I7Q&(6M;A%+G;1BU\$8QC%.$8REM&,9T1C&M6X1C:VT8UOA&,<
MY3A'.M;1CG?$8Q[UN$<^]M&/?P1D( 4Y2$(6TI"'1&0B%;E(1C;2D8^$9"0E
M.4E*5M*2E\1D)C6Y24[_=M*3GP1E*$4Y2E*6TI2G1&4J5;E*5K;2E:^$92QE
M.4M:UO*3.;1E+CNIC5RHHI>J *8J?M&,=(2P&,#4A3Q8V Q?YD*96#SF*G2!
MRQ7:0Q? _$4]-&A-8#8#DQ8<1R[$6<P2:@.8N2#G#>6Q"G&>4Q72M!D]9IB.
M=FJCA_$09SY_P4%NOE.8^O#A/GXASF)0<X8&U: \?N&(001B$(O0Q3FJJ$9Z
MBG,<NL3H%1?Q (YRU 0??< )U+"(=$IP$"9X0 K"P<*-/@ %V !B,TC*P'W\
MX:,I*.D\4X!2$^1"@^-( 4<7,=%%IL,1WF1@+CJJ"Q,J%:5,U2$V4/  E':4
M_Z,H$&DN$!K"9E35$3W4Q@FL*H:+1K"K5E7#,WEH#S5P5 WQ\&$Z%F'/$\9#
M%6H0:U4YFH)%E!6.O^CH5S,Z6" ZPJIZ12M2&1B(JZYTA2T]@6)W*-<4B"&=
M-=WK.78X#C&@] 0XI6 Z@FJ"05#2FFMX %0-J J.GD"U(F0M1U\[PV:@ *14
MM6IK';%5#1:CJHOH86T/^PL*&A:W#WBK#^V!6N3"=8?VR(48(GM"=3 6MV+-
MK1HDVT; <E2PA 7O#EOZ #&L80UJ4$-0.ZH&O^YC$2E( 7M9VEJZ[G ?UE7#
M90.!@OCF5(:BQ:T)%F'!<XRVM)/4!7:)F]2E-A6^8O]8\ VU,567JN&\:I"N
M1T\0X10V([TI^*X.QT%ACP)WB:CE*7+]:T-],#>M/#3N=$N8CT$$. 5K",0?
MVMI1,=2WC<40 WQ5$5XBW]"X/;V'/>*1CG$X0@P='00$XW&.<Z2#J"!L*0I\
M?$-^N+BDZ:BRE2>[4]RF0++IH/ @KGS(V*8V@DKE*(=#: \JG\,>.PPK1]>0
M#GO( \RJ(/,#U+Q"?:3#'.=P[@Z;H=Z.K@&@!@1P@),;PC53\!X[5H,VQ4M5
M&9,0SB$=Q#CV44!Z/IFC?[BS&_=A:#L7V=4M'.]L^Y'@O=97R?*0)P7MD0Z6
M-4,;_H6L-^6!C6)H0ZT:W,?_.%@VCE0SL-#,[7$\[F% ?<A#'O, (3^4[6MU
MG+# QWW &M0:Z:%JD->^3G0$YV'M=/?CUO& H#SB(0^ RJ,9S\!V:%F&C73D
MD-T//,>]Q0Q">VR[&>-(]S[D8=S42MN GV9JLEGF7WW,6QY,7'6O^UW"9 ?U
M!(ZFH"JJNH9<2_#<Q7C&QBMH\4<?,![SR'?!6=9M$T[8K6)%@5\!:P+X4O7%
M%0PXRXS-P6I?NQ_ZT 8Q1XWIDM=#WO$HN<E#IHUV\T,>+37!+^0Q[1"J8\</
M6$3+&?@+"F^X'_=01SKDX<$^QT,=%I3YP3UH]7474-D(E[<\FNUL>LS[SON
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M&C43(C=$749!5:\# ]4'^#UU2+MT(,8U>*!;W=G,/;H=.X&5K:G1C: "%5J
M/34+^L;!C:""6RBU_"ZG<C.J+<H($DU%A+C_!%T&N@>$ E7$\JB0"H3<=&!>
M4X7]NL%4&U6J4LX&8Z!EP%+H),5'H,] \#KOLEX<I*EQ*(94^,Q3LU*>PKP*
MLD:.RE #>L= 2 =Z&%1.U3,$.D81:C':%2%\N%89>UZJBD8;32FDBK%<B(?%
M\P7LBO_&;^3-"(HTO[Q:?QT[S^T'AI-BQ+,W4A2LMFS4Z;0M=FTQB>W=$-5:
M#4K)-=C*JZJO?7B&1D##VW)CPKVJ[2I8AHNO],(PD I.G+U![+VI8C)2:26A
M[\U87=2%\571JE+#^,.]#O12TVNM9) @3"NI875%!CI8J@K.MJ4@EY1A"?J%
M11@^"8[:YGTS$-;AV%W4.&8ME,IA%(I.A8R_O5R$OW55@H1"Q*+.!\7:,*Y-
M#H-:Y//<Z?P%CR.NG%U(>71E_:O-&/35ZZ0@?=@QQ*+9^\4NTHNO)418/Z:J
MR]7<JA)8?O4LK]PQF%Q)E,KBDVI%1$ROCC*Q;Y1=!N)*C.W_28PU(%SP*G1.
M*?0J9R@K(+4%._I4A8R,+)OKJ3?V75J.(-'-W0=26!1P+'U8!'4L/AQ+T#\P
MR5D5Q0:[TMSZJ)4V@4-.2':EJ9=FY'FUX!.RSG+CA_%2/T%[(>1$+ F>RH]%
MKNTSU70VH$MSJV,;5MZ-/C)C7_U5T @Z!U-;@Q>J+I[BN;V$T-.=P5ON:@.Z
MT&2.+<WL!SYE8A:*8%K$!WJ@-UP:Q8X2J>*L0;8%8V6F*@[KX -&20K;O;/B
M3ET\!R]U+H\FL=D+!.PB:0.ZTOV;6@8Z2$MN+9/MJ)4^K)$EW"959[S59Q'*
MZX4T+BUKW>7M!^OB8TX3*Q-KW:BF_Z#HK%M3@[Y^2&W!,DMPJ[^*56RJ6@-M
M>#*AM$I?:D5'IFA.*E@->E;!.M'&>CB0HCUFVV**E3/^Y&JP"]9B^(6#^85A
MDJ",Y+E$:V0#&LXMX[,2(K<8\M#C.K YKN[KIN[J?EC-U45._JCOF]G#Q:R%
M16#$UN&\>NU^$,W!=6+S_051:^:L_6K6+/"(C>IF!.%/:]5XL =^J"*)IF,3
M@D$U4 5L4%>W0J!DZ*A&Z,<F;6RHGE3@-8&O2M,;';5;)2?1Q6U=8#9T(+/$
MUNR0VJXQE610WLQ3NV[VWO%B>+0CRVS+Y%QDXTK2JB&)9BB?2Z>>+/%BT 7J
MMF[L[@<.;__@_V6N/U@%^/7#JF*^\0IF*%_O8@MA66W3< N^4R-&OPSN4;)*
M$Y U&$Q:WJM5X1Q>!NI%_Y74_VW,^87MK3ZZ=*#O>56K^G;%\<IA#T/+RX7D
MAP/(<BNPCS)<!5*[&C+2]MIS^=:S=,OII2VNVCQC-RVIYY7;>)A9CJSK-N,P
M.$/5!=WLAP/AE%1S1-6Q0'!1$+K AXQ'+&NMQFYCA135NHXQ$BSHL*6PKP+*
MW*K+6\VUS:VO+19B+3]JYD(!Y]7G&"+,2#<Y%UQL$\ALU14T%YRU!!7ML[M5
M*#WIIZJA73O<+AYQ B>]<:6IO!8L%C?:"/*S![;W:QTMX'*^VJ[_]S5G\X[*
MA3G=M7"ZUH:6(.M*T61TS$D$*3SG,<6RS FW6X5$AT6],0IDH)P]TIB^R\\-
M-W+2APUM9W,?1N6[V<8T:7G<O#_(4.LR.Q654DP/-Q?<1S6H+P^SX\X%J5!<
MU=&USBS&VV$W<!/HP[%^+08%NQCRSWX@];V*,,OT7SFFL*<NH8W.>0Z\,W[H
MX!+OQUT7YRK73;D-XQ1;7A=3IGOPLM#%;W1V4G>SR'ZHAWD54V)<^8Y4@S]0
M+88[!A-J,Q,(!&WXNW1(!4:;\(O.YN*3K&>H^E3C!T>XL5!344X'(<*LJAH>
M.PBU3HB42QRKKYS6JT95>ZL2:( /)4&._[_TTBOY\F>42E'Z3,IHA4-CC5RT
M<H2%8C3PQ.U?X"7UBO/1AC)'\-.@[+P<72]'R."\^E*6A=(BBEB-#%T>RP5M
M.%F>VGO<4H,RS86O@TS)U#/7(]KU:H1<6 13X\?.K<VDO*:<-=\[F^?E8S)'
M &D/7\21<P1'&$"++E]%3 5:!@A'#P:B6*1J48J!)W[U:^C0H384 ]?H>VC1
MX:(')AX$&I?NEYJ!)M3,:]CLQ,!%#@5J;/8PV< 'CBX^U'9BX\Q^S4QL-"$F
M7;]]?P:JB==/W]"4'G.EV/C@S[Z&&1^<</G0WAJB^1K^0OG47D-=3M7D:O8K
MZT!=#E7%7.-(%?]8FD<'Q7R 8DV@/V)$/E S[J*\D#&A/MP72&2@8MH<2>P+
MM%^QF#EI9G2:XN_#R -S[J.[\<\O;:H2]CV7V>D#,9@=H?Y342[LV+)GTZYM
M^S;NW+IW\^[MV_;4NGR)6G5(UVZXAKE0BVEJPNN:N%-3"!;^)VZ_=&M0USVA
MZJ' UON$#OP),21/C3%1,(2=CK1*BRPW#G*XK[)"IR8&O>ZG+6%/*-VUT0G%
M-'2/8!1=I%U/,3D5B#P.G52>?AJ9D$)Q4_&40E,HI!<(/PT]TQA!IN424WL-
M1;11?/VPI9%:#<D3"'=U+1*57!%-A!ULS9"(PEXF-):":9!YU>)\!DK_Z-5D
M--FT42H-I;/70(0)M5%1RGEU80HW>:6&=!J=H(U%]Z"593_W'&97>_=UY]4#
MB_2G64QJ1 B;.H-L.1R6Q<GG8(P/C5/="7"BX(N$DO4(YR X.O2+HE)F%6!,
M)P3:4#S5N<85G-_]]BFHH8HZ*JFEFCI;<,()J88CC]FW)@ID'K7(GF*HPE)5
M4DVD32!PGC"(JU+VRIT8N3CJ7W4F4$3> RD$JPU:#JJAR[$7C0/?1?%$6Y]#
M]CA"FGHI+,)C/[J VZPJD&J43$/V)(@/3>DLTIAEBQ@%T4UQCB9MBMGUJMY(
MNM!X89&==4?FB6D)>N1:(ETJ[[G-CAL;-M"1_TO3/DPYB((CRVGD:3).33:?
MGQ/*%-M).#7$[,G]\#/42'?J,Z^#*=RJD%53Q6J1/H+9*2%I:]PKS[?"B<OC
M/$D-=)EL]N2RG:KB!FN1CHXY^0><1/6[3$R>TJ1/M$H^](O(-6'M8%^7KGQ<
MR]E1B0)FI\H]-]UUVWVW;-KDDHLN>^OR=S'8W'E1,WSK,O@^S2P2R""J_)5.
MW[I@]LS>ONQSSR^++U+,Q4$UX\@B@RR2R]0-C9/*((,XTDR(A>?R"[GV%!-Z
M((OH4OI%]ORMRS,TC9/+*F59Q,\X!]6NBI^".I*Z(\E!SO>]^_S"]R\A8EQ\
MZ(W'O61*_BW?>.F8I^X^.E#A!'^[0_+H,KXN]?0S3N3!QM.W\ V%8_C4B:N2
M>N/:5 L8_5A7F\4$(A".()/N@F<5R.EB%;)ZG]_N)27Z;0^ >XN;ZTCWJ+[]
MXA[V41SSG$=!%1EN< WAQ_1>UQ^=^,U5^]#;((Y7P8:H8W^BT\4*81./S_'/
M=K@KS"_ZEKRK%.-[ME.'11B8BQG69&^P6Q#?<O' =O'PAC^\W]Z"E<)?_ ]O
M7OPB&,,HQC':K8MD/.-L;+(9-.K&C&Q\(QSC*,<YTK&.=KPC'O.HQ]V8K$5[
M_",@ RG(01*RD(8\)"(3J<8X);*1CGPD)",ID<E)4K*2>)N0"?QHR4URLI.>
M_"0H0RG*48UC#:;TVBA3J<I5LK*5KGSE&_>A#WNX$9:VO"4N<ZG+7?*RE[[\
M)3"#*<QA$K.8QCPF,I.IS&4RLYG.?"8THRG-:5*SFM:\)C:SJ<UM<K.;WOPF
M.,,ISG&2LYSF/"<ZTZG.=;*SG>Y\)SSC*<]YTK.>]KPG/O.ISWU0\K.?_OPG
M0 ,JT($2M* &/2A"$ZK0A3*TH0Y]*$0C*M&)4K2B%KTH1C.JT8URM*,>_2A(
M0RK2D9*TI"8]*4I3JM*5LK2E+GTI3&,JTYG2M*8_-KTI3G.JTYWRM*<^_2E0
M@RK4H1*UJ$8]*E*3JM2E,K6I3GTJ5*,JU:E2M:I6O2I6LZK5K7*UJU[]*EC#
M*M:Q_Y*UK&8]*UK3JM:ULK6M;GTK7.,JU[G2M:YVO2M>\ZI7<N+#'? H"6SZ
MB@_KP28?X&A'#AW25W? :S;\8*P[Y@&/R>(CL0W)1U\!:Q%\_)6P^)B'7^$1
M67P,-C?NZ,8UJ/$-=]"$'Z"=!V%M ]K2_L:OC95+9CE[6\7.H[?SL*QN\C';
MO:9U':&0P@I6 (-(7.,B[0@%#%;  BG4(K8/X0<5DAN-BX!C$D]@P0J>,(EO
MR(8:+#@O>ED  RE$@AHY%(5T8=#<A^"#"N"%14/P@=SS2E>]3Y""*,!!&W[4
M(KLJ<( #5,""2'3#(MV @7K)>YMNH%? OC$O"YZP#MB$0O^ZTJ7"L=;Q! ^S
MH!:@>@5XI;!;WGQ#PL1-ZC5@H( 9TU@%KW@(.*2P  4T8,8J<(5<:M'C!9CX
M(0^F,8WE&YM:,$ !"]@QDA6@@E!HMA^AH+&*Z?N$&0.Y'_B0,8^C[&0EQV8>
MH7" F'>\ OPZY!IH5D&#;W.-)CL@SKUAL@)68&&:4 ')*]BP0VKAY"<O@,V_
MN;("8+#BW,##%2SH\HN/.@\IS-@!,'B""IR\@CAC-P$*<,!W>ZR"^3ZD%BIX
M,@.*G%]*2UD*R)UQEH/,@"<K6 6V?K("&# )PB)ZUC=6[)85T.4O5YJ_F<;U
M$ZJ\V3[ON '3A8$*9BUE5;MY 7#_QDVUZ_P;)B] S[!A-:%5W8])#/K)O_Z-
M*,8,W-K45P$)@'2DBUJ+!3#  :+ 1SYJL8(G3Z(AW3@U URA#W" .1(/>>ZI
M42WN?^<:%A6!!9H=0.J+,)D!J88'.,!Q#5?L>P$.4/65<<V"/>,CV,,&LQ1$
MNXYOP((%LTXU;$31Y 4\H1;P(&TWJ #E6,]9RG:N3;9_OAMN>ULN5/#TK!<0
M"L52FM *,+1O$*WHWL"#!3,61;R/*G,&L  >#NFS J00(E$\&0:L[8<K9MSU
MAI@7U=(6-S6:S()V-&0>,H:YK.D]\7Y0(]IA?TTH"-WD2%BOY%S.+YBI8!%3
M[WCI-/G&;0IFK.'-4IKK$G:SSR^RCFO4HA;@R.&<K4W>;W0>'-9MR#JH40M8
M1.,;*R3ZGB\"=A9D^@F-_4:FDYOK<S?DM*NO13>JS(^,;Q@>M8C&AM.]@*GW
MP[ 9C_WP.W^-LS<$'M=@P9-#L0Y X^/YI\__^DU)[XKJ?AW6(0([%:S7=RG/
M]Q5JA^^3Q8W[/%NX'5:_=MX;L/=^1&+'*K!PR,V<"FR7ESW!DYU<DRD>CD6>
M BC@1;B? ^"=15R#*$3#YS5$S^%?0W37"CB QZV %$S<G#& "M1")*Q O:U
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MID.$@J?=<'X]@:<EP*_972?O!C^TW,0B6;<Q6)M9I+95GZ,J,M;N6<^QP"1
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M>(\W>9>W>9\W>J>W>HOW#:PW<R-W)90"+UA#YQ14/GA#*>#!#6C !5" ?U>
M?P>X@ \X@1=X@6M @ -X!4B @?^W@ .X@R-X@E. !C"X@COXA >XA$?X@U,
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M*\/[,M>(/1VQ)AO[P&QM&+,&(<'FK!B[6G%98PRA,%7)'&$JC[6)G:2P7'T
M,K>E&%K=^ K=,OCC#S>RPU>>*FN=^V;!DMEA9RYG1D%'82P7;T6"MJ6B>72B
MZ3J,RXNN,AST^^"X6OG,*#IPI[6&V,:>F9F<IN98+]CIPW8:E#O6,[TP50%-
MT)EDU2 ,GF<<9!^K__K/@-YS)DG):H84*<W[ZG0_0=UC8:?:@!#;5YK-NFM
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M"P 20-8:B$(GRO'<__A,@RT;E')2>%L@ U"@ AHHQ7-CL6;,$I(4DZL&JS3
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M!9? "\E&#9U ":PB7UT!&@R5%&/V>S=0!%5Q!$4 ="BQ!S,@%(<B('1E;-1
M#=C0#!;!=_Q #;VPB5UR,NC3#^"T 4) A(N5&SPA+ (T1CRA9R^Q<?<T,<1U
M*.#!?H!V9';S+!=B"D,0 U!R T-@+GEX:1L0 SQ@"7]H#=5 "WL =L2X!)>H
M0\;6"[V #!71#(-'<],@BA91"&R#B \R6$(P3"C1"ZUX6_)5 X=08_V @=7'
M/AMX=0WS9("GBP)Q"GY _P,68 &N0P2-^(A"^'8TL >:0 W>8 V\H DL9P (
MX$G_110VJ ,%D /$AQ+U$ 64>$QS\3%'\&8=IC9-T#2\AQ*\90 NUAT( 0CO
M<PD60 2A431) 4Z%$H1$H(= Z -$@(*5\%S[@ ?&9(8*\30*M(9)V4M8 TQ^
M5A!O((S%B(=M-X/)*'N2)VLQ0 -KPT'1)(MVI0$'PQ C^2!J0P>'\@M3$P]R
M("L78HHW)@11J"'% 3EM002)$'X$ !/V85+/PV <:#<<ARB[Z!T#,00T@ ,S
M.1!EF(=["#46(%]A-VN>U 1P0&=^,@]\X"/E:#SGF'!)19>W4@ Q0 2?)1U$
M]O]JT1,F]BA%N&@>!D%U^J@B<[ $-U!_I247F>&(>"=[D!F9/R$_..!=);40
M-FA'%Z $I%1$=.)3)N*-)A%G_M0TMJ 5O%4A'#4'I+05*\DVV=</P,,!3]@&
M,O8M2("'1X!T6J$)05&&IR<$U*:4\<E+"=:4O_@0Y6(N<_$&1N"3L:<!,2!G
M-C J_V$*/),#!* !1!!(VDD+W&F)4Z-41_B9)H&*,9%TSL4335< ,K $IDDP
MU/$MKADIY]$^@JD0)H<=TB(3F\4Y K$$2B 4SX:$"5&0-; !L8<8&U #QA@:
ME]DG\\ $ Q0C1E<=<)!T6"1]$S<$B!!^P96!]V@Y[,/_>;,I$XNQ&=D!&DN
M*6]PEG<GA"C8A5Q8?USY1-U6G+03!=3A Q+"$R3X%K/"$(LQ!\KD#CD0%)(U
M%P7Z;D Q!)@#5(E( )0H)EIQ"0:P 3ZW&$L8"RN)ITUS5?()J0O$E*?W$.GE
M'=8E!$6@!%O*.]98<-(EE@I!"'S7H+3TH%+3#C) )SD2CP[E<V&V%^FD11WZ
M+WIF,+4H:'X9>'*JJ[Q8I?;I$.EE=QMAGD6@DSZ0J?F5'K#Z2B0T*ISY18-5
M!$A0DWU1#B!&2TRJ/$X*+?GHE,=5F%":) :Q@,19$\;*DTO0!&^P@'- !XQ
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MT6W@WH&9?$SD+#0QW/3$W.Q!,?U-MB%\R<]TU"Y:Y4HP!%D>?,%GY7Y@4#P
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M><QZS84.ID+L&Y:PA!O<( 8;V$!>I<G7;^8R64/@+&>7@$>9&H$(-R!"9XO
M0=@1U0>K]0$1C/"<Z "B"4L80FE9^SO>).NVK7TM7O)2T\0"C3K$S.)"54B8
M@@R7AEK2C66.>9DW%&&WN+U+6%GK \X>P4H'2181KHM9^UBRM?<:PA(D)52G
M\D4W,5$N^=:T&.!R_TA+G_IJ@W T$TZ5:%000X(3: N??-!,0WP=8XG>,-OT
MS6 #,^# @J>9N1@ZEK,WZ.P2/M07Z]:@P0N>P0UJ4-XWF*BF824"$?;J@QJL
MEL)#6&UG.UMB(<18<4TKT6*DDY(\CFM[A>5QCW-R4?$A5LA##NMI9:RXRCC5
M+HIKPG5TRA>O1)E#:/1*3>+)F\,T <GU!2IR!K8H)W+YF,])X9-SV0;CTE P
M6JH;0[/4WN4Z]SK745PMQR/E)X(HRC/.;$+J/##$.$%49H;.'/;;YN/^3:9:
M>J% S'C"PC 7,E[<U$#> &":V<!A=HY3:&[V6%#76;Z&D8.!&RIG*"L.U/\.
M"_&;I ,[[LXYQ*"1PQQN9FM;@\8@E"X?04P"B") 2+ ^)G:QV47.#PR9H4-#
MK)>(0V@0&41O'7+NM.4%U \=!CF5$1K@:!)F0B,-,5L2:EW$O*HL*;O+"(EO
M'H4*YV*J^R7F;K<*WXT<$W[QRI12X5T4;5/WJ(FQ\IVIB$;4H)9XPU%ML8WY
M$&YP7X\:XH:1>*UELMA)R7#B!S])KUMBDH7LV-@C+S9(+, !:P\9XBD/D<'=
M/!",)Q=>*>DURS\T&)H?SC!!3=I\">.FG@[FO>LEDPL/_=P;9_$L9SEWQSE5
MJ3*AN\8T7XK-E4+U&E.<H8L1U<_1BV[\W@V,HH+_M[Q\&_#?+'WF3@2W3L>]
M<8[KKR6GF(4L-"$#"S3<X2:12:GBGAFX:_TD<(^)Q#>^ZX?#O20/ZB7)'4_L
M7L1 D>KNN$!BSE/#ZR6G7[_+80YO[8825"48AP,)Q)A+OV.&0ZFG:8< \9N5
MVS2>59?3C8,^<;<7YO($+3NEA+/[-\4P,7T/#<M]*RFZV+CI"4&^P9?OF(ES
MNV?(08RA83OM@AN<:6&ZTA)LX$H9B%1O.#4XQIM67-UTB6D>;Z%Z X_?RK^_
M)#H>]N/M#\S#4IXDI0+^WLU$^,.(+\]+/Q%!J,2;N-.['IH2D0Y90 9TJH-*
M/J'S(D[1/M#+O@6A--:33:CXB[[54ZC8RR.E8STVRR/VX[HIV[@4VK[Y(@2A
M6RSVJK<-="C_2YH%:8(AL $*&Y2_RPWY0[@9%+S_<\ ''#S"BZDA#,*X8[SZ
MNS\G_^2>_-,_F/A!]X.[:3M!#AR3P*,^([3"O\+"'F0W)32T!O1"C5/!;D.S
MP ,] M2^,_1 OAA#,OPUP2D,OW.J]VLW\J/!XX S#.R2,F.)!7$LA\E"$H$[
MTNLX,!1"P*/"(71$+5Q#WMBE<GE"2^R>7KB "J@!JYLH2:Q"Q8O#]QN_/-P2
MZ)##&E002"05)31 >9D+QG@,-G2DHB&H>E-#PGM#.(2.163$G2*^W>@9+BH5
MO;%#"<PI!6Q#/ARX7US&P>E",TS&4/0W]$- 4ES%0_Q$::S%@D <P!*V2PS'
M=&F7D9!"5=1&OGN_;D,N*UR_45R34U2:77S$T5N0/'J_F?^((17,N%SJQ6M$
MQT9<$. [P,,31<W+P 89PV+,PU\;B.8K0/L@C(<TN%OT1X*$.#J(PSV$N(OD
M2%"<1GK<.+8+"OH31Y.\$'(TQW,,O(ZDR)9<D'\\/'PC%>D(PI>$26'D1I<0
MFFJ,OO%#Q7N$KWD,R,_K1V><#J8A&0 D''PDQ58TB8F$N&IB1Y'\R*',1I;,
M26Q4C*V<PI;H/_CK1XMD-\8SEY,\2PFA!JX*,BELRIO4(J,,/,KHP,.[Q=1[
MC+>T/$-<28AC+Q%TRP.<08,$R"\"S)+HR:MD-[F<PY!,S.@XP;S@LD:C2H1,
M$P1LO5PRS,;TR,+!1Z'IQ3#<FX+_C,NL3(B0:T*T3,V+  F14$G)&,6\A"&S
M&\MM9#V[E+3$Y,O<Q,7H<\6C 4:F8+0X5,CI*\ K(1I\[(ODU$KC[,:>F0QG
M#)?J>T?+/,J^*[1CY)F&A,W.#+R,-)/IU,GD\ID(M,XW!,N<^;4ZV<!H"RS5
M?,^,B$(I!#Z,PYO85#V^(TZZ[$V?$3@BA,MMG#@17,3>NZGR9 ["643?W#_%
MN\4\3$71',U3/$((14PW=+JE; X++4*YJ(O23,<U=,?R2T^G"T(ZB,FJA$:0
M),J^#,N#T#&SA$\999<*T!#7Y$T)!5%:#,$ M<#]7+F9!"K0),@-'$R*1$8P
MP4T$C,-&_U/&-Y&4>E-2[;.4_2S2'^71),S1N]!,%G52FKH4*07$HT&NN^1'
M021,'T13Q0!#I_S0,XW&P&$_QAC)@W#/&;U3B)!/_8.YWKS/O72B13S1O(RT
M>L-'!]U1 7TX)=3(%MT\/XV)!%U#*NU1T7,)$773ZL34J]//S(@M;#Q2T4O
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MSS>S)$(46O-,X2Q-@B>^6%'=OD2>>?!BG[WVV]LGKP9RU1L^'(TZF2\J]>A
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M!"7@P :Z000BVG"*6&@ 5#LP$"/B88T=:*"KD?F&XQIR/AX4X1O>H %L_Y!
MQGU<HJMOL4. #](,=LC@4(1 ABET8@0A\($?7(T)'%1+">"R]Z/UXAG1BCF>
M"BRSMYK>-/=^&UR*!EF%+CE%/7;@L(1-Y'R\D,'W)%6(2E""$GN(Q3XZ<0<;
MT"$=!'E8-7K!BP))9;TV004_^K =)"!B'YJ4$2+RT8LE&.4@?B*I2S:WRF,.
M[F:@1C)H5RC@2:>04\C6QZ-%@IE")&U".@&$+^A!B?T<P9C(,&X1$A4+TOF@
M.?!%2+)CX0.=7-)Q!KUD.9BPFX,@K1,;R%<9*4' C8IQ9T&^E"Z-1*2,TC8S
M8Q6)IG*)X",-!M<422,HYW"1(I#B-"HF*B/J<?\["A@4);X@&U9)(X,BC,,:
M,1"H478Q,2#/@13]6+1X"!&/AHDDU]Y8 D+<H%I-V$!G?NJ78R EX(W3Y' =
M)4^Z..WUK[M+7A?PTJ<MFK*?Y"L1]MC#CAV2DC*W8P][. 0C;M2=4WRP#410
M#0?X8"<-%$$/YV!@$_,QCSW0( X.Q.I!"N&.<EC.$*1(1SW&^09$S (1$S&&
M[1AAB,O%PW$^  0J& $=TCT7V_V!K9$R?B EXU%Y]6(]37)]&C=H)H4"BBE"
M1H$*4,KS8GA 1-W;1.*6VZ,3K\F+#DB D(T\(Q^G.$3!FL&/L+U!#Z@8Q4GD
M":A"&((1WF#J!N! BE/_N*4N#P]RM!=,.*R'KI@^<0+\@>D=RTBZ/\VPA@WH
M63YB8\(I\ )X\8(%O$$ZS$,?V($?,(+E3,0IG$(+M1PO9 8I) T%O $VQ%W!
M) *HP$B&300DO4,I2,TH8,/$% @=E-Y!R%,U,$*IK \[0$&/H,(I3$2;@,IT
M&!B3;9M/M!]+)%.F@=T0$N%[R$L%U,#'E5UXE! @I$,LD%WL4<1;Y(,[U,,5
MSL,I& &'8,,-L 0OU4:N\ (-S %)+(2HE ,U&,<7EH/AV0,_E$,?'(!$R!,F
M2(0>[,(\Y(,]Z,,]5 ,/4( 1%,(][((/&,@</&$,H)9*]*!H",W9I8P2-H63
M_TW&6M4$,E0#(LT49(R(52 $-KA#'+2!-KC,/%QA/;0#'\!!+YS7$<S!-U3>
MPOV.9QE%(5!#/M0#'\Y#)QQ CR#"/?0"GY1".\2//>Q#.>R! 0B!R7D#$33$
M_CU.^0A)N#4B1IG=M\#?)LI>?Z#"_"RB"NF4X6'7-.3 !O"-X9WB/<A"'!!"
M.2C*29!".PB6R^750^S#.^@A'U8#%%A S!V"#M5#/MP#>1T 4R""/<B"$ "?
M.^R#0.9#.=P!X%V2-:0>-B!=)1()J&'CZ[D$U^56$8)D2/;"!2!AV:V>@CF$
M+U3#$#0&=OB!'=C!'L"D'6@9'!S"#BR<N?$!#038(?_0I%?Y010H(E3@)%:P
MUQ+T025<PA[D0)KE5"'X 5O4#Q[TP250 C=I0%O,P2'LQ48PPCS8P0Q08DUD
M7#8^7\;55K9IFW\XQ7")FDN0 H@PWD=Q)7]L$^ 5@DS: 1[$I!T81R'T@2+.
M 1_@00PD%2%PTSJ]1!LL 1Y4@B7T 11HP V<!!WX 0_8BA;MP258PA[$  50
M!U3@ 8HXH=)\(UA91EFNT7=8'9+U!UHVV39:1B<&F",>1!_T0C6X1E8"@A_@
MP6_"Y!Y@YE;2Y$G$01Y<PB6,TVNTP3;QY6_JSP4LXU/(P69>0A_H@ 5H(B#P
MP5X@!%)R9DN)#:XP@E^>!$G_4,(%7..F6)QA=%N^G L%^$%(TB=('F$4FJ2X
MW*#J994[&!O'Q42U#,$0$($/^  18)40,!Y"(%1HO,&$44014-E**"A-% K?
M&=014%G"[!T'2!56(%3-$43,D8M:?IN0M"9_XA].-(HDNMU:_@<VQ()_M<&X
MI%$;" &-XJA_$<$'[-T'W, 0;.@2;.@<$*EF'%I0&$&'-DA*$*FC))1J&**-
M52BJ=)8-](Q9/I_R:&FDP6C7I*A,1,^)6L81[,)*3M2K)((F@&9#& &8&"@1
M#.A)O$&14LN%&B)"",$'&*B! LN]P$$3#$$-J(9B'MJ"7JA4'<<;$$%H^ \-
M0-HD_[IG>UY<Z%C/1]9GIF[:2)9D?F*D;+;$+E #TVECFII=DFB&&ZPHJ-9$
M8$W2-[[EJ3):ZU4JI9JJK(Y<Q=7$*)1#'NA$"KGHDK%JU]3H6+;$PY@F4<">
M3<C?MSC!HV0<QH4:1?Q@3>1??^A!.5P"B>JJ0^Q=C7;*L)K0EX('440%@2CF
M3MR?Q(FK300AIFIJO.I6-6A IWJJ?I*KN>T"'LPE2N)KNSZ/L8K$*92"=%JB
MB4KCD@@KMWG;?C)B-98H3311)6Q'D)RDP!ZKO[:$P=C #?C?<'7I90@3K7)I
MIM"6EFIL39""+"S*K$+LP[(E)#K*R\8!*: "5\3L8M1+'/\%F0O]"KK,I[P*
MK6[U0@5H0*1ZZK@@"5 <00W0">U=+,"&*YD"Q0TDU<&.J8J6R] PF!HUK,OF
MK-1RA-.^*-7NH-AJ%-HB!!%<"P\^WUF=#L6Q9]2>#OL1:YB>G:1P"@E1DQ*H
M6;<B+$IT5+5*ZK<$Z\+&1!$@;6+44:6L)AL!T[@<R*4)X=!:KO9XVKW^J]8&
M1:ER[N;:9M:"+=-*8>BNJMD&A5"@55E];<0&+G&1+N*:;KFJK>>F#,^T;LH(
MS4W0UI$IZPL9!=XV&$N,U;B4796IQ.%*JN!.2@D=2),HKT- KY)03PD9Q8'<
M"L\0;F(0[O42&6B%"QQ<ZN62+^;_QL %+&Y^<AONYFZLGN[HBB[:O6QF!"N+
M BYBS$0Q2>ZRRJZ83MK(OBQ,A$_*\@3&9NRM3@H=L=^RRA_#XF^M1AM,O)ZD
M*"'VNJ_XP&QP06]@-$5J9K#X4 :8+@EE@.][4E,0!FWYJG"[9*[F6NM33"XU
M)>S+4E//:+##SNP ?^Y9 :H)"\_>YBL* 6H-H^[[RB];MJ7KAJT2;T8,+>;N
MUFVE"%F^H*;PGLZ/4$J1U;#DWC#\LN6W:# 7$S'@P%$VXDHD"L6GC>\*L_%]
MM/"]/B]/O$1/3#$5.T36]40<XZ_SYG$,BPNX,JOP3"[[&HX?<]SS&K*X#-'S
MIN43HV;^U3J?("/R=X ODSPO!0MN#F\Q\W9QI92=IB2R\-RQ("=O]"KP!=LQ
M:MJ$!>LO6P6O(!M3DJ7N:VW$NC4NS/8,_Q;K#JOK#"]Q\NKP[.*J)@N-X9JR
MN: +O+;Q,KL'I^+G)S-Q+<.?\7Z:IGQRDY@D*,OQV1(S=QS)DA63_G)<M5;O
MZ1C3Z80+SYSQ@#$RKF2S4X3R['TP"-\*.W]JQ 47DYS.2S1&&MM8UPR%]N9+
M+0-34%QQD1U&Y#8P.F^ISLIS$8^K+],NHQUN$$>T%S^P X?/SU8N,_][M&_5
M:Q(F+2^7BPW+L# /,SY#;/1*=.+8'RIWS1F3<34/E_):,"=C, P'UT81\D/#
M+HIRK1OI\BZGS+*J+@RW'V.H;AV?,DZ_[CS?\TS3+1-/M%0;L5-OAO(,M;LJ
MDS)_]$??IZ=:="^3= &W="$C,#?_=/PB3C#+]*TH61QEL4FF]0YZW$FC-% D
M22,_M4KC+\]&8O@ ]A$O23AC5$*_K6Q1VEEGG0&G;5DG&$23Y5B;M60W-H,Q
M]<[<5D=_]4=3PP6@KUC7M>'T;OORM5JO-6I#]45;]4132CSS!-]^&F57-F2;
M6^W>-JKZ=%Z7RV+@"@-?E.X*219[+7?<;G'_VVIK1W5JOY!CLP1N+Z]R1_1K
MEYT08)I7=_8RB]TSX[5M?Q9T]^]J@RYSDS5CUS95+[=**-E;2_?[<E0P\W;
M6O9YD_=X9^]&5]K;9C62P9X5N_.D(('<PI NRW;[[NQ+8W15$_94+_A57W%U
M)W-V2_@;SS9XAS=LD]5\3VU[Q[:&1[9Y;[C@=JG6+:&%.W=TH[=]=[-JK_AD
M!'049P;_XO:!M-%Z4UI *^%WS(0=Z3)J8?@]#T6%I_AD@/+V9LKTAFQ+O*N$
M9S>%[[2)@WCHD%!%>_AC/T62A_=IL[@/;SDT5WENQW=MO[=IY[1W-P7><N0O
M8W4A$\V/!P8=<_FC_]1H'_]W=[LYD?=Q?K:R*<]Y/=<Y7E?R5N-HA#/Y5SOY
MDR=X>O_YZ@TQ? ^Y?=_YA]=W>7-R9M.WEN>N37\YBC=XESMZIQ-3S^[LA;LH
MKGSOQW7+]0HZ8V!YV0GZ4*?Q.&<S_U"34A^)67T:,LMGH1LZ:*>O*H>X*6O*
M3 SU3<.TK$9ZAZ^YFGNY>#>O)^?GO50SC)\VJE-S=SN[7B?Z61FN8)_SH_\P
M@M/O-$8N(G.D+JNSN8-PL:[$Y";[9YD[(H=QO(-PO+/Z[*U$,:6QO-?Z&O,Z
M,XO=K]\1O[]S#!<)4[^1NE<=64HOGS<\>P$[OCO\G.NQ"\LY)=N&PUMPQ?]'
M_"B3,L>/,<C3,Z:'U?.JLYQ_?/26N\C'-GO?\J)3L04O&?;2/'N]\F4+&,D?
M,FP9<O@RLN#"<P6[I\Y;^;?7,S692U?_NT>/I 9PMVMMA"$T I>5BB&T>@W/
M>2$@ B$8>:9TL$L8 I=)3:E(QD8<AL8[1#ASV>&&7R%,_-<'\J3%.B!/1B%,
MO=CC?2&X,"&\8+= A=@;@B$0 O6&O2'(\=M;?-85/M:I[BK7<L<+3]CKO:>V
M'VA9_O6.<'C<+X%E<AG6G0/JDB$H I=A"H#2%ATD0M^CMEN*!U2, BG<B-'T
MA%L2G^8]>"6V$5$;,5%7RN'^K 2D\-*S<=-#&EK_8<,7%:,]M,,LT$&?2S \
M$WV"T7P>C\@^S,*"DN7S(N\5:U^7N80Q('\NTH,['(/;NWL>CSL2!_U*6%>O
MWA$CF$*+G" V.,C1(W'&WXK&';EMM#ZU T0;@0,)&DJG#R%">PC[H3K2!DY$
MB03AG&*$A&!&@7":\</V!J+$0O+VZ2MI+QZV40/G8-O7ZZ%$F3(UULPXDZ9-
MG1LESLDI$-6]>'H>9D2"L<T;G#]K(IFC[:41@3Z7PME)$! @F8"H2D1BM2:<
M.6/)EC4[YVJ;LV-WE7SY9BRA<2<+%1TH=BU91O'VE0*Y$^\<.G,(H6(4F"P<
M1,WF]7,L;Y>>NWD)8>O7_PLN5<!Y.>O$B)AS8K!I!PJI0*&28]6K6;=V_1IV
M;-FS:=>V?;MU+PT:?*1MZ3A?/GZJ=V7VR7GTYK-<YQ1J7(H#TJMGZ0 J=&Z?
MGR(UC3GF)UPU-CG4RY*.:':P3U_]W.W8KA/.KLM#Y@"R7,V&<;+F Z<W&S$M
MT)!KBI!R],E'']6"VT>3&Y#3P[)1/MC,,FMNT.\0>_KAY\!]',/GE(?F&.<R
M&N 2,#'2-@IMK.2FXRP]H/JI9P<A-$)"*[R8JT\TG;@JY[(:U H-0, DVI$L
MKG(,*RNSD#3K*@&YDL\Q;W: BY'A^MD'C]XF8Y$1#RMQ4#G!"IFKDB7.*@3(
M?O_:*:>QRV+BK,#++FRQ3!93K D0B/0LR\4 A;@ -=P,/1311!5=]#(-+A#R
M*D"^Z:<<.WBPXY+&WL%#J18[\RTTY_KI9(:_D)).H";/@H.4+>_PH<B!D.DG
MGSNBL*,/(+,S#B_$CB((U9 XD\\='HJP*MBITNF'%QG&0L2/*$I=-=";_L33
M)A0_U0B.0O#@H8]\F+TU"AUJ.&_5,/OI@P.**!*L0AG4)*L0#WG1P0X\-*FG
MGWCR^.J0/GB((3-ML6TC6.GRRFK(L0(\CDBM4&%/!QNYU9.K6 7"Z @ZEN4E
MAC:X\F^M:A'65BLG?QWHJVO+Z_/BO*CL9QX[E)I%-7[_[&B7($\3@YB1!"FY
MP>05R1K%L5?C,&MB?C21008\K*$5#R- Z[5.:9P=ZZ^P%@X-/I?W4W$@(RB@
MP ]&U5Z;[;9ETXT"2*_2IA]O-.# !PXF[H>2)4C99911D#$&D6Y1:0:;60ZQ
MJI!94"%DH$)0F:60YE!!!AMD4*F\.0TUH0%A0V9!YAA38&Z#$51.T<.49C0?
M+!'+]J&E%#U<G'6>'#;XX 9,'-.DAK$8&1T9RO$BY)3-&=E%<YA9W>64](;?
M/#Z*EX"#$%..&1P50)Q"14-O2BE$#E)B27,L.I9'1O-"!@($E<<9\>48XUVN
MUN"\J@7$""%\R(-?L;# #8J@^X0WZ&$4S$/&*0CQ+&0,AQ>EH,-7$LB^62 B
M?16RP;R>E:!.6 !O'"B%AV(!JU&4P@_S2H0O, <X/9"%#J0P1O-.<4&!F.*"
MA=@%-@"7&#V0HA>N(\5@(G<Y9/CB,,*:'S9Z,<2R- X9O5@>>WA@L;LT#AO-
M.,8I"B&6QFUN%#.D'$'FUXS- :E9+LM6_DIF+;$ARR;#HID[^J$)'/RF'/S0
M6;O@9XS,<7$LDKL@*K"!BE$(#0=T2!XJ)".R4UB0<XB8%;,DR+1^Z",*O!&"
MX*AA!R)@[Q3'R)SBZJ,'$E&#8(9CW^8*8D1CC.))^@L;CZY5-)L,JE!NT^4N
M_WEIJ%Y<X%$!(I'=+"8??NSA!I8I1SPNV0<(K:8=B6@#(C0DB_>L9QYXR,.D
M5O.-%Q:"F;$(&2.6I1IO-/(7[+$,<9HP,_;$H0G)Z<X[;&"CBOS.0:B(DV/B
M 4M !*T?V!"78\:A!Z?,JAQ,@ O.\L$I8NE@"&=B#3::DR#5:&())*J& >G0
MEM64XQ "0<0^]H$,BU+JA;7T6FA(=K":&$)#GH@!60R!# \Y9A_?X ,<3+$:
M+AWA%S?=TCQ&,99XZ:<0&A+G^YA9C1F,J!\;G0,I]NF8XM3G&*O!AH9*(80Y
MT!$9;:(9)M12")=H]86H8Z8>M[2+(X@%?*M!1DH9(?]6>P#)'3KP4N3*J1ID
MR $.HR!I+X1:#K3  14#98\\F#53E7*+C6<)5BQ99$O.U()2O&#6#D;"#UKD
M8Q]1^( APL$:;^1A#H?DAS<\5 T_".T&5)+%#8Q@D(_ZX0TX4XT[XF <0+3*
M3;-@!"'@4 -'"0$0DU1-.A:G!S2:"!$D6FY(D8"(<FJI%RV-9='RMR/F:"PM
M2##"!220FEZ>%[WI=<PO*R W^$RJ'7C@0^KNT8]WZ""9CG$'+YJEV7EH@A+5
MJ-L2VJ#,&Z@%C08H!<TN<0=:;*@214CJJ&+ )DI1HA+MN$P1CD"E=E""$AIV
M!QY X0W'4",3&TP.[O8P7U3_T)$?=["!8"F5B4[0T1UZ: (B^,6/7E#BP1N&
M T)S$$^<O8,'2R!6DH]LB3T\>!]]>,,NQ%6.3D1A"":N!L%0,9QJ9"(6C?'&
M&ZKK(7YT8@^]< PF.$C+O*ST3T?RS(1IX=@YZ+8:EOAL0)=PB'560Q,VT,,\
M]A&+.V2J'[2@SWUL<(2R( (?%"[*'(!4#M"A<:85VD. V<.$-IS"0]/8 Z+[
M@0D.S*&<U*!$)X;3"_JH^3*6X$6KE7(?'D3AL^7 PQ$2H2%K[$$3XBK%$>RS
M(31KEF95I(A\RD&).Z@Y'SI65SYBT0=88T((HFHV)4S<V/LQR<TLT@JP(NND
M6:Y%_S[>T 2E>)"(?;S#$B3=&<[<X6Q8]Z$(ZN)'-50=!:%5(D&T,, &"FQ?
M$ ,)&W%@A(#[08VGZ4</RMU'/9!!BC8\1+ ,NH,F2%@$0&#Z#9:9AY,%[(TE
M(.$^MXI%/MBAAS:W,5MB<QC91(9+\ZH7YSE7VR^#&25NZE%+^^B$ 99@F1@;
MP 9X:$PG"J !/_ C.T)H53[Z( 1&N$H#>L"$'0P0 S^(ZQ(W$!6ID';,@?LN
MFT60SS[N<( 9Q.*2=[@!TO9AAP$JA2"3!*U0:7& (5C&'5#H.HUC,81$)*@:
M!XC;K-QAP%EY(P?7DT\]H*!D^^I@"="*@@&<+K1V 4G@!/^SS#2<!23((WW!
MI1;"2!/->3PHU4'7,@J.9&[+-A@B0>(,9%,1< $;R&)+VDD;WPA@HH 9X )*
M !(U:!"'^\B@"8_6$*FL$A'XF@B-,I##(2ZA@P&>PKY16,(U*$:!#:3^$AOP
M&*5RH 'E1Y4&?-!0+PZ@@=C2; ^4KML>E!"'/<@@!CJ,9KRO!N3#&I2 SKI.
M"4RL'BHF(PK!#W@ Z7SGF(: QD*O#Q)$$_1F0^Y@X/C 7@CFL=Q(;%#E*YB#
MLL(-+6).9BCE#N3AF."N&O9 CZ*  PS!#W;  &C@M?C&!]PMJ@ P!O8@07JA
M,7CA "[@"!!!: A@ Q+ADO;@"*[_KA\\\$[*0@]BH1R$:A]V 2T(P0_VH.OP
M@(YFRY0N0P8F3!,X#P2C[ A(Y-?PP/]T( 9>;E5L(F5<)F-H3KS.YN9T#A #
MT3:J00/:RS>D2X_JX1V\P1)DP ;D0)EDX :6@,9X(19F@<I&A0/H $ADH0::
M(:H08 C:0 _\(!:P(4XN80;&;@9T*Q9*X7*V9 \^P)CP:PYZBNUN +CLX ;&
M8\5PBA_PX1VL[ !B0 ^8B1<L@#X^+JIN !'$11,HP$; K^Z* *%L(/J.+ K4
MSKZ,92SXX!3CA!).[6.P<0XFI1IX</HL0$V.,=$XH%[X1@-J:^EH8#ST)%#Z
MI/9.YT8F_TR<X(+&+($=WR 1AJ,3;D!=]H#@VF )]$ 3D"'58@ 2HZK(TF<.
M#L&#0F8J2*0<<N (3 QDX"(/*H$7\J@?\$'\- H!A. (U%#]/H;HZ.#YD*8*
M!Y(F*\$'J&0?XL$;3B$.A"#D3K(38F$73&P>H@ 4AH,2-. -Y&#)]FH@]. 2
M=N$;^*4*:T!=*"$&FD!4-I!89( #.N9C[ P?X<Q)%L9%4A!L=((SUL,:=&!J
M8H$:ZL@.]F&/DL(4O<$J*<$&U&4-EX @3ZJ.*N A>HJ24(&P^L$2?( FY:ZE
M?(((E& /8J$:!@K;X$ /^B <':/..+'A9"#U(@@3/003:D"W:/\&&V(!#^SP
M#INBW #%]C("$(J 4/Y0$&\3-UE#-PPQ2C@R"GB !W1 !BR@!MY )H-030PS
M./+A'>8A'S1A Y  9]IA#YC)$@S@#<AI0\J!&CQ$%<<N!J@D'^:A'N;!/-GE
MH8;@GKCD!D"M[F+O%_'A#H"3!W)@!C9H)/KA'^? N:(J!C!2,1<2%^W@[^H&
M\P!A\I),/MI!!XI@%)9EM:K!0\;1,^M,,-#Q/SUGIKH%&34@'BF!X  AG#94
M3U@P22K+E@HA]YZ*51R#$IYJ#IAP5)[00]A%9)K!0[AS^222T=ILPCI!(T6F
MJ9B21)KE#?1I1JI!P/*A\I9/!AYBPBS_X243302?;\%B[ :X8A2&XQ).31;:
M0:C:H7*XR3S-LQ[*00<J84)M@"VH:$((@JKV(1^4U$/DCL8H@0::8^DX8%;:
M(0=L9/U"\C'78K):IO;(3>96T"S-@MER0+/8@5_N  _DC0.T,Q^\H3OY!BL3
MQ!)H0"S4A6;88]<^S3'*LQ[*<Q["CB:1R4E2Q^*$@ -J ."81>R@8A_<@1K>
M03]I( ^*- ; [R3GX1W*\QV@<PZT4$OZ)1$0(Y;XD02OQ5E)PS1R*3>K-3=U
MXVY\8U+L!F]\@ @ZY9FL@0;49$OK"#AOA0=LH%T*@5]Z@1_F00?R=%*LP0YD
M@ <:HU/!:51H_P#\:D4'=@!=8\ T^P7S>,I5B #\*M"E&"\'.& ('G9>^A,_
ME$)?>:'S$FT#'H*A>& ($*I@Y0/)B !D=> -YC4*+.!>^69*Z\PX-8H&!BW1
M\A0. *H3+B >;900F E(.0-)JD4/7:HFV)5*E>+PZHAH4FLX+&$&@' <CV!B
M\H$29$ #IB$(?\,:H._1(JT3-* H2,%#-,$"W@!(>J'"^(46VL\2:$7\E GS
MVH 4AL-8-<Q"GPD_H% Q;X .[JD?]F &D@(/]J 4)%0_.[8?V"$*H(!<!N;K
MC'8L&,\!HW)9J $*9& //&0/L)*DA@8.#J$Q-&$&Y&,>E,T0D#$_H/]U]EZS
M+$P0=<<B6GOF1,F"V62 QM@C!_I@.#P)':,@!J*@,8:F:(?&)P#*&NZ '?IA
M%UBR5?:!$G3@UJ(@"G*@!NCN<IUD4L[A#1[B"-Q1-T#W#A @!X!$]\96=CW$
M$ICW4NKS7.9 ,@,7@NA#?VQI=5LD69I"( :EO*P5?V\36WGF*DK+&V+@/?KC
M/G( +@I!PWKA!H8 $YA(#Z2"(U1#X):@$.B(%PS@!DI!*6M :$G%+SE "$ZA
M&F1A"02P6-2SI_+!#GP N"C!?>5I1G3@D\ZB._0!$YJ#2I820-VA#]K PNQ&
M9$]R#_H,2.:A\AXJ#QI#%@P@>B?TU-"(!R[_U#\G<A[\H#E ,1\RB?5 5$CU
MDRR))%#BMW4W!@D,@;%B86OJI!WZ@ [,BF:@8&D3).S@H#O*008V0 _HJ!ID
M("C%U3C)0D9Y 0\8@1%.01UH=P/@(/O*M0_84<WJ@4 GIM#T(!&D*_T @8YH
M@2DEA2+U8%G.*4:!A!TB#QG< 16(@ /(<%<3M@\F<1>JH10DF(Z\ 0]2JS%"
MUXIX6 ,M0 EP)L:6F&_P5FBADR9C04UT*XW4"+)"(Y9DD_:^C2U;L"/YP*((
MT0_D+0["R8*!E2\!"D^%1V@L .[JH0_H43]K@ A& 1MX@2AHDA*4X"RHI!?T
M@! ,(:OJ* :T3 9F_\ /E,J.S^$R*NQC9H (%K@7\H .1GD6E* &HD##0*:R
M\B1BX&!^=\)LJ#5_+UJ]X,:]\'!; 9@ER.+YHN_.-L0;D(%?K,1B@"O&F/(X
M]4$6>D%#ZL@&?O2I)@D;L*%=;^ (C@SSY@"24YC&VL&3%14)NL,=;""&D001
MZ$@?O*%-D' &9'0?Y@$;F$EYB0Y8RV&4ZPL?./:ABNXD7SJFC=4R+O44)G++
MWF 4ZNM2-4P_#> #/K1=<I;"]&- 8N:-YM=[5)2+R8(4^&4>ELDQ,D$9$:$Q
MZ@$;"@%8>V$6VB2/@S*/?=2B$.*FH-8 O,I7_8!?V$$6L&$X=(8(+(QFWO\U
M:3< $#[&1(XSK;O,ON!D2R@!.V6'L<LZ"C: #X $'Y#!Q/@A%@YL;X3Z'L0E
MKVYY_=Q!%I AIL>1QOH@3_45.N' Z,;!0""(8 :U-9_5=%E&+;<%K]^94AZQ
M388."D/K!B:E'F3A&"RJ0;*$;]AT#AA!7/#4PJI!\K:DI!$OR=3%';S!#Q"C
M$+JM'N(AICM2 ]:.%W:!F4JD/T-R[;#A&.BA'RQD"6;%(W;(5;I8, #EW%A7
MF>$@C'7"?FT3HT=\EZ@!F/@7/EQBR^P"ACR;&K!Q, !!%NB(5JH!"J1Q*K!!
M'ZH! 8)G#A+!).M!+GWL!CB9069*#W8A3O*!%J3_U@AF01_*(<GFX!3LH69"
MV[-%]7K>)Z@Z4@A0Q ^J(=+Z)1800 .6H&AI@1J&X[\,@ ,.J!<BC1^H 1/P
M@1V8C!_0= GJ*D'D(1;<E1>$!!6L4A/^;A^,5 X2H3+UJQ/JSP@0(1ZH;J[S
MJ!/R-,X6M2SGS!V$3@3'HA18ZY+*X3HOA X2LZ&6H!<2Q,=6KAVBX T>:,O:
M;*GSH1YH?1[<H1<\,#J@>W8(YA1@K!PTH1SR83$OLAK,\\?X)?TH31](Q3@]
M6QH(> Y*8=A)&K9!I]3KP4/VH1S$D#X.8='M2Q,.P$'R0!8:8]\T81X8]);;
M8!3 5-RMX<P0TA[P@54+_R$=G&8&6E*@Q-U=678Y8 Z[\7&R_F1'N(LS9B$?
MKE;)]&$>[F #&*$>TL$&$6$+I[H3))07;" 1^*(/W#L1Y$$?AL9M:=T/A( .
M9$%7:847VN\-*F,X1NSE"H$:[N&FZJ$7O"_;=)SE96'A=4 .OH$?C%0/9,$J
M<3X'I+&C5C[/8=M]T7+#XRPV@66\T(;$KYZ7=*/GKL);=(!K/SJ0]B!=C>,-
M_G8/HJ#^H%(/\$ 'E' PWB /]F /=.  =@ /HN 1_0 /<H!-VZ (S%X'D,]&
M"J$/HD &BJ Y^*!>U20/^L!69."3[F+M>4 #OKQDEN!O[X#N9T!-))YO8N!O
M _]_ Y0"$.2@#\X> 6S@[.NP$/3 #@*P*>4^\)7@6_8=#OB@#^P@!\1N[DW$
M)Y@@\W/ S8O *?B "62@-^! [\WE:Y*D=1&#9 9UW.##6W:_+-Y@">Q@#^Y
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MI_F!4\]7_O+4D,+662"%2:BL';E>@0I@@.F91I[RD ZUQ W277O^_!JE=0!
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MG;?.__4L5[_\B6YSX]H?S@R8O +2#6ZNXQT [Q<YY24/>!)\8 #UY[/3[2^
MI_.@_:PV0 PR<'K2*V %'^@XS*V.7^62'_&N1;L1>J]T-,0>"$<X,(+=KGZ-
MPR&S$C@Z!BYP:M ;V.L4Z+_(!4^#=TN@\&281)/]\&+:_R"%(4Z1#O5QL8M=
MG,<LC*6-A\&0?@OTGOW2"+KEZ1!_*%2>$T/HQ,Q=KVBIB^,),^B[V*$QA7K\
MXPE7J$+% 9*#QV/B %NH.?XI\6YV9","(RDY&QK0@WKT'0G)6#N"(;&.;GR=
M!O\G1 A*[W;/<YH?*YE&1CX1A'3C7O2*R$@^)E* @WPA[6(I.H,I\(J%0,6N
MO"C,8?IJ'+5JAOSDD<SZ7?*&%[RAX"8H26G.$IJLY)PSE4C-,V9S@MNL9C:M
M:4ENOM&:"LQA'PW907)*,G7N1.<H"1A.6QJ0A] SY2?;>4YFBC-_N;2=[?)9
MSH'2\IK2 JC^QEE+3SZQD?G#7?\/&UHP;JK#%X@813GV0<R-<C0P_#@&(4B1
MCG6Z[AX_A"<_WQC**D(RDI=K9QV'ETM=1G)X0319[.)XO65>C*?Z)*(\@^H\
M75*R:C.U'@;_.4]9WO >=_0I.8G:O13B3*8R!5H5T1G3>^*.JS2#*CO[B+LS
MHI2A_#/I+1O9/8C>-*RNLVE 6;G3(W)2J2E5'"^52=>;YM"5C6P8[62Z5W%L
M#1M@ZRAB$TL7?NS"$+X8*0U1>DO).A6:+%TJ9A]H5;I&]IY3K5TX+ZO,S4TU
MLVG-;&E!.T*$TA2K" 4K(9W93'_:M)98G6LW30E1TVK6LWO]:K1*>]H!QC6S
M((2M#Q/_N5GA<M"/KY6L49D%4%,R-YM9?2YO:0A7KNI6';K0PRX0HMCQ=K0H
MIS!$,[*K7JPZ4WZB76][I?M:U:ZV8*]=;S)OZE,05A:^\+SGNP*+U*%NLJVD
MW>M[X:M=TIK3?P/6X79'"]_I2E>^C -N@L-9804;%;_8HNY$48O@>6Y7MP"&
M;D\!:^+B=C.W%1;LAN7Q"T/,0J/DO;$P\S&+0J27PSYF)HM1:]HCOKBUM(5H
M=>>IW^W=D+X_GE]W.7MD@ )YPQDF[I,Q^T,J!]B'OLVK>HD<Y2ZS5\%<SC*9
M,2M=O=I5S9LE\57??&5_3DNP$?7Q[(I<8(1>S!>%""^. YT^_WZ$L<=E+C"4
M)?Q6O;:U<5L>H+*JR&<&I[G+W4TT>UE:W#VO]JL2QN>B/SU:1X/YS',.-8GK
MNTG0/L^',':U8,O<WCLWV<L 5J:DB;O;45^7U0$^-:I[NBQ)GUE9MW4RG%]L
M:5DG%]><#K5HWTML9(MZ<Y%FLV>57&3YTM+8S 8N=]>L79Y*NZ<4#A=U56L,
M0O3"QH)^-[#V@0S'1E:UCL:RN9T<[31K6JD9]K;U NIKH'D;TTX.8K.,/3L&
M'WQV"P?VL.E[WT-7N]+WKO3%E#72BSLZ>MO;9( !+E^0CU;D$I?UPF5M7S)S
MG-CO4OBJ'P[EQL$<U!BW>3)3?G%E%O^<W[_N,L*%C>%EIIRTU\8VK8,N["KV
MW)[()GFM<?[A45/:XB0'J\*7GNYT8]RUF?YUS#ONNIZ/7.B/]K3#0:[;S?VB
M$(8]++SC[I]R_#+C\NAYM:[,TCKG/-@\)V[8;W[WC+.5VIAV;8@]/?A\4W&G
M[:WZK<EHX7+7EX;HB <ZTA$/>:0#ZL[NNX6['N".79:ZCW^KLEV[[X>Z-[BB
MKR2+2T_ZU_N]] ;+-:Q!JW2F?WO56);VEO>,^P1K6NAW][VBC3_SV!_^TWG^
MM8%?;O9EFWOD01:]]9%[;.KCVLK*)%8[Y"Y^_O!C'J-@!-XM[7N'*WK::9^]
MOI._^*('=OJLRU^UN+5^;_K;^^>]1WZN\9_\Y9O:?=Y$ 5S[X9H".MO?+=[Q
M/6#MI -DD=GD05_^#5[+"=W:B!M]H4/*K8U1"9_7)>#%&9L'"E__E9D)AMVC
M;=D%4EOP$1S5"2#UT9STU=_5&5_!/=Q$[9_/)1REC1Q@R=\/G8.HG=VG)=[/
M.9H) AT';ID';I[,59\%%N#\%=^AU=6]K6#R%5BV8>##.9S2I1BK;9DY- (I
MX/_#^*VA1S76&&'@#'[>%+:@#Q9@PGF;$3K@UZ4=KU%='+*?S(4AFP6B_]GA
M'.K<'\X@/K%@(+J>^OEAI&7?50VB9SD<.ES>QEU>/-3A!1YA Q)B(/I:**;9
MM0U<T7D@"0(B RY@#/HA*"XA(EI;UA%BERG+#CYB"[*B\\5A'\ZA KXB(H:A
M.\2?#VK=X$6A.L##.0#A+)9<(2K3.72>YJ'B'XJB*UXB.IP#/6RB+68<(/;?
M':K#Y5T>+8;A^G%>.ERB.VPB_?7B,9)9.@SC)2Y=(L9A,^A!+["A/O(%/X!#
M(?@"/<[@BYFC/"RC\XDBPI6>#-HB+?*B*J;=(2KB*A+_I+WY(ATF8B."7)$I
MXLG5H=IQ#PO*X4<J$SQ<'N>-XPF.8O -'#(N837:H2O:H"O^HO1Q'_OUX2]:
M(TU:(T7.83=^G4TZV3S2)$ZRWRSR)%$*8C FI$J"'39>8C@88P RW5,VX/SQ
M'*GM).<=7RE*I"BNVB;&0^=18Q,>)%%>8DF*8\RY8PR"5N<=WSE:Y Z^I3I@
M'AR"(UN.EBX40OCMHU_6A7DEPM&II!76SB;"HM"MV0\-)31>95'JXJ=I8_Q5
MFRIZ8SRV8D<^W+5AXSPPX1%.FWXU2^=5)%+=9$7>'3SH'H4)'/YQ&A"FXU-B
M7E8N6V9N7J>=W&TITS#FI-V=_Z8"=B/4Z5PQZF+FI6!2"J>E;=P6 B<K-DX>
M6AL]#IPQPF%S=F'7S<X$YF A+N8ZHF1)SF1E@A8ZE&1J9MX$3A_ +:=H8EY7
M+B"J/:4TRH-=RN!U*A-[BN,EQL,R%J8@7@QDY2<V7IUO5M%H3J,Z9J4IUN&[
MF$/7P-U?_B4_? -Z25A[=M\BHH,[7&)<?B3R>9MYGB U?B4#EF$$%B=[\F89
M]N)KWMT)/J;Z21Q*,J37D2A$JH,12J ZC"9'JF@?9F..CF9(YAG7S0Z AB4V
MCJB(JIT'5N5:PF*-;A)LUN5O'B4?UDZD96A^YJ%I$B35H:*-KF6*IFA.;MPY
MR&ATIO^@>,+F.RKE^EEIQJ%E<3;G319D+8KE)0(IKT$DKF4>2JI#AB8IC[)H
M!&)>?(HC3K[<_I7D.**FAGYCFXZ6HG[G2 WE3UXA\K$HYDFJ]QGBYXDESVFB
M;.9D?S+D2$7I?8*GRZ6=G[$#03SH@[X#*C0"D8HJ(]8E-F(ID-9JFUKIDJIC
MS2'I;VX2>Z9CAF*IKB(IR&$H?C:JF))H36*BK\XCLR*K'&+>YHUGBVXI8EJI
MG0ZKD#*B)&[24SYEC<(E!.ZIAMIB2M*H> +AW:5CCO8IU,DHC;X<AC[E?M)J
MX(GKG:*K2/XKS*7K2+&C'(HDA^;GLI;BOEHA-K)G-ZX@NSK_7)DJB[<&:=C%
MYK@N;*V>Y+C>J:%R:.#9(GLJ*K,Z:MJIZ[@2:J39H)ZNVL3VJ5CJZ0*JJ[W"
MZ3CFX*/&W+ABJ;0ZJZZN6CITC;NY*AL2!-WY0L3"98VFK,;Q9Y[J+#SP[.5%
MY<^2YI'RZLK*:;TVBSO )I^RXY,R8L=69<U5;<**H]>:[<5B([RNJ]J29DEF
MZLT^Y*BEY#F,[+UZ*9AJYORE(XL&:+L2((UZX#3*)B,ZZ>RP)Z&F SR<**DA
M)6C9Z:22:]B"7<S!IC1^9\X.[C&B)<>RJ,$NK>(2KCF.9.V0+#9&[:X^HK]>
MGJ)**8*.Y-^-K;P&Z<S^K<,2KC."_RY94BB<5NS/*EJDW2E*IL-^[NJ^6FO"
M\BG8 >OC.MNJ.BC1RMT^Y ,O&$*NGB:'RF>T4J[)QJ2?+JF!ZNTS,B-7PF?M
M&.%7:FR.BJ.U F[$ J"MCN>RPD-O/J_59JS;5BVZQBWA*NR>A>O>EFRY%N#*
MVFSC9F.(/BV%_JTM=B<Z=*:A@NZ3\APW:J@$9NM#FN.1YB[!;J]X_FUYQH-L
M^NAQ;N]^IBY^EFZ8EMSHLJUM@B'B6JG7NJTGQMSHHFZ5@K %CZO]2NM.AJ$)
MPN?5SF:YO@L)_R[]KMI/NNGB46RZVB)D^5Y[4FH4P^^QYNF=9JKA.JK!/JTZ
M<(,A] ),3/_O&O)#/>"*E9;ARN[M"D-K71ZOF[8K"[8MQA[P%P]Q/")L^[[M
M)BWCV+J#^NZM2-[J'>NM&[LLGRHJYATOBK)KWMKL6+ZM8JYEUK:QN68KG\9K
MQEYLL#[Q.-9PHX*NTDX7KZ;CB1*PV;*GU!:QKA[=V,*K'^,:;*)N%\=OLI(K
MZ@+GQG*R)&>OSGX>[5KNVP+H_[8Q_]HB(QMIZ+8IRH[M3>ZOH4IK+;/MX;HI
M0P*AP\HFO(IJ,SLP-LKQ-0<O*9Q",)FQ^.6#-^A!C[WRW];L4Y8D.'QL-C/Q
MQ7IM*Z^QV<9SQ_[LNH(H-HI#WNKL/H_M=Z)B2DHSUM*N0JMELLK_0RN3K/31
M[+J: T'?+"\_*4(_[+(Z+'Z6\L7RZQ63K#L_K"%?(C@8:P@[M-AF+,\6LSA&
M)3S(=%12[2NO;=ZV@_?6ZC]#,Q#_,PLR-#F*+4X'*$@',\0N+]DJK4(S)#3K
M,T_KK"B_8\\R<2D/<T(S]<-B8#]GM-D.7CA@8U1^GD7?M#W+@R_P03GD SK+
M'3_@0R\40EE#-16_*<^U<H B,U%C\TFK;4^/*S@ -4L',Z_N<D.+*V*+(Y9*
M[32OZU%O$GGR<\+1<5 K];A2-07S-.V&=6 W]42S*&QR0TF^ T<G=DOCM3U;
M\CN",^4NZ5$#M2ACL6"';$V_RUC;M%E#__;.JG)!1_(Z8"D8AC2KZ71DIVOM
MF$,S,['A(O,_=ZX<YJ=SZ_7&HJP?)S-5>W4;@^@[\S)W/_$QKIJQ@K5I1_7%
MC+4ZA$,BS[5PUXX84P-;MS6\\<,[G$(J[+.](BI#5[=:8F-G#S9B'W;'_JE?
MSW'J[G1U\W,1OW90%_@\$O;^9O?8UNRSZNI8"O6!0C5 OQSJCG4]V_.#/V5_
M^_-]GV\_8S-!+WAL[[-#W]U8PP,W9(M45FU7 _B)6_9&*[2@]FJ)ZS=?B^UJ
M2_-\[FERGS48>[B,MRB VAU( _64>N.O(7EFNVWO$O-Z3_-J7TTOCW?8,<(I
M4 1\OUL^E(,?_/_"*V?X3F-K@VMY0[^K]S9T0NLL6E9V:F=W[:!V5*>V2!/P
MFU<Y:_NWG^]Y_>9UYTYS2\-FAGJM8>-T8W>LH/IQ%-+N7A\IN6*K#FMYC?-K
M9P_UI7LRB]OVU2!WLZ#W7#]XGF.QPZEW2T=RKYXO88MTE)JM11^SS3KU>O?L
M%4,E[V*X0V=X6#^E2N/Y&B_ILE9XA(,H9<]OZF9+%)LV=2<LED;E/*(W2PM[
M8D?[WU+M%P<OR!$(JWYYH!6%-Q ",C&QL9LXKR;V8^]OK ,[N:>ZD1-ZL,<<
MJE<YM:LYH,]Y5O_WNY,ZH&MUGN,YLY9[&<9Z;!NT<;-[:L-E-O.VG$__>Z/V
MZF ;=\FJ\KPS>P3JLS1+LP/3]>-&^D+;;:V.NG +?+77NK"1[W&S&MON]J2?
M>[(F;*87NY\'NUBC.:,S(JA;-N:2J\+/O(4;^*ZCK$37]'CB]E[7[T>C0V!_
M^B:!ND4[&ZJKMY_=A_1Z>WGE0S400OS,>[D?/,W?>KVK@WJ_^<-'_*Y/>] /
MNVOO-]J7O; _/%"K>[IN?-!+/#W7.T G/=M#O'\C^2'_;;PW/;FC-#:N@]('
M:-H*_,'G=11CI4B?.]];:7E>^O!FO)Q7-,!'-<23?; K?%Z'\=ASOKV7_$7#
M^Y^_/<WSZCRX=J]K:%FC.ML2/..'0SJ8 ]Y_1#P1&_+96GZ$AT/,MWS?H[EE
M9SJKYWDZ^G[&SG.FGSVU/V7KVR]ZW_;G=SWSA@.THT,XP(/M*SW'BWW:C;U:
M-D,A5(.7_UO]>!5%+QB".*R:[:<]O]HXI'N_]\]U66/C]ONT_#-^86_VY^L[
M0*!3)W @.H,'$:83N%!=P8$-"R*4&$XBQ(8(+UZ4:)#BP8P+,3Y\.!&A/(<$
MT9E3IW*E1G3A!IH#%_&@.(\,'8X$B2X>.GD53T)DB-$@S:)%10;=N9&H18LJ
M04)E:O$HTJ-&IZHSN9*E2J@/%=XTF&YD2X@L=58,"S)C4*PO?\)%*L^KR;'H
MP(EEBA/E6W,'P5&$1[$CP5FE$,-<^#<OQ[@'W75,VI E0HIK&V\4FO/O084S
MF5+\.-IG87@OU44.)V^UQ[0%TYDSYX[C2X.LB6Z53=DL6HO<"O]1R\>O7W'C
MQY$G5[Z<>7/GSZ%'ES[=.+]WNQ#MINI6I&7OF@DZ%2E;H<+"Z&+'[J[U*DF!
MXLXC[;VY:.:.Z?*JC#VTK,O"F8&B22EPQ&%L+?!<$HBLAM+;R[;VQ#O+,_?P
M.NBODZIZL+!P+A-KM 030L<F\*ZB;ZT-*V+(*Z$$,J>\_6QS$3W?!'ILJ8/B
M.T@>;B+$L$(<B<+)MY9VZB@O<08",">4OL.MMA:?,DHVO$9\,!VRV&(1O1\=
M+(VA'P" ( )?C/J,H\X>M&I%RLP#S,()"^N/H ._(_$C')V$21V85NM3O;Z&
M4A!)/@MRYZ<XA^R1QG$*X>4=XJB+5-+_22FME-)\WHF%D?#ZBE(EDV04"#01
M!^(P0-ZDPA,A>-A+B:\,[\HPK@,U0JO+S/XZCSNM[&*J,S2A^DE8>8BU\2X4
M76-OLL4,FC(E%\%!L\2VS#&I3]98:\S(*3-;3QT8)0*P*% )HG$C^ZH2CRDL
MWWQ2M(?6U.@\.FW;#Z*UWD(*RP0W4^<<TAC\=D[/%'*JVI;."==5A)S-<"!L
MY7F'F[RN-6A4^4!D3**U+E11*!E_?5(=<?):T"0E @@@@EV(=5#<-%.<<:/.
M6F,8U('^9?))>FLTB5C>/O:,)=9$6K MB^2YLN-HN0Q'G,'VW,JAW>(]FAQ#
M>GG4TJVY[MIK_^CXP;2431OZ5SOMHDSX+A?5(3#6HJJ^B&;<D$&E%%,0F^6R
M.[642!MD:IEEEEJ>T14G?XT*9S^>MU01&U]V047P8[29"49I.4KG&5^..<:7
M6B _9I9C:M%&X;>Q 7T79'Q!AG1?C#'&=/R@;;;QA4-"?#RM^C2G-30/I!6E
M4-&+]B_@740[/*\,;#>A@K]5]RUP-\:8);5CYM?H?FD*YYA==B%]]%IJV<66
M8W+44AW =X&\%L_+WZ46;)HM>S[_.CM1,_IXYT:TVPB3/X81J3;WL4UC%-*9
MB$ D9[&A6;AL4I!P+*,4?J!   80@"F48A;:Z F7&':0>9CL)PW9RO\'=3:A
M!YTC418"4#A>& YS'.9N=BM&E 2&CG*@ QOR^YP/XZ<ZSQFC%L8X!C:T(<.B
M)'!+?S$4:Q2#CG_U"%4%\8HA')6/KVV1BUV4%''XP8Y3;*I<ZIIB9;[U%X54
MR4T#M!_N+,81)J1L  (8P URI!>R*&06?+"!!"(P@ A$@ )*  7]TN45%;HK
MCPK2QBCB8(%!0H"2$: !'E"!#2.91R9CP<,@ 0G(08YR%&$I3*YD PX^@'*4
MHP2D'VX'&,:)!2W:X=!JG 1'!%&F3F];H<'.MI<-D647>= #'_AP3#TL<P_+
M3"8>\+ '/.@!%.#@) BAY!2)'(,/T=0#-)G_"<UD)G.9WQP%CQ"B#1NT<I0%
M&"0%9A&HED!%&TI@YSU1\2RS<,4EF'M2\<("E5K"PQS^FTC-+O.KH*WK6?'A
MS$ILARN27&D64Z! !@> T919<A2(9 HV_-#,/$BSG,\<)Q[XT$QPZD&:?N!&
MNSRE$\8E,!W8V( =,QH /LR3E[9;Y3W9*:9W2J "%;B #:8P"O1AQ6FK66 M
MH?J4Y1EB%^S0HA>QFE6M5@=3I&A$3)ZR(H_\2D8=::1M>(FA4\)#%H',( 0$
ML -3-:4BV%AE!C&85SK.H!11S*:%"%.]P"I.'=P8Q08R*  !T#%E*8/ #?2V
M$5/.,66*I6-BF4"1_P?ZS0:5Q2E>4P9+(,$,63NA3"U7TYA9E<RL:-V+ $7V
MTAD=;Y^\L0U\2'L0/Z0, +WE;6,!X%G>XI%A;1KK:0=BDW#$8Q2\72QOP]38
MWZ9L ]JP8CJ^$8.<!@ "&,QH!D5[E<J@XQ@4>&Y.W\K=4^2P:K#5$(Y.R1;M
M0"Q7!CG-7(&2JM;^<[12V6>HPH*?6&I##Q%H+%XUBE'(OB2PXG ',BX07,<"
MX+G E>Z% P  "5S#A?OI"HB\PQ@UCD*QV^5#&1?3&3U<MKL836QWI0OCRE8
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M160U9#,<$I0LSH8%;RO0E A-U<8,'1<)-: M \ &-,M[8W,4^F 41L<8;FE
M4:,C[$*!$%+.:,#/@K<DE&]Z?:<4?J RN0OW.I9Y:')AKC7>*H%)NZU^DHT+
MI^! GKDC!Q.Y&)0<@$QK_S#XG;O&%>'E+([G/GUB4&#B<U<O[.JW3M$!:YN0
MDO;,' &.08O"%R) U=PQ1)V3AS2 "0- "907HC"M0MF0A\+7Q>+):1WUNS!*
MHA'3')2@(?E."?",NP0@ I#A,&UCF2]K"F;@ZB;LQ%I.;,GX-LA3E6VPOEIU
M>"5CC\UP_JKS)<*N-92T(QET.6UQ4'YB%C(*^C3 HWH'.5/9,1#3DS/709$A
MDU.& IRY;:.7MISE61/ L0( #Q"KT&A &^JY[(SXLO!  N J3*[./U?/,<#5
M\R@B,"@&E:.%.EGZ<XD%G0((7.>I0A_4#>%U0LNJ-G:$=8%NK0T"R\3D&/*1
M=_\(M&^Y]URC$.@B !8 5(;VI%02&5C@<P9><P#D<P236C:\ED, N,Q.U\O"
M."L1DMXT2#0(8W=5>9(Y>"[5X6HZP8+AN;@KQ4K):'F9;$5>:I4=="1EJZ]A
M$OD4;M?.C 8F;\M"V9_1 17H&*-.EUR[%Z*?L+3O$!P,*O7" ;L3+#8C-!RT
M<]VHP($K51S DHX#@ EVBSL%0!36+GG18;<\>@! 80L;2V\=5)736&C#=B"4
M]R\2YNQ,A1O@H^7&=6O/;CDADK A,L>4UX AZE]@S6E$Y'>)4!02R[*4(()*
M8[ (Q%/K%BZ LHT/4CTSJ->J9$_J6: 4D2*&L@M#B]3_"FU,B.1XWE:@C[04
M)""X)G63 =0F?!IWR..HGU?;E+L4&>R6E+?E#D4T#'J4LYRGX_4]=E&IWVN1
M.6#A(L#&Q 'Q(* 6NIQ#/E>';+IM,9LNIH0;+I',_*!4 3*P\/A9VGJ1L7OR
M., /E%+._&"2]X1#;**;-2H4!*)4,=QV*CE2)T&Q=[M5U1E,E[<G.6XXC'O4
M(\456ULV)-A91I)HVC:-%UC4-%PV #K/-N 4M&%&]6H'A%&Y;><0MG, 8&&Z
M<4,/2DUE[EC090._B@XZ\P ]0ZMB.QQ1<VT4EIU#W%P#F0 A86RQ0E2V_DW:
M4Z8";&$&Y#-EWA(YM]P@GG/M_TJ5=T#%T;["DW'+=P@;250BPM-0TYYSAP;K
M,!WXRI5:'(87-!L=/2X1^O3 65<SB1Q=VUYO1V23J)L[UOU''7P=R",Z5[!A
M&9!H1#2\+)-'&\A4IKO+#TBLU$;!G\5!&S  K[JK!F9!KG$7 L#PMN0WUM^X
MRL<U@( U5PKKHCF"L.US>0-K).'!?Z*<,$2YQ'GI5_::&G_BUJD0KQ@:RXR=
MWG4<,1G8)PKJ+SH936Y[NSC@&JK%B^F;""%7D9&0O<L,!]YGCED;U1O*)G'4
MFP7>:=,4/S6J=%'A,\$Z;*F&:#6\YV5#$7;!G4D]\:-#;.!/GU#UL,$6BI3K
M/\_\0?]"!J Q2 EZ@4-Z3LZV['#;6AV:/6MW04/$=K^ASPH)3],$WA;_XA6
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M:L&$8XB#5]Q(DF$D)B[<$  5O-)*_Z34%%N=[ADUX!J3VB<2!CEF6<D2S/0
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M7:A14@XQ7B_W8>9F#F+U0:&A<3>'&GJ0?X@!>W,W=T759=6#3Q.FA.(5@MR
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MD&IEIW7]P38;=@/; !;0,Q-AU%(.DA4]%XD)HXX@%1A"<A8Z,G4#L(Q8R&D
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M>N7_=R^G0H40"VHDE"O*HH;5"8TP/=P ?!MP"+X -MS0#+^0"#=@8FL5(12
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M^CHV/O_ _HVOW+[,,I9BC58%"L<G'SHD7.%>DFDC7]+VQ99?=FD&788.$30
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MI)53AHW#Q62+T1RY@0T.*/ADQ0U,*=L+)6<V%W-6%.E"Z6D6_0W_,3Z>L]R
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M[ S*%XN]3HI!FP7=F5(!9"24IR#B@W.K!)]B9CW;1B,NOF2_\>$23^P.NOJ
M*S5$J-(:ZYG21A[B?:.CT#D_"A$P<AJB28=E<"L;"9$\$(<=J:F.Z+>*D+N;
M 1-0VP]TTR5M<*OI<B9S0"0%$Y$,1(=$$11)"C>WRQRJH:*\T)_08B\*830
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M.:(H 4N?#3+ R=LI4K21*<2/ ," 4X N"@J'9^BCS*@Y'Y,H;8@I"GP8+*F
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M^#03OARTRA0\*8LG_:1,@"3/'L-!:%"[K",P>*I-E>1+2 0TM= &5-"#&ZB
M97HC#;@!/V"Z.QV'T.0(:$@$(WU1\_\B&F*<D28= H+X( W  3ZPA8,C'6;4
M!D;84C[0 [,<J'$@A3X8TS[P@V> CRMJ!C+=4C\PT]O4P12T01PD)5:5R=5B
MKR?41?F\/6(S+G0XRQ+%M*'QI LUOU_P@Q^X@'"Y@"7P@UT@SV/%-E/0@Q8U
M4N74%!/54E0]Q\7D0^,\!%3E U00N>F\.3&MU'9U43]@A'L%!7TMA5GP!=^[
M4Q(-V$\BFH7:P4)@EP[]4(6=+VJ+2A-]V('2+2F#PLPYL!W4S"^TC<W\"&V
MAK5)FV?84[#K"$BMNMC;0884#(X1IUI(AA\=SXV+2+: 2BWJB&6]T"RJ'-N,
MBF;M.I 3,(C_%4AX-2T284KQ_%72$<3K1++;Y(EC\ 5O\H5FT#<"LJX!LJ+R
M[)>%Y(9G^(5?F(5?6 9M0).D+3NN"QK*'!Z.J#@B.I"*55)D^\*-8"_WRSHV
MY4O1"U3/LEJ^!,Y4/-K,^ME47,I&S,=E !!9007KXKB>E0F7X$2I4M?)#-R1
ME-QNA9Q,8<:;[<-#!+?WRUDG+),YO4X)D5@ADKUM.+V%7=WY:KU&&-W+C5UU
MS3J2S-Q,H8S)C59<M,X-*A/&#5A^>=PZ5<$2W5V#FAADVT'YE*( E=OD!5('
M45X@I5'+S5WE.QYBB]W)Y;;.]-MQP-VMY=[,V09DHQ)DW%X+)==0_[2DS1W2
MW#U+\J2]HZ4BJ02[@<12GFW3[B3/O[7.M-W.[+S*Z[2Q8V6TZ&ROTJ4UTFT6
M?JDWGU2_TLE A9'3FN)#@,V46)D54K-*SWT_M\ X#B'>RQ59/16BZJ5<;GW?
MAPU-+4+>Y-/>VTPM!K:_7Y5/U65=',XG_)D2$K7*S(&&-@7BY54_,./?O1TH
M(:8U?^3?RLQ!;C->P/S>_-7?V^O*  W0%_;AYWUBUTS6 RF3%YY,ARU?L'M>
M,4Y>[LU"&AU2R>W,*>'$I5&O$]9B .9?I9W=&BY?@.0=\87@RH6G;6A,+*WB
M(9[8^H.])%Y>%>PZFN).9(.+!Q%BRWV01O\6' BF8[R-3/*44T4N+DPMSP)&
MWR7VL8#E7:XK+L-C#$A>02WN2K&P9"D#WLFUI.7U0/\57Q&V2N-P7QP<4>[E
MY>DUK9?(X_>#AHECX\54P=05RAQN9OEI/8 "H#95UT1NUF:16# CWMF-4\ND
MWZ[D3&2[4T$ND(ZH9B2695P<BU#&Y=)Y4_($/![&Y,F$IE3BY%8.W+*39H?U
M7T6N7/Y5/_)]6-O=")?HULZTWBY^+EH>X,Z480;26S[4XAX;+34V4=[]9_\%
M7\H$8D%VN^IM9]<T7JWA8;Q-OC5.E@[N8;5PX)$Y8VTV&BI)KMF!3P9B0X/N
M6X=^UJ@,Z%\E(*C_(EC@O6=W-N(']N$T)IW;/5Z5;LH%]DQ68^=U<0?4<V:J
M[J<=OEU9IMTF9FB0_N>N9.C(L2XC/N+)Q%W7A.>>1CF#QF7T33;PA&"5EN7I
MY;@Q'N)=3>&@WN+18^EHC4I>W;9V+F:CYEY=Y%4S'F#K?6JMK6!1SEK\562X
M1M:N^I&(/F@W[>F;QC9S=BZ[7NK_1>IX)>1L\RHOQM]+/EX,G>3;PT4E^*X+
ML 6/WHA$#NQ-IE[7S.R_MEW^*VJ7=N.\)>G@#>QO_D=B0^I.+N"EV890[!?V
MHNVN& =#X 5VR(>$K6KKU@YH#F':#>S-_F%M#N?1$L1;YFKJ7>C;;N,P_TYF
M?C;C>]9EZO5L*C[HVPU=9&WBOB%8*CECYXY@CT[!-"9F^81IR0YH!B+?S:;M
M\RXN,6[E06YKE.OB[<W!P+C9?;Y:R/YFO YJO_[E/N;#V3[G08Z*)&9P?BX=
M;VL+DM3ORMQ=J7SK*G;- .WFS"4'CB[?\#PI;7@I7]"KL\OP&F9JI!;-N47C
MR<24C"7M?T9&D"[@;:C3\J2IK9Y,CH9ISWSE#F_K!K;M$K^Y.&R7ZKYN,,?#
M?^H*2<Y3[Q[D&M_B:7;LY1;O8\U3&1\9?@YD<M@&DQ9=C'[GJ AH J]ORT3'
M&<Y";&+B.I?Q($=P-D;6Y58^_ZUF.L_:Y2YE^/\M74.FT4*FO\IL\^<*<D[^
M;C(F8VY%\P>O[3SG;M=<=%*G\?.F='@F]4#F7=+!\*6"]<H2UD ;9HQN*$+W
MRD)'8V$M;#+G%X[V2LZ)<2H)9%PL6&0S]NR,S"CGW^9]B;NS4VJWM,TA=52O
MJ6UX]21GHY$Q=H8@<$N:=F.2=H/*XX1^]47O!BVG\:ZXX3"/]^OPIU%H!(N.
M:"(/:"$&XB9O%G8O=0$^;%#?;2;FZ?*=2O[39.-><+TF[2#G=G>VM/(]<O+\
M=UOW\]TF!V9G8L8F7P*/<69OWAJW=2DS:8<$^)H:=L?^9V:O\SK?]K1NR)-W
M\< ]=/L-X/4>>+4D>:/_QL$[[V:;[V\!/O5_UO4\GUZ<GW:;#^<0KV [=N[;
M@_+R#/K;1>9F&9%0;-X U6P4-2ACIWJ4YP9VAV.QY]: YJR3+WH=3&MX)7AN
M\(:5[PKRQ5(G)_>+;G1XEW>]%P_\8@1W+QT@3G/OOFGAYI>0MPL )?1@M\IQ
M<$IG ?1VDGN7KW0:1>IK+W )F7MGX?;'EQ"+S_S)Q^J=CW&CI\JU9R @=O+G
MLOA8QT$"EW,ME^^N"'JP+UW 6_"GKVW\+GQH?P^05TEH4/G<[Q=TW'C1'GAM
M0W(*'OFD+7L[U@;53_E!-WK2]ZH@CWE2U_V$=F)NX/PN7OCN+"9 ?RYM,/:A
M_QY]T1M_9S%S2=;YL#]_L(-\M0QZ5PQ]<R?_^"]U4(_V9A=D@""W32 Y;MP*
M:N.6T"!#;N$<)ES8D!PY;89DO<O7;R/'CAX_@@PI<B3)DB9/HDS),1^[4HHH
M%H0&LR YF35AVKS9<*#!F@U_&GSX\"=.F!.')ARJT."X;0,I\FPH#BBW;A$=
M$GU:L"?3H!*Q,AS7DR#5GP\C*EUZD.:VL0+%?E4+-NU-F%&O.CP+EEO3L3)_
M3BVK,*[!P#JI+M1V-NW$@4_;&L3;D/':F5L1\U4\N:$YAD7+ZE7:M[+@AII+
M&T1'&O/FB9<#,Y2H^&M<@4"W:I.\<&C=OY?ER@[:U?^S8*1 $U>F:/-GM\CA
MPB6&KM#<UM]E"4.G_!3UWM-?:0)-._NX9ZV_E3:/S7 H;ZZ$=KWCQT\E_?KV
M[^._S](ES9R7J]=5W5\'1:6>0>G]1-B !BVXF6:012308X)=A:!$TG'WE85
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M;8^HTNVY^>=ATES\CA7??N^-3N;F?JW[KNB-ANH!PJU?2NK4\06"[NN\4FC
M'J[ATMK&.D:$1JFW"2DWV((IT"W7M>] _5-[_A&MH.K1TEL*/R_7[2+N/F\-
MNYR'UM21YN8S&<UI#J#WBNH%G6;$KFX1>X2L-0+<.6K)Z50/2VW9SN$//O]F
M<F8#(\S"I)S:4&;#*X#"*!R#595M38R"+<P4*H0"*3 M]]@"*(C"VY$#*HS"
M,X3,-JSQ,UB5FUT#*AS"%/ !*2S#EL*Q]@HR@A;K)9%CI E6Y_*G$:E/37!G
M^=8EE*4([-9N@7I;&/<?Y 9G_NXKJ#H4*)#Q:JYG+*)"*,<C(]M"(H#R?FF#
M*8#"*T"#[]I"*)C"4YJ;*9!".VJ4*;3Q8^HL*OC!%.@!*ES#P&Z#*9C"IZ#:
M[?[3^R(PUAUH/;WOC9JPLBZMLA8O?\;JND&R-+)O]#XS&$>D,T_EQQ2I4\PR
MB")=4G)#+1P"!ER 'H3R1@9#*+#RCF:#+8Q"**S_PI&:PB$@ B-T,2KH,MC.
M B@\ XW" BA(J1%EPRKX01[T\3+\K5.8L9#VZLY9,CB+KS,MDZ95Y<?9<H%R
M*IL:\4F?3J/85@9:)TL32.+"Z"A;,C>@ @?\POJZ%8CZ0A)0P ST]"Q(\_<V
M6"((0")XFQ( 0 7X @AG0QX$0 TL0XIR@QQ$@#!TS38T@00D0T[;<C9,0014
M0 U@0 3\@"D'W"_4 "IT;##F,(IY+O=@+*3(9_BA\-,6:.SX*PJ[]8JF()U*
MEP*O9P4GIY#LL('67 Y[+."U!2G<0#)@[=I&;RA$P"A$+S4^0R%(  ;,  8P
MM'S>0 !<@##D;S8P 0#4_\ U *\27(!CFUL25  R_*(M3 $$7, ,5  $)(%H
M8^<JW( I,^TF_G;9"K"RNMU UF[8^F5;1V]RQK5,N)QL?2WG!=R1#B00"QU>
M,V67/4,2A,+IU=-CWL)FUT -;, &F/4V+(,/1, QQ.(T)@(%;$ -2  ??#<.
M0  $1$!^1P 3;+4^YH$$V()_ [BY,H,>1$!MC_40!+AAU9,MW(!:;\/"U; ]
MV>H"URJC<675P>K.(NE ^@8W& (MN!I*&S'4,3(39WA+GS,4]ZY5G;!V"P$?
M+!,]S74VX($$U+(MS, /_#%V<@\J4(  ,$*#+<%]@T(L<L,Q;  $;, R5"$W
MY/]!!/P"T$R!!-0">#K%*$  '_C",AS#*$2 $E!WE_'!$JQX-#]OQM8DVA&W
M?(XY[,:.;U4V/N]-U5%DV;:XBT=D[I&-U$IQ%//8FP?##1RYC1)P-H!"! R
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M+88@W6B94?@ 9<2=9L'V @Q^<.+:AICX 9H B<+0N6?RN$ //688 C9H;L"
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MU4TA:P$B$J_V*I"5"'KP&T4$Z(<M/L;I!A&XP YRTI!C4!$W083&S9P!)PJ
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M)WBR*#7"5FR$_:92KMRMI[[/X;[1#R\-MW:*;( EM](I\G1I"3["_@)P%I(
M%<P"&O*@&D7B%(9  VP">$20^2J"":;@#INQ%Q6)&4"A%B>4#U2"(F_ 6UQF
M"FH  RX@"1@A&[DA&93@$)FT1ZMT+U/:31Z-4C,;#-=N,GWLR\'BRSU!+>A(
M0M>ZRA#Y#^=R-!LJL32=+%$"Z3&+(R$(ZQ2BCZ).9WT$8A3>8!D4HAGRX+BL
MDPEJ@ .(X!2ZTZN&  ?"Y0>"$RAD#2R>811J\0+FDABSP1:& !0N#(]4% -L
M(!'XCADR]/G&TR5EJGQDZSTYR,+2TW .#*D^,7K69Y(Z$S3_,Q4T7:L1".FR
M#J=NE%0'<2YNNJ(=D6/U4*$D!J-\&FH9[!!D0C6WEO0[>,2?+#$9BF&DS.1(
ME5(8D"$;S?,$#:0"5L$\"T:[''-5:'/\Y.]\B!(^;:7 3M/=IK(UP2)[@M*3
MV)$3Z6/6 K!#O80H!;3(^J]8N:)9G\=6EY =,<P-0X;).!$[EE.'F"$9DL$9
M[!$[1NN1GD$83)#G+FT;1H&+B,S]]J^&:@1:BVS,3F4U&99)<XM'NFI6A7!?
MEU1D5B5@X=4'N,I6V<W=LL<@$*$:[V^?I/($"R893# QM&<=MT.1)O9%D"$8
M?!->$<=>@R$ S0(F0!#6MK1=H>YC_UM38]G1;-1/7)<PM_2P$'B!'?)&4Z/6
M$3D52 T,:,VS*ZJ#RHJ*O?KB9;TVOIR!":[B4Q>B6I=T?19VWI2V"$T5YY25
MO62U*YYA"8+OPG;65)MTY^362\HP8P.P$F?M6RF"$/D5:^%U*RF$$^-"/.*+
M,.3VJ1R375N,^;P18X?23 X7.S2-M#*C&)BLP!@3G>(QJ;X$5R@7J1@3<[4'
M<G/M>936PE(36CD(;A<68C%W;@O&=;W1!=.'%#:@C^"5RT!"%YIG1\=O,*!'
M6<F&LP"W86@$E9R7RGIE=]D-&IYA"J*Q$K=RYP(48K<2E+C5GX;V9L'"&0PA
M%O!F$:66??]7K=46HC0O,2>7%M0,9OP. S*OM8;@Q 96@;-X#G*,%+?TT$F#
M,CLL@D<PUGP4=C7CD>=6Q"&.#1?$-4]LEUL!-+<N,T\T&#D^ES0/I\N(;MZ\
M=GW"=_Q^3IZJ%5QI4W,#4H6#EGAMX!?^,>%J-[<<SY0:*BRJ-6WA-355EVC-
MPF:!ED9( 0?8;'.'5VF1EY_\";K@-C49PH.M(RJ-]#%OM2D#<&CC*P3O=FZ_
MV!NY=9^\\2/QT?U(]5-CBT;<<]/LZUC$02&ZPB D<%^'LC=:.'<SPA1H8(9+
M6'ZS>"B73HQ_*X/9UF3! GV)I'T76=5<BW"Z>/UFS1YQ[E1?]H?_H:JKOE6<
MBJJ]^H@T3Q,NK7A9N=5L,'-5U.EZN?B"O9C):O>/UW$5_'<>\99\)1-KHTJ[
MV-AMUR+)O&36&/0/<S!@[RL$Z]A(*X9=NP20 ])K=82"PR(7I(*49,AU;=6&
M_UAXE>* IS)>(^EP$H=?>[5H]5#2I/EYX#('NP*ZY&]CM5':"D;:4E,CB<J4
M<RUZ;[5)C\5[;U?"3M &424I]U9:F<P73$'7E!5UEE4VXS._.+@3[4N,X_AB
MUY5MM2?@+A<C9F%$?OB/]9DHGR&@_^5N@9@;GV^%;<40=N'4&)FE5<N1W9:(
M+?%K'?:2QZ,8>%@)G_=5XG4=N4>%<XX4_Z%A-B\MJL0#2*MW7WTE)[4U'Q]S
MD#XM,C_ZA@<Y*)5V'++1?M/S5#8FE3>761<,,YD,20-,KU9%,P=Y:5V6JU\H
MJM8QJG=6D./"(&8SCMMZFZ>2E[]6?YNC?/ISM!858637K=UOAW69L ![7^]0
ME+-AG7^4:'<V*>%VGP:WJ8V4J9%W?#.BL1^36;O7F)EY'<LCA^=11=BQ.T-&
M&>ZOEX>9O3 ;C+&8RO3ZBIN:HVT986J8*(<YMI$J*2G6/S."YPQA%E:ZI8O[
MDC9O$<)XE>64R$3;(4IOM.>1JZTG78F6I_<I<@YZE<%"'/(6+K/CH!$:K>L8
MI,WB8YEAD)O#9?]QSC)W-Z"W5%@?VZ0K.XSGL;.9^%G]6(P?VXJE<D?B0I?U
MVSS7>6+WD["Z\Q*'VK&MN*LB6[--R6A==K1XF+!16;:7M6XJIC4=LZ>WE#3A
MU>@DKW:S4:CCD[\CU[L_6[:3%;?WE1UK.A\/6GB[V(O]29?73WQ-N;PWE^AZ
M<9;+=GUV<I2!5K YJSO=;[[+6G\A.+/INT,_F)RT\:"O8;/M&[[AE8-SRX-=
M%J5-#6J-&\S])DLTH1& NX>%URB;LJW1/!NX-BXL7%]#^[X##) )>\B_UJT/
M;R<TTKJM7,W-'"34J5IY.,>Y_,,;!EW_,,.1]G $EY"KM3M!N8Y7>1[_#Q?!
M7_EJ^7-.>7C2SQJ&[?O(N1D\HJRM9>V70>: /7U]''W-P]@O+AUM@U9PO]CH
M2KO1Q9@<0KW'_W&\6YNT*)RL\Y:C=WIXY?ISL^>Q#<Y6>!B5)="_[<N^7=Q4
MKQM4Y5?2NWF6^UR.2UBB43;)6+WB)+RU)7FIC=F?J?JGM;TU)=J8U0+]HDI.
M]_O$$V>S0]"WZD81PUS?]>:EK7S(E?M;S]VLQ?U^<XV;K[6V[[LB[M $[7I[
MLWV?[OH9[-&MBQ;"1UF=$)RP%VQP80RB][,9_'PY=EJ,36FGFV&'A_=:IWV8
M^7QW^Q:^J?IN=V1S7=ZZP838Y1JBZ5.F5UZY_]O5W4*>J*T6>=&6L(JA;J9;
MKY%76.,BY*O9R@$[PJ7>W9;2UYG#Q2.>SNW\QQ'^AP6WP(/VSN6=Z([\O1T]
M6J>]OMTZIO>[U2'>M?47K;G\Q17IW[O^90<9E%TVI&.>B;4][]G>R: !JR4<
MHOT+V>7^YEM3<$O/4DUM??==\C=)< C'SVFXXB49PFO:\,'Y8'.\TD&X@#/3
MOA%;[G]YA!F3=;]9YM64T+>4?N5S66\/RD\?AD&QFFL_[Y'H@3/BJL\Y/O5[
MD']Y<:]=Y 6?6[&'/>=Q-J6=[8O^TB10YMNUXB_VI@F]KB\V?D/;&]^;'8<Z
M;=E^1NS<MZY>?)__-/^)7^P#O\UK.\Y/.QM0_K&'7]-[^_AIGN;7>VD!WA(A
M$R"@"826C6"V@P(/*BR8<*"V@1 3%BQ(#EI%BQ*A/5,XD*''@1<A+C28;2/#
M@=Q"DJN(<)M!@B\[PCSH<B9)A! ?0M.F+>3$G]FV%8MX4J A6>SR]5O*M*G3
MIU"C2IU*M:K5JUBS+N67CUTI12=9$A3J<B%.@34+EHTY$9JSHAAG<H08$AJW
MCLO.PKV(D&%-F6U_0OLK\&XV;G?CHG5Y-_' M0TCKATYN++<N!<ATYQ;DUQ@
MRS7_MMT(C5G$TY@5E]R)-G!;D# 3,_29D>AGU7*S/0P=L:)8P4 )Q_4(-W+_
M6H6DQ=F%*)I@3XB.B:M%'59@79W+9=OL&Y3ZW+Z555J/_/!90IWD7#X\^&S;
MN*#%CK]LZ[(^Z]T@@4H\.?&NSO]T#8?:?@8]8QY/@=D78$0FF53289&A)I]:
M0CVDTV?@?30=:\49%M-8@ZT5DC-'O:.45BBFJ.**+*K(E5=@25B,7@NF!4TS
M'#XVHTPP=8331]J8-]Y%>354U$6_F5?<8XI9AA%#0BXGD#AUP6:D329=>>1I
MM\'%WT>1<?0:DY>-F9)()6%'5&O,699-705%B19T/6:CW)J4V=3C@$UNYV-'
MA,$9H6TB[>FDDUXV21A%WLW6VX!G 6;EE0I*IJ1P_ZP)^9"@2FKDC)Z4:JD1
M:SNA9^.:)!5&JD-<&IHJ3-K\E.6"<Z))T$:DV>HJ<]=ENI.&A>[YFH4"R<EF
M-O&]!ME )9[8XK/01BMM55U]M:59KQ6%K'0:T30?F&1>:>QI;XTY(*[<]2D9
M:L\0R^>C>(X:9;:[TB;0>CSJY5>$.#53'G^MNEJ>FJFA:O"]"$=TYY^0\O<,
M7WXJ)EY"I(';';(N50E8>6415VA1HK%7&Y_%U87KN[V!24Y[,^*X%ZB593RJ
MO),>*I-.YLW[X;J"#12EG(S6ZM%0&ED8Y,RUUDE=G08^*.5XJ E:$+$_@@@U
M@SZS"C!X>O9\('0N[7AQF/\1D8B4L].FK?;:6KTXBB(H42IVA)YQ.VK/S 4]
MWZA!LH=I@:%F_:"2S%37YFD5R1GEPN]&!\U0LO[X4:!&GH0C-.\!MO7(^WF\
M-X\-;1,EP5=/9A]A-;7KGZI-1NHDT4%6S#F\#+NLUI(VV\?1PT0K;>Z ?5\)
M$FU;WDO:N"@+/5_3\6[(H&Y1UJ6Q2 8>_3B!MXD5+$_&VWS1W-U%5%Z^D(:>
M33/,K_9N=X+V?3*P43]Z_F#<&S19[\(:1+2F3WMNW%XDXD52^,&V AKP@$QY
MT2D00;+D=20^"1.*[R2(LHD(24Y\^13N@O*S.)4L>1?\#_+4):%,+0EW>RI&
MXO*%-S3A *Q=/7+9H$"7M0LBS8'%.8D-'4BGQX#I<H7Z&_6R1$%)H4PG0 33
M[VYCO305JX+LRDC.G#2QI!7K2PD1HJ%6]D2-"%$X+.G4O<0"02@21(4[1-DV
MEC3%F6EC49&Q5T>.%\>EL>MX)1FA%GED0XP!"E&'6B'.WB6<N4&D$+%X!S\(
MB/_ 1CHR6ETY!=S*-QC\H?!G1>,A];H'M,VMKR3,>$;A"K>^8)'*/'(DVQT5
M-\+D!>EH=%S?]&862^'Q:9!/)-@)#X:=U;3REAL9I8-,.</3=*J-ID0AWZ8X
M2X#IZ7(&,B*_!N6T3I%.E>P:)!")&3 ;_O)@R-2DTJ88S8"Y4B-*&I<R/2(D
M]GS38)^)%3QWY3-RFK.4!FJC]0P%KJ4=)2F/#*A 4;2/:C4B>:[+9M;L2,^&
MC.Z&/&Q+,[)1N ?UTXI80Z=;'J?,6V82ACK+X;O**49N4N=X[SR7IE)ZSV+E
M#&?*G&6W3!)*4BK-I.TBYT5Y&$[\T;!A+MV9)I'941#_=O%W*%MI><:EQ5QI
M5)PB,4TF&TK(G)"OE%SJ(!2=^<1R4O*<780JUHQ5U $Y8Q"[,-% U\I6J;SH
M*V+E4\ZBR=(!H2^N],QG:2@:U[GNI*Y)/1A/:8G7KI*TL(<MK#'O5MC!C;*L
M<KT51(?Z,\!FE*26A0A=]=K8G&TPJ5Y%;%4U"5EQOK.T.Y0I0A5[FFLJ-K,?
M(U$L -K6VMJV6I-D[4(GVU>_XE6,![&I6#]%6(:.-$Z\'6H-2[O8A%%GCS1+
M+E2=X4W%4E28S&UN./OJ1M%V$;9'_5H#1UK=GP:6LU#-KF[7NUKVNO>]<27N
M= '!"T4RTK;X%2ANX9LS^;(6_[W>E:HF_5M#LYH6G>"%R#910^"!-#B- \YH
M>QUH(.JREAF/'25K%PR1!D=VM_^5[D:-2EJC.F-'8DWP>TDI8/BZ&#7,\' Q
MU8LR&<>UQ>(DL-EHF]\>-[*@['A;AR&2C#KH00YYR(,<]$ *8O#)Q@*1KXX'
M](LDZR(B^/L4E 7BBV1$N<.'2+*8]9 (GY8MQWPZ1!P8H>4OHX88P1#(,O20
M!U(,]\DVWC*4I1R1*B-9S$FN0QQ6D0T^GT887G;SB 7"##XT812E>>PJ )T'
M/1PB%_(5QI%3\>(O^U=.AE[T1K<,#5#$H1%F5C2RW&PLXOI7&'7(@RE$/>+0
M*GK40_\VJZO)I>C*AC77M"8(AK-!BB3+P11"8D:8*WWE*1?8/+_0PZ =S&O4
M%"/.-#./,U*AAR'<0 F%N'+93"/@9:AY%,Y.MV;;**3>K9K:Y](LTIS]+A*E
M%6T^SC?;]CN@8$@@  ((   " ' ._.+)!N9AFZ%A"@@$ -(.=(:'S3V$6S"X
M!@3/>,'%G7"!^)34I?E! 'R@91N;8@B)$(@P(@" /(QXU_4^<\P7+G&$:](4
M R#XP 4N< % _,F,X, J;$X,# " "6@BQ<"7#O (S(%HOV"Y'@Q,:I##.^+
M!O80 +"!1$?XUK2.>@ (L22KUQBQ%RQOJH$-RFSH0>=#\/+_,U81 8%#8.@C
M/>HIZLX(F?,I&8SPP:R1^0P^L%SG 9! *FH^$*GF+!D; , 0. R18AC:MS/C
M,$,8#W:Z%C?K9Y:R(6:+;WV;/EI +L4BOJR,T@@D&!4(0 7BP(0EQ#X <=CS
MS*L=$5,(  *. +OP3U.(Q!_<T]!(!L8CL(3::V   .  ,6 ^_- WGEPT"  1
MUDZT5L0^Y= 0AAR&8&<T4_ORU,<SKD'LZC8S(QAY8((3?N!P&C A#DW ^[E(
M$0$(Y&+]IP%Y1P<1ID$* 0 !-! '2U #_P8!>O IPJ" ?8<R,29SNN=A\F5F
M[<=#<1!]3L9YJ:9[HG8+_\8';H:!_R>X?FW&>1YW:WRV<,OP1)_R#!9V=2LH
M7^8Q;,R0!P<8 !?P"^;!" X' 1" "O$6@X2%"@,@  =%+J'&<!$@ ,A6&E&"
M"E'( 9:V!"RW 4,A7\AE&I 7 $LP*FO77$@(8<AG@3D32HPF)#$8)33W<@PV
M>FIU>G88+6^E""Q(7,&  0$P!,J 8:O@AQAP"^]G"\R0#+: B!1U"XLH#-=U
M"XB&80(Q#)(X2HZX"K:P#*34<!  "J['#+>@B:W':,EP"WF1#*1(4<G@!(FW
M"L+ : .1##80 !P@##%V"S=P@$-7.,[@B+9P#&_!B8J8#,R@#+9P"\9(;L&@
MC*9H"\G B?\W   WP(F%(PRVH(D5I0RD0(1Z< N-"(W#1E'9: O*<%T8=@N&
MB(RPR&A291IK"(^BU'A2E7Y2%8-(" W+,(^RN(&D$' ,Y'H"H8C:>%W)< @#
M  &D8(P#.8JK8(BLB $0P 2!2&[9, H'> @8I@RKP &_1VBB*(Z,!HR(F&')
M@ K0F W!$ RM]WXL*8JK@&W7E0WLR(@81F["H(FX2(\P>0NB-)/L:'%*$  U
MD&CU^'JKH(VAZ L^29"0J&$$F0S^)@"$\([ZZ#,U)9",9FCR16ZN9R"FD8^F
M07WP&&D:(8]FJ6V*YE]&"0UZ,  1T'^DD!=,  !$" &FP!"6J(G_7D9N3)D-
MV9@,IM!_B4!1PG") X&-L.@,-PD*$#  H" ,;U%3V< '!YB7--D$1&AGID$,
MY>@+PR8,,R"&G,B*BPB1-QE^HVB3.HB.R$6#*2AJ;RAGV9 7M7F3!Q&(<DA]
MKM8L]W6'P*DB7?$V&[A1O_!O%"E5=2D!JY ,/R !?* $$8 !T,@'&!"7/@ *
M>7$(%8 !^L<'$N #AG@(UPD!$7 #IF :#?=P!'$+>5 !$2 !0Y">I<$$$I '
MB7"=$L $FS@%$/![$< $S,.)Q(!Q11E*V4 (!VAG<\<$%3  %' #H'".Q"8!
M,T *21"7/S!K&#8$]WF3>2"?QBAR-Y ,_]F@:>49 4F0GJ80>^99B+? @'QP
M72<'GQ2PH<,V"A7@ Q@J 1%0 Z3PCFR(85-$;J*4;/#V*?@8@_#(AE1(B0#H
MB0STCJ3PG!%0 ?/)#.96=W#Y \9H"C_0?Q)0 QJ)84;'!!25@Q=)A*! DX7C
MF )0"-D0HQ)P" )A"_89E_MI"]=%"C,0ET, "AN  49H"X,*"DW@HQA0",NX
M#* 0IA(@ 4JP"A5E"R'ZHDU@<7?JH5>J!'Q:.,GPGA%P 7H@<EUG&J4(#?!W
MG?$YJ:8!"A+P Z1P _TW Z,P2JN0!.9)IG4WHZ;!5UHJBS7EI /1>HS'F'(V
MI$8J9UI)7+J)A/]#:I:S>91NL8$7%$JNV)T!H ?9D PS  'T=W>ED0A_2H1
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MB?/8PJ4AN[BVI,62!Q"  4P0 %Y*=_=IGIPV"O^) 52;>+; <$0XM%/0<
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M[==FMW![2V>7/W#$.UN4 F'+H^"(J)V7_\T,]3L#P<"8RZ".II $"6EGIG"
MHY -.RR\ZJ@'%6QQ(E>(%,6#%\"G;[?A:XMARM>#_SL' 1PP:_S\O<,&O7*J
MNS5=&F"+ <GPL$I@C4J@N+AX P-0 ^?HDK9 "DL@VE[,<H6ITQ P!4@\ '):
M.+;<IGU=?MTH &#QNEGIP@(9X\:Z<*$8K%!JWN9=K6UF@ &0")0HQ $@NA3%
M!Z+]S40X=!2E#(>Y"E,L $Z0?,V;LM P"K\GYL-VTSRL#"0( %.'8<.0DZ.
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M.%N*[ZCQPRJRI>AJ7N9EAMS%--A?)3?M!K[X ,%,H)X &&P-"9 $@X!#I A
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MJ ;5SK2%&4XI\%HNN8BA03I\28N7&5L._4$L/LG-AD@ \F KF%)K"$:9_6Y
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M^$&RXX,6W#_682YBF94"! \5_^$K6'N\M[@DQ/(N0T %PNBW+>1"2)JDS2#
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MM9-E6[Y7.R88@A!. !T$RI>*V>#+4],AA#*",8/<.&$5I"!=!5BAC$) ( +
M5&6OS%<[4S##%)4:Q2LE ( F,"/_%;FT5+6:(( *5(L1CU$"*4A1A.F,0AFW
M6%VR%#&;)3@.D#>S#7)DM)B2*2@L_EH&Y99(PHE&A"&+I%R/.)I'QLD-1F',
M61"?4U*2^@>.)0,<"4O*&K\M#HD=)8I#*N= .)II9C-J2&!L:J<Y NP\E=-/
MU60H1$+(@AU HB)4HRI5F= $:D?<*"*#B*6K-&0UC>OB'3$WE[!)1'!,>EP>
M&3,XH6C,;09RBI^T>B*<;N:.DTQ*1;.60HIQ3(Q)O)$>;PI6Y\AU;O;9(^;&
MJ,4NADUCH"'3X:;FF,U1B1A,R T[E0&L #BA-ZL '3:)(9IAM$*A\SS+$ #P
M V$XPQ33_]$#,( !K &4SW/\;!YP:N,7Y0$G  "0WP"64"\G#$ "J$!(*S8
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MMQP6UN\;CT8\A&OO:(<9HI3 +;#W;8BXUE'*,,1T4LG=ZH#BV:0 '0:<0*D
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MUZB0$P1<P P4CP\0'B%$:%02PUKNWKLTP?3D1AX D#Q9VUVJ%BQRR2=&'9D
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M!%(4'):@!U@T$1)!WA[0!6JA1J<U7_5U7_FU7_WU7P'V1@T)%[J@"JH "[*
M-K\@$" A*]W@P3 A'YJA$$[A'LI!H494JK KLWZ@&[PA"0XP"$;!.&/Q!5H@
M%!@K8%5V95FV95WV96'666-S$;+@8$WU"P8!$B!!$.J1"[J *I/R [X %^YA
M%QKJH1@J.*]J";#A&W[@ 5_4"8C5!5Q "KHJ9K$V:[5V:[FV:[U6)<Z!#;2
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M "6\(09,NY_Q !/FP09L0 F<6P:X&+O[@+I70A8J8 ?P8 =N0 -DH1]Z(09
MC%GX@ )V8 KP( 9NH-[_3D(?\""^3P(9*D&KZP&\H5L)-  /ZEHDRH$'#-LD
M2J$"\."X-WL#VA*T=R &F,"Y8T# W4$),MPD]J /6L(=^H"MO4$)(APE\N&]
M(UP6-B"M3T@6,.&"K%NK5R(6GGL'=L"PF[N]^X"[\J$4=H"ZO6$'>$ /;D#
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'\@H2 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex-99d3g009.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g009.gif
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M]?[^_LS,S            "'_"TY%5%-#05!%,BXP P$!   A^00!  #\ "P
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M,EEED4_^P$.32&ZY989;3NGECU^*^>,/,V0H YIIRM#F#VZ^.<,,0,PI@PQ
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M]B^%X<M?!S,8OQ;&Q"8L;#,?B]C!C" Q)T:,,Y2A(F>BR#&6=9%E- OC:(Q
MA96)$3<T2]G-UKBRZMS,:#\+6=&.)L>AT5%I1T.:&YFF1SX6#6M60QK6N).U
MJ1GRD ::6M;\@\@"G8UMCSS;VB89-KK%K6Z8K!O?^.:WNY6@DX!+W-\(U[;(
MF9)QJD,<Y50IN<MYJ)6M]!SG4"?+S[%.=+*[G8IJ=SG4C4YWMI/=#W27N],1
M$W>[2^;PCND[$A!OF,[T'?60ESSH)6]\TINF-GT0/FW*@)L\^),W_W0^+5&/
MG.@\GSK1!ZCYN?-0[F14_0)(S_L5JB/X R !.17_!00ZZE.8*B! ^><J3TWP
M5*J:H$)M54&&.FM8OP*AL(#EK*Z T(0F#*$*H\51:VFKA2\<2PR[9:X9ZO!<
M0C3IM718TG*MBPHW9*F^]'4%']*KAP5#6$V9.%,D\M2)$_-IQ:Q81BHR;(NB
MH4(4-W;%*VHLC$Q]F6C,2%4V6G6-<WRC'+=ZQZTB;6-(@QD>BS8T/_YQD'\,
MI"+7BLBS(O*MCG1D?2+Y2+&9S9)UK60FZ<9)OI*2DZ'\V]O^VCA5"HB5,% E
MXS+GH%/&$I:;JZ7G?@DYRMK2<KJ473%_2<S.'A-WR$2F9W'7N]Q53WC"BQYJ
M0<O::R;OM$[B00^:ETUS_S9O>=@#YSG7=,YPN@E.ZIS>.LN7ON$*JIWQDQ\\
MX]D_1S6*?N[K)_\*91(L1,&Z /441 B*4.X"=+O='6BL'C+0!DIPH>B-:*^,
MTM /&B58Q4+">YW%K!/:URK/RM8*L3*MD*[0ORN5X4II6 4JK%2'W!(PN0@6
MKRK0RUX#ZY=>YO7#?"W1POG:J4YYRN&)0;$)(_O8Q9@:Q1&#+*I/A:(7-Y;B
MD*71JB^V:LSH2.,X=C6..K/C''=L5J(E+8]^!*0@!RFU0B;RK8><JR0-.=>L
ML0UL(8!DVV#PMKA=\JY2WJO?,+E)30Y6E6-CI9C'O$K&5LZQF(MLY"1;2UK:
MDO]VEOW=[&;GV3I[%IK-1&TS@U?:9!)/2:^-;35G&[WHS2":J9TF-Y/W3>S)
MMM&[W5XX)WTGWYZON.G3WG#/=]P]+011\%PNJ.5G3_O1T[J/2O4]!PC YQ9P
MGPL,Z#X?&-#OUMK6H4+5K78]P886ZUG _B"P@)5!]DHEH_5%5D6G<I.-[A=:
M_/TO@&,HKI:VM,#O@J&\UO5#!]>070Y>XKKT]:XD:E@O#TYBA]?]Q'Q5\6-:
MA#>(5<PR$D.QC%/5&!/*Z$4Q;HS%8KRJP&&F51KSK,9>W7',C)9'(/>XK'Q4
M9-8F+O%$&CD$2H[R(>$VM4H:$I)YE2N6]:IE+VNRRX+_W=LH ;?R4))YS:8,
M'>+.C-G,89;-E[4LZW:^.%H64[3&W#EE[:P[T=8YM*85;37YO#O0!@_0QU.M
M,Z?I:&NJEIO?S'JAJ[>\W4Y3TML#KJ4MO6D9$&&X@ I4<M?.7/BY75&MMI_^
M!#I _)7*@+3"NZ>Z6RF"%C!5M#IO0A5Z7ESY>H(/52\)D5)L^A;+@_CE+U+\
M:]^LY#?:TPYI2;O%+7&=RZ39-NE)RZ4O!Y_4AT@ 5X17GR^8'BPL3,PIPN)E
M13("U6$2T^(5Y6VQ>>^>BF/\F(LYQD71I/'X-V/Q&I5OU9ZM#(Y& \[+?NSC
M&O^L:$;XL<-[G-:FD76M1I[:_WV2C!^-(_EL4:YD^L-6'X_7K>,D+WDF4;[7
MQH9R<&!N><Q9N=C0T3RR 'AS;=9S0L=S!$@"RV-,FB5TP$1TS)1GQ$0]N4-:
M$UA:Q:,DU:-:IW5UQQ-;VJ1H7;=HW ,]W),]UC--<#)IPM5-E@9<X.,FZB0H
MZS0GQQ4#U)4HH<9VI&9J$61J^%,_I59WCW)/W*5/="=K#&10"E1K$C1XN59X
MZ.5K%71XO\9>ZP5YO.)X\K4LRK)XP)91TM9?'A6&+S1#V-(MX*)M-;0M)=5@
M-:0NWF9@.@0P!4,P=M$O./4O"!-A/L5N/\4P1R!B\R9O_V8Q'!,Q+*-43A4R
M&U-4B?\(<&"T,BBV,VPT8P.'53;F59K(8S[6B9RX?1$G9!4W<>'75AV'<3#0
M<6<S5R>@<>IW'U)&2?$WBR67-UO6.)_4-W\E6"[W<H4E.&?F.&@F<V?F?P&(
M<VYV@+S4.C!0.[[$@ U8 B)P=,V43*!5=*+U=(@66J@E=4WG3-7D@5,W/!JX
M=8OV3=+C:%27/>PX:=E33C-8=G$R@YTV X?R:<QUC_,3A/,$7<\UA/UD4*FF
M:GNW78#770H4*JER*JTB*GWG0+R67NO%4%<8453X4!/U4!4%;(Y'7\*R0OE5
M42=T+,9R+"/D+2>4>9GW+O;R>6LH>M_64JYW>MR&>D04+S#_%43J-GOKME-
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M((,MY'B(%+\@NH\G0XJ]#/)4>,$%*O J6.\HY^"^T1R'V/+G0]_V?/ AQ8)
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M+#L:JZNJ+G.H-+?BK4K<JMI+1/M2KN;R(QPC@SK K]T2K]6ZJCD@ ]T2A$2
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MNP2;K%_ KSH0*7SPRZQRL?*D1EMX+5TL2LNJM>?*JD0X- [3LQ4PA%1@UD.
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MIV3!@274?$#&"+,YG L#3OM:4=M!O#I2QKRSXQJX?7RK+K"Y[-0J:MTJ%T/
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MY!$>"V[;R?G)7LS00!#;+YS;%+7 KEF,PI62&&$7E]2&(1S,+N%#*NP,3J@
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M!$$PXR,.2T,<TU&0SC3:CPHX7&G<305,HY_,#"Z"2^00SCX8P_.L@!? GM/
M0$VL'"A6BB9N2DGL2SJNC1BJ@">M"',DR#X^VP\.Q!W6#IXXRN#(T3ZTC@JX
M !E0GBVJ0.'D XD<R/GUQ!R,2EZX31C4(DXLW,I-CQR8'XMX 3D5 [C_3,\7
ML$<+'%PJ[B2<B=L*W$)&I ]1G)PGX4-NM$CP?9RU?,%4Z* NBLN;B$II_$T7
MI()-580]&LHA9 .UT,>5D&-L2!P\ &(M28<FJL 'SD,4AB))I(JA),)!31._
M/$A63@\QU(/KL43A@.5>D ,^9 -]*(=1:N5!!<.YA4&Y[$P7)()-=466@-H\
MX,,W4-/C?!QCL !K$<85(M(K<H@SS111[%4I#E5-5:.I4<4O)B!L,<P*>-+
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ML(#($I^UQ%)E!$,BR$%M3EN\%4/D3&&<G,7_?,$<=.N;^&FT+BV9 8TG?0/
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MB#('YQB&9#"(+VD*<,4<U?_5HY^TZAVUQOHP:F40IX8F L'JQ+^>DD>$S/Q
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MNN0%N8K!08B U5C* 8ZMX"^852)(QT17N@]WDT O^/8UF6_!MPIVA4T!RT,
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M7"D:QFYKP*N5_S 05H]IE:ZKP7>\/A9Q!L/IS>AB)H3C.1UD>L@"EQU5%MR
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M,"JM*\E,1V )0<OJ0=VB3LOD@:WT[9>T;![,X:04;50N**MLAK<>@F-!-XI
MEBB[=.<PDS?_B2*[=&B8%V3SP>; ;6<4I,@8%',3)M&*!0\&54!7PDU^%2^N
M<VDT Y[6)BR.06("#:;J87$#[P\OPM2<&"8_YAT09H%]N1Q+:(X%+26*S3'V
M3--NIL;X)[TXC)@0-C5-S,FL",..9W?"V5TX+W*,P3O-=5,*T3&(#B'43N".
MX2(ZV3E:\IV)R9%HR&N<MVH2IM[(3Z$=CACX+;=0%'2/JS I!<Q@2M].]W?9
MQZ+_#BSZ$H^)64/@!"CZ^)C_8R6EC,JHZ $?Y@%WCVE']:LAUDJAF^^[1E6N
M%$:VE&TI<R9H%L99"*$8SED?Z*$;]*E]IDH?WH' I.<.B,'T$M&PQE:YUJY4
M:EK4)(P>KMJLLDKXLKKA!HN9A.&<_<=I[L'!2NY@QB%:2,O0EL>F< :H+JRP
MA+9$1RTS'^*!JI-HL9,6?-IV<)I]=E<?&NP80$NT%F&O3O48&N[VV$<8\$VU
MV(FKHV_(B&J ;G,SU^<A$NS?0$L8CFFMNPXBS6$6SDH>0B;UY &3G514N>N:
MZ\%"-0)YB4IE!LPOLXX&-\7-6#H?Z &3BR'S6$*\KGG S@@A&('#P,&+ $QE
M&LY"_TVBI^0!(^-J,PT[Q8B,OGZJO"A29:*OMZB:?0+,<A6B%M[!8,AK9>/-
MO_2HO+US%DPG>^4D3-Q7B5 Z8 S%#XR)$+(HBZ+QB[*H4&+I5]A1I_0 @()/
M;*(E^#(+]9[GD(0GH32/B[R(15*)4OU[(OS OY4&H3"IEXYKPY_"FL3)D,3I
MD7I)(?CI_P8!!0F(G)8I</R[GFK\?@YU))_$* :#OY^T638"C"RJPXWKCK*H
M@U"/$)*[(X#)H@('BZ+*OX^)6>SUBF[%P"T"C&1I5+:)7CI<R7.NEU"/7@QG
MN]I1RXD[(X#IH7:IE;#R7_P[SK/H9##U7_CI(;!HG4J66?\H_,$V',6[J%"J
MT/\:7)#8I\9-XLOI/,XO8LV-ZRB/_" 87=(G/$Q&)2UTX]+/Y83J'#$Z?9QF
M[.*J0H<8Z"DPE911HE#DHE18_:D-A6<,%X9D/=-T"D>]9P5_&4>?&C@-A:_]
M6CH2Z">%_7M*781B9E1B]R!P'7O0)PK[<^;F:!=W>-9EX@Z6/4?3PGOL0R0@
M[8/FIWO>B-?5(LC"&8>XQU/,I]5Y?8? /=DE;=C;(M.KASQT?)QX5-39PR0Z
MO=X/Z%DF8R0T@CK])7]^?4" HN#* 4E'5GM39620@C;(KZWCHH<>_ESXW0 !
M12\T?5-XC%\S!=[CI*08J'X*WC;_-OX\WA>EM<I 9(0VR/W-\>+B!>/D3:,R
MAL0R#R7F1WK5%4+D0=XZ'$C6$G6825H/&(%X$F\6]#Q12*96B+X+97Z.]C6E
M04/'<0.DS+-4LF)?P@0S%D5%5*7DF3V//PBRVJ(AQ=Z.^P)@OD,!Y4*$GG[4
MSSWN 8,. [C@F>)$HKXS]M[?2V,3Z9[ONW4SC*7C8^4O>J/O>R9V%7\R5K&O
MH3[M)1]_ZEO77X/MB\/MJX/F,WX](NTOW'WRL=/R=3[J.5_T?R3T1>CK8</P
M]5N8&S_'@AWJJ;-G;HQ*\%68-R5(8C\P>C]'3I\A(.TS G_M[[W';D3'_/KS
M41\VJ@?T/9'=,W[?+XI_[LXE4:8?,##?.++_^J&?(X(_C[M_]!_>3896\&&7
M0A)C[_OEXM5B_-M"]5^#-H $_D/CTZO_8_M5 ].47_8! H\>/ 0+&CR(<"#"
MA0;UW&&(Y\Y#AQ+O*#3XL.##C! /6G38D6#%BR$IDH3(T:/#DPDE,@1I<-$^
M62E#VF0X4F/(FC=[VK1HT:=0H3R'LNQILB/,H0(_,MUY\"C.H4512GU*5<]2
MC *O9JV*$>S3H#Y=1C5[%JG8B!^+KL4*MZ,?>?OJVKV+%V^MB!3A5J2ZL6-&
MLV@'3Q0)U&7@B(Q7UDPY&#'A@8$'][U9<?'&QQXW<^2Y62?AFHOTT:2Z$"U;
M@EH)3WWK5S)7Q; [BPZ+LS)CU#JYKM8(%.1BW&R%$P>=N79JPTLU0^:\FW-D
MU<=_Q^WM$:'G_\_ J2OUC)CBX\]MR;\F+AZQ;X&K+ZL7R;BP];#3Q_\-2WEW
M3^K0;T.>C]!<>0TX(#!]^('@@7T<F"""#C+HAX(1)@BA@Q,RN&"#&#YH(805
M6GCAA"!R..*'&8)H(HHDKC@BAQ*JR"*+%<[8HH8B=O@@(_G04N.#'\8(HAX]
M_JBBA"=2J&"&)A)YHX\N-F@CA20R:62$3$Y9I9$T-AECDE#"6&*80&[9HY1E
MGOFDF%QR^:*:-6+XXH9B>H@DF$/&V>:-7JY9XH)7%NGFGCCV^::*@WR)YI!V
M!BHEG7!>^&>:BBK9X2#U$(BI7?68PZDY\G0*:JBB<GH.J:.>,TZIY_^4:HZJ
MK;[**JBKIMKJK*O:>FNNJ.JZZZJFCNIII[FFJBNQJO8JJZC$FJJJL;[RNNRK
MPM8*K+"[RG/KI\?2&JRG^\Q3;;B@OH,KM+;6>FNTQ[;J;+J\^HINK)UJ.^RM
ML+HJ+ZCR[&MMO+N:0VZ]_K:[+JG/FN,LM>&Z"V^NH*IKL+.IMDLKJZY*F^\Y
MGX:Z,:?C]/NKM,#&VO"Z\!K<ZCP?V\MPO-RR#*O(RE[\K+&T[LNKOC'+/#+(
M]J);\;LV'VMQJ/6RS##1)+.Z<J_U\NLPRB.7>W2QYG*Z,<U&R\JJ/!\#BVW5
M[,*<+Z?Z9)JI/O2L34\]]]SC=CWTP,UVW??_U,UV/';CS;<[]^##]MUVRRUX
MVW07#OC<]M0C-]Z""][XW)'38P_=?%^.MSV8SUWXYG-?WGGGH,-]...6UVVZ
MX87'?8_F<=.#SS[XO#TXW(FO[?;:I4<N.M^5>UZXY;WCKKOG]*A-?/' ATYX
M[+?7_?OFM$\^..RXDVX]W\-OKC?PF,O=O>-X)[[]Y=T[OSKTH->-O/2.,QXX
M]LE_KOW:S]-OO.ZASZ]\W?%HOK9\[ -_;&L<[?*'N>%UKGV8 Z#[ZN<Y!F8O
M<)>3X#S.1C[F5:]M%%Q>W%[70<-1KWR^\]P'29<[M]T/;Y="&Z;>X0UP@,,;
M-*PA#6<8PQOB$(<V_Y1A#&<HPR#Z,(=#M*$1CXA$(_+PATQ,H@Y_N,0C"C&(
M2BPB%9]812#Z,(HWA"(0NRC%)&H1BS7<H1''L0]S.!&)7%2B%\F8PQX*L8EQ
MG.(.>6C%.7;QBW,THQ/!@<9QL-&+5&QC&'7(Q2TF\HV,C.(4"1E'1.I1CGRT
MHAN]@48U0I&2?'2C'NW(QB^^T8Z@+*,?FSA$4BX1CW<4)10#R40\2I*5/8SE
M(QFYQT*V,957U*46%5G&0P[2E$$\ASXT641BMI*7MQRC)V6I3&]@PY*1A*,P
M%VE+*@K0A0.2!Q8+B4I=1K./?BPE&!&Y1S R,Y? #*4YB6C*:>:1G.V<Y?\F
MGPE.(BJ2E;^,Y"FM2<- NE*.=3PG.L?8RTWR,YN_W.(3]]G*;Q(2H@.EH3GV
MP8Y@JO.3JHQE-C7:2#+ZLI^BI.@J)QK*'%*#F;[$Y#X$Z="2*C2+)@5G/]$Y
M47$&LY?M;&@^8WI0.\)2G#REYQ6#BE.-IE*2]T2H/BU)RFIV<I39=,<^RI%4
MIL*3IP_]Z5,-JLJ14C2,2\5G)<'!30+!,*([!64R';I1J1[5GR>=9$R7:==9
MWG*GG&2G,_?IUTE*=*3WW.A-=TE'&Z(QHXDUY587V<FQRO*14?5H.@N;2Z8N
M$Y=Q'&ID47I7,XH5KI#T:%B]2DPX(E2P(JWL407_*MK8SC6<KJ1L:LM9TKW>
MEIS1).MJNRK#<[S4L:9=:EDK2]5!\M*6A5TE8->91]#RUAO&%&1C2TM<GQ(4
MN 9E*$OUBEC6*I27XSA;6O'R#M$RMY8<36@EGTI%>8[WCJC\JDP["M5/TE&[
M\\3K7DD*UZEZ=[7.A.<H@SA-Q;Z4LD[]ZT,-3-]23M:R^DTM9O4)80P_EX<7
MA6F&:9E9VSKVN.P]:V#[>%F;ME? .>7M%S,9TO;R5::0!&HZU8O7;WY7JIP$
M9E'W"$ONEMBHQO5G+0U\2;>^=:OC;>I<"UQ%;[!CN#'$AEZCO-ES$AG' %:R
M=Q]<8&CB%I/F/:]=TKO;_YP6-*JD#2I$;QQB^#JRQ2 .*TC9[&.6+O? X$CP
M@34LT@]3&*4US*0\40Q4"8?3R/0<<2(K6E^RAGC,.78I3)?[ST5/]\EW5BJ@
M&PIF!V]6Q,ID;3\7J\XUE[6.+=7L23&<V&;J6,E%M/*?61U1&0;YL/^==3XE
M&NI.V[:V?&4OH=],4!R^@\IZ)BVOF3QJ@,YWV)66+Y@US61OQ,[,9R9PD8\*
MQ$/#N:VHW$:C'PS:#^,WPH#5M#EI?.A6&W:@8M8N76O,ZN2ZU!RAC2N!C9Q5
MY$(SI'*U\9'OR]R>!G3!;:9OFJOI6R0GM<Z_%'>^[VW2QMH9N[NN;ZXO:>R>
MVO_8X=Y^MF9O?-HDO[?C'\UQ0BE,\F$Z$L%/MBEM9QCO%>_2A\LN]:^/G.J!
M6IO>:[YASHE:\W&?]=LRY/9=8)CJ)@^\M._%LJ/M>=A/=_'HD&TJT%T;< 3+
MU>=P_BV[]QQK-1<:H]?&<7$?^UX[6IGI682X$+'!C61JW=W3EO)P.;UDX/Y5
MS&Y<:;*Q/&Q!=QG%-.U&A<V(ZB;WG9W[G3R-R]G5;/,PWHQVK8]/OFQQ(%7K
MS0XZN@MJ9*YS=J:X=2M#HYS##H/7N+G5<G,;F6O_NGCQ!L\PRF/H=+MX<\,J
MIO/& :QFI!L\P*>U.>/Y[&74CS;/TT^QBF4;[.,O7)/_P)XJ5UE/_98V7_/X
MO?6J)UQ8S\;VL=".NX8Q+?[<^E3[<<_]@.T*6''\W>NX'C*^N2QP)J9J825?
M 29D,\920[5=@:93,==^$M9LX;=H2@59..=B;R1<HK=W]"9^H\1Y68=[7^5J
M_\==SB5%P5<7C$5-E!>!C?9;TE5IM/=6<D=]$PAAQ[=T_N5O\\=?I:8-VP!K
M; 9>"39$0?9P=.=D9^=Y'35M/(A3#&94)V=15)9<^<5_4\=^JU9L.;AN#4A5
M)%=^!^52PV=AS;1GW@> .>=I_<>#>$9U#N9NOR1[%36#\+5>L"9GBC9^M(:&
M<^9<L^5'=*&!\B=%W_=3>WB&"D7E;*$E8IAV74#_M&U.YTT?A7HZ9GS1A6NT
MIE79U7R;QE!S5U/(=7%N^'Y>=EPT-E_HIGV1-V*#=7/@MT4%F'M39'%GYV=0
M>&L4>&]^-PY$=6*N%F&C:'^7MTEJJ'9P1U-;1DUPM6NU58-EF&<G]G-?YU27
M^%F>IU5"Q6SL5HC AGB\-W]-6&K=QV*SEU\\-&4:F&YVUVZMAHO%9V]QQH1+
M!T7: &DWA(+[L%8F^&]-.(^%=7375G2JV&*XUX;*2(?KMWOW!X?ZAH";2&=@
MA$:3*(^55W;2!XX^%UDI)W+O-VD;R4.PM8RMAW39]H2DII &Z8O1UI$,N7B6
MEEV3-EB&6%Q"Z'"P:(T)_W=*IWAS1FB)X-:!^%=PCU=R.,1U9LB!]Y=2@CB3
M2$92(1B.($EUL"=JSC>+$$=$^4B1-Z8-6G:0X^>2;8B  8EG.QF1+GE9=@AN
M*&=GC%=QIFB3/0B3ELA_R<:/;.F"6X9O:NF$;NE_E@:%H!:5<,A5,EA_N]>6
M#/:(H8AH0*5_ET9P,:9[D99R.NEZ\5>8QB=U;R90X)6)ZX5H:]B"X39J@FF
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MS"?\"01@_C6D"_@_LY( $ ,(4+CTR $ "=B\P2+0$$($"A0"4/!6T1L: !3
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M@*PFK.[<;!$0X))Q=#$ @8T!-90 7<1Q[2:H/T$@H:5?<R;2BQ#:\C==$AA
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M10+X*:NPF&Z8%%[P)VQP#;CZB)\0Q?BIHJ*@"*N(')L(%ZNSK\PJ )>P-\7
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M V0 ![CE&LS7?C+ )*073C) #7!#?L6#4+JE&]C7;A;H@5)"6U+"/;A#$'"
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MCW=[ Y[XKG=X^SBH6WDPEB^HEV\)3P-)<X(F.()UBWE*G[4*L/(DTY>(FRZ
M:7:K_7MY?BV'6V&$@=DDQ=1 !W3"T]* 09D_*WS#2SR!(11"!_1 ,=8_._S#
M\Y7#.WQ!'S1!6SQ@[1?YDC [N ,[D/#)C[+*J[S)GWP[O/S,C_(HP[S-D[#-
MH_S*_YL\SJ]\S?.\R\O\SP?]R>\\T?-\SM^\TC/]RJN\S:<\^<JEQ8/\<&G\
M0&T\UD]\U5,]/H^\;EW\Q&?]/A>TQ_,SXW8]=?WS/Q>IT0,],<:\T#?]T,O\
MT<]]TB/]RR=]U,\\R[/#T:.\T'/#NX,"@L][F(^V!3#X.],YFB\706)[/*\T
M)Q?=?*<@,2[<+R;W!&J^*$_^G0GB3]'2?$L],3Y].W!ZZ4/]WV.[ZL,]^:+\
MZ]?\[+=^[$<^[$=^N^,^W&-[[+N^Z[?\**,#.J0#-PP_\9MQ-1C_\2]_&2N_
M.B!_&9=Q.E0#]"]_.F#_\6O_\&=_.FR_]F._]Q/_\'-#\O]S _5C__ECOQFK
M/SJT__%7P_;'/_G//_>//_%[?_:;,?6KP^P#1#MW PFV8T<0H<"#" LJ+(AP
M83N!#QD:9%A1X<*!$Q-F'*@QGCN.!356=*<N7;5TZ-!Q6UD-G<J5W*K5="G3
M9;J4U7*VU,F2)4R@+8<*!:H3*<R:/%7*3#DT9K5ITD*!VA0)DID**K9RK;"U
M@@5!Z^S=,WL6;=I\^]BV=?L6;ERY<^G6M7L7;]ZZ^M*>9><F1^# 0R9I.QMO
MTAIV?=.N2X.)<62TX:*9U1:DE>2^S'2X68SVU)#*FDF7-FU:'3-Z][@-,<78
M76)WIVF7UO=6GSYZ[5#6G$8->/":X+]_"P=>37CQXL:!+V=.S?EPZ<FC-X=^
M/3EVYM&;*?/^W7MW9<VD20/?73QX]<O4GY\6?EJR\.[EM_^>7ME[^_/WW]>?
M7[W_VL/OO.>TR\XZZIXC[L#KJDO0..6>0VZZ!Z?AYK=F&MSPP S[&P_$[P0<
M\$/X1 Q0/0+YVZ^9_Y*IBI--((E$AZY4\.JKK\1:A[;;]/H1R""%'/\R2'W*
MZHN=&S+888@@<+ A@QI>,2N>-&[X+*TC6?,@C=K,XJ8SLZ+QX+6S[-&RKU<>
M>, 4+?%Q(X-E2HN',309H]/+R-@98HVRHME@DKY":A++OK3$DS0[S43+Q[;X
M<@>=J91A18Q*WZ@4TTPQO5333C?U%%,R0 65TU%+%4/445,=-5,H,(6!TS=@
ML!16&&H]U=5.<ZT45C%F]?576RM%@==+?_7UU6(UW7549GOE]5=9;WV66EG?
M8!;37%=E]5-63]VV4W"Y]?14;LO--(QQU7UVUV>S'=?94FT-P=<WI+565C%"
M.+929K$M%@9Z84#!"2A .!@$#&S$T0(+=!S_ZS0B)9Z8XHKMRD=/'&K@QIZ!
MUCF% P^HH2<>;K1!]!Z^[L'G+&ZXK/,LOE2VC ,W'J6FT)4E4_,!#T8SRPT-
MEIDYY3R+-JLLEOLB6K+<T')Y"'STH8:#0&?&ATZ3TV)ZSLA01LN>1MG*QQYU
MXD,F%$M6R)'MKW!L^^VVY69;!0OBGAMOL/+6>V^W^Z8;1Z[NKF!MME/(\?"Y
M;]RJ<!58R''M&R67''+!*?\;[L GOW$%KSC/T7/+%\:<]-)+']QTOC%/@776
M4W=;<-!C?QUNOS=7H?,;65^A=<ZYZKPKTC]?&_C@0U_<X;#":AABI)NV&/KH
MI?]1-\;8P8&&=59;_^T>3!Z8Q,]H$.7FE5-6889.?5Q.8YU7SI\-+6U86847
M'N]AAQ4.AF!F'7:8X>8L[K!&*UBQ#/BAY14:T,$&AH"E23Q 3F5A!R]6T8J1
M48D9/[L'-<1W#VWP+Q:M .#]*/@*PR#M?^IPGP'1(L!6K((5%W3'*SB@@_K]
MB1+KV,4J=K&8,T4C&EJ*QOR8X0ZB?8U*1A/;/O3A#FY0!12=F,3R[':[MUD1
MBUFTG!9O!S@N<G%A7Q3C&+,81BN"I75I5*/KR+BX+X*EC6^,XQ7G6,?)J<Z.
M93QC'N<81C/>;HURTR,?P:@"0;!#46J9WB(9V4@F9HP&ZDB+RW! EB%4\O\>
M\3B%!SBY 0XH9DLVR$$'.+"!-8S0':;P  =(&83*,,,#&=B !S+8@3*Y@Q*D
M7"7[&*4F4SRP3/J81 :8D3)K+'"59**3.G P!#RY8P@YT-XD;+ &#3P ,KS(
M0<A"=HK9K.,&0]A!)X<PPG6XH0.=], I[F$-&SQ@EK&@!@-'N8$-I($;^(!F
M#A:#2U*2$I^1223,&".VW+"C&LH(12<X 8F&A65SP8-C(>](R,5-=(MNQ.(?
M(_I&&_G1HA>UXAH#V3L^PBZB*-4B2"UJ.XU2KHY^_*-+3VI'C&8TI"]]Z58"
M*3N8UK2C6A0+(L&V-4<>%:D2XYI9KE<#^P5PE-K_L$<0;, C7FP@"/];QA >
M\ KU>> !^Z/& \%W#U9H8'_R\X .^O<*!D;#?QJPA%E,\8 U_,\2&0A4S-1T
M"F[8H /%O$?0F*$/=8QR%1],PP9:@8]UU,"997%'$)QJ#S<\H :FR$0TM$$#
M#[1"&[S8@08RLPX;+&!_W,"$*<WR0$I0@WR<Y(8[>-&!'<"5&AUX !N6$8TU
M,. U]M"!#19SB@RDX7^8R( ;C*89/!E4'PA-1A0UP0:'.<RFA.1H=G-J1KWE
M=(PD7:,*#D=1\()WN^<5G7K3V\:9[C&H.K4H"R27Q@HD#JC:7=XA!WJ/I/X7
MP'FI'I)PX($1FFD('+#&_U2SIX]7I"$:N7$PF[ZZ,7W@@QTZZ  WDE15"9LB
M ZW0AS9JQA=FR%4?IKV!)._ACC50HE!JRH2#,]! ?<")%_I8Q0-.(6%UB-(=
MCPW",ZG*HTDP !,JH\0#6"$S:G@ !T&V@0>TP1=[I($#AC&%8F0VB0T4<WU\
MF:<T<T.U+MDC!\0-QY/"\:@U3.* S64,/<26#WVTHQK3Y41UDU=%^'I7O3\-
M=!U3,#N5GA'0./VB>-.HNT*+=*-]E._QSMM>,%K:O9-FJ1LQO=*,/MK30>TT
M3'FJ1I\.>J8?75X%#IFEF 48UK'&3<9JP&($;X :PJWJ6=9!#5Z$!IOJZT"7
MSO_B/5Y0[0:L:,6R*:&!24RM \R]QXF3_*>]FF4V[JC'61+88\MF #)!DQ,;
M,D ) BX;!UEFAPUT\,SA\NBRNV"9/89@8+.L)@T=H,9CAZ"E4SP@,RUF1S1B
MD0D;?'E+7=+'G]APEG! ML5I'O@G6QCG1*4%B8S"C3OR#(H]6_>Z\:WHH'\Z
M:C$F6HRL$_D83;XY\4J:NYHCN?$JW5V2+]JD,;7I?=48Z96C6J*":$>=EBAK
MHR-UJ?<K\%/-8EH#QV,(V6OQ*6Y 2AO<(-@NN_8]_MT*9GC2 S3P+"<#I8T.
MK,'$<KW',O1:)WO0N:]\^2L'F#$)H=TC#3WCY-YOH(W_Q^[@F3NX@9&_S)<.
M?V8V:]B -1Z[!K2TX@&K4-\D:M"!#MB !@A?W\IPZ/ :!"&35(WKUH]F*#F;
MQ: M?H]5^)P\0=M<Y"V';TM?JO*N%!KEZGWY3F]NZ);G7O9=_'GOB>_H1A??
MY3V?],EY;]Z4WNBZK?Y:T8]>_44F?1T%#@?W5K,,!F;RW?HPA0)7L0QNY *;
M6V*#RL3_@%A$X[C:,!DW3*8.?$2C9F8Y\5Q/'*@CK8-C^.H!9LPL$HA/XL0>
M%(\73$;^Z$_*<N!()HNX[,'+1L,=<L #F [+]HU+WBYEC*L5KBP#UH 5HF$=
MADE.-F^# *5E/J]CALM_EFLR_[@AX]"B!N^AOZ"K'>+#XZK+BS(-^80/O;3H
M^%C.^?1H][YK^)9PY"X'I8(OI*"P"4-MD(QP^=Z+O%P'U!2-"Z>P"K,PYZR0
MC'X/^AXF9_S+^M*PD53&3K+/J9SF'APC\HQD!ZKJ JE,9OXMR5R&G[!M"/1M
MW2I)97QK:$C,\:9- _9PK> G :4)@33@%+CGVSA :/3!>R0O-]P!$S!A(&X
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M\C(MW1(;U?,+MPLMW=,+WY(]UW)T FT+N[ NRS'FZ',^<2K5G% 0WN$L )-
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M'OJ+*P!YOS(R:%I;!?,&,C M@F870G$-5LF>7,DL+,$&(DP;;L 2\DT#:J:
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MR9E\QY&<CIRPRN$ ODN\9^6;0!W;EE9A%4Z!FMJ.&]+ #>@LNNZ;J4UQ@SC
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MP+A,$'9KRL6K;E7GM_U)DC:UOI"&MRN'N TA/Y/ *PW!"QL Q/80!#:@/NO
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M3=5IL JD_&R22S?4<"&<<,66><8K_;^[O,N]/=)EG,;!#<9K#,>>NL6RW,;
M$LVCPPQ'R++"\@2YE2;)KGI-SO]<B_SU$,RP <,4%^X0!!D@V=W% &Z U$/
M 4/073=R,Z-< S;@!FF@ 9^< Y.  ^X#/T/@W9.0!M?,#?: "3C1USX\WFDP
M"3?P )1P2CNP 82=WF[0%+E WQ3$%#^R Y1 $QI@"0S!!O,S!*8PWTQA#^G-
M8?> "1N00&05#SGP/_K "O1=U#!C Q9E"1F0 ]WE 5D2#Z54RO<@%FG0=\Q
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M!U]BTCU6S09"0^R,?)F(>F'3TKW=][ ,A"Q"\; #,>(4&Z -GOP \#TQ-O
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M8KK:M:/.:25S[U(7Z8+D1"Y"3G4XL@<OTB!"?4UB3_:8!.T28HH@_"<::_#
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M"+)F2(9DR 2=6X&WA,L*"#^XU#FY7 '.>DO%F<NXW$L5T#F_?$N[E$N_!,S
MG,O"%$RW5!R[1$P'4<S$I,M^!$P+H$N\_+,+<$S*],N=N "_=) +P$P;J@#,
MU$P+L"%8"[_+=! 5,,TFQ,S1O$S6/$TMM( &^3..>,MSY!!\RXD7^,>,(\"&
M]"L15"_3^S]O(\Y_"BSA=$BLH$-WB 4-6$"FT8" 21)6"(M;L0%N_] '2\@
MOUL9D5P/#FB%H,J!#N"%JE@&&\",R%B '"".1<J )<F7-; +5M  ^A"/0UH#
M!EB#X\H,#QB?3VD%?5B&#1B"XUJD#0BN72'!: @'=> &:FC)' @I'#BA8/&
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M6'[MUWQ-V(4]6('M5VE(!AW<A$B(A!S QYS@M\!3KT155*@XMOJ:K1/-G+#
M/^.L-&HURY!-PSG_Q $.Y8926@8]I(T,\( @" )7M &=N0>/!$D!ZM0-^)A[
MD)J4Z8[]^5D&]2A4X8QXZ 53P$D/&!2"$ ]HZH^+Z\X-^!H"!9GJ@ZPTR8'9
M20.-7(-3T(M"I :\$(V@] L/;595;=KTP#Z,:SCF@@BN>TH8E*A9 4A4 LB_
MY5O_L5; K;; ?4%P:9S O8=Z&#C!G1MAJY'):KEV$%=T"%?+50?-U=QYG=?.
M]5S+30=X_5;2S5QO!=W1K0:*!86+=00S2#J4L+^KR#&0==FFH#H=4TAJTS%D
MT]UHO-TT9-3-((A=L$E8)9\-< XZ9=X"]4[=TXX"=92((94"[8[\[,Z#_VG:
MTUB')/$ 9=286-V _[B3<_'.KR'15["'1$JH+.D*8"U!K# %#]"7(<"$&Z"!
M=K@'2^#:9AV>@MB-4UM( 4Y1YM('NS'!RS+!B%#@B-B'!KZL!F;@!4Y@$\S;
M"L;@!99@"KY@"M:'#8Y@"MY@$28-;HV'=K"I%%;A%6:'%&X'>WAA1UUAFT)A
MFSIA$'3A&N;6%+[A&79A'FX''/;A=JC79,%8(( \?+.R7W!4+,K6X#47"40Q
M%#79RI$KE;6V>X#B-'07.>%0_R&;(?"2 W4#81.V<(BH>S"%CTR(4^C4^>B8
M.]0K$FV9EEQ!54D/A<D+SA"6CQDE:IB*.TF(\WX56NY( PZ IL([A6B(0*A$
M$ZO(%QR(!KL@P:OA2GQP5F)9!VE-3B\K64VS7;QED5 ^"CB$0[@X"JJR5L2M
M0+- 7$ME9=* K%9^L]2(!^P)VUH&BUB^J5TV8T<-7)LR/"..!#-()T"SO]TM
MX"UN$?G:L=/+'+F*K!Q39GMX8F;_)CV8_>*"P($,: "$4),:&)^I, 4:X 5]
MP%2D=8<T> "D<92=<8\-]0L94J5SQ@0&F(2M<.-3" T-$#XU?H"/ 9\.?.2?
M54%](%")T4J"P%13&9.HQ(I/ 0\ H88.& Y3Y5I]@)B$" =4.4C?4F8FPN:W
M *S5F\ :"=3#-=$RLS$-7%G7*V&\N;F++>8PW C?=%0L3A=2'FFI:)R"C,&7
M$S67J^85Z^EZ.4!<88>!PX=7V( %\+U[<&,=:(5E !\=."YAL8'U@:-VIDZY
MH813? 5>8(.J?9L'Z !+6 93Z #XE.I!889HX,DA" M2'0+U55;(4)BN!17E
MZ0!,8(95__C>A)(3#P"Y>&D:&^ %:V %'-B S\#HKVF,]K ' :';0@4=DLVO
M*:8*GF;FW*7B:>TG;G71(;M8($A'*[,%OQ7M?SOJX>3=T,YBSU%.&9&7UWXB
MYQR"XZ *X8!GUA$ABQZ"ZCL%#WCL'3B%&X@%IK$!>!X3WW&=UYAG3+ ?,AH"
M:.K>#K!H3=KM[;F!#1@9-\"!H3D%Z-&'5_  5M(&S[#H-$CDX['0>QD+=RCN
M.+H!2L"$&CAG4["!W.&&YB8(\\B!J ; EQ;4 =8*S][B/_7DWOUDZZM F4Z0
M3= $,V 6GUB!L\(KCU5P;&9PV<:B-DS(&1-IW!Z7%\,1":TQ=__0AL,N"(FC
M!IGC!F9@AD2)J'J %:BZAW"@<; 5CSZI67>X%_^A!AIG!WQ0!VVH$76(A@!K
M#9XJE%TQ*MR(AF6P!AVWA];0TQ=?!N)PARG7\LWAAE."E?\(Z5!3"%4S\:CX
M<!XQ0Q)'+M*NV(O8! N_\"GXA4:&\Z!>YC5_"O-2R"GRV#MK;3$;\9WV\R+1
M+9C[4]8;B"'?7ZK<-KK1:8+(0!#WK>Q[\!GK\.!M\S5$\+J]OJWH$4[A5IO3
MP4[H!-CU"?OCE,>ZYD1?BD^WNOG2],$Z95EOYM=;-H+@7V;8<DR?0337MO/J
M]-L%]"J>+U(G\:I@.#N[99FV1E (!37_B+ I<(6]=;.7/G8HSK8SAV9>/XM;
MEZMN]_-/U_,]?ZQ82 /B&^HUPS1UI[:4MBM2,W=%A?0]E6V37A=N30=I0(90
M"(5DZ(.>F(+5KJU[=]E%GVUYCW>\^C]='Y)S4;&$(V"K"'90QS%A-U'.3BZ%
M9\ZIN/7:IN);5H> I5AED(9 8#1:D.8"=VV)9XHC>?-0[Y$YZWB-?V:8MJOU
M OG7G@J7WOG'RGAQ#_%I$[S=2KW*DOE9KWFC[Z<01 MAID9IF(9T" 07H(6P
ML'AU"8N?[U,4+_8&/_"<C_J&QR*P[VE:%VH'E^(J%D%P-WNL>RQR[_.F_S&O
M'_:[RK[>8O:__^!6=4B':DB'=B@%7&C#^5)[X50SF MT5()!F2-[8\?[40;J
M=W^7L9#[3B[TMN?S<6_MD<>VRD<*MH]\W[TK<*] C%J'I\*H5P^LT"-]I<BV
M9-/LS3=1F+NG'#D[N<CUV1=9SX<7U2?VSX?ZW&?#U.<VH5!SX)<*MS+4BQ]+
M39MA>TCWA'?^5!;^L_\[O1]^P5I\#W_ZR_G[N6<VNK=;\[\QKF>7\"] T]<*
MW#_Z"[1EQ@WW*ZHB]X_##U]Z&@2(>P('"HQ'\)Z]@@<7,C3(\"'$B SU[:MH
M\2+&C!HW<NSH\2/(D"(]ZI-H\F"]DP(3JCSI<"'+EC)GTKSWLF;$F#<M=0JD
M./(GT*!"AUXL*9,G0WHXEZJD9^]I3:0/8_HD:O4J5JOX;C(=F%#JRJYB9][D
M>B\KVK1J_XD:A0A5)5B)2..*I8O3[MV=8P>:G;CV+V"K^GCVM0DSY\FY![F:
M[5NXKLEX50-3KARR+4*%,OO&?>R6[T*N2#T3Q'MPLN74JD?J4QHVLT#7L+W*
MW3O;]D&P/$WK?1V1\>^'I#\31+WZ.&#,N$,O7DX3+^^'^O(AKUXYG_.!](9G
M3WRXI6SCUL>KW@IYK]WHD7MWE:J>+E[@-<63KP]T\-V4- V:50_1*4/1V:.4
M?Z?9=^!5V&W6G6;9<3<?@A$FAYM\ON4V('$$N1;3< X5V%!SM%DH8E2R,6@2
M/A*J"))RWTGE3FW=I;?@;2H5EN**.9+DW52@G0A7:62%V"-].O\:^9%1-WWX
M8VX2/8@8DR0N"660W_GHUY%9MAACE$-V2663 Q69I8I;CE4600:9YMZ3RYDU
M)IEQ5F2FE5.FV2.8MMGI'(!Q?051FQ#*F2-F>]:X'Y=ACGCE2O:X$P^,?LX$
MYZ#U&67BER1:Z61>3%7Z*49T+GJEH2YVFJE) #)HEV?QJ&H2I:"NUIJI&=J*
M4V$Q+1D/K^ZXT\Y3I=H3JZS'T;IIJ[@&&)MNBO+8:%?$%AMA6Z5&U5V;DC9H
MF+.'7HMJ9F!).VU@"BXW&KB,EO9K.^VJP\XZF[:$([D'BGIKHC.IUQB3U-4;
MY[%5=ONLFN<MB^=1SK&DJZ9URAOEN/__JG4O0S *S%ZZ!?VJ3CK55*..-8)L
MX^U*LG%8G,3V*1=?QE_J1%K$*2-'L9#/==5FH _KC+'-7N+[7\PR7T7SB;D&
M!Z5NCK)3S31-5^/,"W",/"I>] H]LVTOT16HH8%ZEI!#5QM):W0YF[0PPBUO
M>Z*AO+W:4M!B"Y4/RUFCQU0\[:A3C33)**,,+R]4,(<WBJD4M]Q#T6FGV3Q_
M*Q;BB?]%=$W)(H2IXT"F_>S!HZKM.5WN1"[Y97<FW/#-I34^5=[A3)-,**$@
MPPH&%50 QSA+24:Z:N;"AN&JII^-N;J>D[P>RKS;FWGQGX,H?)YW:WXV\E3K
M/+KR'2W^.(WM9>T$:3K3(!,***!\4KOM<4PM:/:!$6VMM=$G)=RD[5M*_)^H
MHFW\\ZAC^[AB3*03G;SM=.#!GOTR0KFEQ(]Y:6H'TY !BDYTXA(ML)WM".<M
MA_0%@0G4R (-)[_/[.9X&2K8YEKR_\'QD*USBG),D%;GO!EV:W\06R%:\-,]
M!LG0.^T('S(ZP8E-2.*"*L#@'+AA0BSA,(<I=*'/NL03XAV/,!+Q8!-+-Y4"
M9B=^Z(IB\P:6+^,Q3(ST6QOGF)A%Q1FL2Z0IX4+H\4-I2' 3D9 $!E1P1"1Z
M@RQ8S*+OQKA$-(Z0.78+(T/\M4;++-",T\N+G?S#&3&"I1X-I-[.(O+'#VY)
M29C,7_,*P\$T>1):M(E'L+X2K,S\*AS2"(40(P&)%>@1@^DK'"$7LDD<EF2
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MU"D+3@&9O P'Y$6>5,R<!U@>06#>,MP#-Z0!!^3<!@0!K]$#,]P !]2 !W2
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M&@H$+ZP"*ZQ"*]S5)!2=0W8 KQ$$-RP#*TP"#CQ ?S+#!J"A0"#H&M2#.^B
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M*I:PSBRTWJPN4NG?;6>6XJS/3BEUVDX)6JNX'AFG[)#*JN<,F24O/42Y>L#
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M'6X #<2"0+P"!^SO/3##$ QQ!]R *-?3[4:MOZJ]8;[A]^- +PB$K(NF-M#
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MY+8A7C$4P0S6J'.2#;0QZ,%6#EJ# VI 944?4R!DM)4<9)LOAPTFH438-6P
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MQM=[NQ=]P1<:6>=#-&X3W/9)3&8KXG9R4:X7%0I-O#5@ S'TB-<NQG5=-;5
M?S1P76Z!JU1JD>^ %79:*=8D[S9C>XH2/1A6IW1R44=F9TD7 B&%5?@/5#@0
M6-B%5_@/_V28#EH8$%:XA7'XA6,8AV$XA5]8AV78A?\ $/Y #<S@B,W@"::$
M1=8B@&-/6WQV/)$P1DU35_>6@EWV<8W0@!.6/!U88+%8&T4X'1'6@VD&15,5
M(J[V8+.2(Z%S9?]B%#L"&3+A17#DCBO@ IA8)_"XC_VXCW6"*U"D*^Y8)RQ
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M"@<#C*E.7J&-(<"4&4.P00V&@-N.,",-/H6+.D3KH(C8T /'[45'V&&*7^6
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MO..-%%1.RNFT2<B 7M@<-]@ =B0\[_NPM7B%:G0'?0B_&T +?=@%#5!*;O
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MR>,&J(2F#<"!=: &!UV(96"-#,"^6!#"^ /,@V"'&_  ;H@'5T4+=5B##G@
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MAE/(/O%S!Z.-QLCM!680PMJ)38Z4NAC3-SYKN"8E6VX%7T?4UJX%V_#5/3+
MA@2<VV,*/>9LSE#T+'7[,J>+B.EDWYP$#&LX2(B8V'L 68^-OQV "!;5 %9
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MIS H[35N:[C0%HK@N%K[M(AH-;/>#?7.7S&5;UA+"^O]C?UNU\0PD^@3LZ8
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M4%5,G56A+:;4AV%A3+':Q["B=D&//E#" ^RB02R#!]" &TS"$&C $'Q=*V0
M*PP$,V0 )0@$*W" #;@!"'; *Z &&VB !PP!)0"E&S3$.NS !J3!)*Q!!WA
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M*[C!$-Q !V2@>#)I1ZSC/JX!!W"#/IC">[(##F0 #N0 L-[ !N@A.PP!\-V
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M&V@ TG[JT<9",WI !JP!Y&8 0.*N'@[$K>8J)E@L<D[R*YA"#7@ ?#)#!]C
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M:Q;Q?VH1F!]ZJ2=$[]3#F1O!JX> $3 !79<X';MY'NLS$-"!*)3"G?L "<C
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M4."[8&1&S, :2 +CG-1,S]1)T>)KCN$.<'0+HJ *X%06)_)3)*\/$B$.[D]
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:82-68F=O6B;68B\V*R$68S>68P,/8@," #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex-99d3g010.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g010.gif
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M\_+W^O7Y_/CX]_[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
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M4X@;;KGA2E&$NG^EJRX1XP9V!+Q'5.$MO$14,2\1^/+[+K]%'*&$O/P67 3
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MO>W147/0SC:S_(@'.L1]6G[X_AZ2U7L)^KY:X6.;]Y.U/? MJ_,2 $/U[WZ
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MO5?\-H[S!W3X V[<.SXH07]8!LC+MQ)8!$/D1,]KQ(+<,;#;NV\S WH<NS&
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MA$3X<]/2A40O=#IL]4,0A%88M'MPA3U(=5(W!T2 =H:D=E1/ S\P77X8AD-
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M98XS)SL$-<3^B-KG0_#(=\A"YLCG[,@R/[U-.-L)SE<]\X!=D,.5BYWO0OQ
M'CG7$)&8RD+;Y/J IW6C&N_DJ![\*;]?#XQXTG5_F2TZ:V@4B..?(6ZXL=4;
MA:Q&>ES\44BQ0?N M <E"A%8&C%B4"H:E1%/0<T]4(8@((6[I'.M7,W/,+P
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MQN*6083[",6 .;,S',][P"#%ONM2M4N[K%>>>&P),((^1E9*ZNC[S8PK'/3
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MQ673[::;T*P5LE),)25'!=P8J3/9=]O=AMLXT7U0UCW5_\"N6D;-Z=,/W/A
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M_ULB7(I11F!HIH%@[@/R!9,M=]FDN"&J/]K;,D=D?$J"X%!=O!<%5^30''Y
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M>3J&)IY6ZJ.FE+;>BBMCO!7*IB<#9>.)<0QLDE\[#HA""F^BT#7-?[MY$J!
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M(DH $_ )T.H0=4"C,^ 2XX '%" + ^$-%#"B%HJJJFH % "C I&J$1"KLVH
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MT+S50+']P V^H JJ4 O<\!P6B[GWX Z^( NU,*H%<0_5D*NJX O>X!AW,*%
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MG_< QK;,NIBKRX*[2OWP"56LIA,Z Z-Z#_9*H6[J"\-: '?0&1+MH13]U:!
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ME[0BX"MN8C+@*W_TR4BRGV2@#L !J>%FO^XZ]'"JJD:"T#6&1#(@@JO (N"
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M7C!*D-P!14@W9MC*0<C'I=A'D(R#;U"LJ[3'^^NVHZ1!5$"*>EC&:KR"/YQ
MN[Q+-0@#:K1&:_2"(O3#/BS .)!('JE(43R&IBA(&CQ(_)(&!J R-+,S:1 T
M?W#,)?.'<Y@%S=Q,SF2%63 &5O.'>^!,TO^<!<_L!:?LMF,HS=(DS*70!L]D
MS<T,RJ4@!]G<3%8XAM"LAUZ(3=9DA5YH2(HS!M^43==4"MB\3=/<AJ;X!N74
MS&1(-W=X3N 4SLH)AN)DS>-,"F;(3M)DA:J$".=\3E_JJ.><A>!D"GW SN=$
MR41CAO,\2Z;X!N_$S5E@AJ:8SM_<S&"XR8(83?OT3IX<E&2X3<]D!?E<"FY0
M3L^D3:7(3 ;M!?\4S5Z(4'A0K&.H3]P,AZ98T.=TT+B\1B]  Q(M41,ET2MH
M1K[LRRLP44<H3=14K&!@T%G83J30!NIDSOS2!U%P $X -"[C41]U@'GD,R-=
MKQ!=425=415=TA4A%8<8ZX=LF(9K\)5^N(9IR(;0/%(N!:\D==(E;=*]=-)H
MP^A2,SU3Z?I2,.7+:1Q39ES2,D53.9W3X%+3-;7&:;S3,(A3.NU3/XTM.P73
MO733->73/SU41*VL0+U3-BW41'U42/6K16540E72/8U43,W48IK4,'722@4#
M0]5441U5Q0E1-_U4)455:X124FU55TT73NU4)B735ZU56^V3+U5550734+U5
M7_W5QEC471U4,+U48#U69$6,6&541TU69WU6J4A28KW37;7&7H56;,W6N*Q6
M:G525LU6<-56,9C6:^S69O\-5W1U5CNM5$+E5C#XUG2-UU]=UEG%TW.55WPM
MDGRP!7[M5W_]5X -V'_-APN3UD9]4X1E5FO-5X8E$GK(!$NHA$JPA(B56(NE
M6(O-V(NMV(S%!'HH6+E46'L=6;XTUH8]V0YY6(JUA$NX!(IM69B-69==69F=
M68K-A(^U,#4E5X1UUX5%6:#=#I5UV99]V9J%V95E69E-VDQ@!Y 5V7(E626]
MUJ -KBWUL*%%6J,]VJ(]6J9U6IV52W9=TUTUV:H=+7E(![5=6[9M6[=]V[:]
MV@;+VJ)56JZ]6YNUA*9]VGI-54^%T[,MK5AH <(M7,,]7,1-7,.=!'FX,+K%
M6\BX75J<Y5M4;=<NZ *^Q%PEA=? !2U86($58 $6"%W1'=W2)5W3/5W5+5T6
MD(3&M;#'C5S9U=N<K;!)557-O5.J[5S)^ES495W@#5[A!5[7=5R(E5WDG=G)
M#=N^35B$S=U[Y=W*\MWAK5[K%=T5*%[8/=[DC=R;K5T*RU6HK4;H+=G=E5Z_
M^MSK7=_AU=X*B]WN]5J]!5O;%=NH5=CRY<OS1=^R4E_V_5_L=5\*@]_X75K:
MY5M!5=+\!?]<_IU>T 5@ !;@"2/@ M;:Y:U?DFW7^V54SFU@R/)?"%[?['W=
M]^7>"I;?"P[?D/5;!08#Z%W@_?7@A*+>$+[>$3;>K3WAF+U9^E5A9EU@\O56
M&9XL&J[AZKWA[:59'=[A^47@#09B(-;?(>[=WS5BX47B$K;;);;@'IXP>LU<
MD8WA*28F$+;B]B7A 3;A+:[;%/;B%5Y1S,W?%UY2LQUCLBIB,PY>"98P"C[A
M[W7B.XUB!K;C_JWB/#[=/8ZP/J[@/V;>0&YA%^950C:K,CYD1$;C"5;C->9A
M0(;C'[94,9YD%<)C2Q;=1(:P12Y@3G;D1[;&.-9=4;YC0[9D+$Y38R7>Y -V
M9"AV9:CMX%@FXUFVY%-^,)7-X25N9 P&XTA>TMP5Y%#^Y<8A95H>9@=+Y?A=
MY61>YO$%XF>&YL6IY%)N74SF8TW>8FSVX35]93B.XCK_]F8RDN9#KN5,UF)<
MWEOF%>1(QN<5[>81ZP=IF :(>(=2$ 5I"*S]@N=#IN:Y+>=C;F)6;N8@]F1M
MAN$9\S,[BQ DZU%/D-OZ N=I'F=%9F@=1F85OEQ>9F:4IF-^#K%WX(0%N&A2
MV+(J>TP \^AX5F@&L^;N)6DW%F1]IM48$P5/J+."Z(3_ZX=-N&C_0F@K!MU(
M &D(8P>(->:1M@1,Z&()"]$YEF.)%F(8"[)V(.I^(%+_J^E@SN,5>.H+DVJ:
MI6=&MFJLCC!.U=SRG>-476D/:X=-H+).L+,P*U)_"#FHB,1(; ?"+FS"-FS%
MSKG#9FS$-FS$?FS'3FS*ANS)_UYLRXYLQL;LQK;LQ=9LSCYLS[[LRIYLS0Z%
MLS;CM,:&R [MS:9LR<YLTA[MV.[LT@;MUQ;MVR9MW6YLTX9MV_9MV=;LW@YN
MX';M2 2'J;[EJLX$<$C UY;MT:;MZ#;NSY[MWY[NXS;NXNYNX/9NXOYN\=9N
MZ=YM\GZ';WCCB%9F]EY28MCNZ\9MVH9LPS9H NN'0V.Y)%- LBYJ1'N*'*1O
MWO;MW,YN\9;L\*9NW59PVV9P!D=P P]O"(=LU$YM(TYK;R#P\3[P B]O">]P
MZR;PZ_9P[*YM$Z_N$W=M%0?Q!\]MY4Y:MU9EE@4'#1_Q$!?N <=M''=P^"[M
M\TYQ%M+'[A\'\1W?\ ]'[Y#]Z?4.TS H!O F\NUN;/L>,#=C  9H  58@([K
M:T4AZO^RZ4-6ZR1>8ZW-Y6S69Y/N:BEVL7[(OFM(LCF+:8)HAP8 Z"^W\ L7
M\RPF\[HU<W26:(@6V79V,2_?/TZ(Z4Z8\OMBZJ;6<UOF\Z^U,'Z@UT#79J^6
ML7\.:*$F!45?=#ROX;2&:F(6:1D_YPG#AV7<ZD\&:G<&YD^'8'DF9^8VYS;.
M:O5NWB4/8NCUY59/(4:_<)Q>L&*.<3^N=;F^=>?=X%P/8KS_[G5T 7/5#G8%
MT^GDY6E;'U\P+5]>=_9H?O40EO8$HW;DM?9C)]LG;N\UY_85^G4C=O1YYG,V
MCFL(^V)L?U=U9R%H;VIP1S!QGUV'SF99O5^ZEN1['V5O!^!8#VEB]V,_=^-M
M5MAM+_BV8?<:WO<#ZW?O;?AK-]<6YF:)]_6#!V!WEW6J9GA[!OCFY6HG'?2/
MG_B09]]0Q^&2?^N3__,QW=6?;O:6-Q**AW6+-S",AUQ3WWAS=UY\UOF=)Y)\
MM^*?+["@QUMRG_<W]MF37E&63_ITZ7D('GF%AW?E!5\W;E(6!F-]CGBL-Q>M
M_]^8'W-XC_H'V]: 5W9TKT:D/_L/)UEZ4&]Z GOZNQWZ8R=6;LUYNT\<O*]X
M4:]F4J=Y>7_[<2WZ<U_YNO\?_.Y(^__E>E2>ZK;7^')G5+N&9<DWF<*'=<L?
M]5EO;K G^EGUZ64'U<\'_9<78;T?,+[G6K^7>J@=^#LU^];G^0<.Y]*-?0&;
M?11>? >;:TN'VLC?_<4(_:T__(5>>,7OY&P_?H)7?K1_?1L>?<2'?AFO>8=O
M9?9>X*NW_B*A?-AW_IQ._.X__<UW4I6G_G0G_U]A_@A&?V%7_VO6?-OG_/$=
M?X#P)W @P8(&#R),J' APX8.'T*,*'$BQ8H6+V+,J%$AK!4K6( ,*7(DR9(@
M(\G;J'(ERY8NZ66R=&DFS9HV;^*T9"D3.Y<^?P(->K">&#!&NQA-JE0ITJ1(
MFR[_%2=T*M6J5J]BS:I58,>/)K^"9;$"Y=:R9H/"E(ES+5N:.GF>M0AO%BM6
M=.G6Q7LW[UZ[??&R.A>W(M&E8* R-:Q8:;3!CA]#CBPY;L>PEDNND)1R,N?.
M M.V#9US9T_/"K^]><.#1^K5K5FOCJTZ-FS7L]\P,ZVP\&'#3:$B/KI8JN[B
MQH\CI^SU,G.0FI-#OPI:-/69;^E%%X@Z-??NWK^#]YX[.V^GO1<+1V^T<?;V
M[M_#Y^BQ>7.R\>]G3*NS>EN=U]M_$T=X Q(H7GM$_78>4\$%IQAQ^$$8H821
M54;?99EM-J&&#(&F%G]K^9<)=MD%6*") XX7'8+J)>;; V+L;?\8HXPSME2A
MA98]1Z.._DSW(8@AEA9=B2<2V5V*T*VH&' L&A8&C#M"&:64!G5U8U@83AEC
MCS[>Y!]I  I8I)A')I?DDHLA]I1B3V;9IIL:VFBE21CV\V:$6W*9DX@ BMDG
MF<B5AR:3BCEIIZ&'PA>GG"1AB6A\>.9ITTXC"ME'GT5J<V!13)ZIX)J.@AJJ
M;E4N:E*.HF8'4Z1L_4?BI9AJ.JB+Z1G&)JJWXJJ5HJ6&U&BNR$&ZZB6M"ODJ
MD7\>%^A2#7;1(*&V_AJMM"Z1RNM(ITYK6K"KOA4D=$,:.R /R!JG+'K.JO=@
MMNNR>U&UUH+D:[N3;1LIL=^&&2Z*L;*^R"R3T,X;L, '[6JMO ,[5F^>]R8'
MKK[@D5N<N2W2FIZS ".<\;P%6XNMQF<IS"7#R#G\L('D;:H>@TP6^K'+ ;\+
M+PL>OZR5?L)*^B6)^9I\LHHIR[HL>AC77+2H')=ZL-'2Q;0?SM;I+"3//7,7
ML6Z\?9%4UN;-JA[12X-M)]*+*AWV5"'[V"V85']GM6D3TYJ@T Z:G=T[U[13
MIT#]M'/-.W57%+/!- ,.%-H?CGQ<R52/RZ]16V\M*+I)??]=>&2D.+") Z+L
MXT\_HV3N@#261S2VG&63WM+A_"5NW.)4N^V9N9$?Y>_DE:<>US4,2*//[M/X
M,TT#U^A3"@/MY-Z0Z7(2GKQ*JU?7>G&O]QQ[9X'2[FG08+3L_&3ME%*G/@Z0
MXH\GG0@T?OG>)R1XQQFROQ+TU*F],]L^(RG&%]G/K;W7\7?F'9C+AC\V,8J!
M=,(3 "38<F3F'/@M,#\Q>5I-ZE>L^QE)4_SC'\70U;T(.J8=G&! )_31#_(A
ML!-Z2X@^6NC"%\+P'3"<(0UK:,,;XC"'.MPA#WOXB@8Z4!+I>*$,<5C$'L[#
MB"X\8@Z3>,,C,K&'4IPB%:>H#DS_^(>"P]J).HA8Q2^"T875F!K;?+&/,.[0
MB3:$8@_1L2D.&B9RDS,*-/0113;R4(TN7"$(']*/NVU.?0,Y'T/>D8UV'!*1
M[5AD-A*YR$<B,I&-9*0D*TG)2T92D8Q\I",=F<E/3A*4EA2E)DO924B&,I6C
M5.4F*0%$>*V@!7C;I")7R<E52A*5FTRE*7>)24_FDI>GK.4O#SG,7MZRF,HD
M92:/>4QF\M(:6'3:TW2""6N4DI/+9&4SM4G+;'(SG*/T!1FI1@M:BO.2SO2F
M-XT9S'9JDI>;K ;0E *YKOG/*,6 )#&_Z4Y?MM.8?^NC0_JACX%@[AV<$,5
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M(VD(T C2S7/=FPD'0S6N3IYHN6H,!MT^&M8)ZB./Q3MB37]9N>G5M:Z3:^1
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M84F5$+1!7!6575]U5YNU6J$U5E5U6I^U8B>V'^#!#4)69$>69$O69$56#-Q
M'%*58OLU40=67&%6+/\9DVP(%7DXHA_6)ALLAVUZUG<8)QOTQF>'%G:R 1NP
MP6B/UFB3-FF5]AJ\X1J4]FB1%FF9EF=11VBQ=F=_%G  )VBW=FC#MF>SEFBS
MUG*TUF=1YVBC5FF9%AN\(6GA-ANN(6G9=F>#=FJQ]FK']F>_%FS[MF_+%G !
M]VS]]F_%%FNQ@6ZGUFCMMFFI%G(9=W&5=F^UMG++EF^Y%G/;H7#]]G*Y%FLY
M=V^^%FVM(1O (6A--VA1%W5/UW!==W7]5G.+-F@O5VQK=W;#-G=#5W.#%G"_
M5FH5EW&IMFD;MVTE%VZ1UG)W=VQQ5W>;EWG)EFTZ]VLK-W3Q]FVS=VJU]VC_
MO:%[M]=[MQ<;QJ%[,==Y?U=KHU=  34C]&$3S*8?C)1I)()^_4$B(J(?NJ)^
M]]=^[3<B^K=^YR52<2: "1B _2$O!MA_#]AG )A^_[>!^3> ]9>!&9B"Z?=G
M%%B",7B ([6#-?B#[;=G*KB #5B"3;A_+[A_&3B" 3B!5>: *4*#17B%+T6%
M4::$3WB"2;B"61B&3_A_?=A_%7@B7MB#.UB$.3B)8[B#(?B'>?B)3YB';UAE
M KAGO(:&G=AG4$:%"TJ'5UB&>3B##YB*A=B$J4:%$?AGG#B%ZU=_5X9_H[B'
M@9A]8<(3/L8?1E0:ZCB,FT: ^1B0 ]DT^U,:H"E _P49D1-9D4WSE+Y36189
MDB-9DE=0']J!2R<9DS-9DS>9DSO9DS\9E$-9E$>9E$O9E$\9E5-9E5>9E==M
M9N7HE5M9EF=YF4CACN-%%!YY(JY!%#8!E::!?D?AECVA%-;7'VPY7CHAER>"
M%,23*;)AFD"F%.[XCD7!F?V!EWVY$X!Y;(398SS!F3!"'Z3!$SR!F\>F%)0Y
M&RCB&NYXCX.CG9/9FL]D&D9!E?1A%&S6'Z9!%.XYFJAY%(9E7=:Y*:;A>#*C
MG6_9FB^EGE-&']JE(OCYDL=&%(9E(J!)G2DB&Z(IG#D#GTDA9*!I>41AF,T$
M:*0A7G1Y(J9!GRDBG17ZD?]+X9V9HAVB>2JRP1-4NA1*-*%Q6:4KXAU&09J(
M$Y\)^B*".J-WN9Q-.H^%6A2,F9:K@A,:8!38!5C>61H8@!-(89H9X(GZX3NK
MNE%2Z2+ <Q2J&EB 67YYHC^ANBKX@1,<X*Q%X:J)1:NYNA,8@&,$M5Y(F@'(
MVB(HA11$H0'>6; ]H0'6>1JH>A0:X* ]0QH60!2J.J\]02)(@8DJHA080#RS
MP;$MXAVTNJI[N0':X1T*VRE&@1-B62=*0;+1VJLEHK&Y%+,?V;,?&U(Z80$(
MFI1,";&5)1L< )PKI3,$=0&<N3]-6[3]VE(N D 'VS^+N#^3QR+,&K;W>*UW
M8HG_+%HJIB$![@B*Y,6U)[N7HQNT.8$33HD3SN2ACQLCW@&]T]D!A@59)ENO
MQP:]24%2\B&J]8(3\-A^.\$!*CFV75I8^(&X5WH!?II>J#M^-R%^GTA$+5EE
MWD% +9RA ]3"0?L=6%ME.,'!.P'"VX$![(4B,-N2/UO!?_H=-D$\T6:4HCO"
M(YQ8#EE,++RYH@>H'V6BFT(:2GM>(GN/ 91+&25 (P6P*2*T9_JT16$>4'O"
M+[S#QZ1Y3GR]WV$>.+S'G2*KWZ4?A/R8!]PB]$' FV<3+/LBKF$3&&"W)\*.
MQ"1^Y>6.):(_UYE1JWP?*%S).YR(>6)$%^"0]]E13GNF6S>;NT5T4.V7KA4]
M6*A;AL]<AD4\4B1\;$R[PJ=\S]E96)R'PSTPLA? Q/T!Q/VA6-@;TBT"0!\E
MC_8X&X!EP3&"%,!['K99U"5<&@*T% Z9E&H!@"D\9XFZRK?_O+\M(GX!W!]F
MFQ2,I2+T81H0=5(TG<%/?2(H!;Z?J!T\P9=)5"+:0<"%&X]$7+@?I3][>5)N
M'-LW@1.,^BEHG"(HY:$#'5*:75"/9[N/FGX--=?/!$#S2#Q)?#@[(=:%>QKB
M>A/6^1TH95(ZX:>=8K.)LQ/2)MDO>40]@5(.'=%GNMA'=(_> =L=H%(D@N/!
MLQ/H6U+*_=B%VY=+02(>VI<Y8>&?HN%E^+_#_)))B>+AO2(&N\XOVJCCQ7W-
MIF891;\;P.4]P9&[^3N7VBD$E5*2IZV7G"*ZW"+J'9N-Y1T4/D2)?=3;O0'F
M(8JN'3Q)]*(%_,P?)>11B;X9 &U,_S[D2^GE.6*Q1\&\1[W4(67K*R+K:YW4
M<SE99H83[-FT(_6TQ3.T^1G 0W2RR9Z?P=-LN/T[H\FMA[TB_EMZ@KL3BKV*
MZ3>LJSK!J]L3I.<:A%OOT28;#MY1W)<34*=2R'SDN?WRO7OD0_^)'CYQ1#SR
M60;$0=_;[]Z#(26L![OS+T(:IEI9Z/I2?GRQ"5I02Z$=%F 3KJ$_PU/-Y852
M:C\!KODII)XBY%X?(AXCIF$!S-LB2-R9EB>KPP2U8WTX-UM9C#YQ_IN4GEK-
M[844)+L=LGJ/JA^:@'PJ?AP@WOD;Z$]4@WZC&N@CR'#: @;7&#+LYR];@VP2
M_5UC,$T? _]I _MQ&O6.@8-KUQPP*)6-TZ9^I1I,>R=* :F,.',.U.>@U+2/
M_GZ^*SERE,&;$J4Y6*B1 4:*GCSAW-1)G]64GD2**K@IV[M1#-KIX\0I6[9-
MGO1U*MNN4Z=^UQ:432FJGZ=-U]J)<B!0)TZE;3<MY"2U% -1HT9U<H!QXDB"
MGCCYH]BN042)/",[<'"S\N5W/3EM'2CJ):<%I;QQ.JR7P;NQG-I=V[2@K]_;
MN'/KWLV[M^_?P(,+EWBZ@7$&7?NA#3F*+"=I_8 P(+N)@2>!5JV*7&"\ ?)V
M_D1K?-=/GS2G&QMG0\EQZ,]V/QN3.@EQ8$F0PP?R*^[ ^R:Q#HS_UD]I9'5D
M'%DJI>5/=DS!Y$D#-XG""45!-7!>8SR5T@Y'DRU7$"?O-%#*0!M.DQ]#Y]GF
M#RD*S<>41!O6-QF#(9IT7%4A@I0->/IL)$U))OKSSC2D0#140OJX.) GG6R(
M'T^CG,B082JRF*1".&7S$'@[O?9B-DY)=$T#4H48I%8E(;4614J]L\EH^D X
M7)PC>L*74!XY@.!A^I2GCT"E+#40F)?Y$U5&VW7W77A;78/=>>Q=MIZ/[J$G
M8Z ;7>:.B+U)H]"&41+F3RD+;.*2<2;^F=TF2'U(H6<[,<C 1^T8=@V8&'+V
M&&F<P#90D0+AFMY YW$IY;'()JOLLLSZ_^72--!>P]2:;";&P"CY!!C21J.D
M9!PI_&RR";332#N0>'JYI%(VGK[HCS0+."!N===,P]= &['(I3Z;1'FB2)R0
M:^Y^G8142V(+D +EMM=Z*^>488WR$K$.3&.9?0Y(LV%$ROG;W,8[98QLB@SM
MM0^+*N[DDK@+N6F<)QMZ0FXV%,4)DC[-B;M N6&57*JXF[U#RH0#29PI09U(
M-7(#*N[5CY*8F:KG0NULTM]H_FS8V$ 6>V*/D!:&Q*K- [E%<67XA=LJ<*"-
M&*(H*88XHC_[_%2*P]*TB6\#QAZ:T;/1+J25D#D[L$ V%JOHT+PJH81E4S%Q
MV7%OB8\*D:@Q"?]4GIWO/-C )N^(MV3!)%ZLUH&5*1T>S!<+V5,G6$LX^*@.
M4'91Y14QW>SNO/?N^^_GDBZ18>I0N"!G_6A+$%GOE.)\1&]FM)\H8XV[GE-"
MV<>ND>VTDXT^N"M5;,AK"R>2Z@P5:>R"$/+4JDB=-/\\^$QMK!13I/PG$XD0
M5?94OT6+#8>$-$ ID6PG5%G1XTH6EHULQ3S/<U)&<N2/Q4AC1[0*TX*RL9=V
M#,5[_F@.A20$JW.A[T14(DAF0B@HB8BB@0RXB3Z<=S>":(T@GAH%A92#%'MD
MC&R&4IJ]W(04'L[I83_I!-/NHT('P(R&LNE9A6SC-X;LYX3GHMZSKL?_GK[H
M W%&>D?W>J2["HWO>/[:C:<TMYCEQ.1%&\'&-9PG#7WX;78$-%$_ID%'?JG.
M+13,FF4DA#2IB"Y05+O(1KBTD90![Y&0C*0DB2,\AKP#")PH7C_R\1-2)&\K
M%'&@1)2#19&,HD2_.AP3"](),.'G&B!R"$CLTB0DRNA$HIJ@GMI1L_,HK %1
MX@=<#@,CH%A.C!RR1[_XD32*N.B&DPNA8#A1E5$I($@&#(LP:5(?E$VF'Q3Y
M"7X,@TW[&),A<3(04F2YL%%MPE:_RDJ1, (E?HW&1\G*'#_^],*(H R<_>#'
MNXQ9I'(R!%?XNM8^P$D:P;R+;V8J&^D\98_2_PC$(>7S389"4A/7E*04 +6;
M1-HV&28QI(H$(25.1/..!8QS 8[B5 C+@D00Q65$=@&1 W38E$+I9HC\2\!6
M D6>S;DF*7S+'39#Y%."S$<@<JM@5FCW#J5@Q"(@.:2@-N8^<'JB-I,,JUC'
MVBQJYJ0ETUF,=5Y3'>I,9WT#\1!QM-BOTG"(1:*PDXF*) J#;.4G;^+$21[J
M";\>"X]B:JM:K\.3Z8CKK1+AQWSRRBF$!,@EX$D)[( "30!*4R/R<DD!3R0-
M!9BJ.C(EQ<]<(HIL.)%":KD7059I29'9B102BB%A#0)2.^5U)2N:#H$$,B;8
M.:":R"+5:1N0,6>6BO\ZHAA3750F6XD@M!^=,*VX.-$94QDD2A$U%.GL]:?M
M5B>CO:'3;%4R%).HBP'QRXAA1+$8GZ)4/[ET3%T$B]O3@"10>:W8J,BTET8A
MA[Z#]51A7]NIZI9" 4/]V2:\,S=T=N)-#"Y=4^W#6E,)!!O'?>&(8KN7:FJ5
M:O7QU)X<2=86N_C%MT&)3L!G%%)LC8_2*(4TS)616^'$Q\V#VSOR@J]1D*)0
MU\#M-"@RY&R0@A3&2O(HEHPL'^>$QJ*P<4BFD;>\\7B4T\ARH?:89=NT [>7
MH1^^N"2;!<&'9QL63E5S+(V9V+#+.IY&.^IH28VAT\Y@AJHT1%&*)@^*%-W_
M&DC=C'P-RJ!D%(4F2#9*(8J.**NJ.O:)F7.LXQWOV5U59;&:@]+E'']&R12!
M2U]D+*0E_XG+[>A)?O1\T(Z C\X[-IZ8$@/7]2#*RF+"B#M*,8H?65G*EX&+
MDELV#2=#6=*H]LV0C >^B.RYRX#.R SA]K649ALSE"[%E]"LPD'S62.-@<].
M+*V//5]CC3".M[SG3>]ZVQLG=@'I,>_-[W[GQRBA;)V_!TYPX(S%1/LHC:X+
MSO"&._SA\E8*660*\8K[.R43GZ[%-\[P4>C):G'FN,A'3O*2YP0^?C:YRL<Z
MI&8O?.4P#RM<H,7BF-O\YCC/N<YWSO.>^_SG0 ^Z%="'3O2B&_WH2$^ZTI?.
M]*8[7=XOQ__WTZ=.]:I;_>I81Q9%^($/>'B#&;[H!2UZ$0Q?5,,=]Q!FU+/.
M]K:[_>UP-WE <[)#?&B#%7B0 QQJP(&^<Z &'O!!'>ZP"FJ<0Z IC;OB%\_X
MQCL>Q@#MQS=6H7<0=* #(+!\WSO@ 0_0@ ,5H$$-@ "*+S_^]*A/O>I7?YL=
MAD0<H( #"#!@^1!<_O(AX, '/N !#G2^\R]P 2@$-YGBL_[XR$^^\I\N4(;Z
M QVHD#T(-*"!$%B?]K??_>X[SP$;V, #04A'XE.=^.6;__SH3[_($1^2R>1#
M&7.8_A RD $,:  #UL?]Y;7/^^[3H *#($SJ-X $6( &^'#U< O_<) !U'=_
M]Q<"&!"!'8 !V<=_W$<#>,!^DR$/<'6 'OB!(!B"R8)X\* (3C $3) $&L"
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M>)W2Z T^0 ,X\ *&8 JLJ*[_+I"*XWFT#!L1I3  UU"O&!LDY.D [0"AE1H
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MGD294N5*EBU=OH2ILAP2+%BT<&D#22<@9?EN#3%B9 @1HD.2#-&01(.&#1E
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&JDD" @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex-99d3g011.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g011.gif
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M]//V^?;Y_/CZ\_[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
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M9&FB1$IAV\&=)DNTA)ZR)<[FW"(=N4M,J&JZ16JO*G@M_'<S[&I8>*NP)CI
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MZSQ^__#"L:K"S.*' SP!\]LL8'"Y#.0KO",XR5.WO/NW>]L\, /#?4"'/$#
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MTI_4N._;.](]O10@M7SX0&'VQ'8U 5A#9M0[UWQPZR7=A_*] P>$V',;Y'5
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MPXK\.&X^H#8"6?KC=EVZRG)&$#R"1=<@>UU-_TH01#2J0 RLD![^^$@.,J0
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MADVXP6 #:((:W$UL-"["#VV,5[$(**]Y_W,I#E.,F,0E-L4L9')9!?B5']-
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M:(<F.AR-5=^D'ZT.>\(E,?:+<-;LVT!S\?T!\5_GVKH'4*U-V@'ON_O]M07
M,$8F0GP$[%WPM43&MK$-_E*T?+'-S\1O%2M<@^@C'ML(*S\JKOZRDWXB_Q;%
M-.+!#Z,;8.@&0?9U#4*]LJ'^_$P3^N',QLT>DBL>%"#-[BLF>N\2?@_A@H^V
M&JP=B,T S@_+&H$UILNZKDX!1N%'XJ$$3; ?HH^ZIN_O$"OVR [PNJ_:4*[P
ML@T0>DS(RH^W$BL!!H[9)HO/MH$4'@W7RHSF_SI,U/R-P92-&J:A"8\OQG#P
MSU;+ZC"+_1K0 #0.M%R.X'3"X,#NX,0N)OCK !" L+ LS+!,$@JB[<B0O=I+
M$QJ0NDA!L[8!T>Q0 :8!'NQNO^#-!8</!F/0Y&:0!DLA\<QNK]@K&H1-T-:/
M%+)NL:B+OBRLQF*B'93PZL!LW.+BLBQAM00,T"P1L<3L(H!KXGS"ZR80UBJ0
M[(YP\_P,ZA3K"+1LLH1-O-*/F$2NMT:A[A!+%":"&EY,[QC.PP)QE@A/Y0S/
MVV "W&JBXIR-N18@%*;!PM2OV<#K(";"$M,O$[BQ&S-!%#3KLHY '"Z""A=@
M'T+1 *8OLFBQZU(QUO^$+_M:T>=P#=<FP0-_,"9&;ZUR\;1(0=RP<.,ZC-'^
M,+$"KQA7Z?MHD-N440LCSR9JCKY"L;G":AJVT.<6R]WTH;WLB@%[T?_XX0 C
M1;T(4O\<$" -4"[,\;AR(@)341(B(1[Q3NX@J^I@RP".@!Z6S^)BXO4,TA_:
M :N$4A2XX?\F3#S([!JS#Q 1\I66X0[JC WJ[ _H#/&^[2*;<0OY(1=3#]]<
MSI<B3+&6;B;-;AKZ@0HM01PLXM^^D=%*:_J \2.C</M^$=ZR\!3?T=7&H<>T
MCR#34;'8;KH2X,&,[,:HX0I-<29*D;#T8?]Z[B)8\+::\CSXX<=D0B1#,KG_
M]($;NHP?N.'BT.CD[&PT#X_\7BXK@ZNRRH[_VB$>1@'>)LXF$TL3IF$4KE !
M<!'>-"$;LD'=RC( 36N]J($4$!.RMB$!YDL:*<_E0#,G?&_69BW69BTFJ8P,
M1:WB[&LGH0WID"[:A ["X T3IJ'-BDTFYN\@)_,HM"'J4&VVTDWGD"X3<&L;
M%B !\-#_M"$!UE&-UF$69B$79B$8_#,7@,$_D<$0U0\UU:\Q%RL!D+,>&<T6
M,;'!N(\?+HL,<8W_F.[/X&NQ?'$B8NXF)XO[?D(?I $:4#1%510:[$$,!S+<
M]B_+=E('K0L3FG,B^@$[JTL3$$C[T#,]B>(XS>ZU<C0/*.'-M,JJ\:9! 6HL
MZKB0C]H, <BM)F).2L&K'3"ANS*!&I(. ::O'1H/MA; +"=B(Z7NZE++KZ*4
MK\Z4QD2!;;@4U\A0/F]P)^KT)OX. 8IP^"H/ 7J.NQ @4 554!4@%&XTPVR3
ML1SK2?T..1/@1_^!5"A"RT;S4QWQSDV%LC438+34K=]JZT,#J1VV81L(DB;:
M;U2S2Q^T@11&H:^ <E25DA^"$*NHX4G;@1KJ2O(N AY&M;+BH39)H3GU81N<
M812TBB7/8UA)E6T\<U1GBU='-5JCM1V0M2;:@56/E2:4]?,B=2FV81362MP^
M5+*,*U+JCE,E,^J44IONM%#:M5L)"*UHS"V#"](V@3#K<\,0 !Z <13>%5[5
M:!\T2U,TJQ\$5F#]@<<PD\<NZ  Q4V +]H <-B0;5F(I]H @-F$E]@ /%F$1
MUF +5H%8 V0I=F$M]F%Y3&,SDQ\Z=F!#-F1W;X@8U$O7;_^0\\\(ZS#_'12L
MG!0C'E NDHN#,!,D559C?9;(0M)H11+[,%,\#K!HXZ)I$_8@))9HES9J->AI
MJ[9JG_9J539K14B;DK9K-0AKL?9HT99LX\)LLY9JDU9IR[9HM39IN=9LF?:"
MHM9MDTMM[_9LM_9B(^5IE0(%N:%P"Q<#/]-P$Q=Q#]=P&5=Q$S=R'1=R'U=Q
M$9=Q,;!R(7=S);=Q+9=S(Q=S.Q=T/U.)6JOQ%&#O6@L3=K%2L_!6<]; [H$6
M-$&M=,+VVB%W=7=Q)3=S&U=W@==W?_<S+Y=WAS=W?S=X=]=W1;=XE1=YFY=X
MDS=SMPEW>3=Z%_=Y>S=[IU=YKW=RG5=[HQ=Y_[-7?(W7>#/7?(6748?B8%W6
M(@2699'69$72?>'78^>W8B]V:/%7.SP6?_6W?Q5()$UV?SE(@/]W8 T8;]]6
MB29UM381L_1+'YPT&J34/MG78'1L@W'LQGA,4SS88'N)@W5L@ MSQWJI'TY8
MA%6XR%!XQU:8A$O8A3^8AD58AF_,A&DXA5<88G^VF68XA$%XQVX8AW78@WF8
MAG$8R&QXB#]XA&7XB%^XA3UXB9W88)L8BDE8A4>XAN%)5#_+(B<N'MI!NOZL
M:(#1%QL/K0S V  68"EXO8!3N,0K 537Z)9-+M2U'^HS'DC!4M_XC27+L=[K
M 'R1@H,K%'"/&'\QOD;.# '8@;O<.)"[M;7J<1/""DL9*P%&<?W4U<L0X @P
MF)+?N!^X81JTJFA4E13L*KPTH9/Y(1HRX5Y)N99[XE]M.9=U>9=Y*KF7??F7
M@3F8A7F8B;F8C?F8D3F9E7F9F;F9G?F9H3F:I7F:J;F:K?F:L?\YF[69E'#9
M8&RE6K>YI_QX$Z1QM8*R=MW-]3"!E@T"2SLYG(&JZ# 1D]NYWN@2\QQ+2B_/
MM=P-GG\*NCA9%%[,V#ZNT*20 0$-]Q[,$OO/GX&JT'9-7/U!#PU S+CAQ;1!
M#T?K]?:.GQU:J"B6&I!SU_Y.,CT2K! M'AKO,WGPHXLH:-%6:#&"83DH;YLV
M+BS"8"_"8;'/_W"4R':Z95)V:IEVIH5Z:KV6;C?V:[&O9'TV;RVV:I/(0JGK
M3?U!Y+I2W#3N-:5NZRBO5.WTJ+%1O_(6)@07 N6BJ#.,J'&T@K)K;=E:K8-Z
M)MY:KL?:K-TZK<OZKO&:KO6:J(%ZKG?_.K#;VJP+^[!]FJ\1V["Q<:^)=K%3
MEFW.VO\(^[%Q%++%VJZ-]C+_NL<F^[,K>[-_NJ<7FZT_.[,=6[09NZGC6K5!
MF[0MF[)A6[5-^X=]@A_(]W"%-W0O=WR%EW&=(;BM(;B)6[B)>[B'N[B3^[B=
M(;F7V[F+N[F/6WIUNW"IX;JI01NT@51UFWG!E[HS^(=4.!,J3[:NF@S#=;PT
M3A^HBA3B(<*6[EI=-2<V,WV7MWROEWF].WV/EWCWFWRA-[_[^[[YN\ %_'L)
MW+^K^[\'/, -W,&Y%\&75[_#]\$!7'KW&\,UW+X7_,#_.\,M/,2G=\,O',+U
MFWLIO,-/7,)!_YS$11R_';S$6SS&\[NW);S!9SS%8[S"73QYOS>\@>( 8=B%
M3[C(#+;(8;B7C'R$E]S(N*$1&"'*&0'*I5S*J=S*L;S*KUS+H_S*MSS*(2$>
MF!R&43 3N+,;-V$3C%4;J!6)=:S)C<RV=2@>V '-E@VKMT&%U?O;!E,;F-1/
MP5F#EWC0";W0#?W0$3W1%7W1&;W1'?W1(3W2)7W2*;W2+?W2,3W3!UW."04>
M&N$(JCS413W*07W43=W4CZ#4I1P2=@\>-*$;,>W43DWG1&&KJJC(Q./+$H!7
MT7OS&G _+WH3SG+[./J675J*/%W53WW9F;W9JYS59V*86A-YM6$X18UA$\P\
MTD@TBBQT 491LBB+HBWZQ;9=R :3'_I8%BKZV,DHV9T]U)7]W9G]"*"])_:A
M_38A&JOHXZ8A&A*@ 'C4)L?4ZA+4(((])#%AUSWA\=A=C#Q=WN-=WIV=WF,6
M)Z9!WZFH'?3-M(Z T;@A#G\31Q>,T;@K%"RA*QL^C!X>U26^Y47]"!ZAXF_"
M$>_A<HK$X14T01-$02G;09%3#2;@ >,W#PY!+N4=_LM=/NE-O=Y_@N9OO<@2
MNZ]MS#+EXL<XW>B=:.65?NM?'A("_28NON:Q?J#<?=DCGNM1G>E](NS'WJ"T
M'NW1'N:_'B*%ONT%JNSA'NW5OB?8WN[)_M/S'N[WGB><WN_O'ND#O^4I/B@*
MW_ !"N\3W^7EGO'KWO'["?(CO^6]/BCZWO+]"?.K_.PS?]7GGDJCL9L]/YY
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M\R+/\CVO\CL/]"D:__-##_+*/;D3+^,5#ZGC6AK]4#9BZ.9)3O6-6J3T9V@
M:('U>UWGE#,\!Z"I52_VR5/9C;,F,LBG]F%*1WZIH6VG8P_W9.\84A1\XVL6
M5SL0 "07UD$* :) <0_XG+,- 1TPU$ Q"]#"% (\;\$-"X  ,QSQ@2_Y#)+E
MH?2Y!4%*9C]%@Q?YD^_YGP_ZH2_ZHT_ZI6_ZIX_ZJ:_ZJ\_ZK>_ZKP_[L2_[
M_[-/^[5O^[>/^[FO^[O/^[WO^[\/_,$O_,-/_)\?QAE:_-OAT@,!#]J02N:K
M#9VOWM%A#]5O_=>/_=F/_?2<_%C1#LOZPD<V&HT?K#0L$#*<N/<=#9-P"9?
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M;".I)=E=AYVUU6)_I;76;KL]=5Q@1T6OEDO:=?==>"V!=]Y:8A4UV%M[Y:;
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M/W1]Z?CV>B(JV>J-Y0*,,5\:"&>F"(I=6$,BQ_]:TOV@QL(TH0WFQ",4"EA
M[/P1CP7H3BSB8*^J0YKIB?CV@,#&J4!;"D-#\C3+[M[HH"4"C5-CE3%BYG=(
M<X%F>[]:VPN?QH .X!O79>\ H1"0<$:!@(:-A1PDW6RH.:MLB<C[@)R^G+7_
M:4@PU^4;'A=UJ06LYRF*-C&)[NL=D@P$";=:R%E<>*S1;8!O"RP3G,$$50AS
M;@4,'2Y\Y;%_@7!4%X?8UVQ!7DY(?CAAV[3*>^WK>.,,\H@ /+3.CLN!L7S4
MH"*7HQBE]D2V:]F>3SH;K-L&M^O7#GXL0#!6P<K%,YYK/ #!"'JX.4;;K09
MJ!:R"0_;3*YN.$]/$2W_Q+:+-SP>;<Z"U>7+AGGRBD1VN-#\HYS],.8WJH?2
ML]KMCZ8K#"FOF(>I+&<;>U#M229[FMD%:S3C&&AN7[:*)8V:=+0*5;)"/X;8
M3AL*H48\DC[\KVP\K.U].IQ#.FJ,PCOD?</;2QXJT._3^WO\\/3?J'@\B*(_
M;]E.C*Y-OU'R9G2L/D;J62GC?<I$U'Q_8XM,0/^6'*N^C HL%].Q KR^MI.(
M2\"__=,;FY HG&"_Q/B.>\D/5HD58H&53A&/U[@0SO# #-D'SNC ,T&FTQ@3
M(+D0$13!,2E!$G0-:+H0;K' ?*&4"[S!2>FDI3"^_S" :? ';?@-^]D3C .:
M_XXX$S)!PC.1)C?QP!8T#=,XDW#X RJL0BN\0BS$0E.(BC7QAVBP!# ,0S!L
M%S&LA':I!# T0S&T!&A@0BA4PLY0PM?PAQ)LPC=\PBB,0Q'4AQ&<PSJDDSN\
M0Q9L)CZDDT+,PQ/LP&<(0S.\!'F1ETN@A#!L%TE<PS"LA0SAC$/\PT%DP4U\
MPSY$)CJ$P@]4PM'H0"!A0M?*0E9LQ2HT!20DDR^$1$L,PR,BPT<40T?\,@\I
MQ2=<0D+L0SQTP5]T0SA,PB;\1'[H!5=L1BS,A1$$Q&? Q4D<0THP0S6LQ3!\
MA@QQC3@<QB<T1C*)D)0[B11)029)$@[1$!6,BA)I1_\2=,$S^<045,44[$!#
M[*5Z5,)[+,4H:4<>H1& S!""A#XY$@7?*)!X@!W^(85IL)+GXP91&(4/R@A]
MH,'YR$@-Q(_UV 9LV(9L $FG",F0'$F2?(IMZ(:1= KV2 ]MX(9Q0$F9W 9N
MF,F:W 9M>(J,/!?SL,!,J8_V\$G\P$B.7(]HN8^61!6A)$INR,EMB$F<G$FI
MI,FG1$FE=(^>_!:.;,GZ,,J@7$H+5$FG^,AN.,FG^$B1= JQ1$N:-);PF$JG
M<$JHA$J4I,MS <NO[,FCI _YX$F-S,KPR :5+$EL*,F4-,FT9,N1[$KRF$FG
M= JZE,JFS$FHY$N?K$!F80__7(N[1%H*P3"0 ?G!4]*>EU2 WU" BO2.V[ 3
MUK2-W(B9V^NADD&;V3R:W'A--5&3$JR987*3#UP3WUQ"WX3-.PD-."D-TJ##
MV_R]M7E--FG!XU3.X(L]T>".VH"3UL3-H$G.-VS.7KJ]SQ#.BBK..G&:4SS%
M\B3.V(!.Z!3!Z8R-43S/ZK2-H,E-.L28JMD,]Z23TL#.[P09Z_Q-VFC"ZXP]
M_,3..7G/\RP-^F30U< -W)R8O@@-:=H:V\3/W,S.$10^GKF3_310,>D+$6W0
MCGG0!&43SH2D:#@ XSN4 XBXB("'I.L'XJ &[O&>%,U1'=U1N.*'N7O1?G &
M%D4,:(D0A2(\"*?('1Y=4B9MTEGB#:88!>K1!"]9R$S@CLG!'>QQ4B[M4B_=
MH6V@'@,X@ 6H2".-N(3!! &!T2]M4S=]4_!IAU$(A5'83'_0!TUXG*19E$8Q
M2#C]4T -U-/APU.2/4$]5$1-_U1%751&;51'?51(C51)G51*=5)]>(=WD,WG
MX(=WD <_W8A[> =ZL A.?8=/K5143=4!XH<Z>( (0 7MZ 8*D(!?* E.<( W
MR(>*J 8*H(!J4%5@#=8("H<(&  !J(%1A8YJ(  "Z(62H ,!P %]J(A>8%9G
M%59LS5;P084!Z%8&H(7HH =:D(5W*(ENB(5>&+Y?8  "X 6'>5,8&8M3#0F.
M80P/I+5R1(IZG4"+R%>1&!G0V5>4$-CEN0<<.%8*$( W$ UYH 5:.(>(T =>
M>-B&" =5^(18" ?9Z05:<(=N^ 19T-5SB 50 (58@%C9J0900(5PN >.359_
M&-E/4/^%;H ^>N@%7BA7?7A9=X@%C"W7B'!95  %6@!:?^@&7KB&C5%9ENT%
M=KW6F)6%3TB%FHV(:Z"%<- '6@"%5-!8V3G73X"%<-B9<$@%D$79"]N&4,B$
M!<@$42!2H[ 201&%1CF)O6B(>-@$3?@[NMB':= $-75;N.6&/$U-G]@&O04@
MN;U34= $<ZL+4LB$3< U?A@%30B%:>T):\A3._4(?=B$3!#-Q!B%3- $T]V$
M30B%AS0)N@T4H<"@NF6,=1V 6*@# 8@ C3T'"1  .X@(62" !G!66=A= ;C=
M5&B(=Z   G@#"   "C@'7J  8Q4  I  =[U3.VB XH4 .G#_@&9M"%J8@>EU
M % 8OFMH@.\-!PAH #N@@>(= !P VG#( 0)X7QKX57^ 5AS057VH ^T5  ?(
M 09@@&OMA1DH7@%X@$^HF!Q0V#>HWP&(@&O5AUL5@ "X752H&%!X  2F '#]
MKGTP4@,8X1%. +X%"F[#!-=UO@+0A)+HAVG A(9)CNY)#'T@#A(>TP2(N&D0
MB!/VB6D8X8;9!K<5E 4H *6S"[Q  +@-F )0@$(Y"=%8"@0P7(Y8R+Q8#$W(
M81)6F,P5B><I@",8BC!V8<: 5@EPAVI WT]H"&BE 'GP"S@(@/WM!@B(UE.
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M6U;%#S^D;!)->4_ZA__4E(<JD.-)";!(C4<<M:,))MOT$P]4:&FD (O:>(0
MBZ)@8A4_HB2TT"@;Z0-/)@=X%8]'"6C33U@&-!76@WC:A(EMA.)GTZ%!/=B2
MC4<$Z4^<!["DS9?QZ!/*0_'P Y6S5<D$H$.A1.C@6=IDDDD[_'#CD9%Y-N56
M4&]:FE2.O/;'B0 -P/+>>Z 0,, G+=7!UP#0M>0N!83ITTD=C%TF "<NH2)
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M<3+A2> J0J*V3$-T!PD*F,C%N9::29TPF05@9@@33JQ&-_IPC 2FYI)94&
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MS*CB,>6#/NR#GQA//ECG\9#/)[[#<A9G>9KG>:)G>B(@/=3!#$3 #?393]%
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M>,:$J ZL#=2 !/35U$@L5H4#)WR"&1D&'IU#6]$!1?0"!>! -T!- +P! 3L
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M  [@P&'@\=0R *&JZ[P.0 "\RQL4*T-1P'"XQ#Z<*;]T*39P0@#@@!F!45\
M\\1,6I\N#1EG#">@0BS(PJS:)P.HZCV @@ R@&E$52QDC"JK%1QQE5^0%7'0
M@B(1JM.^ R\HTASOQGJ<[JH^@ !4D=9$S13S@V.\0273<SW;\V:J$"W+L@#
M 7@X!GD8#\F450PITE+-P-0D#/J^A.<L6B?D@,FV_P=,1+'1EL<]W( >:0W+
ME*Y/.8<$*'.K:BH]//)XY&7#?BE,2"S#@$+G=D(U &W$SBTEB24_V.P R %(
MMRK#^+%+_.UB_4(1U2=N", .O43!Y.QET+(^0'(*WW-3._53<Q8_@!$%0%DL
M7.L.A0=)QP0G],4G )HRTX$BP<+/<!5_^DE:YD,LV,'GA@-FS'-,.$<$>,T:
M#4 ZBVK);#")/@"4T0(H),=($P%-F/1,=*F5.48QBX,$1-4=U\%57(,$1( L
MP -F$(<_N(-7D]DW3P>9G /&+(T[7&[6Z$,=C"I,V+*?$H;YYM!8GW9@0_5K
MPW9L.](:^:G K,<-R$,>D?^'ND(5#HQH "O-/BCI*),R#A!M*N@#$02 !*A"
M+Z "&9V"3!#N#'""'?0&!9 :MRJ5OM;J"L4"9<VP4M>P8+_+2;]$_OH#&$5
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M'2I%5^BA+?AW(*JED5H25@6. .  .>6Q-T#(#CZ''O)A0J[W/PSC$\(A/7*
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MU"4B]V:=<> G9$ED^(7>;JFT1?5AZ$';G5N<I&X <$ .E(H.2+\?=&17>"T
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MX;T: N"4]:A*P "G_E(1$/!&'\(W FC41&AGL3M]-0)(1AA+I!"J&K]^8L"
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M+6N]40TM0>60#SV01:#*-9\X4)\_0@"J%%-]NK566W$N)DLWG+"$BC_WX!!
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MS@$ :T J8!(.SPV  O#QA4.0 AQ0;.8H$IB!:BP6%5I*X"]FL8P#R.6Y!\P
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M2]SB/A(F^%@%%3 @!0SP#).:U.0%.NG)[GQ'!X H)4+HT8YQ&E>5J2!"#6B
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M2Y $.0F,)S@%A& (MV /'8$/<\ S;IAQ'5!=HPA*.G -[A $_A@#<U * (B
MCP"(,YF56KF57-F5'4@4Z8 &27"3.OF(4Z '@Z (A^ &Q+@T_+ /=F =,-A)
M',<!(RD.0: #.@ #@% *0NB/,. ,1^B5A%F8AO]YF(A),S!Q"TJ !$BP!$C
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MPO@$4="AF;H&&V"?0<,&^KH#K?@#T:B7TZJJ!/]ZL"J[LBQ+B^5@GFD !EW
ML+JZ!&A0G&Y@@NQXL127 2!@I+O@ALJJ'<RJKS[0E]<(C7IIG0/;LD[[M% K
MAN4PH>;I!V# !4APJTF@"_QP"\)YAE!P@B<XK!F0 1_0EG50K[SWJ?G@#4$P
MASG( ](JL%\5M79[MWBK?K+J!$X !N4)L[[H!NF@H8\(!4IP!4,Z<1E0K(2@
M#^+ !O,8-'.0#]C0BG7H'7*[M"B;MYS;N9[;>M_*!5[@!7^["(1P"\EED[YH
MD4\@K&OX7$5ZI&W(J9/;#3/8 YB;N:G:M)_;N[[[NS23#FF@L.!:!7SK!KJ
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&/QP! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ex-99d3g012.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g012.gif
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M]O7Y_/G\]?[^_LS,S    "'_"TY%5%-#05!%,BXP P$!   A^00!  #^ "P
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M!22JB33EN=RZQ4958G%YQD9U5*G;1!#C5#'6<&9L< Y71:\[<5U4I%6')8Q
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M,(-57\5Q\[<<_&J,:50>Q/O3SCC(@TS(;_5&='5S28V9[^%S$<LV.Z,U%>N
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ML$'87=#T5>GQ!6&O ,[AW8<<RGWNJ^+!V<Q6@0I8D(9KB'4?:1!V"Z:MUG8
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M1SX>SW85  +(8F>[!ES0<W)LW>2&E>T^] #YEF]@\EH-1]39[H)?_#0?UM9
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MW6)K!]>;@VIL-B3%*D" -S 0A PEK7 @7F=+ TT[R<A3 \Q\0]U# Y24SVS
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M2ECS$':Q+B>W@ H7&I*>=I"C'<YL1\!ZA,59#@0*J9OAHZR7E>\9R_\AXM,
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MBECC 934ZS*X2'9!PZFKQ9':<R'FF46X77"!WEC68(A97R!1HJF!H[V7"K"
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MK=$>;"@(  !< $C@PR8L@  $  $\P#1<128$  !0 $AX NA&P.+V S]P@@*
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MEDMNF0,ZF.NYK0.W3'SS0S@Q #  /B2P(RL  H"N 0RX5J0#9AN  12W!U=
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M@ZDG.24E"=B M),> 4RPNYIU:]>O8<>6/9MV;=NW<>?6O9NW[DT?+YR<YA)
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MT-%['D >$+D.+0'01#K2D1,!U$=P.IG&-$CXPK=-(Z=7R03^TH%+:3A@ 1F
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M$XBMUO3G LA- !0@6T*A$ G@X&8H#U/S$*<N.7WE 0+D=5Y2QSQ)%![ ;19
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MHAH2<*,HJ%<YLPKWK, #81 3L@D!?,*-[QJ7* B2JE2EPQJ,8DC"-(H\AE2
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M&$!X0(\GL#A1<R /UP2ECH<QN(B"G=: AS+LJ6@P7R#C&T_,!2[ #U& G/;
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M\X![;B"3=4"$00 $VJ (BE /HU@''J@^!G"&'WD1^"B4#;$V<!&&TI@YGV
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MR:OM20/>3ZJK-?"@CE #CY"4_= *"PHEG[ ME:(  /!3DMJLE[J(8U<-"[
M"4"&&Q&>J*H0('H.[F"Q%UL/&*NQ%INQ[M"Q&3N?.=J5-J *&[NQ[W"Q'INR
M*NL.S  $J> 0X8D*M@JEA,J>4JJK,0 $C: *R^"QCZ"FYR"T0UNQ0^L.<BJN
M3U*L#( /%A, R3<3C^D;'CEV(162#Q Y(^&MCD"7X0D$B0"V82NV8TNV8UL#
MY<D0JF"O9<NV;9L(-I"=BMH(\%JS4MJK-O #JJ -ZK 07JF@-@"X@2NX@"N1
M["FQ_T?RJ %01W8R71= *-+Y&Y'6C?XVAD2#@V@8JXKZ"'3+N9WKN3&@FPUQ
M#HKPN:7;N6H*$7-ZJ#5[J^TI \09!&30!]= E^Z@#,F N[FKN[N;N]F*)/&R
M$[0"+SLA8,'!EARY#^Z@#:K0"*7J$#O*JU):LX?*H=+[I*O*$,KIN4]*O=4;
MKU,J$:O0J^UI PW0 #M !FZPES]8(WPB)7YR%4V+2'"I/@HP1XR3L,YF#JG0
MJ"*1O,L+IX*:F]_I$.(KO=/+O=^+JP?:AH^ J[O:J[AZL^RI"/T+$?4PMS'P
MNC_@ V1P  UPE7%0"T?8OO<P)6N"%2ZD8NO -K*(L)(&)/\:4VF!(9\Q\ AV
M.1$MNPH!3+?8*[?Q:KJ<2\'O$!$.&L2E6P._FKHVD BLT =DT  <<  +P $-
M0 ;>@,,QLB3E2!18]&WW.S@5( "3JQO/*B.H1*8"4Z)<H:>!2I$5H;P[_+;P
M2J@QP, 2,:>)@ JIP,=][,=_G JJH J!*K(/X8Z+(,B K,A\K J.T*%[O,A]
MO,<2:09OP 0',  !H,D)  J+DP$K2KQR,[  T&_.FK\]DD6;D  '!$.!0;&-
ML CCVA!QS,-T;,LDVPJYK,N[K,NK0,@8,:>HL*^W&:? G)-B^[41*9$R8 -
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MH@B@">B\&YN-(L'J" 1\H]V)"C/;]$\/]5$?]4S_]$8ZVOT0KG7KO1NZLZH
MX/5@#F$O]F,_]MH@ 0)0  (0%@]P]18!A8$PA8BH$+VY\UB!YOY>\S9/E@E!
M[Q<(B'3PZ\(5*C\A !1@YF5<YS("J]C*$/M-MS  KY ? Y(/^97ON>;J$%X)
MW86*""H>X!CQ3P514?XIBL+H\PQ1#KMW@5:1#\*>]U?)!WN_$(N^YHXN7&Q3
M$,9:K6:-Y#-RJ@YQVA LP1M*Z ?_W-P-<9WPVO4 GN@.P0E-*?1R+A%X60<0
MWN8-40[I=X$Y?A/Z(.Q7_?J!(/L-8=4=R/T#)4A>>G/'8?0ETJINVA"H4.4>
M#\1U;+?L&;H7K @U@,C+ !#G]O4C6-#@080(\4F@@*_"@W4))1XT9H>.KGP3
M"<ZC]::.(5K(R.GCI]'DR7S(#,5QT]*ERT#&YI6<F"\8LH$G=>[DV=/G3Z!!
MA0XE6M1HT6H* "QE<,'I4VE'I4X=6DT @$Q4M6[EVM4K5U1 M$UTIRC&6;1I
MU:Y5:V.L268V5'%=%[&N4%UO['C+J=%8G#<L/08*6:XOSWW>O&4\F-+02\AN
M8L[[6MGR_V7,F35_E79UZ6?063>/]FD5@";2J56OOKQ,KDEE-6PH2J3(]FW<
MN&OCMA$CE<Y]JL2RGAC/T)L]?"?RJ^BQ#N3!M9 9!HZL#AU:] HZ?A/992&9
MQ,6/)U^>M34*$R1,4,]>POI0YHF;%BW?_GWB]6S7,VGOD=AZ A1P0 ()-$>1
M&AQY!)4%'W'PP0=1:22&1NR1C[D]ZO#HF,,*VH<8.O2B@R7O6K(C$.GBZ=##
M8.R(HPXX9HF''Y6Z*S$FQO#3<4<>>S1('X)H"M+'T:HA "LBDU22*'?^8Z:?
M?0:24A\I!]H&B$=6U,F=1A99!#<O;0OSMB\=<<<\>CIRHPX-[=$PIL-]=(F#
M#C[H*+'$.E!$AAW*-M*%#CJ"\8:/-PQ9Z4[P^EQR448;=?11@Z:YJCY(*UU2
MFPEM:&133COUM#=E@K)''WM&S<>>*.W)9Q]]]#G5U5'-$^<QEUY\(]"^YJG%
M(V/*,8:60.R\$[(VW*##D%J\$:>C.M[L9U9C1X0LCIB M/1:;+/5%C,CD=SV
MV_+V408(M6"(01%'-DVWD74=<?=)<)<S9H]B7XK#$#O>T(6R>6;Q"!DAYR'G
MUT#L&#8R.O9 3CF"R'F,#A=MG"Q>BO\KMOAB@NC#>&/+W$FEMQAJ"%DV5?C3
MDN.#."+1WGVM>X,6;V9Q@P^&$<IG8&!7+A'0F;U!J!Q_Z;AN8B%1-OIHI,W3
M.&FFA<*4+2"4.9EIAR-##F""D%%8PT!\-JDD?GREA0^=W9C3SD+"D:A?8V=1
MM&FXXR9*GW72L=MN?.0NJ%M*]?;;('$36:N&1LSYNQ\:GXLL$'( '[10<8":
M9QR"#0;TWG(TTE5H8XH^_///JYE@@0000,  !#CY6U)O0?>['E1 3DLN"_^F
M9]?(XM@W(7&"B:>H>7S=0[)Q3MJ'6:]=5UYN?!X [3/4_.9[>8/L0669HY\>
M&:U$I#Z\ZLC_]NC<LC@W]!RAJ@MIG'KVD[;&  (R\&3^^:M9?=+V^UDEAD0,
MWSCP[8F,0O[S&X:\8XC,829-$'.61+SQ&$.L+W\3W%@U#" !:[EN:=2[4B,2
MD26,U>-C9Q%@#&R BC/9KA9E,ULMM*,9FP J&"M*#*%F(4$*YK!B^)@  ]*Q
M/--$;WGV<$3_DF&#4%EL&Q,BH0"[][ERT HR>\#):*+4(GWE"$K>4)B,=/C%
MBNE#$P)@0 8T<49-3.-O&U1>*Y#8#R+VKV+*$%S(T$*X;1QN'UH[( ZM: P-
MU:)/^P#DR]X&1D1F*QT)>-Y2A"BWZ2W/'%BJG3:PE$%MB5!V-1!9_PU2D4*_
MY4-.WA$D<?;(!S?(2!\MNH@6$_E*2ZUC @YP  ,80$L'>.)^K0.=/HI(0/W9
M 'O;,@<3.<D][_T-?%,<WW@&Y09DR7!JL*0FH_AAK6MB$I)'ZMOACIB,@]BC
M$4! A3+,4;M*T9&$=J306_RVQ^%%QA"1DU4AWL"K:593GSO"1S6L@0]K5&,:
M B7H#_TV#6XJSQR)< 0Z"V+)LR1B$8\PIS:39 ]5@*R$-GB$0^4VCU%.JY3V
MF54AJKA/E"I)&@9@@#460 "8QI0 FQB//O"Q#HL6))NMRNE1V/BW??P'F ;9
MWQUK  1%E/.<.\FG5PY3S$ZR,Q'):&K%]@X1#W+T99DO<=/YRB.PE/^&-4G2
M(, "D@*   !  )YYI&JF08$%+$ "HDB(-280 ;P^( -YV\I/_:8,&[1B(O4P
M)CM#AE2E]K0?VG@$*#.S"E7DA!EU7&<[X;;'0HB/57R4)SW%^ME7KD,:T\#'
M-$1QVM-*0Q0&74TU&$D  P#  '0]2"C2^ID%1*2O"?W<0ANJ$6WTYIA-%& -
M$)%4<SJT+##XC6:"&P-EV&.$)33A(_C3M#UJZ%;!"(:P7-*&.&0'M.,E+VLR
M   &^-,! *  0C0!  =\XA.>$(5BB>+7N 45"'DTB2I*R,E.#I>$0&A$.<]A
M/2 XP@;PN@QA=\/$[<4 "%2%6PQUUZ(7E:W_J^7E<(<SXXD)Z+(?YXT 0B:
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MRY9>!AQ @71PPAKD_[D'!M:Z"<^M@Q.9^"<G B" J!AE':((1;E%L0G\'>Y
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MT9)G8I/O:HD\J05CB(<,)%E#N(Y</(FXG=L](,T7"9%:(,ST"0=19<2%;=K
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M:_$^B#A^!HI_!F>H>(RO^**I\BOO]E>.9:;E:'(W]T7A! -8*RL^#:#_D
MD,QLZ7,EL5]V8KNAB-5">8S()@KI](A9""1R2'2#IP[_2_A2QW#K+N\ZMO:(
M;P9OCU;:G59HA81)V&0KAX5*..F/!_F%W_*DO0227Y*ZE*T (( [GRV@\(1<
M3P=\L*DCK!283Q*A*R$J!(ITS8ZHAEFC&+;EO4ZRA4LAYT&B_WC37OAK'7'-
M]NIJ_>QF> 5VYNREI=9+\'@M#UQPKP1P!GDG'OFO)Q(C<8!I6 ">SH0$"#V?
M\$$ 4/$'H*4*:,U%>7L?<4XNSL.>(-F1NFAF+G>H=M#C[@<N,EC(6'3<[[#
M?WS+EN4+'_<,EH5+H..N#GEJ/_[)=WA.AP5G_T"'>_C;<._ZS4\2(W%?"F
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M@*J'6OY;2YD$/R"#,)0#:X(,M]T2>29-S:DGI@&J+TXH?@9JP:0#)U" !%R
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MW [M+ :#Q1J?W=XMI*1#!*#>Z9V> OPCBTQM B!C/^##-(2"FF14>ZF%-63
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M JMR9V3GRMVM;6%+]PL@P!J>8#2,NCGDL_L;ZB@FP%K'F@XB$Z3RE2_(!![
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M(&BQ:YSA7+DS.AO"5JVG3X!U(J!C C#@ BI@I>)"1PGC/@FBK=*AFQ;"&B9
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M]5.- 01,TT\H6O;G@(1F52,B6OH\4*.'9DE:)%JA0(G6.D!)D%:L *!Y5IP
M.) C67T"\"?_6ISTE^A9TE*05K4 >'K6J:FB-0U?K.&J[[[\]FN2/M5XPLDT
M(.(CC2CK0&1-*)N$DO!9R@(P(EHT+@!M6=80><&[UIZ%;5O;!N>M6?K(N6.R
MRTU\UJ$ B()6.OQ1>A:G\:9%+VUG<3NROSSW[///LT:LLED57TR6M#*;]20
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M  .&&(%^7" "H=A0#!\0BE P8!-)A @GF&B7X6A"&IO!I">D$8$)["0=09B
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M$P[+0-I\F Y1H"D=&8@ !5PFC0D8D1.;D ;H1NDA+M)&'P'MZ!4]D8EI')&
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MMEBP::ZTI&/X DCV2301@/MRW=1$FET"0%H6F '@ A/X:G[+<JJDG40?%Q"
M34FM_7^E9&(M.4U8I%$!NVH;(A@0+C!1&GQ7$JO'"8 C )!:HPD!Y2R+]Q&!
M5 V5MS_K0"/"$Q)W00#Y(@VGD6>IUQJXMPXB5 T*D"@P\4,)\0!@40T3H'<P
M(0JRA@$4@ ]&E#<2D D;Q!D&9UKLU ^9,(,/@"99AR82<&4%_W%\9"4!;7&"
MK983_  3?:)TF$-K!D!N9 $OQS(6TF  "F -$_!]8F$F ;  #I!K9&$-RR$
M"< ?/8@6&%*%Y%(L+M%G)$%QU3 -6J( =/@1#I8N%L,2+@$35J>'[Q<I0&%5
MK>& _\*$EI<WIP*'(Y$.#' !@@4;IR$-%H(EH0!8E=@:$= K3_18FG [,,&!
M$G(!;35S_5 !%[ .H@ 3+B0*?001CM1Q=6-$%1AR0(>$8O6%<N&#32@642A]
M)[$.%Q  FJ4]3!<N>^@1Z:!UGR!W8 AB9'0WBI8 S1@2O\*,UB >CS86I>$6
M6)<2$; )-#*#1T,C!@ LPI&-'Y$N!?_8$A UB,9W>6PG;(J8$Q,(1L<H -_H
MC((53@9S&IZ@?Q5!(;F!3>O25S Q23"A#Q60'PL0:!R89B&(BH*( +"S6-.P
M( XP 0N0 1G&B_34$A+P%O@VDB#1)[AA/Q40 /[X&7?A-2=Q*)LC ?RA !G0
M?" 1*U(X%N8W,;1&;9A#(U.F:XY'&[;1=N67">SE;O4H$O#X,*?R  ]!@#R)
M$3.):,TRC748B"'5CYN@DEHI6)*H"3"X#J<T/A3R10H)$7T%EU5C69GP">R%
M(LK  &KD:II0B2E% 4SU.K2X *_E";1!+,1(DO>$E7 Q+6/Q*TP9=_1RE$"9
M":K5#^N@)?7_)Q*5]A><)A:FY0DOF'1=EA/@@CJTYGZ/*3JE:1*'<AK\L'8"
M\$6)TY& ^(MC 8\>8G7Z1VM< F*'.!?Y>!+[R"/TLID?(8F<L5@!Y(I=&!%#
M5#<(Z6H.$"7(A"*< %$70"DI11N?0)AG<P&R%Q'5H DAUX/?R0DG<C8.0)F*
M:4]F0@"?( W\X9XE 9E66!)[81JCJ E-8VK\$5"XUI(Y45"<<*"J\0#SEIM"
M 7-VEY4<<2H(P&*:B19O!Z$9$2O9EPZEH9%DX0D"P "*59]EX8<"=QL#4Z'
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M!1H0!FJ0!FF0"V*1#V&P FAPX )^X((PV1%A"BN0#1]A"AHP!Z>PV!$!"!H
M!A&>!ER@ G,@T7K@ H<=&N00!BZ !Z60!BQ@UJ)Q#%"@WOUP"EQPWRG$X%_@
MVA8AWT"^$:>P MX-$K? !1C>#X 0!A)-#UV@!D/]"UNPY'GP BL^$H"@ D<>
M$5 .!N>=XRM0W*60!URP J8PU((0XA$>X3B>$W.P!<_=#^T !ER "Z7  GFP
MT>+P BX0X6A0XJJ=%N&P!2OP!7,>$=^ YAX1#EQ@"AI!Y6]N$<4 !5WN$3I.
MU?LP!VDPY"GM!VH@T7WN FG0YFD "/\EP@8:\. '_@4K\ *\0!&\L (K@ >=
MLP]LL.<R!0@7;A8,+N>?@MJ][A%NG>42(0@JH-X[4MW)W@\I;NR>(0@KT LD
MH@=&+AJ]T.S]D \ZS4(^'N;V*@? _A&GP +7$!+TT.W[H 9<\.113N3#?N70
M#A*\?NX2 >5A<-[DL 5@D.7B  8NP.-!O@(X3N$?$>=S_@LJ\-7[0.*)'@XO
MH 81P>W2WNEI<0HO  @L0.T7\0TN( @?H=09X=)!?0I<'A)X\ )\W0[R(!;9
M\ *\W>=L\&$[P@8NX-\Q0@]4[@)+3B+Y+0<OX.$0<0Q;,.DNQ>M+O@_7T//M
M4 P>+@[%(-'_HYT+N) -&[T/8< %B3[:X4 /Q7 +O< .]OH-N9 +Y%#D/8_<
MOW +O[#B^5 ,8? "54\1R'[I_< +&@#I>A#TWX +N2#PY+#VN' ,A+T/X< +
MMU ,P&WXB!_U,LWIA'T,*C#=$R'>.?T+@U\BX9 +O(#S$-'TI] +T+X/Q^#W
M5@\1X: '*@ (5B\.A+_MBM\.P)#XP)T/UX +O= .Y.#XG'T,I\ +WQ#3LG\*
MOP#<7H\+O"#TV? -7I_X$MT.O5#UGZWXY(#XI[_M8? %("W[;+_BI!_WR4\B
M?3_X+$WV9E_N=@_U&#W:DDTBQ2 .N\_0QP &+] +X@#EH5X,IP ,_W/^#0"!
M1\6I;/WTO!#W#5>N;_T<.FQ7[-0O<0\M.@2DXMA%>EW"T+O8+QL+/Q=S<2D6
M,J0@%2E50OQUZQ<YCM<6AMMG,5\V7+W:S=G23F6Q%7GVM?OR\:6X%VQR/LPG
M\%>_?<?(A<MUC-ZW8T_[<?4:CM>M;_2*T0Q)+TR8<%S4>'5([A?!;RP$43T6
MSNRM8B#)\<+U+:?9BE^ST;/)*]S#B$(=ANO%UW&X/"I*9=L7[O OGU3EGL)U
M#615-"YR+<Z&F;'$7FCQDHMX"ICCD'J^3';A5.4^-BY<.^RE H_%;RX$$3W%
M,<P<N"^=/X<>7?ITZL\!K2A(54X7Q[E4R/]YFN=V.SPNH$!Q,8>VSC!!7ZI5
M(^?%BQ5=LN<S-1_*ES0LLE_DI0L7MG"!BU[Z$>>+%51X@;F+6'+I(5Y4,*4?
M/]+; @H67KC%H7UPR9"+%UB8 Z1^3CF/"Q>ZV(BJ4O1S(8W%0FIGO0EQ"2D<
M*/ (XP47[,)%11:V:+&8+PI\80M>GFJGM_E>T .D4UQ0(3=Z3'&AH7"VP ,-
M'U=(PS'RS-N/C1<6$R>-%[@@,$J5?E%1Q2]:S":, ><S!23XS'1AA3E^ >-'
M%SK<<@XPN%#1S7S"^"(?AXH1D$ #^Z%'C05?2(X>/<AT00[']LDO2?Y8N.8B
M8%S@!2(!&^KG&!?_>IFR+#148/ 6>K[H0HWY5OSO(4!88)"Y/-([;T,<'3H&
MC"&3Q*4YC%0HU:);E;J(J2]4\[ =9U=JZ:5]>E%1TEZ>"D>-.UT Q,0QST,#
M#/?20H.%4^1 U3FFU B)J#SZ(8>+.;[0@(MPV/C"Q'[R@ *M4PC,L+P.0SJ&
MA5(.]L^B8L+=0@Z[* 5##3[]! :,$4W[RCBJY@@#8?JVF*H?7E9(:9];7H!"
MQ2Y2,@783O<!I(LY%NSP%BZ@Z(*^$O-A ]@7!,DG#3!,_$7 <'-Q2!PNNIQO
M!30*LXB<+4JJ.K=M>?.-HR^XH"UGK;YX^B(L6:TN;KGGIGNZZ_Z[A846__$(
M6*AV?-[G9U/((<>4[YS-Q\M?CBGF&,:/$8H>,%1@(QMQ3ED!CYQRR3P<<DI9
MH>*+7 T#\F/LW(@<-;;(9CV'6&HQKC1@-BC@7R)BDZ;B9&PG'($.W#(/<2+:
M @TI.V^G%RC2,/BE=GJ<T:)P?@1$G&S J*\7<7+9><N;V_G&W%+WH?>4=L3)
MN4)Z3E$!%Z$$P0[!'_7X1IS*DNOG.D&NJLR%Q?QX03'.IX<5M(PX+P"#Z;CP
M-')T80L^"8<<5- AM5"N?G-0P19,(8YC=($[TU.!'X9WG0HMJE']\)X OY$&
M%Y2J'6F 0EGRQP) P&9*FG.9GSQGBA6L('9Q@?_"OEJUH&,) B$\+ @YT" P
M>MQ* VSX1CLPYR!IL>1V!]/ ]XJQ!;0AJ M<F,TW>A,ABUSGAY3R2/,>@CD7
MJ,$4 J1.*2CDN,<Y)ALN*%T[3N>"C;2C-+BXBAY4<)?\K6!_X9A#WUY"E P>
MR%XOP%>U7H"&HVS!3[WX!3W0T 6#S0$A_2A&&Z.("Q=H '\7V51#B (V!&UA
M3NT !A<T,#')J6 .WXA@!D\ACHL5K#B < @;5!"&L_ "CR#!A0JF$HX7"(]X
M:=C'E530F8QTX1:YL%X;P]&[GP&C'TUZP6'VL4F09 .!D*L3"U)"CA'EH7YZ
MT$"%+O*+ CZ$*<1\W#'_!!-,%W#-0TECU:W:!C\#(FL%QZI;0A6Z4+O%SR'%
MJ1!2CK21B/6B+E0,G$-U,JL%]5 %/4R)Y#Y)E3!P<A]IV ):D*91#Y7G/Q&3
M@T. XKIGJ4$/-Y4#%VR9$WBFRB&@*U4VW/F0D53H&"LHQ5.*\8MHLHTVMZBG
M<^B1AQ6<4GK'=(@IXNDA-!2L%.JTYQ;F(!(6Z.$AO'F!4";D$D%4;'K48B<;
M$-24IZB%!8M9W8S:@8OH^0JLP&$#.3"'T'9P@9.2\Q^R5/ 6AUPH'&\UD5HX
M:4)'P2]"[!Q./]BP!9"(8PN,Q4C%4(H6WO@P)&S@3C]* 04ND12:H"O(/M3
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MNUI$+P63,@\1S,0IL(>@JC?CR>CYAA>(J0JSQ==A2I60/7'T(;*)G@D!IFS
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M@UOHJZ;5 U/H"@^+G>2)GG#(I%_ZAH@&:H4>Z\<X!3THA6+0N'WXA;D&KU_
M:D"2/XB6:+D(SHT6DU[X#\APC'RX:[V#ZCL$ZHNPZ&^T9Z]@ZL>XA99N[,[C
MVY8>Z;PFH\ED:3_@!7_*AEY(.,-^#HO&Z!LFA\H^CD]&;#\HA6_XALN&LF+
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M$#DT642( VKH08&A:/O!S=NUU[ MF,I\5#9P06PLUC=LP1&FP5!&Y**9VM?
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M-^P/K>B-;<3'"T1//MB'Z5I(/P"#ZJXG=\9*J_9#6LGNS81G3&%<.SBAC+S
MK]2'"G3,S9@"O]Q"!/'$6+#_P<9DR?/YBZM%STQNP1^QPQ:("7R@Q\SH(&=H
MW<XA1(6@$'UQ 7UTX;TIA)/,!WR8E:/Q1?C8&-4];(R(UC&<9:_0%1N\AXFP
MY/TQ[$""2"^H ![0BAX$(IA,HUTP:7UHP$ZR'@O@PH6PSP?YF%^P1!<:4#O,
M@0:<ZXCU:%'V ]WD@><:S_&&@6'L0R^P@*N(2-95W1T^#:MT ;Q@2+_YXI6:
MR@L(EX<8L1BM@/NHG$[1RM5]U$,@TT2HI4)T+<UH%ZW<C*I$Q(!:CB)*8]UU
M,'ST@O7P1%]J+D7PPSSL@1',[: V 1P,PMX^HIB1@37$ QE\0 D$@^.50"=*
MYF2^_QD)^  V;(,/\$ .1!3GL2(.!($Y_!D@MRT]X,'UR$'U" )+U*@,I@0@
M$(\<1!@)[ISUVMY0CH5K6 4+J%Y[A">&; $>X,$7J,&N"BVG0*/GLL%'*'/U
M*!N%E(4<0! L&X66H 0+U#)3O 0:R 0:F,^UUF8Y_K)/J=Z!A*<XS% :S %J
M,$:%H"P8E%S'?*XZMT6S^1A,[F]Y99R6I,%[N9)"L&\7R &'A<&.T)>A<5$6
ML4$NE\HQB!!*B,0"#QLZ=0$;-)T>'XD&H$&0>LQ01"@:'&0LJ=(<E J48A.K
MB"E*@<@^\-477+-*O =%2H0X@,'6Y0$:-&VZM$,:1/,RXO\LF.!,283/'.0!
M&"2A>]2FWH$5?"P(&+!!7QB0CY4;"1X1,Y=(7AQ)VO&Q#,K$%YP6&C@MEK[
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MM90FA_>"R4.^Z9_^N//#8S^!$#B!%="\H-*MK"-#/#&!GQ!'"<1[OI\.)H>
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MSZEITL&'$W'/?;4F:S9!V>6OP0Y;[+&OZK-((<;P)AXZC)BB"BF$(*M#)9J
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0FMT<9SD_DR:BA;-0 @( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ex-99d3g013.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g013.gif
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M\O+V^O3Y^_GV^O[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
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MT@QH0LN9'S-PUCLZV8]Z-9H@\>K7OFXMKG'U6E[S>LBOJ6ULCH7L8Q>4MA'
MS?_-=:,;G!WI-L'EK6]XMJQG![>X449.M("F7* AU\I">\Z6KWSEXU++.<XQ
M.M&Z#>;J4%<##A 3=,U<DNV.:]S;!7=XLHNF\9A9O&M2$WG 8X'R>K<0/'&3
MFWF"-?6L1VN">'.<E/IFG[@+3W3.KYWME!0\*Q5L^-'34XRJGWOWR6Q6M6J^
M!07@J_9K4(0"RX"O^J^Q"DQ@C'K;A!2U(+ VB.!KK0O<)R0A@RN\PA1Z2X,I
MA:$*0QQ3FO+4,S8]\0W_U<-^YU2'2T08PE;\KJ5>+&!.Q#&.IRCDJ_KXJD<
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M!GE P BP/W\0R('\2G\HAT4(2BV @SR+PHK4R2R  Z*4J'(8R#F@0^G# T+
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MX(NV_5-%>0.W7CB'-60^8HN D:1&5SO&+HR U/RG<K#*5D,!0EC+3/NGG(N
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MR +1A39"6"F#<[76ZS)Q35Q>Q#[5M=3"C=&;%=DDO-88E/^'<V!65_M=4!1
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M,[I#U:\?16CU@CD@)0;7!N.ME&"O#ME _3/-9NP7%>]M)8$4/JE0WK*+U=I
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M=UL[*7^B:(*_5Q4H0D-M9H9RUZ/+.Q)P8V?LP)H*:U?#@NCR.'6>J +N,BP
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M/-@??-I'_,*S?<BO?<&G_9 K LVW_=CC.MR+O=-C?=XWO-VCO<7W?<-7?2Y
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M6DS]XD>6-&$*^X(JX,\IK)$W[D"6[*'QX# ._<$-S*<0<L<<K(P."D$=)F@
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MF*M(=0(?P.<6TD=])+/_1!(K.A%(@^,N(-,K&Z)&Y*$?=,^M;L+4X"EL!G(
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M"O2U7G%\>_=%JE?*1K-ZH\QZQXQY_TS&(,MX<8U:[R.T"#$L$V)WKW=\81"
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M47NT*V>UV;N]09N^U;N\X84?-.*]<?NU/WN^L7NYO3O _9N\M;NVLQNY11O
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M['GVDS&+/SELXL\^.\PBFSCSR%"+/?:DL5$.8=&F#PRT&%15@3C^K+(&3_
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MV!?VF \\H32?!GF"C>#,8@=X\YY/<K8*>+Q/'\'8 ;5VTH9 T2,-!/+'@RI
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M2)3YD2'!@K.' Q+]6'TX8KYY-EY$%F7O/-_=*,E5 K["S&6NL\*49FQ@PQN
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MDBJH16&)_TN!IVEH%)TJ%:!:I\D"JJ(ZJG?Z%9AJJ(6ZJ(A*J*K*JGS*#ME
M#:, "F2*!G]9H ::IB"IB6KCIF^*F(=4)D'XJJ]:J$#XI\>:J(IZJ'#(#MP0
MK::X#:9HK=>*K=F:K=-JBMRJK==:K=H:KM^:K=O #A9IK=[:K=PPKM6Z#>8*
MKNPJK^2ZK=)*K_,JK]N@#>QJK,;:K,G:K\_*JLKZK(-*L,<:L,B*L &[K *;
MJ0FKL ZKJ W[KY,ZL=!ZK]BJKN6:L=3:L?%:KMF0#7GY"9B "6A@ @0J 03*
MFX#YFPIYFMDCK#,K'6PBE>\0K=J0#<# LSWKLS\+M$$KM$%+"_]%:[1'B[2T
M  RS0 M,F[1/"PQ/*[53J[1.2[53&[6C<+57N[11F[11:[5%R[2SX+5;^[5*
M.[1IJ[9KR[9MZ[9O"[=Q&[=A.[5D:[9FN[12"[98:[1,*PJ<P F;D F5@ 9I
MX)4JRZL1P)FK& ]T6D^$N5<T*[EW01W]2:O3P DI0 &;N[F:FP(HP+F;VP,4
M\+FD&[JABP*IJ[D4H+HHL+JGN[FI:[JL"[NU:[NH"[JHB[NY>[N]*[NX2P$G
M8 *SR[DI4+JL"[JY^[J]R[RG^[O%^[JYR[O,F[L]4+J>N[P4,+JM&[N@:[VI
MR[VA.[JF:[R=F[W;Z[JMR[N:.[[DV[G_MYN^GPN^VBN[V'NZHWN]M@N^J]NZ
MQ]N\OCN]M,NYS_N_!0R[)Q"Z$T !'1D!NZJX+<L%X]B42FE<DVO!<F$^\3"K
MTT *I. &7KF9AZNX)E "+<N;O+J9O"D!)K"R!>J7$5#"?UD"?OG"O)JX)IS"
M#YS#?[G#BMO"+-O -[RK#(S#--RR?NG 06R@ARO$0:S$0,S#.FS$(.S#1_S"
M.BS$NZK%.?S"+$S%)JRK,DS$)UR@)6 "#=RRNTK"8-RRNPG#8ZRK6JRR/YS&
M/&S$/%P"$U "<@S$+,NK><S&++O#*_S#)/#",0S#*?S%5:S"5\S$?>S'3PS'
M=AS%5GS$*JS#_Y@,QKOJE6/\D9%91\%ZP=9(%)1)"K;*!F<<P@]< GN\R2AL
MQ86\RB2@REU)Q2*\QYJ)R3V<R0\<Q8], F?*JRE;H$1\RW?<QD.LQ#P,Q4\L
MQ[YLR=!,R7;\Q4R<QGP\QSY,PUPLS1$PH(A\S6C:S+OJRCA<R0T,SF2,S6@:
MQ[ULQ'H\ =A\PMXLPX$LR+',R2E,RXIKR]V<R;?LRP9:S%H<SR[LR%5<S8S<
MR)?LRQ( QYS,QIT)RL IRJ-,B1F\#;4*"I_ !M#LPHB[SB']PR.-S:T,PR;=
MRGN<TB0 SBGMTB\=TMA<R"!-QS,=TS>-TUJLPCG-TSP=QSU]TXC\TK%#O<=
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M"I/_(D[FGM=TR"_0B4Y[F+-AIE/G.^UZ5[SFM2W$"Q/'UC!$>0%E>3713)P
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M9F[GKF[KOF[J-N_UMF[TUN[RGN[XGF_XEF[W/F[S1N_MULYM@&WZ_,\5%7
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M.14#Q]C0.HW<9FG!4G3/%OJA,X390'0AF44 *YU#$PQ$S^'>+J@#^^F3\44
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M3+@@61LT6&V5!!:A16VD"Y#!'T"46 9A:\D$-<\!#K1 "[B "ZHU#ZPG#K1
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M8WXV[)M_?_;WL\/>-BZWAS]V\*6_O37Z8&O^OOQ6T^][UZU/33<GF\@$&]9
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M".RA)TUI PDZT#<F\7@O'6A#5_K3KVWQH&>+:1>'<]0@1G4V/?UIP?+2+-"
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M8 F6L(@/&(D.    @ DQ"  #H WZ8 "4V(D $  +P XZ-@H$T(D+ (F8]0
M4  PB!7:, "4:(E3P0"?" I3X0D _T  [B 5H\")G1@ #0")E@   A"'_I -
M E")4I$-"N")F$@)(!@*SDB) N  5T@5U>"+G7@ <:@/F*  W! 6^G     !
M!-( GRB+_B"-!!".89$-#3 )4C&,!8"*6Z$/S0@ #:! E   !M"*1H,)TPB*
MN_@.!0  ED @\$@)]TB.YF@5EI",O_@ (,@-#_   5(* 1  @QB)#SB)J[@-
M4B&- [ -X[B*#I"2^8@&)_8.Y)@ #@"+#"D5[^   ;"* &D5_4B)"P""_;
ME&@ D"B0!+"(TP"+ ^  $)  E(B1_C",Q3@5R*B,[\"4 :  $/  !PD \N@/
MH/")#)"2#?_@BY]P%3^9BRG8 #?) %$Q"@$P .[X%2?YD *"CO[HCB09EUZ!
MCP#@E/1HCUI!#1)) ")Y-*/  !!PC40CD  0EF/9E!T% 0Q0"@/"EW2)%?K
ME%V)C;"8 !MHE67I#^C( !FYD1WID0UHEWW9EKEHDISH $C(E MP%:- C(,(
M 0!P "98"N1XDP6@F+&9B[;I6[1(B5U)E._0#[1( !T9#T!I .S@#P(I -H@
ME3=IB<-8CA7)E /PA-+(D5-1#; (FU;Q#J4XD_K@  )P !4W"<08"HOH-)"H
M#]50#<55#:% #2ZIG?6Y@MI #='I#M2@EU.AFDZ9EQ6(%MFP@NS_H)_<, K5
M0 V<R #9T _TR [9D)_ .16X*0#).)/^P [54''3$ K5V0_X:9](B)^E@(KT
MN:"E4 H+0@W&J _4$ JEL(M(F V@1 U 6 W!5 JC0*!3,9UQZ Y,^8_\X$D1
M1*,((I^850VC0 K1*174<) -L* =Q:/Y"8,GB096\0F8&(?98  "8([:P)0*
MX*,V6J%2T:!Q&0\,Q0T:R9$B6J-.DY.H^7\@28RDL(Z8J(GDN(\TR91.615H
MX(\F^)51.0D!$)8XF15UB@D'^9#\0(LW.0"#B(OU^(I<2179  K:$!5&:IT
M0(=):H^D<),,^9VGR0ZE2)Y>R(D&  KL_[ /#!*.F'"331D/!R  LE@* E
MX:@/#Y",H%BIV5   A":OAH "?D H'ABJBD E/F5!#"J\8 & W"3 M  56J3
M#,")!;"5N9@-PT@ Z@F6@#D5[\")D@D "0"#TMH "W"3!( )ZWJF4?$.#8"L
M!1 *5BH !J"6 1 *EQ  \WJ,]_J)!8 )P^6OR'J5U1D/"7"F5IFO5S&=?2B:
MJP@/O@JLGS"L<5@-!#  I("B"R"1!6 )_;"?E$B8\;"NGZ@ U9F9GUH5JZJ/
MTX"!3/,._ "4U!ADP^J.-DFHV9  ^,H IFD) 0"=O#@ !&",>PJ DY@ G)@
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M?&N)_3") 5 -0=N8_C#)OLS" 8B.#; /R^F><'F2!X )(QB3M/M2"U  !E
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M',1%Z51 F=]#2(X"(.9B?I.ZV>DI79W<<-4-'KEL_T0-(ZK)<AW6_J@/PS@
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M ")T$#2ZV_2G9Q2\$_)<(CJV+!'91A)Q$@^+6"0>M&>Y.@/>6G^$OHMP"<4
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M2-,D.2( 2R >M.NV(C2(CJ(^ ^"S+LP@7"R%*"P-:IB$ M ]>%Q!?SC(QCO
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M*+0SE"U#<\,*2;J+;("@^VD +.$P.RNAF* $_,G#C:"%IL 18R,5B4V1^W*
MY7NI4%#$/FNN:Z.*JEF_L/J$7#(PHJT43%#$HW.QWK S FC.D B%7#JZ^S0
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M*^2;!IG0QX2LQ.0H,)M/P\_@LB$!( 4(I?\!B3^_%?C@X;'7B-KRDC6*\L)
MM%6%WZNXCBVZ$W8P-]L6/F\LC/][K54SR(*KA@+K$PR3E#?_^J"AWY\IHQT8
M(PQZG,;\\]J3X"A42NL(]*VL(+<A^]RD-Q !:(T%" "=4Z;*+X NV^M<(GP%
M8%U&TL<N,HU'["R2<*N$E(KD4,33B#%;J;A5%9!8+*+O<)',2Z<#: !5Z[;(
M5$0#D'9]/-J-=ZVT7HX"$#[#!P@#!!HH&-! G[^$"?M!$*" 08$!!-[YJU;
M@ ,&! 9 \Q>/@ -_H0+0TC8@9,)2 CXI;.GR)<R8,F?2K&GS)DZ8^A8  %"
MV\QL AQH*TIMDH %_?09"  J7KR1T_PY #"I'[\& !K$\V<I0"FJ!;2E###)
M'[<! Z:]B_=@ %E_DPC$5=AP5,)I_P,>^'NWL:.^!@*R>0W LM^E $K[)0#
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M5R@GP,[*[[0<SSL#0-!/;V&!%Q<[88+"'N;QJ)2:0AH&ZQ?0"L5+FT+]+)!
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MVB< 0 !&%D QUQOE)SDDE$$2*@#4R!O8/&@M OQM:#[\E0  M4<&^/&6%PH
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M1NW**>,YZ1+*M4).]Y:[PL!$%7  ZF> 6LC=404 )>C#/FQ-=D@;PH7%2$"
M/NC#)#1'0C1& ;H%A;T6 [A#$"W2WPA)/%Q7*;G;[_0%RKT$_2P -6!.*)R:
M:8@7QKU#6FR*/[ #3P32QQ%' VY#-FB%4B00 6@8_P3NG77DEU $2^*@@6\\
MX)M$&X#Y@S0]4>@-#0 <0#;P@ZDM@#[$($*X P,  %_0C]CU0YEM#A(6X &.
M7^@H2-(-20B)PR)50S_  WA03(N=Q'WTD-B97;O]&<&8QHL$ "*-Q._T S78
M1CSP _.,P@-^17^D76T8P,V]A-*)Q@+X1C50 R:^AC]PF)LXTT+8#%M9$ '
MX94=E?<P! $N2B@8A*8]1XHL2A?:AW((1B@L(@&>GP)P W 4!&'@25>,CHD$
MU7@)@)G!!%+ SNL1FNY-P@=. X6((0#T1S],P[^PQ.M9T.DIAP,8Q@,FQEEX
M&ENAC +\#?V4E0<]H)&,0O^-3$=7C1>#B,:;"(UH*$!*2<R$4.'&,(]IU!R0
M!!/)] ,T%   A(9*., V<$-5<$LBVJ+Z+<L"L(,^;$W,%8#$]455).!8O9Y[
M2 34M9]'?N2^O)].&$"X]89I"$FY'1RZ,<I-54FQE INN81\*,#+$0EX\,P
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M#2AI.PEA0+9W:!X\,*C/P$R) 2!P5=#/'X,!H::%8A#_8!)9G/[Z<1OE8,
M:F_QOM57RI(#!0$,O//7@$"\AC4?Y&T8SV5>4 'N^HLW*>N#4?H*O&S(=4',
M!&[]D0J R9^" _Y2*O5G2<!=: (\O6VIV=_C4OXN"<C6L%^"L?X2?&[X@(!@
M?Y\@4@.\<2-!?=-&GVQ0H-^G *3RO@LUJ4$"  PD%VCPEML!P Y"&>8F0#5.
M>WP?*!! P)T_!P3TA0*0@/G:!: 5"U#  0DLT, #$4Q0P049;-#!!R&,4,("
M26GM))U(\X0  A)P (( */%G&P$L^6HWN((;Z:3\I@M@ %#*^NFMQT+!R:>]
M ABE(6H(<L!''R<QS$895Q-@]YN<! @E&P$,^!'(>/1Q@$D%(.CHQ&H@.&"@
M!_0)ZJ2)(F+MQ,<4<-(!2^)1P*3AUD3)II/B$:\A2G3#Q"Z\2A& I[+6;(FA
M!P)@P$G+WL(0KKP@T"T; S8D )-X#/@/IHY"Z8HLLXS3IX'H8 )EFI/ZZ4>T
M]@;D1H$!(ITD@0(,FVXD<18*,$[:<'HL,G82:)02S%03"]+?D"1M@=-2NJE(
MUW9ZB['$&K(--XAX\RU4:8<KSB&(=.K024OZ@:[&AERU[M.WIF$T 08F(8"!
M?F;%2QQ*3@T@ 6ZXB54VLR*%0 %K'?CI$Z(&O03 "0DNV."#$4Y8X87_&69P
ME!Q/\B2 4EI*8!N$J@%11(TG.K&W!%2$J1J$WB&E )&(XX8W4# 1K<3-#OA,
M)QW]J9?6;$[$R=6&Q,PIQY;&.TD;J1Z;Q+A)=/,GF_KTJ68M:A1BML@PD_8'
MF@!>;FCIP:SMJ4W4!F"VGVQ4:DB; 2AA0(&0?=Z3 0/L.8P ABP)8%S)JA'R
M)-%(4RS1;/IY1_!W](%44A%/'N W3$_BIH [W^DJ9'8&H'7 1#\1<H$"!-O9
M'\JEQHLQRYN%C*7!]<$,/+D=Z$=-O:W3T31^W!' 6-9<$Z!OE@B06J#;+@D@
M(I@L[0U8XHSSI+4EC55:99V^'>PGZ&!LJ)I)_TPE8)JXWRE@@?""/LF=W>*B
M!"S,PH^'$FK,?Y0D L2Q[R>^0:W&N(;QSU___?GOWW\#+\( A*3) /&H!GMX
M P$ K$0;)))(U5P',IQ4@P A@LGF]/$P"[*C  R(W 'J4QNV^&-FFUD  8:7
MC<S@Q7,](V&2_+& .RE-3N8;ESO,0PU])& !0JK;00JPMH0D0'A%.A$\#'
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M.XF!1D2%!8  <00H4P580K8%@-9]#/.0@CQ@  F('SF1FUSE+I>Y!'(92QD
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M40[@ 9;H'7(EHQ8P 0H)$X(('@*$DPCP1/2!. Q HC2%0W"M(?BAX03 10X
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MP#KF,!"9)/^C_! +^8$40 $4/@'0#)6$7'$"5V,>"=$5/4L:,2(B^A%5#,
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M(R4#T)9K;09] H#)"+U#Z#Z*)L!C1H(1!D$ E+ CUZ2?;LUUUUY_#79._3P
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M4-@NB,$,:G"#X-E,V03 JY14XP%W\1<$"**/4800% '(7-URPPW_9V7$8?Y
M@P!V1)A#S>L@T_!*CP(GL5$$X 'X<MUV-O,P?S!M 6QI@)$*H@T!&$R(2O-'
M*3#!#W+M:3,.\ <+JW@;@^FMB@@)U0(($(  N*\@$A*+/X!'L"D& !0&0>#)
M!" 6?ASE+_WH"T::TD7JX.A1.O3' @10IG[(C#"A",V2I.B/2SAR+P>@EC\8
M\$1W(3**#^@'/_HQ**A0ITSZ2( !WYA)A)R1'8HZ0-3V,K6O8.*,:8P0!V^)
MRUSJ<I<XZ0<#RE8 !*W$=9A0   DMI=I4*(!"G"*"UM8$'9,*","T0<#L**
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M2@#<*P@Z&4"C?J1/ (WQI=7>T0]]:&,K/AVSO>^-[WR3)GG7.A=*V'$  CP
M AF=9BGD7&$Z0WLO:%'  Q* &X3H#U80@&U1_\IG+ >0D')MJZ36/%PH1=\W
MP=/&R\.[X@\(-^RB13K  Q3P-XAP&B%6"0 !,CH WRG1 ,YZ1S9^Q4QU_74H
M"; + 5(Y"KM=JD=(*< W!>  B.BCX0^/N"%OW"..&F0H+E_ $"&B.KWHUJ6^
M?2(I?N4 !B@':\L2P )T6F;?\ ,3BUEQR!9P[8R@Y>;J^C2/BG57DN3<C?HN
MO.$/K^]L3$(K#+"$@++Q<@:LR1)TY 8$RA2/24!C."S*""BTTH!1O/(KE%C
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M\>1VVS$;+T.6X6()!.D/]@ *O$(=#9"6 \(V*YF&#E VC]8K\9*-_6)SBQ$
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M7OR]WU4DJ49:J'M"-O::$? M;Y@PFYHJKO"KG'9J,%FKF@]NI(<]:$F3= 0
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M +!#^D -:-!,96.4;ZZ$QQV=LCP I0D S1T/0/F<JD8]Y).U%!KA)EV;CEX
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M.,7836:6<YO>G&8[;3E-7A; D(RD9SWM><]%AK!^^^1G/_WY3X!^3Y\!I=]
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M"=Z*(QO9V,;$*9Y>U'C% 0?([E"X,9!)4&LHM H=A,71H -,+3;H@5T#!O
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M>(",2\B&=P"%5.$&?6 4 Z"&?C@(&S$>LA");#  '>B'A9@$D6 'N1*)40@
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M^[UF9#?8P(3+$A.L) 5%1$\ _^$X_J+"#5N+'<N)_/06.7P^#M65'RF< I!
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M/,\1' 7-_Q</*<('5$@"(M" 'OC[B4=T4T?U5<_XP[<!' "$5/ &@.C7S]_
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M%3<Z%[I1T(8=V<@@!SERB6V(,@">\$<H! "[M_C0'SAMP# [ZA'9#0 4#A2
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M(=PIA3X,(,B!A,*6_F 'O>YTM6W]<E?F>H<#2/$."!Q+SXKSY69^1(I]OED
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MB(,!3)SBM!4EE 4T3(-0# 0U#(T"^"$$,L76==P(]EQJ0$/@V9< M%T50@T
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M6P@+?#F @J%:3#R2L] @.QW J60A-U@-)? C41:E F0,826  % <F]&-LAQ
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M0!E$K$6]8,3<Q AAC,)N30/"O9:=Z .4])UM[L.8Q91/'*HV<-(!Q,.NC,=
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M:K7: +B#(CV G>1C "1I/_H>/V@>$/Q YQ%D03Z1!I@!/@S$0'@##KR8Z74
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M#T2?CI/R*,0T0);Q/0#],0 9G6'-:/^[L\2D6\S[.#4 -4! O>@*V<&[C$)
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MC28B1T3^*$5TD&.Y@X3B  ! SL^X\: "). 39^D'!"@!@0(X0$79>, !$ND
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M TS7'PT@ $$0*\O_23"UM);#\G,@P "H;/1Q4G: 0:HA *8ZI $#4*8[#'"
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MF]A!UAS '0K@$W;I'1* ROPA.H3-H?XN\ J/!WOP<[ C\1*/7#K&%\"C$>[
M"V"*VXB@"7I%!6B*#+Z!'U"!7S+O=_:A%GZJW=X-6EK@!FJ!-T;A$D@!$T*)
M&D()&BX!?"P"O.IM@G:C]R;!Z X"'DYM^'"-T@+ <E0,$QA JOSAK+9! !J
M&[;!$+,!YKJ"&B@A 9;_JN/F[H@.( %$8H(:#;W(8KLB*7MB0WN>)A0<X+"$
M@Q^*AA+FC[ :@*-&@1NLA]-DK0'^#\V2;,H<HKH2YYL4D"D:< ">#@U&3ANV
M01NT(1LX X>NR15A4>@2P!"#T1!YQ@(#H-'X3 !*<)^FP1%M*^EV"1,(@!M
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M!]0!'U(A(1=C"QU(]?;K-'23@XP&$TIAOXY#FZC/ ;3' 11 (K9A :9O !+
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M= 98X38M]A-"B3<UZQ.X-HC36(W7V%VWHB3&H0[ 0([G>(Z]P([M6"_TX@A
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M".8@%OK@, #R2!*##)3AIZ\:J[.Z6S9"'WP!#-ZQJ*,71L9:4)R@",Y:IHX
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4G,=[W*[1V\>#7,@W&L@_(R   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ex-99d3g014.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g014.gif
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M]//V^?7Y_/S[]?[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
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M)F-=F7T,5S(+-Z);I7'B=W$T4WY!0S5QZ31I-8ON"E;O%S7T\60E1Z]]>62
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M<* #'^C 9B3P@17TWP$3",'_R8\9"E3&,C@HP@OZ3X3+H!\)/]A!%.Y/A,U
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M.#S#81]].=9E)5,=OF.B77)U792-4PU4+_SS,1T#3H.C/'X@8)?KSF_K3B1
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M6D,M"Z\W'5M)_WK6]XK$2C191=;@)HOC-F5B90PS5 Z\D#-71S8"/(!(N<Y
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M( ;_(^\I IX<B4R8 Q[  1)L#NRD$A+@08N="D+@R<OLA3JX$!+$WYG-D9[
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M3C(@F4&*4#S%!ETX:$8ER*5$K7$\)CH\@M/FQ!Z\SC[\CTB:_XSI_$](_M:
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M^U8#' PA"C3R"892'W/A*9$!%:)@X!!!_QZL(2-SX N<[R)!\A=R 2F?P!#
M@2R?P FHLCG>X12F0".5\NB.@29IH"X-P0K!X MX;B"0025U "UK@0?]P1A
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M;W))<Z%)3W0C$>$7W(_*C 'O"$$?5NL>> 'OO@",*-7V@#+PM,X>"$$&GD!
MYS/B<L$?/E(&<. )/,[S;L+R4-7C:. /].$7\*[MND[BZHTD;4]6(^[_%$CB
M'J"OY:J3!F3@%,+K'E9O"AK.'9QN"J9@(R,N^?R!5Z>N6W^!!8GP'58O5G_.
M]IR/'VJA,2M.(VVO0+'.^+;5]M95[B2.)MEU!NX2)L=N5&F@#'GUZGCO&W)
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M@Y_ ERFN[X9Y>H40:T%.9TG5'3@3^$P''';O"9@XC\=.;Q?(?*-3EJ\.<,?
M\#:S6&T"^IR &Q+.]FIAW0J7!IQ/:H$N'=+A%^0.#%:0CDV/)VWYD_V!;Y\
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M=*GW,IOYBS+O$$MWE435-,$AC!*UBR7_QR#(=0J&7 %0%WL/N5"$ <4+P6B
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MX6 /QX!=&IY7$ J.%*5@#(9R"2$/X^-:VU0=B:2>Z9 1F,.]L03+,-Q+56O
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M%S[AP"R!/TE,Y8)()4;XHFSF,T@"S_>F<HVL&_Y@!B,6$4/CE) 0X6%).:;
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MLE P12SJ=H(KJ:3$ND:M)\;HC7P!]5#HJM!.36SBWHKG\ZCE-<0-\;K!J[S
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MCH@E) )F_F@!N^*$=,$A$&@#48YXVFH1+&' VN6-RDVU,NN/A.9!3$_[1$9
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M)JBD*XB0J_$R^ 99\"^[>D?P,H]0:\N:K-=8M$1&#LT>JK74][=FAJ(HRG:
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M;::A"^D C<RPBL:T",MP#Y,63?>@9@81"<QP;L+6B@2Q#+FR#Q)'$+26*_?
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M-HP@"4Q(NJ+'3H7QHRYS'Y3F"E6R0RP:[T:M^_&GA:FF\8I. 0FEM1V+?3R
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M/XP!7J"'8P [S.M*:[BY?%-)13,]_TR] Z&'<CC")KB ,< ZK;.*<.%,\;2
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MWP.2C/-+<S5;/7O,4TA22S'*L".(86.>>^VU[+HIHOW7?9"N7$A&=U#;.;P
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MM ./P/7J T\[ N.S:E'[T.//G_HP[*X^Y?ICC\6Y3JS06NEZ_#'((1M%+U#
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M,; #*Y0",)2O' N*LXJ!"A2"Y+'I^]IP(4<+/^ #E[@Q=!'R(\=3/FS"  @
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MS9]MM(E( PLH+PF@0K%^Q3G3-* HT0@8 ,NX@E66P*@-A7_)LT^#Q@PT@(
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MB6B#8 YQ/TC#"7B#2X7S;CM%8UKXA&NTBUN+.& #-2 8-LB#AZ?N>U^R-)@
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M&T0P4:)+?"H%&BD8 16JX1-/?>>8 ^%C^D2!@  T:%:=HUJW<GB0?80"&O$
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M/C' /N,!2DT **>4/3H!! R@6JN5!%(!^4Y"-@MP3!%"'Z@@ L1U7,=5 S1
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M@060LKR9..C*5B1G<T#.INXE+1X*R48V_*204F2 &GCO.TK*+9)^;.($KS!
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M"HO8#NEG$3RD:^UG%0>R5."T5!,H$?A1*:*(*5+&*3S1**"2=D<4 P#2 #'
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M]N03VI1S 5GT2,S&>)-#V20X-Y/>;S9QDRZ^()D[M$>J!G   V0* 0C89YG
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MH3X4P:1&KV8!!2S/)=FP7T0,Q ';%DAL$<A @]KI#XO6"G[[D9_\+L03:AA
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MIY,/310","I"!./(Y*Y\'*8J8EV=H-B+0M3TZ&"B*YB.TJND'G6@H%02M<#
MT@$..GJ'_T6'@,$@/GY8IQVZOHZN=[WK7OM:V,&^#C9<L (3K/\ V<I>MK*3
MS>Q9 %O8Y8#%( YK[4%@^[#;WG8JQ%$.:;<#W-30-K:S+89KH_O<L) VL67A
M"GB[HA2MB'>]Z_T*;81;W-A)A;W];6]J"#O+LO9.-NZ61\2,MC)=CNC(UC(U
MF!%R@'HV,YKGIZL![2]_^>. !'JK,HN&K2(QJ$@D+XY<#3%'4?+LT" 6&"*9
MW"31(\G)Z0B>&'ZT@@2F>,4F1E"(6(35.TTY*AUY<DL<4>'4?!'+Y=H+S)[\
M:W([TJH6#>94T&W@&*A3^M2[<B^'W9R"SH# ,M@A D0,'&+Z8#L^V*X/>[P=
M[FR/!]N#HH]]Y&,?>.?[/OJQ#\ #GA]AX.V'/OZ^=[DC?A_\V/L]<-V/?@ F
M\H.??.0G[W>@6/[O@^=\Y3LO]NM]3SPF6*BI2-M> $QT?:LMI+(0N1$_>ZH
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MC7M&_PS@+3AD1JT126#A $YJ%N421)PB"><B1IB  )G;%@2(AH=<OGYP!A"
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M$_B&5O  _S ="GS0! 1@@$=]AA!@AF?( &_@V&Y8A1,8A\.(/S&H!J7PA!-
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M\#2>8")0LY,'B%.H=*&M0'JN "O[1-VPR.>EGPQQD8)[8 =K>M1HPD?4*WX
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MIIAC.K!  :!,R60L!#"PP)ACNAGF @AHR6233*[PY9M[AEG "T$VR64L!IC
M @LK&)HH"RTDRF@+(Y2@))?:9+/"<HP:BFFBB&YJ@"M(QA-CC6WELPG_!":L
M8,((IWR$#S2N=(.12"3I0PI*'>7'$G\O 6B354GQ:HJ !%X)U% 9F<)K?U@I
M&T$O32GHWX(.=%",?ADF9=-_-6TUJK??@ANNN..2"Q8U.+(P2F^BD#"" 23
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M0E_>H28<  0\# ,LPRB20"] PRNT @74 K\)&058PC.$ ,%U@/JIG@A"B#-
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M9$ SG%H)D$ 5U,.+.$,(:.B=#:@8-,T,R$,TB (LH/\I"1C*(%Q#"I  +*D
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MI2MH_^5B(9(49 ,__3TV"*SC#"@=OAO)JU@CH8 KE#H[Q((F*$ J%$./=,(
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M4.&''>Q "&@6PIK[*^ @$!C.65""$E1!T?HZ6$7\ ,,7".&$:558J?PP!B'
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M,!=5#?  ^((O&/J!&!S8(_N+D[M8$NR4"5RVAWF505%9E9>Y9Q2B8A]W>_G
M#N0U&.K62RG7,#'2CG< ;B-!!H&9'[HA#")SE(V95WGU=0V7F=>97;+#&Y X
M#;37?\] $,[A=W>7A5TU@8'OS!"!'@SX@;]NB\79%KP@3H_9E V9G1=Z9_KA
M'-28#M:X=K=7&?#A%LH@#= @:-& A;5Y%,^L#1"IE[V.!@W!:5]1"P@,H9&9
M3QG:I7M&D2.:#D8XGH-A'MZ!$M)@,,^ HZ<U3%_XS!88%7; !_[5!R)A'[BA
M%B8A3N.LA\=."?^.\2:P06<80EC4^:6S6B;RP1%D>J;_%X7K(1@H(1-NMTNG
M-9LSTGQWP!+N :!YH.MFK!QT(1#>[*D/FC.Q@(-G AM(81H8(AY<@13P5ZL+
MNR;V(1.\>J;)(!/J@4OC&7(QP1$FEUIA52//;)>/85M] !+X01[,-0N"P =&
M&:&9X'YO0A^F@11"@1H80A9"@14(V[!G^R4(2!GL0*9%. V\@:O+(%[+8 ^T
MEQ(DEPT06$S-]P^^81XLP=Q\P*3!C0LPE;21V6OQ ZL?0A9(81;\>B&PH11>
MH11DF[;'^R(4-[?3(!/R(8TO=E6'%G(]=@6I-9>/]1P"X1216ATFP?C_X(P)
M!%F9,X(:X$$?2J&U#P(>6 $;IB&\R9O!9:(?ZL$1<'NF97D>'($,5#6 !U-H
M'8$2+H$2&$'<JCAX?2 9>/F_E@L=ZEK 1MNIVXTO!KS <^458H$?BF'!&QS'
M+2)9,Q>BTT 8Q!J) UA>#[4,VB 1*J%C*\',=H '>.".]Z$6?& 2^,$;MN &
MOY7L:,&ZK\(>2"'&I\$5;B4:;CS'RWPB\B$?%%>$'<&>CQB6?_9G>WH^&Y7#
M;X$2!*$-G'P'$,%W_P 5^($95'&_X0P+KH\(9<(>2N&O_:$=O%P?] $:2J$<
MKMO,:5LAXO-Q4W@7WB"BW^ -Y$ .+M9[O=>G6]O #SK<%B;!#WK !XBA'\B!
M5M0!$;Q.P&R0P,K%PU";P UB&D*!%$JA%$9!%':]THL=,@B"'^IA=BJ<#-;X
MTT']C4G]2_'S?#?V%BXA$@2!'I+5'^9AUE>1Q1'_[+]C0A^XVQ_@059DY16\
M/$B-W=BYG5:#(0WL@ _F8 [NH&UQ5P\FMPW,0&CC>Y+'S0^8EA@<D!FV8+21
M#Q'T0H@Q L8;0L'%V]W+W-O\X1R$ 9HS/N,QP78IP>,K(=OOO!(FP1(LH1L,
M2,S*H0MR5<#"8!M ZL5=(<81 LPE?N+'^Z*2E97Y@.>YUQ%\_N=__A$>P1&(
MON@CX1$FX1$$0>F)X:+ H0]8/@MR@=(M(AZ@5&AN7NM)#Z7>>9$]W=-#?57G
M &/G_#"#]R+/OC__(!_!T18BH0M\H.RV7>OK?NU>!<+=(*+= .P__0SB &A'
MW:>Q+C]+$1*2X1SPXQZ,_R$0(.$2=&$2)F&H%$M"[=[R02,?\"$3()H,Z@#L
MY2 .0!]:XX#(L[D,2O',! ';_< 2:D$0N* QQWF(+I_V<X,?0)B-17B$ 5CL
M6;4,B'R*+7*2*^$2K.[,_@O-^/,/ND&C:M_Y?_$@T&'S=1^6WUC4[]-+)WD2
M,,'XAX^HNRX0'O'YQU\TLF,>-C^$&_GO 7]5Y_50I[@-(N$2_( %A8^H)9_\
M\_\S*/^ LA<@TI A(Y",G#AGT* Y4Z:,F3)J]%#"Y*='CQT8,?KPDXN>/WX?
M_8D<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.GSY] @PH=2K2HT:,F
M^ZGY4PK2W[E,? :Z22/G8)PR#,N@*=.&4J8V;-B4L>C#QY!)W)HB7<NVK=NW
M<./*G4NWKMV[>/,6K>>-4E0W9\C$07@FJY],E-JH*9-Q1QM!R_8I#3E9K^7+
MF#-KWLRYL^?/H-]6)MF47[ZG@M(4/I,&ZQD^F!(WW*&FS1]+S>J)5%IY=.C?
MP(,+'TZ\N/'CH/OMTU?/VJ[$;=J4$93)4O0V?@2I4G9NWTC?;LC#BQ]/OKSY
M\^@SC^973]TX9<&\>2,6+!FW<_7 I]_/O[___P &:)Y^)1$HX($()JC@@@PV
M2)-:WX44H8,45FCAA1AFB!QO26GHX8<@ABCBB$892.*)**:HXHK[Z>>;B2S&
..*..,--:8%X0%\A00 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ex-99d3g015.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g015.gif
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M]_3V^?;X^O[^_LS,S    "'_"TY%5%-#05!%,BXP P$!   A^00!  #^ "P
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MW%=JYL6:"+9F-;NI%\&4XQS;$,PV$5O8<@@F'8-5+(03RP["DH."$4)G8BK
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MW.<_!WK0A3YTHA?=Z!C'AS1BX8A%+"(6TK#'T:4^=:IOFA_($,,& +#UK6]
M#+U0==7%/G:R#SH66N=ZV@&P@4B4W>UO=SLU.L!U+_0!$'V8>]>E 7>^]]WH
MD-AZ!A;1#DWC@QI?X+HA_+YXQO.<'WW8>@? T6=D9&#K8HBZGNV!#WKLH\_[
MV+SG];P/?&Q>S_QH!SC8H6I[K ,<F><SZ>TA^GNXWAZAYH<]S+$.? 2Z]>
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M(^2Z#/" /H $J/,S<-@ R_/!/9L'( 0 ,1!",XQ#K^L#/00 'NR ,LBZ.,P
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M(=PZSLRTQO0 =NC"O -)?EC"2'1)"M3#/@@US<R Q6R_PZ3),=!#+\@\M@2
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M]/0#6*5.%!(A%7+8=HF>#T8=1,17U4$)"9E7<=$&GE3?!HV%]<&'",C?S1#
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M'.J$+US@1R=KT4,VU.$4^]2 2D=!K^]&("]6?ODNS#*,.KAQ!ZS<BGPH=>H
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MEDT(*@[$KFL) ([><0#&RR@VX4;@P'OS $9&+$440WY9(>I>IUE^,R<WXAK
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MX3UQW(:EBC-B !Q]"(\5$.$M83]^<03DT=COF($1X4":/(EPG[QOQV;IF5'
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M/[]^?7G<#C  "TURY:51*@08P-@P@674CX$%# !AA ) :!M"QLSE74+BC&#
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MU3=8\\U:(H1]C-+'^Q!R%%GAAA_B^$8X#/J-;QPO-^HPAAYN%0?$3*M:?2Q
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M=V03'#M&Q>Y0=AA*Y'C&16Z\APD;X<7A&O*0QS%,QDC2^(T$M!?+._@E@V-
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MKIFW$\:V2JGE#4,2KR\B#^MJ#-1J'_OP#?RUKY$!#]Z*&_?P#<206ABUIM[
M#?SZKM_*7^+*--OJDP_+F4HE%N^6B6_"$-^PF_S04/3JG)OQK]@*K<I"L/OP
MK!QCL9&VL@\:(QR95&K10/;ZK*0!LNK00?H@K=D*501+L@WK.?IPL*D5#CZ)
M&_)P#0#+KTGE#=Z0?>O:KA_RK'[GK+4D%Y=F$N^@%NPZLM%&L]^08<_*(U?[
MH.H #QR3L\4QL&JJKA$[L@1E#-.*'F2X$2\[4.(PMP'+F31K@)N!M^0ZLCL1
M5K?B, P-M%+<2B1V6QK@2JT@F[8\U+.OD;.><P\,V[0*(:U\BZR=Z[F?"[JA
M*[JC2S*L  N85 K(H::DJQ_'4 +&RKJQ:Q_WH JP($@YDFRRJ[N[R[N]_^N[
MOPN\P2N\<D0VDJ1OL#>\)Z$.;\ IR0N\0)9E8V5>TNF\U6N]UXN]V:N]VTNZ
ML(!RF]"PJ-49,N"@SLL-9,>]L@L[(@"^XF!AX[NQZ2N_\TN_]6N_][N[]W!R
M$&DSLA2IULNL^+N&\J '2L(AY$<#Y2G "\S #>S #PS!D<9*;T#!=S +7QO!
M&3PT^V ,;/&2?(3!&BS"(TS")6S"Q[H/]X"T)\S"-+$/^K#"+2S#,TS#-6S#
M-XS#.:S#.\S#/>S#/PS$02S$0TS$16S$1XS$2:S$2\S$3>S$3PS%42S%0L,/
MW!"_4XS%6:S%1A7 VRL56TRZ1 N*&07&&?S%9?^,QL=Z#7#@(?"@"@Q$$_00
M'R69"G5LQZD "[CPMT*#6JG "L,0PKG("K<%1G<0R*S[#:50J#;<Q:\("V]
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MG+I2(L]&@1>P&[O\4, EN+MS1IMRY!A--0L/&+O9E'(U(0,-:M "T',*_\W
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M:?K%O  /\8&]&#0;GR(3&9!$V< DFU.]6WH2&5B80BI$V/"C&]NSG3'&1#(
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M3V!C&(:5 !!TK)*-F#QQX)L#?8VC&#2[GBGR LJBH/6%F(G_U4; R798;*/
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M?> ( %&%Y"DE#U@37=08J381H 8F1=)GEC@T%>B=$0@8AJ%?:1"VRM.&*:
M/5B!A95K<37AS%=I,F $.NU2AX8!9G#*FU1$(. FDE09 $Z!OIF!AE7#DB$.
M+W.ZHT]=KWF)4(;RD"&51$M85J%-3"A%UXTF-3?;B#>I@UL"X!@2GHI)X.8@
M>B@MI=2#,8PXVTUH*(  &GI<;),!]/ QC@%J32B5 >)84"1."_]@-BI83,@#
M6I",,:"$8_M1M(!&$_(9Z&A3F]8 C@T*AP8"1)#:I1'LG>L3 DH0MQ]8"C
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M ^%CN=XPQ,#!_^./I1@&)DO$RA")0Q\Q4]ZFAA&S&83R<2A4X2=RR9!WE*
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MU0 $L-R_P(5@;,4AR'=8$#<6-0-6#$,LTC6 WVH24WX6BUK-"W#[:/!D+!M
MRP[AQS?@, #8+J1!8XL#/W_[AH!)M1_>,$!)3RF#5+FU%*W( U=-\)^P:K8?
MQFCRDV%14Q(08R!=0_"5\S 1&I"EBW^ZQRSR,+92=#*1)3# &PH@ QJ8H$+*
M-$FY2B##86P799+4F?8,PJ=<"0068BV!",Y3BJH)&6^4\N)!9M&[Y1$@0[-
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M$ZW@!NPNA]&!NC2C4FEG*3:AAU+@PH\2DP<N-K&)4H3C-_G<)S2'09XO6@=
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MQ/HD_VCTB'+03$R/]'Q#*2(0I&9F5 J'',=]<YD![C 6AP$4."&V13 UOU<
M_F(D%>1![_NX6@+8<E*V&Y[J@>FG6XD195!2.<8("( \_;78K/B+\8S=RI@W
M='=^U(7@C[M;"KK0-I'7<,B? DT6:I%,*ZJJ69FCXZ*"P"'/PH$J;793!S-[
M=L_;M)<!W*R0P!AW5.+X!M@VLP]X?&-T-./', Q  B'=4Q_W ,J,=(V]>^1Z
MGAL+AZX'IP^[+-NJSM:ULO7AR&SG3"C53L@[1B=6/(,[U]^ 1XLZG*%[2!O:
M"=G'?I8=#C7/9 99Y:V@6"L4>N#[S/U ML>^8=5]B([<5/\2AS?$(;Z%O$$
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M:;FW"=RE7=@E#I7B?J406KWW>[5R*T+Q#8C7?J2!'D%!@C+P."3P!K/ -?+
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MA9:F__<@G(@1^_! ;X!J#U2IOY%8R2@#2KNT2QLK4,>E@::FG(-O\#H3=T
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M@TLAA@WEAZW$G#=0A;9[E$^  Y" @\W4R%*\!UAX@[>L QK;$V.HT+',@V-
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MI4%3FCVJ#.P%2$QLWGX@!I (X+3UAJ!)"ZVM$!EH!6\(,\GU+9#)J<L%(1'
MM9N@F/GYGEC9CJ(0'\7X6$[T1(G45 A\C)PP@$](WG"P7GG1#7X &7DR#;J
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MF6F-$P%J@OB/I.!D^[J)X^@>KB+)*PF4W8*%\<T8_./D-;:]YC7)->X'ES
M^:D,=:V(F?CEP7R5C-*_/)@*HY:*C0B64I$>$D%ES_BCRJ@!C#F074Z5R*&(
M>^@RU5)6>AZNJRA/"O80G1J13$*)^4O'N_P$\#J_\LP4UAZ(P, _3'(7^JU+
MX-$#&?_@&]0K 3O^;($6B,=67(< $B*NEGC,C'4\VBBLELEM:9J(0F\HK/DN
MK+_*D)]U"(Q.3\4UP.:%,9_9"*WP[-90XXH8!Y4@["IAG6_PAO*;"Z1E5P/(
M [6A;50M3EQI4"[\1(X(#$%Q1>R][4-TXD;1"-- VH$@0E+NB HV *=Y-,,1
MEPRY@Z<AXIW2#,P>S*OPJ44R/EH*C,0F[TZN'GZXI$B"A:5^:PVIB(_8#Z^9
MG4>&N;(X\40;(_54*D&$&DYFG05A*/&H$B&1RL!66OF)HE8V##-;B"UQD&'0
M!Q]T<[/E%2RGP/5;(@9YL:?Q[5SRX<!XZ15:QU&Q\V- ':7_,NH9P-^;D(=O
M )DX,)3GS4BYH NFE?)\F8D^?P]]@(=A.)'IR(-EVJTR?XR$MA46HL'!.@96
MB(-[L:D5Z0Y6>H[M:(PV)Q-]@ I2'H<348X#2>W6-@%Q</-[:'-C\) :YL=8
M*0W4ZSQ-<8H25&UEW^\"K-D]/$9QD!JW=F76T>LM2>\2\*YWH#3( -E^$!\:
M<#U2!I(-N14"P.GR"5GU.42! DX.B0KW@(-R4@HD_UT5MZ81<.I#T0P*Y M[
M-4!^D75@]\&<8'2J .T[2(522(6&WP0X>)LL?0B0 8KE6&P[RSL@D8$""H>7
M"#_I3K$,OKE*&8'LN_=X=(A,H>?&_Q6K!<GSUE!@-B4 IE4=%DH*4"?P*;^+
M>]D2(JPD&JB!-R ='E)R@0KL1V-%CD#X9\0(P[[YY@T,XPZ-@:P(9C9N03?T
MC<@/(!^7\XKX&3#3A/]M?1?W\7F4A'9%B7ZQVTV%/'B#LKD*3@>HIUAJ@3)%
M5[EN.U.'#OV>$LA*(I0!8A$*P;@<HB=ZG-0/\YC)@<B4&1>(X^#;&J !Q,<<
M^669[Z&]69"!SN_\_]@49J^(\NY72_3@\'L'!-N$FWQ4:\_X1\F27D(E'I>!
M._ Q0C/JA">CW*@<EO"<P^AA\@GW3NQ"(3[$[)DI)K^0KR!JI4BI1;0*[F1J
M@\C -!Q]X?^A"/'IY,NA_#>@?!;:^LSG^2&1C3E,IAX=*I9R"'HPAC',3<[K
M>$&&E2TO_HM6\ILC(^AF1\O 7W0%B#?[^GTS8.!:OX0)]0R(PT\A08,(^]&3
M0> 8Q(3R3!"8E7#6 !GR$A84P2UC10*P$L(:4&"$B)@B1I"8.6)3/W4E.F;L
MI^]-@6$]$_*+(Z#.4(7W: PH-52>C $>^Y4:0$,?Q'<F"M#*F,KJO83&",S
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M+%"7":C.,*P&#>#",6248RC'-\ "4]" H<8',,)%.IJO9!4 "W'.8]S0&\@
M1I1/;$XO71Q3\BXP R_N@3@*1(2#>D$-S8KH[CAA3S#'%_7-(RE> ?C'00[_
M!($9HFUAF5FD%P'HZ5SA5)P$+48122H$#3U4!@G "%001RG< X3R@[.D5%[M
MA/@TL! /,<>*PTZT#3Z94B]5<,CN3@WP9P\Q5VO4R=ZMS41!!#U($W=XDY^D
M4@UG!#>LXEZT,.L81=$A250P37W,  F!SCW.PG 2L1S/L;/RQF)M"EV\'!.W
MB-4NJ ^Q!M]P'EV(HHL8@'"("*9$A:;P P:M(SS8"M ZG7'5"(K4APO'W=R8
MV:#2,2=W,JZV"?M!!/78!<34+&I<\()Z0PBM"Y5M#MMD!*X40+?:XB9L0B^F
M#4X4A1E^"3^0\><81"9^!(15!"!E!"O(36_$H#>HBJPG-[,SMRK( I5UV,4>
M>\KNT,!2.9DE?M6?3)TP)R"7V:O<X$S/9*[^1))=<'%+>O%O%!9$[,/YKL9;
MB, ;D/ SWS,^L^HHM:U!!5<)\0YIH#)B0$S>31DP)T06>S.C7!@K#(-#/_1#
MATCK4.3/HI%"@ ?)H%):_$9]["Q"7T,JQ$'ZN$00Y[-)G__TIRY19K9+R]:8
M*6>$43QQ4M0'%QIT%2=TCHU1R()/_B5&.,1'+Z.S5UU:/YP(;$"21[]SVUG$
M@J"T4S]UIMJ0(?<$&VE--8_/!?-GSA82!\>&X@5QT90T/91"*L#(5W"3/QG
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M."LFBL(.&\MAB X,02CC!HL;O:$>2^$1Z2_UWHMX9" /<$$<3&[11D ++6<
M<"$(ZT#'1&#Y!B*(3DU9%M!9]*+@V)$@E,T <*$>/[$3#:P)[X$FQ#$I,"4.
M0)$>\8?,Z V\B((FH*G/,@>^1B C?[$3<:'1Q (BKE$O>&H2.<1ZDN8I@LP@
MKL%A@+ #\Z, =)$>NJD:">*[2I'*+(\@PL%'-@1_4*0>?]'_&XRI - **.&O
MV8AR"VL@(!,0'S>"IT*2*-[A&X;!K-#*[* )?]2.FMYO($9/!EY"(^LQQ/10
M(U@.EQSCA9*FFOX.R<:I#\_0,8PBE@RO@,2AF_!%%0H$CQ:Q,A/*: J*?O1
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M7P*X JO3(P*NSAEM8^*2<5(GC6M?AY&,"-> 'K/]^,49L.FLOC<#]IX5=\<
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ME7@OOO'_%^$X<H1V9_E&LU4GM5[&1$49!TFP)T423_LR2@Y?. FBOGF#.-\
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M:2 !!S !"3 !U3H!MGJKO,JKOJH"$/ !G "!DHJLXYHV>/H.KY &![  ZYH
MU&JM#P"OVMJKOCJJ,+ -']89@TJIY,JO0*$/T] &1% $"J  Z[H [7JMN!H!
M#Q !$3 !\PH!*M  -@ N>-JG^\JOR*JG__6P"TV@  B   1;L!6PKN_*L S;
M +H* 0_0 #A ./>@#9^9L?T:J?B "DA@!$90!""K  S  .IJK;@*KR>[K2M@
M XE@"AI%##!0"QMDL3.;L>**#X^ !#R  $;  T;  #W+ "6[ !/PM=4*KP[0
M "O !HG@"J. "#<P#,6Z#]EP Q_P :NP#_H*M7<KJ?E M420M48 LB'KLPO0
MM=/J !/ J[;Z HA@"J:0"#@  @V  BE0"_V0"S(  I?+M&AQMW>[#ZC MUUP
M!$80NE?KLP2[ !7@KH9+ 6F M(S[ BJ  J*J BE0%+#P 2%PN1\@"N%@MYM+
MKD#1#$2P SLP!3$]P -%D+-72[ 8< $88*T7P :.8 J.@ @O  $.H (HJP(J
MT K]X JW>[D@, JBL W+_VJLOLNJY. &/, #/N #['N\1H $2:  ;3 -X] -
MS_H'IA )B? '*_"I*F"K$@L!() "T_&]N/L!,> *-V 'T'2^Z NH-3&U/3"\
M/C %/)#!.;L 1M $T]"G^! ,IH (?&"X#R !"_L *PNLHUH;HZ "(2##<N *
M,/ !13&I$GRLR4 $/_ #.^"^[QNZR=L&^""NW. "%/"\8]NP#;L"$'# _" *
MN0L"B3 *MVNO&*O#:%H3[G (.^##%PR_1S"P38 *?%H3S#"MU2H!U>H 34RV
M3]P L* /B=  F*NV<JN[XJK%6^RE.=P/PK $0!#&4V#([8L$?* (D( *Y$!Y
M^_] "@[PM? JM"K<Q*):&W;0 #*, PTLPQ\  ]E@OGX\IS51#X?P X3\PT'
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M#X$@!%N@!5 0!3D0S6%,!,*0#[K M^][M3L+LA*P"[A\T[=*UBX@#OA0 PU
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/.?E)4(829%,"(58" @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ex-99d3g016.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g016.gif
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MQ)BKSIZPQYFSS(6ZX(N^XJ&JRZ"QQZ.TRJ>XS*NZSJZ]T+"_T;.[V)+*V8_
MXY/"Y)K&YI[(YY;6XJC'VK3#U+?"V+G&UKG'V;O(U[S)V:'*YZ3,Z*O)X:G/
MZ:??ZJ[6YJW2ZJK;Z;;.Y;W'XKK*Y++2YK/4[+K6Y+C7[;S9[KGDZ\[.SL+-
MV\71WLC2W\?8Y<'<[\S5X<_8X\3>\-/;Y=?>Z-C?Z,OB\LCD\=/D[-SBZ]/F
M]-+M\M;H]=GG\-OK]N'F[>/H[^KJZN7K\N/O^.KM\NGN^.;Q^.WQ]>OT^NKY
M^_'T]_/V^?;Y^_[^_LS,S"'_"TY%5%-#05!%,BXP P$!   A^00!  #_ "P
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M2P*Y101=WDQA#N9C#K=L2W@U[&K$@W<56<-/6'BXEL-[*WBTZMN^79+"%H;
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M$+IKW\&&ET=W%L)&A)G]#-J4%V -RUX#K4_>VI:S8 T1-ZTD6-""+XC;'Y(
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M"=3/9T4%)Q M0P&SD2:F,<81?:<1U-Q#B-STBVE=$73_WPOC"$?<4%41Y8M
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MPSW,P@!* C18X#T 0R,482/0 HBMPPUJPL)(Q"\,8/^94L[,$DC(H/T)FD<
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M5<0R6&:Z#B\885<+2$+,+D.JS<E--&\!;'& [5R-P*1,G5DR-$?S8#X63;@
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MB%D]F" =H385@S?TR_QB]Z8H?ES%LH-, CRS 3S2M;EJ(;*^RQ0+ =@AG?U
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M7 'QU HMD*'J-L 6O $7%BL O8%Q2N&11H'LVDD<0($ ! 64N&&Q0 '1[(
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M!Y$&\@'>[[DP$"VXH0%^8,T.,2!3#9W&@A\$00#<2B/_!2 /6&HQ"2  -9(
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M:M$Q;R$/O@FB=@ O3:,<!$]Y_TPF>4QFIY#1/"NU]4R/W/R!'_Q  )!R'WA
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M-E1839!?$+$$^P38(:@>MPD2&M]:0N"/R)WX<%" UU?M<'_Q-MB 35Q/@ =
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MEO&0D;? CI^IF;OW(;E@"AOI3?P@DLQQ"P=S"Q6B#KDP8^90E1O)(]R #/U
M#JO)8D*%#T% /B-!#$?%&GKB3?UP@152.]XX$JAQ?OWP!P* G? 89U@5<A60
M <+G*F.77V2%"/=P#_G GNWYGNSIGO&9#^YI#^Z9#_8@G_&YG_.)G_O)GP *
MH/=)G_F0$</7:0<P<5+78DI0;E6%"Z93&#\@&?&P Q[X '__$!0>,PH;, $F
MXH $(2<MV1?<H16*T3Z3D1B"D >@H1AZL!JV4!_=85X[,5JQ QI_ !N@\  0
M\Z$T@B8$D0O HQA,(#S[, HM<S#9X0\44Z,J8Z(-6#_DL .+4Q@;0(9=R1T#
MT!U,,!FN8#"%80>;TAR$-P !L!;,YPI*.CZ&43XX$ 3=>1OD@ .7$AL_$S?J
M,"&QPQ0;H(GU<#($(!X4X K#00Y T!WUL0&W,!RE\ !6\P -(  [8"]AH1CM
M9R$$, H[, &#4@'A**3 ,Z$28PPAXJ(X$%IF" 3^0 R%T1UVX ^Q, "($JJ)
M^G\CDBD[4 J6.@ V\(Y#A0^2Y H!_S (*K,D35(* H!__% //((/!.)ZR* 6
MUMA[X7E5X\D!0.:0")J+>W9L;I9IOX*>W,<2&A!NO1@45,=4QO  $_ *9@16
M-E!QY# * N 'A+2A _  ?5 ./ D9.,.2]P0<H$!(:R, 2)48=O*3N8 # F +
MY9,+6-,-R4D0MU @$]L-02  !_@D#9 '710+!\,7K;JH;S0(5$(>K3  .T ,
MY8 ,%XI_QP"=_J .%SH*XD ."D@!DB$;#_ *Y?"6#U !%%D.KV 6WE!Q,V(#
MN6!$4Q($'A(/A,$8HX +09$+[-&RQ'"A;EJ,834(HQ +\: G_O,@./-N@(%$
MIB ! ^"G0O\A"G5A#.5@#!>*$_!PH7]P1K$P*%7K#Z70'7K #=U0&3#2>A'H
MIOY@M'#A#9])&*$EK>X*14\BK\QA'&<9>NRQ&OX7!.5C#!2P =Q0<05(J^Q*
M >_J#9([%ID25J(0N'EA%5;5M?-A##,[$K?@G4+!A^382]P1I-+H#_$85.\F
M >696+889 70!K.@O,NKO+0P"\[[O,W+O,OKO-!KO<T+O=%[O=HKO=P;O=X[
M"W,'=&C5K<6K+5%'D;XH?DHE&P20I=P8"D*ZL4-A&S/C#Z 0  P2L'UA Y(#
M>A.  ZN1&!-P.*QJ%B*A#LDH%'FQ?][ !+2*OU,U$J4P /NR#P3 $J0UX[Y3
M,3;HT0T4<!:;Y0_U*@HY8;'/\R(_H$F(:P<%##D$4*/S$"+[]S<"$ O^0 \;
M,  /JX4B,A+>8"*'L0\-"R[1N0'3V0,2@#-5& 0K[ ILVX7F "/M(JW/\\1]
MXYQVLAJF@*:P42($0*M],JL6$@"32Q"X4"!^@ZA9"@H"@"1*(G\T(PIZ@!SF
M&(;U4 &Z&ZL&V!;<P<8#$+^9$@##R!H @J[!VYUZP!:Y4,$ZP<C%2B(7FJ5%
MDAJ,MXG6_SI?(L<!YLFMI8B"M C*H2S*HRS*]NB03MAI-<&@H[:^244.$E"-
M2:+%_L#(1;P3E9&EGT$F(XH<VP0=^/#!ET(QH@-ZLB,5"1R&09&LG<-.(S$(
M 1#&?5$5^_ 9/5 /?L,/_7"US_.<3SH98M2D@-$6 $)[_)#-Y5 !SR$G/4H.
MFN1^B:&ADE@Q3<*'L$H/9(.60=$-#[ $R]$/>4  D+?.=5,/-[ !T,$//3 !
M.#,(RLHO8].%C)PR-"-&[?N F>+#I3#((X$/ZM@N5^N-L7 D.2&V%! /YAC+
M/VPGAS0![EH.5V&HU$%+&[ #Y"'2<H'2//(9Y-@/!&)X$^*&P/_Z)#\0-[@P
M !-]Q@2 U)YAL\PW(>?WAL +5,!'O*2XD-OZD/@5A!31*N+*U5[=U4'XBF(M
MUF,-BV&=$A]46V6%=U@M$XX%A>6"#[](5!0#+TUC'LB1"P)@RSH!" 3 .O"0
MSO7 RR,!G*"0!SU@(I?"C&BA%E)1#@H<%.;P URZ 7AP"UYTLJ65)Q0P#WQ8
M%?'Q SN0(@DH ',8%$;U/.HP*/ AVJ Q%K<@ >7' Z" #.S%#6]"QB6<$V98
MC5%KIT'QG/$\$C]R&.D'2 6] <C4#TF,,T"=$PY"HCI!P3SL1.:1G( @ $2B
MT3=<3L;A3;M  +P="P[=.TOP .*0&+#_BM?JYZ@"4!6C4)0$88[][ _R4(>:
M] H"@"A5F =-TMEJU!0L!M"&5[L/,PJBD. ++@JE0*WSP(;\,1*[T,@Y$8R\
M/1)[0P 5N!,[O<*^^[N8W&.H80/:BD.H?'=M37*X.(J=[.(J2%/@9@/IFZYT
M/53&( !QS-$X( $5M]=]G1-Z$"!T>-#(_:4F0@'?LZN,72"X X9280X3  3N
MYW@B-P!LBR9/8GAR,@%.&58R ^9+  2[0\'17%3BK YA03)@#@1!D =HV0V"
M " "4#&:",\$,:Q]K1X[P _R %EJ6!2ZG1-^>]QC*S<&O<+\P*DX,QLNG"GJ
MMQ-O"ZHY,0\P_R))@K H?1L ?&O$R"3>PVBTO8N-!$ .,MN,(LKCHFD,?? 6
MY3> R1&&\U"'5W'3K'JPUTT!8S3@.0'0;HB-'PH6P4XV%+!B0E$.W&$'ZI08
M.D[&!RBD&?@*:Z31A SB(4Y UQH$%9"MM\CMVT>^:^UI]F;**AYQ*!YBW0=^
MX:*N2E46R2Q+GKL:/TZ_=//0Y#BB?$(,#8"EZC PEMXHM OKQRSERKA-Q# E
M-H <3_*K,OP<51@_S0?QS></MC  U#X\_;%9ZK !%"!%$2_Q@R,/Y' *.$"L
MB!$<0EKA(['//] />%S30W$,%:,3@N"F<A+<^&#0M;GH:4( G+V%7?\XK,Y.
MW_S^(*X$T/.1K)S.DN&MJ18R )..T>70[DJ4YL'-&MU0"H/RL'9<3GFL2>4M
M%XEAW_4$(_6 T<+SSP\0U/&@#FWO]NK0K^4 4*!WMT.C'FDZ$C2/)OT@HX7H
M2;-AX+XKU0,5<K%69PA:<'<W4VPMKB[1^*'8K>;N=!&G 1RPRI-EXT(%#ZXQ
M8WS()/X0C$*O$[8A],_Y//5@''PB"/.K\I A.!3#[%'^NE_(\FGI"CHJ-]":
M* & X8U" )V1P!O 8GB8-F7Q^>6T ]6X6?W@QR0M"*; #^4 "-Y-$%4XY4&1
MV_&\TSSB"@*P+U'+YT,AV&TKH@1RW*7RRSO_D.MDO]"QFO*-<CQ=&//_/1+S
M@ ->D@=/GQ,@,@$5!Q"E!.#R5[ >C@WQ"OK;16!4P5<"]/1;*&["#W[P*E0H
MM] ?,0)+^G7K0\RC+0%]_)%K$(0BO@TV\!6,%<"5/W@4*)#S")))/WX_'JCS
MJ(= -X])E2[UJ.X'@5(4D^[[,8&GP:H=_>5Z8 ,I4W44;-1C6M;L6;1IU:Y%
M.PA"*[9Q"^X+0H'# 19Y\Q;0V]>O7[Y_\[8@7!@OBP*!!2]FO/>OXL:(!Q=N
M 9B%"\I]"S^.O!<R9,E]08/N3)ITX],9Q&I-RV^)A6-RTPH*T(?LRJ>W"N82
M4*ILGP VQ!4D]Y2;_S]\.RHH'!4 U,)X=@)L@.>/VP"5"\T] ,+/G[H)-JHK
M[:=GP"NIY&Q0("HJ0(6OZH(0V.6O?.V9.'\$R(5\_BV*^GF% )60P:Z@6PC8
MX2I^0)'(GW(FV. J?V(AD"EN"/BC(-<&$,4[?[K9X('CXN%@!Q"9^F, 4/8I
MR!8""(B-'X1NL\\. EXI"!]0!F /IQT>N 6?D7X0@+JEY DREP!+&4"0CPC
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M2.)9+UB'1[!1F0(H@D-O.)=?V/"+;+R@?Q.T3+@XLY@,5, &K$&+:V#SOH+
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M!"/SAW%@-V!80190KW50 P2JOG&@-^RZA[DS/VA8@Q>  Q; */LX.E53,G\
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MG@)TV4UJC,X+0Y>HAT)#PSW#VU.UIFL'?2UR?_"%YS*_VW.!3FU"]9Z^C2H
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M0KC@3*1I 8T31 L1:\)I:9+*R: QFV'Z"4C?G(VC-' ;N3FDG!9PKT+4L8,
MZ#:K7A5 $!\2SXUR@QODB(<-'C"A?M1#O:4=+!W5L0]X=$2N_B#'<^JQ$F0\
M8 /(*)4W;%K 40A #_'HASKJAU&%:'0 ?>!B1]SICUL(P [<[4<Y@I A8@Q
M$+QRQ0""0 YMW7,#%:F'#8#7_XU]U.,4!"CM/KSS:7^8@@"ND$D] $VNA-R'
M B+=J@"60(Y]Q",4@5Z(>2A@BUP@.]FYX-U["! _@PCDV0V)A0 <K<;H$(,
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M0;R/M+U'?)"3=[S??5"=07A*:NW$+1 #N,E?0;R"R1T$N@26E_7!*$0'J5%
M19 <!: ?:3U% >H+* "<0G!#"!V$P.5!08A""ZE+#/D#R4E@N_2! - 6IW6@
M*  4!>0-J?$ L-U@="Q@112;L)C'#CP%"YG"0=S"#Q@#/TR$.D':K2$$'#Y
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M@Q*&RA\<6D)H5,'(SZ&U3#VH S?$61H-1T%T VQU0T)Z SG$0CUIB WLX/*
MUW_TPQ)(0/CA0EN! C%P5T-PG*[Y [+TP-A]GPU,H%;=U"B4PE 292DTB(*
M%7?,ST-\Y ]XR(<0X:U]Y /T02Z40ZCD@@"(6X)@"CZ$W?O4X$.0!S[4 SG<
M@L3D#3DT0/]IF58%2.!-RHU&T2%W) @^P$,WB$(]K02@*=RZ^ .U.9I!9!L>
M1"%5)@CHE(*Z^8L*NH?0D4-OI:0X/,! FA9 V9E =)"\Y1DRB.1C3N:V[$3/
MI9]/&D0]X$ %Z ]W'%V[K&:"D ,N_(%-!8!HE0@,_8<=8I&%R,? ,"9-5*(A
M\80-<(#:01)1' 7%2$4O 0,T+ ,M*,(+P$:&T4(S*(,FF-(RQ8 D5((DQ, P
M5D(E-,**!04B5((E"&->T(4+- (P+,,LQ &DM$ <:((R-(-S2EALM$ A: (P
M-,,R:$(<\&(+*((E(!C(>,5T @,F="<B$*@P+E-^:L(R-*<BX)+_4!1">9ZB
M=X(G+X+CZP6%I*#?W)@30Z@##@A  $S [6U9!YH648["/)%(/*'A_N1"'O!
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M#2+8UD\@_0N75T;//?C@69\L5]"%#VA7P2WCS9?BBBV^&..,Z[3VRQLIX,"
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M)$5SPAFH3A5JTM815#CQV( --A<+ 9QOJ#^EIX7X\8,'+.8@N1@ A?H1A ?
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M:_X(.Z5SU-I#.X/$/.KC4?*QL3Z$!ML4)@1! (S/&7-I/;72/9NT)B-/T23
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MICL(N"$>T"R7$".25_<L,UJEI+KU=B$>MHQD<2BN3 P>B"&N[*K#=="9R\%
MDW)K"6 *%4\/AA0>XFT#8YP<X,$8XLJ5W!H;81DF#O 'Q &=<N'J#A)@S7:7
M+PQUR@$674$=R $4&H!+C2PEO5P<!F$"4#0LS%(0G)D<XA"B7"%WB $>U,$5
M&D#GKK(*MQ)1>W1_\RT5CR&NC(\<P @OG#*N%"Z!0ULMZ% "7N'+(XD)4.><
M9R.!I+0>*$_(Y,$;=KL0W5D9^P)W2D$>\*$<  'LLOJ)$K=I1UA@'PAUTH<
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MQ"  YVH+$S#)_N -=&JB$S R82$*;AS!>6 <WA#-$_ #^, -#%P0Y: '%OP
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M#%(,"L80"SU  $RL'I]M"[F QP*P UUHNGH@ #\0"X'Q !(@JJ\P (LB'G^
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M@A  .V <3C/<T?X=>C  JT(.X(P1^) '(NL/Y5 !%6 ?W7 CL8$,GUT@YTT
MOH[>HDH0HR  G+VMW8K2!!#L=^T3WB M5\(/?B  /.!;6(&H.ET0'PKCKR
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M^^"& W5$4+ !/ H":@D44%C_I&#"!4%8-ZC)!2#(B3P@ALAH/;CHT@=H@ ?
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M!W7@_P9N*(=FC ?24 =OR%&=X@9DX*EJB8>CP0=XD%%R\(;)X =QB-ARN+M
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M>E!$S@2&"51/!1LHU@T!$]@ BA_<X,/$ '8@X\UT!,0B4#DV/#"*-\8P04
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M$U*BLG4"S#AXV<$?$-7' ?PQIP>IP$3,00$A\M OMET"$ (<A"4$E" ),ZI
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M7U!'LSR3#XVJL#2+%#5<UK1J&;)J3[JJJ[XJJH1>Z#7+FG0)J@H*Z E+F6U
MJ\)JL*[JL$K1J[(JL=K&#O@0=1#DFH2>L]IJL^;JQ#QKLSY33TJ9;4S9B%+
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MK4O8*]T:Q)>VT4OI;1[I[4WT[=Z"FTWD[=X6+N "KA*&B3G=;4\H*3'D@C%
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M&(\Q&9>Q&9\Q&J>Q&J\Q&[>Q&[\Q',>Q',\Q'=>Q&N> !4"Q%.\Q3/3#'E@
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M1S6]-)%+%>'<LLD]Z40T2$7E_++1/<\L,4TI#[630PXX: 7!3SWJAY@--J!
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MN.$67@$7O.% Y@$7'F 'N('#+((?N,$68@$97HP<0A >B.$5<B'%^D$<\F
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M]7QX ^ P<1V9(X9/ G*MC%,7QQ[R@D8A .A6>.WV(I .(_ !&43A!R2   *
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MOXC!#N[RJ4%A7X$Q#E<3TW @#X#3^:[M<&!RDTGQMZEV ,BY&S7V>/I!#R0
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MWY(!I10O;O@0G@T)QFZ7&E"SFW+;Y&P$ "60'($@^Q+V(3"Q7@\"L5)WV_!
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MIIK*K>K KP+1#<10#\0 "FXJ$.6@,** "]W4$8%Y)<C@K*7 #:H3#[@@"J.
MKL9 JYIJIN7@JU]J+OAP#,XJ"K?0/@-UD?GY5NY% <<D/,/S=3IH;*D)E/_!
M9HK^@ FE.2(^QV!M8 ^JR16*UPX$6 !/6X-0 7A?P (/6AD^EW]!&83NMA3+
M-A#MP(%<L6Q;NQ1\-PX6MHW5&!58> X$J!2DYP_CL 9J\ 5?H :"&P/2Z'MM
M 7N/(13\H 1.]U:Y0#,5 #'V6 ]_$#8E=!!/E!%XD </, %0HJ0 \@!$0QWJ
M($1V4$NAFP?=]"*9&S9^Z0_P$*>4^R&"H$*L00[XP ,$, "U1%'D*1"O&TBQ
MZQVO0 "@X!&A2P!_@%/>L &^^R&DH0ZL\45A\P<U4BB"8 ,"( #7@TN]$38D
MP3:@, $! !K=T! 3 #$;L$L+(0@?<C^QJQIQ&C;_$\"E&U"8$/$ >:"Z0A(A
ME$,,T5L!$_  ?3 !3$!3\_ :7_0 3" =#S(/>G!&'P(*:X0D! !(!RQ$WL$-
MQ4(![;LT,B0*)20!82,[J/0AFFL'04,.$Q W A HW=H0%  @;M,2R'#"8?,X
MN/"]_G +M -5[](2^U *9W3"3,"M"L$83$#!!BP !>,G@G&]#^ *WG$>EPC$
M 7 ]?4 !5B, \/(*$%/ ! ,2ZE(!M@$/#:RY7#,0ZDL D/0 )/0#\G0K*7P+
M9$PS"10?<6K#I5L!'()9>!"TF#*T==5[ZK8\2?NV+* & =H/T#>@4?L5A9 :
M(^=Y T$)7 &:_2 )D,:V_U_K%!*Z:->(>/NUF\S4F\'W9_%V#M<'#7.F;&2W
ME*+7#DO) IIW#_>GM^'(8*!)#Z'W7[/0"+&X;AYY@+$G%-IQEKKC(120"^I0
M#J( +A_U!P*P!-R@#MZ@!P-@0!E!,,1@#KE@P%]\3M?\%XO1OKL0#^4P-'Z0
M$'>3O!1U2353+0302O&@O@- &)N!.>K0S;%0#ALEO/(,"O3<$#'A$K^;!]U
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MB%]<JK(*@(C/@ ,.:FC#+!:)B*<P!EE95*K+#&;%IB:KAEP-21>[J!*T*NL
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MC*Y-WDI@B%DXHJ_ ,FA BR/RV39H@Q@(T2!R@7QY@3> @[;0WC5X@S7 8)$
M81= "Q=@@S=8&!=J >)%8<Q-(I]]@S?@8)1PV(6- >Y=AA?H&!9P6"VBX39
M88&E6Q=8EX/_^8(W8 / (*N_:ZJO&@E.7=KU_53(C(4@6))^  4F$,YOO84O
M3B-N"(+Q^I57"(*PB<4\X--AU0,@^%%\2)S[S2518()RU8AT8 )JFE%^,+UY
MA<QXL(4\^ % OLL7I&.SY!ER& 4F6 )1N$MU<(52R&1-OLL#[MC;32&.J #&
M';.3>&"5<($A.H<.3J(6^ 5HP 1"N*(7D 1LN ?N; =@@(.1L+MS4 9N:8=\
MR(=S: 06: -EL.5[@(:QF(D74(9SR(8X0 1LR =^:(=?V(LJBH-@ &9^N >[
MV+*#:81:YLY\: =:B(F0<(%E&(=A+@"Q50MAMH:%^85S. =- "MQ_UD&;GX'
M;(A9D="$<Q@'26 #8'@'?LB'<6B$AUU1%_54' 6%SR.NN2KD;?4K5"HA8@B
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MY%)//;E($,"1?G'#$V#=/+ #/B#-T]*NI,(3K#J  %E//S\(4$&K1/H$CY^
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M9,?$<3!$R.1TOCL?TCKK:>-J6(=4UA@C_\?HY"4 XBDNM<:B$SQP(1!B'(L
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MQ=K@8(SZV%(]2 L&Y5XR#< /E ,\21PEJDJ0[4,_Q,.?Z %G*HDQ $8]J(4
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MFP0P 1[@@ T$S$1>RV_U0! (!$"FBHIN0!!L"0QNAB!@GP(2@,4Q6$6HDE@
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MP[&*&SEV]/@19$B1(TF6-'D294J5*UFV=/D29DR9,VG6E#@(0BN;]7I0X%"
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M 1ML@ =_R,,#"%#:C7!# /1Z!0%ZD*4_R! 'V?3'[XH)SVWIM@>Z4,=0HQF
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MND-Y'F #I$1>5I&1)N 'RH8">,#<_.\!Q&\B_"#<)$! NV, )J#SD&$)'D
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M%$Z#'TK!L%$KS3JO'OZ N>)T YSKHVG3B/#$(NQ@  (@(@]K;/AA%!(D01Y
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MS-<)HH0.FB3R80FD5B;.@S&GU1A<H12( 2_$0> C8A^,P5]%0QZ(P15,(1=
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M )7P#O1P$D@#+U[:%2XT%^0178T!" /PD)R%$6IJ:^LU 5B+9WEXBW#$ACV
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MZBJ0C*I2W> *3-  QMB8I0 /?,S'5FPY#20!H$ ,XO Y/#D]Y) +VH:VIS8
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MC@S0-9Q*#HRA /OCOR9TPB>$PB@<*O_[*=(K,Z&+$B@APA>0!&C(AF5@!!=
M!%J@!86*DA=H!&# !FP@$9<Z'*C3!$U@A+UR#R'4#H9KAFS AF!HA 6Y#D4@
MPXK3#CB8!5K0!#_<#O[P0FSPA4* /!? !%J8!5;#CC:8!6O(AF#HNC&DA8HK
M@#:@!3U4!KXC!#*T!%JKDA?0!+Q:6(4V\(X6&$-LR 9HT 17G!(BI!+SV8!=
M\S%?D\)?!,9@%,9AI$*?HH<>X*X!Q+$AQ#%$>ZB@ Q[4P0[B@3<_9($V$"GW
MBQ(A0;2T.JNTVHYHY*PLE+CO<+!GK!*U.D=;>ZD"'!UI?+\J\0X.L"DD1(Y\
M\,6JFH=<( 9%BH=<H!;DX(=<F!.](0=<2+:J@H=2$"^EPJ-<>(5<<"+#*(=<
ML(45TB1NN(5;F$@.$@=Q" =R ,FO&L:2-,DF*__&G@(<#L!%ECNK],JQ[TB_
M?CC$O=*G=[B191P?=]Q&F/+)F>))9O1&>03'G8R\ZS@?>SP.F:NJ4AB 3B$.
M8R  07 .<7B )9"VYR@%QO"MX>*!K%3)07 7F!D$#^H'4UB5'^ V6+F7!^@#
M$U(31I'+!\B-D[3+NQPOYJ@JT@NW>/3+'$,$_^B'=Q@']^C!GSP<'4O,EM3)
M+/S+G]1"Q/1)\^FQF,O'\B*FJ_PJ8G@*YS"'A@'+Y-B%(*A+K%*'($")I0(%
MF<@%%_J! 1@$3EF+;H@)'LB2>$ -4.@&;M #JRB@/R  /,@V8Q,$<\#+XT1.
MWTK)9<('(*  "U!&QQS_RL>$)DPP3,-3!AZASNW\1LEC3.[T#LKK 442R"58
MPJJ22D&P [CAEP%0#.0@AP< @M!,#OH<JEO(@Z7:+AO0(7\0APV8 -MP+@H0
MAZ*("5?0#;-PE=-X ((!B@"TO.24T E=JN5$)GX8#0Z(3G'S3J-<$F" !FAH
M!E9 A':;SO?[3M-K1_#<S@/@+B"8*BW1!_-DPI_J!\$8"P&@2J/@3*C@!W'(
MB2#-"7' (] DAUP R*]RH%S !8S<I6Z %G40H7@P!H+LGR-MHD_J!EQ(TA,R
MHK$8#G4 #</SAERP"R[R&VZ0@!TMBCP8@(7@S#XHH/@, C3)!29P4(;H ]E@
M_PC-("(*!=1 _2D+/28,G8 -J [(A*84)<KO@*AHE$9&/3-)54P6M=3L,  .
M8!8T3<+ZHRIUJ  <J =UV( -@*0>720;@!F8N1<;@ >3X(%1@ N8T0.A@0>%
M654>@!=_, 6H](<\L(%8V %NT0-XD%5&J8"G\88E8-4'R /C?- @0 @!P(%X
MH"-7,8<W89@=V%6_ 27+6R,"R(VMC 6CP(<=H( LX2,&==#A^@-!\@9XL$]!
MI==Z90A"/29 F( )2 "A/,I+34?;DE2 )=B"I1(#X"XYW2WV6:I7$("E 00!
M*%=^Z4Q^" U<X%)A]4V3@#)1( 9AA0R&P <W90*L</\%[NJ*M& 3C)@ I<"%
M8=T!&S %8[ 65VT3&VB B@F,C+B5H.@6)N@#4."C?D 94> &;K 64PVJ4K&!
MC0 $ NC6<.6V1>H&P5!8?[@% F "X.@60(A0>P5;L,77]CD%+EN 91Q8@WW,
M@2W'QN10'"/"H&RY2LV.!*#'ZGH.IAPJGW509&B)^"$&]RR.W9B)5UF4>4&&
M!C@7I ("H4&JTO"*AV (.PB /#@4I"( ;.D'/"" KM # 4#0 ?F# =@J?/B!
M %!83X*'S>B??AB%'\C3G@)  MBJ?M"#SC4,C"A(==B!U@@""A*$ '@ )B@%
M0; !M5#*L%7>"1U;OR$&[L+_@+6-3'D,RD:57NE\2;5%43.;VW^53AU3 .XZ
MA;S16Z$J%2#H'WSH 7&EV/?DEP>P@4J)3QN(T7B@@!NXE=LMF:(X5U]1V<D=
M@'F)SQOPH%" 2ONM ,L;KHM!C8)4HN2RA7A('BI;)G@0ES[H)8R(W7Y8SX*,
MAVSC 6?=EU+8@27KT[+ V^5580EM7KWQ!AN@@+[4WDM-T>J-Q\3$WK3M3J/<
MX<+!@ K8@-*TS,P;*E"H7&-8"F-@@@  A/8UC&Z8  J8D_@\%X:8APW WWX8
MUA_(@R[NXD495Z[D8-QM$_DLH%'(7,E("#OPXCRX#!N I=HXCE=@E U@@E/H
M2%0I_U[B-.'C((?7[ ,/XEP'QHB 5*(]W5$S,@RI_-,5=F3D;.&\D8<>V  *
MV%!VQ$* M:UK0AW(F^%,!CI_C4GN=-'-2,CDP+P:72;GDLM6AC(=0M6B$(?>
M?9KX! *C<"[\/==&B5D<V($;V $>()BMQ(7))8" I-,SADIN@!D;P %G]N4=
ML(,XIH"O-3QBR .X$( )  3RU P!&( !" #(-8Y:(0!0N)_1Q98!8:.I+8KY
M54K-H "8>^1Z/LE(5I\^F  .Z-=/7M0<6X-?4," *@!"" 9@H 5^VLX5M5X5
M==M/CJD$X*X\F-<3O,R@0JH@, 9DX 9D0 9C*(O0C>5%RO^+T'UGT-RE#8#C
M?>B!!C@&?,"'>JBE>C@44PA@AF )9$;IJ" 9?_ & N@!>8!IF*9I8=D'"*U/
M=2 &4:   4AAE;A8+G5@'MT*5_ DAQW?HWCF]"&'8[B@>@!0VRB'/"8'"H!C
M>T9KD\3G,(D%+HO>?P[EA[;APNDTAB@$[: $AJ"'V;EA?_9KM%* "JB K.:U
MB[91.[AIP\"%N! 68Q!<.KE=0?BJ9-XE&SCKSYW8+8F%5[B5K6P,HCWFDSZ8
M:NEI>@!0;E,'CWW0:C8.=2B%=?8'SASM]C$&"IB IRF*X=*# NJ&X>T'SV!/
MPX7C>+"!#>C/V-;:BD[KY;Z_M0;_$W* X;Z<:QT&Y9V$'3[KC$+H._H 0<.1
MN +$1>J&QX:&Z/$QGPFP 4,>8E4^)G(XU*\E[C262A\5A-2 I0%)"<JV8I6^
M%<[$ :1!JA\0%F(V9IV>[8;H:7\(WD &E#\(@+T("M8NCOC$ ?I!JDAIGW@8
MUE;AAPZ'Z90P7;CAA]OU%%<8 #O8H'I Y,[ @X<=&]0H9N:6\2AT;BT![0WH
MY^HNV+EM'.SN!^-Y@SBL!(7>QL;Y5W3L3B0'1W8T\O(^LTRE #N@X.? 1R(&
MJJULXN((WOPT!@'P ^0F #OH@S;. V[0[T7B;Z  3D>Y!4%X  F %\\N<-$^
M8\DM"1X@2HA7B 6,^('"X <>F "E[(?5[ %7N 59E8"I!A-7$(!&\>4;B.:N
MZ(@-* 5<P @4%]G/V.P@&( ?V!AO>)D\N(53V(&;(,D91W7\_ZMQ+<F%XM:
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M('CHAGCM(W,(?<IW^=/7/)A_CE, 4 R =9=D^T5M 5H8VG'H)>-AJ7<PN4*
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M-K1IY*I^I$,6>S"!"4[@@1.,8 0B&$$)2D "(8A "$(80A-2X0UF4\<<?M@
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M5A!'/4!"%D"!&EC!%QAE,[J?XT5>N(V &V[C(R!!$1#!N F!#G!#/_#!#-0
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MYAWH$=OF#/RO6%SR-P\T03/*/<Q!%;0P*%<!Q7XJ.T "%X3HDF9LG4IP&7H
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M0?UYG2#,>U=8NT]L0V+S@SP\>;8/?'VS"Y)3>3 GO,*7;29DPB1  B0\?"-
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&;J>    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ex-99d3g017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d3g017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .Q%$2
M  0    !   .Q        8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( G,#20,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M?Q_S/9O^$Y\.?]!'_P @2?\ Q-'_  G/AS_H(_\ D"3_ .)KQFDH_L^EW?\
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M7X_YGM?_  GGAK_H)?\ D"3_ .)H_P"$\\-?]!+_ ,@2?_$UXI24?V?2[O\
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M_P#?Q/\ XFCZ]1'_ &7B/+[SR6DKUO\ X5CHG_/Q?_\ ?Q/_ (FC_A6.B?\
M/Q?_ /?Q/_B:/KU$?]EXCR^\\DHKUO\ X5CHG_/Q?_\ ?Q/_ (FC_A6.B?\
M/Q?_ /?Q/_B:/KU$?]F8CR^\\DI*];_X5AHG_/Q?_P#?Q/\ XFC_ (5AH?\
MS\7_ /W\3_XFG]?HC_LROY?>>245ZW_PK#0_^?B__P"_B?\ Q-'_  K#0_\
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M+;.F0,GIUK'MI;<?$;1;V'26TG3YF"VZ2($+]1N(]22!^5;=W_R7&S_ZY?\
MM)J]!Q2FI-:\CZ+=?@>:I/V<HIZ<RMJ]G;OJ5GN/$/A'QQIME<ZW/J5M?.@8
M2DXPS;3A23MP3G@UI^,-9UB]\5V?A;1KDVC2J&EG4X;D$]1R  ,\=:J^//\
MDH/AC_KI'_Z-%/\ &,%WX?\ &UCXKBMI+BS5-DX3^#@J<^G!X]Q40Y9NG.27
M,T_FUL:SYH>UA%NR<>]TG:_F<[X[TO6=(33+74=5;4[?>S0S2+B13QD'))(Z
M=Z]J7[H^E>+>.?$S>)XM/GM;"Y@T^*4A9IU \QSV&"1P!ZU[2OW1]*QQG/[&
MGSJS][]#3"<GMY^S=U:/Z]SR_P =J-4^(>A:3<9-J=FY,]=SG/Z "O1;G2K&
M[TQM.EM8C:,FSRPH 4>WH17'?$/PYJ%[-9:YI"%[RR(RBC+$ [@0.Y![>]8-
MS\3M8O[1],MM$,>I2+Y99&9B#WQ'MR#^)IJE.O1I^R?PWOKMKN#JPH5YNK]J
MUG;?38[ZTT[3?!?A^Z:U246\*M.X9RQ8@?IG Z5QFDVGBKQM:2:P?$,NF0F1
MA;P0;@IQZ[2.,\9.>];WA[PQ?1> [C2]1N)#<WD;Y5W+"'*X51],#.*YOP_X
MMD\#Z8VB:WI5XLT4C&!HU&U\G/4D<9/49ZTZ:?O^S?-.^_EY7%4:Y:?.N6%G
M=>?2]C?\$>)-0OIM1T76'5]0L2?WH&"Z@X.<>AQS[BN7\)?\)/XHCU"SC\0W
M%K;PR;GF8M)(2<@*"6! X/0BM_P)I.H/J&K>)-2MVMY+[<(HG&&"DY)P>W
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M SWJ:45RQT7L[:O3?\[]AUI/FG=OGO[N^VEO+U+OQ U75K'Q7HL.EWDL32J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!:V=K8P>19VT-O$#GRX4"+GZ"IZ**&VW=@DDK(****0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!(23G..A[&K4MAK^A^(-4O=*TZ'48-2*MAIQ$T+@8YSU7V%.4:=W;SZ[[?\
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MS6A\LRC=YBH'9<>H4AB/0YIB^(M%=59-5LV5Q$RD3+R)3B,CG^(\#U[5>-M
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M QK]6!! [Y%6S:VYSFWB.=V?D'.[[WY]_6E^RV^<^1%G(/W!U'0_AVH S_\
MA)=#\II?[7LO+6%YRWGK@1HVQVZ]%;Y2>QXJ7^W=)\]H?[2M?-69H"GFC(D5
M=[)C^\%YQZ<U:^QVVW;]GAQM*XV#H3DCZ9YI?LMON+>1%N+%B=@ZG@GZT 45
M\1:*ZJR:K9LKB)E(F7D2G$9'/\1X'KVH;Q%HJ*S/JMFJH)68F9>!$<2$\_PG
M@^G>KHM+88Q;Q#&,?(.W3\J#:6QSFWB.<Y^0=^OYT 53KFE"=8#J-J)FE6!4
M\T9,C+O5<>I7Y@/3FHAXGT)H1,-8L3$8DF#B=<%'?8K9ST+_ "@]SQ6A]F@W
M!O(CW A@=@SD# /Y4W[':[=OV:';MVX\L8QG./IGF@"J=?T@-M.IVFXR2Q >
M:/OQ@F1?JH!)';!I(_$&C2[?+U2T?=Y.-LRG/G?ZK_OO^'U[5=^RV^<^1%G)
M/W!U/4_CWH%K;KT@B'W>B#^'[OY=O2@#/_X2;0O),W]KV7E".24OYZXV(VUV
MSGHK<$]C39KWP_=WT(GFT^:[AF,46\HSI(%WE5SR&VX; [<UH?8[7;M^S0[<
M$8V#H>2*=]F@W;O(CW9W9V#.<8S^5 %!?$FB/&LBZM9%&2.16$RX*R-M0]>C
M-P/4TLGB+1HBPDU6S4J)BVZ91@0_ZWO_  ?Q>G>KOV2V Q]GBP !C8.@.1^1
MH-K;DDFWB).[.4'\77\^] %1=?TAIEA74[0R-(D002C)=TWHN/4K\P'<<U _
MB+P\T,=V^J:>8U@-U',9EP(LA#(#_=R0,^]:8M;<$$019!!!V#J!@'\!3?L=
MKMV_9H=NW;CRQC;G./IGF@"L==TE9&0ZC:ATE>%E\T9$B)O9?J$^8CTYIB^(
MM%=59-5LV5Q$RD3+R)3B,CG^(\#U[5>^S0$DF"/))8_(.21@G\1Q2"TMAC%O
M$,8Q\@[=/RH I'Q%HH1G.JV858Y)6;SEP$C;;(W7HIX)[&I%US2FG$"ZC;&9
MI1"$$HR9"F\+CU*_-CTYJS]DML8^SQ8((/R#H>H_&E%M &W"",,#N!V#.<8S
M^5 &?_PDVA&(2_VO9>68DF#>>N/+=MB-UZ,W /<TY_$6BQE]^JV:[/.W9F7Y
M?)_UN>?X,_-Z=ZN?8[7&/LT.-H7&P= <@?3-*;6W.<V\1SNS\@YW?>_/OZT
M5#K^D"41'4[02%HE"^:,YESY0_X%@X]<<5&WB70UM_M#:O9"$1O+YAG7;L1P
MCMG/16(4GL3BM#[+;YSY$605.=@_AZ?EVI/L=MLV?9X=N"N-@Q@G)'Y\T 5?
M[=TD3>2=1M?,$IAV>:,[PF\KCUV?-CTYIB^(M%:/S%U6S*%(GW"9<;93B,]>
MC'@>O:KWV:WSGR(LYSG8.N,9_+BD^R6V,?9XL8 QL';I^5 %,^(=&4.3JEF
MBS,Q,R\"(XE)]D/WO3O2C7M(,_D#4K4S><D&SS1GS'7>J8]2H) ].:M_9;?G
M_1XN<@_(._7\^]+]EMPV[R(MVX-G8.HX!^HH SQXGT)H1,-8L3$8DF#B=<%'
M?8K9ST+_ "@]SQ4C:_I"S-"VIV@D61XBAE&0Z)O=<>H7YB.PYJU]CM=NW[-#
MMV[<>6,8SG'TSS3C:VY))@BR223L'4C!/XB@"C_PD6C%8V&JV>V00E#YR_,)
M<^5CG^/!V^N.*1O$FB)&TC:M9!%221F,RX"QMM<]>BMP?0U>^RV_'^CQ<;<?
M(.-O3\NU'V2V(Q]GBP01C8.A.3^9H K?VWI7F^5_:-MYGG?9]OFC/F;=^S']
M[;\V/3FHT\1Z+)$)4U6S:,QQRAA,N"DC;$;KT9N >YJ]]F@SGR(\[MV=@ZXQ
MGZXI!:6P&!;Q 8 QL'0'('X&@"BWB/1%#%M6LP%\[<3,O'D_ZWO_  9&[T[T
M]=?TAIEA74[0R-(D002C)=TWHN/4K\P'<<U;^R6W_/O%SN_@'\77\^]*+6W!
M!$$6000=@Z@8!_ 4 9Y\3Z$L)F.L6(B$3S%S.N B/L9LYZ!_E)['BI6US2DN
M/L[ZC:K-YK0^691N\Q4#LN/4*0Q'H<U9^QVNW;]FAV[=N/+&,9SCZ9YIQMH"
MVXP1ELELE!G)&"?RH HKXBT5U5DU6S97$3*1,O(E.(R.?XCP/7M0WB+15C\Q
MM5LP@25]QF7&V(XD/7HIX/IWJZ+2V&,6\0QC'R#MT_*C[);8Q]GBQ@C&P=^O
MYT 5AKFE&3RQJ-MO\T0[?-&?,*;POU*?-CTYJ$>)]":$3#6+$Q&))@XG7!1W
MV*V<]"_R@]SQ6A]F@SGR(\Y#?<'4#&?RXIOV.UV[?LT.W;MQY8QC.<?3/- %
M4:_I!E,0U.T,@:52OFC.8L>:/^ Y&?3/--3Q%HLA39JMFV_R=N)E^;SO]5CG
M^/'R^O:KWV6WSGR(LDL<[!_%U_/O2"UMQC%O$,;<?(.-OW?R[>E %%O$FAHC
M,VK62JL<DK$S+@(C;';KT5N">QXJ3^W=)$WDG4;7S!*8=GFC.\)O*X]=GS8]
M.:M&TMB,&WAQ@K]P="<D?GS2_9K?.?(BSG.=@ZXQG\N* *(\1:*45QJMF5:.
M.56\Y<%)&VQMUZ,> >YI7\0Z-&C.^J6:HHE+,9EP!$0)?^^"0&],\U<^R6V,
M?9XL  #Y!T'0?A0;6W(P;>(@Y_@'?K^?>@".UU*ROI)8[2[AG>'9YBQN&*;E
M#+G'3*D$>QJU3$ABB),<:(6QDJH&<<"GT %%%% !1110 4444 %%%% !574W
M:/2KQT8JRP.58'!!VFK507L+7-A<0(0&EB9%)Z9(Q0QK<X_1)-.N=%L)+J3Q
M%)<R0(9'5K\JS$#)!7Y<9].*VM2\21Z-=R6UU;.,Q!K,JQ8W+=#&!CALD>N0
M<^M,TJ'7],TFTL?L.FR?9X5BW_;Y!NP,9QY/%,U30+W6KLSW-RMO]GC!L5@<
MGRYNID;@9P1@#TSZUO)Q<]=C&":CYCTUW4Y]1N-/AT>(W%O#'+*7N]J N"=N
M=A)/'I@^W=T?B5;Q;.+3[;SKRY1W\F63RQ$$.UM[ -T;C@'-9E@=97Q3JQCB
ML7N/LUL)D>5U0-M;E2%)(Z\$#ZBI&\&I"EE*MO8W\\*R+-%>)B.0NV\L.&VD
M'..#P<>])J">O]: G*VA??Q,D=NRO:M_:"W*VGV42#F1AD8;^[CG..G;/%4M
M?UC5HM"O-MG]DNX98E+K*QC968<H^P9/8C QGZ9>/"\BV2/$EC;7<5VMW%%;
MPA(5*C&PD %LC/S$9YZ=JGU#2M7U;3+V*ZGMXWE,9@MXVW1QE&#<OM#'=CTX
M]#0N1-/^NG_!&^9_UZ_\ L'6+R2]DLK.QAFNK:-'NMUR51"PR%5MA+'CN .G
M2HX_$@O1:1:;:B:ZN(WD,<TOEB((VUMQ ;G=QP#FJ=UX;DFU*;47TO2+R:ZC
M02Q79+")U&,H^PDC&.,#I4L'A^YTQ[*[L?L<EU#"\$L9001.K-N^78IVX/3@
MY'7GFE:']?UW"\B7PQ<W=RVKF[\Q72_=%C>3?Y8VKP#Z<Y_&J<6N7=EJ_B&6
M_56LK0QB-4E+,"5&U57:!EL\\\'CGK6IH6GWEC]O>^>!I;JZ,X\DG"@JHQR.
MV*HWOAR>\NM74O$+?4!'(LFX[XI(P-ORXP1D _>'IBB\>;7LOT_X(];?-_J7
MHM8N8]0M;34;%;9KO=Y#1S^:"0,E6^48;&>F1QUJMK=Y>6VOZ-'9H\IE\X&+
MS=B-A1@L>>!]#]*D&G:C?ZG8W6I"UB2Q+.BV[LYD<KMW'*C:,$\<_6I-6L+^
M?5--OK$VY-IYN^.9F7?N   (!QTZ_H:7NIKY_J&MB%O$RP131W%J4U"*=+;[
M,D@8.[C*[6X^4CN0,8/%6[/5)GU$Z=?6R6]UY7G((IO,1TS@X)53D$C(([]Z
MR;KPK)J,5S<WGV4WTUS'<"(J9(0(QM"'(&X$$Y.!UZ<5<T?1#9Z@]XUAI=B#
M'Y:PV,2G/.2S2;%/8< 8^O9VA;^NW^8KRO\ UW_R#7/$,FF7EKI]CI\FH:A<
M@ND"R",!1U)8\"JTWB_[)HT=U=Z5>0WTD_V9+%E^9Y/]ENA7_:%/U[0]0N-8
ML]:T>>VCO[:-HBETK&.1#Z[>1CFJMYX;UG4M,MY+S583J]M="Y@=(L11G^YC
MJ5]SS3BH65_G]_\ D$G*[M_6G^9+;^+I0U];:EI,EAJ%M:M=+;M,KK*@!Z.!
MC]*HP^/[AET^6;P[=1V]^-MO(LRL7D_NA>.">YQZXJ9?#.KW]Q?:CK%S9-?R
MV3V=O';!A%&&!Y);GJ:>/"U]]A\,0>;;[M*E5YSN;# #'R\<_CBJM3Z_UO\
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M\TFVO;*YTT&VE:2V-P'CDX.#E>"1[CBMWQ#8:EJ!M8K;4CI]@I9KR6*39+M
MX"G&![GBLVST+Q#-XIL-9U>YTYA;PO$8K4.,9!P1NZY[]*G\9Z-K>NVL%GID
M]K%;;MURD[NOF],+\H)V]<\BH=N:-K?TV5&]I-W_ *2.4FU?4E\!:U-#J=W+
M!!>K'97K.1*\>X _,,$_7OS5_7/&VFZDVCVVC:K*;@W\/FK&LD>Y,X()(&1R
M.*T+WP_K^J>$;G1[E=&MWW1BV6T\Q8U56!(.03VXP*U?$>BW.L0:8EN\2FUO
M8KA_,)&57.0, \U?-"ZOW_1$<L[:=G^I?UF+49M)GBTF:*&]<8CDESM7GD\
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MB62&\*:?I&GO+:201I:1@[F88W-)L5@/8#\ZZ'3;9[/2K2UD*EX84C8KT)
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M>I0V5Q902*[->2^5&4 (!VEN>>F!5RN"=Y]/\0:'H5T7?[/=F2UF//F0>6X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M5DZIINJWC7!L==ET\20)'&$MHI/*</N+C<#DE?EP>!U'-(=-U;?D:_*%\Z=]
MOV6+[C@B-.G1"00>K8YSS0!=@TRPMIY)X+&VBFD^_)'$JLWU(&33OL%G]E2V
M^R0?9T(9(O+&Q2#D$#H.>:SXM,U=-OF>()I,?9\YM8AGR_\ 6]!_RT[_ -W^
M'%1?V1K?V<Q_\)--YABE3S/L<.0S-E'QC&4'R@=#G)R:=V*R)=+\.66GC?)#
M;W%R)Y)DN&@4.F]BV >3QG'6KUUIMC?.C7=E;7#1G*&:)7*_3(XJFNG:J+WS
M3KLIA\XOY'V:/&S9MV9QG&[Y\]<\=.*B72M:6)%;Q),SB.)2YM(OF97R[8Q_
M&ORD=!U&#0Y-NX61J75C:7L'D7=K!<1 Y\N6,.OY&FR:?931PQRV=N\<!#1*
MT2D1D="HQP1[5GRZ7K#LYC\131@BX"@6L1V[_P#5GD?\L^W][^+-(VEZP948
M>(I@BSPR,@M8OF1%Q)'G'1S\Q/4= 0*+L+(T#IE@UZ+TV-L;L=)S$N\?\"QF
MBXTVPO)DFN;*VGECX1Y8E9E^A(XK,.D:X;-8AXGG$PM3"9OL<.3*6!$N,8R%
M!7;]WG.,U.VG:J99&&NRA6GDD5?LT?RHT>U8^G(5OGSU)X/'%%V.R-....&)
M(HD6.- %5%& H'0 =A4"Z98+#-"MC;"*=BTR")=LA/4L,<GZUGII6L*J!O$4
MSE5@#$VD0W%#F0]/^6@X/]W'RXI/[*UK9*I\23;FCF5&^R1?(S-E&Z<[!P >
M#GG-%V!JVUI;64 AM+>*"(<A(D"J/P%,GT^RNI5EN+.WFD52@>2)6(4\$9(Z
M'TJFFGZH+I9&UR1HA.LAB^S1@% FTQYQG!;Y\]<\=.*K_P!D:WY(3_A)I]_D
M1Q[_ +'#]]7W-)C&,LORD=!U&#1=[A8U9K"SN+06D]I!+;* !"\89 !TX/'%
M$%A9VP(M[2"(% A$<87*C.!QV&3Q[UFR:7K#&39XBF0,;C;BUB.S?CRNW/E]
ML_>S\V:>=-U8S!_[?E"!H"4%K%@A,^8,XS^\XS_=Q\N*+L5D7+;2M.LG#VEA
M:P,,X:*%5/.,]!WP/RI8M,L(+M[J&QMH[E_OS)$H=OJ0,FLUM)UHVGE#Q+,L
MWDR)YWV2'.]I ROC&,JN4 Z'.3DU,=.U7[07&NRB/SF?R_LT>-ACVA,XS@-\
M^>N>.G%%V%D:<L4<\3131K)&PPR.N01[BJZ:7I\5FUG'8VJ6K_>@6%0A^JXQ
M5!=*U@0[&\13,^R!=YM(OO(<R-C'_+0<$=!VQ2MI>KE9 /$,P+).%/V6+Y2Y
M_=GISY?0?WOXLT78S5:WA>6*5H8VDBSY;E02F>#@]J)((97C>2)':)MT;,H)
M0XQD>AP368--U877F'7I3%Y\<GE?9H\>6J%6CSC.&;#9Z@C XXJ%=(UP6ZQG
MQ/.9! D9D^QPY+K)N9\8QEE^0CH.HP:5P-B2V@FEBEE@C>2$DQNR E">"0>W
MX57.C:69I9CIMF99?]8Y@7<_U..:JMINK&=G77Y5C,TKB/[+%@(R;43.,X1O
MGSU)X/'%-&EZQMB'_"13$J+<.?LL7S[,^8>G'F9&<?=Q\N*=VA63+TVE:=<W
M2W4]A:RW"8VRO"K.,=,$C-.N=.L;R2.2ZL[>>2(YC:6)6*?0D<5FMI6M-$ZK
MXDF5S'*H<6D7RLSY1L8_@7Y0.AZG)J;^S]4\_?\ VY)L^T>;Y?V:/'E[-OE9
MQG&[YL]<\=.*+L+(LS:1IMQ#%#-I]I)%#_JD>%2J?[H(X_"I196@ADA%K"(I
M23(@C&UR?4=ZS(]*UE80C^(YG<11(7-I$,LK[G?&,?.ORD=!U&#2-I6LD.!X
MDF7/VC:?LD7R[P/+[?\ +/G'][/S9HNPLB:RT&VT_6);VT6*")[=81;Q1!%7
M#%L\>N?2KMU865^$%Y:07 0[D$T8?:?49'%4%TW5A.KMK\K1B:)S']EBP45-
MKIG&<.WSYZ@\#CBH6TC7#;M&/$\XD,#QB3['#D.TFY7QC&57Y .AZG)H<F]0
MLC433[*-HV2SMU:-V="(@"K-]XCC@GN:D^RV^^9_(BW3 "5M@RX P-WKQZUG
MOIVJ-=^:FN2I%Y[R>3]FC(V% JQYQG"L"^>I)P>.*B32M854#>(IG*K &)M(
MAN*',AZ?\M!P?[N/EQ1=C+]KI>GV+!K2PM;=@" 8853@]1P/8?E2P:;86MQ)
M<6]E;0S2??DCB56;ZD#)K/;2M8,.Q?$4ROLG7>+2+[SG,;8Q_P LQP!T/?-2
MC3]4$V\ZY(4\]9-GV:/&P1[3'G&<%OGSU!&.G%%V*R-&"WAM8O*MX8XHP2=D
M:A1DG).![T+;P)/).L,:S2 !Y H#,!T!/?%8RZ1K@MUC/B><R"!(S)]CAR76
M3<SXQC++\A'0=1@U,--U83%_[?E*%IR$-K%@!\>6,XS^[YQ_>S\V:0RZ^F6$
MMF+.2QMGM0<B%HE*#G/W<8ZT\65J+/[&+:$6NW9Y/EC9M]-O3%9D>EZPICW^
M(IG"FWW9M8AOV9\WMQYG?'W<?+BD?2=:9&"^)9E8PRH&%I$=KL^Y'Z=47Y0.
MAQDY-.["QK?9;?S8I?(B\R%2L;[!E >H![#CM3Y(XYHVCE17C8896&01[BLL
MZ=JOV@N-=E$?G,_E_9H\;#'M"9QG ;Y\]<\=.*C&E:QY:+_PD4Q98H49OLD7
MS,C9=^G5Q\I'0=1@T@+L6FV]A;2QZ5;6ED[\@I;@+GU*J5S^8IECI%O:::]G
M(J7"S,[SF1!B5F.6)'3'/3TJM)I>KM$ZIXAF1B)P&%K$=N\@QGI_RS ('][/
MS9IRZ;JPG5VU^5HQ-$YC^RQ8**FUTSC.';Y\]0>!QQ3YF*R-(V\!ECE,,9DB
M!$;E1E >H![5$^FV,BE7LK9E9S(08E.7(P6Z=2.,UF#2-<%FT1\3SF8VHA$W
MV.'(E#$F7&,9*D+M^[QG&:G_ +.U7[49?[=E\KSY)/)^S1XV,FU(\XSA6^?/
M4G@\<478R_;V5K9V_P!GMK:&"#G]W%&%7GKP.*;:Z=8V*NMI9V]N)#EQ#$J;
MC[X'-9R:5K*[=WB.9\+;@YM(ADI_K#T_Y:=_[O\ #BD;2M::)U7Q),KF.50X
MM(OE9GRC8Q_ OR@=#U.31=A9&Q%#%;PI##&D<2#"HB@!1Z "HH;&SM[=[>"U
M@BAD)+QI&%5B>N0.#FJ1T_5#=&0:Y((O/$GD_9H\;-FTQYQG!;Y\]<\=.*A.
MDZU]F6,>)9A*(8D,OV2++.KDN^,8RZX4CH,9&#2N!H)I>GQQP1I86JI;MOA5
M85 C;U48X/TJ2>QM+J:&6XM8)9(3NB>2,,4/JI/3\*S)-+UAC)L\13(&-QMQ
M:Q'9OQY7;GR^V?O9^;-/&FZMOR=?E*^= ^W[+%]Q !(G3HY!)/5<\8XIW8K(
MDD\.Z'+(TDFC:<\CDLS-:H2Q/4DXK0$,2PB%8T$0&T(%&W'ICTK&&DZUY#(?
M$LWF&"2,2?9(>)&?<LF,8RJ_(!T/4Y-3?V;JOVEI/[>E\LW#R"+[-'@1E-JQ
MYQG ;YL]2>.G%#;>X61;M-*TZP=GLK"UMF?[QAA5"?K@5;K%32M854#>(IG*
MK &)M(AN*',AZ?\ +0<'^[CY<4/I6L,KA?$4R%EG"D6D1VESF,]/^68X'][/
MS9H;;W'8VJ*RCIVJ&Z20:Y*(A.DC1?9H\,@3:T><9PS?/GJ"<#CBJZZ1K@MU
MC/B><R"!(S)]CAR763<SXQC++\A'0=1@T@-VBL@Z;JV_(U^4+YT[[?LL7W'!
M$:=.B$@@]6QSGFDBTS5TV^9X@FDQ]GSFUB&?+_UO0?\ +3O_ '?X<4 ;%%87
M]D:W]G,?_"33>88I4\S['#D,S91\8QE!\H'0YR<FK T_5!="0ZY(8O/,GD_9
MH\;-FT1YQG ;Y\]<\=.* -6BL1=*UI8D5O$DS.(XE+FTB^9E?+MC'\:_*1T'
M48-.ETO6'9S'XBFC!%P% M8CMW_ZL\C_ )9]O[W\6: -FBLA=-U83J[:_*T8
MFB<Q_98L%%3:Z9QG#M\^>H/ XXJ$Z1KALUB'B><3"U,)F^QPY,I8$2XQC(4%
M=OW><XS0!NT5DMIVJF61AKLH5IY)%7[-'\J-'M6/IR%;Y\]2>#QQ4::5K"J@
M;Q%,Y58 Q-I$-Q0YD/3_ ):#@_W<?+B@#:HK%.E:QY;K_P )%,&:*9%;[)%\
MK.V4?IU0?*!T/4Y-2II^J"Z61M<D:(3K(8OLT8!0)M,><9P6^?/7/'3B@#5H
MK"_LC6_)"?\ "33[_(CCW_8X?OJ^YI,8QEE^4CH.HP:?)I>L,9-GB*9 QN-N
M+6([-^/*[<^7VS][/S9H VJ*R#INK&8/_;\H0- 2@M8L$)GS!G&?WG&?[N/E
MQ43:3K1M/*'B699O)D3SOLD.=[2!E?&,95<H!T.<G)H W**R3IVJ_:"XUV41
M^<S^7]FCQL,>T)G&<!OGSUSQTXJ-=*U@0[&\13,^R!=YM(OO(<R-C'_+0<$=
M!VQ0!M45C-I>KE9 /$,P+).%/V6+Y2Y_=GISY?0?WOXLTX:;JPNO,.O2F+SX
MY/*^S1X\M4*M'G&<,V&SU!&!QQ0!KT5A+I&N"W6,^)YS(($C,GV.')=9-S/C
M&,LOR$=!U&#4S:;JQG9UU^58S-*XC^RQ8",FU$SC.$;Y\]2>#QQ0!KT5C#2]
M8VQ#_A(IB5%N'/V6+Y]F?,/3CS,C./NX^7%-;2M::)U7Q),KF.50XM(OE9GR
MC8Q_ OR@=#U.30!MT5E?V?JGG[_[<DV?:/-\O[-'CR]FWRLXSC=\V>N>.G%1
M1Z5K*PA'\1S.XBB0N;2(997W.^,8^=?E(Z#J,&@#:HK$;2M9(<#Q),N?M&T_
M9(OEW@>7V_Y9\X_O9^;-2+INK"=7;7Y6C$T3F/[+%@HJ;73.,X=OGSU!X''%
M &O16$VD:X;=HQXGG$A@>,2?8X<AVDW*^,8RJ_(!T/4Y-6'T[5&N_-37)4B\
M]Y/)^S1D;"@58\XSA6!?/4DX/'% &K16*FE:PJH&\13.56 ,3:1#<4.9#T_Y
M:#@_W<?+BAM*U@P[%\13*^R==XM(OO.<QMC'_+,< =#WS0!M45E#3]4$V\ZY
M(4\]9-GV:/&P1[3'G&<%OGSU!&.G%5UTC7!;K&?$\YD$"1F3['#DNLFYGQC&
M67Y".@ZC!H W:*R!INK"8O\ V_*4+3D(;6+ #X\L9QG]WSC^]GYLTR/2]84Q
M[_$4SA3;[LVL0W[,^;VX\SOC[N/EQ0!M45B/I.M,C!?$LRL894#"TB.UV?<C
M].J+\H'0XR<FI3IVJ_:"XUV41^<S^7]FCQL,>T)G&<!OGSUSQTXH UJ*Q1I6
ML>6B_P#"13%EBA1F^R1?,R-EWZ=7'RD=!U&#2R:7J[1.J>(9D8B<!A:Q';O(
M,9Z?\LP"!_>S\V: -FBJ5C:WMO+.UUJ3W:2!/+1H43R\* V"HYW$%N>F<#BK
MM !1110 4444 %%%% !1110 5'/,MO;R3."5C0N0.N ,U)574_\ D%7G_7!_
M_030QK5G,Q_$.RDM5N_[%UQ;,C)N3: Q@=R6#=*ZNVN(KNVBN8'#PRH'1AW!
M&0:\EBAUVT\ V-TVJRR:'*I2YMH((UDBC+$$AB"6Y^G6K'B=$N-6TO389]/7
M15T]7M?[0GDC@?'?<A!+8QU_K75*C&]EW?X'-"K+EN^QZO17D\CSR>%M#M]3
MU(3:3+?M'/<0M(%,0^ZK,X!QG<,^@'/%/MH=-36?%$&BS>?9IH[+'ME,JJ<?
M=5B3D?C4.C:^O?\  M5;VT[?BSU6JEG?_:Y[J+[)=0_9Y-F^:/:LGNA[CWKS
MK^U;&YTCP196]U#+<1W4!DC1P6CP,'<.W)[U%JW_ " _''_80C_]"6G[#6S_
M *U2_4%5O:W]:-_H>JT5YEXNTI-%T_2["Q,<-G>W!:]ENYY/+EDVC'F,#N /
M/0@51M8Y8_">M6K:[8Q60FC2-K0W$D,3=TWE2=IXY!./QI*BFKI_UL'M+.S1
MZW6+K?B?3_#]U8P7_FK]L8JDBJ"J8QRW/ Y'3-<IX%DMK/Q%<:?;)&H>W$I%
MC>_:+;(.,\Y96_X%T/2K7CK3X=5\2>'+"X!,4[3HV.H^4<TE32J*+V#G;@VM
MSJ9M;MH-?M=&9)3<7,32HX V #.<G.<\>E:5>3:9<:I#XXM-.NT+WVF6<\,<
MA_Y;#:Q0_EBLW0A=O?:;J":IID>HS7063,UPUU)\W*2( 5 _ #IS5^P3M9_U
M=V_(GVS5[K^K*Y[717FHU2RTX>.+>ZN8HKB61_*B=L-)N0@;1U/X5%'ID&KW
M7@NSN@QMWTUS(BN5W@*.,CG%0J/=_P!6N6ZEOZ\TOU/3ZR=>U^W\/V]O+/;7
M5P9Y1#'';('<L02."1Z5Q=Y:Z--XMO=-\1W'V?3[.VB&G0R3F./;MP6!R,L#
MQ^?I6?+=7MQX1T*2>_: +J^VVO;@!BL0SM=MW!QSU]*<:*=GZ?B3*HU=?U_P
MQW.F^+[2_P!3CT^6PU+3[F52T2WUOY?F8Z[>3TKH:\VAN)$\9:+)-X@M?$4C
M-)&BP(B&WR.7PA(/'K62[:7<:/J^IZMJ$D?B:">00@W#))$P/RJB@\K^'K3=
M)/;^M?D"J/J>OT5EVUW<1>%H[R_61;A;,2SA!\P8)DX'K7E6D2Q#Q%H-]9O#
M%)<W.V8B^:>XD!/_ "U'"CZ8%3"DY-KL.53EBI=SVFBO)SH=I?Z3XOOYS,;B
MTO9W@Q*P6-EYW!0<9/3)JW>/:ZEK6@P>)+HKICZ4LR&68QH\^!DLP(YQ[_SI
M^Q7?^K7!U+=/ZO8[S3-9M]5FOHH$E5K*<V\GF  %AW&">/RJOK'B:QT:>*VD
MCN;J\E&Y+6TB,DC#UQZ?4U@_#DP%==^S3--!_:#>7(S%BRXX.3U^M+]KM]$^
M(NHSZI+'!'?6T?V6XF.U/EX9=QX'/-)P2G;R_0?,^6_G^IN:)XHL-<GFMHH[
MFVO(!F2VNHO+D4>N/\]:VJ\XB\4:S<7NK6L1T>YG33Y)EN=,#L=PX4%B>3WQ
M]*Q?"<<Z:UH]S;ZGI0GN3F>.&>XDGF&/F$JG*@CD\[1FJ]A?7;^O^ 3[6WG_
M %_P3V&BO&9-,A3P9J6MJ\ZW]MJ;>1(LK 1_.H.%SCG/7&:ZFRTZ'1?B&EO9
MO,([K3&EG\R5G\QPWWCD]:ETDE>_])7&JCO:W]7L=[6=::S;WFLW^EQI*)[(
M(9&8#:=PR,<Y_05Y%;1Z+'X)6]AO77Q%#.1 BSMYBDOT5,]"#G..IKJ(M%M]
M=\6>)8M2$I58+=C&DC(-_E]3@\X/3/%4Z*C>[VO^G^8*HWHCN[N_^RW-K#]D
MNIOM#E-\,>Y8O=SV%6Z\PT^>6YL/ DD\C22?:9 6<Y) ) _059T/2(I)/$FL
M1Q/+J-I?7/V,;SA&V]0N<$G(ZCL*4J2BG=[7_.P1J.5K=;?K_D>C45XQX:6Y
M_M32+V'5-+6\N)AYRI/</<S#^)9%Y4<9YP![UVWQ"CCGTVRAEOX;97N!F.Y,
MBPS\?==T^Z/J12G1Y9*-]PC4YDW8ZC4+Z#3+":]NF*P0KO<@9./I4EM<)=VD
M-S&"$E19%W=<$9%>3QI97'A#Q)8+"VRSV3QK%>>?;HQ!QY; 9]<@DU;G32DM
M?"^GO<B'P[<1LURT<YV/-M!*N^>.>V>.?PKV*VO_ %:XO:O?^MSU*F2R"*)Y
M&R512QQ[5Y:;JXL=+\50>';B672K=8_L\B2%Q$3CS C>@&>_'6M?1[?PK93K
M_8NIRF[N+-S)!%,94E^7):3@[6'U6HE2M%O^MKZ]BE.[2.OT;5H-<TF#4;9)
M$AF!*K* &&"1S@GT]:;I6LV^KM>K;I*IL[AK>3S !EEZD8)XKS7P4LHNM ?6
MD#V+I(NF -\B2AB26']X\X/TJ7^QK6^TCQ??3F8S6E]/);[9658W49W8!P3]
M:TG1C&373_@V(A4E**[_ / /5JSM;UFWT'36OKI)7B5U0B( MEC@=2*X6]EM
M]1U30;7Q)=LFDRZ6LH\R4QI--@9WL".W/7T]:S;N5F\':W;V\SSZ3!J,26,C
ML6^7<,J">JCC%*-#5)]_UL#J^ZVNWZ7/7,\9K/T76;?7=.6^M4E2(NR8E #9
M4X/0FN)U!=+N_'&IKXDO#!';01M8;K@Q!<CYF7!&6S_GBN=66Y/@C0[:.6%+
M&XO9EG>YD=(FY^42%>0#S1&C=>MOQ*=2S/::*\?,<\/@7Q%;B^LKBTCEA$26
M;RO'"V\9"LXY'0\$UZ;HFBV6B61BLT8&4B25W=G9WP 6))/7%1.FHJ]_ZLG^
MHXS<NAIT5XAXAO(+N;4-4MF2.\BO-J2W%\QN@ <82-0 J#WSWYKH]1@T*\\?
MZE%K]R(X&LXBBO.8D=@!U((R1V%5[#1-O^M/\Q>UU:_K>QZ917CTDPE\*>'S
MJ%S,MDNKLD<Y8AO(&<'/7UY[8J_&EC:7WB2ST";S=(_LEY)!'*98UFYZ,2>2
M,]_Y4.C9/4%5NTCU*BO++G38M&\":7>6SSP_;S;+J5TDC%Q$1VY^4#(''L*N
M:?9:2/%?]D>'YA/I%U8O]NBCF,L:D\!LDG#=.]#HK6SVO^']: JFUUO;\3T>
MBO,-($^JZCI/ABZ5B-$FDDNB1PP0XB_/(KG_ !#>07<VH:I;,D=Y%>;4EN+Y
MC=  XPD:@!4'OGOS3C0O*U_ZZ"=6RO;_ (<]>@UFWGUVZTA$E%Q;1K*[$#80
MW3!SG/X5HUR&E'/Q(U@DYS90<U9UI%O_ !';:>;6&YVVS2LEXW[@#<!D)M.Y
M^.YP!]:S<-4O(M2T;_KH=-17FMFJ:A'I=I*Z2V\6MS1*(R0A0(QVJ,GY>V,]
M/RJ^^DV&_P 51"TB$5JBO;1X^2!C%N+(O13GG(P:;II;O^M/\P4FW9?UO_D=
MW17&V"1ZOJMI!K")<0_V5#+!%/\ ,LCG_6-M/!8?+],^]9D"B]U'2+>8F>Q7
M5+N.WW.6#Q!#@9_B7.1WX&*/9:VN+VFE_P"MKGHM%<%> V%QK&GVG^CZ<+RS
M$B1?(L4;X\S&/N@XYQZFM"WLM/L?B#;Q6$4,/_$ND+Q0X"K\ZX.T<#/ZTO9^
M?]6N/G_KYV.MJK>:A!8&V$Q;-Q,L$849RQS_ (&L6_ABOO&$-EJ,<<ME]C,D
M$,O*22;OF)4\$@8^F<USTEM!=O;PR0QW-C#KWDVQD'F 1%/F4$Y^7=D8Z<8[
M40@G:_\ 6M@E*U_ZZ7.YLM2AOYKR*)9 UI-Y,FX#!;:#QSTP15RN%&F6-S#X
MLN9K:.2>&XD,4C#)C(B4@J?X3GN,4R$W>K:K&EY9V-_&-.@EBBOIRBY8'>ZC
M8P)SP3P1QZT_9I[=E^0<[6_G^#L=[17GMM +_4O#<%\T-Y 7O%4;FD0H/NJ2
MZC>!TR1@X[UT_B=IK'PC??V<#&\4&U/+X**, XQTP,TI0LTN_P#G8<97-NBN
M(URQTBTT>\CTUC'<7&F2L((!E)E !\Q\#EO1B<G)ZU/>S1/JG@]5F3)#L,,.
MGDGGZ4>S[?UO_D+G_K[O\SL*JV&H0:E \UN6*)*\1+#'*D@_J*Y2SMX-*GTZ
M6:SLKY+B40QZG:2GS96;(S(/XU]?F(&,X]*-I!%9^'HTBACM[>?67BO'C'EG
MRA*P )';.!]#BG[-"<VCT.BN \1P0Z>^JV6FQI#:MI$LEQ!#PB/D!#M' )&[
MTSCVJV^C:?#KV@P+:Q^7<6TOVD8XN-JJ1YG]_DG[V:%35KW_ *U_R&YN]OZZ
M?YG:45P$3*(3I20B2-M8FA@MY)-D 4+NV/P<KUPHZG':L_5/W%EXGT]/LR0Q
M?9&$-H"L<;%^0!G@\#.,?2FJ5W:_;]/\Q.I;^O7_ "/3Z*Y;4;>R\+7MKK%M
M;Q6UH08+P1J%&&Y5SCJ0PQG_ &JTO#]M-;Z*LLJ_Z5=,US*#V=SG'X# _"LW
M%<O,4GK8UZJ:=J$6IV8NH5=4+NF' !RK%3T/J*Y31(=..CZ=JE]*\6J276V2
M>,$RO+O(,3<$[>VWH .W6J^F*ES)H]E>JK:?+)>$QN?DEE$IVJPZ'C<0#_2K
M]GNB><[ZHYI&BA9TA>9ATCC*@G_OH@?K7&"U6:YU73;>Y@ATZ&\@$,,K?N7?
M;EX/H>/E'3T[57U-XH/#^MZ<--BL9X1!)(EK*7@.YQ@J,#:>#D8'KS0J=VOE
M^-O\QN=COZ*X*+3K2[M/%MQ/ DDT-U,T,C#)B(C4@K_=.>XYJWIJ1:QJ7_$Y
M2.=$TZWEMUFY7Y@3(X!_BSCYNH_&E[/2]_Z:#F_7\'8[*BN<\"^6/"T0B;='
MY\^QLYR/-;!SWKHZF4>6312=U<****D84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !2,JNC(ZAE88((R"*6H;JYBL[2:ZG;;%"A=SZ #)H 1+*U
MCL_L:6T*VNTKY*Q@)@]1MZ8J%]'TR2T2T?3K1K:,Y2%H%*+]%Q@50M]?N/+B
MN;W37M[*:%IDF63S-B@;OW@"@(2.G)]*;'X@N%2SN;O3O(L;QT2*03;G4O\
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MFPM3;R/O>+R5V,V<Y(Q@G/>I&L[9KC[2;>+[0$,:S;!O"^F>N/:IZ*5V,P=
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MW9QC9CC=TSQUXH TJ*R4\00O$)!8:H 8XI,-8R XD;:!C'4=6'51R<"D;Q#
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MW&W^SY=^ P7;MQG?SG;UQDXXH V:*S#K42R.GV/424FDAR+.3!*)O)!QRI'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\]O>W6F>.(K .T[7H^5/O,O&X#\,UZ913=:[O;^KI_H"IV_KU_S/,K-])O\
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M;2WX^OEYB]EU_KI_D>97K&.?PWJ'B:PQI<=F5EC$):*&7L60#C(QQCK]*VO
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M%O;ZU=ZJCRF>ZC2-U)&T!>F.,_K61<>!=)N+Z2<RWJ032^=-9).1!*_JR_\
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M5CSU..YJP?#5D=6_M#S)_P#7BY,&X>7YNW;OZ9SCMG'M5G6-&LM<LOLMZC%
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M,D;"F<],9S^-9MAX'TO3[Z&Y2:]ECMV+V]M-.6A@8]U7U^I-5&=/JOZU_P"
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M2HII>=OQ0W4LWY'J7]J:=]B%Y]OM?LI.!/YR[,],;LXH75=.<SA+^U8VXW3
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MEK=^(VBEB>&?1GDC,-I]FC<="53N <\]^:T$TJQL]'\$WEM:Q17,MW!YDJ*
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M_P!G)NZ_(A+_ )G%-TO_ %OP_P#^N<__ *#5JE%.SU_X9O\ R)]HVK^OZ?\
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M^U3/=6\=S';/<1+<2 E(BX#,!U('4UY[;Z%'>6/C#3+-!%Y5X);9$& CA=P
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MI7_7I%_Z"*U*<KQ;B*-I)2"BBBH*"BBB@ HHHH **** "BBB@ HHHH ****
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M*[("9G8$'I@+U_2K&D^(M/U72GU!;B&*&-V60M*OR $@%CVR!G\:T;:[MKV
M36EQ%/$> \3AE/XBFY33U$E%K3^NAC:CX974+J_G:[*&Z2 *!'GRVB8L">?F
M!)Z<4/H%W<ZG%?WNI1R21V\L 2*WV)A\<C+$YX]3^%:UYJ-CIZJU[>6]LK'"
MF:54!^F31-J-C;HCS7EO&KJ74O*H#*.I&3R!ZTN:5AV5Q--L_P"S]+M;+S/,
M^SPK%OQC=M&,X[5:JO'?6DUI]KBNH)+;!/G+("F!_M=*HV>OVU_K+6-H\,\0
MMA.+B*8.I^8KMX^GK2:E)M@K):&M1114E!1110 4444 %%%% !1110 4444
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MDGH*ZBBIYU=>7_!_S*Y79^?_  /\CS;3E6YDTV.7=+&NOS%3)&%+?NV8$K@
M<\]!6N\,7VOQJWE)N,*@G:,D>3FNRHIRJ7_KT_R%&-G?^NO^9Q>F7$-CJ-E>
MZK-'%;R:3"EO/.<(K=77<> 3\OUQ[51@0V5QIFHS#[/I::K<O&\BE%CB="%)
MS]U2V<9QU'K7H5%/VNM["5/2W];6/--6F@O9_$,D966"2\L &QE7&0./4>_0
MUT.KQG_A*#'"OS2:/.NU1][#+@?J?SKJJ*3J:6_K:PU&SO\ UO<QO#-Q%-X4
MT\P.DICMD1@C X8*,J?0UQDU\K>';-4O($E2\A<Z=!'EK<^8,^86);/7+';D
MG\_3**:J6DY6ZW%R>[R_(XJVAB?3O&A:-26N)@QQR0(A@4[3KJ*RU&TOM6GC
MC@FTJ%+>:8@*&Y+KN/ )RIQW_"NSHI>T_3\K#<?U_%W.>\&&(Z'(8$V1&\N-
MB[=N!YC8X[5S%[=6]IX*\0:9/,JWWVF=OL_\94R9#8Z[<'.>E>D44*I[UQ\N
MAQ5E>Z39>)O$#:@\,3ND"AI1]]?+&4'J?]D<FMWPM!<VWAFQANU*RK']UA@J
MN3M!]PN!5RVTZ&TO[V\C:0R7C(T@8C VKM&./2KE$IIJWI^"%&-CSW3Y(X]/
MT<W#H;:QOYS?(>?)8F38SC^$ \Y/J#6_I+QW?BK4;ZP97L)+>)6EC^Y+*"V2
M".&(& 2/IVKHZ*'4N'(<IJ%XD'BN=9;NWTW-J@2:5=SW RWRIN.T8/4 $DD>
MU8>@ 377A02*6V27VT2)@C#''&!@CZ#%>CT4XU+*UOZU_P P<+LX*[C8:EJA
MVYLH-7MYKI NX;/+4DX]-VTGZ5JZ?=V%[XZN)["2*93IZAYHB"KD2'^(<'%=
M112Y]+?UM8''^OG<****S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1XVA-V_[V<$_+TSGMCFF#5KWRU;^PKX%HXG*[XLJ7;#*?GZH.3VQT)/%:U%
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M[2X+J[MI;M4DM(Q+<;E(6-3TRV,9/IG-4K?Q=I.J6-[+I-['<36T+2[&1E/
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M_K'@TZM)?,L<TJ,+3REV*@E '.-V[@<YQ[4*G=[Z7L#GI^)WE%%%9EA1110
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M5B0"+VV.0I&)5YW?=[]^WK1SR#E1ER^%+2?[<UQ=WDTE[ ()I'=<E0<@@!<
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M];"/:7W>:N-H.TG.>@/'UHYY!RK;^NQ'8:7'9337#3S7-U, ))YRNX@9P,*
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MV=S$D$'.3D$$>U7?[1L<*?MEOAMFW]ZO._[O?O@X]:0ZG8!2QOK8*%9B?-7
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M)Y-8D/Q!\+3S)$FK(&<X&^&11^)*@#\:Z;.1D54H2CNK"4D]F5Q860E\T6D
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M&![BI*0RM_9UB<_Z';\AP?W2\AOO=N_?UH&GV0?>+.WW[U?=Y0SN P#TZ@<
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MOZU:HH K_8+,-N%I!G<'SY8^\!@'ZXXSZ4S^R]/";/L%KL"A-ODKC:#N Z=
M><>O-6Z* *W]GV6XM]CM]Q+DGRESE_O'IW[^M TZQ4@K96XVE",1+QL^YV_A
M[>G:K-% %4Z98$$&QMB"I0@Q+]TG)'3H3R?>G?8++?O^R0;MQ?/EC.XC!/3K
MCCZ58HH J_V;8X ^Q6V JJ!Y2\!3E1TZ \CTI3IUBRE39VY!W9!B7G=][MW[
M^M6:* (HK:WMV9H8(HV< ,40#=@8&<>@X%2T44 %%%% !1110 4444 %%%%
M!574_P#D%7G_ %P?_P!!-6J9+&DT3Q2#*.I5AGJ#0QIV=SS;2-'\2Z]X*LM.
M:72(M)EC7YPLC3A0<]#\N:U+E+G5?%TN@'5KS3K.QM$>,6LGER3' ^8MCD#T
MKL+&RM].LHK.TC\NWA7:B;B<#ZGFJ6K^&M'UXHVI6*3LG"ODJP'IE2#CVK=U
M4YM]-?\ AS"--J"74X/^U==U318;:+46D>&_EMV:"Y2WN+R-<8,;'@D9YQUX
MJ'49I;SP+K=I<ZAJ;3Z?.C&&Z $BAB %=@2)!W[<CZ5Z%<^&M%N]+CTV;3H3
M:1<QQ@;=GN".0?QIMOX8T6TTF;2X+"-+.?\ UL>22_U8G/Z\4_:QZ+J"A*Z*
M$6I?\(WIFGV7V+7-4WQ[O/CB\\KDYPS9'3/'L*XQKA=&\3ZGXA*L5M=4:&?;
MU,;H?Y,!7IVFZ;::18QV5C%Y5O'G8FXMC)R>22>IJK+X;TB:"^ADLPT=_()+
ME3(WSL.AZ\?ABDJD5)OO_G_D/D?*EV_R?ZGGOAU9M*UZ:^,>^\ET.2^<==SM
M)N&?PP*-!U'Q.U[I6HO+.\-[,%D-SJ<)BE4G!$<7!4CT&3Q7I2Z18)J7]H+;
M@77D?9]^XX\O.=N,X_2J5EX2T'3]2.H6FFQ171R0X)(7/HI.!^ J_;1;NU_6
MI/LI6W_K0YK1EU">XU[5I=4U"5=/O+@6]F)CY;87.&'4CI@=!BL:XGU*+P=8
MZX/$M\]S?7""2+SL)]X_*@&"N,<@''M7I=KI=K8QW2V:>2;J1II&R6S(W5OF
MS^72N!M_ASJ/VCRKAM)%NTXEDNHHG$[@'.T+]Q!_NXZ#K13G%RUTM;\-PJ0E
MRNW6_P".Q3U35/$FH:SK$UF]U%'I\QCC*:A%;Q1 =#(CCYP>N20*VKLZGK/B
M/1;-]2NK!;C33-<BRG RV?X2,CKCD=JZ2_\ ">A:I?K?7NFQ2W(Q\Y)&[']X
M X;\<U>.F69U*+4/)'VJ*(PHX8C"$YQC./TJ/:QLK+;_ "*Y)7;OO_F<W\0X
M_*\!7$>YGV&)=SG).'7DGUKIYY6@T^29$WM'$6"CN0,XIFIZ99ZQ8O97\/G6
M[D%DW%<X.1R"#UK*T_P1X=TN^BO;/3O*N(B2C^=(V,C'0L1T-1>+ARO>[?Y?
MY%6:DFCA-'U3Q1--I^K^9.T=U<!',^IPB"0%L%$A."K?B3Q[T_Q+K&HO/JFI
M:=J.K,EE<"(/'(D-M%@@%2F29#SUXZ],"N^M_"6@VFJ_VE!ID*7>=P<$X!]0
MN=H/T%1W'@SP[=7EQ=3:7$\UP")&W,,YZD ' /N,&MO;0YD[?U_7_#&?LY6L
MV84DM]KWB^2PEU>[TZ&ULHYXUM7"&5B 2QR.5&<8Z5S5IJFHV7A&&VL)9&DO
M=7EB>:*18F<<<*YX0MZUZ1?^%=$U,VQO=/29K90D;,S9"CH"<_,/KFE7PMHB
MZ5)I8T^/[%)(9#$22 Q[@YR/PQ4JK!+;^K@Z<GU_JUCAEOO$%EX;\16]W//$
M;:)&A9]0CGN(22,AF3!YZC(%:&JV&KV6@V26VN7<]W>2H\Z27JQ2R?+RD!;A
M>3T%=1!X6T2VTF;2X;!$LY_]:@=LO]6SN_6K.H:-IVJV"V5]:I/;KC:K9RN!
MC@]0??-)U8WT12INVOF>?37LS>#?$NG7-UJ$DULJ-Y-^H,L2L1C,@)#@_08K
M3M4U#2=?\-?\3>[N(M1B99X)6'EKMC!&Q0/E_GQUKI+?PGH=KI=QIL&GHEK<
M?ZU0[9?TRV=WZU<DTFQEGL9G@S)8@BW.]ODR,'OSQZYINK&_]=K"5-VU/.KC
M5=1_X1*]E&J7,,HUTPB<RMF-,].OW1Z=*W;#[7H_CFWTQ=8O-1MKRU>:1;J0
M.8V'0C X!]*N:YX0AN]'^P:9'#"KWRW<PF=BKG/S=<]?3I6II?AO1]%FFFTZ
MPC@DF^^P))QZ#)X'L.*'4CR_?^2#DE?^N[?Y%K3;'^SK,6_VNZNL,6\RZDWO
MR<XSZ"N7\9ZM8ZEX'UH6EP)#;R+!*"I4JX=<CD#/X5U&FZ99Z19BTL8?*@#%
M@NXMR3D\DDUGW'A'0+K5?[3GTR)[O=N+DM@GU*YVD_45G%QYKLT=[:&!<O>:
MOXHMM!;4[K3;6+3UG'V5_+DF;IPV.@]/8UAZCJ%[?>%9[6>[-RUEK*6\-VP!
M,@!X)]2*]#U?P[I.NJ@U.R2?9]UB2K#VR"#BD;P[I+:;#IWV)%M(9!)'$A*@
M,.0>#DGZUI&K%6NOZO<S=.5FEV_2W_!.=A^WZ1XPN=/;5KR\MY]->Y/VEP2D
M@;'RX VCV%<_:/K$'A+1_$!U_49)VNEC:&27,90N5P1U8^Y)KTJ32K*;4?M\
MD.;KR#;[]S?ZLG)&,XZ]^M5QX=TH:3#I8M?]"@</'%YC?*P.X'.<]?>E&JE:
MZ[?K^@Y4V[V\_P E^I'XL_Y%'5_^O23_ -!-.\,?\BII/_7G%_Z"*T+NUAOK
M2:TN4WP3(4D7)&0>HR.:P+?X?^&+6YBN(=,VRQ.'1OM$IP0<@\M41<>5Q94D
M[IHZ6N!_XGW_  L#7O[#_LW=Y=OYOVW?C[G&W;^/6NSL=,L]-:Y-I#Y9N93-
M+\Q.YSU/)X_"LS4O!?A_6+Y[V_T_SKAP S^=(N<# X# =*(2C%Z]AR3:LCB'
MN[K3_#7BQ/-:#6(KR.2XFM9"(\NPQL(P1QG(/-;.KI?Z/#I6F+K=[G5+K%Q>
MS29:/Y1E8^,(">GI721^%=$BT>328[!$LI6#21J[ L0002V=QZ#O5W4-+L=5
MLS:7ULD\!_@<=/<'J#[BK=6-]OZLB%!V^_\ $XA]4U'PUJ.M:;!?7&IQ6VGF
M[C>Z;S'A?.,,W<<YP:@$^H:19Z#K,>OW=_-J,T:36TL@:)PXYV+_  XZ5VVE
M^'])T6WD@T^QCACE_P!8.6+^Q+9)')JO8^$= TW4/MUIID,5SU#Y)"_[H)PO
MX"FJL+_UJ)PE8X![^^M_$FL6RR3VFES:JJW=]"V&3/"J#_"">I'3^>MXE&KO
MKTZ6E]?R6=O;KMCTV]020MCK*A.YP>O7\:[%O#^E-#?Q-:*T=^V^Y4NQWGUZ
M\?ABJVH>#] U0PF]T]96A0(KF1PVT= 6!RWXYH56.GE_DAN#U\_\[ECPY?C4
M_#UE=BX:YWQX,K1>66(.#E<G!R.QQ6%\2?\ D6[?_K]B_F:V)M MVU#2)H(8
MH8=.WE N00"N-H XQW)//'N:NZEI5EJ]LMO?0^;$KB0+N*_,.AX(J%**J*:[
MW_$;BW!Q\K?@>?ZK_P A;QW_ ->,?_H%=MX8_P"14TG_ *\XO_013Y?#^ESS
M7\LEKN>_C$=R?,8>8H& .O'X8IZ::+>;3UM7:&UM(VC$0D;## "@C.#CKD\\
M>YH<TX\OI^"#E:ES?UT,CQ,TZ^(/#AMHXY)A/+M260HI_=GJP#$?D:BUJRU*
M6.XUB[,%K)8V-PL"6L[N=S+]XL57&,<#'OFNCGL+:ZNK:YFCW36K%H6W$;21
M@\#KQZU)<V\5W:RVTZ[X94*.N2,@C!'%3SV2L7;6[.-EEN[73=!CADU&X;4]
MAN66Y)D;$9;"%V 3)ZX(X''-6H#K#G5+"S%Q;?N$DMEO;I))8V)(89#NVT@<
M%LX.:Z&72[*:PCL9(,V\041KN(*;>A#9R"/7.:CCT33H[6>W^S^9'/@RF5VD
M:3'3+,2QQVYX[5;J)WT(C!JQS5W>?8-/U:W!U:RO/L,LL4=S=&93M_C1]S$'
MD<9'TJWI_G:S?WD5U=7<26D, B$4[1Y+)N+G!^;GC#9''2M=?#^FB*>-HI91
M/$89&FN))&*'JH9F) ^A%.N-#T^Y:-I(7#)&(@8Y70L@_A;:1N7V.12<XV#E
M9QNDW5U]AT+2XXKV>U-I+-(+.98I)"),#YBRX SDX.>1VJ:XO-3"VUH\]W;(
M-8BA0FY1IA$R$E'*,W?U.<8/O75_V!I@LK>T6W,<5MGR3'*Z/'GKM<$,/SI1
MH6FK#!$+;Y8)Q<)\[9\P?Q$YRQ^N:KVD;WM_5[_\ 7([6_K:W_!.4U]&@M_$
M6F"XN7M5TU;E%DN'=E;+ _,26(.!P3BNM@:+3-"63]Z\<$'F'<[2.0!D\DDF
MGS:597$]Q-+ 'DN(?L\I).&CYXQG'<U-;6L5I:K;1;S&HP/,D:0X]RQ)/YUG
M*5XV+4;2O_70\\5Y-'-IKFI0O-I=R[7=K:P-N6VG<9&2>6W GGH"3QWKO[TS
MMI=P8%VW!A8H,]&V\?K5+_A&-'Z-9"2/!"Q22,\:9Z[4)*KU[ 5J0PQV\$<,
M2[8XU"J,YP!TIU)*2T%!.+NS'\*>1_PB.F^7MV?9UW_[V/FS[YSFL>_6-M>\
M,+HDMM%$$N1"YC,D8 4= &7/YUOR^'=+FDD9H)%64[I(XYY$CD)ZED5@K9[Y
M'-/N]#T^]:V:6)T:U!6!H)GA,8( (&PCC %/G7/S=[_DQ<KY>4S]:CUE/#6J
M[[JVFE-J_E"WMFB8'!SUD;/'TK1TW[)_PC]KY7E_8_LRXZ;=FW\L8IUII5M9
M3>;%)>,V,8FO9I5_)V(_2H&\.:4Y;-LPC8DM LSK"Q/7,8.PY]Q4MIJQ23O<
MI^"C*/"=J9 Q4&3R0>OE[CLZ]L8Q[8K(-Q=MX.D\2_;;I=04-*$\X^4N'(\O
MR_NXQQG&?>NW5510JJ%4#  & !6:= TQK@S&V.2_FF/S&\HOG.[R\[=V><XS
M5<ZYFV+E=K&3H5K&/%^NSYG#X@.UIW8?,A)R"<'V].V*AUW3!JOC"&%9#%.F
MG-)!,.L<@D7:W^/L373Q65O!=W%W''MGN-OFMN)W;1@<=!QZ4&RMSJ"WYC_T
ME8C"'W'[A.2,=.HI<_O)^7Z!R^ZU_6YPTGB"=M5N+T0A-2L=(G6> \[)5=?S
M4\$>QJ_:3:C;RZ5,L.I*T\B)<R7M[$T4P8')5?,.#GD!%'TKI?[)L?[4DU+[
M,OVN2+R7DR?F3K@CH?KBHK70=-LYXYH8&#19\H/*[K%GCY%8D)_P$"J]I&VW
M]:DN#OO_ %9'*O?WP^&T]T;NX%RMRR^;YC;P/M&,9Z]./I5J.:X^W>)KTSW<
MSZ?)NMX!<.$&(@<;0<$$]CFMN?PQH]SYPEM69)G\QX_.D";\YW! VT-GN!FK
MUOI]K:SW4T,6V2Z</,=Q.X@8Z'IP.U)S5G;K_P #_)E<KNK[?\/_ )G,R-<:
M=I>D:I%?W<]Q<S0+.))BR2B0@'"$[5QG(V@=.]1^'8=7EL]6^PWUG"AU"Y 6
M6U:1@=W7<) /T_.NAM] TRUG2:*W(,9)B1I'9(B>Z(3M7\ *B'AK3$>5HUNX
MQ+(TDB1WTR(S,<D[0^.?I3<XV:%RO3^NYSNBW3WUMH.EH)K*T>"9I1#*5,C1
ML%P''(!)+<$&MS1)IDU;5M,::6:"T:(PO*VY@'7)4L>3CU///6K\VCV$]K#;
M-;!8H/\ 4^4QC:+C'RLI!7\#4ME86VGQ-':Q; S;G)8LSMZLQR6/N32E-._]
M=?Z0U%JQ9HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH S-1\0Z/I#3+J&HV]L8(5GE\U\
M;(V?8K'V+<?6D/B/1@^PZE;[C+-#C?\ QQ F1?JH!)^AJ_);03$F6&-RR[3N
M0'(SG'TS1]EM\Y\B+.2?N#J>I_'O0!GQ>)=%FV^7J=L^[R,8?KY_^I_[[[>M
M,_X2O0/(,_\ :UKY0CDE+[^-D;;7;Z*QP?0UIBUMUZ01#[O1!_#]W\NWI3?L
M=KMV_9H=N",;!T/)% %,>(=(:[^RC48#<>:8?+W<^8$W[?KM^;Z5&OBG0GB6
M1=5M2C1Q2*P?@K(VV,_1FX'J:TOLUN'WB"+=G.=@SG&,_E2?9+8#'V>+  &-
M@Z Y'Y&@#/D\3:)"S"35+92@G+9?H(?];_WQW]*#XGT-94C;5+8.\T5NJE^3
M)*NZ-/JR\@>E:!M;<DDV\1)W9R@_BZ_GWH^RV^0?L\600P.P=1P#^':@#,/B
MSP^+5;DZO:B!K8W0D\S@PA@I?_=W$#/O4Q\0Z0LCQG4;<.DTD#+OY$B)YCK]
M0GS'VJY]CM=NW[-#MV[<>6,;<YQ],\T[[- 228(\DEC\@Y)&"?Q'% &<GB?0
MY%1DU2V976%E(?J)3B(_\"(P/6D_X2G0MDC_ -JVNV..61SO^ZL1VR$^RDX/
MI6B+2V&,6\0QC'R#MT_*C[);8(^SQ<@@_(.0>OYT 4U\0:2]RMNNH0&9IE@"
M;N3(4WA?J4^;Z5!_PEF@&(2_VM:^688YPV_CRW;8C?1FX'J:U!;0!MP@C# [
M@=@SG&,_E3?L=KC'V:'&T+C8.@.0/IF@"@_B?0XS('U2V7RS.'R_W?)_UO\
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M:[=OV:';MVX\L8QG./IGFG?9;?.?(BR2QSL'\77\^] &<GB?0Y#&$U2V;S#
M$P_WO._U7_?>#CUI'\5:"B,[ZK:JJQ23,2_1(WV.WT5A@^AK1%K;C&+>(8VX
M^0<;?N_EV]*#:6Q&#;PXP5^X.A.2/SYH I'Q#I G,)U&#S1*82F[GS GF%?K
ML^;Z4P>)]#,:R#5+8H\<4JG?P4E;;&WT8\#UK1^S6^<^1%G.<[!UQC/Y<4GV
M2VQC[/%@  ?(.@Z#\* *#^)M$CC:1]3ME11,6)?@"$@2_P#?)(!],TJ^(]&>
M985U*W,K2QPJF_DO(F]%^I3YA[5>-K;D8-O$0<_P#OU_/O2BUMP01!%D$$'8
M.H& ?P% &6/%GA\VK7(U>U,"VPNC)YG A+%0_P#N[@1GVJ;_ (2'2/M)MO[1
MM_.$TD&S?SYB)O=?J%^8^U7/L=KMV_9H=NW;CRQC;G./IGFG?9H-V[R(]V2V
M=@SDC!/XB@#-3Q1H<FW9JELVX0L,/U$W^J/_  +MZT-XIT)(FD;5;4(L<LC,
M7X"QMMD/T5N#Z&M'[);#I;Q?P_P#MT_+M1]DMB,?9XL$$8V#H3D_F: *9U_2
M5N?LYU" 3"80;-W/F%-X7Z[/F^E1'Q5H(MUN#JMKY+11S*^_@I(Q1&^C,"!Z
MD5I?9H-V[R(]V=V=@SG&,_E2?9+8KM-O#M "XV#& <@?G0!GOXGT.,R!]4ME
M\LSA\O\ =\G_ %O_ 'QD9]*</$>C%]@U*WW"6&'&_P#CE ,:_5@01]15XVMN
M<YMXCG=GY!SN^]^??UI?LMOG/D19R#]P=1T/X=J ,S_A*M!,+3?VM:^6L,EP
M6W\"-'V.WT#<'T-2_P#"1:/]H:#^T;?S5G:W*;N1(J[V3ZA><>E7?L=MMV_9
MX<;2N-@Z$Y(^F>:7[+;[BWD1;BQ8G8.IX)^M &<GB?0Y%1DU2V976%E(?J)3
MB(_\"(P/6A_$^AQJ[/JELJHLS,2_01'$I_X"3@^E: M+88Q;Q#&,?(.W3\J#
M:6QSFWB.<Y^0=^OYT 4SX@T@7"VYU" 3-,D"INY,CIO5?J5.['I4 \6>'V@6
M<:O:F)H4G#B3@QN_EJWT+_*/>M3[-!N#>1'N!# [!G(& ?RIOV.UV[?LT.W;
MMQY8QC.<?3/- %(^(]&#[#J5ON,LT.-_\<0)D7ZJ 2?H:2+Q+HLVWR]3MGW>
M1C#]?/\ ]3_WWV]:T/LMOG/D19R3]P=3U/X]Z!:VZ]((A]WH@_A^[^7;TH S
M/^$KT#R#/_:UKY0CDE+[^-D;;7;Z*QP?0U,-?TEKG[.-0@,QF,&S=SY@3>5^
MNSYOI5O[':[=OV:';@C&P=#R13OLT&[=Y$>[.[.P9SC&?RH S5\4Z$\2R+JM
MJ4:.*16#\%9&VQGZ,W ]32R>)M$A9A)JELI03ELOT$/^M_[X[^E:'V2V Q]G
MBP !C8.@.1^1H-K;DDFWB).[.4'\77\^] %%?$>C/,L*ZE;F5I8X53?R7D3>
MB_4I\P]JB/BSP^+5;DZO:B!K8W0D\S@PA@I?_=W$#/O6H+6W!!$$6000=@Z@
M8!_ 4W[':[=OV:';MVX\L8VYSCZ9YH IGQ#I"R/&=1MPZ320,N_D2(GF.OU"
M?,?:F)XGT.149-4MF5UA92'ZB4XB/_ B,#UK1^S0$DF"/))8_(.21@G\1Q2"
MTMAC%O$,8Q\@[=/RH SSXGT,1M(=4M@B1RRL=_ 2)MLC?13P?2I%\0:2]RMN
MNH0&9IE@";N3(4WA?J4^;Z5<^R6V,?9XL$$'Y!T/4?C2BV@#;A!&&!W [!G.
M,9_*@#+_ .$LT Q"7^UK7RS#'.&W\>6[;$;Z,W ]33W\3Z'&9 ^J6R^69P^7
M^[Y/^M_[XR,^E7_L=KC'V:'&T+C8.@.0/IFE-K;G.;>(YW9^0<[OO?GW]: *
M)\1Z,)1$=2MQ(6A0*7YS-GRA_P "P<>N*C;Q5H*VOVEM6M1 (GF\POQL1Q&[
M?0.0I]":T_LMOG/D19!4YV#^'I^7:D^QVVS9]GAVX*XV#&"<D?GS0!2/B'2!
M.83J,'FB4PE-W/F!/,*_79\WTIB^)]#>+S5U2V,>R&3<'XVRG$9^C'@>M:/V
M:WSGR(LYSG8.N,9_+BD^R6V,?9XL8 QL';I^5 % ^)M$4.6U.V 19G8E^@A.
M)3_P$]?2G#Q%HYN/LXU&W\[SDM]F_GS'4NJ_4J"<>E7?LMOS_H\7.0?D'?K^
M?>E^RVX;=Y$6[<&SL'4< _44 98\6>'V@6<:O:F)H4G#B3@QN_EJWT+_ "CW
MJ5O$>C),T+:E;B599(63?R'C3>Z_4)\Q]JN_8[7;M^S0[=NW'EC&,YQ],\TX
MVMN228(LDDD[!U(P3^(H SO^$FT0K&PU2VVR" H=_P!X39\K'^_@X]<4C>*=
M"2)I&U6U"+'+(S%^ L;;9#]%;@^AK1^RV_'^CQ<;<?(.-O3\NU'V2V(Q]GBP
M01C8.A.3^9H I_V_I/G>3_:$'F>?]FV[N?-V;]GUV_-CTJ-/$^AR1"5-4MFC
M,<4H8/P4D;9&WT9N!ZFM'[-!G/D1YW;L[!UQC/UQ2"TM@,"WB P!C8.@.0/P
M- &<WBC0E#%M5M0$\_<2_3R<&7_OC(SZ4]?$>C/,L*ZE;F5I8X53?R7D3>B_
M4I\P]JO?9+;_ )]XN=W\ _BZ_GWI1:VX((@BR""#L'4# /X"@#+/BSP^L#3G
M5[41+"\Y<R<"-'\MF^@?Y3[U._B#2([G[,^H0";SG@\LMSYBH'9?J%(;Z&K?
MV.UV[?LT.W;MQY8QC.<?3/-.-M 6W&",MDMDH,Y(P3^5 &<GB?0Y%1DU2V97
M6%E(?J)3B(_\"(P/6AO$^AI%YK:I;"/9-)N+\;8CB0_13P?2M 6EL,8MXAC&
M/D';I^5'V2VQC[/%C!&-@[]?SH ICQ!I)E\H:A!YGG+!MW<^8R>8%^I0;OI4
M \6>'V@6<:O:F)H4G#B3@QN_EJWT+_*/>M3[-!G/D1YR&^X.H&,_EQ3?L=KM
MV_9H=NW;CRQC&<X^F>: *0\1Z,93$-2MS(&F0J'YS#CS1_P'(SZ9IJ>)]#D,
M835+9O,, 3#_ 'O._P!5_P!]X./6M'[+;YSY$626.=@_BZ_GWI!:VXQBWB&-
MN/D'&W[OY=O2@#.?Q5H*(SOJMJJK%),Q+]$C?8[?16&#Z&I#XAT@3F$ZC!YH
ME,)3=SY@3S"OUV?-]*NFTMB,&WAQ@K]P="<D?GS2_9K?.?(BSG.=@ZXQG\N*
M ,X>)]#,:R#5+8H\<4JG?P4E;;&WT8\#UI7\3:)'&TCZG;*BB8L2_ $) E_[
MY) /IFK_ -DML8^SQ8  'R#H.@_"@VMN1@V\1!S_  #OU_/O0!%9ZI8ZA+-'
M9W44SP!#*J')3>H9<_52#]#5NF)#%$28XT0MC)50,XX%/H **** "BBB@ HH
MHH **** "JVH,R:;=.C%66%R"#@@X-6:AO(6N+*>%" TD;(">F2,4/8:W/'[
M?6(VT2WFL?%.NS^(2%VV9D>2-GSR,%<$8]S7H%]XGN[>^CTNPTE]2U)(%EN(
MTF6)(@?]H]_:M/P[ITVD>'K+3[AD:6"/8QC)*D^V0*RM2T+6(/$$NLZ#<V:S
M7$2Q3PWBML;'1@5YS73.<)3MTU_KT.>$91C?KI_7J5KCX@6Z:9:W%M8R27=Q
M.UO]FFE6'RY%^\&<\#J,>N:KZ[XIU5_!5Y>VVF7%C=Q2".1F<$1KG[Z-C$@[
M<>N:>?!FH6^BB"WN[*YNI;A[F[CO+8-#.[?@67'8BHK;P->KX:UBQDN+2&?4
M"K+#;AOL\)4YXSSSCFC]TM?,:<[K^OZZ'6:+<7=UH]M->VIMKAD^:,RB3Z'<
M.N1@_C7#:7J]_;?$.]^TWT\FG274EH(I)24B;;O4@$X'0BND_P"$5MM7LK)O
M$EI;3WULFP-;2R*@&>,<@],=:RM1\$7M[9:Y&L]NDUY>K=6K[F^3''S<<'!/
M3-*+@I/S_P U^@-2<4OZV?ZF;X6UN^G\7WMY?7UP;":RENXX7D8I&@DP,+G'
M1>WK6KIOQ%MK[4K:WDLUAM[J3RX)1=QR/D]-\8.Y,^]68?![1ZOO9XO[/.D#
M3BH)WYSR<8QC'O5'1O!-_87MHEP-$-G:/N$T5DIN)L= Q9<+]0<\53=*3U_K
M?_@$_O$M/ZV_X)I6/BZYOM2O(5T=ELK*>2*YO#<+M0*"0=N,DG'0=..:HOX_
MN4TY-2/AZ=;&>58[>=IUP^3C) !*^W4'UK5TK09;&QUR&\V2I?W4TP6$DG8X
MQCD#YO\ .:\V34+V_P!'M/#B7(D:"Z18K3[(ZW&T-UD/*J![$]LT4X0E*UNW
M?YCJ2E&-[]_^ =OJOQ#M].U.YM8K-9X;1MMQ(;N.-@>X1&.7Q[5;U#Q?)#J%
MC9Z9I;ZB]];?:(2LXCR/?(P!COGVQ69?>![[^U;V;3QH[V]]+YKO?6@EE@)Z
M[,@@Y]#Q6Y'H$L/B73[^-H?LMK8FV*A=K%LCD*!M ^F/I4?N[+^NG^97OW?]
M=?\ (K>.;RZM?!4]S'++:3YBW-#(0R989 8?B*Y6UU6S36]*C\/^*=5U&>6Y
M5)X;^5C'Y7\7WE7GTQDUW'BS2+G7/#T]A:/$D[LC*9B0ORL#S@$]JQ[O0_%.
MNFVM]9FT>*SBF69FLUD,I*GH"W ^M52E%1U[_P"1-6,F].W^9=O_ !7<)JMS
MI^DZ--J<EHH:Z99EC6//.!G[Q]A2R>+A-H=IJ.EZ;<7K7+%1'D1B,CKYCGA>
M>.>M076@:Y8ZU?W^@7EDJ:AM,\5XK'8P&-RE>_L:SKSP#=)I>DVUC<6ERUF[
MO-%?*WE3,_5B%YX["I2IV5_+_@E-SN[?UV+ ^(2'09-1_LQC+#=K:RP).K<G
MNK 8;]*MW7BR_M$L[=] D.K7CL(K%;E3\B_Q,^,#Z5EP>!]1ALI[82V&V34H
MKQ?+#1J%7[RA0#CV&3^%;?B'0[^\U+3]6TB>WCO[/<H6Y#>7(K#!!V\TW[*_
M]=E^HESV_KN_T*/A/4[W4?$_B(7:W,(C,(6UFDW"$[3D#!(P2,Y'6M'5_$LM
MEJJ:5INF2:EJ#1><T2RK$J)G&2QXJ+PWH6IZ;K.KZAJ=Q;3/?F-@8 PP5!!&
M#T'( Y/2DU;0M57Q -<T*YM$NG@\B:&\5C&Z@Y!RO((J7R.:[67Y#7-ROU_4
MPO$WBZ\N_"$L^F6]Q:SK<?9KL^:$DMF!' ]<],CI72VL=W8^"I!</=K=):R,
MQN+@2RJV">7 &<=B*QKCP3>R>&+RS^UP2ZE?7:W4\K K'G<"0, G%==?6[W6
MF7-LA4/+"T:ENF2"**CCR<L>_P"B_P""."?.G+^M7^EC@=/TK46\&1^((?$F
ML"]6V-QLFN?,A) )(*D=./6M:WUQK_6O#$C?:4:]M))62.XVQ9VY.Y,?-[<C
M%5;3P_XP30H]"DN]&AL?*,+S1"5YMAZXS@9Y]JUCX9>'7="N;1HUL],MWA*N
MQWG*X&.,'WY%:2E'F=WWM]S_ . 9QC+E5EKI?[U_P2MIOC::]MKF^FT=[?3;
M42":Z,ZM\R]E7 )SQSQS3-%\?0:IJD-E/:);?:03;NEY'-G SAPO*''8U:T_
MPLZ>#[K0[Z6/=<-*2\1) W,2#R!R.*HZ#X0O[*_MWOH]$6WM4*H;2R42SG&
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M5;/ 'T]*W=)T:XL-8UN\DDCV7\J/%L)+* N.<C&?SI2]FKV_K:WSW!<[M?\
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M/E]!_>_BS2NP-2XMH+N%H;F&.:)OO)(@93]0:9;6%G90F&TM(((CU2*,*I_
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M]@/6M.R\633ZQ-IUYI$UE)]F-U 9)5;S$'J!]T^W--TI)7&IQ;L=-17#V_Q
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M445Y)VA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ex-99d4g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d4g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M -G[IQGID9(S4FF^&HK#6O[4>4/,EDEA$J*0$B5BW.22Q)QR3V^M &[1110
M4444 %%%% !1110 4444 %5M0O[?2]/N+Z[D$=O A=V]A_6K->4^/=4F\6>)
MK/P1I4GR>:&OI5Y QSCZ*.3[X'45M1I>TG;IU]!-V1J_#RWN-;O]1\9ZBF);
MUC#9H?\ EG"I[?B /^ GUKT&H+*S@T^Q@L[9 D$$8CC4=@!@5/4U:G/-M;?H
M"5D%%%%9C"BBB@ J)K>!IA,T,9E'1RHR/QJ6B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *CN)X[6VEN)FVQ1(7=L9PH&2>***<5=V Y74-2\1Z]9F
M/PY:QV=O,N!J%W*,X]41<G/NV/I2>"O =MX2\^YDN6O-1N!B2=EQ@9R0._)Z
MD]<"BBMIU'%.G'1?F*W4Z^BBBL!A1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ex-99d4g002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d4g002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBFLZJI9B !U). * '45SM_XW\/:>Q2744DD'5807/Z<5D/\5-"5@%AO7'J
M(P/YFM8T*DM5%F;JTUU.YHKD+;XE>&[A@K7$T&>\T1 _,9KI;/4;/481+974
M-Q&?XHW!J94YP^)6*C.,MF6J***@H**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL?Q
M'KL.@:1)=R8:0_+%'G[[GI^'K3C%R=D3.<81<I;(A\2>*;+PY;9F/FW+C]U
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MAE.0143ISA\2L7"I"?PNX^BBBH+"BBB@ HHHH 0]*\<\>ZN=2\0O K9M[/\
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MJ/XL=^.#ZBNI\,^(+;Q)H\=[ 0K_ '9H\\QOW'T]*V& 88(!!Z@UY9JEO/\
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M[]C/1I8'WQ-)&WJN15O^U/.&V_MDN1_?QM<?B*>=;U'_ )[@_5!_A3#K=_\
M\]4_[]K_ (5HTWT-Z4XK9A';6TDR3:;?&&=&#(D_RD$=,-TKT_2M'&N7VE>)
MIT-K?0J4N(PH*S$#:&!_K7EXUG47941D9F. HB4DG\J]!\/^-+/2M/CT[6[@
M)=1@DM&F5 /(4X[UQXN%2UX[_H>O@ZD+V>QQ?CG1;O2?$4TUPPDCO':6*11V
MS]T^XXKG;>VFO+J*UMT+S3.$11W)KL_&'BC2O$MW#"!<1V]N#Y<X ^8GKE?3
MBND\">"QIDO]KWA$DS+_ *,"I&Q2/O$'H35JNZ5%.>YLH*=1\FQV.BZ9'H^C
MVNGQX*P1A2?4]S^>:OT"BO&;;=V>DE8X7XG:9?:II=A'86DMRZ7.YEC&2!M/
M-=O$"(D!ZA13J6KE4<H*':_XF4:2C4E/O;\ JGJ6G6VJZ?-97D8>"9=K#T]Q
M[BKE%0FT[HT:35F>7^"O"NI>'?'-R)X':T6!UCN0/E<$C'X^U>C7UC;ZE8S6
M=U&)()E*NI[BK-+6M:O*K/GEN8T</"E!P6QY9%8>+/ -Q(FFPG5=(9BPCQEE
M_ <@_3(-6G\>^);M/)L/"LZ7#<!I Q _# _G7I%%:/$QEK.";[F2PLHZ4YM+
ML<3X3\+ZK!JTFOZ_>/)J,J;!"C?*BGL<<?0=!72:[H]OKVC7&G7&0LJ_*P'*
M,.A'T-:5+64ZTI3Y]F;0H0C#DW3/*]/U#Q=X(3^S;G27U.QC.(9(LG ]B,\>
MQ'%69M?\7^*D-AINCOI<,GRRW4Q(*KWP2!^G->E45L\3%OF<%S=_^ 8K"22Y
M5-\O;_@GF?A'PM=^'_'\X%M.;!+8HMRZ_*[$+G]<UT_CVSN=0\'WEM9P//.Y
M3;&@R3A@372XHJ)XB4JBJ/=6_ N&&C"DZ2V=_P 3*\,036OA?2[>>-HYH[9%
M=&'*D#D&M8T45A)W;9O&/+%+L>>^)/!FHVVLGQ#X7E$5X3NE@S@.>Y';GN#4
M">/_ !);H(;SPI.UPO!9 P!_#!_G7I%%="Q*<4JD5*WWG,\*U)NG)QO]QY>=
M&\4>.[R)]<3^S=*C;<+<<,WX=<^Y_*O2K2U@L;2*UMHUCAB4(B+T %34M15K
M.HDMDNAI1H1IMRO=OJSRG6K;Q%IOQ'O-:TO1Y;I=H5&*$HP* 'H?:KO_  EO
MCW_H5D_[]O\ XUZ116OUE-)2@G96ZF/U22;<9M7=^AYJWB'XB7H\J#0(K9FX
M\PIT_P"^FQ5[PSX'NXM7_MWQ%="[U'.43.0A]2>Y'8#@5WE%2\2^5QA%1OV*
MCA5S*4Y.5NY'<6\5S;R03()(I%*NK#@@]17F;^'_ !+X'U":Y\.C[?IDK;FM
M6Y(^H]?<5ZC25%*M*G=;I]#2M0C4L]FMFCS=OB#XBF3RK;PE<"X/ +!RH/TP
M/YU+H/@_5-3UI-?\5R!YT(,-J,$+Z9[ #T_.O1*2M'B4DU3BHW,UA6VG5DY6
M 4M%%<IUA1110!D:YX?LM>M?*NDQ(O\ JY5^\A_P]J\KUOPAJNC.S&$W%L.D
MT0R,>XZBO:Z3%=%'$SI:+8X,7EU'$^\])=SYS-$<4D\BQ1(7=C@*.]>[WOAG
M1M18M<Z= SGJP7:?S%48O VAVXD$,$L9D&&*RG./0'M7<LPA;5'F+)ZL7I)-
M'DCR1Z0C10,LE\1B28<B/V7W]ZJ6.EW^KS^58VLMQ(3R5' ^IZ"O9[;P+X<M
MFW+IR2,/^>K%_P"=;T-O#;1".")(D'144 ?I42QZ2]Q:^9V4\OE]MZ>1Q'A;
MX=P:9)'>ZJ4N+M>4B',<9_\ 9C7=TM%>?4J2J/FDSTZ=.--6B%%%%069.MZR
MVD_9$CLY+N:ZF\F.-'"\[2>IXZ"DT[7/M=\UA=64]C>+'YHBE*L'3.,JRD@X
M/6L[Q=]H^W^'_LAB%Q]O.SS02N?+?KCFKMAI5[_:YU75+B&6X6$PPQVZ%4C4
MD$GDDDD@?E6MH\EV8<TW4:6Q>_M%/[:_LWRVW_9_/WYXQNVXIL.II-K5UIHC
M8/;Q)*7SP0V<#]*Q;^UN+OQLJ6]_+9LNG9+1HK%AYG3Y@:;HD$UKXRU>.>\D
MNY/LEN?,D55.,OQA0!3Y(\M_(/:2YK6ZG0ZA>Q:=I\]Y-_JX4+G'4X[#W-1:
M/JD>L:7#>QQO%Y@(:)_O1L#@J?<$5C^)YI[J]T_2;6W^TNS_ &J>+S G[I",
M D^K8_(TS0YKFS\27]E=VHM%OO\ 3((_-#C<,+)@C\#CW-)07)?J#J/VENFW
MS-/6=9DTN6SAAL9+R>[=DCCC=5Z+N/)XZ"DT_7#=7YL+NQGL;SR_-6.4JPD3
M."5920<'&1[U0\3+<OK?AY;2:.&<W$NUY$WJ/W39XR/YU'H@N)?$]W_;,X?5
M+:/9 J)LC,#$'>HZDDC!R>,57)'DO_6XG.7M+>?Z&IJ_B"VT6ZT^&Z5MM[*8
MA(.D9QU;VZ"C6/$%MH]S86TJM)->3")$3L"<%C[#(_.J/B&UAO==T6TN$#PS
M"Y1U/<&.LBZT:YTZUM[C4;H75VVH6L$<N.D*R#:/J>I]31&$&E<F=2HG*QW=
M9%GXAMKW7KS2D1P]L,B0_=D(QN"_[I(!^M6M7U!=*TFYO6&?*0E5_O-T4?B<
M"N+,6J:'I^EWUSIOEFPE,MW<"X5BZR']Z< >IS_P&IIP4EJ75J.+5OF=[<7$
M5M;R7$[B.*-2[NW0 =36'!XBN[CRITT&^^PRL D^5W8/1C'G('Z^U3>*K>6^
M\*7\5JOFN\6Y57^, @X'U J6W\0:1+80W2WT"Q2;54%P"">-N.N<\8I12Y;V
MN.4GSVO8DUO51HVG?:S \Y\Q(UC0@%F9@HY/N:BL=2U*YNA%<Z)/:1D$F5YT
M8#VP#FJ'CCGPZH\SRO\ 2[?]YQ\O[U>>>.*N:8K1W9W^(#?[E($)\L8/K\HS
M3Y5[._43E+VG+TT[%N[U)+._L+1HV9KQV16!X7:I;G\J6XU%(-4L[%HV+W0D
M*L#PNP G/YUE>(I$M=6T&\F8);Q73K)(W1"T9"Y/89XHN;F&\\9:3';2),;>
M&>27RV#! P4#)'J:%!-)^3&ZC3:\T7-:U:ZTJ$S1:7+=PI&TDKQR*NP#V)YX
M]*=HVJ76J1>=-IDMG$R*\322*V\'GL>/QIWB#_D6]4_Z])?_ $$U)HO_ " M
M/_Z]H_\ T$5.G)L/WO:6OH"ZDC:Y)I?EMYB6ZSE\\$%BN/TINJZO%I4<6Z*2
M>XG?RX+>(9>1NO'H .23TK/B/_%?W/\ V#(__1C5'K4J:?XHTC4;HA;/RY;<
MRM]V*1MI4D]LX(S5*"YDO(ES?*WY_J:&G:E>7-R\%YI-Q9,%WJ[.KHP]-P[^
MU7+Z\BL+&>[G.(H4+M] *9%J-E/=?98;J&2?9YA1'#$+TSQ6)XIDFNI[#2+6
M#[0\L@N)XMX7,49!P2?5MH_.I4>:5K6*E+EA>]S6T758]9TN*]CB>'=E7BD^
M]&P."I]Q3K[4TLK[3[9HV9KR4QJ0>%(4MD_E6'HUQ<V7B>]M+RT%HNH+]J@3
MS0X+KA9!D>ORG'UJ?Q%*D6M^''E=407;Y9C@#]TU7R+GMT_X!*J/V=^O_!.C
M[5@R>(YVN+E;#2+F]@M9#%-+&ZK\P^\%4G+8K8ANH+C=Y$\4NWKL<-C\JY2^
M-I9_VAJ>BZY%:S1NSW-M(P:)Y!URIY4G'4?K4TXINS'5DTDTSKXW\R-7VLNX
M X88(^M/JKIUR]YIUM<R1&)YHE=HSU4D9Q5JH>CL:IW5PHHHI#"BBB@ HHHH
M **** "BBB@ HHHH 8\,4C(SQJS(=R%ADJ?4>E/Q110 SRH_-\W8OF;=N_'.
M/3/I0(8EE:41J)& #.!R0.@)I]% 6&>3%YQF\M?,*[2^.2/3/I0T,32)(T:E
MTSM8CE<]<&GT4!88T,3NCO&K,ARC$9*GIQZ4A@B,RS&-#*H*JY'(!ZC-244!
M88T4;R)(T:ETSM8CE<]<>E#Q1R@"2-7"D, PS@CH?K3Z* L,DACF7;+&KKD'
M##(R.E*\:21M'(BNC##*PR"/0TZB@!JHJJ%4 *!@ =JJKI6G+=F[6QMA<'GS
M1$-WYU<HIW:$TGN136\-S$8IX4EC/5'4,#^!J&#2]/MI1+;V-M%(.CQQ*I'X
M@5;HHNPLKW&2PQ3Q-%+&LD;##*XR#^%0VFGV=A&4L[6&W4G)$2!<_E5FBB[M
M8+*]QKHDB,CJ&5A@J1D$4JHJ*%10JJ,  < 4M%(8SR8_.,OEKYA7:7QR1Z9]
M*)(8YHVCEC5T8896&0?PI]% 6*UII]E8*RV=I#;JQR1$@7/Y5-Y,?F^;Y:^9
MMV[\<X],^E/HIW8DDM!C0Q/(DC1JSIG8Q'*YZX]*CN+.UO$"7-O%,JG($B!@
M#^-3T4KA9%>VL;2SW?9;6&#=][RD"Y^N*9-I6GW%RMS-8VTDZ])'B!8?C5NB
-G=ARJUK!BBBBD,__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
